PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Savin, VJ; Sharma, R; Sharma, M; McCarthy, ET; Swan, SK; Ellis, E; Lovell, H; Warady, B; Gunwar, S; Chonko, AM; Artero, M; Vincenti, F; Fine, R; Wood, E; Trachtman, H				Savin, VJ; Sharma, R; Sharma, M; McCarthy, ET; Swan, SK; Ellis, E; Lovell, H; Warady, B; Gunwar, S; Chonko, AM; Artero, M; Vincenti, F; Fine, R; Wood, E; Trachtman, H			Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHANGE NEPHROTIC SYNDROME; ISOLATED RAT GLOMERULI; RENAL-TRANSPLANTATION; LYMPHOCYTE-T; CHILDREN; SCLEROSIS; PLASMA; PROTEINURIA; ALLOGRAFTS; LESION	Background, Heavy proteinuria and progressive renal injury recur after transplantation in up to 40 percent of patients with renal failure caused by idiopathic focal segmental glomerulosclerosis. A circulating factor may be responsible for this recurrence. Methods. To determine whether patients with focal segmental glomerulosclerosis have a circulating factor capable of causing glomerular injury, we tested serum samples from 100 patients with the disorder in an in vitro assay of glomerular permeability to albumin. Of the 56 patients who had undergone renal transplantation, 33 had recurrences, Sixty-four patients, many of whom had undergone transplantation, were being treated with dialysis. Thirty-one patients with other renal diseases and nine normal subjects were also studied, Results. The 33 patients with recurrent focal segmental glomerulosclerosis after transplantation had a higher mean (+/-SE) value for permeability to albumin (0.47+/-0.06) than the normal subjects (0.06+/-0.07) or the patients who did not have recurrences (0.14+/-0.06), After plasmapheresis in six patients with recurrences, the permeability was reduced (from 0.79+/-0.06 to 0.10+/-0.05, P=0.008), and proteinuria was significantly decreased, Patients with corticosteroid-sensitive nephrotic syndrome or with membranous nephropathy after transplantation had low levels of serum activity. The circulating factor bound to protein A and hydrophobic-interaction columns and had an apparent molecular mass of about 50 kd. Conclusions, A circulating factor found in some patients with focal segmental glomerulosclerosis is associated with recurrent disease after renal transplantation and may be responsible for initiating the renal injury.	MED COLL WISCONSIN, DEPT MED, MILWAUKEE, WI 53226 USA; HENNEPIN CTY MED CTR, DEPT MED, MINNEAPOLIS, MN USA; ARKANSAS CHILDRENS HOSP, LITTLE ROCK, AR 72202 USA; UNIV NEBRASKA, MED CTR, DEPT PEDIAT, OMAHA, NE USA; CHILDRENS MERCY HOSP, KANSAS CITY, KS USA; UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, KANSAS CITY, KS 66103 USA; UNIV KANSAS, MED CTR, DEPT MED, KANSAS CITY, KS 66103 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA USA	Medical College of Wisconsin; Hennepin County Medical Center; Arkansas Children's Hospital; University of Nebraska System; University of Nebraska Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of California System; University of California San Francisco			Trachtman, Howard/GSE-2340-2022		NIDDK NIH HHS [DK 22040] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK022040] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARTERO M, 1992, AM J MED, V92, P375, DOI 10.1016/0002-9343(92)90267-F; ARTERO ML, 1994, AM J KIDNEY DIS, V23, P574, DOI 10.1016/S0272-6386(12)80381-7; BAKKER WW, 1986, KIDNEY INT, V30, P633; COCHAT P, 1993, PEDIATR NEPHROL, V7, P50, DOI 10.1007/BF00861567; DANTAL J, 1994, NEW ENGL J MED, V330, P7, DOI 10.1056/NEJM199401063300102; DILEEPAN KN, 1993, J LAB CLIN MED, V121, P797; HESLAN JM, 1986, NEPHRON, V42, P187, DOI 10.1159/000183664; HOYER JR, 1972, LANCET, V2, P343; INGULLI E, 1991, PEDIATR NEPHROL, V5, P393, DOI 10.1007/BF01453661; INGULLI E, 1991, TRANSPLANTATION, V51, P401, DOI 10.1097/00007890-199102000-00025; JONES JMB, 1983, CLIN NEPHROL, V20, P72; KOYAMA A, 1991, KIDNEY INT, V40, P453, DOI 10.1038/ki.1991.232; LAGRUE G, 1975, BIOMED EXPRESS, V23, P73; LAUFER J, 1988, TRANSPLANTATION, V46, P540, DOI 10.1097/00007890-198810000-00014; LEWIS EJ, 1982, KIDNEY INT, V22, P315, DOI 10.1038/ki.1982.173; LI JZ, 1994, KIDNEY INT, V46, P1025, DOI 10.1038/ki.1994.363; MALEKZADEH MH, 1979, J PEDIATR-US, V95, P249; MENDOZA SA, 1992, J AM SOC NEPHROL, V3, P889; MORALES JM, 1989, NEPHRON, V53, P283, DOI 10.1159/000185762; MORALES JM, 1988, NEPHRON, V48, P241, DOI 10.1159/000184924; SAVIN VJ, 1994, KIDNEY INT, V46, P382, DOI 10.1038/ki.1994.285; SAVIN VJ, 1981, KIDNEY INT, V20, P188, DOI 10.1038/ki.1981.121; SAVIN VJ, 1992, J AM SOC NEPHROL, V3, P1260; SAVIN VJ, 1993, AM J KIDNEY DIS, V21, P347, DOI 10.1016/S0272-6386(12)80260-5; SENGGUTUVAN P, 1990, PEDIATR NEPHROL, V4, P21, DOI 10.1007/BF00858431; SHALHOUB RJ, 1974, LANCET, V2, P556; SWAN SK, 1991, CLIN TRANSPLANT, V5, P90; TEJANI A, 1988, KIDNEY INT, V33, P729, DOI 10.1038/ki.1988.59; Tejani Amir, 1993, Journal of the American Society of Nephrology, V4, P289; TIBOR N, 1994, RENAL PAHTOLOGY CLIN, P330; TIEBOSCH ATMG, 1987, KIDNEY INT, V32, P112, DOI 10.1038/ki.1987.179; TOMIZAWA S, 1985, NEPHRON, V41, P157, DOI 10.1159/000183572; TRACHTMAN H, 1987, AM J NEPHROL, V7, P13, DOI 10.1159/000167422; VERANI RR, 1986, AM J NEPHROL, V6, P263, DOI 10.1159/000167173; WILKINSON AH, 1989, CLIN SCI, V77, P43, DOI 10.1042/cs0770043; WINETZ JA, 1981, AM J KIDNEY DIS, V1, P91, DOI 10.1016/S0272-6386(81)80035-2; Work T.S., 1969, LAB TECHNIQUES BIOCH; YOSHIZAWA N, 1989, NEPHRON, V51, P370, DOI 10.1159/000185325; ZIMMERMAN SW, 1985, NEPHRON, V40, P241, DOI 10.1159/000183469; ZIMMERMAN SW, 1984, CLIN NEPHROL, V22, P32	40	570	581	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	1996	334	14					878	883		10.1056/NEJM199604043341402	http://dx.doi.org/10.1056/NEJM199604043341402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD374	8596570	Bronze			2022-12-24	WOS:A1996UD37400002
J	Murphy, EL; Bryzman, S; Williams, AE; CoChien, H; Schreiber, GB; Ownby, HE; Gilcher, RO; Kleinman, SH; Matijas, L; Thomson, RA; Nemo, GJ				Murphy, EL; Bryzman, S; Williams, AE; CoChien, H; Schreiber, GB; Ownby, HE; Gilcher, RO; Kleinman, SH; Matijas, L; Thomson, RA; Nemo, GJ			Demographic determinants of hepatitis C virus seroprevalence among blood donors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; UNITED-STATES; INFECTION; ANTIBODIES; ASSOCIATION; SEROEPIDEMIOLOGY; EPIDEMIOLOGY; PREVALENCE; VIREMIA; DISEASE	Objective.-To measure demographic determinants of hepatitis C virus (HCV) seroprevalence among blood donors in the United States. Design.-Cross-sectional epidemiological study. Setting.-Five blood centers in different regions of the United States. Subjects.-A total of 862 398 consecutive volunteer blood donors with one or more nonautologous donations from March 1992 through December 1993. Methods.-Demographic data collection, serological screening with second-generation anti-HCV enzyme immunoassay, and confirmation with anti-HCV recombinant immunoblot. Results.-There were 3126 donors with at least one blood donation confirmed HCV-seropositive, for a crude prevalence of 3.6 per 1000. Age-specific HCV seroprevalence rose from 0.5 per 1000 in donors younger than 20 years to a maximum of 6.9 per 1000 in donors aged 30 to 39 years and declined in older age groups. There was interaction between age and educational attainment, with 30- to 49-year-olds with less than a high school diploma at highest risk of HCV infection (odds ratio [OR], 33.0; 95% confidence interval [CI], 23.0 to 47.2 compared with those younger than 30 years with a bachelor's degree or higher degree), Other independent risk factors for HCV seropositivity included male sex (OR, 1.9, 95% CI, 1.8 to 2.1), black race (OR, 1.7, 95% CI, 1.6 to 1.9), Hispanic ethnicity (OR, 1.3, 95% CI, 1.1 to 1.5), previous blood transfusion (OR, 2.8; 95% CI, 2.5 to 3.1), and first/only time donor status (OR, 4.2; 95% CI, 3.9 to 4.5, compared with repeat donors), Seropositivity for human T-lymphotropic virus types I and II, human immunodeficiency virus, or hepatitis B core antigen was highly associated with HCV seropositivity (OR, 10.4; 95% CI, 9.6 to 11.4 for one vs no marker). Conclusions.-Despite a low overall HCV prevalence in blood donors in the United States, there is marked variation in HCV seroprevalence by demographic subgroup, even after controlling for prior blood transfusion, a recognized risk factor for HCV. Further study of the prevalence of other parenteral risk factors such as past injection drug use among blood donors is needed.	HIGHLAND GEN HOSP,OAKLAND,CA; AMER RED CROSS,JEROME H HOLLAND LAB,ROCKVILLE,MD; WESTAT CORP,ROCKVILLE,MD; AMER RED CROSS,BLOOD SERV,DETROIT,MI; OKLAHOMA BLOOD INST,OKLAHOMA CITY,OK; UNIV CALIF LOS ANGELES,BLOOD & PLATELET CTR,LOS ANGELES,CA 90024; NHLBI,BETHESDA,MD 20892	American Red Cross; Westat; American Red Cross; University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Murphy, EL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT LAB MED,BOX 0884,SAN FRANCISCO,CA 94143, USA.				DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB097078, N01HB097077, N01HB097079] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HB-97077, N01-HB-97079, N01-HB-97078] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AACH RD, 1991, NEW ENGL J MED, V325, P1328; ABDELAAL M, 1994, TRANSFUSION, V34, P135, DOI 10.1046/j.1537-2995.1994.34294143941.x; ALTER HJ, 1991, ANN INTERN MED, V115, P644, DOI 10.7326/0003-4819-115-8-644; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ARCHER GT, 1992, MED J AUSTRALIA, V157, P225, DOI 10.5694/j.1326-5377.1992.tb137122.x; CHIARAMONTE M, 1991, ITAL J GASTROENTEROL, V23, P555; *CTR BIOL EV RES, 1992, MEM REG BLOOD EST RE; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; ESTEBAN JI, 1989, LANCET, V2, P294; ESTEBAN R, 1993, J HEPATOL, V17, pS67, DOI 10.1016/S0168-8278(05)80427-1; GARSON JA, 1992, VOX SANG, V62, P218, DOI 10.1111/j.1423-0410.1992.tb01202.x; HOLSEN DS, 1993, EUR J CLIN MICROBIOL, V12, P673, DOI 10.1007/BF02009378; KALDOR JM, 1992, MED J AUSTRALIA, V157, P227, DOI 10.5694/j.1326-5377.1992.tb137123.x; KELEN GD, 1992, NEW ENGL J MED, V326, P1399, DOI 10.1056/NEJM199205213262105; KHAN M, 1993, GASTROENTEROL JPN, V28, P28, DOI 10.1007/BF02989200; LAI ME, 1993, J MED VIROL, V41, P282, DOI 10.1002/jmv.1890410405; LEE SD, 1991, HEPATOLOGY, V13, P830, DOI 10.1016/0270-9139(91)90249-U; LIN CK, 1992, VOX SANG, V62, P98, DOI 10.1111/j.1423-0410.1992.tb01178.x; MELE A, 1994, AM J PUBLIC HEALTH, V84, P1640, DOI 10.2105/AJPH.84.10.1640; MOORE SB, 1995, TRANSFUSION, V35, P308, DOI 10.1046/j.1537-2995.1995.35495216079.x; NAKAGIRI I, 1993, J CLIN MICROBIOL, V31, P2974, DOI 10.1128/JCM.31.11.2974-2980.1993; NEAL KR, 1994, EPIDEMIOL INFECT, V112, P595, DOI 10.1017/S0950268800051293; OSMOND DH, 1993, JAMA-J AM MED ASSOC, V269, P361, DOI 10.1001/jama.269.3.361; SCHOUB BD, 1992, T ROY SOC TROP MED H, V86, P431, DOI 10.1016/0035-9203(92)90255-B; STEVENS CE, 1990, JAMA-J AM MED ASSOC, V263, P49, DOI 10.1001/jama.263.1.49; THOMAS DL, 1993, ARCH INTERN MED, V153, P1705, DOI 10.1001/archinte.153.14.1705; *US BUR CENS, 1993, 1993 STAT ABSTR US; WATANABE J, 1993, VOX SANG, V65, P199, DOI 10.1111/j.1423-0410.1993.tb02148.x; WEINSTOCK HS, 1993, JAMA-J AM MED ASSOC, V269, P392; WILLIAMS A, 1993, TRANSFUSION, V33, pS59; Zuck TF, 1995, TRANSFUSION, V35, P944, DOI 10.1046/j.1537-2995.1995.351196110900.x	33	99	101	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					995	1000		10.1001/jama.275.13.995	http://dx.doi.org/10.1001/jama.275.13.995			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC123	8596257				2022-12-24	WOS:A1996UC12300026
J	Gallagher, RB				Gallagher, RB			Enter Listeria, unruffled	SCIENCE			English	Editorial Material														Gallagher, Richard/0000-0001-5639-2187				Cossart P, 1996, SCIENCE, V271, P315, DOI 10.1126/science.271.5247.315; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; Mengaud J, 1996, CELL, V84, P923, DOI 10.1016/S0092-8674(00)81070-3	4	3	3	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1825	1825		10.1126/science.271.5257.1825	http://dx.doi.org/10.1126/science.271.5257.1825			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596949				2022-12-24	WOS:A1996UC77800034
J	Sarzotti, M; Robbins, DS; Hoffman, PM				Sarzotti, M; Robbins, DS; Hoffman, PM			Induction of protective CTL responses in newborn mice by a murine retrovirus	SCIENCE			English	Article							CELL-MEDIATED-IMMUNITY; LEUKEMIA-VIRUS INFECTION; CYTOTOXIC T-CELL; INVIVO; TOLERANCE; LYMPHOCYTES; ONTOGENY; MATURATION; EXPRESSION; PARALYSIS	The susceptibility of neonates to virus-induced disease is thought to reflect, in part, the immaturity of their immune systems. However, inoculation of newborn mice with low doses of Cas-Br-M murine leukemia virus induced a protective cytotoxic T lymphocyte (CTL) response. The inability of neonates to develop a CTL response to high doses of virus was not the result of immunological immaturity but correlated with the induction of a nonprotective type 2 cytokine response. Thus, the initial viral dose is critical in the development of protective immunity in newborns.	UNIV MARYLAND, SCH MED, DEPT MICROBIOL & IMMUNOL, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT NEUROL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Sarzotti, M (corresponding author), VET AFFAIRS MED CTR, RES SERV, 10 N GREENE ST, BALTIMORE, MD 21201 USA.			Hoffman, Paul/0000-0003-2055-6455				ACTOR JK, 1993, P NATL ACAD SCI USA, V90, P948, DOI 10.1073/pnas.90.3.948; ADKINS B, 1994, J IMMUNOL, V153, P3378; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; CHEN NX, 1995, TRANSPLANTATION, V59, P933, DOI 10.1097/00007890-199504150-00002; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; FUCHS EJ, 1996, SCIENCE, V271, P1723; GARDNER MB, 1973, JNCI-J NATL CANCER I, V51, P1243, DOI 10.1093/jnci/51.4.1243; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HOFFMAN PM, 1991, J NEUROIMMUNOL, V33, P157, DOI 10.1016/0165-5728(91)90059-G; HOFFMAN PM, 1984, J VIROL, V52, P734, DOI 10.1128/JVI.52.3.734-738.1984; HOFFMAN PM, 1981, J NEUROIMMUNOL, V1, P275, DOI 10.1016/0165-5728(81)90031-X; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; HULI J, 1989, J IMMUNOL, V142, P800; JAMIESON BD, 1988, P NATL ACAD SCI USA, V85, P2265, DOI 10.1073/pnas.85.7.2265; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Lafferty K J, 1986, Prog Clin Biol Res, V224, P87; LAFFERTY KJ, 1975, AUST J EXP BIOL MED, V53, P27, DOI 10.1038/icb.1975.3; LU CY, 1980, P NATL ACAD SCI-BIOL, V77, P1597, DOI 10.1073/pnas.77.3.1597; LUKACHER AE, 1984, J EXP MED, V160, P814, DOI 10.1084/jem.160.3.814; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; MOSIER DE, 1975, J EXP MED, V141, P216, DOI 10.1084/jem.141.1.216; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; OLIFF A, 1981, BLOOD, V58, P244; OTTEN GR, 1991, SCIENCE, V251, P1228, DOI 10.1126/science.1900952; PARISH CR, 1972, TRANSPLANT REV-DENMA, V13, P35; PFEIFFER C, 1991, IMMUNOL REV, V123, P65, DOI 10.1111/j.1600-065X.1991.tb00606.x; PIGUET PF, 1981, J EXP MED, V154, P581, DOI 10.1084/jem.154.3.581; PILARSKI LM, 1977, J EXP MED, V146, P887, DOI 10.1084/jem.146.3.887; POWELL TJ, 1990, J IMMUNOL, V144, P854; ROBBINS DS, 1995, J VIROL, V69, P6847, DOI 10.1128/JVI.69.11.6847-6851.1995; ROBBINS DS, 1991, J NEUROIMMUNOL, V31, P9, DOI 10.1016/0165-5728(91)90081-H; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; SARZOTTI M, 1994, AIDS RES HUM RETROV, V10, P1695, DOI 10.1089/aid.1994.10.1695; SARZOTTI M, 1991, MODERN APPROACHES NE, P355; SARZOTTI M, UNPUB; Sarzotti Marcella, 1993, Viral Immunology, V6, P207, DOI 10.1089/vim.1993.6.207; SCHURMANS S, 1990, J IMMUNOL, V145, P2465; SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x; SPEAR PG, 1974, J EXP MED, V139, P249, DOI 10.1084/jem.139.2.249; ZAMOYSKA R, 1989, EUR J IMMUNOL, V19, P111, DOI 10.1002/eji.1830190118	43	367	376	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 22	1996	271	5256					1726	1728		10.1126/science.271.5256.1726	http://dx.doi.org/10.1126/science.271.5256.1726			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596933				2022-12-24	WOS:A1996UB15100046
J	Metzker, ML; Lu, J; Gibbs, RA				Metzker, ML; Lu, J; Gibbs, RA			Electrophoretically uniform fluorescent dyes for automated DNA sequencing	SCIENCE			English	Article								A class of dyes, BODIPY fluorophores, has been identified for automated DNA sequencing that has improved spectral characteristics compared with conventional fluorescein and rhodamine dyes. Single and double BODIPY dye primers were characterized in commercially available DNA sequencers and showed uniform electrophoretic mobilities and high fluorescence intensities. The improved physical properties of BODIPY dye primers were demonstrated by direct base-calling from the unprocessed fluorescent signals and improved heterozygote analyses of mixed-base populations. The high sensitivity of BODIPY dye primers requires at least 33 percent less reagent consumed per reaction than conventional dye primers, which should affect the costs of large genome-sequencing efforts.			Metzker, ML (corresponding author), BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030, USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000823, P30HG000210] Funding Source: NIH RePORTER; NHGRI NIH HHS [1 RO1 HG00823, 1 P30 HG00210] Funding Source: Medline; NIAID NIH HHS [AI07483] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHAMBERLAIN JS, 1988, NUCLEIC ACIDS RES, V16, P11141, DOI 10.1093/nar/16.23.11141; FORESTER T, 1965, MODERN QUANTUM CHE 3, P93; GIBBS RA, 1990, GENOMICS, V7, P235, DOI 10.1016/0888-7543(90)90545-6; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; JU JY, 1995, P NATL ACAD SCI USA, V92, P4347, DOI 10.1073/pnas.92.10.4347; LARDER BA, 1993, NATURE, V365, P671, DOI 10.1038/365671a0; METZKER ML, 1994, NUCLEIC ACIDS RES, V22, P4259, DOI 10.1093/nar/22.20.4259; METZKER ML, 1995, COMPUT APPL BIOSCI, V11, P187; METZKER ML, UNPUB; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339	13	129	147	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1420	1422		10.1126/science.271.5254.1420	http://dx.doi.org/10.1126/science.271.5254.1420			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596915				2022-12-24	WOS:A1996TY96100047
J	Nellen, JFJB; Smulders, YM; Frissen, PHJ; Slaats, EH; Silberbusch, J				Nellen, JFJB; Smulders, YM; Frissen, PHJ; Slaats, EH; Silberbusch, J			Lesson of the week - Hypovitaminosis D in immigrant women: Slow to be diagnosed	BRITISH MEDICAL JOURNAL			English	Article											Nellen, JFJB (corresponding author), ONZE LIEVE VROUW HOSP,DEPT INTERNAL MED,1E OOSTERPARKSTR 279,POB 95500,1090 HM AMSTERDAM,NETHERLANDS.		Smulders, YM/AAG-7506-2021					KRALL EA, 1989, NEW ENGL J MED, V321, P1777, DOI 10.1056/NEJM198912283212602; Parfitt AM, 1990, METABOLIC BONE DIS C, P329; PEACH H, 1983, LANCET, V2, P1347; PEACH H, 1982, J CLIN PATHOL, V35, P625, DOI 10.1136/jcp.35.6.625; PREECE MA, 1973, LANCET, V1, P907; THALASSINOS NC, 1970, BMJ-BRIT MED J, V1, P76, DOI 10.1136/bmj.1.5688.76	6	36	36	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					570	572		10.1136/bmj.312.7030.570	http://dx.doi.org/10.1136/bmj.312.7030.570			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595292	Green Published			2022-12-24	WOS:A1996TY88500036
J	Harpaz, R; VonSeidlein, L; Averhoff, FM; Tormey, MP; Sinha, SD; Kotsopoulou, K; Lambert, SB; Robertson, BH; Cherry, JD; Shapiro, CN				Harpaz, R; VonSeidlein, L; Averhoff, FM; Tormey, MP; Sinha, SD; Kotsopoulou, K; Lambert, SB; Robertson, BH; Cherry, JD; Shapiro, CN			Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE WORKERS; SURFACE-ANTIGEN; OPERATING-ROOM; EXPOSURE; BLOOD; RISK; CONTAMINATION; OUTBREAK	Background. Although about 1 percent of surgeons are infected with hepatitis B virus (HBV), transmission from surgeons to patients is thought to be uncommon, In July 1992, a 47-year-old woman became ill with acute hepatitis B after undergoing a thymectomy in which a thoracic-surgery resident who had had acute hepatitis B six months earlier assisted. Methods. To determine whether the surgeon transmitted HBV to this patient and others, we conducted chart reviews, interviews, and serologic testing of thoracic-surgery patients at the two hospitals where the surgeon worked from July 1991 to July 1992, Hepatitis B surface antigen (HBsAg) subtypes and DNA sequences from the surgeon and from infected patients were determined. Results. Of 144 susceptible patients in whose surgery the infected surgeon participated, 19 had evidence of recent HBV infection (13 percent), One of the hospitals was selected for additional study, and none of the 124 susceptible patients of the other thoracic surgeons at this hospital had evidence of recent HBV infection (relative risk, infinity; 95 percent confidence interval, 4.7 to infinity). NO evidence was found for any common source of HBV other than the infected surgeon, The HBsAg subtype and the partial HBV DNA sequences from the surgeon were identical to those in the infected patients, Transmission of the infection was associated with cardiac transplantation (relative risk, 4.9; 95 percent confidence interval, 1,5 to 15.5) but not with other surgical procedures, The surgeon was positive for hepatitis B e antigen and had a high serum HBV DNA concentration (15 ng per milliliter), Our investigations identified no deficiencies in the surgeon's infection-control practices. Conclusions. In this outbreak there was surgeon-to-patient HBV transmission despite apparent compliance with recommended infection-control practices, We could not identify any specific events that led to transmission.	CTR DIS CONTROL & PREVENT,HEPATITIS BRANCH,DIV VIRAL & RICKETTSIAL DIS,NATL CTR INFECT DIS,ATLANTA,GA 30333; UNIV CALIF LOS ANGELES,DEPT PEDIAT,LOS ANGELES,CA 90024; LOS ANGELES CTY DEPT HLTH SERV,LOS ANGELES,CA	Centers for Disease Control & Prevention - USA; University of California System; University of California Los Angeles								ALTER HJ, 1975, NEW ENGL J MED, V292, P454, DOI 10.1056/NEJM197502272920904; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; BELL DM, 1995, SURG CLIN N AM, V75, P1189; CARL M, 1982, LANCET, V1, P731; COUTINHO RA, 1982, LANCET, V1, P345; Dean A. G., 1990, EPI INFO VERSION 5 W; DODD RY, 1973, AM J EPIDEMIOL, V97, P111, DOI 10.1093/oxfordjournals.aje.a121487; FELL M, 1989, ANN ROY COLL SURG, V71, P7; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; HADLER SC, 1981, ANN INTERN MED, V95, P133, DOI 10.7326/0003-4819-95-2-133; HAEREM JW, 1981, ACTA MED SCAND, V210, P389; HARPAZ R, 1994, INFECT CONT HOSP EP, V15, P352; Heptonstall J, 1991, CDR (Lond Engl Rev), V1, pR81; HOSIE KB, 1988, LANCET, V2, P1500; Johnston B L, 1992, Can Commun Dis Rep, V18, P89; LABRECQUE DR, 1986, HEPATOLOGY, V6, P205, DOI 10.1002/hep.1840060209; LETTAU LA, 1986, JAMA-J AM MED ASSOC, V255, P934, DOI 10.1001/jama.255.7.934; MEYERS JD, 1978, JAMA-J AM MED ASSOC, V240, P1725, DOI 10.1001/jama.240.16.1725; OLSEN RJ, 1993, JAMA-J AM MED ASSOC, V270, P350, DOI 10.1001/jama.270.3.350; PATE JW, 1990, ANN THORAC SURG, V50, P248, DOI 10.1016/0003-4975(90)90743-P; POPEJOY SL, 1991, SURG GYNECOL OBSTET, V172, P480; PRENDERGAST TJ, 1991, WESTERN J MED, V154, P353; PRENTICE MB, 1992, BRIT MED J, V304, P761, DOI 10.1136/bmj.304.6829.761; QUEBBEMAN EJ, 1992, ARCH SURG-CHICAGO, V127, P213; RIMLAND D, 1977, NEW ENGL J MED, V296, P953, DOI 10.1056/NEJM197704282961701; ROBERTSON BH, 1991, J INFECT DIS, V163, P286, DOI 10.1093/infdis/163.2.286; ROSE DA, 1994, INFECT CONT HOSP EP, V15, P349; SHAFRITZ DA, 1982, P NATL ACAD SCI-BIOL, V79, P5675, DOI 10.1073/pnas.79.18.5675; SWENSON PD, 1991, J VIROL METHODS, V33, P27, DOI 10.1016/0166-0934(91)90004-J; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; WELCH J, 1989, LANCET, V1, P205; WILLIAMS SV, 1975, JAMA-J AM MED ASSOC, V232, P1231, DOI 10.1001/jama.232.12.1231; WONG PS, 1993, ANN THORAC SURG, V56, P108, DOI 10.1016/0003-4975(93)90412-B; 1994, HOSP STAT AHA PROFIL; 1991, MMWR-MORBID MORTAL W, V40, P1; 1991, PROGRAM MANUAL GCG P	36	170	174	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 29	1996	334	9					549	554		10.1056/NEJM199602293340901	http://dx.doi.org/10.1056/NEJM199602293340901			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW696	8569821				2022-12-24	WOS:A1996TW69600001
J	Melcher, T; Maas, S; Herb, A; Sprengel, R; Seeburg, PH; Higuchi, M				Melcher, T; Maas, S; Herb, A; Sprengel, R; Seeburg, PH; Higuchi, M			A mammalian RNA editing enzyme	NATURE			English	Article							MOLECULAR-CLONING; CHANNELS; RECEPTOR	EDITING of RNA(1) by site-selective adcnosine deamination alters codons in brain-expressed pre-messenger RNAs for glutamate receptor (GluR) subunits(2-4) including a codon for a channel determinant (Q/R site) in GluR-B, which controls the Ca2+ permeability of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors(5,6). Editing of GluR pre-mRNAs requires a double-stranded RNA (dsRNA) structure formed by esonic and intronic sequences(4,7) and is catalysed by an unknown dsRNA adenosine deaminase. Here we report the cloning of complementary DNA for RED1, a dsRNA adenosine deaminase expressed in brain and peripheral tissues that efficiently edits the Q/R site in GluR-B pre-mRNA in vitro. This site is poorly edited by DRADA, which is distantly sequence related to RED1. Both deaminases edit the R/G site in GluR-B pre-mRNA, indicating that members of an emerging gene family catalyse adenosine deamination in nuclear transcripts with distinct but overlapping substrate specificities.	UNIV HEIDELBERG, ZMBH, CTR MOLEC BIOL, MOLEC NEUROENDOCRINOL LAB, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg								BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BASS BL, 1993, RNA WORLD, P383; BHATTACHARYA S, 1994, TRENDS BIOCHEM SCI, V19, P105, DOI 10.1016/0968-0004(94)90200-3; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; CHENG JF, 1994, GENOMICS, V23, P75, DOI 10.1006/geno.1994.1461; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; Kim U, 1993, Semin Cell Biol, V4, P285, DOI 10.1006/scel.1993.1034; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; KOHLER M, 1994, J BIOL CHEM, V269, P17367; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MELCHER T, 1995, J BIOL CHEM, V270, P8566, DOI 10.1074/jbc.270.15.8566; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; SACCOMANNO L, 1994, MOL CELL BIOL, V14, P5425, DOI 10.1128/MCB.14.8.5425; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WISDEN W, 1994, IN SITU HYBRIDIZATIO, P9; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0	29	426	438	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 1	1996	379	6564					460	464		10.1038/379460a0	http://dx.doi.org/10.1038/379460a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559253				2022-12-24	WOS:A1996TT30400063
J	Kinomura, S; Larsson, J; Gulyas, B; Roland, PE				Kinomura, S; Larsson, J; Gulyas, B; Roland, PE			Activation by attention of the human reticular formation and thalamic intralaminar nuclei	SCIENCE			English	Article							NEURONS; WAKING; STATES; BRAIN; CORE; CAT	It has been known for over 45 years that electrical stimulation of the midbrain reticular formation and of the thalamic intralaminar nuclei of the brain alerts animals. However, lesions of these sectors fail to impair arousal and vigilance in some cases, making the role of the ascending activating reticular system controversial. Here, a positron emission tomographic study showed activation of the midbrain reticular formation and of thalamic intralaminar nuclei when human participants went from a relaxed awake state to an attention-demanding reaction-time task. These results confirm the role of these areas of the brain and brainstem in arousal and vigilance.	KAROLINSKA INST,DEPT NEUROSCI,DIV HUMAN BRAIN RES,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet			Gulyas, Balazs/F-9508-2015					[Anonymous], 1993, BRAIN ACTIVATION; BERGSTROM M, 1981, J COMPUT ASSIST TOMO, V5, P136, DOI 10.1097/00004728-198102000-00027; DECETY J, 1992, NEUROREPORT, V3, P761, DOI 10.1097/00001756-199209000-00010; DENOYER M, 1991, BRAIN RES, V539, P287, DOI 10.1016/0006-8993(91)91633-C; FRENCH JD, 1952, AMA ARCH NEUROL PSY, V68, P591, DOI 10.1001/archneurpsyc.1952.02320230017002; GLENN LL, 1982, J NEUROSCI, V2, P1387; GREENBERG J, 1979, Acta Neurologica Scandinavica Supplementum, V60, P12; HU B, 1989, NEUROSCIENCE, V31, P1, DOI 10.1016/0306-4522(89)90026-2; INGVAR DH, 1964, ARCH NEUROL-CHICAGO, V11, P13, DOI 10.1001/archneur.1964.00460190017002; KAWASHIMA R, 1995, CEREB CORTEX, V2, P111; KETY SS, 1950, AM J MED, V8, P205, DOI 10.1016/0002-9343(50)90363-9; KITSIKIS A, 1981, BEHAV BRAIN RES, V3, P361, DOI 10.1016/0166-4328(81)90005-X; LINDSLEY DB, 1950, ELECTROEN CLIN NEURO, V2, P483, DOI 10.1016/0013-4694(50)90086-1; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; OSULLIVAN BT, 1994, EUR J NEUROSCI, V6, P137, DOI 10.1111/j.1460-9568.1994.tb00255.x; Roland P. E., 1993, Human Brain Mapping, V1, P3, DOI 10.1002/hbm.460010103; Roland P E, 1994, Hum Brain Mapp, V1, P173, DOI 10.1002/hbm.460010303; ROLAND P E, 1976, Archives of Neurology, V33, P551; ROLAND PE, 1987, J NEUROSCI, V7, P2373; SALLANON M, 1988, ARCH ITAL BIOL, V126, P87; Schaltenbrand G., 1959, EINFUHRUNG STEREOTAK; Scheibel ME, 1958, RETICULAR FORMATION, P31; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; STERIADE M, 1982, J NEUROPHYSIOL, V48, P352, DOI 10.1152/jn.1982.48.2.352; STERIADE M, 1982, BRAIN RES, V238, P13, DOI 10.1016/0006-8993(82)90767-3; STERIADE M, 1982, EXP BRAIN RES, V46, P37; WEBSTER HH, 1988, BRAIN RES, V458, P285, DOI 10.1016/0006-8993(88)90471-4	28	460	478	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					512	515		10.1126/science.271.5248.512	http://dx.doi.org/10.1126/science.271.5248.512			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560267				2022-12-24	WOS:A1996TR32200044
J	Nightingale, SL				Nightingale, SL			Progress in international harmonization of drug approval requirements	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1993, JAMA-J AM MED ASSOC, V270, P302	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					273	273						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544255				2022-12-24	WOS:A1996TP96500007
J	Horton, R				Horton, R			The infected metropolis	LANCET			English	Editorial Material																		[Anonymous], 1995, WORLD URBANIZATION P; Barrera R, 1995, Bull Pan Am Health Organ, V29, P193; Bellow S., 1995, IT ALL ADDS UP; HORTON R, 1995, LANCET, V346, P790, DOI 10.1016/S0140-6736(95)91616-4; Karlen A., 1995, PLAGUES PROGR SOCIAL; ROHTER L, 1995, NY TIMES INT    0923, P5; STEERE AC, 1995, INFECTIOUS DISEASES IN AN AGE OF CHANGE, P1; 1995, LANCET, V346, P809	8	15	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 20	1996	347	8995					134	135		10.1016/S0140-6736(96)90333-5	http://dx.doi.org/10.1016/S0140-6736(96)90333-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544541	Bronze			2022-12-24	WOS:A1996TQ24400002
J	Reimold, AM; Grusby, MJ; Kosaras, B; Fries, JWU; Mori, R; Maniwa, S; Clauss, IM; Collins, T; Sidman, RL; Glimcher, MJ; Glimcher, LH				Reimold, AM; Grusby, MJ; Kosaras, B; Fries, JWU; Mori, R; Maniwa, S; Clauss, IM; Collins, T; Sidman, RL; Glimcher, MJ; Glimcher, LH			Chondrodysplasia and neurological abnormalities in ATF-2-deficient mice	NATURE			English	Article							AMP RESPONSE ELEMENT; NF-KAPPA-B; CYCLIC-AMP; E-SELECTIN; BINDING PROTEIN; C-FOS; GENE; TRANSCRIPTION; EXPRESSION; ACTIVATION	ACTIVATING transcription factor-2 (ATF-2) is a basic region leucine zipper protein whose DNA target sequence is the widely distributed cAMP response element (CRE). We report here that mice carrying a germline mutation in ATF-2 demonstrated unique actions of ATF-2 not duplicated by other ATF/CREB family members. Mutant mice had decreased postnatal viability and growth, with a defect in endochondral ossification at epiphyseal plates similar to human hypochondroplasia. The animals had ataxic gait, hyperactivity and decreased hearing. In the brain, there were reduced numbers of cerebellar Purkinje cells, atrophic vestibular sense organs and enlarged ventricles. Unlike CREB alpha/delta-deficient mice whose main defect is in longterm potentiation, the widespread abnormalities in ATF-2 mutant mice demonstrate its absolute requirement for skeletal and central nervous system development, and for maximal induction of select genes with CRE sites, such as E-selectin.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,NEW ENGLAND REG PRIMATE RES CTR,DIV NEUROGENET,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,VASC RES DIV,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT ORTHOPAED SURG,LAB STUDY SKELETAL DISORDERS & REHABIL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Reimold, AM (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,665 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Fries, Jochen/AAM-5999-2020	Fries, Jochen/0000-0003-2054-6345				BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; CLAUSS IM, 1993, DEV DYNAM, V197, P146, DOI 10.1002/aja.1001970207; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FRIES JWU, 1993, AM J PATHOL, V143, P725; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hayat M.A., 1989, PRINCIPLES TECHNIQUE, DOI DOI 10.1007/978-1-349-09857-6; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KARA CJ, 1990, MOL CELL BIOL, V10, P1347, DOI 10.1128/MCB.10.4.1347; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LEMERRER M, 1994, NAT GENET, V6, P318; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MATSUURA S, 1990, BIOCHEM BIOPH RES CO, V168, P993, DOI 10.1016/0006-291X(90)91127-E; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; TAKEDA J, 1991, ONCOGENE, V6, P1009; VANHUIJSDUIJNEN RH, 1992, J BIOL CHEM, V267, P22385; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464	29	236	246	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					262	265		10.1038/379262a0	http://dx.doi.org/10.1038/379262a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538792				2022-12-24	WOS:A1996TQ16900048
J	Mande, SC; Mehra, V; Bloom, BR; Hol, WGJ				Mande, SC; Mehra, V; Bloom, BR; Hol, WGJ			Structure of the heat shock protein chaperonin-10 of Mycobacterium leprae	SCIENCE			English	Article							GROES; BINDING; MODELS; CYCLE	Members of the chaperonin-10 (cpn10) protein family, also called heat shock protein 10 and in Escherichia coli GroES, play an important role in ensuring the proper folding of many proteins. The crystal structure of the Mycobacterium leprae cpn10 (MI-cpn10) oligomer has been elucidated at a resolution of 3.5 angstroms. The architecture of the MI-cpn10 heptamer resembles a dome with an oculus in its roof. The inner surface of the dome is hydrophilic and highly charged. A flexible region, known to interact with cpn60, extends from the lower rim of the dome. With the structure of a cpn10 heptamer now revealed and the structure of the E. coli GroEL previously known, models of cpn10:cpn60 and GroEL:GroES complexes are proposed.	UNIV WASHINGTON,DEPT BIOL STRUCT,SEATTLE,WA 98195; UNIV WASHINGTON,BIOMOLEC STRUCT CTR,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MICROBIOL & IMMUNOL,SEATTLE,WA 98195; ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine			Mande, Shekhar/C-2136-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023545, R01AI023545] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23545, AI07118] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BOOM BR, 1992, SCIENCE, V257, P105; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, X PLOR USER MANUAL; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; COWTAN K, 1994, NEWSLETTER PROTEIN C, V31, P34; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FOSSATI G, 1995, J BIOL CHEM, V270, P26159, DOI 10.1074/jbc.270.44.26159; HARRIS JR, 1995, J STRUCT BIOL, V115, P68, DOI 10.1006/jsbi.1995.1031; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HUGHES AL, 1993, MOL BIOL EVOL, V10, P1343; HUNTER SW, 1990, J BIOL CHEM, V265, P14065; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM J, UNPUB; KOVALENKO O, 1994, BIOCHEMISTRY-US, V33, P14974, DOI 10.1021/bi00254a004; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MAYERHARTL MK, 1995, SCIENCE, V269, P836; MEHRA V, 1992, J EXP MED, V175, P275, DOI 10.1084/jem.175.1.275; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURRAY CJL, 1994, GLOBAL COMP ASSESSME, P54; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TSALKOVA T, 1993, BIOCHEMISTRY-US, V32, P3377, DOI 10.1021/bi00064a022; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5	40	127	129	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					203	207		10.1126/science.271.5246.203	http://dx.doi.org/10.1126/science.271.5246.203			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539620				2022-12-24	WOS:A1996TP36400042
J	Shakhnovich, E; Abkevich, V; Ptitsyn, O				Shakhnovich, E; Abkevich, V; Ptitsyn, O			Conserved residues and the mechanism of protein folding	NATURE			English	Article							CHYMOTRYPSIN INHIBITOR-2; 3-DIMENSIONAL STRUCTURE; TRANSITION; SEQUENCES	EXPERIMENTAL(1-6) and simulation(7) studies show that small monomeric proteins fold in one kinetic step, which entails overcoming the free-energy barrier between the unfolded and the native protein through a transition state(8,9). Two models of transition state formation have been proposed: a 'nonspecific' one in which it depends on the formation of a sufficient number of native-like contacts regardless of what amino acids are involved(10-12) and a 'specific' one, in which it depends on formation of a specific subset of the native structure (a folding nucleus)(8,13,14). The latter requires that some amino acids form most of their contacts in the transition state, whereas others only do so on reaching the native conformation. If so, mutations affecting the stability of the transition state nucleus should have a greater effect on the folding kinetics than mutations elsewhere, and the residues involved should be evolutionarily conserved. Lattice-model simulations and experiments(8,13-16) suggest that such mutations exist. Here we present a method for determining the folding nucleus of a protein with known structure with two-state folding kinetics. This method is based on the alignment of many sequences designed to fold into the native conformation of a protein to identify the positions where amino acids are most conserved in designed sequences. The method is applied to chymotrypsin inhibitor 2 (CI2), a protein whose transition state has been previously studied by protein engineering(14-16). The involvement of residues in folding nucleus of CI2 is clearly correlated with their conservation in design, and the residues forming the nucleus are highly conserved in 23 natural sequences homologous to CI2.	RUSSIAN ACAD SCI,INST PROT RES,PUSHCHINO 142292,RUSSIA; NCI,MOLEC STRUCT SECT,LMMB,BETHESDA,MD	Russian Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shakhnovich, E (corresponding author), HARVARD UNIV,DEPT CHEM,12 OXFORD ST,CAMBRIDGE,MA 02138, USA.							ABKEVICH VI, 1994, J CHEM PHYS, V101, P6052, DOI 10.1063/1.467320; ABKEVICH VI, 1994, BIOCHEMISTRY-US, V33, P10026, DOI 10.1021/bi00199a029; ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P7243, DOI 10.1021/bi00147a006; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; FERSHT AR, 1995, P NATL ACAD SCI USA, V92, P10869, DOI 10.1073/pnas.92.24.10869; GOLDSTEIN RA, 1992, P NATL ACAD SCI USA, V89, P4918, DOI 10.1073/pnas.89.11.4918; GUO Z, 1995, BIOPOLYMERS, V35, P137; GUTIN AM, 1995, BIOCHEMISTRY-US, V34, P3066, DOI 10.1021/bi00009a038; GUTIN AM, 1995, P NATL ACAD SCI USA, V92, P1282, DOI 10.1073/pnas.92.5.1282; HAO MH, 1995, J CHEM PHYS, V102, P1334, DOI 10.1063/1.468920; ITZHAKI LS, 1995, J MOL BIOL, V254, P260, DOI 10.1006/jmbi.1995.0616; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11270, DOI 10.1021/bi00093a002; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; KOLINSKI A, 1993, J CHEM PHYS, V98, P7420, DOI 10.1063/1.464706; MATOUSCHEK A, 1992, J MOL BIOL, V224, P819, DOI 10.1016/0022-2836(92)90564-Z; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; MYAZAWA S, 1985, MACROMOLECULES, V18, P534; OLTSEN DE, 1994, P NATL ACAD SCI USA, V91, P10422; SALI A, 1994, J MOL BIOL, V235, P1614, DOI 10.1006/jmbi.1994.1110; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHINDLER T, 1995, NAT STRUCT BIOL, V2, P663, DOI 10.1038/nsb0895-663; SHAKHNOVICH E, 1991, PHYS REV LETT, V67, P1665, DOI 10.1103/PhysRevLett.67.1665; SHAKHNOVICH EI, 1993, PROTEIN ENG, V6, P793, DOI 10.1093/protein/6.8.793; SHAKHNOVICH EI, 1993, P NATL ACAD SCI USA, V90, P7195, DOI 10.1073/pnas.90.15.7195; SHAKHNOVICH EI, 1994, PHYS REV LETT, V72, P3907, DOI 10.1103/PhysRevLett.72.3907; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P2142, DOI 10.1021/bi00174a022; WOLYNES PG, 1995, SCIENCE, V267, P1619, DOI 10.1126/science.7886447; [No title captured]	31	310	314	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					96	98		10.1038/379096a0	http://dx.doi.org/10.1038/379096a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538750				2022-12-24	WOS:A1996TN21600064
J	SRIVASTAVA, D; CSERJESI, P; OLSON, EN				SRIVASTAVA, D; CSERJESI, P; OLSON, EN			A SUBCLASS OF BHLH PROTEINS REQUIRED FOR CARDIAC MORPHOGENESIS	SCIENCE			English	Article							LOOP-HELIX PROTEINS; MUSCLE TRANSCRIPTION; GENE-EXPRESSION; HEART; MYOCYTES	Skeletal muscle development is controlled by a family of muscle-specific basic helix-loop-helix (bHLH) transcription factors. Two bHLH genes, dHAND and eHAND, have now been isolated that are expressed in the bilateral heart primordia and subsequently throughout the primitive tubular heart and its derivatives during chick and mouse embryogenesis. Incubation of stage 8 chick embryos with dHAND and eHAND antisense oligonucleotides revealed that either oligonucleotide alone had no effect on embryonic development, whereas together they arrested development at the looping heart tube stage. Thus, dHAND and eHAND may play redundant roles in the regulation of the morphogenetic events of vertebrate heart development.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center								BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BARTH J, 1994, BIOTECHNIQUES, V17, P324; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BLANAR MA, 1995, P NATL ACAD SCI USA, V92, P5870, DOI 10.1073/pnas.92.13.5870; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CROSS JC, 1995, DEVELOPMENT, V121, P2513; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; EVANS SM, 1993, DEV BIOL, V159, P485, DOI 10.1006/dbio.1993.1258; EVANS SM, 1993, CIRC RES, V73, P569, DOI 10.1161/01.RES.73.3.569; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOFFMAN JIE, 1995, PEDIATR CARDIOL, V16, P103, DOI 10.1007/BF00801907; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KIRBY ML, 1990, CIRCULATION, V83, P332; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; LITVIN J, 1993, DEV BIOL, V156, P409, DOI 10.1006/dbio.1993.1088; LITVIN J, 1992, TRENDS CARDIOVAS MED, V2, P27, DOI 10.1016/1050-1738(92)90041-P; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P2602; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PAYNE RM, 1995, CIRCULATION, V91, P494, DOI 10.1161/01.CIR.91.2.494; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; RUDNICKI MA, 1985, BIOESSAYS, V17, P203; SARTORELLI V, 1993, CIRC RES, V72, P925, DOI 10.1161/01.RES.72.5.925; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SCHOENWOLF GC, 1989, LABORATORY STUDIES C; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SPRINGHORN JP, 1992, J BIOL CHEM, V267, P14360; SRIVASTAVA DK, UNPUB, P42502; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WOLF C, 1991, DEV BIOL, V142, P363; YOSH WJ, 1995, CELL, V82, P689; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZON G, 1991, OLIGONUCLEOTIDES ANA, P87	43	437	447	0	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1995	1999		10.1126/science.270.5244.1995	http://dx.doi.org/10.1126/science.270.5244.1995			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533092				2022-12-24	WOS:A1995TL42000043
J	McGovern, PG; Pankow, JS; Shahar, E; Doliszny, KM; Folsom, AR; Blackburn, H; Luepker, RV				McGovern, PG; Pankow, JS; Shahar, E; Doliszny, KM; Folsom, AR; Blackburn, H; Luepker, RV			Recent trends in acute coronary heart disease - Mortality, morbidity, medical care, and risk factors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; SURVIVAL; RATES; CHOLESTEROL; DECLINE; DEATH	Background. Mortality from coronary heart disease (CHD) has declined in the United States since the late 1960s. To understand the reasons for the decline during the period from 1985 to 1990, we examined trends in mortality and morbidity due to CHD, medical care, and risk factors for CHD in a large metropolitan population, Methods. We identified all deaths from CHD in residents of the Minneapolis-St. Paul, Minnesota, metropolitan area who were 30 to 74 years old and classified the deaths according to whether they occurred in or out of the hospital, For 1985 and 1990, we obtained lists of patients in this age range who were discharged with a diagnosis of acute CHD from all area hospitals, and we selected the medical records of 50 percent of these patients for abstraction. Definite myocardial infarctions were identified with a standardized diagnostic algorithm, The 1985 and 1990 cohorts of patients hospitalized for myocardial infarction were followed for at least three years to identify those who died from any cause. Trends in risk factors for CHD were investigated through surveys of 25-to-74-year-olds that were conducted in 1985 through 1987 and 1990 through 1992. Results. Between 1985 and 1990, mortality from CHD fell by 25 percent for both men and women, and the decline in in-hospital mortality (41 percent) exceeded the decline in out-of-hospital mortality (17 percent) among men, The rates of hospitalization for acute myocardial infarction declined slightly, by 5 to 10 percent, between 1985 and 1990. Survival among patients hospitalized for acute myocardial infarction increased substantially during that period. After adjustment for age and previous myocardial infarction, the relative risk of dying within three years of hospitalization for a myocardial infarction (for the 1990 cohort as compared with the 1985 cohort) was 0.76 for men (95 percent confidence interval, 0.65 to 0.89) and 0.84 for women (95 percent confidence interval, 0.71 to 1.00). Substantial increases in the use of thrombolytic therapy, heparin, aspirin, and coronary angioplasty paralleled the survival trends, In general, the risk-factor profile of the area population with respect to CHD also improved considerably during that time, Conclusions. The recent decline in mortality due to CHD in the Minneapolis-St. Paul metropolitan area can be explained by both the declining incidence of myocardial infarction in the population and the improved survival of patients with myocardial infarction.			McGovern, PG (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.			Pankow, James/0000-0001-7076-483X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023727, T32HL007036] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07036, R01-HL-23727] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1988, LANCET, V2, P349; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; ASSAF AR, 1993, NEW ENGL J MED, V329, P931, DOI 10.1056/NEJM199309233291307; BURKE GL, 1991, NEW ENGL J MED, V324, P941, DOI 10.1056/NEJM199104043241402; BURKE GL, 1989, INT J EPIDEMIOL, V18, pS73; BURNAND B, 1992, J CLIN EPIDEMIOL, V45, P929, DOI 10.1016/0895-4356(92)90109-Z; BUTTS WC, 1974, CLIN CHEM, V20, P1344; DELLBORG M, 1994, EUR HEART J, V15, P5, DOI 10.1093/oxfordjournals.eurheartj.a060379; EDLAVITCH SA, 1988, AM J EPIDEMIOL, V127, P1164, DOI 10.1093/oxfordjournals.aje.a114910; EDLAVITCH SA, 1990, J CLIN EPIDEMIOL, V43, P93, DOI 10.1016/0895-4356(90)90061-S; Fibrinolytic Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; FOLSOM AR, 1987, AM J EPIDEMIOL, V125, P1012, DOI 10.1093/oxfordjournals.aje.a114617; FROME EL, 1985, AM J EPIDEMIOL, V121, P309, DOI 10.1093/oxfordjournals.aje.a114001; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GILLUM RF, 1994, J AM COLL CARDIOL, V23, P1273, DOI 10.1016/0735-1097(94)90367-0; GOLDBERG RJ, 1993, CIRCULATION, V87, P1947, DOI 10.1161/01.CIR.87.6.1947; GOMEZMARIN O, 1987, NEW ENGL J MED, V316, P1353, DOI 10.1056/NEJM198705283162201; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; *NAT CTR HLTH STAT, 1990, VITAL HLTH STATISTIC, V13; NAYLOR CD, 1994, J AM COLL CARDIOL, V24, P1431, DOI 10.1016/0735-1097(94)90136-8; PANKOW JS, 1994, J CLIN EPIDEMIOL, V47, P1051, DOI 10.1016/0895-4356(94)90121-X; PASHOS CL, 1993, JAMA-J AM MED ASSOC, V270, P1832, DOI 10.1001/jama.270.15.1832; PASHOS CL, 1994, J AM COLL CARDIOL, V23, P1023, DOI 10.1016/0735-1097(94)90585-1; RAPAPORT E, 1988, TRENDS CORONARY HEAR, P221; SEMPOS CT, 1993, JAMA-J AM MED ASSOC, V269, P3009, DOI 10.1001/jama.269.23.3009; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; SPRAFKA JM, 1990, AM J EPIDEMIOL, V132, P489, DOI 10.1093/oxfordjournals.aje.a115685; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; TARONE RE, 1981, J CHRON DIS, V34, P463, DOI 10.1016/0021-9681(81)90006-0; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; THOM TJ, 1988, TRENDS CORONARY HEAR, P7; WEISFELDT ML, 1988, TRENDS CORONARY HEAR, P171; World Health Organization, 1980, INT CLASSIFICATION D; 1990, MON VITAL STAT REP S, V41	34	568	587	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	1996	334	14					884	890		10.1056/NEJM199604043341403	http://dx.doi.org/10.1056/NEJM199604043341403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD374	8596571				2022-12-24	WOS:A1996UD37400003
J	Spitz, AM; Velebil, P; Koonin, LM; Strauss, LT; Goodman, KA; Wingo, P; Wilson, JB; Morris, L; Marks, JS				Spitz, AM; Velebil, P; Koonin, LM; Strauss, LT; Goodman, KA; Wingo, P; Wilson, JB; Morris, L; Marks, JS			Pregnancy, abortion, and birth rates among US adolescents - 1980, 1985, and 1990	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To analyze pregnancy, abortion, and birth rates among US adolescent girls in 1980, 1985, and 1990. Design.-Retrospective analysis of trends in data on pregnancies, abortions, and births. Population.-US adolescent girls aged 13 to 19 years. Main Outcome Measures.-Pregnancy, abortion, and birth rates (with and without adjustment for sexual experience) among teenaged girls aged 15 to 19 years and girls under 15 years. Results.-Although pregnancy rates among all teenaged girls 15 to 19 years old remained fairly stable from 1980 to 1985, they increased by 9% during the last half of the decade, totaling 95.9 pregnancies per 1000 teenaged girls 15 to 19 years old by 1990. Because rates of sexual experience increased even faster, pregnancy rates among sexually experienced teens aged 15 to 19 actually declined between 1980 and 1990 by approximately 8%. Abortion rates among these teens remained stable during the 1980s, with 35.8 and 36.0 abortions per 1000 in 1980 and 1990, respectively. As with overall pregnancy rates, abortion rates among these sexually experienced teenaged girls declined during the 1980s. Between 1980 and 1985, birth rates among teenaged girls aged 15 to 19 years declined by 4%, but they increased by 18% during the latter half of the decade, totaling 59.9 births per 1000 in 1980. Among these sexually experienced teenagers, birth rates also declined between 1980 and 1985 and then increased over the next 5 years. In 1990, pregnancies and abortions among girls younger than 15 years accounted for only 3% of all adolescent pregnancies and abortions. However, the number of births among these younger adolescents increased by 15% over the decade. In that age group, trends in pregnancy, abortion, and birth rates over the decade were similar to those for older teens, However, during the late 1980s, the abortion rate declined and the pregnancy rate remained stable, resulting in a 26% increase in the birth rate. Conclusions.-Despite efforts to reduce adolescent pregnancy in the United States, pregnancy and birth rates for that group continue to be the highest among developed countries. Considering that 95% of adolescent pregnancies are unintended, increased efforts to prevent these pregnancies are warranted.	NATL CTR HLTH STAT, DIV VITAL STAT, HYATTSVILLE, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Spitz, AM (corresponding author), CTR DIS CONTROL & PREVENT, DIV REPROD HLTH, NATL CTR CHRON DIS PREVENT & HLTH PROMOT, ATLANTA, GA 30341 USA.							*A GUTTM I, 1994, SEX AM TEEN; ATRASH HK, 1990, CONT OB GYN, V35, P58; Brown S., 1995, BEST INTENTIONS; Burt M R, 1990, Adv Adolesc Mental Health, V4, P265; *CDC, 1983, AB SURV 1979 1980; DICLEMENTE RJ, 1992, PEDIATRICS, V89, P197; FRASER AM, 1995, NEW ENGL J MED, V332, P1113, DOI 10.1056/NEJM199504273321701; FROST JJ, 1995, FAM PLANN PERSPECT, V27, P188, DOI 10.2307/2136274; HENSHAW SK, 1990, FAM PLANN PERSPECT, V22, P76, DOI 10.2307/2135512; HENSHAW SK, 1992, US TEENAGE PREGNANCY; HENSHAW SK, 1988, INS OUTSJ HLTH POPUL, P46; Hofferth Sandra, 1987, RISKING FUTURE ADOLE, VII, P123; HOLLMAN FW, 1993, CURRENT POPULATION R; JAY MS, 1988, ADOLESCENT PEDIAT G, V1, P83, DOI 10.1016/S0932-8610(88)80029-X; Jones E.M., 1986, TEENAGE PREGNANCY IN; KOCHANEK KD, 1991, MONTHLY VITAL STAT S, V39, P1; Koonin L M, 1993, MMWR CDC Surveill Summ, V42, P29; Lawson H W, 1989, MMWR CDC Surveill Summ, V38, P11; MACIAK BJ, 1987, JAMA-J AM MED ASSOC, V258, P2069; MCANARNEY ER, 1989, JAMA-J AM MED ASSOC, V262, P74, DOI 10.1001/jama.262.1.74; MOORE KA, 1995, ADOLESCENT PREGNANCY; MOSHER WD, 1991, FAM PLANN PERSPECT, V23, P108, DOI 10.2307/2135822; ORR DP, 1988, J ADOLESCENT HEALTH, V9, P273, DOI 10.1016/0197-0070(88)90249-5; Peterson L., 1995, ADV DATA VITAL HLTH; PICCININO LJ, IN PRESS ADV DATA VI; PITTMAN K, 1988, TEENAGE PREGNANCY AD; *PUBL HLTH SERV, 1986, 1990 HLTH OBJ NAT MI; Spitz A M, 1993, MMWR CDC Surveill Summ, V42, P1; SPITZ AM, 1987, MMWR-MORBID MORTAL W, V36, P1; *US DEP HHS, 1991, US DHHS PUBL; VENTURA SJ, 1992, MONTHLY VITAL STAT S, V41, P1; ZUCKERMAN BS, 1994, J PEDIATR, V105, P857; 1995, MMWR-MORBID MORTAL W, V44, P131; 1992, TEENAGE PREGNANCY TO; 1993, MONTHLY VITAL STAT S, V42, P1; 1990, MONTHLY VITAL STAT S, V41, P1	36	47	49	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					989	994		10.1001/jama.275.13.989	http://dx.doi.org/10.1001/jama.275.13.989			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC123	8596256				2022-12-24	WOS:A1996UC12300025
J	Goonasekera, CDA; Shah, V; Wade, AM; Barratt, TM; Dillon, MJ				Goonasekera, CDA; Shah, V; Wade, AM; Barratt, TM; Dillon, MJ			15-year follow-up of renin and blood pressure in reflux nephropathy	LANCET			English	Article							VESICOURETERIC REFLUX; CHILDREN; PLASMA; HYPERTENSION	Background Beginning in 1978 a cohort of patients with reflux nephropathy first seen at a London Children's hospital have had 5-yearly follow-ups. This is the fourth (15-year) report from that series. Methods Of the original 100 normotensive children with reflux nephropathy 78 were traced for the 15-year study in 1994. Five patients were excluded because of nephrectomy, ten for other reasons, and eight refused to take part, leaving 55. 26 were on oral contraceptives. Supine blood pressure and plasma renin activity (PRA) were measured, and daily sodium excretion was assessed on a sample of overnight urine. Findings Of the 55 patients (15 male, 40 female, median age 27 years, range 20-31), five had systolic and two had diastolic hypertension. Compared with the 10-year (1988) follow-up there was no change in blood pressure standard deviation scores (SDS) in this cohort. PRA showed an increasing dissociation from controls after 15 years of age and was significantly above that of controls by age 25. Exclusion of the patients on oral contraceptives did not significantly alter the results. The PRA values in 1988 were not individually predictive of the development of hypertension over the ensuing 5 years. Interpretation Previously, in the long-term study of reflux nephropathy, blood pressure SDS had progressively increased with age. By 15 years blood pressure had levelled out and the PRA, though raised, did not predict the development of hypertension. Oral contraceptive use did not significantly modify the results.	INST CHILD HLTH, DIV CLIN SCI, LONDON WC1N 1EH, ENGLAND; INST CHILD HLTH, DIV BIOCHEM & GENET, LONDON WC1N 1EH, ENGLAND; INST CHILD HLTH, DIV EPIDEMIOL, LONDON WC1N 1EH, ENGLAND; INST CHILD HLTH, BIOSTAT UNIT, LONDON WC1N 1EH, ENGLAND; GREAT ORMOND ST HOSP CHILDREN NHS TRUST, RENAL UNIT, LONDON, ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust			Goonasekera, Chulananda/G-9327-2016	Goonasekera, Chulananda/0000-0002-9754-6477				[Anonymous], 1987, PEDIATRICS, V79, P1; BAILEY RR, 1984, CONTRIBUTIONS NEPRHO, P146; BRAREN V, 1988, UROLOGY, V32, P228, DOI 10.1016/0090-4295(88)90390-1; DERKX FHM, 1986, J CLIN ENDOCR METAB, V63, P1008, DOI 10.1210/jcem-63-4-1008; DILLON MJ, 1975, J CLIN PATHOL, V28, P625, DOI 10.1136/jcp.28.8.625; DILLON MJ, 1987, PEDIATR NEPHROL, V1, P59, DOI 10.1007/BF00866886; DILLON MJ, 1984, CONTRIBUTIONS NEPHRO, P68; GILL DG, 1976, ARCH DIS CHILD, V51, P951, DOI 10.1136/adc.51.12.951; Graystone JE, 1968, HUMAN GROWTH, P182; GUSMANO R, 1988, CONTRIB NEPHROL, V61, P201; JARDIM H, 1991, ARCH DIS CHILD, V66, P1213, DOI 10.1136/adc.66.10.1213; LINDEMAN RD, 1984, KIDNEY INT, V26, P861, DOI 10.1038/ki.1984.229; SAVAGE JM, 1987, ARCH DIS CHILD, V62, P678, DOI 10.1136/adc.62.7.678; SAVAGE JM, 1978, LANCET, V2, P441; SMELLIE JM, 1989, URINARY TRACT INFECT, P39; SMELLIE JM, 1979, REFLUX NEPHROPATHY, P14; STILL JL, 1967, ARCH DIS CHILD, V42, P34, DOI 10.1136/adc.42.221.34; The WHO multicentre trial of the vasopressor effects of combined oral contraceptives, 1989, CONTRACEPTION, V40, P129; WALLACE DMA, 1978, BRIT J UROL, V50, P479, DOI 10.1111/j.1464-410X.1978.tb06195.x; WOLFISH NM, 1993, J PEDIATR-US, V123, P559, DOI 10.1016/S0022-3476(05)80950-3	20	50	51	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	1996	347	9002					640	643		10.1016/S0140-6736(96)91201-5	http://dx.doi.org/10.1016/S0140-6736(96)91201-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596377				2022-12-24	WOS:A1996TZ28500009
J	Multhaup, G; Schlicksupp, A; Hesse, L; Beher, D; Ruppert, T; Masters, CL; Beyreuther, K				Multhaup, G; Schlicksupp, A; Hesse, L; Beher, D; Ruppert, T; Masters, CL; Beyreuther, K			The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I)	SCIENCE			English	Article							CEREBROSPINAL-FLUID; WILSON DISEASE; MENKES DISEASE; CANDIDATE GENE; CEREBRAL-HEMORRHAGE; TRANSPORTING ATPASE; SENILE PLAQUES; GROWTH-FACTOR; BETA-PROTEIN; MUTATION	The transition metal ion copper(II) has a critical role in chronic neurologic diseases. The amyloid precursor protein (APP) of Alzheimer's disease or a synthetic peptide representing its copper-binding site reduced bound copper(II) to copper(I). This copper ion-mediated redox reaction led to disulfide bond formation in APP, which indicated that free sulfhydryl groups of APP were involved. Neither superoxide nor hydrogen peroxide had an effect on the kinetics of copper(II) reduction. The reduction of copper(II) to copper(I) by APP involves an electron-transfer reaction and could enhance the production of hydroxyl radicals, which could then attack nearby sires. Thus, copper-mediated toxicity may contribute to neurodegeneration in Alzheimer's disease.	UNIV HEIDELBERG,DEPT VIROL,D-69120 HEIDELBERG,GERMANY; UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA; MENTAL HLTH RES INST VICTORIA,NEUROPATHOL LAB,PARKVILLE,VIC 3052,AUSTRALIA	Ruprecht Karls University Heidelberg; University of Melbourne	Multhaup, G (corresponding author), UNIV HEIDELBERG,ZMBH CTR MOLEC BIOL,NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.		Ruppert, Thomas/AAC-2467-2021	Ruppert, Thomas/0000-0001-9152-2266; Beher, Dirk/0000-0001-8005-5359				BASUN H, 1991, J NEURAL TRANSM, V4, P231; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BEYREUTHER K, 1993, ANN NY ACAD SCI, V695, P91, DOI 10.1111/j.1749-6632.1993.tb23035.x; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; BUSH AI, 1993, J BIOL CHEM, V268, P16109; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CORK LC, 1990, AM J PATHOL, V137, P1383; DYRKS T, 1993, FEBS LETT, V324, P231, DOI 10.1016/0014-5793(93)81399-K; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; FITZGERALD DJ, 1995, SCIENCE, V268, P1920, DOI 10.1126/science.7604269; GIACCONE G, 1989, NEUROSCI LETT, V97, P232, DOI 10.1016/0304-3940(89)90169-9; GILBERT HF, 1982, J BIOL CHEM, V257, P2086; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HARTMANN HA, 1992, MED HYPOTHESES, V38, P75, DOI 10.1016/0306-9877(92)90162-6; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HERSHEY CO, 1983, NEUROLOGY, V33, P1350, DOI 10.1212/WNL.33.10.1350; HESSE L, 1994, FEBS LETT, V349, P109, DOI 10.1016/0014-5793(94)00658-X; HYMAN BT, 1995, P NATL ACAD SCI USA, V92, P3586, DOI 10.1073/pnas.92.8.3586; JOSELOW M, 1951, J BIOL CHEM, V191, P11; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; LANDERS JW, 1958, AM J CLIN PATHOL, V29, P590; LANDGRAF W, 1991, J BIOL CHEM, V266, P16305; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LU HS, 1992, J BIOL CHEM, V267, P8770; LYNCH SM, 1993, J LIPID RES, V34, P1745; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARINDRASORASAK S, 1992, LAB INVEST, V67, P643; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; NULTHAUP G, 1994, FEBS LETT, V355, P151; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; PICKART L, 1987, METHOD ENZYMOL, V147, P314; PIKE CJ, 1993, NEUROSCIENCE, V56, P269, DOI 10.1016/0306-4522(93)90331-9; ROCH JM, 1992, J BIOL CHEM, V267, P2214; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SIMONS M, 1995, J NEUROSCI RES, V41, P121, DOI 10.1002/jnr.490410114; SMALL DH, 1994, J NEUROSCI, V14, P2117; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WANG D, 1995, J NEUROPATH EXP NEUR, V54, P548, DOI 10.1097/00005072-199507000-00009; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; YAMAZAKI T, 1995, J CELL BIOL, V129, P431, DOI 10.1083/jcb.129.2.431	57	611	621	0	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1406	1409		10.1126/science.271.5254.1406	http://dx.doi.org/10.1126/science.271.5254.1406			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596911				2022-12-24	WOS:A1996TY96100043
J	vonBartheld, CS; Byers, MR; Williams, R; Bothwell, M				vonBartheld, CS; Byers, MR; Williams, R; Bothwell, M			Anterograde transport of neurotrophins and axodendritic transfer in the developing visual system	NATURE			English	Article							NERVE GROWTH-FACTOR; RETROGRADE TRANSPORT; AXONAL-TRANSPORT; RECEPTORS; BRAIN; INTERNALIZATION; EXPRESSION; SYNAPSES; NEURONS; DEATH	Neurotrophic factors support the differentiation and survival of neurons(1,2) and influence properties of synaptic transmission(3,4). The neurotrophic hypothesis postulates a retrograde action of trophic factors: their production and release by target cells and their uptake by innervating axons(5). Besides the retrograde route of trophic messengers, the survival of neurons and the development of synapses is thought to be also regulated by anterograde, afferent trophic signals(6-10). We now show that exogenous neurotrophins are transported in the anterograde direction, from cell bodies to the axon terminals, and that the intact neurotrophin is released after anterograde transport, taken up and utilized by second-order visual neurons in the developing chick brain. These results suggest that anterogradely transported neurotrophins may play a role in synaptic plasticity and may have effects at more than one synapse beyond the initial release site.	UNIV WASHINGTON,DEPT ANESTHESIOL,SEATTLE,WA 98195; KAROLINSKA INST,DEPT DEV BIOL,S-17177 STOCKHOLM,SWEDEN	University of Washington; University of Washington Seattle; Karolinska Institutet	vonBartheld, CS (corresponding author), UNIV WASHINGTON,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195, USA.							[Anonymous], [No title captured]; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; BYERS MR, 1974, BRAIN RES, V75, P97, DOI 10.1016/0006-8993(74)90773-2; CATSICAS M, 1992, J NEUROSCI, V12, P4642; CHANGEUX JP, 1976, NATURE, V264, P705, DOI 10.1038/264705a0; Clarke P.G.H., 1991, Concepts in Neuroscience, V2, P201; CLAUDE P, 1982, J NEUROSCI, V2, P431; Cowan W. M., 1970, CONT RES METHODS NEU, P217, DOI 10.1007/978-3-642-85986-1_11; EMFORS P, 1990, NEURON, V5, P511; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FERGUSON IA, 1990, J NEUROSCI, V10, P2176; HAMMERSCHLAG R, 1982, TRENDS NEUROSCI, V5, P12, DOI 10.1016/0166-2236(82)90009-1; HERZOG KH, 1994, DEVELOPMENT, V120, P1643; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; KORSCHING S, 1993, J NEUROSCI, V13, P2739; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; NIETOBONA MP, 1993, J NEUROSCI RES, V36, P520, DOI 10.1002/jnr.490360504; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RICHARDSON PM, 1986, J NEUROSCI, V6, P2312; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SMITH RS, 1994, J NEUROCHEM, V62, P1698; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; VAUGHN JE, 1989, SYNAPSE, V3, P255, DOI 10.1002/syn.890030312; VONBARTHELD CS, 1991, J COMP NEUROL, V310, P103, DOI 10.1002/cne.903100110; VONBARTHELD CS, 1994, NEURON, V12, P639, DOI 10.1016/0896-6273(94)90219-4; WAYNE DB, 1990, DEV BIOL, V138, P484, DOI 10.1016/0012-1606(90)90214-4; WILLIAMS R, 1995, EUR J NEUROSCI, V7, P116, DOI 10.1111/j.1460-9568.1995.tb01026.x; ZHOU XF, IN PRESS NEUROSCIENC	31	256	256	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					830	833		10.1038/379830a0	http://dx.doi.org/10.1038/379830a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587607				2022-12-24	WOS:A1996TX50100060
J	Irvine, S; Cawood, E; Richardson, D; MacDonald, E; Aitken, J				Irvine, S; Cawood, E; Richardson, D; MacDonald, E; Aitken, J			Evidence of deteriorating semen quality in the United Kingdom: Birth cohort study in 577 men in Scotland over 11 years	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MALE-FERTILITY; CHANGING PARAMETERS; TESTICULAR CANCER; SPERM COUNTS; EPIDEMIOLOGY; INFERTILITY; TERMS	Objective-To determine whether the quality of semen has changed in a group of over 500 Scottish men born between 1951 and 1973. Design-Retrospective review of data on semen quality collected in a single laboratory over 11 years and according to World Health Organisation guidelines. Setting-Programme of gamete biology research funded by Medical Research Council. Subjects-577 volunteer semen donors. Of these, 171 were born before 1959, 120 were born in 1960-4, 171 in 1965-9, and 115 in 1970-4. Main outcome measures-Conventional criteria of semen quality including semen volume (ml), sperm concentration (10(6)/ml), overall motility (% motile), total number of sperm in the ejaculate (10(6)), and total number of motile sperm in the ejaculate (10(6)). Results-When the four birth cohort groups were compared a later year of birth was associated with a lower sperm concentration, a lower total number of sperm in the ejaculate, and a lower number of motile sperm in the ejaculate. The median sperm concentration fell from 98 x 10(6)/ml among donors born before 1959 to 78 x 10(6)/ml among donors born after 1970 (P = 0.002). The total number of sperm in the ejaculate fell from 301 x 10(6) to 214 x 10(6) (P = 0.0005), and the total number of motile sperm in the ejaculate fell from 169.7 x 10(6) to 129.0 x 10(6) (P = 0.0065). Conclusion-This study provides direct evidence that semen quality is deteriorating, with a later year of birth being significantly associated with a reduced number of sperm in adult life.	UNIV EDINBURGH, CTR REPROD BIOL, REPROD MED LABS, EDINBURGH EH3 9EW, MIDLOTHIAN, SCOTLAND	University of Edinburgh	Irvine, S (corresponding author), MRC, CTR REPROD BIOL, REPROD BIOL UNIT, EDINBURGH EH3 9EW, MIDLOTHIAN, SCOTLAND.			Aitken, Robert John/0000-0002-9152-156X				AITKEN RJ, 1982, FERTIL STERIL, V38, P68; AITKEN RJ, 1991, AM J OBSTET GYNECOL, V164, P542, DOI 10.1016/S0002-9378(11)80017-7; [Anonymous], 1987, WHO LAB MANUAL EXAMI; [Anonymous], 1992, WHO LAB MANUAL EXAMI; AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; Barratt C. L. R., 1993, Human Reproduction (Oxford), V8, P1521; BOSTOFTE E, 1983, INT J FERTIL, V28, P91; BOYLE P, 1987, EUR J CANCER CLIN ON, V23, P827, DOI 10.1016/0277-5379(87)90286-0; BOYLE P, 1985, LANCET, V1, P1311; BROMWICH P, 1994, BRIT MED J, V309, P19, DOI 10.1136/bmj.309.6946.19; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; GIWERCMAN A, 1992, INT J ANDROL, V15, P373, DOI 10.1111/j.1365-2605.1992.tb01351.x; IRVINE DS, 1995, HUM REPROD, V10, P2752, DOI 10.1093/oxfordjournals.humrep.a135786; IRVINE DS, 1994, ENDOCRIN METAB CLIN, V23, P725, DOI 10.1016/S0889-8529(18)30064-1; JACKSON MB, 1988, HORM RES, V30, P153, DOI 10.1159/000181052; JAMES WH, 1980, ANDROLOGIA, V12, P381; JOHNSON L, 1986, J ANDROL, V7, P331; LETO S, 1981, FERTIL STERIL, V36, P766; MACLEOD J, 1979, FERTIL STERIL, V31, P103; MACLEOD J, 1951, J UROLOGY, V66, P436, DOI 10.1016/S0022-5347(17)74358-3; MENKVELD R, 1986, ARCH ANDROLOGY, V17, P143, DOI 10.3109/01485018608990186; MORTIMER D, 1982, ARCH ANDROLOGY, V8, P251, DOI 10.3109/01485018208990205; NELSON CMK, 1974, FERTIL STERIL, V25, P503; OSSER S, 1984, ARCH ANDROLOGY, V12, P113, DOI 10.3109/01485018409161159; OSTERLIND A, 1986, BRIT J CANCER, V53, P501, DOI 10.1038/bjc.1986.79; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SHARPE RM, 1995, ENV HLTH PERSPECT, V103, P2; SHERINS RJ, 1995, NEW ENGL J MED, V332, P327, DOI 10.1056/NEJM199502023320510; TEMPLETON A, 1990, BRIT MED J, V301, P148, DOI 10.1136/bmj.301.6744.148; 1980, LAB MANUAL EXAMINATI; 1995, IEH ASSESSMENT ENV O; 1995, MALE REPROD HLTH ENV	32	336	352	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 24	1996	312	7029					467	471		10.1136/bmj.312.7029.467	http://dx.doi.org/10.1136/bmj.312.7029.467			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597676	Green Published			2022-12-24	WOS:A1996TX38300020
J	Chopra, I; Hodgson, J; Metcalf, B; Poste, G				Chopra, I; Hodgson, J; Metcalf, B; Poste, G			New approaches to the control of infections caused by antibiotic-resistant bacteria - An industry perspective	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									SMITHKLINE BEECHAM PHARMACEUT,RES & DEV,EPSOM KT18 5X0,SURREY,ENGLAND; SMITHKLINE BEECHAM PHARMACEUT,RES & DEV,UPPER MERION,PA	GlaxoSmithKline; GlaxoSmithKline								ALLEN NE, 1985, ANNU REP MED CHEM, V20, P155; CASADEVALL A, 1994, ANTIMICROB AGENTS CH, V38, P1695, DOI 10.1128/AAC.38.8.1695; DALE DC, 1994, CLIN INFECT DIS   S2, V18, P180; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; DeMarsh PL, 1996, J INFECT DIS, V173, P203, DOI 10.1093/infdis/173.1.203; DOUGAN G, 1994, MICROBIOL-SGM, V140, P215, DOI 10.1099/13500872-140-2-215; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Garrett L., 1994, COMING PLAGUE NEWLY; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; JACOB L, 1994, CIBA F SYMP, V186, P197; LAMBERT HP, 1984, BRIT MED BULL, V40, P102, DOI 10.1093/oxfordjournals.bmb.a071938; Levy Stuart B., 1992, ANTIBIOTIC PARADOX M; MAHAN MJ, 1995, P NATL ACAD SCI USA, V92, P669, DOI 10.1073/pnas.92.3.669; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NEUHAUS FC, 1992, EMERGING TARGETS ANT, P205; Podzorski Raymond P., 1993, Clinical Microbiology Newsletter, V15, P137, DOI 10.1016/0196-4399(93)90042-L; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; Russell A.D., 1990, UNDERSTANDING ANTIBA; SIBER GR, 1994, SCIENCE, V265, P1385, DOI 10.1126/science.8073278; SILVER LL, 1993, ANTIMICROB AGENTS CH, V37, P377, DOI 10.1128/AAC.37.3.377; SPARLING PF, 1994, P NATL ACAD SCI USA, V91, P2456, DOI 10.1073/pnas.91.7.2456; STAGER CE, 1992, CLIN MICROBIOL REV, V5, P302, DOI 10.1128/CMR.5.3.302-327.1992; SUTCLIFFE JA, 1988, ANNU REP MED CHEM, V23, P141; TALLY FT, 1995, J ANTIMICROB CHEMOTH, V35, P449, DOI 10.1093/jac/35.4.449; UTT EA, 1995, CAN J MICROBIOL, V41, P152, DOI 10.1139/m95-020	25	53	53	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					401	403		10.1001/jama.275.5.401	http://dx.doi.org/10.1001/jama.275.5.401			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8569021				2022-12-24	WOS:A1996TT30300035
J	Bonn, D				Bonn, D			What prospects for hormonal contraceptives for men?	LANCET			English	News Item																			0	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					316	316		10.1016/S0140-6736(96)90482-1	http://dx.doi.org/10.1016/S0140-6736(96)90482-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569371				2022-12-24	WOS:A1996TT48500023
J	Buckwalter, JA				Buckwalter, JA			Joint distraction for osteoarthritis	LANCET			English	Editorial Material											Buckwalter, JA (corresponding author), UNIV IOWA HOSP & CLIN,DEPT ORTHOPAED SURG,IOWA CITY,IA 52242, USA.							ABDO RV, 1992, FOOT ANKLE, V13, P307, DOI 10.1177/107110079201300602; BUCKWALTER JA, 1994, J BONE JOINT SURG AM, V76A, P1405, DOI 10.2106/00004623-199409000-00019; KITAOKA HB, 1994, J BONE JOINT SURG AM, V76A, P974, DOI 10.2106/00004623-199407000-00003; OGILVIEHARRIS DJ, 1993, J BONE JOINT SURG AM, V75A, P1167, DOI 10.2106/00004623-199308000-00006; TAKAKURA Y, 1995, J BONE JOINT SURG BR, V77B, P50, DOI 10.1302/0301-620X.77B1.7822395; VANVALBURG AA, 1995, J BONE JOINT SURG BR, V77, P720, DOI 10.1302/0301-620X.77B5.7559696	6	20	43	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					279	280		10.1016/S0140-6736(96)90463-8	http://dx.doi.org/10.1016/S0140-6736(96)90463-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569359				2022-12-24	WOS:A1996TT48500006
J	Sheng, ZH; Rettig, J; Cook, T; Catterall, WA				Sheng, ZH; Rettig, J; Cook, T; Catterall, WA			Calcium-dependent interaction of N-type calcium channels with the synaptic core complex	NATURE			English	Article							TRANSMITTER RELEASE; MEMBRANE-PROTEIN; ACTIVE ZONES; SYNAPTOTAGMIN; SYNTAXIN; VESICLES; DOCKING	NEUROTRANSMITTER release is initiated by influx of Ca2+ through voltage-gated Ca2+ channels(1,2), within 200 mu s of the action potential arriving at the synaptic terminal(3), as the Ca2+ concentration increases from 100 nM to >200 mu M(4). Exocytosis requires high Ca2+ concentration, with a threshold of 20-50 mu M and half-maximal activation at 190 mu M(5,6). The synaptic membrane syntaxin(7,8), 25K synaptosome-associated protein (SNAP25)9, and vesicle-associated membrane protein (VAMP)/synaptobrevin(10-12), are thought to form a synaptic core complex which mediates vesicle docking and membrane fusion(13-19) Synaptotagmin may be the low-affinity Ca2+-sensor(20-24), but other Ca2+-sensors are involved(25-27) as residual neurotransmission persists in synaptotagmin-null mutants. Syntaxin binds to N-type Ca2+ channels(7,8,28,29) at a site in the intracellular loop connecting domains II and III30. Here we describe Ca2+ dependent interaction of this site with syntaxin and SNAP25 which has a biphasic dependence on Ca2+, with maximal binding at 20 mu M free Ca2+, near the threshold for transmitter release. Ca2+-dependent interaction of Ca2+ channels with the synaptic core complex may be important for Ca2+-dependent docking and fusion of synaptic vesicles.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle			Rettig, Jens/K-5103-2013	Rettig, Jens/0000-0001-6160-3954				BARRETT EF, 1972, J PHYSIOL-LONDON, V227, P691, DOI 10.1113/jphysiol.1972.sp010054; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; DAVIETOV BA, 1993, J BIOL CHEM, V268, P26386; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; LEVEQUE C, 1994, J BIOL CHEM, V269, P6309; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; SHENG ZH, 1994, NEURON, V13, P1301; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SOLLNER T, 1994, TRENDS NEUROSCI, V17, P344, DOI 10.1016/0166-2236(94)90178-3; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	30	300	307	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					451	454		10.1038/379451a0	http://dx.doi.org/10.1038/379451a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559250				2022-12-24	WOS:A1996TT30400060
J	Feldman, DE; Brainard, MS; Knudsen, EI				Feldman, DE; Brainard, MS; Knudsen, EI			Newly learned auditory responses mediated by NMDA receptors in the owl inferior colliculus	SCIENCE			English	Article							LONG-TERM POTENTIATION; OPTIC TECTUM; BARN OWL; VISUAL RESPONSES; SPACE; MAPS; NEURONS; CORTEX; ANTAGONIST; PLASTICITY	Alignment of auditory and visual receptive fields in the optic tectum of the barn owl (Tyto alba) is maintained through experience-dependent modification of auditory responses in the external nucleus of the inferior colliculus (ICX), which provides auditory input to the tectum. Newly learned tectal auditory responses, induced by altered visual experience, were found to be pharmacologically distinct from normal responses expressed at the same tectal sites. N-methyl-D-aspartate (NMDA) receptor antagonists administered systemically or applied locally in the ICX reduced learned responses more than normal responses. This differential blockade was not observed with non-NMDA or broad-spectrum antagonists. Thus, NMDA receptors preferentially mediate the expression of novel neuronal responses induced by experience during development.			Feldman, DE (corresponding author), STANFORD UNIV, SCH MED, DEPT NEUROBIOL, FAIRCHILD SCI BLDG, STANFORD, CA 94305 USA.			Brainard, Michael/0000-0002-9425-9907	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000155] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC00155-14] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AIZENMAN E, 1989, NEURON, V2, P1257, DOI 10.1016/0896-6273(89)90310-3; BEAR MF, 1990, J NEUROSCI, V10, P909; BRAINARD MS, 1995, J NEUROPHYSIOL, V73, P595, DOI 10.1152/jn.1995.73.2.595; BRAINARD MS, 1993, J NEUROSCI, V13, P4589; BRAINARD MS, 1993, INT CONGR SER, V1036, P113; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; DAW NW, 1993, ANNU REV NEUROSCI, V16, P207, DOI 10.1146/annurev.ne.16.030193.001231; DUNIA R, 1989, HEARING RES, V37, P241, DOI 10.1016/0378-5955(89)90025-7; Feldman D. P., UNPUB; FELDMAN DE, 1994, J NEUROSCI, V14, P5939; FOX K, 1989, J NEUROSCI, V9, P2443; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; GOZLAN H, 1994, J NEUROPHYSIOL, V72, P3017, DOI 10.1152/jn.1994.72.6.3017; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; KNUDSEN EI, 1983, J COMP NEUROL, V218, P187, DOI 10.1002/cne.902180206; KNUDSEN EI, 1982, J NEUROSCI, V2, P1177; KNUDSEN EI, 1991, J NEUROSCI, V11, P1727; KNUDSEN EI, 1991, SCIENCE, V253, P85, DOI 10.1126/science.2063209; KOHR G, 1993, J NEUROSCI, V13, P3612; KWON YH, 1991, J NEUROPHYSIOL, V66, P414, DOI 10.1152/jn.1991.66.2.414; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MILLER KD, 1989, P NATL ACAD SCI USA, V86, P5183, DOI 10.1073/pnas.86.13.5183; MOONEY R, 1992, J NEUROSCI, V12, P2464; MOTT DD, 1991, SCIENCE, V252, P1718, DOI 10.1126/science.1675489; NETER J, 1990, APPLIED LINEAR STATI; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; OCONNOR JJ, 1994, NATURE, V367, P557, DOI 10.1038/367557a0; OLSEN JF, 1989, J NEUROSCI, V9, P2591; SCHERER WJ, 1989, J NEUROSCI, V9, P3837; SCHMIDT JT, 1990, J NEUROSCI, V10, P233; SILLAR KT, 1991, BRAIN RES, V545, P24, DOI 10.1016/0006-8993(91)91265-3; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0	36	72	72	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					525	528		10.1126/science.271.5248.525	http://dx.doi.org/10.1126/science.271.5248.525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560271				2022-12-24	WOS:A1996TR32200048
J	Visa, N; AlzhanovaEricsson, AT; Sun, X; Kiseleva, E; Bjorkroth, B; Wurtz, T; Daneholt, B				Visa, N; AlzhanovaEricsson, AT; Sun, X; Kiseleva, E; Bjorkroth, B; Wurtz, T; Daneholt, B			A pre-mRNA-binding protein accompanies the RNA from the gene through the nuclear pores and into polysomes	CELL			English	Article							PREMESSENGER RIBONUCLEOPROTEIN PARTICLE; ELECTRON-MICROSCOPE TOMOGRAPHY; SALIVARY-GLAND CELLS; CHIRONOMUS-TENTANS; DROSOPHILA-MELANOGASTER; HNRNP PROTEINS; HEAT-SHOCK; COMPLEXES; INVIVO; VISUALIZATION	In the larval salivary glands of C. tentans, it is possible to visualize by electron microscopy how Balbiani ring (BR) pre-mRNA associates with proteins to form pre-mRNP particles, how these particles move to and through the nuclear pore, and how the BR RNA is engaged in the formation of giant polysomes in the cytoplasm. Here, we study C. tentans hrp36, an abundant protein in the BR particles, and establish that it is similar to the mammalian hnRNP A1. By immunoelectron microscopy it is demonstrated that hrp36 is added to BR RNA concomitant with transcription, remains in nucleoplasmic BR particles, and is translocated through the nuclear pore still associated with BR RNA. It appears in the giant BR RNA-containing polysomes, where it remains as an abundant protein in spite of ongoing translation.			Visa, N (corresponding author), KAROLINSKA INST, MED NOBEL INST, DEPT CELL & MOLEC BIOL, S-17177 STOCKHOLM, SWEDEN.		Visa, Neus/C-9459-2016; Visa, Neus/R-8037-2019	Visa, Neus/0000-0003-3145-3953; Visa, Neus/0000-0003-3145-3953; Kiseleva, Elena/0000-0001-6949-182X				AMERO SA, 1991, GENE DEV, V5, P188, DOI 10.1101/gad.5.2.188; ANDERSON JT, 1993, MOL CELL BIOL, V13, P6102, DOI 10.1128/MCB.13.10.6102; BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3093, DOI 10.1093/nar/21.13.3093; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BEYER AL, 1990, EUKARYOTIC NUCLEUS, V2, P431; BIAMONTI G, 1994, FEBS LETT, V340, P1, DOI 10.1016/0014-5793(94)80162-2; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CASE ST, 1978, J MOL BIOL, V124, P223, DOI 10.1016/0022-2836(78)90157-2; DANEHOLT B, 1977, J CELL BIOL, V73, P149, DOI 10.1083/jcb.73.1.149; Daneholt B., 1982, P382; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOYLE D, 1969, J CELL BIOL, V40, P61, DOI 10.1083/jcb.40.1.61; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; EDSTROM JE, 1978, CHROMOSOMA, V66, P33, DOI 10.1007/BF00285814; FRANCKE C, 1982, EMBO J, V1, P59, DOI 10.1002/j.1460-2075.1982.tb01124.x; GREENBERG JR, 1981, P NATL ACAD SCI-BIOL, V78, P2923, DOI 10.1073/pnas.78.5.2923; HAYNES SR, 1990, MOL CELL BIOL, V10, P316, DOI 10.1128/MCB.10.1.316; JONES RE, 1980, J CELL BIOL, V86, P235, DOI 10.1083/jcb.86.1.235; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KISELEVA EV, 1989, FEBS LETT, V257, P251, DOI 10.1016/0014-5793(89)81545-5; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUMAR A, 1975, J MOL BIOL, V96, P353, DOI 10.1016/0022-2836(75)90165-5; LEZZI M, 1981, CHROMOSOMA, V83, P327, DOI 10.1007/BF00327356; LONNROTH A, 1992, EXP CELL RES, V199, P292, DOI 10.1016/0014-4827(92)90437-D; MARTIN TE, 1980, CELL BIOL COMPREHENS, P137; MATUNIS EL, 1993, J CELL BIOL, V121, P219, DOI 10.1083/jcb.121.2.219; MATUNIS EL, 1994, P NATL ACAD SCI USA, V91, P2781, DOI 10.1073/pnas.91.7.2781; MATUNIS EL, 1992, J CELL BIOL, V116, P257, DOI 10.1083/jcb.116.2.257; MATUNIS MJ, 1992, J CELL BIOL, V116, P245, DOI 10.1083/jcb.116.2.245; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; Mehlin Hans, 1993, Trends in Cell Biology, V3, P443, DOI 10.1016/0962-8924(93)90034-X; MILLER OL, 1972, ACTA ENDOCRINOL-COP, P155; MINIKH V B, 1985, Biokhimiya, V50, P604; Pinol-Roma Serafin, 1993, Trends in Cell Biology, V3, P151, DOI 10.1016/0962-8924(93)90135-N; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1989, METHOD ENZYMOL, V180, P410; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RAYCHAUDHURI G, 1992, MOL CELL BIOL, V12, P847, DOI 10.1128/MCB.12.2.847; RICE CM, 1993, NUCLEIC ACIDS RES, V21, P2967, DOI 10.1093/nar/21.13.2967; RISAU W, 1983, CELL, V33, P529, DOI 10.1016/0092-8674(83)90434-8; SHEN J, 1995, P NATL ACAD SCI USA, V92, P1822, DOI 10.1073/pnas.92.6.1822; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SKOGLUND U, 1983, CELL, V34, P847, DOI 10.1016/0092-8674(83)90542-1; SKOGLUND U, 1986, NATURE, V319, P560, DOI 10.1038/319560a0; SPIRIN AS, 1985, TRENDS BIOCHEM SCI, V10, P162, DOI 10.1016/0968-0004(85)90158-6; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; THOMAS JO, 1983, J MOL BIOL, V171, P439, DOI 10.1016/0022-2836(83)90039-6; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WIESLANDER L, 1994, PROG NUCLEIC ACID RE, V48, P275, DOI 10.1016/S0079-6603(08)60858-2; WURTZ T, 1990, P NATL ACAD SCI USA, V87, P831, DOI 10.1073/pnas.87.2.831; WURTZ T, 1996, IN PRESS MOL CELL BI; WYSS C, 1982, EXP CELL RES, V139, P309, DOI 10.1016/0014-4827(82)90255-5	60	208	214	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					253	264		10.1016/S0092-8674(00)80980-0	http://dx.doi.org/10.1016/S0092-8674(00)80980-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565071	Bronze			2022-12-24	WOS:A1996TR59500012
J	Carpenter, PB; Mueller, PR; Dunphy, WG				Carpenter, PB; Mueller, PR; Dunphy, WG			Role for a Xenopus Orc2-related protein in controlling DNA replication	NATURE			English	Article							ORIGIN RECOGNITION COMPLEX; SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; CELL-CYCLE; INVITRO; SYSTEM; EGGS; PHOSPHORYLATION; INITIATION; MITOSIS	THE six-subunit origin recognition complex (ORC) is essential for the initiation of DNA replication at specific origins in the budding yeast Saccharomyces cerevisiae(1-9). An important issue is whether DNA replication in higher eukaryotes, in which the characteristics of replication origins are poorly defined(10), occurs by an ORC-dependent mechanism, We have identified a Xenopus laevis Orc2-related protein (XORC2) by its ability to rescue a mitotic-catastrophe mutant of the fission yeast Schizosaccharomyces pombe, We show that immunodepletion of XORC2 from Xenopus egg extracts(11-13) abolishes the replication of chromosomal DNA but not elongation synthesis on a single-stranded DNA template, Indirect immunofluorescence indicates that XORC2 binds to chromatin well before the commencement of DNA synthesis, and even under conditions that prevent the association of replication licensing factor(s) with the DNA. These findings suggest that Orc2 plays an important role at an early step of chromosomal replication in animal cells.	CALTECH, HOWARD HUGHES MED INST, DIV BIOL 21676, PASADENA, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute			Mueller, Paul/B-6699-2012					ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; ALLSHIRE RC, 1990, P NATL ACAD SCI USA, V87, P4043, DOI 10.1073/pnas.87.11.4043; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; FANG F, 1993, J CELL SCI, V106, P983; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; KORNBLUTH S, 1992, MOL CELL BIOL, V12, P3216, DOI 10.1128/MCB.12.7.3216; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MECHALI M, 1982, CELL, V30, P93, DOI 10.1016/0092-8674(82)90015-0; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MILLS AD, 1989, J CELL SCI, V94, P471; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; ZUBER M, 1989, EXP CELL RES, V182, P384, DOI 10.1016/0014-4827(89)90243-7	30	180	181	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	1996	379	6563					357	360		10.1038/379357a0	http://dx.doi.org/10.1038/379357a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552193				2022-12-24	WOS:A1996TR32300062
J	Takai, T; Ono, M; Hikida, M; Ohmori, H; Ravetch, JV				Takai, T; Ono, M; Hikida, M; Ohmori, H; Ravetch, JV			Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice	NATURE			English	Article							IMMUNOGLOBULIN; LYMPHOCYTES; RECEPTORS; CELLS	DESPITE its widespread distribution on both lymphoid and myeloid cells, the biological role of the low-affinity immunoglobulin-G receptor, Fc gamma RII, is not fully understood. Defects in this receptor or its signalling pathway in B cells result in perturbations in immune-complex-mediated feedback inhibition of antibody production(1-6). We now report that Fc gamma RII-deficient animals display elevated immunoglobulin levels in response to both thymus-dependent and thymus-independent antigens. Additionally, the effector arm of the allergic response is perturbed in these mice, Mast cells from Fc gamma RII(-/-) are highly sensitive to IgG-triggered degranulation, in contrast to their wild-type counterparts, Fc gamma RII-deficient mice demonstrate an enhanced passive cutaneous analphylaxis reaction, the result of a decreased threshold for mast-cell activation by Fc gamma RIII crosslinking, These results demonstrate that Fc gamma RII acts as a general negative regulator of immune-complex-triggered activation in vivo for both the afferent and efferent limbs of the immune response, Exploiting this property offers new therapeutic opportunities for the treatment of allergic and autoimmune disorders.	MEM SLOAN KETTERING CANC CTR,DIV MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	Takai, T (corresponding author), OKAYAMA UNIV,FAC ENGN,DEPT BIOTECHNOL,TSUSHIMA NAKA,OKAYAMA 700,JAPAN.		Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041				AMIGORENA S, 1992, SCIENCE, V243, P378; BIJSTERBOSCH MK, 1985, J EXP MED, V162, P1825, DOI 10.1084/jem.162.6.1825; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; DAERON M, 1992, J IMMUNOL, V149, P1365; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON S, 1995, IMMUNITY, V3, P635; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; LOBELL RB, 1993, J BIOL CHEM, V268, P1207; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; PHILIPPS NE, 1984, J IMMUNOL, V132, P327; QUI WQ, 1990, SCIENCE, V248, P732; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; WEINSHANK RL, 1988, J EXP MED, V167, P1909, DOI 10.1084/jem.167.6.1909; WILSON HA, 1987, J IMMUNOL, V138, P1712	17	685	754	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					346	349		10.1038/379346a0	http://dx.doi.org/10.1038/379346a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552190				2022-12-24	WOS:A1996TR32300059
J	Walworth, NC; Bernards, R				Walworth, NC; Bernards, R			rad-dependent response of the chk1-encoded protein kinase at the DNA damage checkpoint	SCIENCE			English	Article							SCHIZOSACCHAROMYCES-POMBE; ATAXIA-TELANGIECTASIA; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; GENE; REPAIR; CANCER; FAMILIES; MUTANTS; INSTABILITY	Exposure of eukaryotic cells to agents that generate DNA damage results in transient arrest of progression through the cell cycle. In fission yeast, the DNA damage checkpoint associated with cell cycle arrest before mitosis requires the protein kinase p56(chk1). DNA damage induced by ultraviolet light, gamma radiation, or a DNA-alkylating agent has now been shown to result in phosphorylation of p56(chk1). This phosphorylation decreased the mobility of p56(chk1) on SDS-polyacrylamide gel electrophoresis and was abolished by a mutation in the p56(chk1) catalytic domain, suggesting that it might represent autophosphorylation. Phosphorylation of p56(chk1) did not occur when other checkpoint genes were inactive. Thus, p56(chk1) appears to function downstream of several of the known Schizosaccharomyces pombe checkpoint gene products, including that encoded by rad3(+), a gene with sequence similarity to the ATM gene mutated in patients with ataxia telangiectasia. The phosphorylation of p56(chk1) provides an assayable biochemical response to activation of the DNA damage checkpoint in the G(2) phase of the cell cycle.	NETHERLANDS CANC INST,DIV MOLEC CARCINOGENESIS,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Walworth, Nancy/0000-0001-5940-8236; Bernards, Rene/0000-0001-8677-3423				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; BASI G, 1993, GENE, V114, P59; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BORRESEN AL, 1990, GENE CHROMOSOME CANC, V2, P339, DOI 10.1002/gcc.2870020412; Carr Andrew, COMMUNICATION; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FORD MD, 1984, MUTAT RES, V125, P115, DOI 10.1016/0027-5107(84)90038-1; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KUNKEL TA, 1987, METHOD ENZYMOL, V155, P166; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCCREADY S, 1993, MOL MICROBIOL, V10, P885, DOI 10.1111/j.1365-2958.1993.tb00959.x; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; MURRAY JM, 1991, NUCLEIC ACIDS RES, V19, P3525, DOI 10.1093/nar/19.13.3525; NASMYTH KA, 1977, CELL, V12, P101; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1981, NATURE, V292, P448; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; SUNNERHAGEN P, 1990, MOL CELL BIOL, V10, P3750, DOI 10.1128/MCB.10.7.3750; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; WALWORTH NC, UNPUB; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1993, GENETICS, V134, P63; WEINERT TA, 1994, GENE DEV, V8, P662; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	39	351	358	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					353	356		10.1126/science.271.5247.353	http://dx.doi.org/10.1126/science.271.5247.353			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553071	Green Submitted			2022-12-24	WOS:A1996TQ52800042
J	Eck, MJ; Pluskey, S; Trub, T; Harrison, SC; Shoelson, SE				Eck, MJ; Pluskey, S; Trub, T; Harrison, SC; Shoelson, SE			Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2	NATURE			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; FACTOR RECEPTOR-BETA; TYROSINE PHOSPHORYLATION; PROTEIN MODELS; ASSOCIATION; ACTIVATION; SUBUNIT; SYP	THE domain organization of many signalling proteins facilitates a segregation of binding, catalytic and regulatory functions(1,2). The mammalian SH2 domain protein tyrosine phosphatases (PTPs) contain tandem SH2 domains and a single carboxy-terminal catalytic domain(3). SH-PTP1 (PTP1C, HCP) and SH-PTP2 (Syp, PTP2C, PTP1D) function downstream from tyrosine kinase-linked insulin, growth factor, cytokine and antigen receptors(4-12). As well as directing subcellular localization by binding to receptors and their substrates, the two SH2 domains of these PTPs function together to regulate catalysis(7,13,14). Here we report the structure of the tandem SH2 domains of SH-PTP2 in complex with monophosphopeptides. A fixed relative orientation of the two domains, stabilized by a disulphide bond and a small hydrophobic patch within the interface, separates the peptide binding sites by similar to 40 Angstrom. The defined orientation of the SH2 domains in the structure, and data showing that peptide orientation and spacing between binding sites is critical for enzymatic activation, suggest that spatial constraints are important in this multidomain protein-protein interaction.	HARVARD UNIV,CHILDRENS HOSP,MOLEC MED LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Eck, MJ (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115, USA.							BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BRUNGER AT, 1992, XPLOR VERSION 2 1 SY; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CASE RD, 1994, J BIOL CHEM, V269, P10467; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; NAVAZA J, 1992, MOL REPLACEMENT, P87; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577	30	164	168	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					277	280		10.1038/379277a0	http://dx.doi.org/10.1038/379277a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538796				2022-12-24	WOS:A1996TQ16900052
J	FitzGerald, MG; MacDonald, DJ; Krainer, M; Hoover, I; ONeil, E; Unsal, H; SilvaArrieto, S; Finkelstein, DM; BeerRomero, P; Englert, C; Sgroi, DC; Smith, BL; Younger, JW; Garber, JE; Duda, RB; Mayzel, KA; Isselbacher, KJ; Friend, SH; Haber, DA				FitzGerald, MG; MacDonald, DJ; Krainer, M; Hoover, I; ONeil, E; Unsal, H; SilvaArrieto, S; Finkelstein, DM; BeerRomero, P; Englert, C; Sgroi, DC; Smith, BL; Younger, JW; Garber, JE; Duda, RB; Mayzel, KA; Isselbacher, KJ; Friend, SH; Haber, DA			Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICAL PROGRESS; FAMILIAL BREAST; LINKAGE; HISTORY; RISK	Background. Mutations in a germ-line allele of the BRCA1 gene contribute to the familial breast cancer syndrome. However, the prevalence of these mutations is unknown in women with breast cancer who do not have the features of this familial syndrome. We sought BRCA1 mutations in women who were given a diagnosis of breast cancer at an early age, because early onset is characteristic of a genetic predisposition to cancer. Methods. Clinical information and peripheral-blood mononuclear cells were obtained from 418 women from the Boston metropolitan area in whom breast cancer was diagnosed at or before the age of 40. A comprehensive BRCA1 mutational analysis, involving automated nucleotide sequencing and a protein-truncation assay, was undertaken in 30 of these women, who had breast cancer before the age of 30. In addition, the BRCA1 mutation 185delAG, which is prevalent in the Ashkenazi Jewish population, was sought with an allele-specific polymerase-chain-reaction assay in 39 Jewish women among the 418 women who had breast cancer at or before the age of 40. Results. Among 30 women with breast cancer before the age of 30, 4 (13 percent) had definite, chain-terminating mutations and 1 had a missense mutation. Two of the four Jewish women in this cohort had the 185delAG mutation, Among the 39 Jewish women with breast cancer at or before the age of 40, 8 (21 percent) carried the 185delAG mutation (95 percent confidence interval, 9 to 36 percent). Conclusions. Germ-line BRCA1 mutations can be present in young women with breast cancer who do not belong to families with multiple affected members. The specific BRCA1 mutation known as 185delAG is strongly associated with the onset of breast cancer in Jewish women before the age of 40.	MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MED & SURG ONCOL,BOSTON,MA 02114; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; DANA FARBER CANC INST,BOSTON,MA 02115; BETH ISRAEL HOSP,BOSTON,MA 02215; FAULKNER HOSP,BOSTON,MA 02130; CTR CANC RISK ANAL,BOSTON,MA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center			Sgroi, Dennis/AAV-2487-2021	Krainer, Michael/0000-0002-7011-4957; Englert, Christoph/0000-0002-5931-3189				CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLAUS EB, 1991, AM J HUM GENET, V48, P232; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P1548; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; EASTON DF, 1993, AM J HUM GENET, V52, P678; Fleiss JL, 1981, STAT METHODS RATES P; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GOLDGAR DE, 1995, NAT GENET, V11, P113, DOI 10.1038/ng1095-113; HABER DA, 1991, CELL, V64, P5, DOI 10.1016/0092-8674(91)90200-I; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HARRIS JR, 1992, NEW ENGL J MED, V327, P390, DOI 10.1056/NEJM199208063270606; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RIES LAG, 1994, NIH942789 PUBL; ROWELL S, 1994, AM J HUM GENET, V55, P861; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; SLATTERY ML, 1993, JAMA-J AM MED ASSOC, V270, P1563, DOI 10.1001/jama.270.13.1563; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119	27	331	339	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	1996	334	3					143	149		10.1056/NEJM199601183340302	http://dx.doi.org/10.1056/NEJM199601183340302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ017	8531968				2022-12-24	WOS:A1996TQ01700002
J	Leahy, DJ; Aukhil, I; Erickson, HP				Leahy, DJ; Aukhil, I; Erickson, HP			2.0 angstrom crystal structure of a four-domain segment of human fibronectin encompassing the RGD loop and synergy region	CELL			English	Article							3-DIMENSIONAL STRUCTURE; ELECTRON-MICROSCOPY; PLASMA FIBRONECTIN; ANOMALOUS DIFFRACTION; CELL-ADHESION; HUMAN CD4; PROTEIN; BINDING; MOLECULE; TENASCIN	We have determined the 2.0 Angstrom crystal structure of a fragment of human fibronectin encompassing the seventh through the RGD-containing tenth type III repeats (FN7-10). The structure reveals an extended rod-like molecule with a long axis of similar to 140 Angstrom and highly variable relationships between adjacent domains, An unusually small rotation between domains 9 and 10 creates a distinctive binding site, in which the RGD loop from domain 10 and the ''synergy'' region from domain 9 are on the same face of FN7-10 and thus easily accessible to a single integrin molecule. The cell-binding RGD loop is well-ordered in this structure and extends similar to 10 Angstrom away from the FN7-10 core.	UNIV N CAROLINA, DEPT PERIODONT, CHAPEL HILL, NC 27514 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University	Leahy, DJ (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOPHYS & BIOPHYS CHEM, BALTIMORE, MD 21218 USA.				NATIONAL CANCER INSTITUTE [R01CA047056, R37CA047056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007801] Funding Source: NIH RePORTER; NCI NIH HHS [CA47056] Funding Source: Medline; NHLBI NIH HHS [HL51202] Funding Source: Medline; NIDCR NIH HHS [DE7801] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; AOTA S, 1991, J BIOL CHEM, V266, P15938; AOTA S, 1994, J BIOL CHEM, V269, P24756; AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CHAN AWE, 1993, PROTEIN SCI, V2, P1574, DOI 10.1002/pro.5560021004; CONSTANTINE KL, 1992, J MOL BIOL, V223, P281, DOI 10.1016/0022-2836(92)90731-X; CRAIG WS, 1995, BIOPOLYMERS, V37, P157, DOI 10.1002/bip.360370209; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; DOOLITTLE RF, 1986, URFS ORFS; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; ERICKSON HP, 1983, J BIOL CHEM, V258, P4539; ERICKSON HP, 1981, J CELL BIOL, V91, P673, DOI 10.1083/jcb.91.3.673; GURRATH M, 1992, EUR J BIOCHEM, V210, P911, DOI 10.1111/j.1432-1033.1992.tb17495.x; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; Hynes RO, 1990, FIBRONECTINS; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSHI P, 1993, J CELL SCI, V106, P389; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOSSIAKOFF AA, 1992, PROTEINS, V14, P65, DOI 10.1002/prot.340140108; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREZEL AM, 1994, SCIENCE, V264, P1944, DOI 10.1126/science.8009227; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAI CS, 1993, J MOL BIOL, V230, P625, DOI 10.1006/jmbi.1993.1174; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEAHY DJ, 1994, PROTEINS, V19, P48, DOI 10.1002/prot.340190107; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LITVINOVICH SV, 1995, J MOL BIOL, V248, P611, DOI 10.1006/jmbi.1995.0246; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; POTTS JR, 1994, CURR OPIN CELL BIOL, V6, P648, DOI 10.1016/0955-0674(94)90090-6; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROCCO M, 1983, J BIOL CHEM, V258, P4545; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; RYU SE, 1994, STRUCTURE, V2, P59, DOI 10.1016/S0969-2126(00)00008-3; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAMKUN JW, 1984, P NATL ACAD SCI-BIOL, V81, P5140, DOI 10.1073/pnas.81.16.5140; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS MJ, 1994, J MOL BIOL, V235, P1302, DOI 10.1006/jmbi.1994.1083; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YAMADA T, 1995, J BIOL CHEM, V270, P5687, DOI 10.1074/jbc.270.11.5687	58	580	605	1	35	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	1996	84	1					155	164		10.1016/S0092-8674(00)81002-8	http://dx.doi.org/10.1016/S0092-8674(00)81002-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548820	hybrid			2022-12-24	WOS:A1996TQ17000018
J	Sullivan, DJ; Gluzman, IY; Goldberg, DE				Sullivan, DJ; Gluzman, IY; Goldberg, DE			Plasmodium hemozoin formation mediated by histidine-rich proteins	SCIENCE			English	Article							FALCIPARUM INFECTED ERYTHROCYTES; MALARIA PARASITES; FERRIPROTOPORPHYRIN-IX; HEME POLYMERASE; GLYCOPROTEIN; CHLOROQUINE; IDENTIFICATION; SEQUENCE; PIGMENT; CDNA	The digestive vacuole of Plasmodium falciparum is the site of hemoglobin degradation, heme polymerization into crystalline hemozoin, and antimalarial drug accumulation. Antibodies identified histidine-rich protein II (HRP II) in purified digestive vacuoles. Recombinant or native HRP II promoted the formation of hemozoin, and chloroquine inhibited the reaction. The related HRP III also polymerized heme, and an additional HRP was identified in vacuoles. It is proposed that after secretion by the parasite into the host erythrocyte cytosol, HRPs are brought into the acidic digestive vacuole along with hemoglobin. After hemoglobin proteolysis, HRPs bind the liberated heme and mediate hemozoin formation.	WASHINGTON UNIV,SCH MED,DEPT MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital					NIAID NIH HHS [AI-31615] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031615] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BURCH MK, 1985, BIOCHEMISTRY-US, V24, P5919, DOI 10.1021/bi00342a034; CHOU AC, 1980, BIOCHEMISTRY-US, V19, P1543, DOI 10.1021/bi00549a600; CHOU AC, 1992, LIFE SCI, V51, P2073, DOI 10.1016/0024-3205(92)90158-L; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; CREEDON KA, 1994, J BIOL CHEM, V269, P16364; DORN A, 1995, NATURE, V374, P269, DOI 10.1038/374269a0; EGAN TJ, 1994, FEBS LETT, V352, P54, DOI 10.1016/0014-5793(94)00921-X; FITCH CD, 1982, ANTIMICROB AGENTS CH, V21, P819, DOI 10.1128/AAC.21.5.819; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; Goldberg Daniel E., 1993, Seminars in Cell Biology, V4, P355, DOI 10.1006/scel.1993.1042; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; HARLOW E, 1988, ANTIBODIES LABORATOR; HOWARD RJ, 1986, J CELL BIOL, V103, P1269, DOI 10.1083/jcb.103.4.1269; KATAGIRI M, 1987, BIOCHEM BIOPH RES CO, V149, P1070, DOI 10.1016/0006-291X(87)90517-1; KOIDE T, 1986, BIOCHEMISTRY-US, V25, P2220, DOI 10.1021/bi00356a055; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENSTRA R, 1987, BIOCHEM BIOPH RES CO, V146, P368, DOI 10.1016/0006-291X(87)90734-0; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; MORGAN WT, 1985, BIOCHEMISTRY-US, V24, P1496, DOI 10.1021/bi00327a031; MULLER HM, 1993, EMBO J, V12, P2881, DOI 10.1002/j.1460-2075.1993.tb05950.x; OLLIARO PL, 1995, PARASITOL TODAY, V11, P294, DOI 10.1016/0169-4758(95)80042-5; ORJIH AU, 1981, SCIENCE, V214, P667, DOI 10.1126/science.7027441; PANTON LJ, 1989, MOL BIOCHEM PARASIT, V35, P149, DOI 10.1016/0166-6851(89)90117-5; PARRA ME, 1991, J CLIN MICROBIOL, V29, P1629, DOI 10.1128/JCM.29.8.1629-1634.1991; POLOGE LG, 1988, CELL, V55, P869, DOI 10.1016/0092-8674(88)90142-0; ROCK EP, 1987, PARASITOLOGY, V95, P209, DOI 10.1017/S0031182000057681; Sambrook J., 1989, MOL CLONING LAB MANU; Scheibel L. W., 1988, Malaria: principles and practice of malariology. Volume 1., P219; SCHWARZER E, 1992, J EXP MED, V176, P1033, DOI 10.1084/jem.176.4.1033; SHIFF CJ, 1993, T ROY SOC TROP MED H, V87, P646, DOI 10.1016/0035-9203(93)90273-S; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; STAHL HD, 1985, NUCLEIC ACIDS RES, V13, P7837, DOI 10.1093/nar/13.21.7837; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Sullivan D.J., UNPUB; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDERJAGT DI, 1986, MOL BIOCHEM PARASIT, V18, P389, DOI 10.1016/0166-6851(86)90095-2; WALKERJONAH A, 1992, MOL BIOCHEM PARASIT, V51, P313, DOI 10.1016/0166-6851(92)90081-T; WELLEMS TE, 1986, P NATL ACAD SCI USA, V83, P6065, DOI 10.1073/pnas.83.16.6065; WELLEMS TE, 1991, P NATL ACAD SCI USA, V88, P3382, DOI 10.1073/pnas.88.8.3382	43	346	354	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					219	222		10.1126/science.271.5246.219	http://dx.doi.org/10.1126/science.271.5246.219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539625				2022-12-24	WOS:A1996TP36400047
J	Gunel, M; Awad, IA; Finberg, K; Anson, JA; Steinberg, GR; Batjer, PH; Kopitnik, TA; Morrison, L; Giannotta, SL; NelsonWilliams, C; Lifton, RP				Gunel, M; Awad, IA; Finberg, K; Anson, JA; Steinberg, GR; Batjer, PH; Kopitnik, TA; Morrison, L; Giannotta, SL; NelsonWilliams, C; Lifton, RP			A founder mutation as a cause of cerebral cavernous malformation in Hispanic Americans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATURAL-HISTORY; FAMILIAL OCCURRENCE; ANGIOMAS; BRAIN	Background. Cerebral cavernous malformation is a vascular disease of the brain causing headaches, seizures, and cerebral hemorrhage. Familial and sporadic cases are recognized, and a gene causing familial disease has been mapped to chromosome 7. Hispanic Americans have a higher prevalence of cavernous malformation than do other ethnic groups, raising the possibility that affected persons in this population have inherited the same mutation from a common ancestor. Methods. We compared the segregation of genetic markers and clinical cases of cavernous malformation in Hispanic-American kindreds with familial disease; we also compared the alleles for markers linked to cavernous malformation in patients with familial and sporadic cases. Results. All kindreds with familial disease showed linkage of cavernous malformation to a short segment of chromosome 7 (odds supporting linkage, 4x10(10):1), Forty-seven affected members of 14 kindreds shared identical alleles for up to 15 markers linked to the cavernous-malformation gene, demonstrating that they had inherited the same mutation from a common ancestor. Ten patients with sporadic cases also shared these same alleles, indicating that they too had inherited the same mutation. Thirty-three asymptomatic carriers of the disease gene were identified, demonstrating the variability and age dependence of the development of symptoms and explaining the appearance of apparently sporadic cases. Conclusions. Virtually all cases of familial and sporadic cavernous malformation among Hispanic Americans of Mexican descent are due to the inheritance of the same mutation from a common ancestor. (C) 1996, Massachusetts Medical Society.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,BOYER CTR MOLEC MED,NEW HAVEN,CT 06510; YALE UNIV,NEUROSURG SECT,NEW HAVEN,CT; YALE UNIV,DEPT CELL BIOL,NEW HAVEN,CT; YALE UNIV,DEPT MED & GENET,NEW HAVEN,CT; UNIV NEW MEXICO,DEPT NEUROSURG,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,DEPT NEUROL,ALBUQUERQUE,NM 87131; STANFORD UNIV,DEPT NEUROSURG,PALO ALTO,CA 94304; STANFORD UNIV,DEPT NEUROL,PALO ALTO,CA 94304; STANFORD UNIV,DEPT NEUROSURG,PALO ALTO,CA 94304; NORTHWESTERN UNIV,DEPT NEUROSURG,CHICAGO,IL 60611; UNIV TEXAS,SW MED CTR,DEPT NEUROSURG,DALLAS,TX 75235; UNIV SO CALIF,DEPT NEUROSURG,LOS ANGELES,CA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Yale University; University of New Mexico; University of New Mexico; Stanford University; Stanford University; Stanford University; Northwestern University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Southern California				Morrison, Leslie/0000-0002-0092-193X				Armitage P., 1987, STAT METHODS MED RES; Barrow D., 1993, CAVERNOUS MALFORMATI, P65; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BICKNELL JM, 1978, ARCH NEUROL-CHICAGO, V35, P746, DOI 10.1001/archneur.1978.00500350050010; CLARK JV, 1970, J NEUROL NEUROSUR PS, V33, P871, DOI 10.1136/jnnp.33.6.871; DELCURLING O, 1991, J NEUROSURG, V75, P702, DOI 10.3171/jns.1991.75.5.0702; DOBYNS WB, 1987, ANN NEUROL, V21, P578, DOI 10.1002/ana.410210609; DUBOVSKY J, 1995, HUM MOL GENET, V4, P453, DOI 10.1093/hmg/4.3.453; GANGEMI M, 1990, Neurological Research, V12, P131; GUNEL M, 1995, P NATL ACAD SCI USA, V92, P6620, DOI 10.1073/pnas.92.14.6620; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HASTBACKA J, 1992, NAT GENET, V2, P343; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; HAYMAN LA, 1982, AM J MED GENET, V11, P147, DOI 10.1002/ajmg.1320110205; HSU FPK, 1993, CAVERNOUS MALFORMATI, P13; HUHN SL, 1993, CAVERNOUS MALFORMATI, P87; JOHNSON PC, 1993, CAVERNOUS MALFORMATI, P1; KIDD HA, 1947, LANCET, V1, P747; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MASON I, 1988, NEUROLOGY, V38, P324, DOI 10.1212/WNL.38.2.324; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; Ojemann R G, 1993, Clin Neurosurg, V40, P98; OTTEN P, 1989, NEUROCHIRURGIE, V35, P82; PERL J, 1993, CAVERNOUS MALFORMATI, P37; RIGAMONTI D, 1987, J NEUROSURG, V67, P518, DOI 10.3171/jns.1987.67.4.0518; RIGAMONTI D, 1988, NEW ENGL J MED, V319, P343, DOI 10.1056/NEJM198808113190605; ROBINSON JR, 1993, NEUROSURGERY, V32, P730, DOI 10.1227/00006123-199305000-00005; ROBINSON JR, 1991, J NEUROSURG, V75, P709, DOI 10.3171/jns.1991.75.5.0709; Russell DS, 1989, PATHOLOGY TUMOURS NE, P730; SPENCER DD, 1984, NEUROLOGY, V34, P432, DOI 10.1212/WNL.34.4.432; STEICHENGERSDORF E, 1992, EUR J PEDIATR, V151, P861, DOI 10.1007/BF01957941; ZABRAMSKI JM, 1994, J NEUROSURG, V80, P422, DOI 10.3171/jns.1994.80.3.0422	32	172	179	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1996	334	15					946	951		10.1056/NEJM199604113341503	http://dx.doi.org/10.1056/NEJM199604113341503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD596	8596595				2022-12-24	WOS:A1996UD59600003
J	Campuzano, V; Montermini, L; Molto, MD; Pianese, L; Cossee, M; Cavalcanti, F; Monros, E; Rodius, F; Duclos, F; Monticelli, A; Zara, F; Canizares, J; Koutnikova, H; Bidichandani, SI; Gellera, C; Brice, A; Trouillas, P; DeMichele, G; Filla, A; DeFrutos, R; Palau, F; Patel, PI; DiDonato, S; Mandel, JL; Cocozza, S; Koenig, M; Pandolfo, M				Campuzano, V; Montermini, L; Molto, MD; Pianese, L; Cossee, M; Cavalcanti, F; Monros, E; Rodius, F; Duclos, F; Monticelli, A; Zara, F; Canizares, J; Koutnikova, H; Bidichandani, SI; Gellera, C; Brice, A; Trouillas, P; DeMichele, G; Filla, A; DeFrutos, R; Palau, F; Patel, PI; DiDonato, S; Mandel, JL; Cocozza, S; Koenig, M; Pandolfo, M			Friedreich's ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion	SCIENCE			English	Article							MYOTONIC-DYSTROPHY; MUTATION; DNA; IDENTIFICATION; CHROMOSOME-9; LINKAGE; GENE	Friedreich's ataxia (FRDA) is an autosomal recessive, degenerative disease that involves the central and peripheral nervous systems and the heart. A gene, X25, was identified in the critical region for the FRDA locus on chromosome 9q13. The gene encodes a 210-amino acid protein, frataxin, that has homologs in distant species such as Caenorhabditis elegans and yeast. A few FRDA patients were found to have point mutations in X25, but the majority were homozygous for an unstable GAA trinucleotide expansion in the first X25 intron.	UNIV STRASBOURG 1,INST BIOL & BIOL MOLEC & CELLULAIRE,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE; CNRS,F-67404 ILLKIRCH GRAFFENS,FRANCE; CHU,F-67404 ILLKIRCH GRAFFENS,FRANCE; BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030; UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,I-80131 NAPLES,ITALY; CNR,CTR ENDOCRINOL ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; IST MEDITERRANEO NEUROSCI SANATRIX,I-86077 POZZILLI,ISERNIA,ITALY; UNIV HOSP LA FE,UNIDAD GENET,E-46006 VALENCIA,SPAIN; UNIV VALENCIA,DEPT GENET,E-46100 BURJASSOT,VALENCIA,SPAIN; IST NAZL NEUROL C BESTA,DIV BIOCHIM & GENET SISTEMA NERVOSO,I-20133 MILAN,ITALY; HOP LA PITIE SALPETRIERE,F-75651 PARIS 13,FRANCE; HOP NEUROL,F-69003 LYON,FRANCE; UNIV NAPLES FEDERICO II,DIV NEUROL 2,DIPARTIMENTO PATOL SISTEMA,I-80131 NAPLES,ITALY	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Baylor College of Medicine; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Valencia; IRCCS Istituto Neurologico Besta; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Lyon; University of Naples Federico II			brice, alexis/AAE-8275-2019; Di Donato, Stefano/B-9717-2012; Canizares, Joaquin/X-9702-2019; Zara, Federico/U-3477-2017; Canizares, Joaquin/M-3255-2014; Campuzano, V/G-1826-2014; Cavalcanti, Francesca/N-3901-2019; CAMPUZANO, VICTORIA/K-7883-2019; Brice, Alexis/A-2170-2009; Palau, Francesc/A-9391-2014; Campuzano, Victoria/ABG-7429-2020; Pandolfo, Massimo/B-2853-2010; Gellera, Cinzia/J-7887-2016; Cocozza, Sergio/F-6488-2010; Koutnikova, Hana/I-7758-2017; CAVALCANTI, FRANCESCA/I-3651-2014; Patel, Pragna/H-9129-2017	brice, alexis/0000-0002-0941-3990; Canizares, Joaquin/0000-0001-9002-5516; Zara, Federico/0000-0001-9744-5222; Canizares, Joaquin/0000-0001-9002-5516; Campuzano, V/0000-0001-8128-2641; Cavalcanti, Francesca/0000-0001-5769-4582; Palau, Francesc/0000-0002-8635-5421; Campuzano, Victoria/0000-0001-8128-2641; Gellera, Cinzia/0000-0002-3582-665X; CAVALCANTI, FRANCESCA/0000-0001-5769-4582; Patel, Pragna/0000-0003-3584-1072; Bidichandani, Sanjay/0000-0001-6191-6475; Molto, Maria Dolores/0000-0001-5219-2022; COSSEE, Mireille/0000-0002-5931-7454	NINDS NIH HHS [NS34192] Funding Source: Medline; Telethon [722] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034192] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BIDICHANDANI SI, UNPUB; CAMPUZANO V, UNPUB; CARVAJAL JJ, 1995, HUM MOL GENET, V4, P1411, DOI 10.1093/hmg/4.8.1411; CHAMBERLAIN S, 1988, NATURE, V334, P248, DOI 10.1038/334248a0; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; DUCLOS F, 1994, HUM MOL GENET, V3, P909, DOI 10.1093/hmg/3.6.909; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FINOCCHIARO G, 1988, NEUROLOGY, V38, P1292, DOI 10.1212/WNL.38.8.1292; Friedreich N, 1863, VIRCHOWS ARCH PATHOL, V26, P391, DOI 10.1515/9783112391280-017; FROHMAN MA, 1989, TECHNIQUE, V1, P165; FUJITA R, 1989, GENOMICS, V4, P110, DOI 10.1016/0888-7543(89)90323-6; GACY AM, 1995, CELL, V81, P533; GEOFFROY G, 1976, Canadian Journal of Neurological Sciences, V3, P279; GEOFFROY G, 1984, HEREDITARY ATAXIAS R; HANAUER A, 1990, AM J HUM GENET, V46, P133; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; HARDING AE, 1983, Q J MED, V52, P489; HEWER RL, 1968, BRIT MED J, V3, P649, DOI 10.1136/bmj.3.5619.649; HOFFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166; HUGHES JT, 1968, BRAIN, V91, P803, DOI 10.1093/brain/91.4.803; IMBERT G, 1993, NAT GENET, V4, P72, DOI 10.1038/ng0593-72; JITPIMOLMARD S, 1993, ACTA NEUROPATHOL, V86, P29, DOI 10.1007/BF00454895; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KLOCKGETHER T, 1990, J NEUROL NEUROSUR PS, V53, P297, DOI 10.1136/jnnp.53.4.297; KOCH KS, 1995, NUCLEIC ACIDS RES, V23, P1098, DOI 10.1093/nar/23.7.1098; LAMARCHE JB, 1984, CAN J NEUROL SCI, V11, P592, DOI 10.1017/S0317167100035113; MANDEL JL, 1994, NAT GENET, V7, P453, DOI 10.1038/ng0894-453; MONROS E, UNPUB; MONTERMINI L, 1995, AM J HUM GENET, V57, P1061; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; OHOY KL, 1993, SCIENCE, V259, P809, DOI 10.1126/science.8094260; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PANDOLFO M, 1994, BIOCHEM MED METAB B, V52, P115, DOI 10.1006/bmmb.1994.1041; PENTLAND B, 1983, J NEUROL NEUROSUR PS, V46, P1138, DOI 10.1136/jnnp.46.12.1138; ROMEO G, 1983, AM J HUM GENET, V35, P523; SAID G, 1986, NEUROLOGY, V36, P1292, DOI 10.1212/WNL.36.10.1292; Saleeba Jennifer A., 1992, Human Mutation, V1, P63, DOI 10.1002/humu.1380010110; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHELBOURNE P, 1992, HUM MOL GENET, V1, P467, DOI 10.1093/hmg/1.7.467; SKRE H, 1975, CLIN GENET, V7, P287; SOLOVYEV VV, 1994, COMPUT APPL BIOSCI, V10, P661; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WALDMANN TA, 1983, ANN INTERN MED, V99, P367, DOI 10.7326/0003-4819-99-3-367	49	2147	2219	3	126	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1423	1427		10.1126/science.271.5254.1423	http://dx.doi.org/10.1126/science.271.5254.1423			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596916				2022-12-24	WOS:A1996TY96100048
J	Mittal, R; Erickson, JW; Cerione, RA				Mittal, R; Erickson, JW; Cerione, RA			Uncoupling of GTP binding from target stimulation by a single mutation in the transducin alpha subunit	SCIENCE			English	Article							INTRINSIC FLUORESCENCE; REGULATORY PROTEINS; ACTIVATION; PHOSPHODIESTERASE; DEACTIVATION; KINETICS; CGMP	Glutamic acid-203 of the alpha subunit of transducin (alpha(T)) resides within a domain that undergoes a guanosine triphosphate (GTP)-induced conformational change that is essential for effector recognition. Changing the glutamic acid to an alanine in bovine alpha(T) yielded an alpha subunit (alpha(T)E203A) that was fully dependent on rhodopsin for GTP-guanosine diphosphate (GDP) exchange and showed GTP hydrolytic activity similar to that measured for wild-type alpha(T). However, unlike the wild-type protein, the GDP-bound form of alpha(T)E203A was constitutively active toward the effector of transducin, the cyclic guanosine monophosphate phosphodiesterase. Thus, the alpha(T)E203A mutant represents a short-circuited protein switch that no longer requires GTP for the activation of the effector target phosphodiesterase.	CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853	Cornell University								ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOSWAMI BB, 1991, BIOTECHNIQUES, V5, P626; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; MITTAL R, UNPUB; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; VANDOP C, 1984, J BIOL CHEM, V259, P23; YEE R, 1978, J BIOL CHEM, V253, P8902	16	19	19	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1413	1416		10.1126/science.271.5254.1413	http://dx.doi.org/10.1126/science.271.5254.1413			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596913				2022-12-24	WOS:A1996TY96100045
J	Smith, PL; Baukrowitz, T; Yellen, G				Smith, PL; Baukrowitz, T; Yellen, G			The inward rectification mechanism of the HERG cardiac potassium channel	NATURE			English	Article							K+ CHANNELS; INACTIVATION; CELLS	A human genetic defect associated with 'long Q-T syndrome', an abnormality of cardiac rhythm involving the repolarization of the action potential, was recently found to lie in the HERG gene, which codes for a potassium channel(1). The HERG K+ channel is unusual in that it seems to have the architectural plan of the depolarization-activated K+ channel family (six putative transmembrane segments), yet it exhibits rectification like that of the inward-rectifying K+ channels, a family with different molecular structure (two transmembrane segments)(2-4). We have studied HERG channels expressed in mammalian cells and find that this inward rectification arises from a rapid and voltage-dependent inactivation process that reduces conductance at positive voltages. The inactivation gating mechanism resembles that of C-type inactivation, often considered to be the 'slow inactivation' mechanism of other K+ channels. The characteristics of this gating suggest a specific role for this channel in the normal suppression of arrhythmias.	MASSACHUSETTS GEN HOSP,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Yellen, Gary/0000-0003-4228-7866; Baukrowitz, Thomas/0000-0003-4562-0505	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029693] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS029693] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BAUKROWITZ T, 1995, NEURON, V15, P951, DOI 10.1016/0896-6273(95)90185-X; Baukrowitz T, 1996, SCIENCE, V271, P653, DOI 10.1126/science.271.5249.653; CAO YW, 1995, J BIOL CHEM, V270, P17697, DOI 10.1074/jbc.270.30.17697; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1995, J GEN PHYSIOL, V105, P309, DOI 10.1085/jgp.105.3.309; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; JUNNAN ME, 1994, BIOTECHNIQUES, V17, P876; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; NICHOLS CG, 1994, J PHYSIOL-LONDON, V476, P399, DOI 10.1113/jphysiol.1994.sp020141; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SHIBASAKI T, 1987, J PHYSIOL-LONDON, V387, P227, DOI 10.1113/jphysiol.1987.sp016571; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; YELLEN G, 1994, BIOPHYS J, V66, P1068, DOI 10.1016/S0006-3495(94)80888-4; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	24	640	651	0	46	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					833	836		10.1038/379833a0	http://dx.doi.org/10.1038/379833a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587608				2022-12-24	WOS:A1996TX50100061
J	Bachman, JG; Alcser, KH; Doukas, DJ; Lichtenstein, RL; Corning, AD; Brody, H				Bachman, JG; Alcser, KH; Doukas, DJ; Lichtenstein, RL; Corning, AD; Brody, H			Attitudes of Michigan physicians and the public toward legalizing physician-assisted suicide and voluntary euthanasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIE	Background. There has been a continuing public debate about assisted suicide and the proper role, if any, of physicians in this practice. Legislative bans and various forms of legalization have been proposed. Methods. We mailed questionnaires to three stratified random samples of Michigan physicians in specialties likely to involve the care of terminally ill patients: 500 in the spring of 1994, 500 in the summer of 1994, and 600 in the spring of 1995. Similar questionnaires were mailed to stratified random samples of Michigan adults: 449 in the spring of 1994 and 899 in the summer of 1994. Several different questionnaire forms were used, all of which included questions about whether physician-assisted suicide should be banned in Michigan or legalized under certain conditions. Results. Usable questionnaires were returned by 1119 of 1518 physicians eligible for the study (74 percent), and 998 of 1307 eligible adults in the sample of the general public (76 percent). Asked to choose between legalization of physician-assisted suicide and an explicit ban, 56 percent of physicians and 66 percent of the public supported legalization, 37 percent of physicians and 26 percent of the public preferred a ban, and 8 percent of each group were uncertain, When the physicians were given a wider range of choices, 40 percent preferred legalization, 37 percent preferred ''no law'' (i.e., no government regulation), 17 percent favored prohibition, and 5 percent were uncertain. If physician-assisted suicide were legal, 35 percent of physicians said they might participate if requested - 22 percent would participate in either assisted suicide or voluntary euthanasia, and 13 percent would participate only in assisted suicide. Support for physician-assisted suicide was lowest among the strongly religious. Conclusions. Most Michigan physicians prefer either the legalization of physician-assisted suicide or no law at all; fewer than one fifth prefer a complete ban on the practice, Given a choice between legalization and a ban, two thirds of the Michigan public prefer legalization and one quarter prefer a ban. (C) 1996, Massachusetts Medical Society.	UNIV MICHIGAN, SCH MED, DEPT FAMILY PRACTICE, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH PUBL HLTH, ANN ARBOR, MI 48109 USA; MICHIGAN STATE UNIV, CTR ETH & HUMANITIES LIFE SCI, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT FAMILY PRACTICE, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT PHILOSOPHY, E LANSING, MI 48824 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Michigan State University; Michigan State University; Michigan State University	Bachman, JG (corresponding author), UNIV MICHIGAN, INST SOCIAL RES, SURVEY RES CTR, ANN ARBOR, MI 48106 USA.		Doukas, David/ABB-9276-2021; Brody, Howard/GQA-6310-2022					ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; [Anonymous], 1978, MAIL TELEPHONE SURVE; BACHMAN JG, 1994, NEW ENGL J MED, V331, P812, DOI 10.1056/NEJM199409223311215; BATTIN MP, 1995, ACAD MED, V70, P583; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; FINLAY B, 1985, SOCIOL SOC RES, V69, P548; KAMISAR Y, 1993, HASTINGS CENT REP, V23, P32, DOI 10.2307/3563366; MCCARRICK P M, 1992, Kennedy Institute of Ethics Journal, V2, P79; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; MILLER FG, 1995, HASTINGS CENT REP, V25, P8, DOI 10.2307/3562107; Nunnally JC, 1978, PSYCHOMETRIC THEORY, V2nd, DOI DOI 10.1037/018882; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; Pellegrino E D, 1992, J Clin Ethics, V3, P95; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; Quill TE, 1993, DEATH DIGNITY MAKING; Schuman H., 1981, QUESTIONS ANSWERS AT; SCHWARZ N, 1992, CONTEXT AFFECTS SOCI; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; TENO J, 1991, J AM GERIATR SOC, V39, P827, DOI 10.1111/j.1532-5415.1991.tb02707.x; VOGT WP, 1993, DICT STATISTICS METH; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; WOOD FW, 1990, AM PROFILE OPINIONS; 1994, DEATH IS SOUGHT ASSI; 1991, J AM GERIATR SOC, V39, P826; 1994, FINAL REPORT MICHIGA	29	201	201	4	50	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					303	309		10.1056/NEJM199602013340506	http://dx.doi.org/10.1056/NEJM199602013340506			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV695	8532027				2022-12-24	WOS:A1996TV69500006
J	Lloyd, SE; Pearce, SHS; Fisher, SE; Steinmeyer, K; Schwappach, B; Scheinman, SJ; Harding, B; Bolino, A; Devoto, M; Goodyer, P; Rigden, SPA; Wrong, O; Jentsch, TJ; Craig, IW; Thakker, RV				Lloyd, SE; Pearce, SHS; Fisher, SE; Steinmeyer, K; Schwappach, B; Scheinman, SJ; Harding, B; Bolino, A; Devoto, M; Goodyer, P; Rigden, SPA; Wrong, O; Jentsch, TJ; Craig, IW; Thakker, RV			A common molecular basis for three inherited kidney stone diseases	NATURE			English	Article							LINKED RECESSIVE NEPHROLITHIASIS; MUSCLE CHLORIDE CHANNEL; EXPRESSION; MUTATIONS; GENE	KIDNEY stones (nephrolithiasis), which affect 12% of males and 5% of females in the western world, are familial in 45% of patients(1,2) and are most commonly associated with hypercalciuria(1). Three disorders of hypercalciuric nephrolithiasis (Dent's disease(3), X-linked recessive nephrolithiasis (XRN)(4), and X-linked recessive hypophosphataemic rickets (XLRH)(5)) have been mapped to Xp11.22 (refs 5-7). A microdeletion(6) in one Dent's disease kindred allowed the identification of a candidate gene, CLCN5 (refs 8,9) which encodes a putative renal chloride channel. Here we report the investigation of 11 kindreds with these renal tubular disorders for CLCN5 abnormalities; this identified three nonsense, four missense and two donor splice site mutations, together with one intragenic deletion and one microdeletion encompassing the entire gene. Heterologous expression of wild-type CLCN5 in Xenopus oocytes yielded outwardly rectifying chloride currents, which were either abolished or markedly reduced by the mutations. The common aetiology for Dent's disease, XRN and XLRH indicates that CLCN5 may be involved in other renal tubular disorders associated with kidney stones.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,MOLEC ENDOCRINOL GRP,LONDON W12 0NN,ENGLAND; UNIV OXFORD,GENET LAB,OXFORD OX1 3QU,ENGLAND; UNIV HAMBURG,CTR MOLEC NEUROBIOL,D-20246 HAMBURG,GERMANY; SUNY HLTH SCI CTR,DEPT MED,SYRACUSE,NY 13210; IST GIANNINA GASLINI,GENET MOLEC LAB,I-16148 GENOA,ITALY; HOP MONTREAL ENFANTS,MONTREAL,PQ H3H 1P3,CANADA; GUYS HOSP,DEPT PAEDIAT NEPHROL,LONDON SE1 9RT,ENGLAND; MIDDLESEX HOSP,DEPT NEPHROL,LONDON W1N 8AA,ENGLAND	Imperial College London; University of Oxford; University of Hamburg; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Genoa; IRCCS Istituto Giannina Gaslini; Guy's & St Thomas' NHS Foundation Trust; University of London; University College London			Pearce, Simon/AAB-3692-2019; Fisher, Simon E./E-9130-2012; Bolino, Alessandra/O-2933-2013; Bolino, Alessandra/AAN-5442-2020; Devoto, Marcella/AAP-7595-2021; Craig, Ian/AAF-9167-2019	Pearce, Simon/0000-0001-8384-8063; Fisher, Simon E./0000-0002-3132-1996; Bolino, Alessandra/0000-0002-8980-4878; Schwappach, Blanche/0000-0003-0225-6432; Jentsch, Thomas/0000-0002-3509-2553; DEVOTO, MARCELLA/0000-0002-4431-5114; Craig, Ian/0000-0002-4063-1005; Thakker, Rajesh/0000-0002-1438-3220				ADACHI S, 1994, J BIOL CHEM, V269, P17677; Bolino A., 1993, European Journal of Human Genetics, V1, P269; Brandt S, 1995, FEBS LETT, V377, P15, DOI 10.1016/0014-5793(95)01298-2; COE FL, 1992, NEW ENGL J MED, V327, P1141, DOI 10.1056/NEJM199210153271607; FISHER SE, 1995, GENOMICS, V29, P598, DOI 10.1006/geno.1995.9960; FISHER SE, 1994, HUM MOL GENET, V3, P2053; FRIEDMAN PA, 1995, PHYSIOL REV, V75, P429, DOI 10.1152/physrev.1995.75.3.429; FRYMOYER PA, 1991, NEW ENGL J MED, V325, P681, DOI 10.1056/NEJM199109053251003; GREENE JR, 1993, MOL GEN GENET, V241, P542, DOI 10.1007/BF00279896; HIGGINS JT, 1977, PFLUG ARCH EUR J PHY, V371, P87, DOI 10.1007/BF00580776; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482P, pS19; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; KREIG PA, 1984, NUCLEIC ACIDS RES, V12, P7057; MEYERKLEINE C, 1995, AM J HUM GENET, V57, P1325; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; POOK MA, 1993, HUM MOL GENET, V2, P2129, DOI 10.1093/hmg/2.12.2129; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; SAMBROOK J, 1989, LABORATORY MANUAL; SCHEINMAN SJ, 1993, J CLIN INVEST, V91, P2351, DOI 10.1172/JCI116467; SMITH LH, 1989, J UROLOGY, V141, P707, DOI 10.1016/S0022-5347(17)40990-6; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; Steinmeyer K, 1995, J BIOL CHEM, V270, P31172, DOI 10.1074/jbc.270.52.31172; THAKKER RV, 1993, J CLIN INVEST, V91, P2815, DOI 10.1172/JCI116524; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; WRONG OM, 1994, Q J MED, V87, P473	28	580	595	0	43	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					445	449		10.1038/379445a0	http://dx.doi.org/10.1038/379445a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559248	Green Submitted			2022-12-24	WOS:A1996TT30400058
J	Lukowitz, W; Mayer, U; Jurgens, G				Lukowitz, W; Mayer, U; Jurgens, G			Cytokinesis in the Arabidopsis embryo involves the syntaxin-related KNOLLE gene product	CELL			English	Article							VESICULAR TRANSPORT; THALIANA; EXPRESSION; DROSOPHILA; EPIMORPHIN; PROTEINS; CLONING; FAMILY; GENOME; LIGHT	The embryo of the flowering plant Arabidopsis develops by a regular pattern of cell divisions and cell shape changes. Mutations in the KNOLLE (KN) gene affect the rate and plane of cell divisions as well as cell morphology, resulting in mutant seedlings with a disturbed radial organization of tissue layers. At the cellular level, mutant embryos are characterized by incomplete cross walls and enlarged cells with polyploid nuclei, The KN gene was isolated by positional cloning. The predicted KN protein has similarity to syntaxins, a protein family involved in vesicular trafficking. During embryogenesis, KN transcripts are detected in patches of single cells or small cell groups. Our results suggest a function for KN in cytokinesis.	UNIV MUNICH, LEHRSTUHL GENET, INST GENET & MIKROBIOL, D-80638 MUNICH, GERMANY	University of Munich								AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; ASADA T, 1994, J CELL SCI, V107, P2249; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BASSHAM DC, 1995, P NATL ACAD SCI USA, V92, P7262, DOI 10.1073/pnas.92.16.7262; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BURKE TJ, 1988, MOL GEN GENET, V213, P435, DOI 10.1007/BF00339613; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; COX KH, 1988, PLANT MOL BIOL PRACT, P1; DASCHER C, 1994, J BIOL CHEM, V269, P29363; DUCKETT CM, 1994, DEVELOPMENT, V120, P3247; FISHKIND DJ, 1995, CURR OPIN CELL BIOL, V7, P23, DOI 10.1016/0955-0674(95)80041-7; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; GEBHARDT C, 1989, THEOR APPL GENET, V78, P65, DOI 10.1007/BF00299755; GIRAUDAT J, 1992, PLANT CELL, V4, P1251, DOI 10.1105/tpc.4.10.1251; Goodbody K. C., 1994, V139, P221; GUNNING BES, 1982, CYTOSKELETON PLANT G, P230; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HARRIS SD, 1994, GENETICS, V136, P517; HAUGE BM, 1993, PLANT J, V3, P745, DOI 10.1111/j.1365-313X.1993.00745.x; HEPLER PK, 1990, PROTOPLASMA, V157, P182, DOI 10.1007/BF01322651; HEPLER PK, 1967, J ULTRA MOL STRUCT R, V19, P498, DOI 10.1016/S0022-5320(67)80076-5; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HIME G, 1992, DEVELOPMENT, V114, P165; HIRAI Y, 1992, CELL, V69, P471, DOI 10.1016/0092-8674(92)90448-L; HWANG I, 1991, PLANT J, V1, P367, DOI 10.1046/j.1365-313X.1991.t01-5-00999.x; INOUE A, 1992, J BIOL CHEM, V267, P10613; JANTTI J, 1994, J CELL SCI, V107, P3623; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; Jurgens G, 1994, COLOUR ATLAS DEV EMB EMBRYOS COLOR ATLAS, P7; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Kimura M, 1985, NEUTRAL THEORY MOL E; KONING AJ, 1991, PLANT CELL, V3, P657, DOI 10.1105/tpc.3.7.657; KOOMNEEF M, 1983, ARABID INFO SERV, V20, P89; Lambert AM, 1993, CURR OPIN CELL BIOL, V5, P116, DOI 10.1016/S0955-0674(05)80016-X; LEHNER CF, 1992, J CELL SCI, V103, P1021; LEUTWILER LS, 1984, MOL GEN GENET, V194, P15, DOI 10.1007/BF00383491; LIU CM, 1995, DEV GENET, V16, P321, DOI 10.1002/dvg.1020160405; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAHEWSHWARI P, 1950, INTRO EMBRYOLOGY ANG; MANSFIELD SG, 1991, CAN J BOT, V69, P461, DOI 10.1139/b91-063; Matallana E., 1992, Methods in Arabidopsis research., P144; MAYER U, 1991, NATURE, V353, P402, DOI 10.1038/353402a0; MAYER U, 1993, DEVELOPMENT, V117, P149; MCINTOSH K, 1995, INT J PLANT SCI, V156, P1, DOI 10.1086/297222; MISERA S, 1994, MOL GEN GENET, V244, P242, DOI 10.1007/BF00285451; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; OWEN HA, 1995, PROTOPLASMA, V185, P7, DOI 10.1007/BF01272749; PELHAM HRB, 1993, CELL, V73, P425, DOI 10.1016/0092-8674(93)90128-D; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; Rogers SO., 1989, PLANT MOL BIOL MAN A, V10, P73, DOI [10.1007/978-94-009-0951-9_6, DOI 10.1007/978-94-017-5294-7_]; ROPER W, 1977, PROTOPLASMA, V93, P89, DOI 10.1007/BF01276284; Sambrook J., 1989, MOL CLONING LAB MANU; SCHERES B, 1995, DEVELOPMENT, V121, P53; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; SIMANIS V, 1995, SEMIN CELL BIOL, V6, P79, DOI 10.1016/1043-4682(95)90004-7; SPRING J, 1993, TRENDS BIOCHEM SCI, V18, P124, DOI 10.1016/0968-0004(93)90018-I; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Swofford D., 1998, PAUP PHYLOGENETIC AN; TIMBERLAKE W E, 1986, P343; TORRESRUIZ RA, 1994, DEVELOPMENT, V120, P2967; TREZZINI GF, 1993, PLANT MOL BIOL, V21, P385, DOI 10.1007/BF00019954; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757; Wick SM, 1991, CURR OPIN CELL BIOL, V3, P253, DOI 10.1016/0955-0674(91)90149-S	69	398	424	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	1996	84	1					61	71		10.1016/S0092-8674(00)80993-9	http://dx.doi.org/10.1016/S0092-8674(00)80993-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548827	Bronze			2022-12-24	WOS:A1996TQ17000009
J	Matsumoto, M; Nakagawa, T; Inoue, T; Nagata, E; Tanaka, K; Takano, H; Minowa, O; Kuno, J; Sakakibara, S; Yamada, M; Yoneshima, H; Miyawaki, A; Fukuuchi, Y; Furuichi, T; Okano, H; Mikoshiba, K; Noda, T				Matsumoto, M; Nakagawa, T; Inoue, T; Nagata, E; Tanaka, K; Takano, H; Minowa, O; Kuno, J; Sakakibara, S; Yamada, M; Yoneshima, H; Miyawaki, A; Fukuuchi, Y; Furuichi, T; Okano, H; Mikoshiba, K; Noda, T			Ataxia and epileptic seizures in mice lacking type 1 inositol 1,4,5-trisphosphate receptor	NATURE			English	Article							CEREBELLAR PURKINJE-CELLS; MOUSE CEREBELLUM; P400 PROTEIN; PURIFICATION; EXPRESSION; CURRENTS; INVITRO; SLICES	THE inositol 1,4,5-trisphosphate (InsP(3)) receptor acts as an InsP(3)-gated Ca2+ release channel in a variety of cell types(1,2). Type 1 InsP(3) receptor (IP(3)R1) is the major neuronal member of the IP(3)R family in the central nervous system(3,4), predominantly enriched in cerebellar Purkinje cells but also concentrated in neurons in the hippocampal CA1 region, caudate-putamen, and cerebral cortex(5,6). Here we report that most IP(3)R1-deficient mice generated by gene targeting die in utero, and born animals have severe ataxia and tonic or tonic-clonic seizures and die by the weaning period. An electroencephalogram showed that they suffer from epilepsy, indicating that IP(3)R1 is essential for proper brain function. However, observation by light microscope of the haematoxylin-eosin staining of the brain and peripheral tissues of IP(3)R1-deficient mice showed no abnormality, and the unique electrophysiological properties of the cerebellar Purkinje cells of IP(3)R1-deficient mice were not severely impaired.	UNIV TOKYO,INST MED SCI,DEPT MOLEC NEUROBIOL,MINATO KU,TOKYO 108,JAPAN; INST CANC RES,DEPT CELL BIOL,TOSHIMA KU,TOKYO 170,JAPAN; KEIO UNIV,SCH MED,DEPT NEUROL,SHINJUKU KU,TOKYO 160,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC NEUROBIOL LAB,TSUKUBA,IBARAKI 305,JAPAN; EXPLORATORY RES ADV TECHNOL,CALCIOSIGNAL NET PROJECT,MEGURO KU,TOKYO 153,JAPAN	University of Tokyo; Keio University; RIKEN			Miyawaki, Atsushi/K-3569-2014; Furuichi, Teiichi/B-5086-2014; Okano, Hideyuki/I-7584-2019; Minowa, Osamu/AAM-1238-2020; Inoue, Takafumi/AAM-9533-2020; Noda, Tetsuo/B-1667-2016; Yamada, Maki/U-5251-2019; Mikoshiba, Katsuhiko/N-7943-2015; Yamada, Maki/A-1573-2015	Miyawaki, Atsushi/0000-0002-2329-3235; Furuichi, Teiichi/0000-0002-9676-1888; Inoue, Takafumi/0000-0002-2728-0060; Yamada, Maki/0000-0002-1956-6069; Nakagawa, Toshiyuki/0000-0001-8415-4119; Sakakibara, Shin-ichi/0000-0001-8983-2249				AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CREPEL F, 1986, J PHYSIOL-LONDON, V372, P1; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; Eccles JC, 1967, CEREBELLUM NEURONAL; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1993, RECEPTOR CHANNEL, V1, P11; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P171, DOI 10.1113/jphysiol.1980.sp013357; Lyon M., 1989, GENETIC VARIANTS STR; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MAEDA N, 1989, DEV BIOL, V133, P67, DOI 10.1016/0012-1606(89)90297-2; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; NAGATA E, 1994, NEUROSCIENCE, V61, P983, DOI 10.1016/0306-4522(94)90418-9; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; NAKANISHI S, 1991, J NEUROSCI, V11, P2075; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YAMAMOTOHINO M, 1995, NEUROREPORT, V6, P273, DOI 10.1097/00001756-199501000-00012	24	341	348	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					168	171		10.1038/379168a0	http://dx.doi.org/10.1038/379168a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538767				2022-12-24	WOS:A1996TP36000059
J	Long, JA; Moan, EI; Medford, JI; Barton, MK				Long, JA; Moan, EI; Medford, JI; Barton, MK			A member of the KNOTTED class of homeodomain proteins encoded by the STM gene of Arabidopsis	NATURE			English	Article							MAIZE HOMEOBOX GENE; THALIANA; MUTATION; CELLS; SITE	THE KNOTTED class of plant genes encodes homeodomain proteins(1,2). These genes have been found in all plant species where they have been sought(3-5) and, where examined, show expression patterns that suggest they play an important role in shoot meristem function(5-7). Until now, all mutant phenotypes associated with these genes have been due to gain-of-function mutations(4,5,8,9), making it difficult to deduce their wild-type function. Here we present evidence that the Arabidopsis SHOOT-MERISTEMLESS (STM) gene, required for shoot apical meristem formation during embryogenesis, encodes a class I KNOTTED-like protein. We also describe the expression pattern of this gene in the wild-type plant. To our knowledge, STM is the first gene shown to mark a specific pattern element in the developing plant embryo both phenotypically and molecularly.	UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706; UNIV WISCONSIN,MOLEC & CELLULAR BIOL PROGRAM,MADISON,WI 53706; PENN STATE UNIV,DEPT BIOL,COLLEGE PARK,PA 16802	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University								AROIAN RV, 1993, MOL CELL BIOL, V13, P626, DOI 10.1128/MCB.13.1.626; BARTON MK, 1993, DEVELOPMENT, V119, P823; BECRAFT PW, 1994, GENETICS, V136, P295; Bowman J., 1994, ARABIDOPSIS ATLAS MO, P133; BURKE TJ, 1988, MOL GEN GENET, V213, P435, DOI 10.1007/BF00339613; FREELING M, 1985, GENETICS, V111, P617; JACKSON D, 1994, DEVELOPMENT, V120, P405; JURGENS G, 1995, CELL, V81, P467, DOI 10.1016/0092-8674(95)90065-9; Jurgens G, 1994, COLOUR ATLAS DEV EMB EMBRYOS COLOR ATLAS, P7; KERSTETTER R, 1994, PLANT CELL, V6, P1877, DOI 10.1105/tpc.6.12.1877; KUIPER MTR, 1988, J BIOL CHEM, V263, P2848; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; MA HC, 1994, PLANT MOL BIOL, V24, P465, DOI 10.1007/BF00024114; MANSFIELD SG, 1991, CAN J BOT, V69, P447, DOI 10.1139/b91-062; MCCONNELL JR, 1995, DEV GENET, V16, P358, DOI 10.1002/dvg.1020160409; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P1926, DOI 10.1128/MCB.6.6.1926; MULLER KJ, 1995, NATURE, V374, P727, DOI 10.1038/374727a0; SINHA N, 1993, GENE DEV, V7, P878; SMITH LG, 1992, DEVELOPMENT, V116, P21; VOLLBRECHT E, 1991, NATURE, V350, P241, DOI 10.1038/350241a0	20	1165	1247	10	185	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					66	69		10.1038/379066a0	http://dx.doi.org/10.1038/379066a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538741				2022-12-24	WOS:A1996TN21600055
J	Blangy, A; Lane, HA; dHerin, P; Harper, M; Kress, M; Nigg, EA				Blangy, A; Lane, HA; dHerin, P; Harper, M; Kress, M; Nigg, EA			Phosphorylation by p34(cdc2) regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo	CELL			English	Article							CELL-FREE-EXTRACTS; MITOTIC SPINDLE; MICROTUBULE DYNAMICS; ASPERGILLUS-NIDULANS; P34CDC2 KINASE; PROTEIN-KINASE; FISSION YEAST; GENE; CYCLE; IDENTIFICATION	We have isolated a human homolog of Xenopus Eg5, a kinesin-related motor protein implicated in the assembly and dynamics of the mitotic spindle. We report that microinjection of antibodies against human Eg5 (HsEg5) blocks centrosome migration and causes HeLa cells to arrest in mitosis with monoastral microtubule arrays. Furthermore, an evolutionarily conserved cdc2 phosphorylation site (Thr-927) in HsEg5 is phosphorylated specifically during mitosis in HeLa cells and by p34(cdc2)/cyclin B in vitro. Mutation of Thr-927 to nonphosphorylatable residues prevents HsEg5 from binding to centrosomes, indicating that phosphorylation controls the association of th is motor with the spindle apparatus. These results indicate that HsEg5 is required for establishing a bipolar spindle and that p34(cdc2) protein kinase directly regulates its localization.	CNRS, INST RECH CANC, F-94801 VILLEJUIF, FRANCE; UNIV GENEVA, DEPT MOLEC BIOL, CH-1211 GENEVA 4, SWITZERLAND	Centre National de la Recherche Scientifique (CNRS); University of Geneva	Blangy, A (corresponding author), SWISS INST EXPTL CANC RES, 155 CHEM BOVERESSES, CH-1066 EPALINGES, SWITZERLAND.			BLANGY, Anne/0000-0001-7043-0784; nigg, erich/0000-0003-4835-5719				AFSHAR K, 1995, CELL, V81, P129, DOI 10.1016/0092-8674(95)90377-1; AULT JG, 1994, CURR OPIN CELL BIOL, V6, P41, DOI 10.1016/0955-0674(94)90114-7; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN KD, 1994, J CELL BIOL, V125, P1303, DOI 10.1083/jcb.125.6.1303; DESAI A, 1995, J CELL BIOL, V128, P1, DOI 10.1083/jcb.128.1.1; ENDOW SA, 1992, ANNU REV CELL BIOL, V8, P29; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GOLDSTEIN LSB, 1993, J CELL BIOL, V120, P1, DOI 10.1083/jcb.120.1.1; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HOLLENBECK PJ, 1993, J NEUROCHEM, V60, P2265, DOI 10.1111/j.1471-4159.1993.tb03513.x; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; HOULISTON E, 1994, DEV BIOL, V164, P147, DOI 10.1006/dbio.1994.1187; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HOYT MA, 1994, CURR OPIN CELL BIOL, V6, P63, DOI 10.1016/0955-0674(94)90117-1; Hunt T, 1991, Semin Cell Biol, V2, P213; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; INOUE S, 1981, J CELL BIOL, V91, pS131, DOI 10.1083/jcb.91.3.131s; Karsenti E, 1991, Semin Cell Biol, V2, P251; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; MATTHIES HJG, 1993, J BIOL CHEM, V268, P11176; MCINTOSH JR, 1991, ANNU REV CELL BIOL, V7, P403, DOI 10.1146/annurev.cellbio.7.1.403; MCINTOSH JR, 1991, J CELL BIOL, V115, P577, DOI 10.1083/jcb.115.3.577; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOUDJOU M, 1991, J CELL BIOL, V115, P129, DOI 10.1083/jcb.115.1.129; MURPHY TD, 1995, CELL, V81, P139, DOI 10.1016/0092-8674(95)90378-X; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; NISLOW C, 1990, J CELL BIOL, V111, P511, DOI 10.1083/jcb.111.2.511; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCONNELL MJ, 1993, J CELL BIOL, V120, P153, DOI 10.1083/jcb.120.1.153; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; Saunders William S., 1993, Trends in Cell Biology, V3, P432, DOI 10.1016/0962-8924(93)90032-V; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; Sawin K E, 1991, Trends Cell Biol, V1, P122, DOI 10.1016/0962-8924(91)90117-R; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; THOMAS D, 1990, GENET ANAL-BIOMOL E, V7, P87, DOI 10.1016/0735-0651(90)90033-C; THROWER DA, 1995, EMBO J, V14, P918, DOI 10.1002/j.1460-2075.1995.tb07073.x; TIHY F, 1992, GENOMICS, V13, P1371, DOI 10.1016/0888-7543(92)90075-4; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	69	746	796	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1159	1169		10.1016/0092-8674(95)90142-6	http://dx.doi.org/10.1016/0092-8674(95)90142-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548803	Bronze			2022-12-24	WOS:A1995TM76200012
J	Li, ZY; Otevrel, T; Gao, YJ; Cheng, HL; Seed, B; Stamato, TD; Taccioli, GE; Alt, FW				Li, ZY; Otevrel, T; Gao, YJ; Cheng, HL; Seed, B; Stamato, TD; Taccioli, GE; Alt, FW			The XRCC4 gene encodes a novel protein involved in DNA double-strand break repair and V(D)J recombination	CELL			English	Article							HAMSTER OVARY CELL; PRE-B CELLS; CYCLE-DEPENDENT REPAIR; RAY-SENSITIVE MUTANTS; LIGHT CHAIN GENES; IONIZING-RADIATION; SCID MUTATION; MOUSE THYMOCYTES; MICE; REARRANGEMENT	The XR-1 Chinese hamster ovary cell line is impaired in DNA double-strand break repair (DSBR) and in ability to support V(D)J recombination of transiently introduced substrates. We now show that XR-1 cells support recombination-activating gene 1- and 2-mediated initiation of V(D)J recombination within chromosomally integrated substrate, but are highly impaired in ability to complete the process by forming coding and recognition sequence joins. On this basis, we isolated a human cDNA sequence, termed XRCC4, whose expression confers normal V(D)J recombination ability and significant restoration of DSBR activity to XR-1, clearly demonstrating that this gene product is involved in both processes. The XRCC4 gene maps to the previously identified locus on human chromosome 5, is deleted in XR-1 cells, and encodes a ubiquitously expressed product unrelated to any described protein.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; LANKENAU MED RES CTR,WYNNEWOOD,PA 19096	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Lankenau Medical Center; Lankenau Institute for Medical Research	Li, ZY (corresponding author), HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115, USA.				NCI NIH HHS [CA58301] Funding Source: Medline; NIAID NIH HHS [AI20047, AI35714] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020047, P01AI035714, R01AI020047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; ALT FW, 1982, NATURE, V296, P325, DOI 10.1038/296325a0; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; DERBYSHIRE MK, 1994, MOL CELL BIOL, V14, P156, DOI 10.1128/MCB.14.1.156; FAIRMAN MP, 1992, NUCLEIC ACIDS RES, V20, P4145, DOI 10.1093/nar/20.16.4145; FERRIER P, 1990, J EXP MED, V171, P1909, DOI 10.1084/jem.171.6.1909; FINIE NJ, 1995, P NATL ACAD SCI USA, V92, P320; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GELLERT M, 1995, PHILOS T ROY SOC B, V347, P43, DOI 10.1098/rstb.1995.0007; GERSTEIN RM, 1993, NATURE, V363, P625, DOI 10.1038/363625a0; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GIACCIA A, 1985, SOMAT CELL MOLEC GEN, V11, P485, DOI 10.1007/BF01534842; GIACCIA AJ, 1990, AM J HUM GENET, V47, P459; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; GLIMCHER LH, 1982, NATURE, V298, P283, DOI 10.1038/298283a0; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HENDRICKSON EA, 1990, MOL CELL BIOL, V10, P5397, DOI 10.1128/MCB.10.10.5397; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; JEGGO PA, 1991, MUTAT RES, V254, P125, DOI 10.1016/0921-8777(91)90003-8; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; JEGGO PA, 1983, MUTAT RES, V112, P313, DOI 10.1016/0167-8817(83)90026-3; JEGGO PA, 1992, P NATL ACAD SCI USA, V89, P6423, DOI 10.1073/pnas.89.14.6423; JONES NJ, 1988, MUTAT RES, V193, P139, DOI 10.1016/0167-8817(88)90044-2; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LANSFORD R, 1995, IN PRESS MOL IMMUNOL; LEWIS SM, 1988, CELL, V55, P1099, DOI 10.1016/0092-8674(88)90254-1; LIEN LL, 1991, P NATL ACAD SCI USA, V88, P7873, DOI 10.1073/pnas.88.17.7873; LIN WC, 1994, P NATL ACAD SCI USA, V91, P2733, DOI 10.1073/pnas.91.7.2733; MALYAPA RS, 1994, RADIAT RES, V140, P321; MALYNN BA, 1995, INT IMMUNOL, V7, P1637, DOI 10.1093/intimm/7.10.1637; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MILLER RD, 1995, P NATL ACAD SCI US, V92; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORZYCKAWROBLEWSKA E, 1988, SCIENCE, V242, P261, DOI 10.1126/science.3140378; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OTEVREL T, 1995, GENOMICS, V27, P211, DOI 10.1006/geno.1995.1029; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; Sambrook J., 1989, MOL CLONING LAB MANU; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SELIG S, 1995, P NATL ACAD SCI USA, V92, P3702, DOI 10.1073/pnas.92.9.3702; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STAMATO TD, 1983, SOMAT CELL GENET, V9, P165, DOI 10.1007/BF01543175; STAMATO TD, 1987, MUTAT RES, V183, P61, DOI 10.1016/0167-8817(87)90046-0; STAMATO TD, 1988, RADIAT RES, V115, P325, DOI 10.2307/3577168; TACCIOLI GE, 1995, CURR OPIN IMMUNOL, V7, P436, DOI 10.1016/0952-7915(95)80085-9; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TACCIOLI GE, 1994, J BIOL CHEM, V269, P1; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; WHITMORE GF, 1989, INT J RADIAT BIOL, V56, P657, DOI 10.1080/09553008914551881; YANCOPOULOS GD, 1990, P NATL ACAD SCI USA, V87, P5759, DOI 10.1073/pnas.87.15.5759; YANCOPOULOS GD, 1990, MOL CELL BIOL, V10, P1697, DOI 10.1128/MCB.10.4.1697; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	79	376	386	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1079	1089		10.1016/0092-8674(95)90135-3	http://dx.doi.org/10.1016/0092-8674(95)90135-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548796	Bronze			2022-12-24	WOS:A1995TM76200005
J	Gough, A; Faint, J; Salmon, M; Bacon, P; Emery, P				Gough, A; Faint, J; Salmon, M; Bacon, P; Emery, P			HLA-DR4 and career prospects in rheumatology: Is there a link?	BRITISH MEDICAL JOURNAL			English	Article							ARTHRITIS	Objective-To determine whether HLA type is associated with career progress in rheumatology. Design-Comparison of HLA type after HLA analysis of samples of venous blood. Setting-Department of Rheumatology Research, University of Birmingham. Subjects-All (37) staff in the department. Results-All the senior academics and most staff with a PhD expressed HLA-DR4. The prevalence of expression in each of these groups was significantly greater than that found in the controls. None of the junior doctors or secretaries expressed DR4. Conclusion-The junior doctors in the department have poor career prospects as HLA-DR4 seems to be associated with academic achievement.	UNIV BIRMINGHAM,DEPT RHEUMATOL RES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham			emery, paul/B-3560-2013		Arthritis Research UK [18475] Funding Source: Medline	Arthritis Research UK(Versus Arthritis)		BIDWELL JL, 1986, MOL IMMUNOL, V23, P1111, DOI 10.1016/0161-5890(86)90009-X; EMERY P, 1992, BRIT MED J, V305, P1387, DOI 10.1136/bmj.305.6866.1387; GOUGH A, 1994, ARTHRITIS RHEUM, V37, P1166, DOI 10.1002/art.1780370809; VANZEBEN D, 1991, ARTHRITIS RHEUM, V34, P822, DOI 10.1002/art.1780340707; WORDSWORTH BP, 1989, P NATL ACAD SCI USA, V86, P10049, DOI 10.1073/pnas.86.24.10049	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1665	1666		10.1136/bmj.311.7021.1665	http://dx.doi.org/10.1136/bmj.311.7021.1665			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541751	Green Published			2022-12-24	WOS:A1995TL94200010
J	SEEDS, NW; WILLIAMS, BL; BICKFORD, PC				SEEDS, NW; WILLIAMS, BL; BICKFORD, PC			TISSUE-PLASMINOGEN ACTIVATOR INDUCTION IN PURKINJE NEURONS AFTER CEREBELLAR MOTOR LEARNING	SCIENCE			English	Article							IMPAIRED ACQUISITION; NEURITE OUTGROWTH; SENSORY NEURONS; LOCOMOTOR TASKS; RATS; DEGRADATION; BINDING; MEMORY; CELLS	The cerebellar cortex is implicated in the learning of complex motor skills. This learning may require synaptic remodeling of Purkinje cell inputs. An extracellular serine protease, tissue plasminogen activator (tPA), is involved in remodeling various nonneural tissues and is associated with developing and regenerating neurons. in situ hybridization showed that expression of tPA messenger RNA was increased in the Purkinje neurons of rats within an hour of their being trained for a complex motor task. Antibody to tPA also showed the induction of tPA protein associated with cerebellar Purkinje cells. Thus, the induction of tPA during motor learning may play a role in activity-dependent synaptic plasticity.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,CTR MED SCI TRAINING,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,VET ADM MED CTR,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	SEEDS, NW (corresponding author), UNIV COLORADO,HLTH SCI CTR,PROGRAM NEUROSCI,DENVER,CO 80262, USA.		Bickford, Paula C/J-5970-2012	Bickford, Paula C/0000-0001-9657-7725	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004418] Funding Source: NIH RePORTER; NIA NIH HHS [AG-04418] Funding Source: Medline; NIGMS NIH HHS [T32-GM 08497] Funding Source: Medline; NINDS NIH HHS [NS-09818] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; ANDERSON B, 1992, BEHAV NEUROSCI, V106, P509; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BICKFORD P, 1992, NEUROBIOL AGING, V13, P475, DOI 10.1016/0197-4580(92)90075-9; BICKFORD P, 1993, BRAIN RES, V620, P133, DOI 10.1016/0006-8993(93)90279-V; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; FRIEDMAN GC, 1994, DEV BRAIN RES, V81, P41, DOI 10.1016/0165-3806(94)90066-3; GILBERT PFC, 1974, BRAIN RES, V70, P1, DOI 10.1016/0006-8993(74)90208-X; GILBERT PFC, 1977, BRAIN RES, V128, P309, DOI 10.1016/0006-8993(77)90997-0; GREENOUGH WT, 1988, TRENDS NEUROSCI, V11, P147; ITO M, 1977, CEREBELLUM NEURAL CO; KALDERON N, 1979, P NATL ACAD SCI USA, V76, P5992, DOI 10.1073/pnas.76.11.5992; Kleim J. A., 1994, Society for Neuroscience Abstracts, V20, P1435; KRYSTOSEK A, 1978, FED PROC, V37, P1702; KRYSTOSEK A, 1991, SCIENCE, V213, P1532; LALONDE R, 1990, BRAIN RES REV, V15, P325, DOI 10.1016/0165-0173(90)90006-A; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MARS WM, 1993, AM J PATHOL, V143, P949; MCGUIRE PG, 1990, NEURON, V4, P633, DOI 10.1016/0896-6273(90)90121-U; MOONEN G, 1983, NATURE, V298, P753; PITTMAN RN, 1985, DEV BIOL, V110, P91, DOI 10.1016/0012-1606(85)90067-3; PITTMAN RN, 1989, J NEUROSCI, V9, P4269; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; QUIGLEY JP, 1987, P NATL ACAD SCI USA, V84, P2776, DOI 10.1073/pnas.84.9.2776; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; Seeds N W, 1990, Adv Exp Med Biol, V265, P169; SEEDS NW, UNPUB; SEEDS NW, 1992, NERVE GROWTH CONE, P219; SIMMONS, 1990, J HISTOTECHN, V12, P169; SOREQ H, 1983, DEV BRAIN RES, V11, P149, DOI 10.1016/0165-3806(83)90212-2; VERRALL S, 1989, J CELL BIOL, V109, P265, DOI 10.1083/jcb.109.1.265; VERRALL S, 1989, THESIS U COLORADO HL; WATSON M, 1984, BRAIN RES, V296, P129, DOI 10.1016/0006-8993(84)90518-3	36	255	261	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1992	1994		10.1126/science.270.5244.1992	http://dx.doi.org/10.1126/science.270.5244.1992			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533091				2022-12-24	WOS:A1995TL42000042
J	Camins, BC; Bock, N; Watkins, DL; Blumberg, HM				Camins, BC; Bock, N; Watkins, DL; Blumberg, HM			Acceptance of isoniazid preventive therapy by health care workers after tuberculin skin test conversion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOSOCOMIAL TRANSMISSION; EPIDEMIOLOGY; INFECTION; OUTBREAK	Objective.-To examine health care workers' (HCWs') acceptance of and adherence to isoniazid preventive therapy in the setting of a comprehensive tuberculin skin-testing program. Design.-Descriptive case series. Setting.-University-affiliated inner-city public hospital in Atlanta, Ga. Participants.-A total of 125 HCWs (91 hospital employees and 34 house staff or medical students [the physician group]) who had a positive tuberculin skin test between July 1992 and January 1994 and were offered isoniazid preventive therapy. Interventions.-Health care workers with a recent tuberculin skin test conversion were required to have a chest x-ray performed and see a physician and were encouraged but not required to undergo preventive therapy. Main Outcome Measures.-Acceptance and initiation of preventive therapy with isoniazid by HCWs, completion of at least 6 months of preventive therapy, and differences between the employee and physician groups. Results.-All 125 HCWs with a recent positive tuberculin skin test had a chest radiograph performed, 123 (98.4%) saw a physician, and 105 (84%) initiated preventive therapy. Sixty-nine (66%) of the 105 HCWs who initiated preventive therapy (55% of the 125 total) completed at least 6 months of isoniazid therapy. More of the physician group than of the employee group completed preventive therapy (25 of 34 [74%] vs 44 of 91 [48%], respectively; P<.01). Of the 36 HCWs who started but did not complete preventive therapy, 12 discontinued therapy because of an adverse drug effect and 24 were nonadherent. Conclusions.-Acceptance of tuberculosis preventive therapy by HCWs was high in the setting of a comprehensive tuberculin skin-testing program, and completion of therapy was much higher in the physician group than in previously reported series.	EMORY UNIV,SCH MED,DEPT MED,DIV INFECT DIS,ATLANTA,GA 30303; GRADY MEM HOSP,ATLANTA,GA	Emory University			Blumberg, Henry/W-2156-2019	Blumberg, Henry/0000-0002-3110-2443	NHLBI NIH HHS [K07 HL03078-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL003078] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETTCONNOR E, 1979, JAMA-J AM MED ASSOC, V241, P33, DOI 10.1001/jama.241.1.33; BLUMBERG HM, 1995, ANN INTERN MED, V122, P658, DOI 10.7326/0003-4819-122-9-199505010-00003; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; CATANZARO A, 1995, LANCET, V345, P204, DOI 10.1016/S0140-6736(95)90216-3; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRASER VJ, 1994, INFECT CONT HOSP EP, V15, P95; GIESELER PJ, 1987, AM REV RESPIR DIS, V135, P3; HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540; JARVIS WR, 1993, RES MICROBIOL, V144, P117, DOI 10.1016/0923-2508(93)90025-W; LECOEUR HF, 1989, AM REV RESPIR DIS, V140, P1189, DOI 10.1164/ajrccm/140.5.1189; MCGOWAN JE, 1995, CLIN INFECT DIS, V21, P489, DOI 10.1093/clinids/21.3.489; SALPETER S, 1992, WESTERN J MED, V157, P421; SEPKOWITZ KA, 1994, ANN INTERN MED, V120, P71, DOI 10.7326/0003-4819-120-1-199401010-00012; WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7; ZAZA S, 1995, J INFECT DIS, V172, P1542, DOI 10.1093/infdis/172.6.1542; 1994, MMWR-MORBID MORTAL W, V43, P1; 1994, AM J RESP CRIT CARE, V149, P1359	19	26	27	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					1013	1015						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC123	8596233				2022-12-24	WOS:A1996UC12300029
J	Khachigian, LM; Lindner, V; Williams, AJ; Collins, T				Khachigian, LM; Lindner, V; Williams, AJ; Collins, T			Egr-1-induced endothelial gene expression: A common theme in vascular injury	SCIENCE			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; HUMAN ATHEROSCLEROTIC PLAQUES; SMOOTH-MUSCLE; TRANSCRIPTION FACTOR; ARTERIAL INJURY; BINDING; PROMOTER; EGR-1; SITE; ANGIOPLASTY	A number of pathophysiologically relevant genes, including platelet-derived growth factor B-chain (PDGF-B), are induced in the vasculature after acute mechanical injury. In rat aorta, the activated expression of these genes was preceded by a marked increase in the amount of the early-growth-response gene product Egr-1 at the endothelial wound edge. Egr-1 interacts with a novel element in the proximal PDGF-B promoter, as well as with consensus elements in the promoters of other genes induced by endothelial injury. This interaction is crucial for injury-induced PDGF-B promoter-dependent expression. Sp1, whose binding site in the PDGF-B promoter overlaps that of Egr-1, occupies this element in unstimulated cells and is displaced by increasing amounts of Egr-1. These findings implicate Egr-1 in the up-regulated expression of PDGF-B and other potent mediators in mechanically injured arterial endothelial cells.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV VASC RES,BOSTON,MA 02115; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	Harvard University; Brigham & Women's Hospital; University of Washington; University of Washington Seattle			Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; BARRETT TB, 1988, P NATL ACAD SCI USA, V85, P2810, DOI 10.1073/pnas.85.8.2810; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; CUI MZ, 1994, ARTERIOSCLER THROMB, V14, P807, DOI 10.1161/01.ATV.14.5.807; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DIRKS RPH, 1995, NUCLEIC ACIDS RES, V23, P1119, DOI 10.1093/nar/23.7.1119; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GIMBRONE MA, 1995, AM J CARDIOL, V75, pB67, DOI 10.1016/0002-9149(95)80016-L; HANCOCK WW, 1994, AM J PATHOL, V145, P1008; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P755; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KHACHIGIAN LM, UNPUB; KIM SJ, 1989, J BIOL CHEM, V264, P402; LINDNER V, 1995, AM J PATHOL, V146, P1488; Lindner V, 1996, AM J PATHOL, V148, P427; MACKMAN N, 1995, FASEB J, V9, P883, DOI 10.1096/fasebj.9.10.7615158; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MARMUR JD, 1993, J CLIN INVEST, V91, P2253, DOI 10.1172/JCI116452; MATTSSON E, 1995, TRENDS CARDIOVAS MED, V5, P200, DOI 10.1016/1050-1738(95)00075-K; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; REED MJ, 1995, AM J PATHOL, V147, P1068; REKHTER MD, 1994, CIRC RES, V75, P410, DOI 10.1161/01.RES.75.3.410; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671	35	476	491	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1427	1431		10.1126/science.271.5254.1427	http://dx.doi.org/10.1126/science.271.5254.1427			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596917				2022-12-24	WOS:A1996TY96100049
J	Nelson, KB; Dambrosia, JM; Ting, TY; Grether, JK				Nelson, KB; Dambrosia, JM; Ting, TY; Grether, JK			Uncertain value of electronic fetal monitoring in predicting cerebral palsy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WESTERN-AUSTRALIA; ANTECEDENTS; RISK	Background. Electronic monitoring of the fetal heart rate is commonly performed, in part to detect hypoxia during delivery that may result in brain injury: It is not known whether specific abnormalities on electronic fetal monitoring are related to the risk of cerebral palsy. Methods. Among 155,636 children born from 1983 through 1985 in four California counties, we identified singleton infants with birth weights of at least 2500 g who survived to three years of age and had moderate or severe cerebral palsy. The children with cerebral palsy were compared with randomly selected control children with respect to characteristics noted in the birth records. Results. Seventy-eight of 95 children with cerebral palsy and 300 of 378 controls underwent intrapartum fetal monitoring. Characteristics found to be associated with an increased risk of cerebral palsy were multiple late decelerations in the heart rate, commonly defined as slowing of the heart rate well after the onset of uterine contractions (odds ratio, 3.9; 95 percent confidence interval, 1.7 to 9.3), and decreased beat-to-beat variability of the heart rate (odds ratio, 2.7; 95 percent confidence interval, 1.1 to 5.8); there was no association between the highest or lowest fetal heart rate recorded for each child and the risk of cerebral palsy. Even after adjustment for other risk factors, the association of abnormalities on fetal monitoring with an increased risk of cerebral palsy persisted (adjusted odds ratio, 2.7; 95 percent confidence interval, 1.4 to 5.4). The 21 children with cerebral palsy who had multiple late decelerations or decreased variability in heart rate on fetal monitoring represented only 0.19 percent of singleton infants with birth weights of 2500 g or more who had these fetal-monitoring findings, for a false positive rate of 99.8 percent. Conclusions. Specific abnormal findings on electronic monitoring of the fetal heart rate were associated with an increased risk of cerebral palsy. However, the false positive rate was extremely high. Since cesarean section is often performed when such abnormalities are noted and is associated with risk to the mother, our findings arouse concern that, if these indications were widely used, many cesarean sections would be performed without benefit and with the potential for harm. (C) 1996, Massachusetts Medical Society.	NINCDS,NEUROEPIDEMIOL BRANCH,BETHESDA,MD 20892; NINCDS,BIOMETRY & FIELD STUDIES BRANCH,BETHESDA,MD 20892; HOWARD HUGHES MED INST,BETHESDA,MD 20817; UNIV PENN,SCH MED,PHILADELPHIA,PA 19104; CALIF DEPT HLTH SERV,CALIF BIRTH DEFECTS MONITORING PROGRAM,EMERYVILLE,CA 94608	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Howard Hughes Medical Institute; University of Pennsylvania; California Department of Health Care Services								BADER TJ, 1995, OBSTET GYNECOL, V85, P643; Blair E, 1993, Paediatr Perinat Epidemiol, V7, P272, DOI 10.1111/j.1365-3016.1993.tb00405.x; Cohen A B, 1982, Med Decis Making, V2, P79, DOI 10.1177/0272989X8200200111; CUMMINS SK, 1993, J PEDIATR-US, V123, P230, DOI 10.1016/S0022-3476(05)81693-2; CUNNINGHAM GC, 1979, INTRAUTERINE GROWTH; GRANT A, 1989, EFFECTIVE CARE PREGN, V2, P846; Grether J K, 1992, Paediatr Perinat Epidemiol, V6, P339, DOI 10.1111/j.1365-3016.1992.tb00774.x; HAGBERG B, 1989, ACTA PAEDIATR SCAND, V78, P283, DOI 10.1111/j.1651-2227.1989.tb11071.x; KRAGELOHMANN I, 1995, DEV MED CHILD NEUROL, V37, P191; LEVENO KJ, 1986, NEW ENGL J MED, V315, P615, DOI 10.1056/NEJM198609043151004; Lumley J, 1988, Paediatr Perinat Epidemiol, V2, P299, DOI 10.1111/j.1365-3016.1988.tb00223.x; MACDONALD D, 1985, AM J OBSTET GYNECOL, V152, P524, DOI 10.1016/0002-9378(85)90619-2; MACGILLIVRAY I, 1995, PAEDIATR PERINAT EP, V9, P146, DOI 10.1111/j.1365-3016.1995.tb00130.x; NAULTY CM, 1994, AM J PERINAT, V11, P377, DOI 10.1055/s-2007-994601; NEILSON JP, 1994, BIRTH-ISS PERINAT C, V21, P101, DOI 10.1111/j.1523-536X.1994.tb00242.x; NELSON KB, 1985, AM J DIS CHILD, V139, P1031, DOI 10.1001/archpedi.1985.02140120077032; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; NELSON KB, 1995, PEDIATRICS, V95, P263; NIELSEN TF, 1984, ACTA OBSTET GYN SCAN, V63, P103, DOI 10.3109/00016348409154643; NIELSEN TF, 1995, REPRODUCTIVE HLTH CA, P279; PANETH N, 1993, CLIN INVEST MED, V16, P159; Paul R H, 1994, J Perinatol, V14, P393; ROSTOW VP, 1989, NEW ENGL J MED, V321, P1057, DOI 10.1056/NEJM198910123211526; SCHELLER JM, 1994, OBSTET GYNECOL, V83, P624, DOI 10.1097/00006250-199404000-00025; SHY KK, 1987, ANNU REV PUBL HEALTH, V8, P165, DOI 10.1146/annurev.publhealth.8.1.165; STANLEY FJ, 1992, BRIT MED J, V304, P1658, DOI 10.1136/bmj.304.6843.1658; STANLEY FJ, 1993, DEV MED CHILD NEUROL, V35, P191; THACKER SB, 1995, OBSTET GYNECOL, V86, P613, DOI 10.1016/0029-7844(95)00232-G; TORFS CP, 1990, J PEDIATR-US, V116, P615, DOI 10.1016/S0022-3476(05)81615-4; VINTZILEOS AM, 1995, OBSTET GYNECOL, V85, P149, DOI 10.1016/0029-7844(94)00320-D; YUDKIN PL, 1995, PAEDIATR PERINAT EP, V9, P156, DOI 10.1111/j.1365-3016.1995.tb00131.x	31	299	305	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1996	334	10					613	618		10.1056/NEJM199603073341001	http://dx.doi.org/10.1056/NEJM199603073341001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX693	8592523				2022-12-24	WOS:A1996TX69300001
J	King, GE; Markowitz, LE; Heath, J; Redd, SC; Coleman, S; Bellini, WJ; Sievert, A				King, GE; Markowitz, LE; Heath, J; Redd, SC; Coleman, S; Bellini, WJ; Sievert, A			Antibody response to measles mumps rubella vaccine of children with mild illness at the time of vaccination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENZYME IMMUNOASSAYS; OPPORTUNITIES; INFANTS	Objective.-To examine the response to measles-mumps-rubella (MMR) vaccine among children with and without mild illness. Design.-Prospective cohort. Participants.-A total of 386 children aged 15 to 23 months. Main Outcome Measures.-Seroconversion rates to measles, mumps, and rubella in ill and well children. Setting.-Six public health immunization clinics in two counties in the greater metropolitan Atlanta, Ga, area from February 1992 to April 1993. Results.-Acute upper respiratory tract infection, otitis media, and diarrhea were observed in 128 (33%), 41 (11%), and 13 (3%) of the children (groups are not mutually exclusive); 157 children had one of these mild illnesses and 229 were well. Overall seroconversion rates were 98% for measles, 83% for mumps, and 98% for rubella antigens, Measles seroconversion rates for ill children compared with well children, respectively, were as follows: upper respiratory tract infection, 99% vs 97%; mild fever, 98% vs 97%; otitis media, 98% vs 98%; diarrhea, 100% vs 98%; and any mild illness, 99% vs 97%. Estimates of the magnitude of antibody response to measles, mumps, and rubella antigens were the same for children with and without mild illness. There was no association of mild illness with increased rates and severity of adverse events reported in the 2 weeks after vaccination. Conclusions.-Vaccinating children who present with mild illnesses with MMR vaccine is a safe and efficacious practice. These results support recommendations of the Advisory Committee on Immunization Practices and the American Academy of Pediatrics.	CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,ATLANTA,GA 30333; DEKALB CTY BOARD HLTH,DECATUR,GA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								ATKINSON WL, 1992, 32 INT C ANT AG CHEM; DENNEHY PH, 1994, PEDIATRICS, V94, P514; FARIZO KM, 1992, PEDIATRICS, V89, P589; FORGHANI B, 1979, J CLIN MICROBIOL, V9, P657; HALSEY NA, 1985, NEW ENGL J MED, V313, P544, DOI 10.1056/NEJM198508293130904; HUMMEL KB, 1992, J CLIN MICROBIOL, V30, P2874, DOI 10.1128/JCM.30.11.2874-2880.1992; HUTCHINS SS, 1989, PEDIATRICS, V83, P369; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P296; KROBER MS, 1991, JAMA-J AM MED ASSOC, V265, P2095, DOI 10.1001/jama.265.16.2095; MCCONNOCHIE KM, 1992, PEDIATRICS, V89, P1019; NDIKUYEZE A, 1988, INT J EPIDEMIOL, V17, P448, DOI 10.1093/ije/17.2.448; PETER G, 1994, REPORT COMMITTEE INF, P35; Ratman S, 1995, J PEDIATR, V127, P432; 1987, MMWR-MORBID MORTAL W, V36, P45; 1994, MMWR-MORBID MORTAL W, V43, P57; 1994, MMWR-MORBID MORTAL W, V43, P26; 1993, MMWR-MORBID MORTAL W, V42, P5; 1989, MMWR-MORBID MORTAL W, V38, P9	18	16	17	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1996	275	9					704	707		10.1001/jama.275.9.704	http://dx.doi.org/10.1001/jama.275.9.704			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX174	8594268				2022-12-24	WOS:A1996TX17400026
J	Bourke, GJ				Bourke, GJ			Airbags and fatal injuries to children	LANCET			English	Editorial Material											Bourke, GJ (corresponding author), UNIV COLL DUBLIN,DEPT EPIDEMIOL & PUBL HLTH MED,DUBLIN,IRELAND.							HERBERT D C, 1964, Med J Aust, V1, P61; NORMAN LG, 1962, 12 WHO PUBL HLTH PAP; 1995, H9517 NAT TRANSP SAF; 1995, MMWR-MORBID MORTAL W, V44, P845; 1993, MMWR-MORBID MORTAL W, V42, P280; 1995, TRAFFIC SAFETY FACTS	6	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					560	560		10.1016/S0140-6736(96)91269-6	http://dx.doi.org/10.1016/S0140-6736(96)91269-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596316				2022-12-24	WOS:A1996TX69400007
J	Nightingale, SL				Nightingale, SL			New tuberculosis test approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					585	585		10.1001/jama.275.8.585	http://dx.doi.org/10.1001/jama.275.8.585			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594230				2022-12-24	WOS:A1996TW62700005
J	Hubbard, R; Lewis, S; Richards, K; Johnston, I; Britton, J				Hubbard, R; Lewis, S; Richards, K; Johnston, I; Britton, J			Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis	LANCET			English	Article							PULMONARY FIBROSIS; RESPIRATORY-TRACT; WORKERS; DISEASES; LUNG; POLISHER	Background We have previously suggested that cryptogenic fibrosing alveolitis (CFA) may be caused by occupational exposures, particularly to metal or wood dust. We have specifically investigated this hypothesis in a case-control study of patients with CFA. Methods We obtained lifetime occupational histories by postal questionnaire from 218 patients with CFA and 569 controls matched for age, sex, and community, living in the Trent region of the UK. Information was subsequently verified by telephone interview in 165 cases and 408 controls. Serum IgE, rheumatoid factor, and antinuclear antibodies and skin sensitivity to common allergens were measured in cases and in one matched control for each. Findings The relative risk of CFA, after adjustment for smoking, was significantly increased in relation to questionnaire-reported exposure to metal dust (odds ratio 1.68 [95% CI 1.07-2.65], p=0.024) or to wood dust (1.71 [1.01-2.92], p=0.048). Similar results were obtained with the telephone interview data. Significant exposure-response effects were found for both metal-dust and wood-dust exposure. CFA was also associated with the presence of rheumatoid factor or antinuclear antibodies, but not with positive allergen skin tests or raised IgE concentrations. There was no evidence of interaction between the effects of rheumatoid factor, antinuclear antibodies, positive shin allergen tests, or IgE concentrations and exposure to metal or wood dust. The combined aetiological fraction attributable to exposure to metal or wood dust was of the order of 20%. Interpretation Occupational exposures to metal or wood dust are independent risk factors for CFA. Avoidance or limitation of these exposures may provide an opportunity to prevent the disease.	UNIV NOTTINGHAM, CITY HOSP, DIV RESP MED, NOTTINGHAM NG5 1PB, ENGLAND; QUEENS MED CTR, QUEENS RESP UNIT, NOTTINGHAM NG7 2UH, ENGLAND	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; University of Nottingham			Britton, John R/G-9705-2011					[Anonymous], 1994, Respir Med, V88, P165; BARTTER T, 1991, ARCH INTERN MED, V151, P1197, DOI 10.1001/archinte.151.6.1197; BICKLER G, 1993, BRIT MED J, V306, P1167, DOI 10.1136/bmj.306.6886.1167; CAROSSO A, 1987, BRIT J IND MED, V44, P53; CARRINGTON CB, 1978, NEW ENGL J MED, V298, P801, DOI 10.1056/NEJM197804132981501; COULTAS DB, 1994, AM J RESP CRIT CARE, V150, P967, DOI 10.1164/ajrccm.150.4.7921471; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P235, DOI 10.1056/NEJM198401263100406; CUGELL DW, 1992, CLIN CHEST MED, V13, P269; DEVUYST P, 1986, EUR J RESPIR DIS, V68, P131; IWAI K, 1994, AM J RESP CRIT CARE, V150, P670, DOI 10.1164/ajrccm.150.3.8087336; JEDERLINIC PJ, 1990, AM REV RESPIR DIS, V142, P1179, DOI 10.1164/ajrccm/142.5.1179; JOHNSTON I, 1990, BRIT MED J, V301, P1017, DOI 10.1136/bmj.301.6759.1017; JOHNSTON IDA, 1993, EUR RESPIR J, V6, P891; LILIS R, 1985, CHEST, V88, P306, DOI 10.1378/chest.88.2.306; MARSH P, 1994, RESP MED, V88, P369, DOI 10.1016/0954-6111(94)90043-4; NEMERY B, 1990, AM REV RESPIR DIS, V141, P1373, DOI 10.1164/ajrccm/141.5_Pt_1.1373; NEMERY B, 1990, EUR RESPIR J, V3, P202; RAMAGE JE, 1988, AM REV RESPIR DIS, V137, P1229, DOI 10.1164/ajrccm/137.5.1229; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SCOTT J, 1990, BRIT MED J, V301, P1015, DOI 10.1136/bmj.301.6759.1015; SOSMAN AJ, 1969, NEW ENGL J MED, V281, P977, DOI 10.1056/NEJM196910302811802; TOWNSHEND RH, 1982, BRIT J IND MED, V39, P411; Turner-Warwick M, 1971, Clin Allergy, V1, P83; TURNERWARWICK M, 1980, THORAX, V35, P171, DOI 10.1136/thx.35.3.171; TURNERWARWICK M, 1970, BMJ-BRIT MED J, V3, P492, DOI 10.1136/bmj.3.5721.492; VALLYATHAN V, 1982, CHEST, V81, P372, DOI 10.1378/chest.81.3.372; VANASSENDELFT AH, 1985, CHEST, V87, P394, DOI 10.1378/chest.87.3.394; VANDENPLAS O, 1993, AM REV RESPIR DIS, V147, P338, DOI 10.1164/ajrccm/147.2.338; WALDRON HA, 1994, OCCUPATIONAL LUNG DI, P593	29	241	248	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 3	1996	347	8997					284	289		10.1016/S0140-6736(96)90465-1	http://dx.doi.org/10.1016/S0140-6736(96)90465-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569361				2022-12-24	WOS:A1996TT48500008
J	vanDijk, MR; Janse, CJ; Waters, AP				vanDijk, MR; Janse, CJ; Waters, AP			Expression of a Plasmodium gene introduced into subtelomeric regions of Plasmodium berghei chromosomes	SCIENCE			English	Article							SIZE POLYMORPHISM; FALCIPARUM; BREAKAGE; DNA	Targeted integration of exogenous DNA into the genome of malaria parasites will allow their phenotype to be modulated by means of gene disruption or the stable expression of foreign and mutated genes. Described here is the site-specific integration through reciprocal exchange, and subsequent expression, of a selectable marker gene into the genome of the pathogenic, bloodstage forms of the rodent malaria parasite Plasmodium berghei. Stable integration of a single copy of the marker gene (retained for more than 70 generations in the absence of drug pressure) into a nontranscribed subtelomeric repeat array of different chromosomes was observed. Expression of the gene within the subtelomeres indicated that the previously recorded absence of transcription in these regions could be due to a corresponding absence of genes rather than active silencing mechanisms.	LEIDEN UNIV, DEPT PARASITOL, 2300 AL LEIDEN, NETHERLANDS	Leiden University; Leiden University - Excl LUMC			Waters, Andy P/C-9377-2009	Waters, Andy P/0000-0001-8900-2982; Janse, Chris J/0000-0002-6410-6205				BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; DORE E, 1990, MOL CELL BIOL, V10, P2423, DOI 10.1128/MCB.10.5.2423; GERRING SL, 1991, METHOD ENZYMOL, V194, P57; GOONEWARDENE R, 1993, P NATL ACAD SCI USA, V90, P5234, DOI 10.1073/pnas.90.11.5234; JANSE CJ, 1992, NUCLEIC ACIDS RES, V20, P581, DOI 10.1093/nar/20.3.581; LANZER M, 1993, NATURE, V361, P654, DOI 10.1038/361654a0; LANZER M, 1996, MOL BIOCHEM PARASIT, V70, P1; PACE T, 1990, MOL CELL BIOL, V10, P6759, DOI 10.1128/MCB.10.12.6759; POLOGE LG, 1990, MOL CELL BIOL, V10, P3243, DOI 10.1128/MCB.10.6.3243; POLOGE LG, 1988, CELL, V55, P869, DOI 10.1016/0092-8674(88)90142-0; PONZI M, 1992, NUCLEIC ACIDS RES, V20, P4491, DOI 10.1093/nar/20.17.4491; PONZI M, 1990, MOL BIOCHEM PARASIT, V41, P73, DOI 10.1016/0166-6851(90)90098-7; SCHERF A, 1992, EMBO J, V11, P2293, DOI 10.1002/j.1460-2075.1992.tb05288.x; VANDIJK MR, 1995, SCIENCE, V268, P1358, DOI 10.1126/science.7761856; VANDIJK MR, 1994, MOL BIOCHEM PARASIT, V68, P167, DOI 10.1016/0166-6851(94)00163-4; VANDIJK MR, UNPUB; WU Y, IN PRESS P NATL ACAD; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973	18	76	76	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 2	1996	271	5249					662	665		10.1126/science.271.5249.662	http://dx.doi.org/10.1126/science.271.5249.662			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571132				2022-12-24	WOS:A1996TT87000051
J	Dai, G; Levy, O; Carrasco, N				Dai, G; Levy, O; Carrasco, N			Cloning and characterization of the thyroid iodide transporter	NATURE			English	Article							EXPRESSION; PROTEIN	IODIDE (I-) is an essential constituent of the thyroid hormones T-3 and T-4, and is accumulated by the thyroid. The transport of iodide, the first step in thyroid hormogenesis, is catalysed by the Na+/I- symporter, an intrinsic membrane protein that is crucial for the evaluation, diagnosis and treatment of thyroid disorders. Although several other important thyroid proteins involved in hormogenesis have been characterized, the Na+/I- symporter has not. Here we report the isolation of a complementary DNA clone that encodes this symporter, as a result of functional screening of a cDNA library from a rat thyroid derived cell line (FRTL-5) in Xenopus laevis oocytes. Oocyte microinjection of an RNA transcript made in vitro from this cDNA clone elicited a more than 700-fold increase in perchlorate-sensitive Na+/I- symport activity over background. To our knowledge, this is the first iodide-transporting molecule to have its cDNA cloned, providing a missing link in the thyroid hormone biosynthetic pathway.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine			Carrasco, Nancy/AAH-1053-2019	Carrasco, Nancy/0000-0003-4137-6162				CARRASCO N, 1986, BIOCHEMISTRY-US, V25, P4486, DOI 10.1021/bi00364a004; CARRASCO N, 1993, BIOCHIM BIOPHYS ACTA, V1154, P65, DOI 10.1016/0304-4157(93)90017-I; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DAI G, 1996, IN PRESS HDB BIOL PH, V2; DEGROOT LJ, 1995, ENDOCRINOLOGY, P507; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; KAMINSKY SM, 1994, P NATL ACAD SCI USA, V91, P3789, DOI 10.1073/pnas.91.9.3789; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIKHTAREV IA, 1995, NATURE, V375, P365, DOI 10.1038/375365a0; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; Surratt C K, 1993, Curr Opin Nephrol Hypertens, V2, P744; VILIJN F, 1989, J BIOL CHEM, V264, P11901; VULSMA T, 1991, ACTA ENDOCRINOL-COP, V124, P405, DOI 10.1530/acta.0.1240405; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1090, DOI 10.1210/endo-114-4-1090; WERNER SC, 1991, THYROID FUNDAMENTAL, P1; WILLIAMS D, 1994, NATURE, V371, P556, DOI 10.1038/371556a0; ZHANG YM, 1994, J BIOL CHEM, V269, P19573	19	871	933	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					458	460		10.1038/379458a0	http://dx.doi.org/10.1038/379458a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559252				2022-12-24	WOS:A1996TT30400062
J	Hicke, L; Riezman, H				Hicke, L; Riezman, H			Ubiquitination of a yeast plasma membrane receptor signals its ligand-stimulated endocytosis	CELL			English	Article							PHEROMONE RECEPTOR; INSULIN-RECEPTOR; ALPHA-FACTOR; PROTEIN; DEGRADATION; INTERNALIZATION; VACUOLE; GENE; CEREVISIAE; SUBUNIT	Binding of alpha factor to Ste2p, a G protein-coupled plasma membrane receptor, activates a signal transduction pathway and stimulates endocytosis of the receptor-ligand complex. Ligand binding also induces ubiquitination of the Ste2p cytoplasmic tail. Protein ubiquitination is required for stimulated endocytosis of Steep, as internalization is 5- to 15-fold slower in ubc mutants that lack multiple ubiquitin-conjugating enzymes. In a C-terminal truncated form of Ste2p that is rapidly ubiquitinated and endocytosed in response to ligand binding, a single lysine to arginine substitution in its cytoplasmic tail eliminates both ubiquitination and internalization. Thus, ubiquitination of Ste2p itself is required for ligand-stimulated endocytosis. We propose that ubiquitination mediates degradation of receptor-ligand complexes, not via the proteasome, but by acting as a signal for endocytosis leading to subsequent degradation in the lysosome/vacuole.			Hicke, L (corresponding author), UNIV BASEL, BIOCTR, DEPT BIOCHEM, CH-4056 BASEL, SWITZERLAND.			Riezman, Howard/0000-0003-4680-9422				BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; BERKOWER C, 1994, MOL BIOL CELL, V5, P1185, DOI 10.1091/mbc.5.11.1185; CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; DULIC V, 1991, METHOD ENZYMOL, V194, P697; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; ITIN C, 1995, EMBO J, V14, P2250, DOI 10.1002/j.1460-2075.1995.tb07219.x; JENNESS DD, 1986, CELL, V46, P345, DOI 10.1016/0092-8674(86)90655-0; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MIYAZAWA K, 1994, BLOOD, V83, P137; MORI S, 1992, J BIOL CHEM, V267, P6429; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; OZKAYNAK E, 1984, NATURE, V312, P663, DOI 10.1038/312663a0; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; Riezman Howard, 1993, Trends in Cell Biology, V3, P273, DOI 10.1016/0962-8924(93)90056-7; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; SCHANDEL KA, 1994, MOL CELL BIOL, V14, P7245, DOI 10.1128/MCB.14.11.7245; SCHIMMOLLER F, 1993, J CELL SCI, V106, P823; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; TAN PK, 1993, J CELL BIOL, V123, P1707, DOI 10.1083/jcb.123.6.1707; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YEE NS, 1994, J BIOL CHEM, V269, P31991; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N	52	642	656	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					277	287		10.1016/S0092-8674(00)80982-4	http://dx.doi.org/10.1016/S0092-8674(00)80982-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565073	Bronze			2022-12-24	WOS:A1996TR59500014
J	Struthers, MD; Cheng, RP; Imperiali, B				Struthers, MD; Cheng, RP; Imperiali, B			Design of a monomeric 23-residue polypeptide with defined tertiary structure	SCIENCE			English	Article							ZINC-FINGER PEPTIDE; 4-HELIX BUNDLE; CRYSTAL-STRUCTURE; METAL-BINDING; PROTEIN ZFY; SPECTROSCOPY; DOMAIN; MOTIFS; PROBE	Small proteins or protein domains generally require disulfide bridges or metal sites for their stabilization. Here it is shown that the beta beta alpha architecture of zinc fingers can be reproduced in a 23-residue polypeptide in the absence of metal ions. The sequence was obtained through an iterative design process. A key feature of the final design is the incorporation of a type II' beta turn to aid in beta-hairpin formation. Nuclear magnetic resonance analysis reveals that the alpha helix and beta hairpin are held together by a defined hydrophobic core. The availability of this structural template has implications for the development of functional polypeptides.	CALTECH, DIV CHEM & CHEM ENGN, PASADENA, CA 91125 USA	California Institute of Technology				Imperiali, Barbara/0000-0002-5749-7869				BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BETZ SF, 1993, CURR OPIN STRUC BIOL, V3, P601, DOI 10.1016/0959-440X(93)90090-8; EIS PS, 1993, BIOCHEMISTRY-US, V32, P7981, DOI 10.1021/bi00082a020; Fasman GD, 1989, PREDICTION PROTEIN S, P193; FEZOUI Y, 1994, P NATL ACAD SCI USA, V91, P3675, DOI 10.1073/pnas.91.9.3675; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; GHADIRI MR, 1992, J AM CHEM SOC, V114, P4000, DOI 10.1021/ja00036a072; GOODSELL DS, 1993, TRENDS BIOCHEM SCI, V18, P65, DOI 10.1016/0968-0004(93)90153-E; GRATHWOHL C, 1976, BIOPOLYMERS, V15, P2025, DOI 10.1002/bip.1976.360151012; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; IMPERIALI B, 1992, J AM CHEM SOC, V114, P3182, DOI 10.1021/ja00035a002; KURODA Y, 1995, PROTEIN ENG, V8, P97, DOI 10.1093/protein/8.2.97; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LIEBERMAN M, 1991, J AM CHEM SOC, V113, P1470, DOI 10.1021/ja00004a090; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; MICHAEL SF, 1992, P NATL ACAD SCI USA, V89, P4796, DOI 10.1073/pnas.89.11.4796; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; OSTERHOUT JJ, 1992, J AM CHEM SOC, V114, P331, DOI 10.1021/ja00027a043; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PESSI A, 1993, NATURE, V362, P367, DOI 10.1038/362367a0; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; QUINN TP, 1994, P NATL ACAD SCI USA, V91, P8747, DOI 10.1073/pnas.91.19.8747; RALEIGH DP, 1995, J AM CHEM SOC, V117, P7558, DOI 10.1021/ja00133a035; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; SMITH DDS, 1995, PROTEIN ENG, V8, P13, DOI 10.1093/protein/8.1.13; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STRUTHERS MS, UNPUB; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P5660, DOI 10.1021/bi00476a002; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P9808, DOI 10.1021/bi00494a008; WETLAUFER DB, 1990, TRENDS BIOCHEM SCI, V15, P414, DOI 10.1016/0968-0004(90)90275-G; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YAN YB, 1994, PROTEIN SCI, V3, P1069, DOI 10.1002/pro.5560030709	38	278	284	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	1996	271	5247					342	345		10.1126/science.271.5247.342	http://dx.doi.org/10.1126/science.271.5247.342			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553067				2022-12-24	WOS:A1996TQ52800038
J	Spinozzi, F; Agea, E; Bistoni, O; Forenza, N; Monaco, A; Bassotti, G; Nicoletti, I; Riccardi, C; Grignani, F; Bertotto, A				Spinozzi, F; Agea, E; Bistoni, O; Forenza, N; Monaco, A; Bassotti, G; Nicoletti, I; Riccardi, C; Grignani, F; Bertotto, A			Increased allergen-specific, steroid-sensitive gamma delta T cells in bronchoalveolar lavage fluid from patients with asthma	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN IGE SYNTHESIS; INTERLEUKIN-4; LYMPHOCYTES; RECEPTOR; APOPTOSIS; COMPLEX	Objective: To test the hypothesis that allergen-specific, steroid-sensitive gamma delta T lymphocytes are increased in bronchoalveolar lavage fluid of patients with asthma. Design: Case series. Setting: The outpatient allergy services at the University of Perugia, Perugia, Italy. Patients: 12 untreated atopic patients (6 children and 6 adults) with mildly symptomatic chronic asthma were studied. Bronchoalveolar ravage fluid from 10 healthy nonsmoking volunteers and age-matched children with cystic fibrosis (n = 5) or anatomic malformation of the airways (n = 4) served as control samples. Intervention: Three patients received treatment with deflazacort, 60 mg twice daily, for 1 week. Measurements: CD3(+), CD4(+), and CD8(+) T cells from patients and controls were examined by two-color flow cytometry for coexpression of V delta 1 and V delta 2 isoforms of the gamma delta T-cell receptor. In vitro pulmonary gamma delta T-cell proliferation in response to a specific allergen, the apoptotic death of these cells after incubation with 10(-7) M dexamethasone, and bronchoalveolar lavage fluid T-lymphocyte composition before and after 1 week of deflazacort therapy were evaluated in 3 Dermatophagoides pteronyssinus-sensitive patients. Results: The proportion of gamma delta T lymphocytes, primarily CD4(+) or CD4(-) CD8(-) cells, was higher in asthmatic patients than in controls (P < 0.05 by one-way analysis of variance). Most lung gamma delta CD4(+) lymphocytes expressed the gamma delta T-cell receptor V delta 1 chain. These cells proliferated in response to allergen stimulation, underwent steroid-induced apoptosis in vitro, and disappeared after systemic steroid treatment. Conclusions: Allergen-specific, steroid-sensitive gamma delta T cells may be one of the cellular components involved in the airway inflammation that characterizes allergic bronchial asthma.					bistoni, onelia/G-8234-2011; Riccardi, Carlo/N-4610-2014	Riccardi, Carlo/0000-0001-9257-3997				BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; DELPRETE G, 1992, ALLERGY, V47, P450; DELPRETE G, 1988, J IMMUNOL, V140, P4193; FAJAC I, 1992, CLIN EXP IMMUNOL, V87, P127; GASCAN H, 1992, EUR J IMMUNOL, V22, P1133, DOI 10.1002/eji.1830220505; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; MIGLIORATI G, 1993, BLOOD, V81, P1352; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; MORITA CT, 1991, EUR J IMMUNOL, V21, P2999, DOI 10.1002/eji.1830211215; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OKUDA M, 1992, ALLERGY, V47, P255, DOI 10.1111/j.1398-9995.1992.tb00659.x; PAWANKAR R, 1995, J ALLERGY CLIN IMMUN, V95, P190; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; QIAN DP, 1993, P NATL ACAD SCI USA, V90, P11875, DOI 10.1073/pnas.90.24.11875; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; SPINOZZI F, 1992, ARCH INTERN MED, V152, P99, DOI 10.1001/archinte.152.1.99; SPINOZZI F, 1995, SCAND J IMMUNOL, V41, P504, DOI 10.1111/j.1365-3083.1995.tb03599.x; SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WU CY, 1991, EUR J IMMUNOL, V21, P2645, DOI 10.1002/eji.1830211053	23	67	69	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					223	227		10.7326/0003-4819-124-2-199601150-00005	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ016	8533997				2022-12-24	WOS:A1996TQ01600005
J	Panter, KR; Hannah, ME				Panter, KR; Hannah, ME			Umbilical cord prolapse: So far so good?	LANCET			English	Editorial Material											Panter, KR (corresponding author), UNIV TORONTO,WOMENS COLL HOSP,DEPT OBSTET & GYNAECOL,TORONTO,ON,CANADA.							FENTON AN, 1951, AM J OBSTET GYNECOL, V62, P52, DOI 10.1016/0002-9378(51)91090-3; FERRARA TB, 1989, AM J OBSTET GYNECOL, V161, P1114; Goldthorp W O, 1967, Br J Clin Pract, V21, P21; KOONINGS PP, 1990, J REPROD MED, V35, P690; Kurzrock J, 1932, AM J OBSTET GYNECOL, V23, P403, DOI 10.1016/S0002-9378(32)90832-1; LEVENO KJ, 1990, OBSTET GYNECOL, V76, P12; MACFARLANE AJ, 1990, 3 4 MORE STUDY TRIPL, P218; MESLEH T, 1993, J OBSTET GYNECOL, V13, P24; MURPHY DJ, 1995, BRIT J OBSTET GYNAEC, V102, P826, DOI 10.1111/j.1471-0528.1995.tb10850.x; YLAOUTINEN A, 1985, ACTA OBSTET GYN SCAN, V64, P567	10	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					74	74		10.1016/S0140-6736(96)90207-X	http://dx.doi.org/10.1016/S0140-6736(96)90207-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538343				2022-12-24	WOS:A1996TP28100006
J	Quon, KC; Marczynski, GT; Shapiro, L				Quon, KC; Marczynski, GT; Shapiro, L			Cell cycle control by an essential bacterial two-component signal transduction protein	CELL			English	Article							GRAM-NEGATIVE BACTERIA; CAULOBACTER-CRESCENTUS; BACILLUS-SUBTILIS; DNA-REPLICATION; GENE-EXPRESSION; DIVISION; MUTAGENESIS; PROMOTER; DIFFERENTIATION; IDENTIFICATION	Dividing cells must coordinate cell cycle events to ensure genetic stability. Here we identify an essential two-component signal transduction protein that controls multiple events in the Caulobacter cell cycle, including cell division, stalk synthesis, and cell cycle-specific transcription. This protein, CtrA, is homologous to response regulator transcription factors and controls transcription from a group of cell cycle-regulated promoters critical for DNA replication, DNA methylation, and flagellar biogenesis. CtrA activity in the cell cycle is controlled both transcriptionally and by phosphorylation. As purified CtrA binds an essential DNA sequence motif found within its target promoters, we propose that CtrA acts in a phosphorelay signal transduction system to control bacterial cell cycle events directly at the transcriptional level.			Quon, KC (corresponding author), STANFORD UNIV, SCH MED, BECKMAN CTR, DEPT DEV BIOL, STANFORD, CA 94305 USA.				NIGMS NIH HHS [GM5 1426, GM 32506/512OMZ] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032506, R01GM032506] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEY MRK, 1991, GENETICS, V129, P333; BRUN YV, 1992, GENE DEV, V6, P2395, DOI 10.1101/gad.6.12a.2395; BRUN YV, 1994, ANNU REV BIOCHEM, V63, P419, DOI 10.1146/annurev.bi.63.070194.002223; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; DELGADO J, 1993, MOL MICROBIOL, V10, P1037, DOI 10.1111/j.1365-2958.1993.tb00974.x; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINGWALL A, 1992, J BACTERIOL, V174, P1760, DOI 10.1128/jb.174.6.1760-1768.1992; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; ELY B, 1991, METHOD ENZYMOL, V204, P372; EVINGER M, 1977, J BACTERIOL, V132, P294, DOI 10.1128/JB.132.1.294-301.1977; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; FISHER JA, 1988, J BACTERIOL, V170, P4706, DOI 10.1128/jb.170.10.4706-4713.1988; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GOBER JW, 1992, MOL BIOL CELL, V3, P913, DOI 10.1091/mbc.3.8.913; GOBER JW, 1995, MICROBIOL REV, V59, P31, DOI 10.1128/MMBR.59.1.31-47.1995; GUENZI E, 1994, MOL MICROBIOL, V12, P505, DOI 10.1111/j.1365-2958.1994.tb01038.x; HECHT GB, 1995, EMBO J, V14, P3915, DOI 10.1002/j.1460-2075.1995.tb00063.x; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; HUGHES KT, 1993, SCIENCE, V262, P1277, DOI 10.1126/science.8235660; HUGUENEL ED, 1982, DIFFERENTIATION, V21, P71, DOI 10.1111/j.1432-0436.1982.tb01199.x; IRETON K, 1994, J BACTERIOL, V176, P5320, DOI 10.1128/JB.176.17.5320-5329.1994; IRETON K, 1992, P NATL ACAD SCI USA, V89, P8808, DOI 10.1073/pnas.89.18.8808; IRETON K, 1994, EMBO J, V13, P1566, DOI 10.1002/j.1460-2075.1994.tb06419.x; JENAL U, 1994, J MOL BIOL, V243, P227, DOI 10.1006/jmbi.1994.1650; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KOKJOHN TA, 1987, J BACTERIOL, V169, P1499, DOI 10.1128/jb.169.4.1499-1508.1987; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; KUTSUKAKE K, 1994, MOL GEN GENET, V243, P605, DOI 10.1007/BF00279569; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MARCZYNSKI GT, 1995, GENE DEV, V9, P1543, DOI 10.1101/gad.9.12.1543; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; Miller J.H., 1972, EXPT MOL GENETICS; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NEWTON A, 1989, P NATL ACAD SCI USA, V86, P6651, DOI 10.1073/pnas.86.17.6651; OHTA N, 1992, P NATL ACAD SCI USA, V89, P10297, DOI 10.1073/pnas.89.21.10297; OSLEY MA, 1977, P NATL ACAD SCI USA, V74, P124, DOI 10.1073/pnas.74.1.124; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; RAMAKRISHNAN G, 1994, J BACTERIOL, V176, P7587, DOI 10.1128/JB.176.24.7587-7600.1994; RAMPERSAUD A, 1994, J BIOL CHEM, V269, P12559; RIZZO MF, 1993, J BACTERIOL, V175, P6970, DOI 10.1128/jb.175.21.6970-6981.1993; RUDOLPH J, 1995, EMBO J, V14, P667, DOI 10.1002/j.1460-2075.1995.tb07045.x; RUSSO FD, 1991, J MOL BIOL, V222, P567, DOI 10.1016/0022-2836(91)90497-T; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMIDT JM, 1966, J CELL BIOL, V28, P423, DOI 10.1083/jcb.28.3.423; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; STEPHENS CM, 1995, J BACTERIOL, V177, P1662, DOI 10.1128/jb.177.7.1662-1669.1995; STEPHENS CM, 1993, MOL MICROBIOL, V9, P1169, DOI 10.1111/j.1365-2958.1993.tb01246.x; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; TSUNG K, 1989, J BIOL CHEM, V264, P10104; VANWAY SM, 1993, J BACTERIOL, V175, P367, DOI 10.1128/JB.175.2.367-376.1993; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; WANG SP, 1993, P NATL ACAD SCI USA, V90, P630, DOI 10.1073/pnas.90.2.630; YU J, 1992, J BACTERIOL, V174, P3327, DOI 10.1128/jb.174.10.3327-3338.1992; ZHUANG WY, 1992, J BACTERIOL, V177, P34; ZWEIGER G, 1994, J MOL BIOL, V235, P472, DOI 10.1006/jmbi.1994.1007	59	384	388	0	23	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	1996	84	1					83	93		10.1016/S0092-8674(00)80995-2	http://dx.doi.org/10.1016/S0092-8674(00)80995-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548829	Bronze			2022-12-24	WOS:A1996TQ17000011
J	Turton, MD; OShea, D; Gunn, I; Beak, SA; Edwards, CMB; Meeran, K; Choi, SJ; Taylor, GM; Heath, MM; Lambert, PD; Wilding, JPH; Smith, DM; Ghatei, MA; Herbert, J; Bloom, SR				Turton, MD; OShea, D; Gunn, I; Beak, SA; Edwards, CMB; Meeran, K; Choi, SJ; Taylor, GM; Heath, MM; Lambert, PD; Wilding, JPH; Smith, DM; Ghatei, MA; Herbert, J; Bloom, SR			A role for glucagon-like peptide-1 in the central regulation of feeding	NATURE			English	Article							NEUROPEPTIDE-Y CONTENT; C-FOS; RATS; EXPRESSION; INSULIN; HYPOTHALAMUS; BEHAVIOR; SATIETY; BRAIN; CELLS	THE sequence of glucagon-like peptide-(1) (7-36) amide (GLP-1) is completely conserved in all mammalian species studied, implying that it plays a critical physiological role(1). We have shown that GLP-1 and its specific receptors are present in the hypothalamus(2,3). No physiological role for central GLP-1 has been established. We report here that intracerebroventricular (ICV) GLP-1 powerfully inhibits feeding in fasted rats, ICV injection of the specific GLP-1-receptor antagonist, exendin (9-39)(4), blocked the inhibitory effect of GLP-1 on food intake. Exendin (9-39) alone had no influence on fast-induced feeding but more than doubled food intake in satiated rats, and augmented the feeding response to the appetite stimulant, neuropeptide Y. Induction of c-fos is a marker of neuronal activation(5). Following ICV GLP-1 injection, c-fos appeared exclusively in the paraventricular nucleus of the hypothalamus and central nucleus of the amygdala, and this was inhibited by prior administration of exendin (9-39). Both of these regions of the brain are of primary importance in the regulation of feeding(6). These findings suggest that central GLP-1 is a new physiological mediator of satiety.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,ENDOCRINE UNIT,LONDON W12 0NN,ENGLAND; UNIV CAMBRIDGE,DEPT ANAT,CAMBRIDGE CB2 3DY,ENGLAND	Imperial College London; University of Cambridge			Wilding, John PH/A-7106-2008; Wilding, John/ABB-6443-2020	Wilding, John PH/0000-0003-2839-8404; Wilding, John/0000-0003-2839-8404; Smith, David/0000-0001-6831-280X; O'Shea, Donal/0000-0002-1408-5274				ANTIN J, 1975, J COMP PHYSIOL PSYCH, V89, P784, DOI 10.1037/h0077040; ARNOLD FJL, 1992, NEUROSCIENCE, V51, P377, DOI 10.1016/0306-4522(92)90322-S; BILLINGTON CJ, 1983, AM J PHYSIOL, V245, pR920, DOI 10.1152/ajpregu.1983.245.6.R920; BLUNDELL JE, 1985, BRAIN RES BULL, V15, P371, DOI 10.1016/0361-9230(85)90004-8; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHOW HL, 1984, EUR J PHARMACOL, V102, P297, DOI 10.1016/0014-2999(84)90261-9; CLARK JT, 1985, ENDOCRINOLOGY, V117, P2435, DOI 10.1210/endo-117-6-2435; GOKE R, 1993, J BIOL CHEM, V268, P19650; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; KANSE SM, 1988, FEBS LETT, V241, P209, DOI 10.1016/0014-5793(88)81063-9; KREYMANN B, 1989, BRAIN RES, V502, P325, DOI 10.1016/0006-8993(89)90628-8; KULKARNI RN, 1995, REGUL PEPTIDES, V57, P201; LAMBERT PD, 1993, ENDOCRINOLOGY, V133, P29, DOI 10.1210/en.133.1.29; LAMBERT PD, 1995, BRAIN RES, V670, P59, DOI 10.1016/0006-8993(94)01224-6; MORLEY JE, 1987, ENDOCR REV, V8, P256, DOI 10.1210/edrv-8-3-256; ORSKOV C, 1992, DIABETOLOGIA, V35, P701; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RAI A, 1993, AM J PHYSIOL, V265, pG118, DOI 10.1152/ajpgi.1993.265.1.G118; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SUZUKI S, 1989, ENDOCRINOLOGY, V125, P3109, DOI 10.1210/endo-125-6-3109; VEALE PR, 1994, EUR J PHARMACOL, V262, P133, DOI 10.1016/0014-2999(94)90036-1; WANG ZL, 1995, J CLIN INVEST, V95, P417, DOI 10.1172/JCI117671; WILDING JPH, 1993, NEUROENDOCRINOLOGY, V57, P581, DOI 10.1159/000126410; WILDING JPH, 1992, J ENDOCRINOL, V132, P299, DOI 10.1677/joe.0.1320299	24	1477	1584	1	126	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					69	72		10.1038/379069a0	http://dx.doi.org/10.1038/379069a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538742				2022-12-24	WOS:A1996TN21600056
J	Hiramatsu, R; Akagi, K; Matsuoka, M; Sakumi, K; Nakamura, H; Kingsbury, L; David, C; Hardy, RR; Yamamura, K; Sakano, H				Hiramatsu, R; Akagi, K; Matsuoka, M; Sakumi, K; Nakamura, H; Kingsbury, L; David, C; Hardy, RR; Yamamura, K; Sakano, H			The 3' enhancer region determines the B/T specificity and pro-B pre-B specificity of immunoglobulin V-kappa-J(kappa) joining	CELL			English	Article							CHAIN INTRON ENHANCER; V(D)J RECOMBINATION; GENE REARRANGEMENT; CONSTANT REGION; LOCUS CONTAINS; ETS ONCOGENE; BONE-MARROW; CELL; HEAVY; EXPRESSION	Using transgenic substrates, we found that the immunoglobulin kappa gene 3' enhancer (E3') acts as a negative regulator in V-kappa-J(kappa) joining. Although the E3' was originally identified as a transcriptional enhancer, it acts in a suppressive manner for recombinational regulation. Base substitution analysis has shown that the PU.1-binding site within the E3' regulates the B/T specificity of V-kappa-J(kappa) joining. In a substrate with a mutated PU.1-binding site (GAGGAA to TCTTCG), V-kappa-J(kappa) joining occurred not only in B cells, but also in T cells. The E3' region is also responsible for determining the pro-B/pre-B specificity of V-kappa-J(kappa) joining. When the E3' region was deleted, kappa gene rearrangement actively occurred at the early pro-B stage of B cell development: nongermline (N) nucleotides were common at recombination junctions.	KUMAMOTO UNIV, SCH MED, INST MOLEC EMBRYOL & GENET, DEPT DEV GENET, KUMAMOTO 862, JAPAN; MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55905 USA; FOX CHASE CANC CTR, INST CANC RES, PHILADELPHIA, PA 19111 USA; UNIV TOKYO, GRAD SCH SCI, DEPT BIOPHYS & BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN	Kumamoto University; Mayo Clinic; Fox Chase Cancer Center; University of Tokyo	Hiramatsu, R (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV IMMUNOL, BERKELEY, CA 94720 USA.		Sakumi, Kunihiko/G-4808-2011	Matsuoka, Masao/0000-0002-0473-754X				AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CAPONE M, 1993, EMBO J, V12, P4335, DOI 10.1002/j.1460-2075.1993.tb06118.x; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; ENGLER P, 1991, J IMMUNOL, V146, P2826; ENGLER P, 1993, MOL CELL BIOL, V13, P571, DOI 10.1128/MCB.13.1.571; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; GOODHARDT M, 1987, P NATL ACAD SCI USA, V84, P4229, DOI 10.1073/pnas.84.12.4229; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HEINRICH G, 1984, J EXP MED, V159, P417, DOI 10.1084/jem.159.2.417; HROMAS R, 1993, BLOOD, V82, P2998; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; HSIEH CL, 1992, J BIOL CHEM, V22, P15963; IGLESIAS A, 1991, EMBO J, V10, P2147, DOI 10.1002/j.1460-2075.1991.tb07749.x; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KUNG JT, 1981, J IMMUNOL, V127, P873; LANDAU NR, 1987, MOL CELL BIOL, V7, P3237, DOI 10.1128/MCB.7.9.3237; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LAUSTER R, 1993, EMBO J, V12, P4615, DOI 10.1002/j.1460-2075.1993.tb06150.x; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; MAKI R, 1980, SCIENCE, V209, P1366, DOI 10.1126/science.6774416; MATTHIAS P, 1993, MOL CELL BIOL, V13, P1547, DOI 10.1128/MCB.13.3.1547; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PONGUBALA JMR, 1995, J BIOL CHEM, V270, P10304, DOI 10.1074/jbc.270.17.10304; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; ROSS IL, 1994, ONCOGENE, V9, P121; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SERWE M, 1993, EMBO J, V12, P2321, DOI 10.1002/j.1460-2075.1993.tb05886.x; STORB U, 1983, P NATL ACAD SCI-BIOL, V80, P6642, DOI 10.1073/pnas.80.21.6642; TAKEDA S, 1993, EMBO J, V12, P2329, DOI 10.1002/j.1460-2075.1993.tb05887.x; WATRIN F, 1994, TRANSGENESIS TARGETE, P1; YANCOPOULOS GD, 1986, ANNU REV IMMUNOL, V4, P339, DOI 10.1146/annurev.iy.04.040186.002011; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	53	55	55	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1113	1123		10.1016/0092-8674(95)90138-8	http://dx.doi.org/10.1016/0092-8674(95)90138-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548799	Bronze			2022-12-24	WOS:A1995TM76200008
J	GALLAGHER, EJ; LOMBARDI, G; GENNIS, P				GALLAGHER, EJ; LOMBARDI, G; GENNIS, P			EFFECTIVENESS OF BYSTANDER CARDIOPULMONARY-RESUSCITATION AND SURVIVAL FOLLOWING OUT-OF-HOSPITAL CARDIAC-ARREST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPERIENCE; SYSTEM; CPR	Objective.-To examine the independent relationship between effectiveness of bystander cardiopulmonary resuscitation (CPR) and survival following out-of-hospital cardiac arrest. Design.-Prospective observational cohort. Setting.-New York City. Participants.-A total of 2071 consecutive out-of-hospital cardiac arrests meeting Utstein criteria. Intervention.-Trained prehospital personnel assessed the quality of bystander CPR on arrival at the scene. Satisfactory execution of CPR required performance of both adequate compressions and ventilations in conformity with current American Heart Association guidelines. Main Outcome Measure.-Adjusted association between CPR effectiveness and survival. Survival was defined as discharge from hospital to home. Results.-Outcome was determined on all members of the inception cohort-none were lost to follow-up. When the association between bystander CPR and survival was adjusted for effectiveness of CPR in the parent data set (N=2071), only effective CPR was retained in the logistic model (adjusted odds ratio [OR]=5.7; 95% confidence interval [CI], 2.7 to 12.2; P<.001). Of the subset of 662 individuals (32%) who received bystander CPR, 305 (46%) had it performed effectively. Of these, 4.6% (14/305) survived vs 1.4% (5/357) of those with ineffective CPR (OR=3.4; 95% CI, 1.1 to 12.1; P<.02). After adjustment for witness status, initial rhythm, interval from collapse to CPR, and interval from collapse to advanced life support, effective CPR remained independently associated with improved survival (adjusted OR=3.9; 95% CI, 1.1 to 14.0; P<.04). Conclusion.-The association between bystander CPR and survival in out-of-hospital cardiac arrest appears to be confounded by CPR quality. Effective CPR is independently associated with a quantitatively and statistically significant improvement in survival.	ALBERT EINSTEIN COLL MED,DEPT EMERGENCY MED,BRONX,NY 10467; ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10467; ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10467; YALE UNIV,SCH MED,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,NEW HAVEN,CT	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yale University								BACHMAN JW, 1986, JAMA-J AM MED ASSOC, V256, P477, DOI 10.1001/jama.256.4.477; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BOSSAERT L, 1989, RESUSCITATION, V17, pS55, DOI 10.1016/0300-9572(89)90091-9; CHANDRA NC, 1992, CURR EMERG CARDIAC C, V3, P5; COBB LA, 1980, ANNU REV MED, V31, P454; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408; EISENBERG MS, 1991, AM J EMERG MED, V9, P544, DOI 10.1016/0735-6757(91)90108-V; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; EITEL DR, 1988, ANN EMERG MED, V17, P808, DOI 10.1016/S0196-0644(88)80560-2; GENNIS P, 1994, ANN EMERG MED, V24, P194, DOI 10.1016/S0196-0644(94)70130-X; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; LUND I, 1976, LANCET, V2, P702; NEWMAN MM, 1994, CURR EMERG CARDIAC C, V17, P11; STUEVEN H, 1986, ANN EMERG MED, V15, P707, DOI 10.1016/S0196-0644(86)80430-9; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; VALENZUELA TD, 1992, JAMA-J AM MED ASSOC, V267, P272, DOI 10.1001/jama.267.2.272; WHITE BC, 1985, JAMA-J AM MED ASSOC, V254, P3308; 1994, ADV CARDIAC LIFE SUP; 1992, JAMA-J AM MED ASSOC, V268, P2184	22	377	381	1	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1922	1925		10.1001/jama.274.24.1922	http://dx.doi.org/10.1001/jama.274.24.1922			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568985				2022-12-24	WOS:A1995TL16900033
J	Davey, PG; Bax, RP; Newey, J; Reeves, D; Rutherford, D; Slack, R; Warren, RE; Watt, B; Wilson, J				Davey, PG; Bax, RP; Newey, J; Reeves, D; Rutherford, D; Slack, R; Warren, RE; Watt, B; Wilson, J			Growth in the use of antibiotics in the community in England and Scotland in 1980-93	BRITISH MEDICAL JOURNAL			English	Article									SMITHKLINE BEECHAM PHARMACEUT,HARLOW CM19 5AW,ESSEX,ENGLAND; HALLWOOD HLTH CTR,WEAVER VALE WA7 2OT,CHESHIRE,ENGLAND; SOUTHMEAD HOSP,DEPT MED MICROBIOL,BRISTOL BS10 5NB,AVON,ENGLAND; PIPELANDS HLTH CTR,ST ANDREWS KY16 8JZ,FIFE,SCOTLAND; PUBL HLTH LAB SERV LAB,NOTTINGHAM NG7 2UH,ENGLAND; PUBL HLTH LAB,SHREWSBURY SY3 8XQ,ENGLAND; CITY HOSP EDINBURGH,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; NOTTINGHAMSHIRE FAMILY HLTH SERV AUTHOR,NOTTINGHAM NG1 5EP,ENGLAND	GlaxoSmithKline; Southmead Hospital	Davey, PG (corresponding author), NINEWELLS HOSP,DEPT CLIN PHARMACOL,DUNDEE DD1 9SY,SCOTLAND.							BORDER P, 1994, DIS FIGHTING BACK GR, P1; Davey P G, 1992, Pharmacoeconomics, V1, P409; MCGAVOCK H, 1993, BRIT MED J, V307, P1118, DOI 10.1136/bmj.307.6912.1118; TABOULET F, 1990, J EC MED, V8, P37	4	68	71	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					613	613						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595337	Green Published			2022-12-24	WOS:A1996TZ84000027
J	Finn, PJ; Plank, LD; Clark, MA; Connolly, AB; Hill, GL				Finn, PJ; Plank, LD; Clark, MA; Connolly, AB; Hill, GL			Progressive cellular dehydration and proteolysis in critically ill patients	LANCET			English	Article							BODY-WATER; NUTRITION; MUSCLE	Background According to a recent hypothesis, the profound loss of body protein that occurs in critically ill patients is triggered and maintained by cell shrinkage secondary to cellular dehydration. We tested this hypothesis by studying sequential changes in intracellular water, total body protein, total body potassium, and intracellular potassium in patients receiving intensive care for blunt trauma or sepsis. Methods Nine patients with multiple blunt trauma and 11 with severe sepsis were studied in an intensive care unit for 21 days. Intracellular water was measured in two ways--by subtraction of extracellular water (bromide dilution) from total body water (tritium dilution), and by bioimpedance spectroscopy. Total body protein was measured by whole-body neutron activation analysis and total body potassium by whole-body counting. Findings Over the study period intracellular water decreased by 15-20%, total body protein by 15%, and total body potassium by about 20%. Intracellular potassium concentration did not change, and was similar to that in healthy adult volunteers. In the trauma patients, sequential measurements of the ratio of potassium to protein In lost tissue indicated that cells were losing water in quantities greater than would be expected from protein losses. Interpretation The loss of protein and potassium from body stores in major trauma or sepsis is accompanied by progressive cellular dehydration. This insight opens up new therapeutic options for limiting the loss of body protein in critically ill patients.	UNIV AUCKLAND, DEPT SURG, AUCKLAND HOSP, AUCKLAND 3, NEW ZEALAND	Auckland City Hospital; University of Auckland				Plank, Lindsay/0000-0003-2737-0151				BAXTER CR, 1966, CARE TRAUMA PATIENT, P541; BERGSTROM J, 1979, ACTA CHIR SCAND    S, V494, P356; BERGSTROM JP, 1987, ACTA CHIR SCAND, V153, P261; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; CHANDRA RK, 1994, J NUTR, V124, pS1433, DOI 10.1093/jn/124.suppl_8.1433S; Cuthbertson DP, 1942, LANCET, V1, P433; ELWYN DH, 1975, ANN SURG, V182, P76, DOI 10.1097/00000658-197507000-00015; GATZEN C, 1992, SURGERY, V112, P181; HALLBRUCKER C, 1991, EUR J BIOCHEM, V197, P717, DOI 10.1111/j.1432-1033.1991.tb15963.x; HAUSSINGER D, 1993, LANCET, V341, P1330, DOI 10.1016/0140-6736(93)90828-5; HAUSSINGER O, 1995, CLIN NUTR, V14, P4, DOI 10.1016/S0261-5614(06)80003-8; HILL GL, 1992, JPEN-PARENTER ENTER, V16, P197, DOI 10.1177/0148607192016003197; Hill GL, 1993, METABOLIC SUPPORT CR, P3; *ICRP, 1975, 23 IRCP REP; KARNER J, 1981, J PARENT ENT NUTR, V5, P368; LINDSTEDT E, 1975, ANN SURG, V181, P842, DOI 10.1097/00000658-197506000-00014; LUCAS CE, 1983, SURG CLIN N AM, V63, P439; McGee JO, 1992, OXFORD TXB PATHOLOGY; MITRA S, 1989, PHYS MED BIOL, V34, P61, DOI 10.1088/0031-9155/34/1/006; MITRA S, 1993, PHYS MED BIOL, V38, P1971, DOI 10.1088/0031-9155/38/12/019; MONK DN, IN PRESS ANN SURG; ROTH E, 1985, CLIN CHEM, V31, P1305; STREAT SJ, 1985, METABOLISM, V34, P688, DOI 10.1016/0026-0495(85)90099-X; VANLOAN MD, 1993, BASIC LIFE SCI, P67; WINDSOR J A, 1988, Australian and New Zealand Journal of Surgery, V58, P711, DOI 10.1111/j.1445-2197.1988.tb01101.x; WINDSOR JA, 1988, ANN SURG, V207, P290, DOI 10.1097/00000658-198803000-00011; Ziegler T. R., 1993, Clinical Nutrition, V12, pS82, DOI 10.1016/S0261-5614(09)90014-0; [No title captured]	28	122	135	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	1996	347	9002					654	656		10.1016/S0140-6736(96)91204-0	http://dx.doi.org/10.1016/S0140-6736(96)91204-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596380				2022-12-24	WOS:A1996TZ28500012
J	McGrath, AM; Jackson, GA				McGrath, AM; Jackson, GA			Survey of neuroleptic prescribing in residents of nursing homes in Glasgow	BRITISH MEDICAL JOURNAL			English	Article							DRUG-USE		PARKHEAD HOSP,GLASGOW G31 5BA,LANARK,SCOTLAND; KNIGHTSWOOD HOSP,GLASGOW G13 2XF,LANARK,SCOTLAND					jackson, graham/0000-0002-0526-7084				BROWN JW, 1993, J NERV MENT DIS, V181, P695, DOI 10.1097/00005053-199311000-00008; JENCKS SF, 1991, JAMA-J AM MED ASSOC, V265, P502; MONANE M, 1993, ARCH INTERN MED, V153, P633, DOI 10.1001/archinte.153.5.633; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; SENLA TP, 1994, J AM GERIATR SOC, V42, P648	5	105	105	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					611	612						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TZ840	8595335				2022-12-24	WOS:A1996TZ84000025
J	Pantel, K; Izbicki, J; Passlick, B; Angstwurm, M; Haussinger, K; Thetter, O; Riethmuller, G				Pantel, K; Izbicki, J; Passlick, B; Angstwurm, M; Haussinger, K; Thetter, O; Riethmuller, G			Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases	LANCET			English	Article							MICROMETASTATIC CARCINOMA-CELLS; MONOCLONAL-ANTIBODIES; EXPRESSION; TISSUES; CYTOKERATIN; EPITHELIA; GENE	Background Metastasis is generally looked on as a late event in the natural history of epithelial tumours. However, the poor prognosis of patients with apparently localised lung cancer indicates that micrometastases occur often before diagnosis of the primary tumour. Methods At primary surgery, disseminated tumour cells were detected immunocytochemically in bone marrow of 139 patients with non-small-cell lung carcinomas without evidence of distant metastases (pT(1-4)pN(1-2)M(0)). Tumour cells in bone-marrow aspirates were detected with monoclonal antibody CK2 against cytokeratin polypeptide 18. Patients were followed up for a median of 39 months (range 14-52) after surgery. 215 patients without epithelial cancer (ie, with benign epithelial tumours, nonepithelial neoplasms, or inflammatory diseases) acted as controls. Findings In 83 of 139 (59.7%) patients cytokeratin-positive cells were detected at frequencies of 1 in 100 000 to 1 in 1 000 000. Even without histopathological involvement of lymph nodes (pN(0)), tumour cells were found in 38 of 70 (54.3%) patients. 1 positive cell was found in each of 6 out of 215 controls. Surgical manipulation during primary tumour resection did not affect the frequency of these cells. In Cox's regression analyses, the presence of such cells was a significant and independent predictor for a later clinical relapse in node-negative patients (p=0.028). Interpretation Early dissemination of isolated tumour cells is a frequent and intrinsic characteristic of non-small-cell lung carcinomas. The finding of these cells may help to decide whether adjuvant systemic therapy is required for the individual patient.	UNIV MUNICH, CHIRURG KLINIKUM INNENSTADT, D-80336 MUNICH, GERMANY; UNIV HAMBURG, KRANKENHAUS EPPENDORF, KLIN ALLGEMEINCHIRURG, HAMBURG, GERMANY; ZENT KRANKENHAUS GAUTING, ABT THORAXCHIRURG, GAUTING, GERMANY; ZENT KRANKENHAUS GAUTING, ABT PULMONOL, GAUTING, GERMANY	University of Munich; University of Hamburg	Pantel, K (corresponding author), UNIV MUNICH, INST IMMUNOL, D-80336 MUNICH, GERMANY.							BOS JL, 1989, CANCER RES, V49, P4682; BURKHARDT R, 1980, B CANCER, V67, P291; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DATTA YH, 1994, J CLIN ONCOL, V12, P475, DOI 10.1200/JCO.1994.12.3.475; DEBUS E, 1982, EMBO J, V1, P1641, DOI 10.1002/j.1460-2075.1982.tb01367.x; GOTTLINGER HG, 1986, INT J CANCER, V38, P47; GRUNOW N, 1991, PATHOLOGE, V12, P270; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARRISON WJ, 1962, J CLIN PATHOL, V15, P254, DOI 10.1136/jcp.15.3.254; HAYASHI N, 1995, LANCET, V345, P1257, DOI 10.1016/S0140-6736(95)90922-2; IMMERMAN SC, 1981, ANN THORAC SURG, V32, P23, DOI 10.1016/S0003-4975(10)61368-9; KRISMANN M, 1995, J CLIN ONCOL, V13, P2769, DOI 10.1200/JCO.1995.13.11.2769; LATZA U, 1990, J CLIN PATHOL, V43, P213, DOI 10.1136/jcp.43.3.213; LINDEMANN F, 1992, LANCET, V340, P685, DOI 10.1016/0140-6736(92)92230-D; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Minna JD, 1989, CANCER PRINCIPLES PR, P591; MOMBURG F, 1987, CANCER RES, V47, P2883; PAGE A, 1987, CAN J SURG, V30, P96; Pantel K, 1994, J Hematother, V3, P165, DOI 10.1089/scd.1.1994.3.165; PANTEL K, 1991, CANCER RES, V51, P4712; PANTEL K, 1995, JNCI-J NATL CANCER I, V87, P1162, DOI 10.1093/jnci/87.15.1162; PANTEL K, 1993, CANCER RES, V53, P1027; PANTEL K, 1993, JNCI-J NATL CANCER I, V85, P1419, DOI 10.1093/jnci/85.17.1419; PASSLICK B, 1994, J CLIN ONCOL, V12, P1827, DOI 10.1200/JCO.1994.12.9.1827; RIETHMULLER G, 1994, LANCET, V343, P1177, DOI 10.1016/S0140-6736(94)92398-1; SCHLIMOK G, 1987, P NATL ACAD SCI USA, V84, P8672, DOI 10.1073/pnas.84.23.8672; TRAWEEK ST, 1993, AM J PATHOL, V142, P1111; WOOD DP, 1994, J UROLOGY, V151, P303	28	336	346	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	1996	347	9002					649	653		10.1016/S0140-6736(96)91203-9	http://dx.doi.org/10.1016/S0140-6736(96)91203-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596379				2022-12-24	WOS:A1996TZ28500011
J	Abramovitz, DL; Friedman, RA; Pyle, AM				Abramovitz, DL; Friedman, RA; Pyle, AM			Catalytic role of 2'-hydroxyl groups within a group II intron active site	SCIENCE			English	Article							TETRAHYMENA RIBOZYME; TERTIARY INTERACTIONS; MESSENGER-RNA; MECHANISM; BINDING; RIBOSE; SUBSTRATE; DOMAIN-5; CORE	Domain 5 is an essential active-site component of group II intron ribozymes. The role of backbone substituents in D5 function was explored through synthesis of a series of derivatives containing deoxynucleotides at each position along the D5 strand. Kinetic screens revealed that eight 2'-hydroxyl groups were likely to be critical for activity of D5. Through two separate methods, including competitive inhibition and direct kinetic analysis, effects on binding and chemistry were distinguished. Depending on their function, important 2'-hydroxyl groups lie on opposite faces of the molecule, defining distinct loci for molecular recognition and catalysis by D5.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University					NIGMS NIH HHS [GM41371, GM50313] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041371, R01GM050313] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITZ D, UNPUB; BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; BOULANGER SC, 1995, MOL CELL BIOL, V15, P4479; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CHANFREAU G, 1994, SCIENCE, V266, P1383, DOI 10.1126/science.7973729; COSTA M, 1995, EMBO J, V14, P1276, DOI 10.1002/j.1460-2075.1995.tb07111.x; Daniels DL, 1996, J MOL BIOL, V256, P31, DOI 10.1006/jmbi.1996.0066; DOUDNA JA, 1995, RNA, V1, P36; FERSHT A, 1985, ENZYME STRUCTURE MEC, P102; FRANZEN JS, 1993, NUCLEIC ACIDS RES, V21, P627, DOI 10.1093/nar/21.3.627; FRIEDMAN RA, 1992, BIOPOLYMERS, V32, P145, DOI 10.1002/bip.360320205; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8299, DOI 10.1021/bi00083a034; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8312, DOI 10.1021/bi00083a035; JAEGER L, 1993, J MOL BIOL, V234, P331, DOI 10.1006/jmbi.1993.1590; JAEGER L, 1994, J MOL BIOL, V236, P1271, DOI 10.1016/0022-2836(94)90055-8; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KNITT DS, 1994, BIOCHEMISTRY-US, V33, P13864, DOI 10.1021/bi00250a041; KOCH JL, 1992, MOL CELL BIOL, V12, P1950, DOI 10.1128/MCB.12.5.1950; KWAKMAN JHJM, 1990, J BIOMOL STRUCT DYN, V8, P413, DOI 10.1080/07391102.1990.10507813; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MAJOR F, 1991, SCIENCE, V253, P1255, DOI 10.1126/science.1716375; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; MUSIERFORSYTH K, 1992, NATURE, V357, P513, DOI 10.1038/357513a0; PEEBLES CL, 1995, P NATL ACAD SCI USA, V92, P4422, DOI 10.1073/pnas.92.10.4422; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PODAR M, 1995, MOL CELL BIOL, V15, P4466; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P2716, DOI 10.1021/bi00175a047; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P13856, DOI 10.1021/bi00250a040; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; PYLE AM, 1995, CURR OPIN STRUC BIOL, V5, P303, DOI 10.1016/0959-440X(95)80091-3; PYLE AM, IN PRESS NUCLEIC ACI; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; STROBEL SA, 1993, BIOCHEMISTRY-US, V32, P13593, DOI 10.1021/bi00212a027; STROBEL SA, 1995, SCIENCE, V267, P675, DOI 10.1126/science.7839142; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; YU YT, 1995, RNA, V1, P46	41	99	117	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1410	1413		10.1126/science.271.5254.1410	http://dx.doi.org/10.1126/science.271.5254.1410			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596912				2022-12-24	WOS:A1996TY96100044
J	Lee, N				Lee, N			South Africa's AIDS play provokes controversy	LANCET			English	News Item																			0	0	0	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					610	610		10.1016/S0140-6736(96)91306-9	http://dx.doi.org/10.1016/S0140-6736(96)91306-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596329				2022-12-24	WOS:A1996TX69400041
J	Lehtinen, M; Dillner, J; Knekt, P; Luostarinen, T; Aromaa, A; Kimbauer, R; Koskela, P; Paavonen, J; Peto, R; Schiller, JT; Hakama, M				Lehtinen, M; Dillner, J; Knekt, P; Luostarinen, T; Aromaa, A; Kimbauer, R; Koskela, P; Paavonen, J; Peto, R; Schiller, JT; Hakama, M			Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: Nested case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To study human papillomavirus type 16 in the aetiology of cervical c Design-Within a cohort of 18 814 Finnish women followed for up to 23 years a nested case-control study was conducted based on serological diagnosis of past infection with human papillomavirus type 16. Subjects-72 women (27 with invasive carcinoma and 45 with in situ carcinoma) and 143 matched controls were identified during the follow up. Main outcome measure- Relative risk of cervical carcinoma in presence of IgG antibodies to human papillomavirus type 16. Results-After adjustment for smoking and for antibodies to various other agents of sexually transmitted disease, such as herpes simplex virus type 2 and Chlamydia trachomatis, the only significant association was with infection with human papillomavirus type 16 (odds ratio 12.5; 95% confidence interval 2.7 to 57, 2P < 0.001). Conclusion-This prospective study provides epidemiological evidence that infection with human papillomavirus type 16 confers an excess risk for subsequent development of cervical carcinoma.	TAMPERE UNIV, TAMPERE SCH PUBL HLTH, SF-33101 TAMPERE, FINLAND; NATL PUBL HLTH INST, OULU, FINLAND; NATL PUBL HLTH INST, DEPT CHRON VIRAL DIS, SF-00300 HELSINKI, FINLAND; KAROLINSKA INST, MICROBIOL & TUMORBIOL CTR, STOCKHOLM, SWEDEN; SOCIAL INSURANCE INST, CTR RES & DEV, SF-00381 HELSINKI, FINLAND; FINNISH CANC REGISTRY, SF-00170 HELSINKI, FINLAND; UNIV VIENNA, SCH MED, DEPT IMMUNODERMATOL, VIENNA, AUSTRIA; HELSINKI UNIV, HELSINKI, FINLAND; UNIV OXFORD, CLIN TRIAL SERV UNIT, OXFORD, ENGLAND; UNIV OXFORD, IMPERIAL CANC RES FUND, CANC STUDIES UNIT, OXFORD, ENGLAND; NCI, CELLULAR ONCOL LAB, BETHESDA, MD 20892 USA	Tampere University; Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; Karolinska Institutet; Finnish Cancer Registry; University of Vienna; University of Helsinki; University of Oxford; University of Oxford; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Schiller, John/ABK-8287-2022	Luostarinen, Tapio/0000-0003-3231-8550; lehtinen, matti/0000-0002-9481-0535				Breslow N. E., 1980, IARC SCI PUBLICATION, V32; Chabaud Martine, 1994, P59; DILLNER J, 1994, CANCER RES, V54, P134; DILLNER J, 1995, INT J CANCER, V60, P377; HAKAMA M, 1993, AM J EPIDEMIOL, V137, P166, DOI 10.1093/oxfordjournals.aje.a116656; HANNA L, 1980, J CLIN MICROBIOL, V12, P409, DOI 10.1128/JCM.12.3.409-412.1980; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; KIMBAUER R, 1994, JNCI-J NATL CANCER I, V86, P494; LEHTINEN M, 1986, EUR J CLIN MICROBIOL, V5, P596, DOI 10.1007/BF02017713; MARDH PA, 1989, CHLAMYDIA, P1; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; NONNENMACHER B, 1995, J INFECT DIS, V172, P19, DOI 10.1093/infdis/172.1.19; PAAVONEN J, 1996, SEXUALLY TRANSMITTED; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958	14	132	136	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 2	1996	312	7030					537	539		10.1136/bmj.312.7030.537	http://dx.doi.org/10.1136/bmj.312.7030.537			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595281	Green Published			2022-12-24	WOS:A1996TY88500021
J	Esteban, JI; Gomez, J; Martell, M; Cabot, B; Quer, J; Camps, J; Gonzalez, A; Otero, T; Moya, A; Esteban, R; Guardia, J				Esteban, JI; Gomez, J; Martell, M; Cabot, B; Quer, J; Camps, J; Gonzalez, A; Otero, T; Moya, A; Esteban, R; Guardia, J			Transmission of hepatitis C virus by a cardiac surgeon	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSTTRANSFUSION HEPATITIS; NEEDLESTICK INJURY; DENTAL PRACTICE; INFECTION; RNA; HCV; ANTIBODIES; REGIONS; ASSAY	Background. In the course of a study conducted from 1992 through 1994 of the efficacy of screening blood donors for antibodies to hepatitis C virus (HCV), we found that two patients had acquired hepatitis C after cardiac surgery, with the transmission apparently unrelated to blood transfusions, Because their surgeon had chronic hepatitis C, we sought to determine whether he was transmitting the virus to his patients. Methods. Of 222 of the surgeon's patients who participated in studies of post-transfusion hepatitis between 1988 and 1994, 6 contracted postoperative hepatitis C, despite the use of only seronegative blood for transfusions, All six patients had undergone valve-replacement surgery, Analyses were performed to compare nucleotide sequences encompassing the hypervariable region at the junction between the coding regions for envelope glycoproteins E1 and E2 in the surgeon, the patients, and 10 controls infected with the same HCV genotype. Results. The surgeon and five of the six patients with hepatitis C unrelated to transfusion were infected with HCV genotype 3; the sixth patient had genotype 1 and was considered to have been infected from another source, Thirteen other patients of the surgeon had transfusion associated hepatitis C and were also infected with genotype 1. The average net genetic distance between the sequences from the five patients with HCV genotype 3 and those from the surgeon was 2.1 percent (range, 1.1 to 2.5 percent; P<0,001), as compared with an average distance of 7.6 percent (range, 6.1 to 8.3 percent) between the sequences from the patients and those from the controls, The results of a phylogenetic-tree analysis indicated a common epidemiologic origin of the viruses from the surgeon and the five patients. Conclusions. Our findings provide evidence that a cardiac surgeon with chronic hepatitis C may have transmitted HCV to five of his patients during open-heart surgery.	UNIV AUTONOMA BARCELONA,HOSP GEN VALLE HEBRON,LIVER UNIT,DEPT MED,E-08035 BARCELONA,SPAIN; UNIV VALENCIA,DEPT GENET,VALENCIA,SPAIN	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; University of Valencia			Martell, Maria/J-8191-2013; Quer, Josep/A-6741-2012; Moya, Andrés/A-8190-2008; Jordi, Gómez/L-6112-2015	Martell, Maria/0000-0002-0935-0029; Quer, Josep/0000-0003-0014-084X; Moya, Andrés/0000-0002-2867-1119; Gomez, Jordi/0000-0002-7806-1503; esteban, rafael/0000-0001-5280-392X				AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; [Anonymous], VIRAL HEPATITIS LIVE; Brown AJL, 1994, EVOLUTIONARY BIOL VI, P75; CARIANI E, 1991, LANCET, V337, P850, DOI 10.1016/0140-6736(91)92555-G; CHUNG HT, 1993, HEPATOLOGY, V18, P1045; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; DANILA RN, 1991, NEW ENGL J MED, V325, P1406, DOI 10.1056/NEJM199111143252003; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; GONZALEZ A, 1995, HEPATOLOGY, V22, P439, DOI 10.1016/0270-9139(95)90563-4; HIJIKATA M, 1991, BIOCHEM BIOPH RES CO, V175, P220, DOI 10.1016/S0006-291X(05)81223-9; HOSIE KB, 1988, LANCET, V2, P1500; HUANG YY, 1994, TRANSFUSION, V34, P661, DOI 10.1046/j.1537-2995.1994.34894353459.x; LAU JYN, 1993, LANCET, V342, P504; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; MARTELL M, 1992, J VIROL, V66, P3225, DOI 10.1128/JVI.66.5.3225-3229.1992; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1016/0270-9139(92)90001-P; NEI M, 1989, MOL BIOL EVOL, V6, P290; NELSON KE, 1992, NEW ENGL J MED, V327, P1601; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; OKAMOTO H, 1993, J GEN VIROL, V74, P2385, DOI 10.1099/0022-1317-74-11-2385; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PRENTICE MB, 1992, BRIT MED J, V304, P761, DOI 10.1136/bmj.304.6829.761; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SEEFF LB, 1991, ANN INTERN MED, V115, P411, DOI 10.7326/0003-4819-115-5-411_1; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; SUZUKI K, 1994, J INFECT DIS, V170, P1575, DOI 10.1093/infdis/170.6.1575; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; VILADOMIU L, 1992, HEPATOLOGY, V15, P767, DOI 10.1002/hep.1840150504; WANG YJ, 1994, VOX SANG, V67, P187, DOI 10.1111/j.1423-0410.1994.tb01657.x; WEINER AJ, 1993, J VIROL, V67, P4365, DOI 10.1128/JVI.67.7.4365-4368.1993; WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J; YOUNG KKY, 1993, J CLIN MICROBIOL, V31, P882, DOI 10.1128/JCM.31.4.882-886.1993; 1991, MMWR-MORBID MORTAL W, V40, P1; 1991, LANCET, V338, P1040	37	296	302	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 29	1996	334	9					555	560		10.1056/NEJM199602293340902	http://dx.doi.org/10.1056/NEJM199602293340902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW696	8569822				2022-12-24	WOS:A1996TW69600002
J	Nightingale, SL				Nightingale, SL			Fat substitute Olestra approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					585	585		10.1001/jama.275.8.585	http://dx.doi.org/10.1001/jama.275.8.585			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594230				2022-12-24	WOS:A1996TW62700031
J	Gittoes, NJL; Miller, MR; Daykin, J; Sheppard, MC; Franklyn, JA				Gittoes, NJL; Miller, MR; Daykin, J; Sheppard, MC; Franklyn, JA			Upper airways obstruction in 153 consecutive patients presenting with thyroid enlargement	BRITISH MEDICAL JOURNAL			English	Article									UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham								Committee on Research into Chronic Bronchitis, 1966, QUESTIONNAIRE RESP S; COOPER JC, 1991, ANN ROY COLL SURG, V73, P32; EMPEY DW, 1972, BRIT MED J, V3, P503, DOI 10.1136/bmj.3.5825.503; MILLER MR, 1990, Q J MED, V74, P177; MILLER MR, 1988, THORAX, V43, P265, DOI 10.1136/thx.43.4.265	5	61	62	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					484	484		10.1136/bmj.312.7029.484	http://dx.doi.org/10.1136/bmj.312.7029.484			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597682	Green Published			2022-12-24	WOS:A1996TX38300027
J	Roberts, J				Roberts, J			Light and dark in life and death	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					466	466		10.1136/bmj.312.7029.466a	http://dx.doi.org/10.1136/bmj.312.7029.466a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597675	Green Published			2022-12-24	WOS:A1996TX38300018
J	Krueger, NX; VanVactor, D; Wan, HI; Gelbart, WM; Goodman, CS; Saito, H				Krueger, NX; VanVactor, D; Wan, HI; Gelbart, WM; Goodman, CS; Saito, H			The transmembrane tyrosine phosphatase DLAR controls motor axon guidance in Drosophila	CELL			English	Article							CELL-ADHESION MOLECULE; GROWTH CONE GUIDANCE; NERVOUS-SYSTEM AXONS; IMMUNOGLOBULIN SUPERFAMILY; CYTOPLASMIC REGION; GENETIC-ANALYSIS; FASCICLIN-II; C-ELEGANS; RECEPTOR; PROTEIN	DLAR is a receptor-like, transmembrane protein-tyrosine phosphatase in Drosophila that is expressed almost exclusively by developing neurons. Analysis of Dlar loss-of-function mutations shows that DLAR plays a key role during motoneuron growth cone guidance. Segmental nerve b (SNb) motor axons normally exit the common motor pathway, enter the ventral target region, and then synapse on specific ventral muscles. In Dlar mutant embryos, SNb axons bypass their normal target region and instead continue to extend along the common pathway. SNd motor axons also make pathfinding errors, while SNa and SNc axons appear normal. Thus, DLAR controls the ability of certain motor axons to navigate specific choice points in the developing Drosophila nervous system.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DIV NEUROBIOL,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of California System; University of California Berkeley; Harvard University			Saito, Haruo/AAF-6113-2019	Saito, Haruo/0000-0001-7891-1689; Van Vactor, Jr., David L./0000-0001-8156-9482	NIGMS NIH HHS [GM53415] Funding Source: Medline; PHS HHS [AL26598] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; AULD VJ, 1995, CELL, V81, P757, DOI 10.1016/0092-8674(95)90537-5; BARNES WM, 1987, METHOD ENZYMOL, V152, P538; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; BEIER DR, 1992, P NATL ACAD SCI USA, V89, P9102, DOI 10.1073/pnas.89.19.9102; BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BIXBY JL, 1993, J NEUROSCI, V13, P3421; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DESAI CJ, 1996, CELL, V84; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOODMAN CS, 1996, IN PRESS ANN REV NEU, V19; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARIHARAN IK, 1991, P NATL ACAD SCI USA, V88, P11266, DOI 10.1073/pnas.88.24.11266; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KOPCZYNSKI CC, 1992, J CELL BIOL, V119, P503, DOI 10.1083/jcb.119.3.503; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LIN DM, 1995, NEURON, V14, P707, DOI 10.1016/0896-6273(95)90215-5; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; Maness P F, 1990, Adv Exp Med Biol, V265, P117; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; OGRADY P, 1994, J BIOL CHEM, V269, P25193; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PAN MG, 1993, J BIOL CHEM, V268, P19284; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PULIDO R, 1995, J BIOL CHEM, V270, P6722, DOI 10.1074/jbc.270.12.6722; RAMOS RGP, 1993, GENE DEV, V7, P2533, DOI 10.1101/gad.7.12b.2533; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER T, 1995, NEURON, V15, P259, DOI 10.1016/0896-6273(95)90032-2; Schultz Leonard D., 1993, Cell, V73, P1445; SPINARDI L, 1991, NUCLEIC ACIDS RES, V19, P4009, DOI 10.1093/nar/19.14.4009; STOKER AW, 1995, DEVELOPMENT, V121, P1833; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; YAN H, 1993, J BIOL CHEM, V268, P24880; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; Zinn Kai, 1993, Seminars in Cell Biology, V4, P397, DOI 10.1006/scel.1993.1047	62	293	297	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					611	622		10.1016/S0092-8674(00)81036-3	http://dx.doi.org/10.1016/S0092-8674(00)81036-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598047	Bronze			2022-12-24	WOS:A1996TX17600013
J	Chua, SC; Chung, WK; WuPeng, XS; Zhang, YY; Liu, SM; Tartaglia, L; Leibel, RL				Chua, SC; Chung, WK; WuPeng, XS; Zhang, YY; Liu, SM; Tartaglia, L; Leibel, RL			Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; HUMAN DNA; OBESITY; YEAST; CONSTRUCTION; INSERTS; CLONING; MODEL; MICE	Mice harboring mutations in the obese (ob) and diabetes (db) genes display similar phenotypes, and it has been proposed that these genes encode the ligand and receptor, respectively, for a physiologic pathway that regulates body weight. The cloning of ob, and the demonstration that it encodes a secreted protein (leptin) that binds specifically to a receptor (OB-R) in the brain, have validated critical aspects of this hypothesis. Here it is shown by genetic mapping and genomic analysis that mouse db, rat fatty (a homolog of db), and the gene encoding the OB-R are the same gene.	ROCKEFELLER UNIV,HUMAN BEHAV & METAB LAB,NEW YORK,NY 10021; MILLENNIUM PHARMACEUT,CAMBRIDGE,MA 02139	Rockefeller University; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals					NICHD NIH HHS [HD28047] Funding Source: Medline; NIDDK NIH HHS [DK26687, DK47473] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047473, P30DK026687] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUBERT R, 1985, J NUTR, V115, P327, DOI 10.1093/jn/115.3.327; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHARTIER FL, 1992, NAT GENET, V1, P132, DOI 10.1038/ng0592-132; CHUA SJ, UNPUB; CHUNG WK, 1995, 2ND CHROM ONE M VIEN; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HUMMEL KP, 1966, SCIENCE, V153, P1127, DOI 10.1126/science.153.3740.1127; KERSHAW EE, 1995, GENOMICS, V27, P149, DOI 10.1006/geno.1995.1017; KOLETSKY S, 1973, EXP MOL PATHOL, V19, P53, DOI 10.1016/0014-4800(73)90040-3; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LEIBEL RL, 1993, CRIT REV FOOD SCI, V33, P351, DOI 10.1080/10408399309527632; LEITER EH, 1980, DIABETOLOGIA, V19, P66, DOI 10.1007/BF00258314; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MAFFEI M, 1995, NAT MED, V1, P1; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PIERCE JC, 1992, MAMM GENOME, V3, P550, DOI 10.1007/BF00350620; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TRUETT GE, 1991, P NATL ACAD SCI USA, V88, P7806, DOI 10.1073/pnas.88.17.7806; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZUCKER LM, 1961, J HERED, V52, P275, DOI 10.1093/oxfordjournals.jhered.a107093	28	954	991	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					994	996		10.1126/science.271.5251.994	http://dx.doi.org/10.1126/science.271.5251.994			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584938				2022-12-24	WOS:A1996TV70400051
J	Cheng, EHY; Levine, B; Boise, LH; Thompson, CB; Hardwick, JM				Cheng, EHY; Levine, B; Boise, LH; Thompson, CB; Hardwick, JM			Bax-independent inhibition of apoptosis by Bcl-x(L)	NATURE			English	Article							SINDBIS VIRUS; MICE	THE Bcl-2-related protein, Bcl-x(L), has been shown to block apoptosis induced by a variety of stimuli(1-5) and to be a stronger protector against apoptosis than Bcl-2 under certain circumstances(2,5). Using site-specific mutagenesis, we show here that the amino-acid residues critical for protection of cells by Bcl-x(L) against Sindbis virus-induced apoptosis are clustered within the Bcl-2-homology regions 1 and 2 (BH1 and BH2 regions). The residues necessary for Bcl-x(L) function are not identical to those required for Bcl-2 function(6), Although it has been suggested that heterodimerization between Bcl-x(L) and Bax is essential for the anti death activity of Bcl-x(L) (refs 7, 8), our results suggest that the interaction with Bax is not required for Bcl-x(L) to exert its death-repressing activity, Specific mutations that disrupt the ability of Bcl-x(L) to interact with Bax or Bak still preserve 70-80% of the anti-death activity of wild-type Bcl-x(L).	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC GENET,CHICAGO,IL 60637; UNIV CHICAGO,DEPT CELL BIOL,CHICAGO,IL 60637	Columbia University; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago	Cheng, EHY (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,DEPT NEUROL,NEUROVIROL LABS,MEYER 6-181,BALTIMORE,MD 21287, USA.		Boise, Lawrence/AAD-2314-2019	Boise, Lawrence/0000-0001-9436-8815				BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOLSE LH, 1993, CELL, V74, P597; Bomer C, 1994, J CELL BIOL, V126, P1059; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; DOLE MG, 1995, CANCER RES, V55, P2576; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; GOTTSCHALK AR, IN PRESS CELL DEATH; HERTZ JM, 1992, J VIROL, V66, P857, DOI 10.1128/JVI.66.2.857-864.1992; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KAMADA S, 1995, CANCER RES, V55, P354; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; Lewis J, 1996, J VIROL, V70, P1828, DOI 10.1128/JVI.70.3.1828-1835.1996; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LUSTIG S, 1988, J VIROL, V62, P2329, DOI 10.1128/JVI.62.7.2329-2336.1988; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; TANAKA S, 1993, J BIOL CHEM, V268, P10920; UBOL S, 1994, P NATL ACAD SCI USA, V91, P5202, DOI 10.1073/pnas.91.11.5202; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	29	432	461	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					554	556		10.1038/379554a0	http://dx.doi.org/10.1038/379554a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596636				2022-12-24	WOS:A1996TU69300054
J	Rozenberg, P; Goffinet, F; Philippe, HJ; Nisand, I				Rozenberg, P; Goffinet, F; Philippe, HJ; Nisand, I			Ultrasonographic measurement of lower uterine segment to assess risk of defects of scarred uterus	LANCET			English	Article							PREVIOUS CESAREAN-SECTION; X-RAY PELVIMETRY; VAGINAL DELIVERY; RUPTURE; DEHISCENCE; PREGNANCY; DIAGNOSIS; BIRTH	Background Ultrasonography has been used to examine the scarred uterus in women who have had previous caesarean sections in an attempt to assess the risk of rupture of the scar during subsequent labour. The predictive value of such measurements has not been adequately assessed, however. We aimed to evaluate the usefulness of sonographic measurement of the lower uterine segment before labour in predicting the risk of intrapartum uterine rupture. Methods In this prospective observational study, the obstetricians were not told the ultrasonographic findings and did not use them to make decisions about type of delivery. Eligible patients were those with previous caesarean sections booked for delivery at our hospital. 642 patients underwent ultrasound examination at 36-38 weeks' gestation, and were allocated to four groups according to the thickness of the lower uterine segment. Ultrasonographic findings were compared with those of physical examination at delivery. Findings The overall frequency of defective scars was 4.0% (15 ruptures, 10 dehiscences). The frequency of defects rose as the thickness of the lower uterine segment decreased: there were no defects among 278 women with measurements greater than 4.5 mm, three (2%) among 177 women with values of 3.6-4.5 mm, 14 (10%) among 136 women with values of 2.6-3.5 mm, and eight (16%) among 51 women with values of 1.6-2.5 mm. With a cutoff value of 3.5 mm, the sensitivity of ultrasonographic measurement was 88.0%, the specificity 73.2%, positive predictive value 11.8%, and negative predictive value 99.3%. Interpretation Our results show that the risk of a defective scar is directly related to the degree of thinning of the lower uterine segment at around 37 weeks of pregnancy. The high negative predictive value of the method may encourage obstetricians in hospitals where routine repeat elective caesarean is the norm to offer a trial of labour to patients with a thickness value of 3.5 mm or greater.			Rozenberg, P (corresponding author), CTR HOSP INTERCOMMUNAL,DEPT OBSTET & GYNAECOL,LEON TOUHLADJIAN,F-78303 POISSY,FRANCE.			GOFFINET, Francois/0000-0001-9643-0299				ACTON CM, 1978, AUSTRALAS RADIOL, V22, P254, DOI 10.1111/j.1440-1673.1978.tb02068.x; ARAKI T, 1982, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V34, P738; AVRECH OM, 1994, ULTRASOUND OBST GYN, V4, P151, DOI 10.1046/j.1469-0705.1994.04020151.x; BEDI DG, 1986, J CLIN ULTRASOUND, V14, P529, DOI 10.1002/jcu.1870140706; BROWN JE, 1986, AM J OBSTET GYNECOL, V155, P4; CHAPMAN K, 1994, BRIT J OBSTET GYNAEC, V101, P549, DOI 10.1111/j.1471-0528.1994.tb13163.x; CHAZOTTE C, 1990, AM J OBSTET GYNECOL, V163, P738, DOI 10.1016/0002-9378(90)91059-L; COWAN RK, 1994, OBSTET GYNECOL, V83, P933, DOI 10.1097/00006250-199406000-00006; FLAMM BL, 1988, AM J OBSTET GYNECOL, V158, P1079, DOI 10.1016/0002-9378(88)90224-4; FLAMM BL, 1994, OBSTET GYNECOL, V83, P927, DOI 10.1097/00006250-199406000-00005; GALE JT, 1986, J ULTRAS MED, V5, P713; KRISHNAMURTHY S, 1991, BRIT J OBSTET GYNAEC, V98, P716, DOI 10.1111/j.1471-0528.1991.tb13462.x; LAVIN JP, 1982, OBSTET GYNECOL, V59, P135; LEUNG AS, 1993, AM J OBSTET GYNECOL, V169, P945, DOI 10.1016/0002-9378(93)90032-E; MEEHAN FP, 1990, INT J GYNECOL OBSTET, V31, P249, DOI 10.1016/0020-7292(90)91019-M; MICHAELS WH, 1988, OBSTET GYNECOL, V71, P112; NIELSEN TF, 1989, AM J OBSTET GYNECOL, V160, P569, DOI 10.1016/S0002-9378(89)80029-8; OSMERS R, 1988, INT J GYNECOL OBSTET, V26, P279, DOI 10.1016/0020-7292(88)90274-3; PHELAN JP, 1987, AM J OBSTET GYNECOL, V157, P1510, DOI 10.1016/S0002-9378(87)80252-1; THUBISI M, 1993, BRIT J OBSTET GYNAEC, V100, P421, DOI 10.1111/j.1471-0528.1993.tb15265.x; 1981, NIH8220967 PUBL	21	175	194	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					281	284		10.1016/S0140-6736(96)90464-X	http://dx.doi.org/10.1016/S0140-6736(96)90464-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569360				2022-12-24	WOS:A1996TT48500007
J	RoelkeParker, ME; Munson, L; Packer, C; Kock, R; Cleaveland, S; Carpenter, M; OBrien, SJ; Pospischil, A; HofmannLehmann, R; Lutz, H; Mwamengele, GLM; Mgasa, MN; Machange, GA; Summers, BA; Appel, MJG				RoelkeParker, ME; Munson, L; Packer, C; Kock, R; Cleaveland, S; Carpenter, M; OBrien, SJ; Pospischil, A; HofmannLehmann, R; Lutz, H; Mwamengele, GLM; Mgasa, MN; Machange, GA; Summers, BA; Appel, MJG			A canine distemper virus epidemic in Serengeti lions (Panthera leo)	NATURE			English	Article								CANINE distemper virus (CDV) is thought to have caused several fatal epidemics in canids within the Serengeti-Mara ecosystem of East Africa, affecting silver-backedjackals (Canis mesomelas) and bat-cared foxes (Otocyon megalotis) in 1978 (ref. 1), and African wild dogs (Lycaon pictus) in 1991 (refs 2, 3). The large, closely monitored Serengeti lion population(4,5) was not affected in these epidemics. However, an epidemic caused by a morbillivirus closely related to CDV emerged abruptly in the lion population of the Serengeti National Pack, Tanzania, in early 1994, resulting in fatal neurological disease characterized by grand mal seizures and myoclonus; the lions that died had encephalitis and pneumonia. Here we report the identification of CDV from these lions, and the close phylogenetic relationship between CDV isolates from lions and domestic dogs. By August 1994, 85% of the Serengeti lion population had anti-CDV antibodies, and the epidemic spread north to lions in the Maasai Mara National reserve, Kenya, and uncounted hyaenas, bat-eared foxes, and leopards were also affected.	UNIV TENNESSEE,COLL VET MED,DEPT PATHOL,KNOXVILLE,TN 37901; SERENGETI WILDLIFE RES INST,TANZANIA NATL PARKS,ARUSHA,TANZANIA; MESSERLI FDN,ZURICH,SWITZERLAND; UNIV MINNESOTA,DEPT ECOL EVOLUT & BEHAV,ST PAUL,MN 55108; KENYA WILDLIFE SERV,NAIROBI,KENYA; INST ZOOL,LONDON NW1 4RY,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND; NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; UNIV ZURICH,INST VET PATHOL,CH-8057 ZURICH,SWITZERLAND; UNIV ZURICH,DEPT VET INTERNAL MED,CH-8057 ZURICH,SWITZERLAND; SOKOINE UNIV AGR,DEPT VET PATHOL,MOROGORO,TANZANIA; VET INVEST CTR,ARUSHA,TANZANIA; CORNELL UNIV,COLL VET MED,DEPT PATHOL,ITHACA,NY 14853; CORNELL UNIV,COLL VET MED,JAMES A BAKER INST ANIM HLTH,ITHACA,NY 14853	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; University of Minnesota System; University of Minnesota Twin Cities; University of London; London School of Hygiene & Tropical Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Zurich; University of Zurich; Sokoine University of Agriculture; Cornell University; Cornell University			Hofmann-Lehmann, Regina/C-6528-2009; OBRIEN, STEPHEN/ABD-1346-2020	Hofmann-Lehmann, Regina/0000-0001-9750-4296; Carpenter, Margaret/0000-0003-1606-1986; Kock, Richard/0000-0002-6561-3209; OBRIEN, STEPHEN/0000-0001-7857-0757				ALEXANDER KA, 1994, J WILDLIFE DIS, V30, P481, DOI 10.7589/0090-3558-30.4.481; APPEL M, 1973, AM J VET RES, V34, P1459; APPEL MJ, 1987, VIRUS INFECT CARNIVO, P00133; APPEL MJG, 1992, J VET DIAGN INVEST, V4, P258, DOI 10.1177/104063879200400306; APPEL MJG, 1994, J VET DIAGN INVEST, V6, P277, DOI 10.1177/104063879400600301; BARRETT T, 1993, VIROLOGY, V193, P1010, DOI 10.1006/viro.1993.1217; BROWN EW, 1993, J ZOO WILDLIFE MED, V24, P357; BROWN EW, 1994, J VIROL, V68, P5953, DOI 10.1128/JVI.68.9.5953-5968.1994; CARMICHAEL LE, 1980, AM J VET RES, V41, P784; FELSTEINSTEIN J, 1995, PHYLOGENY INFERENCE; GILBERT DA, 1991, J HERED, V82, P378, DOI 10.1093/oxfordjournals.jhered.a111107; Hofer Heribert, 1993, Symposia of the Zoological Society of London, V65, P347; MACDONALD DW, 1992, NATURE, V360, P633, DOI 10.1038/360633b0; Moehlman PD, 1983, RECENT ADV STUDY MAM, P423; MONTALI RJ, 1991, VIRUS INFECTIONS CAR, P437; ORVELL C, 1985, J GEN VIROL, V66, P443, DOI 10.1099/0022-1317-66-3-443; Packer C., 1988, P363; PACKER C, 1995, AM NAT, V145, P833, DOI 10.1086/285771; SWAFFORD DL, 1984, PHYLOGENETIC ANAL US; WILDT DE, 1987, NATURE, V329, P328, DOI 10.1038/329328a0	20	521	549	3	163	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					441	445		10.1038/379441a0	http://dx.doi.org/10.1038/379441a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559247	Bronze, Green Published			2022-12-24	WOS:A1996TT30400057
J	Liese, JG; Jendrossek, V; Jansson, A; Petropoulou, T; Kloos, S; Gahr, M; Belohradsky, BH				Liese, JG; Jendrossek, V; Jansson, A; Petropoulou, T; Kloos, S; Gahr, M; Belohradsky, BH			Chronic granulomatous disease in adults	LANCET			English	Article							HUMAN-NEUTROPHILS; INFECTION; PHAGOCYTE; VARIANT	Background Chronic granulomatous disease (CGD), an inherited disorder of granulocyte function caused by failure of intracellular superoxide production, normally presents in the first years of life with severe recurrent bacterial and fungal infections. Methods From the files of two children's hospitals we identified 11 CGD patients who were remarkable for an unusually late diagnosis, at 13-43 years of age. Their clinical and laboratory features were examined. Findings The first clinical manifestation occurred at a median age of 3.6 years but CGD was not diagnosed until a median age of 22 years. Pneumonias and abscesses caused by Staphylococcus aureus and Aspergillus species were the most frequent infections. Granulomas, often leading to chronic complications, occurred in 7 of the patients. With 1.1 severe infections in 100 patient months, the 11 patients had a lower frequency of severe infections than patients with classic CGD; however, such infections could be equally life-threatening. 8 of the patients had X-linked CGD with small but detectable quantities of cytochrome b(558), normally absent in X-linked CGD; and 3 had autosomal-recessive CGD. 9 patients had residual production of reactive oxygen metabolites, a feature that could explain the low incidence of infections. Interpretation CGD in adults may be more common than previously assumed. In view of the possibility of timely treatment, infection prophylaxis, and genetic counselling for affected families, CGD should be excluded in any patient with unexplained infections or granulomas.	UNIV GOTTINGEN,KINDERKLIN,W-3400 GOTTINGEN,GERMANY	University of Gottingen	Liese, JG (corresponding author), UNIV MUNICH,KINDERKLIN,LINDWURMSTR 4,D-80337 MUNICH,GERMANY.		Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107				BRIDGES RA, 1959, AMA J DIS CHILD, V97, P387, DOI 10.1001/archpedi.1959.02070010389004; CAZZOLA M, 1985, HAEMATOLOGICA, V76, P1581; CHUSID MJ, 1975, JAMA-J AM MED ASSOC, V233, P1295, DOI 10.1001/jama.233.12.1295; COHEN MS, 1981, AM J MED, V71, P59, DOI 10.1016/0002-9343(81)90259-X; CURNUTTE JT, 1986, ADV HUM GENET, V19, P229; DILWORTH JA, 1977, AM J MED, V63, P233, DOI 10.1016/0002-9343(77)90237-6; FINN A, 1990, ARCH DIS CHILD, V65, P942, DOI 10.1136/adc.65.9.942; GALLIN JI, 1983, ANN INTERN MED, V99, P657, DOI 10.7326/0003-4819-99-5-657; JENDROSSEK V, 1993, BLOOD, V81, P211; JOHNSTON RB, 1977, PEDIATR CLIN N AM, V24, P365; LANDING BH, 1957, PEDIATRICS, V20, P431; LUTTER R, 1984, J BIOL CHEM, V259, P9603; MARGOLIS DM, 1990, J INFECT DIS, V162, P723, DOI 10.1093/infdis/162.3.723; MOUY R, 1991, NEW ENGL J MED, V325, P1516; MOUY R, 1989, J PEDIATR-US, V114, P555, DOI 10.1016/S0022-3476(89)80693-6; NAKAMURA M, 1987, BLOOD, V69, P1404; NERURKAR LS, 1987, SOUTHERN MED J, V80, P1296, DOI 10.1097/00007611-198710000-00022; NEWBURGER PE, 1980, BLOOD, V55, P85; NEWBURGER PE, 1986, BLOOD, V68, P914; PREISIG E, 1971, EUR J CLIN INVEST, V1, P409, DOI 10.1111/j.1365-2362.1971.tb00550.x; ROOS D, 1992, J LEUKOCYTE BIOL, V51, P164, DOI 10.1002/jlb.51.2.164; SCHAPIRO BL, 1991, NEW ENGL J MED, V325, P1786, DOI 10.1056/NEJM199112193252506; SMITH RM, 1991, BLOOD, V77, P673; STYRT B, 1984, PEDIATR INFECT DIS J, V3, P556, DOI 10.1097/00006454-198411000-00015; TAUBER AI, 1983, MEDICINE, V62, P286, DOI 10.1097/00005792-198309000-00003; 1991, NEW ENGL J MED, V324, P509	26	106	108	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					220	223		10.1016/S0140-6736(96)90403-1	http://dx.doi.org/10.1016/S0140-6736(96)90403-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551880				2022-12-24	WOS:A1996TT06900009
J	Redd, SC; Kazembe, PN; Luby, SP; Nwanyanwu, O; Hightower, AW; Ziba, C; Wirima, JJ; Chitsulo, L; Franco, C; Olivar, M				Redd, SC; Kazembe, PN; Luby, SP; Nwanyanwu, O; Hightower, AW; Ziba, C; Wirima, JJ; Chitsulo, L; Franco, C; Olivar, M			Clinical algorithm for treatment of Plasmodium falciparum malaria in children	LANCET			English	Article							DIAGNOSIS; ANEMIA; INFECTIONS; THERAPY; AFRICA	Background Identification of children who need antimalarial treatment is difficult in settings where confirmatory laboratory testing is not available, as in much of sub-Saharan Africa. The current national policy in Malawi is to treat all children with fever, usually defined as the mother's report of fever in the child, for presumed malaria. To assess this policy and to find out whether a better clinical case definition could be devised, we studied acutely ill children presenting to two hospital outpatient departments in Malawi. Methods The parent or guardian of each enrolled child (n=1124) was asked a standard series of questions about the symptoms and duration of the child's illness. Each child was examined, axillary and rectal temperatures and blood haemoglobin concentrations were measured, and a giemsa-stained thick smear was examined for malaria parasites. Logistic regression procedures were used to identify clinical predictors of parasitaemia. Findings High temperature (37.7 degrees C or above), nailbed palter, enlarged spleen, and being seen at one of the clinics rather than the other were associated with an increased risk of malaria parasitaemia in univariate analyses. A revised malaria case definition of rectal temperature of 37.7 degrees C or higher, spienomegaly, or nailbed pallor was 85% sensitive in identifying parasitaemic children and 41% specific; the corresponding sensitivity and specificity for the nationally recommended definition that equates mother's history of fever with malaria were 93% and 21%. The revised case definition had 89% sensitivity in identifying parasitaemic children with concentration below g/L and 89% sensitivity in identifying children with parasite density greater than 10 000/mu L, characteristics that indicate a clear need for antimalarial treatment. Interpretation These results suggest that better clinical definitions are feasible, that splenomegaly and pallor are helpful in identifying children with malaria, and that much overtreatment of children without parasitaemia could be avoided.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV PARASIT DIS,ATLANTA,GA 30341; KAMUZU CENT HOSP,DEPT PAEDIAT,LILONGWE,MALAWI; MALAWI MINIST HLTH,COMMUNITY HLTH SCI UNIT,LILONGWE,MALAWI; UNIV MALAWI,COLL MED,CHICHIRI,MALAWI	Centers for Disease Control & Prevention - USA; University of Malawi								BASSETT MT, 1991, J TROP MED HYG, V94, P65; BJORCK M, 1992, HEALTH POLICY PLANN, V7, P290, DOI 10.1093/heapol/7.3.290; BJORKMAN A, 1990, T ROY SOC TROP MED H, V84, P177, DOI 10.1016/0035-9203(90)90246-B; BJORKMAN A, 1991, B WORLD HEALTH ORGAN, V69, P297; BLOLAND PB, 1993, J INFECT DIS, V167, P932, DOI 10.1093/infdis/167.4.932; DELFINI LF, 1973, J TROP MED HYG, V76, P111; Field J. W., 1937, Transactions of the Royal Society of Tropical Medicine and Hygiene London, V30, P569, DOI 10.1016/S0035-9203(37)90070-1; GJORUP T, 1986, AM J EPIDEMIOL, V124, P657, DOI 10.1093/oxfordjournals.aje.a114438; GREENWOOD BM, 1987, PARASITOL TODAY, V3, P206, DOI 10.1016/0169-4758(87)90061-5; GROVER SA, 1993, JAMA-J AM MED ASSOC, V270, P2218, DOI 10.1001/jama.270.18.2218; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; MILLER KD, 1986, AM J TROP MED HYG, V35, P451, DOI 10.4269/ajtmh.1986.35.451; NARDONE DA, 1990, ARCH INTERN MED, V150, P201, DOI 10.1001/archinte.150.1.201; OLIVAR M, 1991, T ROY SOC TROP MED H, V85, P729, DOI 10.1016/0035-9203(91)90432-X; PETERSEN E, 1991, J INFECT DIS, V164, P949, DOI 10.1093/infdis/164.5.949; REDD SC, 1992, LANCET, V340, P1140, DOI 10.1016/0140-6736(92)93160-O; ROUGEMONT A, 1991, LANCET, V338, P1292, DOI 10.1016/0140-6736(91)92592-P; SANCHEZCARRILLO CI, 1989, J CLIN EPIDEMIOL, V42, P751, DOI 10.1016/0895-4356(89)90071-1; SCHELLENBERG JRMA, 1994, PARASITOL TODAY, V10, P439, DOI 10.1016/0169-4758(94)90179-1; SMITH T, 1994, STAT MED, V13, P2345, DOI 10.1002/sim.4780132206; STROBACH RS, 1988, ARCH INTERN MED, V148, P831, DOI 10.1001/archinte.148.4.831; SUTRISNA B, 1991, LANCET, V338, P471, DOI 10.1016/0140-6736(91)90544-Y; TAMAYO SG, 1993, J GEN INTERN MED, V8, P69, DOI 10.1007/BF02599986; TRAORE M, 1991, EVALUATION IMPACT FO, P1; WURAPA FK, 1986, J TROP MED HYG, V89, P33; 1992, AFRO22 TECHN PAP, P1	26	68	70	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					223	227		10.1016/S0140-6736(96)90404-3	http://dx.doi.org/10.1016/S0140-6736(96)90404-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551881	Green Submitted			2022-12-24	WOS:A1996TT06900010
J	Graur, D; Duret, L; Gouy, M				Graur, D; Duret, L; Gouy, M			Phylogenetic position of the order Lagomorpha (rabbits, hares and allies)	NATURE			English	Article							RODENTIA	EVER since they have been classified as ruminants in the Old Testament (Leviticus 11:6, Deuteronomy 14:7) and equated with hyraxes in the vulgate Latin translation, rabbits and their relatives (order Lagomorpha) have frequently experienced radical changes in taxonomic rank By using 91 orthologous protein sequences, we have attempted to answer the classical question ''What, if anything, is a rabbit?''(1). Here we show that Lagomorpha is significantly more closely related to Primates and Scandentia (tree shrews) than it is to rodents. This newly determined phylogenetic position invalidates the superordinal taxon Glires (Lagomorpha + Rodentia), and indicates that the morphological 'synapomorphies' previously used to cluster rodents and lagomorphs into Glires(2,3), may actually represent symplesiomorphies or homoplasies that are of no phylogenetic value. This raises the possibility that the ancestral eutherian morphotype may have possessed many rodent-like morphological characters.	UNIV LYON 1,LAB BIOMETRIE GENET & BIOL POPULAT,CNRS,URA 2055,F-69622 VILLEURBANNE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Graur, D (corresponding author), TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT ZOOL,IL-69978 RAMAT AVIV,ISRAEL.			Duret, Laurent/0000-0003-2836-3463				BAILEY WJ, 1992, SCIENCE, V256, P86, DOI 10.1126/science.1301735; CASANE D, 1994, GENETICS, V138, P471; DEJONG WW, 1993, MAMMAL PHYLOGENY : PLACENTALS, P5; DURET L, 1994, NUCLEIC ACIDS RES, V22, P2360, DOI 10.1093/nar/22.12.2360; EASTEAL S, 1990, GENETICS, V124, P165; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Felsenstein J, 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; GEORGE DG, 1994, NUCLEIC ACIDS RES, V22, P3569; GRAUR D, 1992, COMP BIOCHEM PHYS B, V101, P495, DOI 10.1016/0305-0491(92)90327-N; GRAUR D, 1991, NATURE, V351, P649, DOI 10.1038/351649a0; Hasegawa, 1992, COMPUTER SCI MONOGRA, V27; Kimura M, 1985, NEUTRAL THEORY MOL E; KISHINO H, 1990, J MOL EVOL, V30, P151; LI WH, 1989, MOL BIOL EVOL, V6, P424; LI WH, 1990, P NATL ACAD SCI USA, V87, P6703, DOI 10.1073/pnas.87.17.6703; Luckett W. P., 1993, Journal of Mammalian Evolution, V1, P127, DOI 10.1007/BF01041591; McKenna MC., 1975, PHYLOGENY PRIMATES, P21, DOI [DOI 10.1007/978-1-4684-2166-8_2, 10.1007/978-1-4684-2166-8_2]; MIGNOTTE F, 1990, EUR J BIOCHEM, V194, P561, DOI 10.1111/j.1432-1033.1990.tb15653.x; MILINKOVITCH MC, 1995, TRENDS ECOL EVOL, V10, P328, DOI 10.1016/S0169-5347(00)89120-X; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; NOVACEK MJ, 1988, PHYLOGENY CLASSIFICA, V2, P31; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WOOD AE, 1957, EVOLUTION, V11, P417, DOI 10.2307/2406062	25	222	228	0	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					333	335		10.1038/379333a0	http://dx.doi.org/10.1038/379333a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552186				2022-12-24	WOS:A1996TR32300055
J	Kashina, AS; Baskin, RJ; Cole, DG; Wedaman, KP; Saxton, WM; Scholey, JM				Kashina, AS; Baskin, RJ; Cole, DG; Wedaman, KP; Saxton, WM; Scholey, JM			A bipolar kinesin	NATURE			English	Article							ELECTRON-MICROSCOPY; MITOTIC SPINDLE; FISSION YEAST; IN-VITRO; PROTEIN; MOTOR; MICROTUBULES; GENE; ORGANIZATION; ANTIBODY	CHROMOSOME Segregation during mitosis depends on the action of the mitotic spindle, a self-organizing, bipolar protein machine which uses microtubules (MTs) and their associated motors(1,2). Members of the BimC subfamily of kinesin-related MT-motor proteins are believed to be essential for the formation and functioning of a normal bipolar spindle(3-14). Here we report that KRP(130), a homotetrameric BimC-related kinesin purified from Drosophila melanogaster embryos(13), has an ultrastructure. It consists of four kinesin-related polypeptides assembled into a bipolar aggregate with motor domains at opposite ends, analogous to a miniature myosin filament(15). Such a bipolar 'minifilament' could crosslink spindle MTs and slide them relative to one another. We do not know of any other MT motors that have a bipolar structure.	INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington	Kashina, AS (corresponding author), UNIV CALIF DAVIS,SECT MOLEC & CELLULAR BIOL,DAVIS,CA 95616, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046295] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046295, R01 GM046295-09] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOS LA, 1987, J CELL SCI, V87, P105; ANDREWS SB, 1993, P NATL ACAD SCI USA, V90, P6503, DOI 10.1073/pnas.90.14.6503; BARTON NR, 1995, MOL BIOL CELL, V6, P1563, DOI 10.1091/mbc.6.11.1563; COLE DG, 1994, J BIOL CHEM, V269, P22913; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOGAN CJ, 1993, P NATL ACAD SCI USA, V90, P6611, DOI 10.1073/pnas.90.14.6611; HOULISTON E, 1994, DEV BIOL, V164, P147, DOI 10.1006/dbio.1994.1187; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; HUXLEY H, 1954, NATURE, V173, P973, DOI 10.1038/173973a0; HUXLEY HE, 1963, J MOL BIOL, V7, P281, DOI 10.1016/S0022-2836(63)80008-X; KOONCE MP, 1987, NATURE, V328, P737, DOI 10.1038/328737a0; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; MITCHISON TJ, 1992, PHILOS T ROY SOC B, V336, P99, DOI 10.1098/rstb.1992.0049; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; SANDERS WS, 1992, CELL, V70, P451; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; TSUPRUN VL, 1991, DOKL AKAD NAUK SSSR+, V320, P1270; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VEMOS I, 1995, TRENDS CELL BIOL, V5, P297; YUMURA S, 1985, NATURE, V314, P194, DOI 10.1038/314194a0	28	291	302	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					270	272		10.1038/379270a0	http://dx.doi.org/10.1038/379270a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538794	Green Accepted			2022-12-24	WOS:A1996TQ16900050
J	Barr, S				Barr, S			The 1990 Florida dental investigation: Is the case really closed?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							TRANSMISSION	In 1994, a magazine article, a newspaper article, and a segment of the television newsmagazine 60 Minutes presented information that cast doubt on the Centers for Disease Control and Prevention's conclusion that a dentist in Florida had infected six of his patients with the human immunodeficiency virus (HIV). These reports were based on previously unavailable documentary evidence, which suggested that the infected patients had unreported or undetected risk factors for HIV infection and that the molecular analyses used to determine that the dentist and his patients had the same strains of HIV had potentially serious flaws. A recent article in this journal sought to dismiss the relevance of this information in the eyes of the scientific community. That report, however, failed to respond directly to many key pieces of evidence, and it offered no rebuttal beyond personal invective and a reassertion of previously published material. Although scientists and clinicians should not rely solely on media reports when drawing conclusions about this complex and controversial case, they deserve a chance to consider and reflect on this material in a meaningful way.										BARR S, 1994, LEARS MAGAZINE   APR, P68; BARR S, 1994, NY TIMES        0416; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; CIESIELSKI CA, 1994, ANN INTERN MED, V121, P886, DOI 10.7326/0003-4819-121-11-199412010-00011; CRANDALL KA, 1995, J VIROL, V69, P2351, DOI 10.1128/JVI.69.4.2351-2356.1995; DEBRY RW, 1993, NATURE, V361, P691, DOI 10.1038/361691a0; HILLIS DM, 1994, NATURE, V369, P24, DOI 10.1038/369024a0; HOLMES EC, 1993, NATURE, V364, P766, DOI 10.1038/364766b0; JAFFE HW, 1994, ANN INTERN MED, V121, P855, DOI 10.7326/0003-4819-121-11-199412010-00005; KORBER B, 1992, AIDS RES HUM RETROV, V8, P1549, DOI 10.1089/aid.1992.8.1549; SMITH TF, 1992, SCIENCE, V256, P1155, DOI 10.1126/science.256.5060.1155	11	8	9	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					250	254		10.7326/0003-4819-124-2-199601150-00009	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ016	8534001				2022-12-24	WOS:A1996TQ01600009
J	Bateman, AC				Bateman, AC			Pathogenesis of sudden ischaemic cardiac death	LANCET			English	Editorial Material							CORONARY-ARTERY DISEASE; THROMBOSIS				Bateman, AC (corresponding author), QUEEN ALEXANDRA HOSP, DEPT HISTOPATHOL, PORTSMOUTH, HANTS, ENGLAND.							ALFONSO F, 1995, J AM COLL CARDIOL, V26, P135, DOI 10.1016/0735-1097(95)00186-4; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DAVIES MJ, 1985, BRIT HEART J, V53, P363; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; DIMAIO VJM, 1993, AM J FOREN MED PATH, V14, P273, DOI 10.1097/00000433-199312000-00001; DISCIASCIO G, 1994, AM HEART J, V128, P419, DOI 10.1016/0002-8703(94)90612-2; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; HENNEKENS CH, 1995, J AM COLL CARDIOL, V25, pS18; LEACH IH, 1995, EUR HEART J, V16, P1181, DOI 10.1093/oxfordjournals.eurheartj.a061073; MULLER JE, 1994, J AM COLL CARDIOL, V23, P809, DOI 10.1016/0735-1097(94)90772-2; WARNES CA, 1984, AM HEART J, V108, P431, DOI 10.1016/0002-8703(84)90404-6	11	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	1996	347	8994					70	71		10.1016/S0140-6736(96)90204-4	http://dx.doi.org/10.1016/S0140-6736(96)90204-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538340				2022-12-24	WOS:A1996TP28100003
J	Levy, A				Levy, A			Why flush?	LANCET			English	Editorial Material											Levy, A (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,BRISTOL BS2 8HW,AVON,ENGLAND.							GELLER J, 1991, J AM GERIATR SOC, V39, P1208, DOI 10.1111/j.1532-5415.1991.tb03576.x; GINSBURG J, 1983, BRIT MED J, V387, P262; HARDIMAN PJ, 1995, J N AM MENOPAUSE SOC, V2, P159; Huggins C, 1941, CANCER RES, V1, P293; KARLING P, 1994, J UROLOGY, V152, P1170, DOI 10.1016/S0022-5347(17)32530-2; LABRIE F, 1995, J CLIN ENDOCR METAB, V80, P2002, DOI 10.1210/jc.80.7.2002; LOPRINZI CL, 1994, J UROLOGY, V151, P634, DOI 10.1016/S0022-5347(17)35034-6; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; SMITH JA, 1994, J UROLOGY, V152, P132, DOI 10.1016/S0022-5347(17)32835-5	9	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					73	74		10.1016/S0140-6736(96)90206-8	http://dx.doi.org/10.1016/S0140-6736(96)90206-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538342				2022-12-24	WOS:A1996TP28100005
J	Tait, DR; Ward, KN; Brown, DWG; Miller, E				Tait, DR; Ward, KN; Brown, DWG; Miller, E			Measles and rubella misdiagnosed in infants as Exanthem subitum (roseola infantum)	BRITISH MEDICAL JOURNAL			English	Article							HUMAN HERPESVIRUS-6		UNIV LONDON,ROYAL POSTGRAD MED SCH,DEPT VIROL,LONDON W12 0NN,ENGLAND; CENT PUBL HLTH LAB,PUBL HLTH LAB SERV,DIV VIRUS REFERENCE,ENTER & RESP VIRUS DIV,LONDON NW9 5HT,ENGLAND; PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,DIV IMMUNISAT,LONDON NW9 5EQ,ENGLAND	Imperial College London; University of London; Public Health England; Public Health England								BROWN DWG, 1994, BRIT MED J, V308, P1015, DOI 10.1136/bmj.308.6935.1015; JURETIC M, 1963, HELVETICA PAEDIATRIC, V1, P80; Miller E, 1994, Commun Dis Rep CDR Rev, V4, pR146; WARD KN, 1993, J MED VIROL, V39, P131, DOI 10.1002/jmv.1890390209; YAMANISHI K, 1988, LANCET, V1, P1065	5	42	42	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					101	102						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555893				2022-12-24	WOS:A1996TQ16800030
J	Boleti, H; Karsenti, E; Vernos, I				Boleti, H; Karsenti, E; Vernos, I			Xklp2, a novel Xenopus centrosomal kinesin-like protein required for centrosome separation during mitosis	CELL			English	Article							SPINDLE FORMATION; EXTRACTS; SEQUENCES; CELLS	We describe a novel Xenopus plus end-directed kinesin-like protein (KLP), Xklp2, localized on centrosomes throughout the cell cycle and on spindle pole microtubules during metaphase. Using mitotic spindles assembled in Xenopus egg extracts and different recombinant GST-Xklp2 mutants, we show that this motor is targeted to spindle poles through its C-terminal domain. Xklp2-truncated polypeptides lacking the motor domain block centrosome separation and disrupt preassembled metaphase spindles. Antibodies directed against the tail of Xklp2 have a similar effect. These results show that Xklp2 protein is required for centrosome separation and maintenance of spindle bipolarity. This study is an example of the application of the dominant negative mutant effect on spindle assembly in Xenopus egg extracts, demonstrating the usefulness of this approach in probing the function of proteins in this system.	EUROPEAN MOLEC BIOL LAB,CELL BIOPHYS PROGRAMME,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	Boleti, H (corresponding author), EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.		Vernos, Isabelle/C-1687-2015	Vernos, Isabelle/0000-0003-1469-9214				ANDERSEN SSL, 1994, J CELL BIOL, V127, P1289, DOI 10.1083/jcb.127.5.1289; BLOOM GS, 1994, PROTEIN PROFILE, V1; CHANDRA R, 1993, METHODS CELL BIOL; DING R, 1993, J CELL BIOL, V120, P141, DOI 10.1083/jcb.120.1.141; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; FELIX MA, 1994, J CELL BIOL, V124, P19, DOI 10.1083/jcb.124.1.19; GARD DL, 1994, DEV BIOL, V161, P131, DOI 10.1006/dbio.1994.1015; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; GORBSKY GJ, 1992, BIOESSAYS, V14, P73, DOI 10.1002/bies.950140202; HARLOW E, 1988, ANTIBODIES LABORATOR; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HERINGA J, 1993, PROTEINS, V17, P391, DOI 10.1002/prot.340170407; HILLER G, 1978, CELL, V14, P795, DOI 10.1016/0092-8674(78)90335-5; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1991, J CELL SCI S, V14, P125; Karsenti E, 1991, Semin Cell Biol, V2, P251; KISHINIO A, 1988, NATURE, V293, P566; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCINTOSH JR, 1991, J CELL BIOL, V115, P577, DOI 10.1083/jcb.115.3.577; MCINTOSJH RJ, 1994, MICROTUBULES; MILLER L, 1977, IN VITRO CELL DEV B, V13, P557; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; REINSCH S, 1994, J CELL BIOL, V126, P1509, DOI 10.1083/jcb.126.6.1509; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SAWIN ES, 1995, P NATL ACAD SCI USA, V92, P4289; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SCHATTEN G, 1994, DEV BIOL, V165, P299, DOI 10.1006/dbio.1994.1256; SELLERS JR, 1993, METHODS CELL BIOL; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SINARD JH, 1990, J CELL BIOL, V111, P2417, DOI 10.1083/jcb.111.6.2417; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STELZER EHK, 1989, P SOC PHOTOOPT INSTR, V1026, P146; SULLIVAN W, 1990, DEVELOPMENT, V110, P311; VERNOS I, 1993, DEV BIOL, V157, P232, DOI 10.1006/dbio.1993.1127; VERNOS I, 1995, TRENDS CELL BIOL, V5, P297, DOI 10.1016/S0962-8924(00)89045-5; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WATERS JC, 1993, J CELL BIOL, V122, P361, DOI 10.1083/jcb.122.2.361	47	131	134	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					49	59		10.1016/S0092-8674(00)80992-7	http://dx.doi.org/10.1016/S0092-8674(00)80992-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548825	Bronze			2022-12-24	WOS:A1996TQ17000008
J	Kuwayama, H; Ecke, M; Gerisch, G; VanHaastert, PJM				Kuwayama, H; Ecke, M; Gerisch, G; VanHaastert, PJM			Protection against osmotic stress by cGMP-mediated myosin phosphorylation	SCIENCE			English	Article							HEAVY-CHAIN PHOSPHORYLATION; DICTYOSTELIUM-DISCOIDEUM; SIGNAL-TRANSDUCTION; ATPASE ACTIVITY; CYCLIC-AMP; MUTANTS; LACKING; GENE; REPLACEMENT; DISRUPTION	Conventional myosin functions universally as a generator of motive force in eukaryotic cells. Analysis of mutants of the microorganism Dictyostelium discoideum revealed that myosin also provides resistance against high external osmolarities. An osmo-induced increase of intracellular guanosine 3',5'-monophosphate was shown to mediate phosphorylation of three threonine residues on the myosin tail, which caused a relocalization of myosin required to resist osmotic stress. This redistribution of myosin allowed cells to adopt a spherical shape and may provide physical strength to withstand extensive cell shrinkage in high osmolarities.	UNIV GRONINGEN, DEPT BIOCHEM, 9747 AG GRONINGEN, NETHERLANDS; MAX PLANCK INST BIOCHEM, D-82143 MARTINSRIED, GERMANY	University of Groningen; Max Planck Society								CHOWDHURY S, 1992, J CELL BIOL, V118, P561, DOI 10.1083/jcb.118.3.561; CHRISPEELS MJ, 1994, TRENDS BIOCHEM SCI, V19, P421, DOI 10.1016/0968-0004(94)90091-4; COX D, 1992, J CELL BIOL, V116, P943, DOI 10.1083/jcb.116.4.943; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; GERISCH G, 1993, SYM SOC EXP BIOL, V47, P297; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; JANSSENS PMW, 1987, MICROBIOL REV, V51, P396, DOI 10.1128/MMBR.51.4.396-418.1987; JUNGBLUTH A, 1994, J CELL SCI, V107, P117; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUWAYAMA H, 1993, J CELL BIOL, V123, P1453, DOI 10.1083/jcb.123.6.1453; KUWAYAMA H, UNPUB; LIU G, 1993, J CELL SCI, V106, P591; LUCKVIELMETTER D, 1990, FEBS LETT, V269, P239, DOI 10.1016/0014-5793(90)81163-I; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MAGER WH, 1993, MOL MICROBIOL, V10, P253, DOI 10.1111/j.1365-2958.1993.tb01951.x; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MATO JM, 1977, P NATL ACAD SCI USA, V74, P2348, DOI 10.1073/pnas.74.6.2348; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; OYAMA M, UNPUB; PAGH K, 1986, J CELL BIOL, V103, P1527, DOI 10.1083/jcb.103.4.1527; PASTERNAK C, 1989, J CELL BIOL, V109, P203, DOI 10.1083/jcb.109.1.203; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; SCHUSTER SC, UNPUB; SPUDICH JA, 1989, CELL REGUL, V1, P1; STREET HE, 1984, PHYSL FLOWERING PLAN; TRUONG T, 1992, J BIOL CHEM, V267, P9767; VANHAASTERT PJM, 1983, J CELL BIOL, V96, P347, DOI 10.1083/jcb.96.2.347; WITKE W, 1992, CELL, V68, P53, DOI 10.1016/0092-8674(92)90205-Q; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667; YUMURA S, 1985, NATURE, V314, P194, DOI 10.1038/314194a0	33	101	101	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	1996	271	5246					207	209		10.1126/science.271.5246.207	http://dx.doi.org/10.1126/science.271.5246.207			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539621	Green Submitted			2022-12-24	WOS:A1996TP36400043
J	Cocker, JH; Piatti, S; Santocanale, C; Nasmyth, K; Diffley, JFX				Cocker, JH; Piatti, S; Santocanale, C; Nasmyth, K; Diffley, JFX			An essential role for the Cdc6 protein in forming the pre-replicative complexes of budding yeast	NATURE			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; DIVISION; CYCLE	ORIGINS Of DNA replication in Saccharomyces cerevisiae are bound by two protein complexes during the cell cycle(1,2). Post-replicative complexes closely resemble those generated in vitro by purified origin recognition complex (ORC)(1,3-5), which is essential for DNA replication in vivo(6-11). Pre-replicative complexes (pre-RCs) are characterized by an extended region of nuclease protection overlapping the ORC footprint(1). We show here that the Cdc6 protein (Cdc6p), which is necessary for origin firing in vivo(12-16), is essential for the establishment and maintenance of pre-RCs, suggesting that it is a component of these complexes. Without Cdc6p, G1 origins closely resemble post-replicative origins, providing evidence that ORC is also a component of pre-RCs, These results suggest that pre-RCs play an essential role in initiating DNA replication and support a two-step mechanism for the assembly of functional initiation complexes.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Piatti, Simonetta/0000-0003-1958-8919; Nasmyth, Kim/0000-0001-7030-4403; Diffley, John/0000-0001-5184-7680; Santocanale, Corrado/0000-0003-1337-5656				BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BROWN JA, 1991, MOL CELL BIOL, V11, P5301, DOI 10.1128/MCB.11.10.5301; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; CHEREST H, 1985, GENE, V34, P269; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351; [No title captured]	26	294	299	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					180	182		10.1038/379180a0	http://dx.doi.org/10.1038/379180a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538771				2022-12-24	WOS:A1996TP36000063
J	Macready, WG; Siapas, AG; Kauffman, SA				Macready, WG; Siapas, AG; Kauffman, SA			Criticality and parallelism in combinatorial optimization	SCIENCE			English	Article							SYSTEMS; MODEL	Local search methods constitute one of the most successful approaches to solving large-scale combinatorial optimization problems. As these methods are increasingly parallelized, optimization performance initially im proves but then abruptly degrades to no better than that of random search beyond a certain point. The existence of this transition is demonstrated for a family of generalized spin-glass models and the traveling salesman problem. Finite-size scaling is used to characterize size-dependent effects near the transition, and analytical insight is obtained through a mean-field approximation.	MIT, DEPT ELECT ENGN & COMP SCI, CAMBRIDGE, MA 02139 USA; SANTA FE INST, SANTA FE, NM 87501 USA	Massachusetts Institute of Technology (MIT); The Santa Fe Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049619] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azencott R., 1992, SIMULATED ANNEALING; Binnet J. J, 1992, THEORY CRITICAL PHEN; Cheeseman PC., 1991, IJCAI, V91, P331; Creswick RJ, 1992, INTRO RENORMALIZATIO; CVIJOVIC D, 1995, SCIENCE, V267, P664, DOI 10.1126/science.267.5198.664; DERRIDA B, 1981, PHYS REV B, V24, P2613, DOI 10.1103/PhysRevB.24.2613; Fischer KH., 1991, SPIN GLASSES, DOI [10.1017/CBO9780511628771, DOI 10.1017/CBO9780511628771]; FORREST S, 1993, SCIENCE, V261, P872, DOI 10.1126/science.8346439; Glover F., 1990, ORSA Journal on Computing, V2, P4, DOI [10.1287/ijoc.1.3.190, 10.1287/ijoc.2.1.4]; HOGG T, 1991, IEEE T SYST MAN CYB, V21, P1325, DOI 10.1109/21.135679; KIRKPATRICK S, 1994, SCIENCE, V264, P1297, DOI 10.1126/science.264.5163.1297; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; LIN S, 1973, OPER RES, V21, P498, DOI 10.1287/opre.21.2.498; MACKEN CA, 1989, P NATL ACAD SCI USA, V86, P6191, DOI 10.1073/pnas.86.16.6191; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; Reinelt G., 1994, TRAVELING SALESMAN C; SIAPAS AG, UNPUB; WEINBERGER ED, 1991, PHYS REV A, V44, P6399, DOI 10.1103/PhysRevA.44.6399	18	34	51	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	1996	271	5245					56	59		10.1126/science.271.5245.56	http://dx.doi.org/10.1126/science.271.5245.56			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539600				2022-12-24	WOS:A1996TP02200040
J	Hannigan, GE; LeungHagesteijn, C; FitzGibbon, L; Coppolino, MG; Radeva, G; Filmus, J; Bell, JC; Dedhar, S				Hannigan, GE; LeungHagesteijn, C; FitzGibbon, L; Coppolino, MG; Radeva, G; Filmus, J; Bell, JC; Dedhar, S			Regulation of cell adhesion and anchorage-dependent growth by a new beta(1)-integrin-linked protein kinase	NATURE			English	Article							EXPRESSION; DIFFERENTIATION; INTEGRINS; SEQUENCE	THE interaction of cells with the extracellular matrix regulates cell shape, motility, growth, survival, differentiation and gene expression, through integrin-mediated signal transduction(1-3). We used a two-hybrid screen to isolate genes encoding proteins that interact with the beta(1)-integrin cytoplasmic domain. The most frequently isolated complementary DNA encoded a new, 59K serine/threonine protein kinase, containing four ankyrin-like repeats. We report here that this integrin-linked kinase (ILK) phosphorylated a beta(1)-integrin cytoplasmic domain peptide in vitro and coimmunoprecipitated with beta(1) in lysates of mammalian cells. Endogenous ILK kinase activity was reduced in response to fibronectin. Overexpression of p59(ILK) disrupted epithelial cell architecture and inhibited adhesion to integrin substrates, while inducing anchorage-independent growth. We propose that ILK is a receptor-proximal protein kinase regulating integrin-mediated signal transduction.	UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, CANC BIOL RES PROGRAM, TORONTO, ON M4N 3M5, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO, ON M4N 3M5, CANADA; UNIV OTTAWA, DEPT BIOCHEM, OTTAWA, ON K1N 6N5, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Ottawa			Hannigan, Greg/A-5092-2009	Dedhar, Shoukat/0000-0003-4355-1657				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BUICK RN, 1987, EXP CELL RES, V170, P300, DOI 10.1016/0014-4827(87)90308-9; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHEN YP, 1994, J BIOL CHEM, V269, P18307; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DEDHAR S, 1993, CLIN EXP METASTAS, V11, P391, DOI 10.1007/BF00132982; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FILMUS J, 1994, ONCOGENE, V9, P3627; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Sambrook J., 1989, MOL CLONING LAB MANU; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; STEPHENS LE, 1993, J CELL BIOL, V123, P1607, DOI 10.1083/jcb.123.6.1607; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	29	932	1015	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 4	1996	379	6560					91	96		10.1038/379091a0	http://dx.doi.org/10.1038/379091a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538749				2022-12-24	WOS:A1996TN21600063
J	YOUNG, TK; GELSKEY, DE				YOUNG, TK; GELSKEY, DE			IS NONCENTRAL OBESITY METABOLICALLY BENIGN - IMPLICATIONS FOR PREVENTION FROM A POPULATION SURVEY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							BODY-FAT DISTRIBUTION; CARDIOVASCULAR-DISEASE; RISK-FACTORS; MEN BORN; PARTICIPANTS; LIPIDS; FOLLOW; MASS	Objective.-To determine if individuals who are overall obese but have low waist-to-hip ratios have unfavorable lipid profiles, blood pressures, and glucose statuses. Design.-Cross-sectional study. Setting.-The Manitoba Heart Health Survey surveyed a representative sample of residents of the Canadian province of Manitoba. Participants.-A total of 2792 adults aged 18 to 74 years were interviewed, 2339 of whom underwent clinical examinations. Main Outcome Measures.-Blood pressure, fasting plasma glucose, total cholesterol, triglycerides, high-density lipoprotein, and low-density lipoprotein measurements were compared across categories of body mass index (BMI) and waist-to-hip ratio (WHR). Main Results.--Manitobans with noncentral obesity tend to occupy positions between those of the nonobese and the centrally obese in terms of the effect on blood pressure, plasma lipids, and glucose. In multiple linear regression models involving age, BMI, and WHR as independent variables and one of the metabolic variables as dependent variables, both BMI and WHR are significant independent predictors of most metabolic variables. Where both are significant, BMI tends to be the stronger predictor, with a larger standardized regression coefficient. Conclusions.-Noncentral obesity is not metabolically benign; BMI as an overall measure of obesity is as important as, and sometimes more important than, WHR in predicting metabolic effects. The recognition of the epidemiological significance of the WHR as a centrality measure of obesity should not divert attention from the metabolic risk status of noncentrally obese individuals who require continued health education to reduce weight.	CADHAM PROV LAB,WINNIPEG,MB,CANADA		YOUNG, TK (corresponding author), UNIV MANITOBA,FAC MED,DEPT COMMUNITY HLTH SCI,7509 BANNATYNE AVE,WINNIPEG,MB R3E 0W3,CANADA.							CONNELLY PW, 1992, CAN MED ASSOC J, V146, P1977; DOWSE GK, 1991, DIABETES CARE, V14, P271, DOI 10.2337/diacare.14.4.271; GELSKEY DE, 1994, J CLIN EPIDEMIOL, V47, P547, DOI 10.1016/0895-4356(94)90301-8; HODGE AM, 1993, INT J OBESITY, V17, P399; ISO H, 1991, INT J EPIDEMIOL, V20, P88, DOI 10.1093/ije/20.1.88; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; VAGUE J, 1956, AM J CLIN NUTR, V4, P20, DOI 10.1093/ajcn/4.1.20; YOUNG TK, 1989, AM J CLIN NUTR, V49, P786, DOI 10.1093/ajcn/49.5.786	10	41	43	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1939	1941		10.1001/jama.274.24.1939	http://dx.doi.org/10.1001/jama.274.24.1939			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568989				2022-12-24	WOS:A1995TL16900037
J	Doyle, G				Doyle, G			A new breed of parasuicide patient	BRITISH MEDICAL JOURNAL			English	Note											Doyle, G (corresponding author), ST LUKES HOSP,DEPT YOUNG PEOPLES,MIDDLESBROUGH TS4 3AF,CLEVELAND,ENGLAND.							1994, INT STATISTICAL CLAS	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1696	1696		10.1136/bmj.311.7021.1696	http://dx.doi.org/10.1136/bmj.311.7021.1696			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541763	Green Published			2022-12-24	WOS:A1995TL94200024
J	Sivolapenko, GB; Douli, V; Pectasides, D; Skarlos, D; Sirmalis, G; Hussain, R; Cook, J; CourtenayLuck, NS; Merkouri, E; Konstantinides, K; Epenetos, AA				Sivolapenko, GB; Douli, V; Pectasides, D; Skarlos, D; Sirmalis, G; Hussain, R; Cook, J; CourtenayLuck, NS; Merkouri, E; Konstantinides, K; Epenetos, AA			Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody	LANCET			English	Article							MONOCLONAL-ANTIBODIES; TUMOR-LOCALIZATION; NEOPLASMS; THERAPY; ANALOG	Specific tumour imaging with radiolabelled monoclonal antibodies has been extensively investigated. Although some success has been reported, there are many limitations due to the slow kinetics, poor extravasation, catabolism by the reticuloendothelial system, and nonspecific uptake of macromolecules such as antibodies. We have tried to overcome some of the problems associated with monoclonal antibodies while retaining their specificity by using an antibody-derived synthetic peptide. A synthetic pentadecapeptide (alpha M2) derived from the third heavy-chain complementarity-determining region (CDR-3H) of a tumour-associated monoclonal antibody was produced and shown to retain its specificity against the pan-carcinoma cell-surface antigen, polymorphic epithelial mucin, detected by the parent antibody. The peptide was radiolabelled with technetium-99m and injected intravenously to image malignant lesions in 26 women with primary, recurrent, or metastatic breast cancer. Visualisation of breast tumours and their metastases was obtained shortly after administration of alpha M2, and was optimum by 3 h. Overall, 57 (77%) of 74 sites were visualised. Successful imaging was achieved in 14 of 15 primary tumour sites and all of eight local recurrences. Five of six metastases in the opposite breast, eight of 15 metastatic axillary lymph nodes, and all of six metastatic supraclavicular lymph nodes were imaged. Metastatic sites in the lungs, mediastinum, chest wall, and liver were poorly visualised because of background cardiac blood pool, alpha M2 detected small lesions (<2 cm) as efficiently as larger ones. The peptide was rapidly (3 h) cleared from the circulation. No acute or chronic adverse reactions due to the alpha M2 were observed. Specific tumour targeting with the radiolabelled anticancer peptide alpha M2 offers new opportunities for breast cancer imaging and possibly therapy.	SAMARITAN HOSP,ANTISOMA LTD,LONDON,ENGLAND; ENCEPHALOS RES & THERAPEUT INST,ATHENS,GREECE; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CLIN ONCOL,ICRF,ONCOL UNIT,LONDON W12 0NN,ENGLAND; METAXA CANC HOSP,PIRAES,GREECE; AGII ANARGIRI CANC HOSP,ATHENS,GREECE; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT IMMUNOL,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London				Sivolapenko, Gregory/0000-0003-2388-362X				BOULIANNE GL, 1984, NATURE, V312, P643, DOI 10.1038/312643a0; BOVEN E, 1991, EUR J CANCER, V27, P1430, DOI 10.1016/0277-5379(91)90025-9; BUCHSBAUM DJ, 1985, INT J NUCL MED BIOL, V12, P79, DOI 10.1016/0047-0740(85)90160-3; COURTENAYLUCK NS, 1986, CANCER RES, V46, P6489; EPENETOS AA, 1986, CANCER RES, V46, P3183; EPENETOS AA, 1989, BRIT J CANCER, V59, P152, DOI 10.1038/bjc.1989.32; ESTEBAN JM, 1987, INT J CANCER, V39, P50, DOI 10.1002/ijc.2910390110; HALPERN SE, 1990, J NUCL MED, V31, P1436; HIRD V, 1991, BRIT J CANCER, V64, P911, DOI 10.1038/bjc.1991.425; HUSSAIN R, IN PRESS PEPTIDES; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; KALOFONOS HP, 1988, CANCER RES, V48, P1977; KRENNING EP, 1989, LANCET, V1, P242; SCHATTEN C, 1991, LANCET, V337, P395, DOI 10.1016/0140-6736(91)91169-U; SCHROFF RW, 1985, CANCER RES, V45, P879; SWALLOW DM, 1987, NATURE, V328, P82, DOI 10.1038/328082a0; VIRGOLINI I, 1994, NEW ENGL J MED, V331, P1116, DOI 10.1056/NEJM199410273311703	17	49	51	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1662	1666		10.1016/S0140-6736(95)92839-1	http://dx.doi.org/10.1016/S0140-6736(95)92839-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551823				2022-12-24	WOS:A1995TL42300009
J	Berlowitz, DR; Ash, AS; Brandeis, GH; Brand, HK; Halpern, JL; Moskowitz, MA				Berlowitz, DR; Ash, AS; Brandeis, GH; Brand, HK; Halpern, JL; Moskowitz, MA			Rating long-term care facilities on pressure ulcer development: Importance of case-mix adjustment	ANNALS OF INTERNAL MEDICINE			English	Article							NURSING-HOMES; QUALITY; MORTALITY; SORES; RISK	Objective: To determine the importance of case-mix adjustment in interpreting differences in rates of pressure ulcer development in Department of Veterans Affairs long-term care facilities. Design: A sample assembled from the Patient Assessment File, a Veterans Affairs administrative database, was used to derive predictors of pressure ulcer development; the resulting model was validated in a separate sample. Facility-level rates of pressure ulcer development, both unadjusted long-term care and adjusted for case mix using the predictive model, were compared. Setting: Department of Veterans Affairs long-term care facilities. Patients: The derivation sample consisted of 31 150 intermediate medicine and nursing home residents who were initially free of pressure ulcers and were institutionalized between October 1991 and April 1993. The validation sample consisted of 17 946 residents institutionalized from April 1993 to October 1993. Measurement: Development of a stage 2 or greater pressure ulcer. Results: 11 factors predicted pressure ulcer development. Validated performance properties of the resulting model were good. Model-predicted rates of pressure ulcer development at individual long-term care facilities varied from 1.9% to 6.3%, and observed rates ranged from 0% to 10.9%. Case-mix-adjusted rates and ranks of facilities differed considerably from unadjusted ratings. For example, among five facilities that were identified as high outliers on the basis of unadjusted rates, two remained as outliers after adjustment for case mix. Conclusions: Gong-term care facilities differ in case mix. Adjustments for case mix result in different judgments about facility performance and should be used when facility incidence rates are compared.	BOSTON UNIV, MED CTR, GEN INTERNAL MED SECT, BOSTON, MA 02118 USA; DEPT VET AFFAIRS, WASHINGTON, DC USA	Boston University	Berlowitz, DR (corresponding author), VET AFFAIRS MED CTR, HLTH SERV RES & DEV FIELD PROGRAM, 200 SPRINGS RD, BEDFORD, MA 01730 USA.		Ash, Arlene/AAG-2914-2019	Ash, Arlene/0000-0002-8448-0253; Berlowitz, Dan/0000-0002-8783-5611				ALLMAN RM, 1986, ANN INTERN MED, V105, P337, DOI 10.7326/0003-4819-105-3-337; ALLMAN RM, 1995, JAMA-J AM MED ASSOC, V273, P865, DOI 10.1001/jama.273.11.865; ALLMAN RM, 1989, NEW ENGL J MED, V320, P850; ANDERSEN KE, 1982, BMJ-BRIT MED J, V284, P1370, DOI 10.1136/bmj.284.6326.1370; BERGSTROM N, 1992, J AM GERIATR SOC, V40, P747, DOI 10.1111/j.1532-5415.1992.tb01845.x; BERLOWITZ DR, 1989, J AM GERIATR SOC, V37, P1043, DOI 10.1111/j.1532-5415.1989.tb06918.x; BERLOWITZ DR, 1993, IMPROVING CARE NURSI; BLUMENTHAL D, 1993, JAMA-J AM MED ASSOC, V269, P2775, DOI 10.1001/jama.269.21.2775; BRANDEIS GH, 1994, J AM GERIATR SOC, V42, P388, DOI 10.1111/j.1532-5415.1994.tb07486.x; BRANDEIS GH, 1990, JAMA-J AM MED ASSOC, V264, P2905, DOI 10.1001/jama.264.22.2905; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; GERON SM, 1991, GERONTOLOGIST, V31, P292, DOI 10.1093/geront/31.3.292; GREEN J, 1991, JAMA-J AM MED ASSOC, V265, P1849; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; HOSMER EW, 1989, APPL LOGISTIC REGRES; Institute of Medicine (US) Committee on Nursing Home Regulation, 1986, IMPR QUAL CAR NURS H; KANE RA, 1988, INQUIRY-J HEALTH CAR, V25, P132; KANE RL, 1990, J AM GERIATR SOC, V38, P704, DOI 10.1111/j.1532-5415.1990.tb01432.x; KASSIRER JP, 1994, NEW ENGL J MED, V330, P634, DOI 10.1056/NEJM199403033300910; LOCALIO AR, 1995, ANN INTERN MED, V122, P125, DOI 10.7326/0003-4819-122-2-199501150-00009; MCNEIL BJ, 1992, INQUIRY-J HEALTH CAR, V29, P298; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; O'Leary D S, 1993, Jt Comm J Qual Improv, V19, P487; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; RUDMAN D, 1993, J AM GERIATR SOC, V41, P1317, DOI 10.1111/j.1532-5415.1993.tb06482.x; RUDMAN D, 1993, AM J PHYS MED REHAB, V72, P276, DOI 10.1097/00002060-199310000-00005; RUDMAN D, 1993, J GEN INTERN MED, V8, P653, DOI 10.1007/BF02598281; SCHNEIDER DP, 1988, HLTH CARE FINANC REV, V10, P39; SCHWARTZ M, 1994, RISK ADJUSTMENT MEAS; *US AG HLTH CAR PO, 1992, PRESS ULC AD PRED PR; *US HLTH CAR FIN A, 1987, HCFA PUBL; VERSLUYSEN M, 1986, BRIT MED J, V292, P1311, DOI 10.1136/bmj.292.6531.1311; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WILKING SV, 1990, ANN M AM GER SOC ATL; WU AW, 1995, ANN INTERN MED, V122, P149, DOI 10.7326/0003-4819-122-2-199501150-00013; ZINN JS, 1993, MED CARE, V31, P475, DOI 10.1097/00005650-199306000-00001; 1990, INT J TECHNOL ASSESS, V6, P181	37	73	73	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1996	124	6					557	+		10.7326/0003-4819-124-6-199603150-00003	http://dx.doi.org/10.7326/0003-4819-124-6-199603150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ529	8597318				2022-12-24	WOS:A1996TZ52900003
J	Knekt, P; Jarvinen, R; Reunanen, A; Maatela, J				Knekt, P; Jarvinen, R; Reunanen, A; Maatela, J			Flavonoid intake and coronary mortality in Finland: A cohort study	BRITISH MEDICAL JOURNAL			English	Article							LOW-DENSITY-LIPOPROTEIN; DISEASE; WINE; RISK	Objective-To study the association between dietary intake of flavonoids and subsequent coronary mortality. Design-A cohort study based on data collected at the Finnish mobile clinic health examination survey from 1967-72 and followed up until 1992. Settings-30 communities from different parts of Finland. Subjects-5133 Finnish men and women aged 30-69 years and free from heart disease at baseline. Main outcome measure-Dietary intake of flavonoids, total mortality, and coronary mortality. Results-In women a significant inverse gradient was observed between dietary intake of flavonoids and total and coronary mortality. The relative risks between highest and lowest quarters of flavonoid intake adjusted for age, smoking, serum cholesterol concentration, blood pressure, and body mass index were 0.69 (95% confidence interval 0.53 to 0.90) and 0.54 (0.33 to 0.87) for total and coronary mortality, respectively. The corresponding values for men were 0.76 (0.63 to 0.93) and 0.78 (0.56 to 1.08), respectively. Adjustment for intake of antioxidant vitamins and fatty acids weakened the associations for women; the relative risks for coronary heart disease were 0.73 (0.41 to 1.32) and 0.67 (0.44 to 1.00) in women and men, respectively. Intakes of onions and apples, the main dietary sources of flavonoids, presented similar associations. The relative risks for coronary mortality between highest and lowest quarters of apple intake were 0.57 (0.36 to 0.91) and 0.81 (0.61 to 1.09) for women and men, respectively. The corresponding values for onions were 0.50 (0.30 to 0.82) and 0.74 (0.53 to 1.02), respectively. Conclusion-The results suggest that people with very low intakes of flavonoids have higher risks of coronary disease.	SOCIAL INSURANCE INST,CTR RES & DEV,HELSINKI,FINLAND; SOCIAL INSURANCE INST,CTR RES & DEV,TURKU,FINLAND; KUOPIO UNIV,DEPT CLIN NUTR,KUOPIO,FINLAND	University of Eastern Finland	Knekt, P (corresponding author), NATL PUBL HLTH INST,MANNERHEIMINTIE 166,SF-00300 HELSINKI,FINLAND.							[Anonymous], 1975, APPL MULTIPLE REGRES, DOI 10.4324/9780203774441.; AROMAA A, 1981, SERIES AL, V17; COX DR, 1972, J R STAT SOC B, V34, P187; DEWHALLEY CV, 1990, BIOCHEM PHARMACOL, V39, P1743, DOI 10.1016/0006-2952(90)90120-A; FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V; GAZIANO JM, 1994, NATURAL ANTIOXIDANTS; GRYGLEWSKI RJ, 1987, BIOCHEM PHARMACOL, V36, P317, DOI 10.1016/0006-2952(87)90288-7; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; Herrmann K., 1976, Journal of Food Technology, V11, P433, DOI 10.1108/09566160010378107; HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; HERTOG MGL, 1994, THESIS WAGENINGEN; HUANG TC, 1961, ANAL CHEM, V33, P1405, DOI 10.1021/ac60178a040; HUSSAIN SR, 1987, PHYTOCHEMISTRY, V26, P2489; JDRVINEN R, 1993, INT J EPIDEMIOL, V22, P520; KINSELLA JE, 1993, FOOD TECHNOL-CHICAGO, V47, P85; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; KNEKT P, 1990, AM J CLIN NUTR, V52, P903, DOI 10.1093/ajcn/52.5.903; KNEKT P, 1988, SERIES ML, V83; RANKIN SM, 1993, BIOCHEM PHARMACOL, V45, P67, DOI 10.1016/0006-2952(93)90378-A; REUNANEN A, 1983, ACTA MED SCAND S, V673, P1; STARKE H, 1976, Z LEBENSM UNTERS FOR, V161, P131, DOI 10.1007/BF01112856; Wildanger W., 1973, Zeitschrift fuer Lebensmittel-Untersuchung und -Forschung, V151, P103, DOI 10.1007/BF01842919; YUTING C, 1990, Free Radical Biology and Medicine, V9, P19	24	987	1026	1	46	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					478	481		10.1136/bmj.312.7029.478	http://dx.doi.org/10.1136/bmj.312.7029.478			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597679	Green Published			2022-12-24	WOS:A1996TX38300023
J	Agrawal, RK; Penczek, P; Grassucci, RA; Li, YH; Leith, A; Nierhaus, KH; Frank, J				Agrawal, RK; Penczek, P; Grassucci, RA; Li, YH; Leith, A; Nierhaus, KH; Frank, J			Direct visualization of A-, P-, and E-site transfer RNAs in the Escherichia coli ribosome	SCIENCE			English	Article							PHENYLALANINE TRANSFER-RNA; ANTICODON INTERACTION SITE; CRYSTAL-STRUCTURE; A-SITES; LOCALIZATION; RESOLUTION; TOPOGRAPHY; BINDING; SUBUNIT	Transfer RNA (tRNA) molecules play a crucial role in protein biosynthesis in all organisms. Their interactions with ribosomes mediate the translation of genetic messages into polypeptides. Three tRNAs bound to the Escherichia coli 70S ribosome were visualized directly with cryoelectron microscopy and three-dimensional reconstruction, The detailed arrangement of A- and P-site tRNAs inferred from this study allows localization of the sites for anticodon interaction and peptide bond formation on the ribosome.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, ALBANY, NY 12201 USA; SUNY ALBANY, DEPT BIOMED SCI, ALBANY, NY 12222 USA; MAX PLANCK INST MOLEC GENET, D-14195 BERLIN, GERMANY	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Max Planck Society			Leith', Ardean/AAI-5163-2020		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029169] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR01219] Funding Source: Medline; NIGMS NIH HHS [1R01 GM29169] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEYER D, 1994, J BIOL CHEM, V269, P30713; BRIMACOMBE R, 1995, EUR J BIOCHEM, V230, P365; BURMA DP, 1986, STRUCTURE FUNCTION G, P438; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GORNICKI P, 1984, J BIOL CHEM, V259, P493; GRAJEVSKAJA RA, 1982, EUR J BIOCHEM, V128, P47; JOHNSON AE, 1982, J MOL BIOL, V156, P113, DOI 10.1016/0022-2836(82)90462-4; KILL R, 1984, BIOCHEMISTRY-US, V25, P3245; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; LULJAS A, 1991, BIOCHIMIE, V73, P1093; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; NIERHAUS KH, 1990, BIOCHEMISTRY-US, V29, P4997, DOI 10.1021/bi00473a001; NOLLER HF, 1990, RIBOSOME, P73; OAKES M, 1986, STRUCTURE FUNCTION G, P47; OLEINIKOV AV, 1993, J BIOL CHEM, V268, P917; PAULSEN H, 1983, J MOL BIOL, V167, P411, DOI 10.1016/S0022-2836(83)80342-8; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Silberklang M, 1979, Methods Enzymol, V59, P58; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STOFFLER G, 1986, STRUCTURE FUNCTION G, P28; SUSSMAN JL, 1978, J MOL BIOL, V123, P607, DOI 10.1016/0022-2836(78)90209-7; SUSSMAN JL, 1976, BIOCHEM BIOPH RES CO, V68, P89, DOI 10.1016/0006-291X(76)90014-0; WAGENKNECHT T, 1988, J MOL BIOL, V203, P753, DOI 10.1016/0022-2836(88)90207-0; WATSON JD, 1964, B SOC CHIM BIOL, V46, P1399; WOWER J, 1993, EMBO J, V12, P617, DOI 10.1002/j.1460-2075.1993.tb05694.x; WOWER J, 1994, BIOCHIMIE, V76, P1235, DOI 10.1016/0300-9084(94)90054-X; Zhu J. N, UNPUB; ZIMMERMANN RA, 1990, RIBOSOME, P331	35	189	194	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 16	1996	271	5251					1000	1002		10.1126/science.271.5251.1000	http://dx.doi.org/10.1126/science.271.5251.1000			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584922				2022-12-24	WOS:A1996TV70400053
J	Laudanna, C; Campbell, JJ; Butcher, EC				Laudanna, C; Campbell, JJ; Butcher, EC			Role of Rho in chemoattractant-activated leukocyte adhesion through integrins	SCIENCE			English	Article							GTP-BINDING-PROTEIN; HUMAN-NEUTROPHILS; ADP-RIBOSYLATION; CALPHOSTIN-C; GENE-PRODUCT; KINASE-C; BOTULINUM; STIMULATION; INHIBITION; VENULES	Heterotrimeric guanine nucleotide binding protein (G protein)-linked receptors of the chemoattractant subfamily can trigger adhesion through leukocyte integrins, and in this role they are thought to regulate immune cell-cell interactions and trafficking. In lymphoid cells transfected with formyl peptide or interleukin-8 receptors, agonist stimulation activated nucleotide exchange on the small guanosine triphosphate-binding protein RhoA in seconds. Inactivation of Rho by C3 transferase exoenzyme blocked agonist-induced lymphocyte alpha 4 beta 1 adhesion to vascular cell adhesion molecule-1 and neutrophil beta 2 integrin adhesion to fibrinogen. These findings suggest that Rho participates in signaling from chemoattractant receptors to trigger rapid adhesion in leukocytes.	STANFORD UNIV,CTR DIGEST DIS,STANFORD,CA 94305; VET AFFAIRS HLTH CARE SYST,PALO ALTO,CA 94304	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Laudanna, C (corresponding author), STANFORD UNIV,DEPT PATHOL,LAB IMMUNOL & VASC BIOL,STANFORD,CA 94305, USA.			Campbell, James/0000-0003-4252-5182	NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008930] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09302] Funding Source: Medline; NIAID NIH HHS [1F32 AI08930] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; CAMPBELL JC, UNPUB; CLARKE MSF, 1992, J CELL SCI, V102, P533; COCKCROFT S, 1989, BIOCHEM J, V263, P715, DOI 10.1042/bj2630715; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HONDA S, 1994, J IMMUNOL, V152, P4026; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LAUDANNA C, UNPUB; LEY K, 1993, J IMMUNOL, V151, P6347; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; NIELSON CP, 1990, J ALLERGY CLIN IMMUN, V86, P801, DOI 10.1016/S0091-6749(05)80186-1; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; SEKINE A, 1989, J BIOL CHEM, V264, P8602; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034	23	420	431	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					981	983		10.1126/science.271.5251.981	http://dx.doi.org/10.1126/science.271.5251.981			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584934				2022-12-24	WOS:A1996TV70400047
J	Abbott, A				Abbott, A			DNA chips intensify the sequence search	NATURE			English	Editorial Material																		1995, NATURE, V373, P372	1	5	5	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					392	392						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559237				2022-12-24	WOS:A1996TT30400017
J	Weeks, KM; Cech, TR				Weeks, KM; Cech, TR			Assembly of a ribonucleoprotein catalyst by tertiary structure capture	SCIENCE			English	Article							16-S RIBOSOMAL-RNA; PRE-MESSENGER RNA; GROUP-I INTRON; ESCHERICHIA-COLI; CBP2 PROTEIN; YEAST; INVITRO; BINDING; SUBSTRATE; SEQUENCE	CBP2 is an RNA tertiary structure binding protein required for efficient splicing of a yeast mitochondrial group I intron. CBP2 must wait for folding of the two RNA domains that make up the catalytic core before it can bind. In a subsequent step, association of the 5' domain of the RNA is stabilized by additional interactions with the protein. Thus, CBP2 functions primarily to capture otherwise transient RNA tertiary structures. This simple one-RNA, one-protein system has revealed how the kinetic pathway of RNA folding can direct the assembly of a specific ribonucleoprotein complex. There are parallels to steps in the formation of a much more complex ribonucleoprotein, the 30S ribosomal subunit,			Weeks, KM (corresponding author), UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309, USA.							ALBERTY RA, 1957, J PHYS CHEM-US, V62, P154; BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; CAREY J, 1993, BIOCHEMISTRY-US, V2, P2610; CLELAND WW, 1975, BIOCHEMISTRY-US, V14, P3220, DOI 10.1021/bi00685a029; COLE PE, 1972, BIOCHEMISTRY-US, V11, P4368, DOI 10.1021/bi00773a025; CROTHERS DM, 1974, J MOL BIOL, V87, P63, DOI 10.1016/0022-2836(74)90560-9; EGUCHI Y, 1990, CELL, V60, P199, DOI 10.1016/0092-8674(90)90736-X; FERSHT A, 1985, ENZYME STRUCTURE MEC, P150; FERSHT AR, 1971, J MOL BIOL, V60, P279, DOI 10.1016/0022-2836(71)90294-4; GAMPEL A, 1987, MOL CELL BIOL, V7, P2545, DOI 10.1128/MCB.7.7.2545; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GAMPEL A, 1991, GENE DEV, V5, P1870, DOI 10.1101/gad.5.10.1870; GESTELAND RF, 1993, RNA WORLD; GU XG, 1992, BIOCHEMISTRY-US, V31, P10295, DOI 10.1021/bi00157a017; HELD WA, 1974, J BIOL CHEM, V249, P3103; HELD WA, 1973, BIOCHEMISTRY-US, V12, P3273, DOI 10.1021/bi00741a020; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; JAEGER L, 1991, J MOL BIOL, V221, P1153, DOI 10.1016/0022-2836(91)90925-V; LI Y, 1995, BIOCHEMISTRY-US, V34, P14394, DOI 10.1021/bi00044a016; LONG KS, 1995, BIOCHEMISTRY-US, V34, P8885, DOI 10.1021/bi00027a041; MANDIYAN V, 1989, J MOL BIOL, V210, P323, DOI 10.1016/0022-2836(89)90334-3; MCGRAW P, 1983, J BIOL CHEM, V258, P9459; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; NOMURA M, 1969, COLD SPRING HARB SYM, V34, P49, DOI 10.1101/SQB.1969.034.01.009; PARTONO S, 1988, MOL CELL BIOL, V8, P2562, DOI 10.1128/MCB.8.6.2562; PINGOUD A, 1973, FEBS LETT, V30, P1, DOI 10.1016/0014-5793(73)80605-2; POWERS T, 1993, J MOL BIOL, V232, P362, DOI 10.1006/jmbi.1993.1396; POWERS T, 1995, RNA, V1, P194; SALDANHA RJ, 1995, BIOCHEMISTRY-US, V34, P1275, DOI 10.1021/bi00004a022; SIEBER G, 1978, BIOCHEMISTRY-US, V17, P3505, DOI 10.1021/bi00610a013; TALBOT SJ, 1994, BIOCHEMISTRY-US, V33, P1406, DOI 10.1021/bi00172a017; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WEEKS KM, 1995, CELL, V82, P221, DOI 10.1016/0092-8674(95)90309-7; WEEKS KM, 1995, BIOCHEMISTRY-US, V34, P7728, DOI 10.1021/bi00023a020; WEEKS KM, UNPUB; ZARRINKAR PP, 1994, SCIENCE, V265, P918, DOI 10.1126/science.8052848	36	105	109	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					345	348		10.1126/science.271.5247.345	http://dx.doi.org/10.1126/science.271.5247.345			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553068				2022-12-24	WOS:A1996TQ52800039
J	Mannuzzu, LM; Moronne, MM; Isacoff, EY				Mannuzzu, LM; Moronne, MM; Isacoff, EY			Direct physical measure of conformational rearrangement underlying potassium channel gating	SCIENCE			English	Article							SHAKER K+ CHANNELS; SODIUM-CHANNEL; S4 REGION; INACTIVATION; DROSOPHILA; CURRENTS; CHARGE; GENE	In response to membrane depolarization, voltage-gated ion channels undergo a structural rearrangement that moves charges or dipoles in the membrane electric field and opens the channel-conducting pathway. By combination of site-specific fluorescent labeling of the Shaker potassium channel protein with voltage clamping, this gating conformational change was measured in real time. During channel activation, a stretch of at least seven amino acids of the putative transmembrane segment S4 moved from a buried position into the extracellular environment. This movement correlated with the displacement of the gating charge, providing physical evidence in support of the hypothesis that S4 is the voltage sensor of voltage-gated ion channels.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; LAWRENCE BERKELEY LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory			isacoff, ehud/AAP-1459-2020	Isacoff, Ehud Y./0000-0003-4775-9359				Aggarwal Sanjay K., 1995, Biophysical Journal, V68, pA138; BEZANILLA F, 1994, BIOPHYS J, V66, P1011, DOI 10.1016/S0006-3495(94)80882-3; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.bi.55.070186.004513; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; ISACOFF E, 1990, COLD SPRING HARB SYM, V55, P9; IVERSON LE, 1990, J NEUROSCI, V10, P2903; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; Lakowicz J.R., 2006, PRINCIPLES FLUORESCE, P1, DOI 10.1007/978-0-387-46312-4/COVER; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOGOTHETIS DE, 1992, NEURON, V8, P531, DOI 10.1016/0896-6273(92)90281-H; MCCORMACK K, 1994, NEURON, V12, P301, DOI 10.1016/0896-6273(94)90273-9; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PEROZO E, 1993, NEURON, V11, P353, DOI 10.1016/0896-6273(93)90190-3; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; SCHOPPA NE, 1992, SCIENCE, V255, P1712, DOI 10.1126/science.1553560; SIGG D, 1994, SCIENCE, V264, P578, DOI 10.1126/science.8160016; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; STEFANI E, 1994, BIOPHYS J, V66, P996, DOI 10.1016/S0006-3495(94)80881-1; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TIMPE LC, 1988, NEURON, V1, P659, DOI 10.1016/0896-6273(88)90165-1; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P321, DOI 10.1085/jgp.103.2.321; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P279, DOI 10.1085/jgp.103.2.279	30	500	515	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					213	216		10.1126/science.271.5246.213	http://dx.doi.org/10.1126/science.271.5246.213			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539623				2022-12-24	WOS:A1996TP36400045
J	Edmondstone, WM				Edmondstone, WM			Cardiac chest pain: Does body language help the diagnosis?	BRITISH MEDICAL JOURNAL			English	Article											Edmondstone, WM (corresponding author), ROYAL NAVAL HOSP,GOSPORT PO12 2AA,HANTS,ENGLAND.							BRAUNWALD E, 1992, HEART DISEASE TXB CA, P1	1	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1660	1661		10.1136/bmj.311.7021.1660	http://dx.doi.org/10.1136/bmj.311.7021.1660			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541748	Green Published			2022-12-24	WOS:A1995TL94200007
J	CUKIERMAN, E; HUBER, I; ROTMAN, M; CASSEL, D				CUKIERMAN, E; HUBER, I; ROTMAN, M; CASSEL, D			THE ARF1 GTPASE-ACTIVATING PROTEIN - ZINC-FINGER MOTIF AND GOLGI-COMPLEX LOCALIZATION	SCIENCE			English	Article							ADP-RIBOSYLATION FACTOR; BINDING-PROTEIN; GUANINE-NUCLEOTIDE; PHOSPHOLIPASE-D; BREFELDIN-A; MEMBRANES; COATOMER; EXCHANGE; COP	Hydrolysis of guanosine triphosphate (GTP) by the small guanosine triphosphatase (GTPase) adenosine diphosphate ribosylation factor-1 (ARF1) depends on a GTPase-activating protein (GAP). A complementary DNA encoding the ARF1 GAP was cloned from rat liver and predicts a protein with a zinc finger motif near the amino terminus. The GAP function required an intact zinc finger and additional amino-terminal residues. The ARF1 GAP was localized to the Golgi complex and was redistributed into a cytosolic pattern when cells were treated with brefeldin A, a drug that prevents ARF1-dependent association of coat proteins with the Golgi. Thus, the GAP is likely to be recruited to the Golgi by an ARF1-dependent mechanism.	TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL	Technion Israel Institute of Technology			cukierman, edna/AAU-8932-2020; Cukierman, Edna/A-3951-2013	cukierman, edna/0000-0002-1452-9576; 				BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUKIERMAN E, UNPUB; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; IRELAND LS, 1995, EMBO J, V13, P3812; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MARTICK S, 1991, NUCLEIC ACIDS RES, V19, P4008; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; POON P, UNPUB; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TEAL SB, 1994, J BIOL CHEM, V269, P3135; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561	22	264	268	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1999	2002		10.1126/science.270.5244.1999	http://dx.doi.org/10.1126/science.270.5244.1999			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533093				2022-12-24	WOS:A1995TL42000044
J	Kopczynski, CC; Davis, GW; Goodman, CS				Kopczynski, CC; Davis, GW; Goodman, CS			A neural tetraspanin, encoded by late bloomer, that facilitates synapse formation	SCIENCE			English	Article							MONOCLONAL-ANTIBODIES; NERVOUS-SYSTEM; INCLUDING CD9; ANTIGEN; DROSOPHILA; SUPERFAMILY; CD53; PROTEINS; MELANOMA; CD37	Upon contacting its postsynaptic target, a neuronal growth cone transforms into a presynaptic terminal. A membrane component on the growth cone that facilitates synapse formation was identified by means of a complementary DNA-based screen followed by genetic analysis. The late bloomer (lbl) gene in Drosophila encodes a member of the tetraspanin family of cell surface proteins. LBL protein is transiently expressed on motor axons, growth cones, and terminal arbors. In lbl mutant embryos, the growth cone of the RP3 motoneuron contacts its target muscles, but synapse formation is delayed and neighboring motoneurons display an increase in ectopic sprouting.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMIOT M, 1990, J IMMUNOL, V145, P4322; ANTON ES, 1995, J NEUROSCI, V15, P584; BATE M, 1995, NEURON, V15, P513, DOI 10.1016/0896-6273(95)90141-8; BELL GM, 1992, J EXP MED, V175, P527, DOI 10.1084/jem.175.2.527; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BOSCA L, 1994, J EXP MED, V179, P1119, DOI 10.1084/jem.179.4.1119; BROADIE K, 1993, DEVELOPMENT, P227; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CLASSON BJ, 1989, J EXP MED, V169, P1497, DOI 10.1084/jem.169.4.1497; DALBY B, 1995, GENETICS, V139, P757; DAVERN KM, 1991, MOL BIOCHEM PARASIT, V48, P67, DOI 10.1016/0166-6851(91)90165-3; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; EMI N, 1993, IMMUNOGENETICS, V37, P193; FITTER S, 1995, BLOOD, V86, P1348, DOI 10.1182/blood.V86.4.1348.bloodjournal8641348; GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219; GIL ML, 1992, J IMMUNOL, V148, P2826; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOODMAN CS, IN PRESS ANN REV NEU; HADJIARGYROU M, 1995, J NEUROSCI, V15, P574; HOREJSI V, 1991, FEBS LETT, V288, P1, DOI 10.1016/0014-5793(91)80988-F; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; IMAI T, 1992, J IMMUNOL, V149, P2879; IMAI T, 1995, J IMMUNOL, V155, P1229; Jarecki J, 1995, J NEUROSCI, V15, P8177; KAPRIELIAN Z, 1995, J NEUROSCI, V15, P562; KESHISHIAN H, 1993, J NEUROBIOL, V24, P757, DOI 10.1002/neu.480240606; KITANI S, 1991, J BIOL CHEM, V266, P1903; KOPCZYNSKI CC, UNPUB; LEBELBINAY S, 1995, J IMMUNOL, V155, P101; LEBELBINAY S, 1995, J LEUKOCYTE BIOL, V57, P956, DOI 10.1002/jlb.57.6.956; LITTLETON JT, 1993, DEVELOPMENT, V118, P1077; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; RASMUSSEN AM, 1994, J IMMUNOL, V153, P4997; ROBERTS JJ, 1995, BRIT J HAEMATOL, V89, P853; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; SI ZY, 1993, INT J CANCER, V54, P37, DOI 10.1002/ijc.2910540107; SINK H, 1991, DEVELOPMENT, V112, P307; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; TOLE S, 1993, DEV DYNAM, V197, P94, DOI 10.1002/aja.1001970203; TOMLINSON MG, 1993, EUR J IMMUNOL, V23, P136, DOI 10.1002/eji.1830230122; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5	44	147	149	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1867	1870		10.1126/science.271.5257.1867	http://dx.doi.org/10.1126/science.271.5257.1867			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596956				2022-12-24	WOS:A1996UC77800047
J	Welker, E; ArmstrongJames, M; Bronchti, G; Ourednik, W; GheorghitaBaechler, F; Dubois, R; Guernsey, DL; VanderLoos, H; Neumann, PE				Welker, E; ArmstrongJames, M; Bronchti, G; Ourednik, W; GheorghitaBaechler, F; Dubois, R; Guernsey, DL; VanderLoos, H; Neumann, PE			Altered sensory processing in the somatosensory cortex of the mouse mutant barrelless	SCIENCE			English	Article							OCULAR DOMINANCE COLUMNS; VISUAL-CORTEX; THALAMOCORTICAL AFFERENTS; STRUCTURAL ORGANIZATION; TERMINAL ARBORS; ADULT-RAT; LAYER-IV; MORPHOLOGY; VIBRISSAE; UNITS	Mice homozygous for the barrelless (brl) mutation, mapped here to chromosome 11, lack barrel-shaped arrays of cell clusters termed ''barrels'' in the primary somatosensory cortex. Deoxyglucose uptake demonstrated that the topology of the cortical whisker representation is nevertheless preserved. Anterograde tracers revealed a lack of spatial segregation of thalamic afferents into individual barrel territories, and single-cell recordings demonstrated a lack of temporal discrimination of center from surround information. Thus, structural segregation of thalamic inputs is not essential to generate topological order in the somatosensory cortex, but it is required for discrete spatiotemporal relay of sensory information to the cortex.	UNIV LONDON QUEEN MARY & WESTFIELD COLL, DEPT PHYSIOL, LONDON E1 4NS, ENGLAND; DALHOUSIE UNIV, DEPT ANAT & NEUROBIOL, HALIFAX, NS B3H 4H7, CANADA; DALHOUSIE UNIV, DEPT PATHOL, DIV MOL PATHOL & MOL GENET, HALIFAX, NS B3H 4H7, CANADA	University of London; Queen Mary University London; Dalhousie University; Dalhousie University	Welker, E (corresponding author), UNIV LAUSANNE, INST ANAT, RUE BUGNON 9, CH-1005 LAUSANNE, SWITZERLAND.			Neumann, Paul/0000-0002-8480-4799	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGMON A, 1993, J NEUROSCI, V13, P5365, DOI 10.1523/JNEUROSCI.13-12-05365.1993; ARMSTRONGJAMES M, 1991, J COMP NEUROL, V303, P193, DOI 10.1002/cne.903030203; ARMSTRONGJAMES M, 1987, J COMP NEUROL, V263, P265, DOI 10.1002/cne.902630209; BELFORD GR, 1979, J COMP NEUROL, V183, P305, DOI 10.1002/cne.901830207; Blue ME, 1991, CEREB CORTEX, V1, P380, DOI 10.1093/cercor/1.5.380; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; CATALANO SM, 1995, P NATL ACAD SCI USA, V92, P2549, DOI 10.1073/pnas.92.7.2549; COHENTANNOUDJI M, 1994, NATURE, V368, P460, DOI 10.1038/368460a0; de No RL, 1922, TRAB LAB BIOL U MADR, V20, P41; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DOLLEMANVANDERWEEL MJ, 1994, J NEUROSCI METH, V51, P9, DOI 10.1016/0165-0270(94)90021-3; DURHAM D, 1984, J COMP NEUROL, V223, P424, DOI 10.1002/cne.902230308; ERZURUMLU RS, 1990, DEV BRAIN RES, V56, P229; FOX K, 1994, J NEUROSCI, V14, P7665; GARRAGHTY PE, 1990, J COMP NEUROL, V294, P583, DOI 10.1002/cne.902940406; HUBEL DH, 1972, J COMP NEUROL, V146, P421, DOI 10.1002/cne.901460402; JENSEN KF, 1987, J NEUROSCI, V7, P3544; JENSEN KF, 1987, J NEUROSCI, V7, P3529; JHAVERI S, 1991, P NATL ACAD SCI USA, V88, P4489, DOI 10.1073/pnas.88.10.4489; LEVAY S, 1975, J COMP NEUROL, V159, P559, DOI 10.1002/cne.901590408; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; MA PM, 1991, J COMP NEUROL, V309, P161, DOI 10.1002/cne.903090202; SCHLAGGAR BL, 1994, J COMP NEUROL, V346, P80, DOI 10.1002/cne.903460106; Senft SL, 1991, CEREB CORTEX, V1, P308, DOI 10.1093/cercor/1.4.308; SIMONS DJ, 1985, J NEUROPHYSIOL, V54, P615, DOI 10.1152/jn.1985.54.3.615; STRYKER MP, 1986, J NEUROSCI, V6, P2117; VANDERLOOS H, 1976, NEUROSCI LETT, V2, P1, DOI 10.1016/0304-3940(76)90036-7; VANDERLOOS H, 1986, J HERED, V77, P66, DOI 10.1093/oxfordjournals.jhered.a110201; VONDERMALSBURG C, 1987, NEURAL MOL BASES LEA, P00411; WELKER E, 1993, EUR J NEUROSCI, V5, P691, DOI 10.1111/j.1460-9568.1993.tb00534.x; WELKER E, 1992, J NEUROSCI, V12, P153; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5; WOOLSEY TA, 1975, J COMP NEUROL, V164, P79, DOI 10.1002/cne.901640107; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X	34	124	126	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1996	271	5257					1864	1867		10.1126/science.271.5257.1864	http://dx.doi.org/10.1126/science.271.5257.1864			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596955				2022-12-24	WOS:A1996UC77800046
J	Forsthuber, T; Yip, HC; Lehmann, PV				Forsthuber, T; Yip, HC; Lehmann, PV			Induction of T(H)1 and T(H)2 immunity in neonatal mice	SCIENCE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MEMORY T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; TOLERANCE INDUCTION; MIGRATION PATHWAYS; DETERMINANT; PEPTIDE; SPLEEN	The neonatal period has been thought of as a window in ontogeny, during which the developing immune system is particularly susceptible to tolerization. In the present study, the classic system for induction of neonatal tolerance to protein antigens was reexamined in mice. The presumably tolerogenic protocol was found to trigger a vigorous T helper cell type 2 (T(H)2) immune response. Thus, neonatal ''tolerization'' induces immune deviation, not tolerance in the immunological sense. Neonates are not immune privileged but generate T(H)2 or T(H)1 responses, depending on the mode of immunization.	CASE WESTERN RESERVE UNIV,DEPT PATHOL,CLEVELAND,OH 44106	Case Western Reserve University			Forsthuber, Thomas/AID-8080-2022	/0000-0003-0692-7125	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036219] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36219-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMOWICZ D, 1990, EUR J IMMUNOL, V20, P1647, DOI 10.1002/eji.1830200805; ASHERSON GL, 1965, IMMUNOLOGY, V9, P205; ASHERSON GL, 1967, BRIT MED BULL, V23, P24, DOI 10.1093/oxfordjournals.bmb.a070510; BERNARD CCA, 1977, CLIN EXP IMMUNOL, V29, P100; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BRADLEY LM, 1992, J IMMUNOL, V148, P324; Burnet FM, 1949, PRODUCTION ANTIBODIE, P102; CHEN H, 1995, TRANSPLANTATION, V60, P1182; Chen NX, 1995, TRANSPLANTATION, V60, P1187; CLAYTON JP, 1989, J EXP MED, V169, P1681, DOI 10.1084/jem.169.5.1681; DORSCH S, 1975, NATURE, V258, P233, DOI 10.1038/258233a0; EINSTEIN ER, 1968, IMMUNOCHEMISTRY, V5, P567, DOI 10.1016/0019-2791(68)90092-X; FALK GA, 1969, J IMMUNOL, V103, P1248; FORSTHUBER T, UNPUB; GAMMON G, 1986, NATURE, V319, P413, DOI 10.1038/319413a0; GAMMON GM, 1986, J EXP MED, V164, P667, DOI 10.1084/jem.164.2.667; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; JUNG TM, 1988, J IMMUNOL, V141, P4110; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MACKAY CR, 1992, EUR J IMMUNOL, V22, P887, DOI 10.1002/eji.1830220402; MACKAY CR, 1991, IMMUNOL TODAY, V12, P189, DOI 10.1016/0167-5699(91)90051-T; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Owen R. D., 1946, JOUR HEREDITY, V37, P291; OWEN RD, 1945, SCIENCE, V102, P400, DOI 10.1126/science.102.2651.400; PABST R, 1988, IMMUNOL TODAY, V9, P43, DOI 10.1016/0167-5699(88)91258-3; PABST R, 1989, IMMUNOL REV, V108, P83, DOI 10.1111/j.1600-065X.1989.tb00014.x; PATERSON PY, 1958, ANN NY ACAD SCI, V73, P811, DOI 10.1111/j.1749-6632.1959.tb40860.x; POWELL TJ, 1990, J IMMUNOL, V144, P854; QIN Y, 1989, EUR J IMMUNOL, V19, P373, DOI 10.1002/eji.1830190223; RIEGER M, 1977, J IMMUNOGENET, V4, P61; SWIERKOS.JE, 1974, FED PROC, V33, P814; SWIERKOSZ JE, 1975, J IMMUNOL, V115, P631; WELCH AM, 1976, EUR J IMMUNOL, V6, P910, DOI 10.1002/eji.1830061214	35	582	602	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1728	1730		10.1126/science.271.5256.1728	http://dx.doi.org/10.1126/science.271.5256.1728			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596934				2022-12-24	WOS:A1996UB15100047
J	Myers, MP; WagerSmith, K; RothenfluhHilfiker, A; Young, MW				Myers, MP; WagerSmith, K; RothenfluhHilfiker, A; Young, MW			Light-induced degradation of TIMELESS and entrainment of the Drosophila circadian clock	SCIENCE			English	Article							PERIOD GENE-PRODUCT; VISUAL-SYSTEM; MELANOGASTER; RHYTHMS	Two genes, period (per) and timeless (tim), are required for production of circadian rhythms in Drosophila. The proteins encoded by these genes (PER and TIM) physically interact, and the timing of their association and nuclear localization is believed to promote cycles of per and tim transcription through an autoregulatory feedback loop. Here it is shown that TIM protein may also couple this molecular pacemaker to the environment, because TIM is rapidly degraded after exposure to light. TIM accumulated rhythmically in nuclei of eyes and in pacemaker cells of the brain. The phase of these rhythms was differentially advanced or delayed by light pulses delivered at different times of day, corresponding with phase shifts induced in the behavioral rhythms.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NSF,SCI & TECHNO CTR BIOL TRIMING,NEW YORK,NY 10021; ROCKEFELLER UNIV,LAB GENET,NEW YORK,NY 10021	Howard Hughes Medical Institute; National Science Foundation (NSF); Rockefeller University; Rockefeller University			, 机智的马小跳和机智的羊不愁/ABC-5169-2020	Rothenfluh, Adrian/0000-0002-3813-5723				ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BARGIELLO TA, 1984, P NATL ACAD SCI-BIOL, V81, P2142, DOI 10.1073/pnas.81.7.2142; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; DUSHAY MS, 1990, GENETICS, V125, P557; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EWER J, 1992, J NEUROSCI, V12, P3321; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; KAY SA, 1995, CELL, V83, P361, DOI 10.1016/0092-8674(95)90113-2; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LEVINE JD, 1994, NEURON, V13, P967, DOI 10.1016/0896-6273(94)90262-3; MATSUMOTO A, 1994, J NEUROGENET, V9, P141, DOI 10.3109/01677069409167276; MYERS M, UNPUB; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; PITTENDRIGH CS, 1981, HDB BEHAVIORAL NEURO, V4, P95; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; REDDY P, 1984, CELL, V38, P701, DOI 10.1016/0092-8674(84)90265-4; ROTHENFLUHHILFI.A, UNPUB; RUTILA J, COMMUNICATION; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SEHGAL A, UNPUB; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; WAGERSMITH K, UNPUB; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZERR DM, 1990, J NEUROSCI, V10, P2749	29	396	403	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1736	1740		10.1126/science.271.5256.1736	http://dx.doi.org/10.1126/science.271.5256.1736			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596937				2022-12-24	WOS:A1996UB15100050
J	Mazzaferro, V; Regalia, E; Doci, R; Andreola, S; Pulvirenti, A; Bozzetti, F; Montalto, F; Ammatuna, M; Morabito, A; Gennari, L				Mazzaferro, V; Regalia, E; Doci, R; Andreola, S; Pulvirenti, A; Bozzetti, F; Montalto, F; Ammatuna, M; Morabito, A; Gennari, L			Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATURAL-HISTORY; RESECTION; CANCER; MALIGNANCY; RECURRENCE	Background. The role of orthotopic liver transplantation in the treatment of patients with cirrhosis and hepatocellular carcinoma is controversial, and determining which patients are likely to have a good outcome after liver transplantation is difficult. Methods. We studied 48 patients with cirrhosis who had small, unresectable hepatocellular carcinomas and who underwent liver transplantation. In 94 percent of the patients, the cirrhosis was related to infection with hepatitis B virus, hepatitis C virus, or both. The presence of tumor was confirmed by biopsy or serum alpha-fetoprotein assay. The criteria for eligibility for transplantation were the presence of a tumor 5 cm or less in diameter in patients with single hepatocellular carcinomas and no more than three tumor nodules, each 3 cm or less in diameter, in patients with multiple tumors. Twenty-eight patients with sufficient hepatic function underwent treatment for the tumor, mainly chemoembolization, before transplantation. After liver transplantation, the patients were followed prospectively for a median of 26 months (range, 9 to 54), No anticancer treatment was given after transplantation. Results. The overall mortality rate was 17 percent. After four years, the actuarial survival rate was 75 percent and the rate of recurrence-free survival was 83 percent. Hepatocellular carcinoma recurred in four patients (8 percent). The overall and recurrence-free survival rates at four years among the 35 patients (73 percent of the total) who met the predetermined criteria for the selection of small hepatocellular carcinomas at pathological review of the explanted liver were 85 percent and 92 percent, respectively, whereas the rates in the 13 patients (27 percent) whose tumors exceeded these limits were 50 percent and 59 percent, respectively (P=0.01 for overall survival; P=0.002 for recurrence-free survival). In this group of 48 patients with early-stage tumors, tumor-node-metastasis status, the number of tumors, the serum alphafetoprotein concentration, treatment received before transplantation, and 10 other variables were not significantly correlated with survival. Conclusions. Liver transplantation is an effective treatment for small, unresectable hepatocellular carcinomas in patients with cirrhosis.	NATL CANC INST,DEPT PATHOL,I-20133 MILAN,ITALY; NATL CANC INST,DEPT ANESTHESIA,I-20133 MILAN,ITALY; UNIV MILAN,INST MED STAT & BIOMETRY,MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan			Regalia, Enrico/L-9933-2017; Mazzaferro, Vincenzo/C-2726-2017; Mazzaferro, Vincenzo/AAL-4707-2020	Regalia, Enrico/0000-0002-9528-5859; Mazzaferro, Vincenzo/0000-0002-4013-8085; 				BARBARA L, 1992, HEPATOLOGY, V16, P132, DOI 10.1002/hep.1840160122; BELGHITI J, 1991, ANN SURG, V214, P114, DOI 10.1097/00000658-199108000-00004; BISMUTH H, 1993, ANN SURG, V218, P145, DOI 10.1097/00000658-199308000-00005; COLOMBO M, 1993, SEMIN LIVER DIS, V13, P374; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; *EUR LIV TRANSPL R, 1994, REP EUR LIV TRANSPL; HAUG CE, 1992, TRANSPLANTATION, V53, P376, DOI 10.1097/00007890-199202010-00021; HERMANEK P, 1987, TNM CLASSIFICATION M, P53; ISMAIL T, 1990, BRIT J SURG, V77, P983, DOI 10.1002/bjs.1800770908; IWATSUKI S, 1985, ANN SURG, V202, P401, DOI 10.1097/00000658-198510000-00001; IWATSUKI S, 1991, ANN SURG, V214, P221, DOI 10.1097/00000658-199109000-00005; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANTEL N, 1959, J NATL CANCER I, V22, P719; MAZZAFERRO V, 1994, TRANSPLANT P, V26, P3557; MORENO E, 1992, AM J SURG, V163, P395; OGRADY JG, 1988, ANN SURG, V207, P373, DOI 10.1097/00000658-198804000-00002; OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E; OKUDA K, 1991, OXFORD TXB CLIN HEPA, V2, P1019; OLTHOFF KM, 1990, ARCH SURG-CHICAGO, V125, P1261; PENN I, 1991, SURGERY, V110, P726; RINGE B, 1989, ANN SURG, V209, P88, DOI 10.1097/00000658-198901000-00013; RINGE B, 1991, WORLD J SURG, V15, P270, DOI 10.1007/BF01659064; SELBY R, 1995, WORLD J SURG, V19, P53, DOI 10.1007/BF00316980; SPREAFICO C, 1994, RADIOLOGY, V192, P687, DOI 10.1148/radiology.192.3.8058934; STARZL TE, 1993, HEPATOLOGY, V17, P1127; STARZL TE, 1985, J PEDIATR-US, V106, P604, DOI 10.1016/S0022-3476(85)80081-0; STEVES MA, 1992, AM SURGEON, V58, P608; TAN KC, 1995, BRIT J SURG, V82, P253, DOI 10.1002/bjs.1800820239; TREY C, 1966, NEW ENGL J MED, V274, P473, DOI 10.1056/NEJM196603032740901; TZAKIS A, 1989, ANN SURG, V210, P649, DOI 10.1097/00000658-198911000-00013; UTSUNOMIYA T, 1992, HEPATOLOGY, V16, P694, DOI 10.1002/hep.1840160313; YOKOYAMA I, 1990, HEPATO-GASTROENTEROL, V37, P188; YOKOYAMA I, 1991, CANCER, V68, P2095, DOI 10.1002/1097-0142(19911115)68:10<2095::AID-CNCR2820681002>3.0.CO;2-Y	33	5104	5357	7	438	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1996	334	11					693	699		10.1056/NEJM199603143341104	http://dx.doi.org/10.1056/NEJM199603143341104			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ528	8594428	Bronze			2022-12-24	WOS:A1996TZ52800004
J	Ohta, M; Inoue, H; Cotticelli, MG; Kastury, K; Baffa, R; Palazzo, J; Siprashvili, Z; Mori, M; McCue, P; Druck, T; Croce, CM; Huebner, K				Ohta, M; Inoue, H; Cotticelli, MG; Kastury, K; Baffa, R; Palazzo, J; Siprashvili, Z; Mori, M; McCue, P; Druck, T; Croce, CM; Huebner, K			The FHIT gene, spanning the chromosome 3p14.2 fragile site acid renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers	CELL			English	Article							PROTEIN-KINASE-C; ESOPHAGEAL CANCER; CGG REPEAT; TRANSLOCATION; REGION; INSTABILITY; DNA; SEQUENCE; CHINA	A 200-300 kb region of chromosome 3p14.2, including the fragile site locus FRA3B, is homozygously deleted in multiple tumor-derived cell lines. Exon amplification from cosmids covering this deleted region allowed identification of the human FHIT gene, a member of the histidine triad gene family, which encodes a protein with 69% similarity to an S. pombe enzyme, diadenosine 5', 5triple prime P-1, P-4-tetraphosphate asymmetrical hydrolase. The FHIT locus is composed of ten exons distributed over at least 500 kb, with three 5' untranslated exons centromeric to the renal carcinoma-associated 3p14.2 breakpoint, the remaining exons telomeric to this translocation breakpoint, and exon 5 within the homozygously deleted fragile region. aberrant transcripts of the FHIT locus were found in similar to 50% of esophageal, stomach, and colon carcinomas.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, KIMMEL CANC CTR, PHILADELPHIA, PA 19107 USA; KYUSHU UNIV, MED INST BIOREGULAT, DEPT SURG, BEPPU, OITA 874, JAPAN	Jefferson University; Kyushu University			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NCI NIH HHS [CA51083, CA21124, CA39860] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083, R35CA039860, P01CA021124] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLDOG FL, 1993, P NATL ACAD SCI USA, V90, P8509, DOI 10.1073/pnas.90.18.8509; BOLDOG FL, 1994, GENE CHROMOSOME CANC, V11, P216, DOI 10.1002/gcc.2870110403; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; DRUCK T, 1995, CANCER RES, V55, P5348; FONG LYY, 1978, J NATL CANCER I, V61, P145, DOI 10.1093/jnci/61.1.145; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GLOVER TW, 1988, CANCER GENET CYTOGEN, V31, P69, DOI 10.1016/0165-4608(88)90013-1; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Huang Y, 1995, BIOCHEM J, V312, P925, DOI 10.1042/bj3120925; JONES C, 1994, HUM MOL GENET, V3, P2123, DOI 10.1093/hmg/3.12.2123; KASTURY K, 1996, IN PRESS GENOMICS; KASTURY K, 1996, IN PRESS CANC RES; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LAFORGIA S, 1993, CANCER RES, V53, P3118; LI FP, 1993, ANN INTERN MED, V118, P106, DOI 10.7326/0003-4819-118-2-199301150-00005; LISITSYN NA, 1995, P NATL ACAD SCI USA, V92, P151, DOI 10.1073/pnas.92.1.151; LO KW, 1994, INT J ONCOL, V4, P1359; LUBINSKI J, 1994, CANCER RES, V54, P3710; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; MICHAELIS SC, 1995, CANCER GENET CYTOGEN, V81, P1, DOI 10.1016/0165-4608(94)00208-8; MOZIER NM, 1991, FEBS LETT, V279, P14, DOI 10.1016/0014-5793(91)80238-X; OHTA M, 1995, IN PRESS INT J CANC; PARADEE W, 1995, GENOMICS, V27, P358, DOI 10.1006/geno.1995.1057; PEARSON JD, 1990, J BIOL CHEM, V265, P4583; RASSOOL FV, 1992, AM J HUM GENET, V50, P1243; ROCHE J, 1994, HUM MOL GENET, V3, P215, DOI 10.1093/hmg/3.1.215; Seraphin B., 1992, DNA Sequence, V3, P177, DOI 10.3109/10425179209034013; SERAPHIN B, 1994, HUM MOL GENET, V3, P215; SUTHERLAND GR, 1991, GENET ANAL TECH APPL, V8, P1616; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WILKE CM, 1994, GENOMICS, V22, P319, DOI 10.1006/geno.1994.1390; YANG CS, 1980, CANCER RES, V40, P2633; YANG GC, 1987, J NATL CANCER I, V79, P1241; YOKOTA J, 1989, CANCER RES, V49, P3598; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375	37	957	1133	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 23	1996	84	4					587	597		10.1016/S0092-8674(00)81034-X	http://dx.doi.org/10.1016/S0092-8674(00)81034-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598045	Bronze			2022-12-24	WOS:A1996TX17600011
J	Behar, E; Chao, NJ; Hiraki, DD; Krishnaswamy, S; Brown, BW; Zehnder, JL; Grumet, FC				Behar, E; Chao, NJ; Hiraki, DD; Krishnaswamy, S; Brown, BW; Zehnder, JL; Grumet, FC			Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MINOR HISTOCOMPATIBILITY ANTIGENS; CARDIAC TRANSPLANTATION; LYMPHOCYTES-T; REJECTION; CLONING; MARROW; GENE	Background. Graft-versus-host disease (GVHD) caused by poorly defined minor (i.e,, other than HLA) histocompatibility antigens remains a serious problem in recipients of bone marrow transplants. We sought to determine whether the CD31 adhesion molecule is a minor alloantigen. Methods. We directly sequenced samples of complementary DNA (cDNA) encoding CD31 molecules from 21 unrelated normal subjects. Sequence-specific primers were then designed to amplify alleles by the polymerase chain reaction, thereby permitting CD31 typing of genomic DNA from additional normal subjects. To assess the relevance of CD31 matching to bone marrow transplantation, we performed CD31 typing of 46 recipients of bone marrow (32 without GVHD and 14 with severe [grade III or IV] acute GVHD) and their HLA-identical sibling donors. The immunoreactivity of CD31 phenotypes with anti-CD31 monoclonal antibodies was compared by flow cytometry. Results. Direct sequencing of cDNA for CD31 from the 21 normal subjects identified a single polymorphism, (C) under bar TG-->(G) under bar TG (Leu-->Val), at codon 125; we designated the resulting alleles CD31.L and CD31.V, respectively. The CD31 genotypes of these and 142 other unrelated subjects were of the expected frequencies. Among the transplant recipients, 71 percent of those with acute GVHD had CD31 genotypes that were not identical to the donor's genotype, as compared with 22 percent of the recipients without GVHD (P = 0.004). The binding of anti-CD31 monoclonal antibodies as measured by fluorescence-activated cell sorting correlated with the CD31 types of homozygous cell lines. Conclusions. The adhesion molecule CD31 is polymorphic. When donor and recipient genotypes are not identical, the risk of GVHD increases. Prospective CD31 typing may reduce the risk of acute GVHD. (C) 1996, Massachusetts Medical Society.	STANFORD UNIV,CTR BLOOD,DEPT PATHOL,PALO ALTO,CA 94304; STANFORD UNIV,DEPT HLTH RES & POLICY,PALO ALTO,CA 94304; STANFORD UNIV,DEPT MED,PALO ALTO,CA 94304	Stanford University; Stanford University; Stanford University					NHLBI NIH HHS [HL33811] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL033811] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Armitage P., 1994, STAT METHODS MED RES, V3; BEHAR E, 1994, TISSUE ANTIGENS, V44, P332, DOI 10.1111/j.1399-0039.1994.tb02406.x; BRASILE L, 1985, TRANSPLANTATION, V40, P672, DOI 10.1097/00007890-198512000-00020; CERILLI J, 1987, TRANSPL P, V19, P4468; CHAO NJ, 1993, NEW ENGL J MED, V329, P1225, DOI 10.1056/NEJM199310213291703; DAVENPORT C, 1995, J IMMUNOL, V154, P2568; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; DUNN MJ, 1992, LANCET, V339, P1566, DOI 10.1016/0140-6736(92)91832-S; FERRARA JLM, 1991, NEW ENGL J MED, V324, P667; FLEISCHHAUER K, 1990, NEW ENGL J MED, V323, P1818, DOI 10.1056/NEJM199012273232607; Fleiss JL, 1981, STAT METHODS RATES P; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; GUMINA RJ, 1993, THROMB HAEMOSTASIS, V69, P923; HANSEN JA, 1994, CLIN TRANSPLANTS 199, P193; HARTL DL, 1987, PRIMER PROPULATION G, P23; KALIL J, 1989, TRANSPLANT P, V21, P711; KIRSCHBAUM NE, 1994, BLOOD, V84, P4028, DOI 10.1182/blood.V84.12.4028.bloodjournal84124028; KITAJIMA T, 1994, IMMUNOL LETT, V40, P207, DOI 10.1016/0165-2478(93)00017-8; LEITNER T, 1993, BIOTECHNIQUES, V15, P120; MARIJT WAF, 1993, BLOOD, V82, P3778; METZELAAR MJ, 1991, THROMB HAEMOSTASIS, V66, P700; MILSTEIN CP, 1974, NATURE, V248, P160, DOI 10.1038/248160a0; MORAES JR, 1989, TRANSPLANTATION, V48, P951, DOI 10.1097/00007890-198912000-00010; NEWMAN PJ, 1989, J CLIN INVEST, V83, P1778, DOI 10.1172/JCI114082; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; PIERSON GR, 1987, UCLA S MOL CELLULAR, V53, P307; SEKIMATA M, 1992, INT IMMUNOL, V4, P301, DOI 10.1093/intimm/4.2.301; SIMMONS DL, 1990, J EXP MED, V171, P2147, DOI 10.1084/jem.171.6.2147; STASTNY P, 1981, TRANSPLANTATION CLIN, P132; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; SULLIVAN KM, 1981, BLOOD, V57, P267, DOI 10.1182/blood.V57.2.267.267; SULLIVAN KM, 1994, BONE MARROW TRANSPL, P339; VANDERHARST D, 1994, BLOOD, V83, P1060; VANELS CACM, 1992, IMMUNOGENETICS, V35, P161, DOI 10.1007/BF00185109; VINCI G, 1994, TRANSPLANTATION, V58, P361, DOI 10.1097/00007890-199408000-00019; ZEHNDER JL, 1992, J BIOL CHEM, V267, P5243; ZEHNDER JL, 1995, BLOOD, V85, P1282, DOI 10.1182/blood.V85.5.1282.bloodjournal8551282; 1991, LANCET, V337, P649	39	121	128	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					286	291		10.1056/NEJM199602013340502	http://dx.doi.org/10.1056/NEJM199602013340502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV695	8532023				2022-12-24	WOS:A1996TV69500002
J	Davie, AP; Francis, CM; Love, MP; Caruana, L; Starkey, IR; Shaw, TRD; Sutherland, GR; McMurray, JJV				Davie, AP; Francis, CM; Love, MP; Caruana, L; Starkey, IR; Shaw, TRD; Sutherland, GR; McMurray, JJV			Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction	BRITISH MEDICAL JOURNAL			English	Article									WESTERN GEN HOSP,DEPT CARDIOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh			mcmurray, John/B-2467-2013	mcmurray, John/0000-0002-6317-3975				DARGIE HJ, 1994, BMJ-BRIT MED J, V308, P321, DOI 10.1136/bmj.308.6924.321; FRANCIS CM, 1995, BRIT MED J, V310, P634, DOI 10.1136/bmj.310.6980.634; MACALLAN DC, 1990, J ROY SOC MED, V83, P559, DOI 10.1177/014107689008300909; REMES J, 1991, EUR HEART J, V12, P315, DOI 10.1093/oxfordjournals.eurheartj.a059896; WHEELDON NM, 1993, Q J MED, V86, P17	5	185	189	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					222	222						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563589				2022-12-24	WOS:A1996TT48600029
J	Margossian, SP; Li, HL; Zassenhaus, HP; Butow, RA				Margossian, SP; Li, HL; Zassenhaus, HP; Butow, RA			The DExH box protein Suv3p is a component of a yeast mitochondrial 3'-to-5' exoribonuclease that suppresses group I intron toxicity	CELL			English	Article							CONSERVED DODECAMER SEQUENCE; TETRAHYMENA-THERMOPHILA RIBOZYME; SACCHAROMYCES-CEREVISIAE; POSTTRANSCRIPTIONAL PROCESSES; KINETIC DESCRIPTION; ENCODED PROTEIN; MESSENGER-RNAS; ACTIVE-SITE; GENE; PURIFICATION	The yeast mitochondrial protein Suv3p is a putative NTP-dependent RNA helicase. Here we report that in cells lacking Suv3p, there is an similar to 50-fold increase in the excised form of the group I intron omega of the mitochondrial 21S rRNA gene. Surprisingly, little mature 21S rRNA accumulates in those cells; instead, unligated 21S rRNA exons appear. Intron overaccumulation could lead to spliced exon reopening via a reaction known to be catalyzed by group I introns in vitro. We also show that Suv3p is a functional component of a novel mitochondrial NTP-dependent 3'-to-5' exoribonuclease activity that can degrade group I intron RNAs. These findings account for group I intron overaccumulation in cells lacking Suv3p and define a novel function for putative RNA helicases in direct RNA degradation.	ST LOUIS UNIV, SCH MED, DEPT MOLEC MICROBIOL & IMMUNOL, ST LOUIS, MO 63104 USA	Saint Louis University	Margossian, SP (corresponding author), UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA.				NIGMS NIH HHS [GM22525] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022525, R01GM022525] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONITZ SG, 1982, J BIOL CHEM, V257, P6268; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; CONRAD H, 1987, THESIS OHIO STATE U; CONRADWEBB H, 1990, NUCLEIC ACIDS RES, V18, P1369, DOI 10.1093/nar/18.6.1369; DAKE E, 1988, J BIOL CHEM, V263, P7691; DMOCHOWSKA A, 1995, CURR GENET, V28, P108, DOI 10.1007/BF00315775; FAYE G, 1976, FEBS LETT, V69, P167, DOI 10.1016/0014-5793(76)80678-3; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GARRIGA G, 1984, CELL, V39, P631, DOI 10.1016/0092-8674(84)90470-7; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HUDSPETH MES, 1980, BIOCHIM BIOPHYS ACTA, V610, P221, DOI 10.1016/0005-2787(80)90003-9; IOST I, 1994, NATURE, V372, P193, DOI 10.1038/372193a0; LARIMER FW, 1990, GENE, V95, P85, DOI 10.1016/0378-1119(90)90417-P; LOCKER J, 1981, PLASMID, V6, P302, DOI 10.1016/0147-619X(81)90038-X; MAHESHWARI KK, 1984, BIOCHIM BIOPHYS ACTA, V781, P153, DOI 10.1016/0167-4781(84)90133-7; MERTEN S, 1980, P NATL ACAD SCI-BIOL, V77, P1417, DOI 10.1073/pnas.77.3.1417; MIN JJ, 1993, MOL CELL BIOL, V13, P4167, DOI 10.1128/MCB.13.7.4167; MIN JJ, 1993, J BACTERIOL, V175, P6245, DOI 10.1128/JB.175.19.6245-6253.1993; MIN JJ, 1993, J BIOL CHEM, V268, P7350; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; MOHR G, 1994, NATURE, V370, P147, DOI 10.1038/370147a0; MUELLER DM, 1986, J BIOL CHEM, V261, P1816; OSINGA KA, 1984, EMBO J, V3, P829, DOI 10.1002/j.1460-2075.1984.tb01892.x; PARTONO S, 1988, MOL CELL BIOL, V8, P2562, DOI 10.1128/MCB.8.6.2562; PERLMAN PS, 1990, INTERVENING SEQUENCE, P112; ROSE MD, 1988, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; STEPIEN PP, 1992, P NATL ACAD SCI USA, V89, P6813, DOI 10.1073/pnas.89.15.6813; STEPIEN PP, 1995, CURR GENET, V27, P234, DOI 10.1007/BF00326154; TABAK HF, 1984, CELL, V39, P623, DOI 10.1016/0092-8674(84)90469-0; VANDERHORST G, 1987, EMBO J, V6, P2139, DOI 10.1002/j.1460-2075.1987.tb02481.x; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; VONTIGERSTROM RG, 1982, BIOCHEMISTRY-US, V21, P6397, DOI 10.1021/bi00268a012; WEEKS KM, 1995, BIOCHEMISTRY-US, V34, P7728, DOI 10.1021/bi00023a020; ZASSENHAUS HP, 1988, NUCLEIC ACIDS RES, V16, P3283, DOI 10.1093/nar/16.8.3283; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1983, NATURE, V301, P578, DOI 10.1038/301578a0; ZHU H, 1987, MOL CELL BIOL, V7, P2530, DOI 10.1128/MCB.7.7.2530; ZHU H, 1989, MOL CELL BIOL, V9, P1507, DOI 10.1128/MCB.9.4.1507	44	102	104	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					199	209		10.1016/S0092-8674(00)80975-7	http://dx.doi.org/10.1016/S0092-8674(00)80975-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565066	Bronze			2022-12-24	WOS:A1996TR59500007
J	Newcomb, RA; Storer, BE; Longnecker, MP; Mittendorf, R; Greenberg, ER; Willett, WC				Newcomb, RA; Storer, BE; Longnecker, MP; Mittendorf, R; Greenberg, ER; Willett, WC			Pregnancy termination in relation to risk of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FULL TERM PREGNANCY; REPRODUCTIVE FACTORS; SPONTANEOUS-ABORTION; WOMEN; PROGESTERONE; INCREASE	Objective. - To evaluate the association between pregnancy terminations and of breast cancer. Design and Setting. - Population-based case-control study in Wisconsin, Massachusetts, Maine, and New Hampshire. Study Participants. - Cases were women younger than 75 years with a new diagnosis of breast cancer (n=6888), identified from statewide tumor registries. Controls younger than 65 years (n=9529) were randomly selected from lists of licensed drivers, or for older subjects, from lists of Medicare beneficiaries. Exposures and Outcomes. - Breast cancer risk in relation to spontaneous or induced abortions. Results.- After adjustment for parity, age at first birth, and other risk factors, pregnancy termination (induced or spontaneous) was associated with a relative risk (RR) of breast cancer of 1.12 (95% confidence interval [CI], 1.04 to 1.21), compared with the risk among women who had never had a termination, Induced terminations were associated with a RR of 1.23 (95% CI, 1.00 to 1.51), which was somewhat greater than the risk associated with spontaneous terminations (RR, 1.21, 95% CI, 1.02 to 1.20). The association with induced abortions was stronger for those performed before legalization of abortion in 1973 (RR, 1.35; 95% CI, 1.01 to 1.80) than after this time (RR, 1.12; 95% CI, 0.84 to 1.49), suggesting a bias in reporting this sensitive procedure. Conclusions. - A weak positive association was observed between abortion-whether induced or spontaneous - and risk of breast cancer. The increase in risk of breast cancer was somewhat greater among women with a history of induced terminations. However, this association may be due to reporting bias and was not significantly different than the slight risk for spontaneous terminations.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT EPIDEMIOL, LOS ANGELES, CA USA; UNIV CHICAGO, CHICAGO LYING IN HOSP, DEPT OBSTET & GYNECOL, CHICAGO, IL USA; DARTMOUTH HITCHCOCK MED SCH, NORRIS COTTON CANC CTR, HANOVER, NH USA; HARVARD UNIV, SCH MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA	Fred Hutchinson Cancer Center; University of California System; University of California Los Angeles; University of Chicago; Dartmouth College; Norris Cotton Cancer Center; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Newcomb, RA (corresponding author), UNIV WISCONSIN, CTR COMPREHENS CANC, MED SCI CTR, ROOM 4780, 1300 UNIV AVE, MADISON, WI 53706 USA.			Longnecker, Matthew/0000-0001-6073-5322	NCI NIH HHS [CA 47305, CA 47147] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047147, R01CA047305] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1990, BRIT J CANCER, V62, P122, DOI 10.1038/bjc.1990.242; ANDERSON BA, 1994, DEMOGRAPHY, V31, P115, DOI 10.2307/2061911; BERNSTEIN L, 1986, J NATL CANCER I, V76, P1035; BERNSTEIN L, 1990, ORAL CONTRACEPTIVES, P169; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BRINTON LA, 1983, BRIT J CANCER, V47, P757, DOI 10.1038/bjc.1983.128; BRUZZI P, 1988, BRIT MED J, V297, P1096, DOI 10.1136/bmj.297.6656.1096; CALLE EE, 1995, CANCER CAUSE CONTROL, V6, P460, DOI 10.1007/BF00052187; CUMMINGS P, 1994, BRIT MED J, V308, P1672, DOI 10.1136/bmj.308.6945.1672; CUNNINGHAM DS, 1993, J REPROD MED, V38, P301; CUNNINGHAM FG, 1989, WILLIAMS OBSTETRICS; DALING JR, 1994, JNCI-J NATL CANCER I, V86, P1584, DOI 10.1093/jnci/86.21.1584; EWERTZ M, 1988, BRIT J CANCER, V58, P99, DOI 10.1038/bjc.1988.172; HADJIMICHAEL OC, 1986, BRIT J CANCER, V53, P281, DOI 10.1038/bjc.1986.46; HARRIS BML, 1989, BMJ-BRIT MED J, V299, P1430, DOI 10.1136/bmj.299.6713.1430; HELMRICH SP, 1983, AM J EPIDEMIOL, V117, P35, DOI 10.1093/oxfordjournals.aje.a113513; HOWE HL, 1989, INT J EPIDEMIOL, V18, P300, DOI 10.1093/ije/18.2.300; JONES EF, 1992, DEMOGRAPHY, V29, P113, DOI 10.2307/2061366; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; Koonin L M, 1993, MMWR CDC Surveill Summ, V42, P29; KRIEGER N, 1989, BREAST CANCER RES TR, V13, P205, DOI 10.1007/BF02106571; KVALE G, 1987, AM J EPIDEMIOL, V126, P831, DOI 10.1093/oxfordjournals.aje.a114720; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; LAVECCHIA C, 1987, INT J EPIDEMIOL, V16, P347, DOI 10.1093/ije/16.3.347; LINDEFORSHARRIS BM, 1991, AM J EPIDEMIOL, V134, P1003, DOI 10.1093/oxfordjournals.aje.a116173; LIPWORTH L, 1995, INT J CANCER, V61, P181, DOI 10.1002/ijc.2910610207; LONGNECKER MP, 1992, EPIDEMIOLOGY, V3, P535, DOI 10.1097/00001648-199211000-00014; LUBIN JH, 1982, J NATL CANCER I, V68, P211; MICHELS KB, 1995, CANCER CAUSE CONTROL, V6, P75, DOI 10.1007/BF00051683; NEWCOMB PA, 1994, NEW ENGL J MED, V330, P81, DOI 10.1056/NEJM199401133300201; PARAZZINI F, 1991, INT J CANCER, V48, P816, DOI 10.1002/ijc.2910480605; Rebar RW, 1994, MATERNAL FETAL MED P, P144; ROSENBERG L, 1988, AM J EPIDEMIOL, V127, P981, DOI 10.1093/oxfordjournals.aje.a114901; Rothman K, 1986, MODERN EPIDEMIOLOGY; RUSSO J, 1980, AM J PATHOL, V100, P497; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; SELLERS TA, 1993, CANCER CAUSE CONTROL, V4, P21, DOI 10.1007/BF00051710; TALAMINI R, 1985, AM J EPIDEMIOL, V4, P70; VESSEY MP, 1982, BRIT J CANCER, V45, P327, DOI 10.1038/bjc.1982.58; WILCOX AJ, 1984, AM J EPIDEMIOL, V120, P727, DOI 10.1093/oxfordjournals.aje.a113940; WILLIAMS EMI, 1990, BRIT MED J, V300, P578, DOI 10.1136/bmj.300.6724.578; WITT BR, 1990, FERTIL STERIL, V53, P1029; 1977, MANUAL INT CLASSIFIC	43	46	47	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					283	287						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544267				2022-12-24	WOS:A1996TP96500023
J	Diaz, JJ; Dodon, MD; SchaererUthurralt, N; Simonin, D; Kindbeiter, K; Gazzolo, L; Madjar, JJ				Diaz, JJ; Dodon, MD; SchaererUthurralt, N; Simonin, D; Kindbeiter, K; Gazzolo, L; Madjar, JJ			Post-transcriptional transactivation of human retroviral envelope glycoprotein expression by herpes simplex virus Us11 protein	NATURE			English	Article							REX-RESPONSE ELEMENT; RNA-BINDING PROTEIN; VIRAL MESSENGER-RNA; HTLV-I REX; GENE-EXPRESSION; INFECTED-CELLS; TYPE-1; SEQUENCE; PRODUCT; DNA	HERPES simplex virus type 1 (HSV-1) Us11 protein, a true late gene product packaged within the virion, is delivered into cells after infection, exhibits a nucleocytoplasmic localization at early times, and later accumulates in the nucleoli(1-5). This RNA-binding basic phosphoprotein, capable of oligomerization, is supposed to be involved in post-transcriptional regulation of gene expression after HSV-1 infection(6,7). Expression of human T-cell leukaemia/lymphoma virus type-I (HTLV-I) and of human immunodeficiency virus type 1 (HIV-1) is post-transcriptionally regulated by Rex and Rev, respectively(8). These proteins are required for the cytoplasmic expression of unspliced gag-pol and singly spliced env transcripts(9,10). Here we show that HSV-1 Us11 protein is able to bind Rex- and Rev-responsive elements and to transactivate envelope retroviral glycoprotein expression.			Diaz, JJ (corresponding author), UNIV LYON 1,CNRS UMR30,FAC MED,RUE GUILLAUME PARADIN,F-69372 LYON 08,FRANCE.		Duc-Dodon, Madeleine/I-6580-2016; DIAZ, Jean-Jacques/AAT-3846-2021; DIAZ, Jean-Jacques/H-3018-2014	DIAZ, Jean-Jacques/0000-0002-7914-4319; DIAZ, Jean-Jacques/0000-0002-7914-4319				BALLAUN C, 1991, J VIROL, V65, P4408, DOI 10.1128/JVI.65.8.4408-4413.1991; BOGERD HP, 1992, J VIROL, V66, P7572, DOI 10.1128/JVI.66.12.7572-7575.1992; BOGERD HP, 1991, P NATL ACAD SCI USA, V88, P5704, DOI 10.1073/pnas.88.13.5704; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DIAZ JJ, 1993, J GEN VIROL, V74, P397, DOI 10.1099/0022-1317-74-3-397; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; INOUE J, 1991, ONCOGENE, V6, P1753; JOHNSON PA, 1986, J GEN VIROL, V67, P871, DOI 10.1099/0022-1317-67-5-871; MACLEAN CA, 1987, J GEN VIROL, V68, P1921, DOI 10.1099/0022-1317-68-7-1921; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MASSE T, 1990, MOL GEN GENET, V220, P377, DOI 10.1007/BF00391742; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; PALKER TJ, 1992, J VIROL, V66, P5879, DOI 10.1128/JVI.66.10.5879-5889.1992; PUVIONDUTILLEUL F, 1987, EUR J CELL BIOL, V43, P487; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; RIMSKY L, 1989, NATURE, V341, P453, DOI 10.1038/341453a0; RIXON FJ, 1984, NUCLEIC ACIDS RES, V12, P2473, DOI 10.1093/nar/12.5.2473; ROLLER RJ, 1990, J VIROL, V64, P3463, DOI 10.1128/JVI.64.7.3463-3470.1990; ROLLER RJ, 1992, J VIROL, V66, P3624, DOI 10.1128/JVI.66.6.3624-3632.1992; ROLLER RJ, 1991, J VIROL, V65, P5873, DOI 10.1128/JVI.65.11.5873-5879.1991; STALLCUP MR, 1983, J BIOL CHEM, V258, P2802; TAN W, 1995, J VIROL, V69, P2932, DOI 10.1128/JVI.69.5.2932-2945.1995; TANAKA Y, 1991, J IMMUNOL, V147, P354	30	78	79	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					273	277		10.1038/379273a0	http://dx.doi.org/10.1038/379273a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538795				2022-12-24	WOS:A1996TQ16900051
J	Huang, YY; Kandel, ER; Varshavsky, L; Brandon, EP; Qi, M; Idzerda, RL; McKnight, GS; Bourtchouladze, R				Huang, YY; Kandel, ER; Varshavsky, L; Brandon, EP; Qi, M; Idzerda, RL; McKnight, GS; Bourtchouladze, R			A genetic test of the effects of mutations in PKA on mossy fiber LTP and its relation to spatial and contextual learning	CELL			English	Article							LONG-TERM POTENTIATION; DEPENDENT PROTEIN-KINASE; HIPPOCAMPAL-FORMATION; ANATOMICAL DATA; MUTANT MICE; MEMORY; RAT; ORGANIZATION; LOCALIZATION; ENHANCEMENT	Using a genetic approach, we assessed the effects of mutations in protein kinase A (PKA) on long-term potentiation (LTP) in the messy fiber pathway and its relationship to spatial and contextual learning. Ablation by gene targeting of the C beta(1) or the RI beta isoform of PKA produces a selective defect in messy fiber LTP, providing genetic evidence for the role of these isoforms in the messy fiber pathway. Despite the elimination of messy fiber LTP, the behavioral responses to novelty, spatial learning, and conditioning to context are unaffected. Thus, contrary to current theories about hippocampal function, messy fiber LTP does not appear to be required for spatial or contextual learning. In the absence of messy fiber LTP, adequate spatial and contextual information might reach the CA1 region via other pathways from the entorhinal cortex.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	Columbia University; University of Washington; University of Washington Seattle	Huang, YY (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,722 W 168TH ST,NEW YORK,NY 10032, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032875] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32875] Funding Source: Medline; NIMH NIH HHS [MH50733] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; BACH ME, 1995, CELL, V81, P905; BARNES CA, 1988, TRENDS NEUROSCI, V11, P163, DOI 10.1016/0166-2236(88)90143-9; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BERGER TW, 1991, LONG TERM POTENTIATI, P327; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; BUCKMASTER PS, 1994, HIPPOCAMPUS, V4, P393, DOI 10.1002/hipo.450040402; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CADD GG, 1990, J BIOL CHEM, V265, P19502; CRUSIO WE, 1989, BEHAV BRAIN RES, V32, P81, DOI 10.1016/S0166-4328(89)80075-0; DOUGLAS RJ, 1969, J COMP PHYSIOL PSYCH, V69, P473, DOI 10.1037/h0028163; DOUGLAS RJ, 1990, SPONTANEOUS ALTERNAT, P73; EICHENBAUM H, 1993, TRENDS NEUROSCI, V16, P163, DOI 10.1016/0166-2236(93)90140-H; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HOLM IE, 1991, J COMP NEUROL, V308, P409, DOI 10.1002/cne.903080308; HOPKINS WF, 1988, J NEUROPHYSIOL, V59, P667, DOI 10.1152/jn.1988.59.2.667; Huang Y Y, 1994, Learn Mem, V1, P74; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; HUANG YY, 1994, LEARN MEMORY, V79, P69; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; JARRARD LE, 1976, J COMP PHYSIOL PSYCH, V90, P1035, DOI 10.1037/h0078659; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; JONES B, 1972, EXP NEUROL, V36, P362, DOI 10.1016/0014-4886(72)90030-1; JUNG MW, 1993, HIPPOCAMPUS, V3, P165, DOI 10.1002/hipo.450030209; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MCNAUGHTON BL, 1989, EXP BRAIN RES, V76, P485, DOI 10.1007/BF00248904; MCNAUGHTON BL, 1986, J NEUROSCI, V6, P563; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MORRIS RGM, 1989, NEUROSCIENCE, V9, P3040; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; SCHWEGLER H, 1988, BEHAV GENET, V18, P153, DOI 10.1007/BF01067837; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SOLBERG R, 1994, EXP CELL RES, V214, P595, DOI 10.1006/excr.1994.1297; SPENCER WA, 1962, PHYSL HIPPOCAMPE, P71; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; SWANSON LW, 1982, NEUROSCI RES PROG B, V20, P613; TREVES A, 1994, HIPPOCAMPUS, V4, P374, DOI 10.1002/hipo.450040319; TREVES A, 1992, HIPPOCAMPUS, V2, P189, DOI 10.1002/hipo.450020209; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WITTER MP, 1993, HIPPOCAMPUS, V3, P33; YECKEL MF, 1995, HIPPOCAMPUS, V5, P108, DOI 10.1002/hipo.450050204; YECKEL MF, 1990, P NATL ACAD SCI USA, V87, P5832, DOI 10.1073/pnas.87.15.5832; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	52	219	222	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1211	1222		10.1016/0092-8674(95)90146-9	http://dx.doi.org/10.1016/0092-8674(95)90146-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548807	Bronze			2022-12-24	WOS:A1995TM76200016
J	Woyka, J				Woyka, J			Hospice at home	BRITISH MEDICAL JOURNAL			English	Article											Woyka, J (corresponding author), HARROW HLTH CARE CTR,HARROW HA1 4LF,MIDDX,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1687	1688		10.1136/bmj.311.7021.1687	http://dx.doi.org/10.1136/bmj.311.7021.1687			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541758	Green Published			2022-12-24	WOS:A1995TL94200018
J	AYALA, FJ				AYALA, FJ			THE MYTH OF EVE - MOLECULAR-BIOLOGY AND HUMAN ORIGINS	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; II NUCLEOTIDE-SEQUENCES; HUMAN MITOCHONDRIAL-DNA; HUMAN-EVOLUTION; ALLELIC GENEALOGY; MHC POLYMORPHISM; SEVERE MALARIA; ANTIGEN; LOCI; SUBSTITUTION	It has been proposed that modern humans descended from a single woman, the ''mitochondrial Eve'' who lived in Africa 100,000 to 200,000 years ago. The human immune system DRB1 genes are extremely polymorphic, with gene lineages that coalesce into an ancestor who lived around 60 million years ago, a time before the divergence of the apes from the Old World monkeys. The theory of gene coalescence suggests that, throughout the last 60 million years, human ancestral populations had an effective size of 100,000 individuals or greater. Molecular evolution data favor the African origin of modern humans, but the weight of the evidence is against a population bottleneck before their emergence. The mitochondrial Eve hypothesis emanates from a confusion between gene genealogies and individual genealogies.			AYALA, FJ (corresponding author), UNIV CALIF IRVINE, IRVINE, CA 92717 USA.							ARDEN B, 1982, P NATL ACAD SCI-BIOL, V79, P2342, DOI 10.1073/pnas.79.7.2342; AYALA FJ, 1994, P NATL ACAD SCI USA, V91, P6787, DOI 10.1073/pnas.91.15.6787; AYALA FJ, IN PRESS MOL PHYLOGE; BERGSTROM T, 1995, IMMUNOL REV, V143, P13, DOI 10.1111/j.1600-065X.1995.tb00668.x; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BONTROP RE, 1994, IMMUNOGENETICS, V39, P81; BONTROP RE, 1995, IMMUNOL REV, V143, P33, DOI 10.1111/j.1600-065X.1995.tb00669.x; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BROWN WM, 1980, P NATL ACAD SCI-BIOL, V77, P3605, DOI 10.1073/pnas.77.6.3605; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CARBONELL E, 1995, SCIENCE, V269, P826, DOI 10.1126/science.7638598; Clark G. A., 1992, MIDDLE PALEOLITHIC A, P183; CLARK GA, 1989, AM ANTHROPOL, V91, P962, DOI 10.1525/aa.1989.91.4.02a00090; CLARK GA, 1994, RECHERCHE, V25, P316; DEEB SS, 1994, P NATL ACAD SCI USA, V91, P7262, DOI 10.1073/pnas.91.15.7262; DORIT RL, 1995, SCIENCE, V268, P1183, DOI 10.1126/science.7761836; FAN WM, 1989, HUM IMMUNOL, V26, P107, DOI 10.1016/0198-8859(89)90096-7; FIGUEROA F, 1988, NATURE, V335, P265, DOI 10.1038/335265a0; GABUNIA L, 1995, NATURE, V373, P509, DOI 10.1038/373509a0; GIBBONS A, 1995, SCIENCE, V267, P1272, DOI 10.1126/science.7871421; GOLDSTEIN DB, 1995, P NATL ACAD SCI USA, V92, P6723, DOI 10.1073/pnas.92.15.6723; GRIFFITHS RC, 1980, THEOR POPUL BIOL, V17, P37, DOI 10.1016/0040-5809(80)90013-1; GYLLENSTEN UB, 1989, P NATL ACAD SCI USA, V86, P9986, DOI 10.1073/pnas.86.24.9986; GYLLENSTEN UB, 1990, P NATL ACAD SCI USA, V87, P1835, DOI 10.1073/pnas.87.5.1835; HAMMER MF, 1995, NATURE, V378, P376, DOI 10.1038/378376a0; HEDRICK PW, 1994, AM NAT, V143, P945, DOI 10.1086/285643; HILL AVS, 1992, NATURE, V355, P403, DOI 10.1038/355403a0; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; HUGHES AL, 1992, NATURE, V355, P402, DOI 10.1038/355402b0; JONES S, 1992, CAMBRIDGE ENCY HUMAN, P246; KAUFMAN J, 1995, IMMUNOL REV, V143, P63, DOI 10.1111/j.1600-065X.1995.tb00670.x; Kimura M, 1985, NEUTRAL THEORY MOL E; Kingman J.F.C., 1982, STOCHASTIC PROCESS A, V13, P235, DOI [DOI 10.1016/0304-4149(82)90011-4, 10.1016/0304-4149(82)90011-4]; Kingman JFC, 1982, J APPL PROB A, V19A, P27, DOI DOI 10.2307/3213548; KLEIN J, 1994, PHILOS T R SOC B, V346, P351, DOI 10.1098/rstb.1994.0152; KLEIN J, 1986, CRC CR REV IMMUNOL, V6, P295; Klein J., 1986, NATURAL HIST MAJOR H; LAWLOR DA, 1988, NATURE, V335, P268, DOI 10.1038/335268a0; LEAKEY MG, 1995, NATURE, V376, P565, DOI 10.1038/376565a0; Li Wen-Hsiung, 1993, P253; Lowenstein J.M., 1986, Pacific Discovery, V39, P38; MARSH SGE, 1993, IMMUNOGENETICS, V37, P79; MARSH SGE, 1991, IMMUNOGENETICS, V33, P321, DOI 10.1007/BF00216691; MAYER WE, 1988, EMBO J, V7, P2765, DOI 10.1002/j.1460-2075.1988.tb03131.x; MCCONNELL TJ, 1988, NATURE, V332, P651, DOI 10.1038/332651a0; MCDEVITT H, 1995, IMMUNOL REV, V143, P113, DOI 10.1111/j.1600-065X.1995.tb00672.x; Menozzi Cavalli-Sforza P, 1994, HIST GEOGRAPHY HUMAN; MILLER LH, 1994, P NATL ACAD SCI USA, V91, P2415, DOI 10.1073/pnas.91.7.2415; NEI M, 1987, MOL EVOLUTIONARY GEN, P395; OHUIGIN C, 1993, IMMUNOGENETICS, V38, P165; PARES JM, 1995, SCIENCE, V269, P830, DOI 10.1126/science.7638599; POTTS WK, 1995, IMMUNOL REV, V143, P181, DOI 10.1111/j.1600-065X.1995.tb00675.x; ROGERS AR, 1995, HUM BIOL, V67, P1; RUVOLO M, 1993, MOL BIOL EVOL, V10, P1115; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SATTA Y, 1993, P NATL ACAD SCI USA, V90, P7480, DOI 10.1073/pnas.90.16.7480; SATTA Y, 1991, MOL EVOLUTION MAJOR, P51; SCHWAIGER FW, 1995, IMMUNOL REV, V143, P199, DOI 10.1111/j.1600-065X.1995.tb00676.x; SNEATH P H, 1973, P573; Spuhler James N., 1993, P262; STONEKING M, 1990, GENETICS, V124, P717; STRINGER CB, 1992, PHILOS T ROY SOC B, V337, P217, DOI 10.1098/rstb.1992.0099; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; STRINGER CB, 1990, SCI AM, V263, P98, DOI 10.1038/scientificamerican1290-98; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; Swofford David L., 1990, P411; TAJIMA F, 1983, GENETICS, V105, P437; TAKAHATA N, 1990, P NATL ACAD SCI USA, V87, P2419, DOI 10.1073/pnas.87.7.2419; TAKAHATA N, 1990, GENETICS, V124, P967; TAKAHATA N, 1985, GENETICS, V110, P325; TAKAHATA N, 1993, MOL BIOL EVOL, V10, P2; TAVARE S, 1984, THEOR POPUL BIOL, V26, P119, DOI 10.1016/0040-5809(84)90027-3; THORNE AG, 1992, SCI AM, V266, P76, DOI 10.1038/scientificamerican0492-76; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WADDLE DM, 1994, NATURE, V368, P452, DOI 10.1038/368452a0; WADDLE DM, 1992, CONTINUITY REPLACEME, P83; WHITE TD, 1995, NATURE, V375, P88, DOI 10.1038/375088a0; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0; WHITFIELD LS, 1995, NATURE, V378, P379, DOI 10.1038/378379a0; WILLS C, 1995, EVOLUTION, V49, P593, DOI 10.1111/j.1558-5646.1995.tb02296.x; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0; WOLPOFF MH, 1988, SCIENCE, V241, P772, DOI 10.1126/science.3136545; 1992, B WORLD HEALTH ORGAN, V70, P801	88	144	150	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 22	1995	270	5244					1930	1936		10.1126/science.270.5244.1930	http://dx.doi.org/10.1126/science.270.5244.1930			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533083				2022-12-24	WOS:A1995TL42000025
J	Kenyon, TA; Valway, SE; Ihle, WW; Onorato, IM; Castro, KG				Kenyon, TA; Valway, SE; Ihle, WW; Onorato, IM; Castro, KG			Transmission of multidrug-resistant Mycobacterium tuberculosis during a long airplane flight	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. In April 1994, a passenger with infectious multidrug-resistant tuberculosis traveled on commercial-airline flights from Honolulu to Chicago and from Chicago to Baltimore and returned one month later, We sought to determine whether she had infected any of her contacts on this extensive trip. Methods. Passengers and crew were identified from airline records and were notified of their exposure, asked to complete a questionnaire, and screened by tuberculin skin tests. Results. Of the 925 people on the airplanes, 802 (86.7 percent) responded. All 11 contacts with positive tuberculin skin tests who were on the April flights and 2 of 3 contacts with positive tests who were on the Baltimore-to-Chicago flight in May had other risk factors for tuberculosis, More contacts on the final, 8.75-hour flight from Chicago to Honolulu had positive skin tests than those on the other three flights (6 percent, as compared with 2.3, 3.8, and 2.8 percent). Of 15 contacts with positive tests on the May flight from Chicago to Honolulu, 6 (4 with skin-test conversions) had no other risk factors; all 6 had sat in the same section of the plane as the index patient (P = 0.001). Passengers seated within two rows of the index patient were more likely to have positive tuberculin skin tests than those in the rest of the section (4 of 13, or 30.8 percent, vs. 2 of 55, or 3.6 percent; rate ratio, 8.5; 95 percent confidence interval, 7.7 to 41.3; P = 0.01). Conclusions. The transmission of Mycobacterium tuberculosis that we describe aboard a commercial aircraft involved a highly infectious passenger, a long flight, and close proximity of contacts to the index patient. (C) 1996, Massachusetts Medical Society.	CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,NATL CTR HIV STD & TB PREVENT,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA			Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				AMLER RW, 1982, JAMA-J AM MED ASSOC, V248, P2129, DOI 10.1001/jama.248.17.2129; BRADEN CR, 1995, CLIN INFECT DIS, V21, P565, DOI 10.1093/clinids/21.3.565; *CDC, 1987, DHHS PUBL, P95; Dean A.G., 1994, EPI INFO VERSION 6 W; DRIVER CR, 1994, JAMA-J AM MED ASSOC, V272, P1031, DOI 10.1001/jama.272.13.1031; HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P26, DOI 10.1080/00039896.1968.10665011; HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968; *IMM NAT SERV, 1994, STAT YB IMM NAT SERV; MCFARLAND JW, 1993, LANCET, V342, P112, DOI 10.1016/0140-6736(93)91311-9; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; MENZIES R, 1994, ANN INTERN MED, V120, P190, DOI 10.7326/0003-4819-120-3-199402010-00003; MILLER MA, 1993, M AM PUBL HLTH ASS E; MOSER MR, 1979, AM J EPIDEMIOL, V110, P1; *PHS, 1991, TECHN INSTR MED EX A; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; RITZINGER FR, 1965, AEROMED REV, V4, P1; ROSE CE, 1979, AM REV RESPIR DIS, V119, P603; THOMPSON NJ, 1979, AM REV RESPIR DIS, V119, P587; WILSON RA, 1994, TRANSPORTATION AM ST; 1995, MMWR-MORBID MORTAL W, V44, P387; 1992, AM REV RESPIR DIS, V146, P1623; 1995, MMWR-MORBID MORTAL W, V44, P137; 1992, MMWR-MORBID MORTAL W, V41, P59	23	263	271	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1996	334	15					933	938		10.1056/NEJM199604113341501	http://dx.doi.org/10.1056/NEJM199604113341501			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD596	8596593				2022-12-24	WOS:A1996UD59600001
J	Strick, TR; Allemand, JF; Bensimon, D; Bensimon, A; Croquette, V				Strick, TR; Allemand, JF; Bensimon, D; Bensimon, A; Croquette, V			The elasticity of a single supercoiled DNA molecule	SCIENCE			English	Article							TORSIONAL RIGIDITY; DEPOLARIZATION; MACROMOLECULES; FLUORESCENCE; ENERGETICS; DYNAMICS	Single linear DNA molecules were bound at multiple sites at one extremity to a treated glass cover slip and at the other to a magnetic bead. The DNA was therefore torsionally constrained, A magnetic field was used to rotate the beads and thus to coil and pull the DNA. The stretching force was determined by analysis of the Brownian fluctuations of the bead. Here, the elastic behavior of individual lambda DNA molecules over- and underwound by up to 500 turns was studied, A sharp transition was discovered from a low to a high extension state at a force of similar to 0.45 piconewtons for underwound molecules and at a force of similar to 3 piconewtons for overwound ones. These transitions, probably reflecting the formation of alternative structures in stretched coiled DNA molecules, might be relevant for DNA transcription and replication.	UNIV PARIS 07,ENS,PHYS STAT LAB,F-75231 PARIS 05,FRANCE; INST PASTEUR,ADN,BIOPHYS LAB,F-75015 PARIS,FRANCE	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Strick, TR (corresponding author), UNIV PARIS 06,ENS,PHYS STAT LAB,24 RUE LHOMOND,F-75231 PARIS 05,FRANCE.		Bensimon, David/E-7768-2015; Strick, Terence R/J-1886-2012	Bensimon, David/0000-0003-1971-9907; Croquette, Vincent/0000-0003-1400-0039; Allemand, Jean - Francois/0000-0001-7496-0977; Strick, Terence/0000-0003-1744-3679				ADRIAN M, 1990, EMBO J, V9, P4551, DOI 10.1002/j.1460-2075.1990.tb07907.x; ALLISON SA, 1979, CHEM PHYS, V41, P35, DOI 10.1016/0301-0104(79)80131-7; BARKLEY MD, 1979, J CHEM PHYS, V70, P2991, DOI 10.1063/1.437838; BEDNAR J, 1994, J MOL BIOL, V235, P825, DOI 10.1006/jmbi.1994.1042; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; FULLER FB, 1971, P NATL ACAD SCI USA, V68, P815, DOI 10.1073/pnas.68.4.815; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; KLENIN KV, 1995, BIOPHYS J, V68, P81, DOI 10.1016/S0006-3495(95)80161-X; Kornberg A., 1992, DNA REPLICATION; LANGOWSKI J, 1994, BIOPOLYMERS, V34, P639, DOI 10.1002/bip.360340506; MARKO JF, 1994, SCIENCE, V265, P506, DOI 10.1126/science.8036491; MARKO JF, 1995, PHYS REV E, V52, P2912, DOI 10.1103/PhysRevE.52.2912; MARKO JF, COMMUNICATION; MCCLELLAN JA, 1991, J MOL BIOL, V219, P145, DOI 10.1016/0022-2836(91)90555-K; MORSE RH, 1988, CELL, V54, P285, DOI 10.1016/0092-8674(88)90190-0; MURCHIE AIH, 1992, BIOCHIM BIOPHYS ACTA, V1131, P1, DOI 10.1016/0167-4781(92)90091-D; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SCHLICK T, 1992, J MOL BIOL, V223, P1089, DOI 10.1016/0022-2836(92)90263-J; SELVIN PR, 1992, SCIENCE, V255, P82, DOI 10.1126/science.1553534; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SIMON A, 1995, P INSTRUMENTATION PH, P93; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; VINOGRAD J, 1965, P NATL ACAD SCI USA, V53, P1104, DOI 10.1073/pnas.53.5.1104; VOLOGODSKII A, 1994, MACROMOLECULES, V27, P5623, DOI 10.1021/ma00098a016; VOLOGODSKII AV, 1992, J MOL BIOL, V227, P1224, DOI 10.1016/0022-2836(92)90533-P; VOLOGODSKII AV, 1994, ANNU REV BIOPH BIOM, V23, P609, DOI 10.1146/annurev.bb.23.060194.003141; WHITE JH, 1969, AM J MATH, V91, P693, DOI 10.2307/2373348; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653	34	1001	1030	4	164	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1835	1837		10.1126/science.271.5257.1835	http://dx.doi.org/10.1126/science.271.5257.1835			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596951				2022-12-24	WOS:A1996UC77800037
J	Hall, SL; Padgett, RA				Hall, SL; Padgett, RA			Requirement of U12 snRNA for in vivo splicing of a minor class of eukaryotic nuclear pre-mRNA introns	SCIENCE			English	Article							COMPENSATORY BASE CHANGE; MESSENGER-RNA; SITE SELECTION; U6 SNRNA; PAIRING INTERACTION; U2 SNRNP; YEAST; RIBONUCLEOPROTEINS; INVITRO; SPLICEOSOME	A conserved sequence element in a minor class of eukaryotic pre-messenger RNA (pre-mRNA) introns was previously proposed to base pair with a complementary sequence in the U12 small nuclear RNA (snRNA) in a manner analogous to the pairing of U2 snRNA with the branch site sequence of the major class of introns. Here, mutations generated in this conserved sequence element block the splicing of a member of this minor intron class in vivo. This block was relieved by coexpression of a U12 snRNA containing compensatory mutations that restore the proposed base pairing interaction, These results show that this minor class of pre-mRNA introns is a distinct class existing alongside the major class of introns in animal genomes, and these results also establish an in vivo function for U12 snRNA.	CLEVELAND CLIN FDN,DEPT MOLEC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045371] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM45371] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Baserga S., 1993, RNA WORLD, P359; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; MADHANI HD, 1994, GENE DEV, V8, P1071, DOI 10.1101/gad.8.9.1071; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MATERA AG, 1993, J CELL BIOL, V121, P715, DOI 10.1083/jcb.121.4.715; MONTZKA KA, 1988, P NATL ACAD SCI USA, V85, P8885, DOI 10.1073/pnas.85.23.8885; NELSON KK, 1989, GENE DEV, V3, P1562, DOI 10.1101/gad.3.10.1562; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PADGETT RA, 1985, P NATL ACAD SCI USA, V82, P8349, DOI 10.1073/pnas.82.24.8349; PADGETT RA, 1984, SCIENCE, V225, P898, DOI 10.1126/science.6206566; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; QUERY CC, 1994, GENE DEV, V8, P587, DOI 10.1101/gad.8.5.587; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; RUSKIN B, 1985, CELL, V41, P833, DOI 10.1016/S0092-8674(85)80064-7; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SUN JS, 1995, GENE DEV, V9, P843, DOI 10.1101/gad.9.7.843; TARN WY, 1995, RNA, V1, P644; TARN WY, IN PRESS CELL; WASSARMAN KM, 1992, MOL CELL BIOL, V12, P1276, DOI 10.1128/MCB.12.3.1276; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	29	169	170	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1716	1718		10.1126/science.271.5256.1716	http://dx.doi.org/10.1126/science.271.5256.1716			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596930				2022-12-24	WOS:A1996UB15100043
J	Sherertz, RJ; Reagan, DR; Hampton, KD; Robertson, KL; Streed, SA; Hoen, HM; Thomas, R; Gwaltney, JM				Sherertz, RJ; Reagan, DR; Hampton, KD; Robertson, KL; Streed, SA; Hoen, HM; Thomas, R; Gwaltney, JM			A cloud adult: The Staphylococcus aureus - Virus interaction revisited	ANNALS OF INTERNAL MEDICINE			English	Article							NEWBORN NURSERY; MOLECULAR EPIDEMIOLOGY; BACTERIAL ADHERENCE; GEL-ELECTROPHORESIS; NASAL CARRIAGE; CARE UNIT; OUTBREAK; INFECTION; SPREAD; COLDS	Background: Nasal carriage of Staphylococcus aureus is common among health care workers, but outbreaks caused by such carriers are relatively uncommon. We previously reported outbreaks of S. aureus skin infections that affected newborn infants and were attributed to an S. aureus nasa I carrier who had had an associated upper respiratory tract infection (URI) during the outbreak period. Objective: To investigate the contribution of a nasal methicillin-resistant S. aureus (MRSA) carrier (physician 4) who contracted a URI to an outbreak of MRSA infections that involved 8 of 43 patients in a surgical intensive care unit during a 3-week period. Design: An epidemiologic study of an outbreak of MRSA infections and a quantitative investigation of airborne dispersal of S. aureus associated with an experimentally induced rhinoviral Infection. Setting: A university hospital. Participants: 43 patients in a surgical intensive care unit and 1 physician. Measurements: Molecular typing was done, and risk factors for MRSA colonization were analyzed. Agar settle plates and volumetric air cultures were used to evaluate the airborne dispersal of S. aureus by physician 4 before and after a rhinoviral infection and with or without a surgical mask. Results: A search for nasal carriers of MRSA identified a single physician (physician 4); molecular typing showed that the MRSA strain from physician 4 and those from the patients were identical. Multivariate logistic regression analysis identified exposure to physician 4 and duration of ventilation as independent risk factors for colonization with MRSA (P less than or equal to 0.008). Air cultures showed that physician 4 dispersed little S. aureus in the absence of a URI. After experimental induction of a rhinovirus URI, physician 4's airborne dispersal of S. aureus without a surgical mask increased 40-fold; dispersal was significantly reduced when physician 4 wore a mask (P less than or equal to 0.015). Conclusions: Physician 4 became a ''cloud adult,'' analogous to the ''cloud babies'' described by Eichenwald and coworkers who shed S. aureus into the air in association with viral URIs. Airborne dispersal of S. aureus in association with a URI may be an important mechanism of transmission of S. aureus.	E TENNESSEE STATE UNIV, JAMES H QUILLEN COLL MED, JOHNSON CITY, TN 37614 USA; N CAROLINA BAPTIST HOSP INC, WINSTON SALEM, NC USA; UNIV VIRGINIA, SCH MED, CHARLOTTESVILLE, VA USA	East Tennessee State University; Wake Forest University; Wake Forest Baptist Medical Center; University of Virginia	Sherertz, RJ (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, MED CTR BLVD, WINSTON SALEM, NC 27157 USA.							BACK NA, 1993, JAMA-J AM MED ASSOC, V270, P1329, DOI 10.1001/jama.270.11.1329; BARRY AL, 1991, AM SOC MICROBIOLOGY, V11, P17; BELANI A, 1986, INFECT CONT HOSP EP, V7, P487, DOI 10.1017/S0195941700065097; BETHUNE DW, 1965, LANCET, V1, P480; BIBEL DJ, 1982, J INVEST DERMATOL, V79, P250, DOI 10.1111/1523-1747.ep12500072; BOYCE JM, 1993, CLIN INFECT DIS, V17, P496, DOI 10.1093/clinids/17.3.496; BOYCE JM, 1983, JAMA-J AM MED ASSOC, V249, P2803, DOI 10.1001/jama.249.20.2803; CHOWDHURY MNH, 1992, J HOSP INFECT, V22, P299, DOI 10.1016/0195-6701(92)90015-E; COOVADIA YM, 1989, J HOSP INFECT, V14, P303, DOI 10.1016/0195-6701(89)90070-4; DANCER SJ, 1988, J INFECTION, V16, P87, DOI 10.1016/S0163-4453(88)96249-4; DANCER SJ, 1990, J INFECTION, V20, P73, DOI 10.1016/S0163-4453(90)92434-M; DUNKLE LM, 1981, AM J MED, V70, P455, DOI 10.1016/0002-9343(81)90787-7; EICHENWALD HF, 1960, AM J DIS CHILD, V100, P161, DOI 10.1001/archpedi.1960.04020040163003; Fa W., 1995, PRINCIPLES PRACTICES, V4, P1754; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GAYNES R, 1991, J INFECT DIS, V163, P117, DOI 10.1093/infdis/163.1.117; GOERING RV, 1990, J CLIN MICROBIOL, V28, P426, DOI 10.1128/JCM.28.3.426-429.1990; GOERING RV, 1993, INFECT CONT HOSP EP, V14, P595; GWALTNEY JM, 1978, ANN INTERN MED, V88, P463, DOI 10.7326/0003-4819-88-4-463; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; GWALTNEY JM, 1975, J INFECT DIS, V132, P62, DOI 10.1093/infdis/132.1.62; GWALTNEY JM, 1982, UPPER AIRWAY PHYSL A, P399; HALEY RW, 1982, J INFECT DIS, V145, P875, DOI 10.1093/infdis/145.6.875; HAMRE D, 1966, AM J EPIDEMIOL, V83, P238, DOI 10.1093/oxfordjournals.aje.a120579; HARE R, 1956, BMJ-BRIT MED J, V2, P840, DOI 10.1136/bmj.2.4997.840; HEDBERG K, 1990, PEDIATR INFECT DIS J, V9, P268, DOI 10.1097/00006454-199004000-00009; HOEGER PH, 1988, PEDIATR INFECT DIS J, V7, P340, DOI 10.1097/00006454-198805000-00010; HUIJSMANSEVERS AGM, 1978, ARCH CHIR NEERL, V30, P141; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; KINSMAN OS, 1983, J MED MICROBIOL, V16, P215, DOI 10.1099/00222615-16-2-215; KNIGHT V, 1964, PROG MED VIROL, V6, P1; LIANOU P, 1989, ACTA DERM-VENEREOL, V69, P330; LIPSKY BA, 1987, DIABETES CARE, V10, P483, DOI 10.2337/diacare.10.4.483; MULLIGAN ME, 1993, AM J MED, V94, P313, DOI 10.1016/0002-9343(93)90063-U; NAHMIAS AJ, 1960, JAMA-J AM MED ASSOC, V174, P1269, DOI 10.1001/jama.1960.03030100037009; NAKASHIMA AK, 1984, INFECT CONT HOSP EP, V5, P326, DOI 10.1017/S0195941700060513; NICHOL KP, 1967, NEW ENGL J MED, V277, P667, DOI 10.1056/NEJM196709282771301; PEACOCK JE, 1980, ANN INTERN MED, V93, P526, DOI 10.7326/0003-4819-93-4-526; REAGAN DR, 1991, ANN INTERN MED, V114, P101, DOI 10.7326/0003-4819-114-2-101; RICHARDSON JF, 1990, J HOSP INFECT, V16, P109, DOI 10.1016/0195-6701(90)90055-S; Sahm D.H., 1991, MANUAL CLIN MICROBIO; SANFORD BA, 1987, P SOC EXP BIOL MED, V185, P120; SINGH G, 1978, DERMATOLOGICA, V157, P21, DOI 10.1159/000250804; STONE AA, 1992, BEHAV MED, V18, P115, DOI 10.1080/08964289.1992.9936961; TANNER EI, 1980, J HYG-CAMBRIDGE, V85, P219, DOI 10.1017/S0022172400063257; THOMPSON RL, 1982, ANN INTERN MED, V97, P309, DOI 10.7326/0003-4819-97-3-309; WHITE A, 1961, J LAB CLIN MED, V58, P273; WILLIAMS RE, 1963, BACTERIOL REV, V27, P56, DOI 10.1128/MMBR.27.1.56-71.1963; WINKLER J, 1990, J INFECT DIS, V162, P1400, DOI 10.1093/infdis/162.6.1400	49	148	158	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1996	124	6					539	+		10.7326/0003-4819-124-6-199603150-00001	http://dx.doi.org/10.7326/0003-4819-124-6-199603150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ529	8597316				2022-12-24	WOS:A1996TZ52900001
J	vanderWal, G; OnwuteakaPhilipsen, BD				vanderWal, G; OnwuteakaPhilipsen, BD			Cases of euthanasia and assisted suicide reported to the public prosecutor in North Holland over 10 years	BRITISH MEDICAL JOURNAL			English	Article									VRIJE UNIV AMSTERDAM,INST RES EXTRAMURAL MED,1081 BT AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam								VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; VANDERWAL G, 1992, EUTHANASIA ASSISTED	2	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					612	613						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595336				2022-12-24	WOS:A1996TZ84000026
J	Tishkoff, SA; Dietzsch, E; Speed, W; Pakstis, AJ; Kidd, JR; Cheung, K; BonneTamir, B; SantachiaraBenerecetti, AS; Moral, P; Krings, M; Paabo, S; Watson, E; Risch, N; Jenkins, T; Kidd, KK				Tishkoff, SA; Dietzsch, E; Speed, W; Pakstis, AJ; Kidd, JR; Cheung, K; BonneTamir, B; SantachiaraBenerecetti, AS; Moral, P; Krings, M; Paabo, S; Watson, E; Risch, N; Jenkins, T; Kidd, KK			Global patterns of linkage disequilibrium at the CD4 locus and modern human origins	SCIENCE			English	Article							HUMAN MITOCHONDRIAL-DNA; STEPWISE MUTATION MODEL; HUMAN-EVOLUTION; HUMAN-POPULATIONS; TRANSGENIC MICE; CONTROL REGION; SEQUENCES; POLYMORPHISMS; EXPRESSION; SCALE	Haplotypes consisting of alleles at a short tandem repeat polymorphism (STRP) and an Alu deletion polymorphism at the CD4 locus on chromosome 12 were analyzed in more than 1600 individuals sampled from 42 geographically dispersed populations (13 African, 2 Middle Eastern, 7 European, 9 Asian, 3 Pacific, and 8 Amerindian). Sub-Saharan African populations had more haplotypes and exhibited more variability in frequencies of haplotypes than the Northeast African or non-African populations. The Alu deletion was nearly always associated with a single STRP allele in non-African and Northeast African populations but was associated with a wide range of STRP alleles in the sub-Saharan African populations. This global pattern of haplotype variation and linkage disequilibrium suggests a common and recent African origin for all non-African human populations.	S AFRICAN INST MED RES,SCH PATHOL,DEPT HUMAN GENET,JOHANNESBURG 2000,SOUTH AFRICA; UNIV WITWATERSRAND,JOHANNESBURG 2000,SOUTH AFRICA; TEL AVIV UNIV,SACKLER FAC MED,DEPT HUMAN GENET,IL-69978 RAMAT AVIV,ISRAEL; UNIV PAVIA,DIPARTIMENTO GENET & MICROBIOL A BUZZATI TRAVERSO,I-27100 PAVIA,ITALY; UNIV BARCELONA,DEPT ANIM BIOL,E-08028 BARCELONA,SPAIN; UNIV MUNICH,INST ZOOL,D-80021 MUNICH,GERMANY; MASSEY UNIV,SCH BIOL SCI,PALMERSTON NORTH,NEW ZEALAND; UNIV MUNICH,INST ZOOL,D-80333 MUNICH 2,GERMANY; STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305	University of Witwatersrand; Tel Aviv University; Sackler Faculty of Medicine; University of Pavia; University of Barcelona; University of Munich; Massey University; University of Munich; Stanford University	Tishkoff, SA (corresponding author), YALE UNIV,SCH MED,DEPT GENET,333 CEDAR ST,NEW HAVEN,CT 06520, USA.		Moral, Pedro/K-9587-2014; Klein, Richard G/B-5910-2009	Moral, Pedro/0000-0001-5072-5892; 	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039239, R37MH039239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009379] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00348] Funding Source: Medline; NIAAA NIH HHS [AA09379] Funding Source: Medline; NIMH NIH HHS [MH39239] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AYALA FJ, 1994, P NATL ACAD SCI USA, V91, P6787, DOI 10.1073/pnas.91.15.6787; BATZER MA, 1994, P NATL ACAD SCI USA, V91, P12288, DOI 10.1073/pnas.91.25.12288; BENGTSSON BO, 1981, TISSUE ANTIGENS, V18, P356, DOI 10.1111/j.1399-0039.1981.tb01404.x; BLUM MD, 1993, J EXP MED, V177, P1343, DOI 10.1084/jem.177.5.1343; Bowcock A M, 1991, Gene Geogr, V5, P151; BOWCOCK AM, 1991, P NATL ACAD SCI USA, V88, P839, DOI 10.1073/pnas.88.3.839; BOWCOCK AM, 1994, NATURE, V368, P455, DOI 10.1038/368455a0; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CASTIGLIONE CM, 1995, AM J HUM GENET, V57, P1445; CAVALLISFORZA LL, 1988, P NATL ACAD SCI USA, V85, P6002, DOI 10.1073/pnas.85.16.6002; DEKA R, 1995, AM J HUM GENET, V56, P461; DIRIENZO A, 1991, P NATL ACAD SCI USA, V88, P1597, DOI 10.1073/pnas.88.5.1597; DIRIENZO A, 1994, P NATL ACAD SCI USA, V91, P3166, DOI 10.1073/pnas.91.8.3166; DORIT RL, 1995, SCIENCE, V268, P1183, DOI 10.1126/science.7761836; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; EDWARDS MC, 1991, NUCLEIC ACIDS RES, V19, P4791, DOI 10.1093/nar/19.17.4791-a; EDWARDS MC, 1992, GENOMICS, V14, P590, DOI 10.1016/S0888-7543(05)80156-9; GILLESPIE FP, 1993, MOL CELL BIOL, V13, P2952, DOI 10.1128/MCB.13.5.2952; GOLDSTEIN DB, 1995, P NATL ACAD SCI USA, V92, P6723, DOI 10.1073/pnas.92.15.6723; GOLDSTEIN DB, 1995, GENETICS, V139, P463; GOODFELLOW PN, 1995, NATURE, V378, P379; HAKIM I, 1990, PLURIDISCIPLINARY AP, P43; HAMMER MF, 1995, NATURE, V378, P376, DOI 10.1038/378376a0; HARPENDING HC, 1993, CURR ANTHROPOL, V34, P483, DOI 10.1086/204195; HASEGAWA M, 1993, J MOL EVOL, V37, P347, DOI 10.1007/BF00178865; HAWLEY ME, 1995, J HERED, V86, P409, DOI 10.1093/oxfordjournals.jhered.a111613; HEDGES SB, 1992, SCIENCE, V255, P737, DOI 10.1126/science.1738849; Hill A., 1994, INTEGRATIVE PATHS PA, P123; HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532; JONES JS, 1986, NATURE, V319, P449, DOI 10.1038/319449b0; JORDE LB, 1995, AM J HUM GENET, V57, P523; KIDD KK, IN PRESS ALCOHOLISM; LAHR MM, 1995, EVOL ANTHR, V3, P48; MADDISON DR, 1992, SYST BIOL, V41, P111, DOI 10.2307/2992510; MAHTANI MM, 1993, HUM MOL GENET, V2, P431, DOI 10.1093/hmg/2.4.431; MARTINSON JJ, 1995, AM J HUM GENET, V57, P1186; MCNEMAR Q, 1969, PSYCHOL STATISTICS; MERRIWETHER DA, 1991, J MOL EVOL, V33, P543, DOI 10.1007/BF02102807; MICHALATOSBELOI.S, UNPUB; NEI M, 1989, HUM HERED, V39, P276, DOI 10.1159/000153872; NEI M, 1993, MOL BIOL EVOL, V10, P927; Nei M, 1987, MOL EVOLUTIONARY GEN; PENNY D, 1995, MOL BIOL EVOL, V12, P863; REYNOLDS J, 1983, GENETICS, V105, P767; RISCH N, 1995, NAT GENET, V9, P152, DOI 10.1038/ng0295-152; RITTE U, 1993, HUM BIOL, V65, P359; ROGERS AR, 1995, HUM BIOL, V67, P1; RUVOLO M, 1991, P NATL ACAD SCI USA, V88, P1570, DOI 10.1073/pnas.88.4.1570; SATTA Y, 1994, P NATL ACAD SCI USA, V91, P7184, DOI 10.1073/pnas.91.15.7184; SHEBA C, 1962, AM J PHYS ANTHROPOL, V20, P167, DOI 10.1002/ajpa.1330200218; SHRIVER MD, 1993, GENETICS, V134, P983; SLATKIN M, 1995, MOL BIOL EVOL, V12, P473; SLATKIN M, 1995, GENETICS, V139, P457; SLATKIN M, 1994, GENETICS, V137, P331; STRINGER CB, 1993, ORIGIN AND EVOLUTION OF HUMANS AND HUMANNESS, P75; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; STRINGER CB, 1992, HOMO SAPIENS EVOLUTI, P9; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; TAUTZ D, 1994, CURR OPIN GENET DEV, V4, P832, DOI 10.1016/0959-437X(94)90067-1; TEMPLETON AR, 1993, AM ANTHROPOL, V95, P51, DOI 10.1525/aa.1993.95.1.02a00030; TEMPLETON AR, 1992, SCIENCE, V255, P737, DOI 10.1126/science.1590849; Tishkoff S. A., 1995, American Journal of Human Genetics, V57, pA42; TISHKOFF SA, 1995, AM J PHYS ANTHR S, V20, P211; VALDES AM, 1993, GENETICS, V133, P737; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WAINSCOAT JS, 1986, NATURE, V319, P491, DOI 10.1038/319491a0; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; WILSON AC, 1969, P NATL ACAD SCI USA, V63, P1088, DOI 10.1073/pnas.63.4.1088; WOLPOFF M, 1989, HUMAN REVOLUTION BEH, V1, P62; WOLPOFF MH, 1992, HOMO SAPIENS EVOLUTI, P25; WORKMAN PL, 1970, AM J HUM GENET, V22, P24; ZISCHLER H, 1995, NATURE, V378, P489, DOI 10.1038/378489a0; ZOOSSMANNDISKIN A, 1991, ISRAEL J MED SCI, V27, P245	74	484	490	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1380	1387		10.1126/science.271.5254.1380	http://dx.doi.org/10.1126/science.271.5254.1380			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596909				2022-12-24	WOS:A1996TY96100036
J	Quinn, J; Fyrberg, AM; Ganster, RW; Schmidt, MC; Peterson, CL				Quinn, J; Fyrberg, AM; Ganster, RW; Schmidt, MC; Peterson, CL			DNA-binding properties of the yeast SWI/SNF complex	NATURE			English	Article							TRANSCRIPTIONAL ACTIVATOR; CRUCIFORM DNA; PROTEIN; GENES; ENHANCERS; HMG1	The SWI/SNF complex is required for the enhancement of transcription by many transcriptional activators in yeast(1,2) Genetic and biochemical studies indicate that the complex facilitates activator function by antagonizing chromatin-mediated transcriptional repression(3-6). The absence of known DNA-binding motifs in several SWI/SNF subunits and the failure to identify SWI/SNF-dependent DNA-binding activities in crude yeast extracts have led to the belief that the complex does not bind DNA(7,8). Here we show that the SWI/SNF complex has a high affinity for DNA and that its DNA-binding properties are similar to those of proteins containing HMG-box domains(9). The complex interacts with the minor groove of the DNA helix, binds synthetic four-way junction DNA, and introduces positive supercoils into relaxed plasmid DNA. These properties are likely to be important in the remodelling of chromatin structure by the SWI/SNF complex.	UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605; UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Quinn, Janet/AAR-9957-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM049650, R01GM049650] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM049650, R37 GM049650] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIANCHI ME, 1988, EMBO J, V7, P843, DOI 10.1002/j.1460-2075.1988.tb02883.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; CAIMS BR, 1994, P NATL ACAD SCI USA, V91, P1950; CLARK DJ, 1991, EMBO J, V10, P387, DOI 10.1002/j.1460-2075.1991.tb07960.x; COPENHAVER GP, 1994, NUCLEIC ACIDS RES, V22, P2651, DOI 10.1093/nar/22.13.2651; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DIFFLEY JFX, 1992, J BIOL CHEM, V267, P3368; FISHER RP, 1992, J BIOL CHEM, V267, P3358; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HIRSCHHORN JN, 1992, GENE DEV, V6, P228; KNAB AM, 1993, J BIOL CHEM, V268, P22322; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LEE MS, 1991, P NATL ACAD SCI USA, V88, P9675, DOI 10.1073/pnas.88.21.9675; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; PETERSON CL, 1988, MOL CELL BIOL, V8, P4972, DOI 10.1128/MCB.8.11.4972; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; PUTNAM CD, 1992, MOL CELL BIOL, V12, P4970, DOI 10.1128/MCB.12.11.4970; STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044; TREICH I, 1995, MOL CELL BIOL, V15, P4240; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; WEMER MH, 1995, CELL, V81, P705; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3	27	176	177	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					844	847		10.1038/379844a0	http://dx.doi.org/10.1038/379844a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587611				2022-12-24	WOS:A1996TX50100064
J	Whynes, DK; Baines, DL; Tolley, KH				Whynes, DK; Baines, DL; Tolley, KH			Explaining variations in general practice prescribing costs per ASTRO-PU (age, sex, and temporary resident originated prescribing unit)	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM,SCH MED,SCH PUBL HLTH,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham	Whynes, DK (corresponding author), UNIV NOTTINGHAM,DEPT ECON,NOTTINGHAM NG7 2RD,ENGLAND.		Baines, Darrin/ABI-5893-2020	Baines, Darrin/0000-0001-9502-4678				BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; CARLISLE RD, 1993, BRIT MED J, V306, P1383, DOI 10.1136/bmj.306.6889.1383; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; 1994, PRESCRIPTION IMPROVE; 1994, EL942 NHS MAN EX DEP	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					488	489		10.1136/bmj.312.7029.488	http://dx.doi.org/10.1136/bmj.312.7029.488			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597684	Green Published			2022-12-24	WOS:A1996TX38300029
J	Hinchey, J; Chaves, C; Appignani, B; Breen, J; Pao, L; Wang, A; Pessin, MS; Lamy, C; Mas, JL; Caplan, LR				Hinchey, J; Chaves, C; Appignani, B; Breen, J; Pao, L; Wang, A; Pessin, MS; Lamy, C; Mas, JL; Caplan, LR			A reversible posterior leukoencephalopathy syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NERVOUS-SYSTEM TOXICITY; BONE-MARROW TRANSPLANTATION; HUMAN-ENDOTHELIAL-CELLS; WHITE-MATTER LESIONS; HYPERTENSIVE ENCEPHALOPATHY; LIVER-TRANSPLANTATION; CORTICAL BLINDNESS; RENAL ARTERIOPATHY; CYCLOSPORINE; ECLAMPSIA	Background and Methods. In some patients who are hospitalized for acute illness, we have noted a reversible syndrome of headache, altered mental functioning, seizures, and loss of vision associated with findings indicating predominantly posterior leukoencephalopathy on imaging studies, To elucidate this syndrome, we searched the log books listing computed tomographic (CT) and magnetic resonance imaging (MRI) studies performed at the New England Medical Center in Boston and Hopital Sainte Anne in Paris; we found 15 such patients who were evaluated from 1988 through 1994. Results. Of the 15 patients, 7 were receiving immunosuppressive therapy after transplantation or as treatment for aplastic anemia, 1 was receiving interferon for melanoma, 3 had eclampsia, and 4 had acute hypertensive encephalopathy associated with renal disease (2 with lupus nephritis, 1 with acute glomerulonephritis, and 1 with acetaminophen-induced hepatorenal failure), Altogether, 12 patients had abrupt increases in blood pressure, and 8 had some impairment of renal function. The clinical findings included headaches, vomiting, confusion, seizures, cortical blindness and other visual abnormalities, and motor signs, CT and MRI studies showed extensive bilateral white-matter abnormalities suggestive of edema in the posterior regions of the cerebral hemispheres, but the changes often involved other cerebral areas, the brain stem, or the cerebellum. The patients were treated with antihypertensive medications, and immunosuppressive therapy was withdrawn or the dose was reduced, In all 15 patients, the neurologic deficits resolved within two weeks. Conclusions. Reversible, predominantly posterior leukoencephalopathy may develop in patients who have renal insufficiency or hypertension or who are immunosuppressed, The findings on neuroimaging are characteristic of subcortical edema without infarction. (C) 1996, Massachusetts Medical Society.	TUFTS UNIV NEW ENGLAND MED CTR, DEPT NEUROL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; HOP ST ANNE, SERV NEUROL, F-75674 PARIS, FRANCE	Tufts Medical Center; Tufts University; GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite								ABUELMAGD KM, 1991, TRANSPLANT P, V23, P3190; ANTONOVYCH TT, 1988, TRANSPL P, V20, P951; BENIGNI A, 1992, TRANSPLANTATION, V54, P775, DOI 10.1097/00007890-199211000-00002; BHATT BD, 1988, NEW ENGL J MED, V318, P788; BROWN Z, 1987, TRANSPLANT P, V19, P1178; BUNCHMAN TE, 1991, J CLIN INVEST, V88, P310, DOI 10.1172/JCI115293; BYROM FB, 1954, LANCET, V2, P201; CAPLAN LR, 1980, NEUROLOGY, V30, P72, DOI 10.1212/WNL.30.1.72; COHEN RB, 1993, ANN INTERN MED, V118, P114, DOI 10.7326/0003-4819-118-2-199301150-00007; DAHMUS MA, 1992, AM J OBSTET GYNECOL, V167, P935, DOI 10.1016/S0002-9378(12)80015-9; DEGROEN PC, 1988, NEW ENGL J MED, V318, P789; DEGROEN PC, 1987, NEW ENGL J MED, V317, P861, DOI 10.1056/NEJM198710013171404; DEKLIPPEL N, 1992, LANCET, V339, P1114, DOI 10.1016/0140-6736(92)90707-A; DIGRE KB, 1993, ARCH NEUROL-CHICAGO, V50, P399, DOI 10.1001/archneur.1993.00540040055015; DINSDALE HB, 1971, EUR NEUROL, V6, P29, DOI 10.1159/000114461; DINSDALE HB, 1974, ARCH NEUROL-CHICAGO, V31, P80, DOI 10.1001/archneur.1974.00490380028002; DONALDSON JO, 1993, LANCET, V342, P504; DONALDSON JO, 1993, LANCET, V341, P1447; DUNCAN R, 1989, J NEUROL NEUROSUR PS, V52, P899, DOI 10.1136/jnnp.52.7.899; EIDELMAN BH, 1991, TRANSPLANT P, V23, P3175; FISHER M, 1985, ANN NEUROL, V18, P268, DOI 10.1002/ana.410180219; FOGO A, 1990, TRANSPLANTATION, V49, P1190, DOI 10.1097/00007890-199006000-00038; FREISE CE, 1991, TRANSPLANT P, V23, P3173; GOTTRAND F, 1991, NEW ENGL J MED, V324, P1744; HAUSER RA, 1988, ARCH NEUROL-CHICAGO, V45, P1078, DOI 10.1001/archneur.1988.00520340032007; HERZOG TJ, 1990, OBSTET GYNECOL, V76, P980; HOLLER E, 1989, BLOOD, V73, P2018; HUGHES RL, 1990, NEW ENGL J MED, V323, P420; HUMPHREYS TR, 1993, J AM ACAD DERMATOL, V29, P490, DOI 10.1016/S0190-9622(08)82005-1; IGARASHI T, 1994, ANN RHEUM DIS, V53, P350, DOI 10.1136/ard.53.5.350; JACOBS BC, 1992, MAGNETIC RESONANCE I, P636; JOHANSSON BB, 1983, ACTA MED SCAND, P107; KUPFERSCHMIDT H, 1995, ANN INTERN MED, V123, P598, DOI 10.7326/0003-4819-123-8-199510150-00006; MERIMSKY O, 1992, ANTI-CANCER DRUG, V3, P567, DOI 10.1097/00001813-199212000-00002; MOUTABARRIK A, 1991, TRANSPLANT P, V23, P3137; MUELLER AR, 1994, TRANSPLANTATION, V58, P155, DOI 10.1097/00007890-199407270-00006; RAPS EC, 1993, ANN NEUROL, V33, P222, DOI 10.1002/ana.410330215; RAROQUE HG, 1990, NEUROLOGY, V40, P167, DOI 10.1212/WNL.40.1.167; REMUZZI G, 1989, AM J KIDNEY DIS, V13, P261, DOI 10.1016/S0272-6386(89)80032-0; ROBERTSON DM, 1970, AM J PATHOL, V59, P115; RUBIN AM, 1987, NEUROLOGY, V37, P1072, DOI 10.1212/WNL.37.6.1072; SANDERS TG, 1991, RADIOLOGY, V180, P475, DOI 10.1148/radiology.180.2.2068315; SCHERRER U, 1990, NEW ENGL J MED, V323, P693, DOI 10.1056/NEJM199009133231101; SCHWARTZ RB, 1992, AM J ROENTGENOL, V159, P379, DOI 10.2214/ajr.159.2.1632361; Sheth RD, 1996, EUR NEUROL, V36, P25, DOI 10.1159/000117195; SHUTTER LA, 1993, NEUROLOGY, V43, P2417, DOI 10.1212/WNL.43.11.2417; SIBAI BM, 1980, OBSTET GYNECOL, V55, P74; SLOANE JP, 1985, LANCET, V2, P280; SOMMER BG, 1986, TRANSPLANT P, V18, P151; SOMMER BG, 1985, AM J SURG, V149, P756, DOI 10.1016/S0002-9610(85)80181-1; STEIN DP, 1992, ANN NEUROL, V31, P644, DOI 10.1002/ana.410310612; TOLLEMAR J, 1988, NEW ENGL J MED, V318, P788; TROMMER BL, 1988, STROKE, V19, P326, DOI 10.1161/01.STR.19.3.326; TRUWIT CL, 1991, AM J NEURORADIOL, V12, P651; VAUGHN DJ, 1993, AM J NEURORADIOL, V14, P1014; VERBEKE M, 1994, CARDIOVASC RES, V28, P1152, DOI 10.1093/cvr/28.8.1152; WEINGARTEN K, 1994, AM J ROENTGENOL, V162, P665, DOI 10.2214/ajr.162.3.8109519; WIJDICKS EFM, 1994, ANN NEUROL, V35, P498, DOI 10.1002/ana.410350422; WILL AD, 1987, NEUROLOGY, V37, P1555, DOI 10.1212/WNL.37.9.1555; ZOJA C, 1986, LAB INVEST, V55, P455	60	2261	2438	2	85	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 22	1996	334	8					494	500		10.1056/NEJM199602223340803	http://dx.doi.org/10.1056/NEJM199602223340803			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV686	8559202				2022-12-24	WOS:A1996TV68600003
J	Wilm, M; Shevchenko, A; Houthaeve, T; Breit, S; Schweigerer, L; Fotsis, T; Mann, M				Wilm, M; Shevchenko, A; Houthaeve, T; Breit, S; Schweigerer, L; Fotsis, T; Mann, M			Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry	NATURE			English	Article							PEPTIDES	MOLECULAR analysis of complex biological structures and processes increasingly requires sensitive methods far protein sequencing. Electrospray mass spectrometry(1) has been applied to the high-sensitivity sequencing of short peptides(2), but technical difficulties have prevented similar success with gel-isolated proteins. Here we report a simple and robust technique for the sequencing of proteins isolated by polyacrylamide gel electrophoresis, using nano-electrospray(3,4) tandem mass spectrometry(5,6). As little as 5 ng protein starting material on Coomassie- or silver-stained gels can be sequenced. Multiple-sequence stretches of up to 16 amino acids are obtained, which identify the protein unambiguously if already present in databases or provide information to clone the corresponding gene. We have applied this method to the sequencing and cloning of a protein which inhibits the proliferation of capillary endothelial cells in vitro and thus may have potential antiangiogenic effects on solid tumours.	EUROPEAN MOLEC BIOL LAB,PROT & PEPTIDE GRP,D-69117 HEIDELBERG,GERMANY; UNIV HEIDELBERG,CHILDRENS HOSP,DIV ONCOL & HAEMATOL,D-69120 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg			Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; Wilm, Matthias/0000-0002-5461-6834				BIEMANN K, 1987, SCIENCE, V237, P992, DOI 10.1126/science.3303336; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690; HUNKAPILLER M, 1984, NATURE, V310, P105, DOI 10.1038/310105a0; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JENO P, 1995, ANAL BIOCHEM, V224, P451; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Matsudaira PT., 1993, PRACTICAL GUIDE PROT; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; WALKER JE, 1992, J MOL BIOL, V226, P1051, DOI 10.1016/0022-2836(92)91052-Q; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9	16	1465	1530	5	179	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					466	469		10.1038/379466a0	http://dx.doi.org/10.1038/379466a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559255				2022-12-24	WOS:A1996TT30400065
J	Li, TG; Janda, KD; Lerner, RA				Li, TG; Janda, KD; Lerner, RA			Cationic cyclopropanation by antibody catalysis	NATURE			English	Article							BIOSYNTHESIS; SQUALENE	REACTIONS involving highly reactive carbocations play a central role in many important chemical processes, such as cyclization reactions(1,2). However, the potential for controlling the pathways of such reactions to obtain energetically disfavoured (but desirable) products has been hard to realize because of the difficulties inherent in controlling the conformation and chemical environment of the carbocation intermediates. Antibody catalysts, with their high specificity and binding energies, can provide the degree of conformational and chemical control necessary for directing such reactions(3,4). Here we show how antibody catalysis can guide cationic cyclization reactions selectively to form products (in high yield) that would otherwise be highly disfavoured. Most notable is the formation of a strained bicyclic compound containing a rare cyclopropane group. To explain our results, we propose a common reaction scheme in which the key step is the formation of a highly reactive protonated cyclopropane intermediate; subtle structural modifications to the substrate (the compound on which the catalytic antibody acts) lead to dramatic differences in the structure of the final product.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute								ABE I, 1993, CHEM REV, V93, P2189, DOI 10.1021/cr00022a009; ALTMAN LJ, 1978, J AM CHEM SOC, V100, P6174, DOI 10.1021/ja00487a037; BAYLESS JH, 1967, J AM CHEM SOC, V89, P147, DOI 10.1021/ja00977a029; BEATON JM, 1955, J CHEM SOC, P3992, DOI 10.1039/jr9550003992; BROWN HC, 1982, PURE APPL CHEM, V54, P1783, DOI 10.1351/pac198254101783; COLLINS CJ, 1969, CHEM REV, V69, P543, DOI 10.1021/cr60260a004; DJERASSI C, 1990, NEW J CHEM, V14, P713; FLEMING I, 1976, J CHEM SOC CHEM COMM, P182, DOI 10.1039/c39760000182; GUILFORD WJ, 1982, J AM CHEM SOC, V104, P3506, DOI 10.1021/ja00376a045; JANDA KD, 1993, SCIENCE, V259, P490, DOI 10.1126/science.8424171; JANDA KD, 1990, BIOTECHNOL PROGR, V6, P178, DOI 10.1021/bp00003a002; JOHNSON WS, 1968, ACCOUNTS CHEM RES, V1, P1, DOI 10.1021/ar50001a001; Lee C. C., 1970, PROGR PHYS ORG CHEM, V7, P129; LEWINSOHN E, 1993, ARCH BIOCHEM BIOPHYS, V94, P2189; LI TY, 1994, SCIENCE, V264, P1289, DOI 10.1126/science.8191282; LI TY, 1995, J AM CHEM SOC, V117, P3308, DOI 10.1021/ja00116a050; LOGRASSO PV, 1993, ARCH BIOCHEM BIOPHYS, V307, P193, DOI 10.1006/abbi.1993.1578; MARCH J, 1985, ADV ORG CHEM, P673; OLAH GA, 1995, ANGEW CHEM INT EDIT, V34, P1393, DOI 10.1002/anie.199513931; OLAH GA, 1970, CARBONIUM IONS; RUZICKA L, 1947, HELV CHIM ACTA, V30, P140, DOI 10.1002/hlca.19470300117; SAUNDERS M, 1973, ACCOUNTS CHEM RES, V6, P53, DOI 10.1021/ar50062a003; SCHROEPFER GJ, 1982, ANNU REV BIOCHEM, V51, P555, DOI 10.1146/annurev.bi.51.070182.003011; SILVER MS, 1960, J AM CHEM SOC, V82, P2971, DOI 10.1021/ja01496a079; SKELL PS, 1960, J AM CHEM SOC, V82, P2971, DOI 10.1021/ja01496a078	25	41	41	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	1996	379	6563					326	327						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552185				2022-12-24	WOS:A1996TR32300052
J	Guadagno, TM; Newport, JW				Guadagno, TM; Newport, JW			Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity	CELL			English	Article							CYCLIN-DEPENDENT KINASE-2; HUMAN CELL-CYCLE; PROTEIN-KINASE; DNA-REPLICATION; CATALYTIC SUBUNIT; CDC25 PROTEIN; S-PHASE; XENOPUS; PHOSPHORYLATION; YEAST	In higher eukaryotes, Cdk2 kinase plays an essential role in regulating the G1-S transition. Here, we use cycling Xenopus egg extracts to examine the requirement of Cdk2 kinase on progression into mitosis. Interestingly, when Cdk2 kinase activity is inhibited by the Cdk-specific inhibitor, p21(Clp1), a block to mitosis occurs, and inactive Cdc2-cyclin B accumulates. This block occurs in the absence of nuclei and is not due to direct inhibition of Cdc2 by Cip. Importantly, this block to mitosis is reversible by restoring Cdk2-cyclin E kinase activity to a Cip-treated cycling extract. Moreover, immunodepletion of Cdk2 from interphase extracts prevents activation of Cdc2 upon the addition of exogenous cyclin B. Thus, our data show that Cdk2 kinase is a positive regulator of Cdc2-cyclin B complexes and establish a link between Cdk2 kinase and cell cycle progression into mitosis.			Guadagno, TM (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.				NICHD NIH HHS [HD07721-03] Funding Source: Medline; NIGMS NIH HHS [GM 33523-07] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD007721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033523, R01GM033523] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1995, MOL BIOL CELL, V6, P3877; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEICHMAN KA, 1994, CELL, V79, P556; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HUNTER T, 1994, CELL, V79, P673; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1	57	197	200	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					73	82		10.1016/S0092-8674(00)80994-0	http://dx.doi.org/10.1016/S0092-8674(00)80994-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548828	Bronze			2022-12-24	WOS:A1996TQ17000010
J	Omran, M; Russell, G				Omran, M; Russell, G			Continuing increase in respiratory symptoms and atopy Aberdeen schoolchildren	BRITISH MEDICAL JOURNAL			English	Article									ROYAL ABERDEEN CHILDRENS HOSP,DEPT MED PAEDIAT,ABERDEEN AB9 2ZG,SCOTLAND	University of Aberdeen								ANDERSON PG, 1993, CARDIOVASC PATHOL, V2, P6; AUSTIN JB, 1994, ARCH DIS CHILD, V71, P211, DOI 10.1136/adc.71.3.211; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171	5	117	118	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	1996	312	7022					34	34		10.1136/bmj.312.7022.34	http://dx.doi.org/10.1136/bmj.312.7022.34			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555858	Green Published			2022-12-24	WOS:A1996TP20900024
J	Burling, FT; Weis, WI; Flaherty, KM; Brunger, AT				Burling, FT; Weis, WI; Flaherty, KM; Brunger, AT			Direct observation of protein solvation and discrete disorder with experimental crystallographic phases	SCIENCE			English	Article							MANNOSE-BINDING PROTEIN; MOLECULAR-DYNAMICS SIMULATION; ANOMALOUS SCATTERING FACTORS; ATOMIC FLUCTUATIONS; CRYSTAL-STRUCTURES; WATER-STRUCTURE; REFINEMENT; ANHARMONICITY; ANISOTROPY; DOMAIN	A complete and accurate set of experimental crystallographic phases to a resolution of 1.8 angstroms was obtained for a 230-residue dimeric fragment of rat mannose-binding protein A with the use of multiwavelength anomalous dispersion (MAD) phasing. An accurate image of the crystal structure could thus be obtained without resort to phases calculated from a model. Partially reduced disulfide bonds, local disorder, and differences in the mobility of chemically equivalent molecules are apparent in the experimental electron density map. A solvation layer is visible that includes well-ordered sites of hydration around polar and charged protein atoms, as well as diffuse, partially disordered solvent shells around exposed hydrophobic groups. Because the experimental phases and the resulting electron density map are free from the influence of a model, they provide a stringent test of theoretical models of macromolecular solvation, motion, and conformational heterogeneity.	STANFORD UNIV,DEPT BIOL STRUCT,STANFORD,CA 94305; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06520; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520	Stanford University; Howard Hughes Medical Institute; Yale University; Yale University			Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150; Brunger, Axel/0000-0001-5121-2036	NIGMS NIH HHS [GM50565] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050565] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD E, 1988, ACTA CRYSTALLOGR A, V44, P270, DOI 10.1107/S0108767387011875; BADGER J, 1991, P NATL ACAD SCI USA, V88, P622, DOI 10.1073/pnas.88.2.622; BADGER J, 1995, NAT STRUCT BIOL, V2, P77, DOI 10.1038/nsb0195-77; BENNETT WS, 1984, CRC CR REV BIOCH MOL, V15, P291, DOI 10.3109/10409238409117796; BRICOGNE G, 1984, ACTA CRYSTALLOGR A, V40, P410, DOI 10.1107/S0108767384000866; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, UNPUB; BURLING FT, 1994, ISRAEL J CHEM, V34, P165; CLORE GM, 1994, STRUCTURE, V2, P89, DOI 10.1016/S0969-2126(00)00011-3; CROMER DT, 1983, J APPL CRYSTALLOGR, V16, P437, DOI 10.1107/S0021889883010791; CROMER DT, 1970, J CHEM PHYS, V53, P1891, DOI 10.1063/1.1674266; DOSTER W, 1989, NATURE, V337, P754, DOI 10.1038/337754a0; Drenth J, 1994, PRINCIPLES PROTEIN X; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GREGORET LM, 1991, PROTEINS, V9, P99, DOI 10.1002/prot.340090204; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HENDRICKSON WA, UNPUB; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; ICHIYE T, 1987, PROTEINS, V2, P236, DOI 10.1002/prot.340020308; ICHIYE T, 1988, BIOCHEMISTRY-US, V27, P3487, DOI 10.1021/bi00409a054; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARLE J, 1980, INT J QUANTUM CHEM, V7, P356; KARPLUS M, 1990, NATURE, V347, P631, DOI 10.1038/347631a0; KOMEIJI Y, 1993, PROTEINS, V16, P268, DOI 10.1002/prot.340160305; KURIYAN J, 1991, PROTEINS, V10, P340, DOI 10.1002/prot.340100407; KURIYAN J, 1986, J MOL BIOL, V190, P227, DOI 10.1016/0022-2836(86)90295-0; LEVITT M, 1988, P NATL ACAD SCI USA, V85, P7557, DOI 10.1073/pnas.85.20.7557; LEVITT M, 1993, STRUCTURE, V1, P223, DOI 10.1016/0969-2126(93)90011-5; LOUNNAS V, 1994, BIOPHYS J, V66, P601, DOI 10.1016/S0006-3495(94)80835-5; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; NALL BT, 1991, CONFORMATIONS FORCES; OTWINOWSKI Z, 1993, JAN P CCP4 STUD WEEK; OTWINOWSKI Z, 1991, JAN P CCP4 STUD WEEK; PAHLER A, 1990, ACTA CRYSTALLOGR A, V46, P537, DOI 10.1107/S0108767390002379; PHILLIPS JC, 1980, ACTA CRYSTALLOGR A, V36, P856, DOI 10.1107/S0567739480001817; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; REES DC, 1983, ACTA CRYSTALLOGR A, V39, P94, DOI 10.1107/S0108767383000173; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; ROMO TD, 1995, PROTEINS, V22, P311, DOI 10.1002/prot.340220403; Schulz GE, 1991, CURR OPIN STRUC BIOL, V1, P883, DOI 10.1016/0959-440X(91)90082-5; STEINBACH PJ, 1993, P NATL ACAD SCI USA, V90, P9135, DOI 10.1073/pnas.90.19.9135; TEETER MM, 1984, P NATL ACAD SCI-BIOL, V81, P6014, DOI 10.1073/pnas.81.19.6014; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P6, DOI 10.1107/S0108767387099987; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; WEIS WI, UNPUB; Westhof E., 1993, WATER BIOL MACROMOLE; 1994, CCP4 SUITE PROGRAMS	55	221	223	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 5	1996	271	5245					72	77		10.1126/science.271.5245.72	http://dx.doi.org/10.1126/science.271.5245.72			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539602				2022-12-24	WOS:A1996TP02200046
J	Chen, C; Kano, M; Abeliovich, A; Chen, L; Bao, SW; Kim, JJ; Hashimoto, K; Thompson, RF; Tonegawa, S				Chen, C; Kano, M; Abeliovich, A; Chen, L; Bao, SW; Kim, JJ; Hashimoto, K; Thompson, RF; Tonegawa, S			Impaired motor coordination correlates with persistent multiple climbing fiber innervation in PKC gamma mutant mice	CELL			English	Article							PROTEIN-KINASE-C; CEREBELLAR PURKINJE-CELLS; INFERIOR OLIVARY NEURONS; VESTIBULO-OCULAR REFLEX; CENTRAL-NERVOUS-SYSTEM; LONG-TERM DEPRESSION; RAT-BRAIN; IMMUNOCYTOCHEMICAL LOCALIZATION; GLUTAMATE SENSITIVITY; INVITRO	It is generally believed that a smooth execution of a compound movement, or motor coordination, requires learning of component movements as well as experience-based refinement of the motor program as a whole. PKC gamma mutant mice display impaired motor coordination but intact eyeblink conditioning, a form of component movement learning. Cerebellar long-term depression, a putative cellular mechanism for component motor learning, is also unimpaired. Thus, PKC gamma mutant mice are defective in refinement of the motor program. In the accompanying paper, we demonstrate that innervation of multiple climbing fibers onto Purkinje cells persists in adulthood in these mutant mice. We propose that this defective elimination of surplus climbing fibers underlies motor discoordination.	MIT,CTR LEARNING & MEMORY,CAMBRIDGE,MA 02139; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; JICHI MED SCH,DEPT PHYSIOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; UNIV SO CALIF,NEUROSCI PROGRAM,LOS ANGELES,CA 90089	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Jichi Medical University; University of Southern California	Chen, C (corresponding author), MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139, USA.			Kano, Masanobu/0000-0002-0725-3292; Hashimoto, Kouichi/0000-0002-3884-8213; Chen, Lu/0000-0002-8097-2699; Kim, Jeansok/0000-0001-7964-106X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS32925] Funding Source: Medline; ACF HHS [NIA AF05142] Funding Source: Medline; OMHHE CDC HHS [1F32MN10521-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); ACF HHS; OMHHE CDC HHS		ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; ALLEN GI, 1974, PHYSIOL REV, V54, P957, DOI 10.1152/physrev.1974.54.4.957; CHEN C, 1995, IN PRESS LTP CURRE 3; CHEN C, 1995, LEARN MEMORY, V2, P18; CHEN S, 1993, NEUROSCIENCE, V56, P177, DOI 10.1016/0306-4522(93)90572-W; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; CREPEL F, 1991, J PHYSIOL-LONDON, V432, P123, DOI 10.1113/jphysiol.1991.sp018380; CREPEL F, 1982, TRENDS NEUROSCI, V5, P266, DOI 10.1016/0166-2236(82)90168-0; CREPEL F, 1988, BRAIN RES, V458, P397, DOI 10.1016/0006-8993(88)90486-6; DAUM I, 1993, BEHAV NEUROSCI, V107, P748, DOI 10.1037/0735-7044.107.5.748; Dow R. S., 1958, PHYSL PATHOLOGY CERE; DUFOSSE M, 1978, BRAIN RES, V150, P611, DOI 10.1016/0006-8993(78)90825-9; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Fetz E E, 1993, Curr Opin Neurobiol, V3, P932, DOI 10.1016/0959-4388(93)90165-U; GELLMAN R, 1985, J NEUROPHYSIOL, V54, P40, DOI 10.1152/jn.1985.54.1.40; GORMEZANO I, 1962, SCIENCE, V138, P33, DOI 10.1126/science.138.3536.33; GRANT SGN, 1994, TRENDS NEUROSCI, V17, P71, DOI 10.1016/0166-2236(94)90077-9; HASHIMOTO T, 1988, J NEUROSCI, V8, P1678; HAYFORD M, 1995, CURR OPIN NEUROBIOL, V5, P141; HEMART N, 1995, EUR J NEUROSCI, V7, P45, DOI 10.1111/j.1460-9568.1995.tb01019.x; HERMS J, 1993, NEUROREPORT, V4, P899, DOI 10.1097/00001756-199307000-00015; HUANG FL, 1988, J NEUROSCI, V8, P4734; ITO M, 1982, J PHYSIOL-LONDON, V324, P113, DOI 10.1113/jphysiol.1982.sp014103; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; Ito M, 1984, CEREBELLUM NEURAL CO; ITO M, 1994, CELLULAR MOL MECHANI, P25; Kano M, 1995, CELL, V83, P1223, DOI 10.1016/0092-8674(95)90147-7; Kano M., 1992, P54; KASHIWABUCHI N, 1995, CELL, V81, P245, DOI 10.1016/0092-8674(95)90334-8; KONNERTH A, 1992, P NATL ACAD SCI USA, V89, P7051, DOI 10.1073/pnas.89.15.7051; KOSE A, 1988, J NEUROSCI, V8, P4262; KRUPA DJ, 1993, SCIENCE, V260, P989, DOI 10.1126/science.8493536; LAVOND DG, 1985, BRAIN RES, V326, P179, DOI 10.1016/0006-8993(85)91400-3; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; LINDEN DJ, 1991, SCIENCE, V254, P1656, DOI 10.1126/science.1721243; LISBERGER SG, 1992, NATURE, V360, P159, DOI 10.1038/360159a0; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; Llinas R, 1993, Curr Opin Neurobiol, V3, P958, DOI 10.1016/0959-4388(93)90168-X; LLINAS R, 1981, J PHYSIOL-LONDON, V315, P569, DOI 10.1113/jphysiol.1981.sp013764; LLINAS R, 1986, J PHYSIOL-LONDON, V376, P163, DOI 10.1113/jphysiol.1986.sp016147; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MCCORMICK DA, 1984, SCIENCE, V223, P296, DOI 10.1126/science.6701513; MERCHENTHALER I, 1993, J COMP NEUROL, V336, P378, DOI 10.1002/cne.903360306; MOLCHAN SE, 1994, P NATL ACAD SCI USA, V91, P8122, DOI 10.1073/pnas.91.17.8122; MORIYA M, 1994, NEUROREPORT, V5, P929, DOI 10.1097/00001756-199404000-00019; NAGAO S, 1989, EXP BRAIN RES, V77, P531; SAITO N, 1988, J NEUROSCI, V8, P369; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P8383; SKELTON RW, 1988, BEHAV NEUROSCI, V102, P586, DOI 10.1037/0735-7044.102.4.586; STANTON ME, 1992, BEHAV NEUROSCI, V106, P657, DOI 10.1037/0735-7044.106.4.657; TANAKA C, 1992, NEUROCHEM INT, V21, P499, DOI 10.1016/0197-0186(92)90081-2; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.neuro.15.1.403; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519; THOMPSON RF, 1994, ANNU REV NEUROSCI, V17, P519, DOI 10.1146/annurev.neuro.17.1.519; THOMPSON RF, 1993, SYNAPTIC PLASTICITY, P230; WATANABE E, 1984, BRAIN RES, V297, P169, DOI 10.1016/0006-8993(84)90555-9; WELSH JP, 1995, NATURE, V374, P453, DOI 10.1038/374453a0; YEO CH, 1984, BEHAV BRAIN RES, V13, P261, DOI 10.1016/0166-4328(84)90168-2	61	276	281	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1233	1242		10.1016/0092-8674(95)90148-5	http://dx.doi.org/10.1016/0092-8674(95)90148-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548809	Bronze			2022-12-24	WOS:A1995TM76200018
J	Strick, R; Laemmli, UK				Strick, R; Laemmli, UK			SARs are cis DNA elements of chromosome dynamics: Synthesis of a SAR repressor protein	CELL			English	Article							TOPOISOMERASE-II SITES; ATTACHMENT SITES; HISTONE H-1; BINDING; CHROMATIN; EXTRACTS; SCAFFOLD; REGIONS; LOOP; CONDENSATION	SARs are candidate DNA elements for defining the bases of chromatin loops and possibly for serving as cis elements of chromosome dynamics. SARs contain numerous A tracts, whose altered DNA structure is recognized by cooperatively interacting proteins such as topoisomerase II. We constructed multi-AT hook (MATH) proteins and demonstrate that they specifically bind the clustered A tracts of SARs in chromatin and chromosomes. They are also potent inhibitors of chromosome assembly in mitotic Xenopus extracts, demonstrating the importance of SARs in this process. Titration of SARs with MATH20 (20 hooks) blocks shape determination of chromatids but not chromatin condensation per se. SARs are also required for shape maintenance of chromosomes. If MATH20 is added after formation of chromatids, they collapse and are reshaped by an active, mitotic process into spherical chromatid balls.	UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	Strick, R (corresponding author), UNIV GENEVA,DEPT BIOCHEM,30 QUAI ERNEST ANSERMET,CH-1211 GENEVA 4,SWITZERLAND.			Galora De Mora, Raul Pavlov/0000-0001-8342-9782				ABUDAYA A, 1995, NUCLEIC ACIDS RES, V23, P3385, DOI 10.1093/nar/23.17.3385; ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; ASHLEY CT, 1989, J BIOL CHEM, V264, P8394; CLARK RJ, 1971, NATURE-NEW BIOL, V229, P101, DOI 10.1038/newbio229101a0; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DIMITROV S, 1994, J CELL BIOL, V126, P591, DOI 10.1083/jcb.126.3.591; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GOTO T, 1982, J BIOL CHEM, V257, P5866; HARLOW E, 1988, ANTIBODIES LABORATOR; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; IZAURRALDE E, 1989, J MOL BIOL, V210, P573, DOI 10.1016/0022-2836(89)90133-2; KAS E, 1989, J MOL BIOL, V210, P587, DOI 10.1016/0022-2836(89)90134-4; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; LAEMMLI UK, 1977, COLD SPRING HARB SYM, V42, P351; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; LOHKA MJ, 1984, J CELL BIOL, V98, P122; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; POLJAK L, 1995, TRENDS CELL BIOL, V5, P348, DOI 10.1016/S0962-8924(00)89068-6; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; REITMAN M, 1990, MOL CELL BIOL, V10, P2774, DOI 10.1128/MCB.10.6.2774; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; Sambrook J., 1989, MOL CLONING LAB MANU; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x	41	131	136	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1137	1148		10.1016/0092-8674(95)90140-X	http://dx.doi.org/10.1016/0092-8674(95)90140-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548801	Bronze			2022-12-24	WOS:A1995TM76200010
J	Heathcote, JA				Heathcote, JA			Why do old men have big ears?	BRITISH MEDICAL JOURNAL			English	Article											Heathcote, JA (corresponding author), S VIEW LODGE,BROMLEY BR1 3DR,KENT,ENGLAND.								0	39	40	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1668	1668		10.1136/bmj.311.7021.1668	http://dx.doi.org/10.1136/bmj.311.7021.1668			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541753	Green Published			2022-12-24	WOS:A1995TL94200012
J	Williams, TM; Kim; Williams, G				Williams, TM; Kim; Williams, G			Excessive impertinence or a missed diagnosis?	BRITISH MEDICAL JOURNAL			English	Note											Williams, TM (corresponding author), ROYAL LIVERPOOL UNIV HOSP,DEPT MED,POB 147,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							CAVALIERO G, 1986, B POTTERS J; Gilles de la Tourette G., 1885, ARCH NEUROL-CHICAGO, V9, P158; PEARCE JMS, 1994, J ROY SOC MED, V87, P396; Potter B., 1903, TALE SQUIRREL NUTKIN; POTTER B, 1905, TALE MRS TIGGY WINKL; ROBERTSON MM, 1988, BRIT J PSYCHIAT, V152, P383, DOI 10.1192/bjp.152.3.383; SACKS O, 1992, BRIT MED J, V305, P1515, DOI 10.1136/bmj.305.6868.1515; SIMKIN B, 1992, BRIT MED J, V305, P1563, DOI 10.1136/bmj.305.6868.1563; TAYLOR J, 1987, ARTIST WORLD	9	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1700	1701		10.1136/bmj.311.7021.1700	http://dx.doi.org/10.1136/bmj.311.7021.1700			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541765	Green Published			2022-12-24	WOS:A1995TL94200026
J	Reiman, EM; Caselli, RJ; Yun, LS; Chen, KW; Bandy, D; Minoshima, S; Thibodeau, SN; Osborne, D				Reiman, EM; Caselli, RJ; Yun, LS; Chen, KW; Bandy, D; Minoshima, S; Thibodeau, SN; Osborne, D			Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITRON EMISSION TOMOGRAPHY; AMYLOID-BETA-PEPTIDE; TYPE-4 ALLELE; RISK; METABOLISM; BINDING; BRAIN	Background. Variants of the apolipoprotein pared regional rates of glucose metabolism in the two groups. E allele appear to account for most cases of late-onset Alzheimer's disease, and persons with two copies of the epsilon 4 allele appear to have an especially high risk of dementia. Positron-emission tomography (PET) has identified specific regions of the brain In which the rate of glucose metabolism declines progressively in patients with probable Alzheimer's disease, We used PET to investigate whether these same regions of the brain are affected in subjects homozygous for the epsilon 4 allele before the onset of cognitive impairment. Methods. Apolipoprotein E genotypes were established in 235 volunteers 50 to 65 years of age who reported a family history of probable Alzheimer's disease, Neurologic and psychiatric evaluations, a battery of neuropsychological tests, magnetic resonance imaging, and PET were performed in 11 E4 homozygotes and 22 controls without the epsilon 4 allele who were matched for sex, age, and level of education. An automated method was used to generate an aggregate surface-projection map that compared regional rates of glucose metabolism in the two groups. Results. The epsilon 4 homozygotes were cognitively normal, They had significantly reduced rates of glucose metabolism In the same posterior cingulate, parietal, temporal, and prefrontal regions as in previously studied patients with probable Alzheimer's disease, They also had reduced rates of glucose metabolism in additional prefrontal regions, which may be preferentially affected during normal aging. Conclusions. In late middle age, cognitively normal subjects who are homozygous for the epsilon 4 allele for apolipoprotein E have reduced glucose metabolism in the same regions of the brain as in patients with probable Alzheimer's disease, These findings provide preclinical evidence that the presence of the epsilon 4 allele is a risk factor for Alzheimer's disease, PET may offer a relatively rapid way of testing future treatments to prevent Alzheimer's disease. (C) 1996, Massachusetts Medical Society.	UNIV ARIZONA, DEPT PSYCHIAT, TUCSON, AZ USA; UNIV ARIZONA, DEPT RADIOL, TUCSON, AZ 85724 USA; MAYO CLIN, DEPT NEUROL, SCOTTSDALE, AZ USA; MAYO CLIN, DEPT PSYCHOL, SCOTTSDALE, AZ USA; ARIZONA STATE UNIV, DEPT COMP SCI, TEMPE, AZ 85287 USA; UNIV MICHIGAN, DIV NUCL MED, ANN ARBOR, MI 48109 USA; MAYO CLIN, DEPT LAB MED & PATHOL, ROCHESTER, MN USA	University of Arizona; University of Arizona; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix; Arizona State University; Arizona State University-Tempe; University of Michigan System; University of Michigan; Mayo Clinic	Reiman, EM (corresponding author), GOOD SAMARITAN REG MED CTR, POSITRON EMISS TOMOG CTR, 1111 E MCDOWELL RD, PHOENIX, AZ 85006 USA.		Chen, kewei/P-6304-2015	Chen, kewei/0000-0001-8497-3069				American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRUN A, 1976, ARCH PSYCHIAT NERVEN, V223, P15, DOI 10.1007/BF00367450; CASELLI RJ, 1995, ARCH NEUROL-CHICAGO, V52, P1004, DOI 10.1001/archneur.1995.00540340096018; CAULEY JA, 1993, GENET EPIDEMIOL, V10, P27, DOI 10.1002/gepi.1370100104; COFFEY CE, 1992, NEUROLOGY, V42, P527, DOI 10.1212/WNL.42.3.527; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crook T, 1986, DEV NEUROPSYCHOL, V2, P261, DOI 10.1080/87565648609540348; Davignon J, 1988, Trans Am Clin Climatol Assoc, V99, P100; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; First M.B., 1990, USERS GUIDE STRUCTUR; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRAFTON ST, 1992, ARCH NEUROL-CHICAGO, V49, P1161, DOI 10.1001/archneur.1992.00530350075022; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HIXSON JE, 1990, J LIPID RES, V31, P545; KAPLITT MG, 1995, ABSTR SOC NEUROSCI, V21, P1008; KENNEDY AM, 1995, NEUROSCI LETT, V186, P17, DOI 10.1016/0304-3940(95)11270-7; KUHL DE, 1982, J CEREBR BLOOD F MET, V2, P163, DOI 10.1038/jcbfm.1982.15; Lezak MD, 2012, NEUROPSYCHOLOGICAL A, V5; LOESSNER A, 1995, J NUCL MED, V36, P1141; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MCGEER EG, 1990, CAN J NEUROL SCI, V17, P1; MIELKE R, 1994, DEMENTIA, V5, P36, DOI 10.1159/000106692; MINOSHIMA S, 1994, LANCET, V344, P895, DOI 10.1016/S0140-6736(94)92871-1; MINOSHIMA S, 1995, J NUCL MED, V36, P1238; MINOSHIMA S, 1994, J NUCL MED, V35, P1528; MINOSHIMA S, 1995, J COMPUT ASSIST TOMO, V19, P541, DOI 10.1097/00004728-199507000-00006; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; PIETRINI P, 1993, DEMENTIA, V4, P94, DOI 10.1159/000107349; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; RIGGS JE, 1994, ARCH NEUROL-CHICAGO, V51, P750, DOI 10.1001/archneur.1994.00540200024011; ROSES AD, 1994, LANCET, V343, P1564, DOI 10.1016/S0140-6736(94)92960-2; SALMON E, 1991, ACTA NEUROL BELG, V91, P288; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SCHWARTZ WJ, 1979, SCIENCE, V205, P723, DOI 10.1126/science.462184; SMALL GW, 1995, JAMA-J AM MED ASSOC, V273, P942, DOI 10.1001/jama.273.12.942; SMITH GS, 1992, ARCH NEUROL-CHICAGO, V49, P1142, DOI 10.1001/archneur.1992.00530350056020; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; Talairach J., 1988, COPLANAR STEREOTAXIC; TERRY RD, 1987, ANN NEUROL, V21, P530, DOI 10.1002/ana.410210603; WILSON PWF, 1994, JAMA-J AM MED ASSOC, V272, P1666, DOI 10.1001/jama.272.21.1666; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; [No title captured]	50	1084	1111	0	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1996	334	12					752	758		10.1056/NEJM199603213341202	http://dx.doi.org/10.1056/NEJM199603213341202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ979	8592548	Bronze			2022-12-24	WOS:A1996TZ97900002
J	Davidson, AC; Emberlin, J; Cook, AD; Venables, KM; Wallis, DN; Webb, J; Brooke, D; Brookes, B; Brown, R; Findlay, A; Harris, M; Hulbert, D; Little, G; Nonoo, C; ODonnell, C; Park, G; Soorma, A				Davidson, AC; Emberlin, J; Cook, AD; Venables, KM; Wallis, DN; Webb, J; Brooke, D; Brookes, B; Brown, R; Findlay, A; Harris, M; Hulbert, D; Little, G; Nonoo, C; ODonnell, C; Park, G; Soorma, A			A major outbreak of asthma associated with a thunderstorm: Experience of accident and emergency departments and patients' characteristics	BRITISH MEDICAL JOURNAL			English	Article							GRASS-POLLEN; MECHANISM	Objective-To investigate the time course of an epidemic of asthma after a thunderstorm, characteristics of patients affected, and the demand on emergency medical resources. Design-study of registers and records in accident and emergency departments and questionnaire to staff. Setting-London area. Subjects-All patients presenting at 12 accident and emergency departments with asthma or other airways disease. Main outcome measures-Numbers of patients, clinical features, information on shortage of resources-equipment, drugs, and staff. Results-The epidemic had a sudden onset on 24 June 1994; 640 patients with asthma or other airways disease attended during 30 hours from 1800 on 24 June, nearly 10 times the expected number. Over half (365) the patients were aged 21 to 40 years. A history of hay fever was recorded in 403 patients; for 283 patients this was the first known attack of asthma; a history of chronic obstructive airways disease was recorded in 12 patients. In all, 104 patients were admitted (including five to an intensive care unit). Several departments ran out of equipment or drugs, called in additional doctors, or both. Conclusions-This study supports the view that this epidemic was larger than previously reported epidemics and the hypothesis that ''thunderstorm associated asthma'' is related to aeroallergens. Demands on resources were considerable; a larger proportion of patients needing intensive care would have caused greater problems.	NEWHAM GEN HOSP,DEPT ACCID & EMERGENCY,LONDON E13 8RU,ENGLAND; POLLEN RES UNIT,WORCESTER WR2 6AJ,ENGLAND; NATL HEART & LUNG INST,DEPT OCCUPAT & ENVIRONM MED,LONDON SW3 6LR,ENGLAND	University of Worcester; Imperial College London								Alderman P M, 1986, Arch Emerg Med, V3, P260; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834, DOI 10.5694/j.1326-5377.1992.tb136994.x; CAMPBELLHEWSON G, 1994, BRIT MED J, V309, P1086, DOI 10.1136/bmj.309.6961.1086a; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1983, LANCET, V2, P253; *DEP HLTH ADV GROU, 1995, 4 DEP HLTH ADV GROUP; EGAN P, 1985, MED J AUSTRALIA, V142, P330, DOI 10.5694/j.1326-5377.1985.tb113389.x; HABENICHT HA, 1984, J ALLERGY CLIN IMMUN, V74, P64, DOI 10.1016/0091-6749(84)90088-5; HIGHAM JH, 1994, BRIT MED J, V309, P604; KNOX RB, 1993, CLIN EXP ALLERGY, V23, P354, DOI 10.1111/j.1365-2222.1993.tb00339.x; MURRAY V, 1994, BRIT MED J, V309, P131, DOI 10.1136/bmj.309.6947.131c; Norris-Hill J, 1993, AEROBIOLOGIA, V9, P27, DOI DOI 10.1007/BF02311367; PACKE GE, 1985, LANCET, V2, P199; PACKE GE, 1986, LANCET, V1, P850; PREMARATNE UN, IN PRESS RESPIR MED; RODRIGO MJ, 1990, J ALLERGY CLIN IMMUN, V85, P778, DOI 10.1016/0091-6749(90)90198-D; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; 1985, LANCET, V1, P1079	18	94	95	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					601	604						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595332				2022-12-24	WOS:A1996TZ84000022
J	Belmont, LD; Mitchison, TJ				Belmont, LD; Mitchison, TJ			Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules	CELL			English	Article							DYNAMIC INSTABILITY; TRANSITION FREQUENCIES; CYTOPLASMIC EXTRACTS; XENOPUS; KINASE; STATHMIN; CELLS; PHOSPHORYLATION; INTERPHASE; LEUKEMIA	Using a polymerization inhibition assay, we have purified a small, heat stable protein that physically interacts with tubulin dimers and increases the catastrophe rate of microtubules. Sequence analysis identified this protein as oncoprotein 18 (Op18)/stathmin, a conserved phosphoprotein that is highly expressed in leukemia cells. Immunodepletion experiments in Xenopus egg extracts showed that Op18/stathmin is involved in physiological regulation of mitotic microtubule dynamics. Op18/stathmin is a microtubule regulator that preferentially interacts with unpolymerized subunits. It is a candidate for increasing the microtubule catastrophe rate in mitosis and might also regulate microtubule dynamics in response to external signals.	UNIV CALIF SAN FRANCISCO,DEPT MOLEC & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Belmont, LD (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.				NIGMS NIH HHS [GM39565-07] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM039565, R01GM039565] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN SSL, 1994, J CELL BIOL, V127, P1289, DOI 10.1083/jcb.127.5.1289; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BERETTA L, 1993, J BIOL CHEM, V268, P20076; BRAVERMAN R, 1986, J BIOL CHEM, V261, P14342; CASSIMERIS L, 1993, CELL MOTIL CYTOSKEL, V26, P275, DOI 10.1002/cm.970260402; CURMI PA, 1994, BIOCHEM J, V300, P331, DOI 10.1042/bj3000331; GARD DL, 1987, J CELL BIOL, V105, P2191, DOI 10.1083/jcb.105.5.2191; GLIKSMAN NR, 1992, J CELL BIOL, V119, P1271, DOI 10.1083/jcb.119.5.1271; GLIKSMAN NR, 1993, MOL BIOL CELL, V4, P1035, DOI 10.1091/mbc.4.10.1035; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; LUO XN, 1994, J BIOL CHEM, V269, P10312; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; MARKLUND U, 1994, J BIOL CHEM, V269, P30626; MAUCUER A, 1993, J BIOL CHEM, V268, P16420; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; OOKATA K, 1995, J CELL BIOL, V128, P849, DOI 10.1083/jcb.128.5.849; ROWLANDS DC, 1995, LAB INVEST, V72, P100; SALMON ED, 1984, J CELL BIOL, V99, P2165, DOI 10.1083/jcb.99.6.2165; SAWIN KE, 1992, J CELL SCI, V101, P303; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; SCHUBART UK, 1987, J BIOL CHEM, V262, P11871; SIMON JR, 1992, CELL MOTIL CYTOSKEL, V21, P1, DOI 10.1002/cm.970210102; SOBEL A, 1989, J BIOL CHEM, V264, P3765; VANDRE DD, 1991, J CELL SCI, V98, P577; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; VERLHAC MH, 1994, DEVELOPMENT, V120, P1017; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WILSON L, 1995, CHEM BIOL, V2, P569, DOI 10.1016/1074-5521(95)90119-1	37	572	589	3	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					623	631		10.1016/S0092-8674(00)81037-5	http://dx.doi.org/10.1016/S0092-8674(00)81037-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598048	Bronze			2022-12-24	WOS:A1996TX17600014
J	OBrien, WA; Hartigan, PM; Martin, D; Esinhart, J; Hill, A; Benoit, S; Rubin, M; Lahart, C; Wray, N; Finegold, SM; George, WL; Dickinson, GM; Klimas, N; Diamond, G; ZollaPazner, SB; Jensen, PC; Hawkes, C; Oster, C; Gordin, F; Labriola, AM; Spivey, P; Matthews, T; Weinhold, K; Drusano, G; Egorin, MJ				OBrien, WA; Hartigan, PM; Martin, D; Esinhart, J; Hill, A; Benoit, S; Rubin, M; Lahart, C; Wray, N; Finegold, SM; George, WL; Dickinson, GM; Klimas, N; Diamond, G; ZollaPazner, SB; Jensen, PC; Hawkes, C; Oster, C; Gordin, F; Labriola, AM; Spivey, P; Matthews, T; Weinhold, K; Drusano, G; Egorin, MJ			Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; CONTROLLED TRIAL; CLINICAL-TRIALS; END-POINTS; REVERSE-TRANSCRIPTASE; P24 ANTIGEN; ZIDOVUDINE; MARKER; NEOPTERIN; RESISTANCE	Background. Clinical trials of antiretroviral drugs can take years to complete because the outcomes measured are progression to the acquired immunodeficiency syndrome (AIDS) or death. Trials could be accelerated by the use of end points such as changes in CD4+ lymphocyte counts and plasma levels of human immunodeficiency virus type 1 (HIV-1) RNA and beta(2)-microglobulin, but there is uncertainty about whether these surrogate measures are valid predictors of disease progression. Methods. We analyzed data from the Veterans Affairs Cooperative Study on AIDS, which compared immediate with deferred zidovudine therapy. Patients' plasma levels of HIV-1 RNA and beta(2)-microglobulin were measured in stored plasma. Results. Among the 129 patients in the immediate-treatment group, 34 had disease that progressed to AIDS, as compared with 57 of the 141 patients in the deferred-treatment group (P=0.03). Progression to AIDS correlated strongly with base-line CD4+ lymphocyte counts (P=0.001) and plasma levels of HIV-1 RNA (P<0.001), but not with base-line levels of beta(2)-microglobulin (P=0.14). A decrease of at least 75 percent in the plasma level of HIV-1 RNA over the first six months of zidovudine therapy accounted for 59 percent of the benefit of treatment, defined as the absence of progression to AIDS (95 percent confidence interval, 13 to 112 percent). Plasma beta(2)-microglobulin levels and CD4+ lymphocyte counts explained less of the effect of treatment. A 75 percent decrease in the plasma HIV-1 RNA level plus a 10 percent increase in the CD4+ lymphocyte count could explain 79 percent of the treatment effect (95 percent confidence interval, 27 to 145 percent). Conclusions. Treatment-induced changes in the plasma HIV-1 RNA level and the CD4+ lymphocyte count, taken together, are valid predictors of the clinical progression of HIV-related disease and can be used to assess the efficacy of zidovudine and possibly other antiretroviral drugs as well. (C) 1996, Massachusetts Medical Society.	UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA; VET AFFAIRS COOPERAT STUDIES PROGRAM, COORDINATING CTR, W HAVEN, CT USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; GLAXO INC, RES TRIANGLE PK, NC 27709 USA; VET AFFAIRS MED CTR, NEW YORK, NY USA; NYU, SCH MED, NEW YORK, NY USA; DUKE UNIV, MED CTR, DURHAM, NC USA; VET AFFAIRS MED CTR, DURHAM, NC 27705 USA; VET AFFAIRS MED CTR, HOUSTON, TX 77030 USA; VET ADM MED CTR, MIAMI, FL 33125 USA; VET ADM MED CTR, SAN FRANCISCO, CA 94121 USA; WALTER REED ARMY MED CTR, WASHINGTON, DC USA; VET ADM MED CTR, WASHINGTON, DC 20422 USA; DUKE UNIV, VIROL CTR, DURHAM, NC 27706 USA; UNIV MARYLAND, PHARMACOL LAB, COLLEGE PK, MD 20742 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of North Carolina; University of North Carolina Chapel Hill; GlaxoSmithKline; US Department of Veterans Affairs; Veterans Health Administration (VHA); New York University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); United States Department of Defense; United States Army; Walter Reed National Military Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; University System of Maryland; University of Maryland College Park	OBrien, WA (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR, DEPT MED, 11301 WILSHIRE BLVD, LOS ANGELES, CA 90073 USA.		Zolla-Pazner, Susan/S-1864-2019	Zolla-Pazner, Susan/0000-0002-0750-2666				BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; COX DR, 1979, THEORETICAL STATISTI; CUNNINGHAM AL, 1993, J ACQ IMMUN DEF SYND, V6, pS32; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCUS SA, 1995, J INFECT DIS, V171, P305, DOI 10.1093/infdis/171.2.305; FREEDMAN LS, 1992, STAT MED, V11, P167, DOI 10.1002/sim.4780110204; FUCHS D, 1988, IMMUNOL TODAY, V9, P150, DOI 10.1016/0167-5699(88)91203-0; GRAHAM NMH, 1993, J ACQ IMMUN DEF SYND, V6, P1258; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOLODNIY M, 1993, J ACQ IMMUN DEF SYND, V6, P366; HOLODNIY M, 1994, J ACQ IMMUN DEF SYND, V7, P363; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KRAMER A, 1989, J ACQ IMMUN DEF SYND, V2, P291; LACEY CJN, 1987, AIDS, V1, P123; LAGAKOS SW, 1993, CLIN INFECT DIS, V16, pS22, DOI 10.1093/clinids/16.Supplement_1.S22; LIN DY, 1993, STAT MED, V12, P835, DOI 10.1002/sim.4780120904; MACHADO SG, 1990, J ACQ IMMUN DEF SYND, V3, P1065; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MELMED RN, 1989, J ACQ IMMUN DEF SYND, V2, P70; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; NISHANIAN P, 1990, J INFECT DIS, V162, P21, DOI 10.1093/infdis/162.1.21; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; OBRIEN WA, 1995, BLOOD, V86, P1082; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; SAAG MS, 1993, NEW ENGL J MED, V329, P1065, DOI 10.1056/NEJM199310073291502; Simberkoff MS, 1996, J ACQ IMMUN DEF SYND, V11, P142, DOI 10.1097/00042560-199602010-00005; SPECTOR SA, 1989, J INFECT DIS, V159, P822, DOI 10.1093/infdis/159.5.822; VALENTINE F T, 1990, AIDS (London), V4, pS201; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; 1994, LANCET, V343, P871; 1987, MMWR MORB MORTAL S1, V36, pS1	40	638	645	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 15	1996	334	7					426	431		10.1056/NEJM199602153340703	http://dx.doi.org/10.1056/NEJM199602153340703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU696	8552144	Bronze			2022-12-24	WOS:A1996TU69600003
J	Utz, JP; Swensen, SJ; Gertz, MA				Utz, JP; Swensen, SJ; Gertz, MA			Pulmonary amyloidosis - The Mayo Clinic experience from 1980 to 1993	ANNALS OF INTERNAL MEDICINE			English	Article						amyloidosis; biopsy; bronchoscopy; amyloid; respiratory tract diseases	LOWER RESPIRATORY-TRACT; TRANS-BRONCHIAL BIOPSY; TRACHEOBRONCHOPATHIA OSTEOPLASTICA; LOCALIZED AMYLOIDOSIS; SYSTEMIC AMYLOIDOSIS; HILAR ADENOPATHY; PLEURAL DISEASE; NEEDLE-BIOPSY; MANIFESTATIONS; DIAGNOSIS	Objective: To define the prognosis for and radiographic presentation of patients with pulmonary amyloidosis. Design: Retrospective review of the Mayo Clinic experience with biopsy-proven pulmonary amyloidosis from 1980 to 1993. Setting: Tertiary care center. Patients: Patients with pulmonary biopsy specimens showing amyloid deposition. Measurements: Medical records were reviewed, and pertinent information was recorded, including demographic data, type of pulmonary biopsy, results of biopsies of nonpulmonary sites and of immunoelectrophoresis, and other clinical, radiographic, and laboratory information necessary for distinguishing localized pulmonary amyloidosis, primary systemic amyloidosis, secondary amyloidosis, and familial amyloidosis. Results: 35 of 55 patients with pulmonary amyloidosis had primary systemic amyloidosis that presented radiographically as an interstitial or reticulonodular pattern with or without pleural effusion. The median survival after diagnosis was 16 months. Nodular pulmonary ''amyloidomas'' (nodular amyloid lesions) were not associated with systemic disease and were associated with a benign prognosis. Three of 4 patients with localized tracheobronchial amyloidosis required Nd:YAC (neodymium:yttrium-aluminum-garnet) laser therapy for obstructive symptoms. ''Senile'' amyloid deposition was an incidental finding in some patients at autopsy. Conclusions: Localized amyloidomas are characterized by a benign course and are not associated with systemic amyloidosis. Despite its localized nature, tracheobronchial amyloid deposition may be asymptomatic or may result in significant morbidity due to obstructive phenomena. Pulmonary amyloidosis associated with primary systemic amyloidosis generally presents as a diffuse interstitial pattern with or without pleural effusion. Complete survival data indicate that long-term outcome is poor after diagnosis. We describe the largest series of patients diagnosed by bronchoscopic lung biopsy. Despite reports to the contrary, we have found bronchoscopic lung biopsy to be a safe and effective diagnostic technique.	MAYO MED CTR, ROCHESTER, MN USA	Mayo Clinic	Utz, JP (corresponding author), MAYO CLIN & MAYO FDN, MAYO MED SCH, 200 1ST ST SW, E-18, ROCHESTER, MN 55905 USA.		Gertz, Morie/K-2873-2019					ALROY GG, 1972, CHEST, V61, P465, DOI 10.1378/chest.61.5.465; BIERNY JP, 1978, AM J ROENTGENOL, V131, P1082; BREUER R, 1985, THORAX, V40, P870, DOI 10.1136/thx.40.11.870; BUXBAUM JN, 1988, CECIL TXB MED, P1198; CANDEIRA SR, 1991, CHEST, V100, P292, DOI 10.1378/chest.100.1.292-a; CELLI BR, 1978, CHEST, V74, P543, DOI 10.1378/chest.74.5.543; CORDIER JF, 1986, CHEST, V90, P827, DOI 10.1378/chest.90.6.827; DAHLGREN SE, 1970, ACTA PATH MICRO IM A, VA 78, P1; DAHLIN DC, 1950, MED CLIN N AM, P1107; DAIL DH, 1988, PULMONARY PATHOLOGY, P535; DESAI RA, 1979, CHEST, V76, P170, DOI 10.1378/chest.76.2.170; FLEMMING AFS, 1980, BRIT J DIS CHEST, V74, P183, DOI 10.1016/0007-0971(80)90032-7; GALLEGO FG, 1974, NEW ENGL J MED, V291, P531; GERTZ MA, 1989, MAYO CLIN PROC, V64, P1505, DOI 10.1016/S0025-6196(12)65706-1; GOTTLIEB LS, 1972, AM REV RESPIR DIS, V105, P425; GROSS BH, 1981, RADIOLOGY, V138, P11, DOI 10.1148/radiology.138.1.7455070; HOLMES S, 1988, BRIT J DIS CHEST, V82, P414, DOI 10.1016/0007-0971(88)90097-6; HUI AN, 1986, ARCH PATHOL LAB MED, V110, P212; JONES AW, 1977, BRIT J DIS CHEST, V71, P268, DOI 10.1016/0007-0971(77)90124-3; KAMBERG S, 1962, NEW ENGL J MED, V266, P587, DOI 10.1056/NEJM196203222661204; KAVURU MS, 1990, CHEST, V98, P20, DOI 10.1378/chest.98.1.20; KAW YT, 1991, DIAGN CYTOPATHOL, V7, P628, DOI 10.1002/dc.2840070617; KHAN JA, 1996, CLIN PULM MED, V2, P66; KIDD CR, 1974, NEW ENGL J MED, V290, P972; KIM C H, 1990, Korean Journal of Internal Medicine, V5, P63; KLINE LR, 1985, AM REV RESPIR DIS, V132, P191; KNAPP MJ, 1988, ARCH PATHOL LAB MED, V112, P57; KUNZE WP, 1979, PATHOL RES PRACT, V164, P413, DOI 10.1016/S0344-0338(79)80058-8; KYLE RA, 1983, MAYO CLIN PROC, V58, P665; LEWINSOHN G, 1976, CHEST, V69, P682, DOI 10.1378/chest.69.5.682; MARTIN CJ, 1974, ARCH OTOLARYNGOL, V100, P290; NIENHUIS DM, 1990, ANN OTO RHINOL LARYN, V99, P689, DOI 10.1177/000348949009900903; OSNOSS KL, 1980, CHEST, V78, P786, DOI 10.1378/chest.78.5.786; PETERMANN W, 1987, EUR J RESPIR DIS, V71, P210; PITKANEN P, 1984, AM J PATHOL, V117, P391; POH SC, 1975, THORAX, V30, P186, DOI 10.1136/thx.30.2.186; RUBINOW A, 1978, AM REV RESPIR DIS, V118, P603; SAKULA A, 1968, THORAX, V23, P105, DOI 10.1136/thx.23.1.105; SHINOI K, 1962, DIS CHEST, V42, P442, DOI 10.1378/chest.42.4.442; SIONGCHUAN L, 1975, THORAX, V30, P178; SMITH RRL, 1979, AM J MED, V66, P96, DOI 10.1016/0002-9343(79)90488-1; STRANGE C, 1987, CHEST, V92, P367, DOI 10.1378/chest.92.2.367; THOMPSON PJ, 1983, THORAX, V38, P84, DOI 10.1136/thx.38.2.84; TOMASHEFSKI JF, 1980, ACTA CYTOL, V24, P224; WEISMANN RE, 1947, J THORAC SURG, V16, P269; WEISS L, 1960, AM J CLIN PATHOL, V33, P318; WILSON SR, 1976, RADIOLOGY, V120, P283, DOI 10.1148/120.2.283; YOOD RA, 1983, JAMA-J AM MED ASSOC, V249, P1322, DOI 10.1001/jama.249.10.1322	48	241	258	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1996	124	4					407	+		10.7326/0003-4819-124-4-199602150-00004	http://dx.doi.org/10.7326/0003-4819-124-4-199602150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV220	8554249				2022-12-24	WOS:A1996TV22000004
J	Daub, H; Weiss, FU; Wallasch, C; Ullrich, A				Daub, H; Weiss, FU; Wallasch, C; Ullrich, A			Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors	NATURE			English	Article							SWISS 3T3 CELLS; TYROSINE PHOSPHORYLATION; KINASE; GROWTH; FIBROBLASTS; ACTIVATION; TRANSDUCTION; MECHANISM; STIMULATE	TRANSDUCTION of a mitogenic signal from the cell membrane to the nucleus involves the adapter proteins SHC and Grb2, which mediate activation of the Ras/mitogen-activated protein (MAP) kinase pathway(1-5). In contrast to receptor tyrosine kinases (RTKs), the signalling steps leading to Ras/MAP kinase activation by G-protein-coupled receptors (GPCRs) are still poorly characterized but appear to include beta gamma subunits of heterotrimeric G-proteins and as-yet unidentified tyrosine kinases(6-8). We report here that the epidermal growth factor receptor (EGFR) and the neu oncoprotein become rapidly tyrosine-phosphorylated upon stimulation of Rat-1 cells with the GPCR agonists endothelin-1, lysophosphatic acid and thrombin, suggesting that there is an intracellular mechanism for transactivation. Specific inhibition of EGFR function by either the selective tyrphostin AG1478 or a dominant-negative EGFR mutant suppressed MAP kinase activation and strongly inhibited induction of fos gene expression and DNA synthesis, Our results demonstrate a role for RTKs as downstream mediators in GPCR mitogenic signalling and suggest a ligand-independent mechanism of RTK activation through intracellular signal crosstalk.			Daub, H (corresponding author), MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,AM KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.		Weiss, Frank Ulrich/A-6386-2009	Weiss, Frank Ulrich/0000-0003-3369-6369				AMBAR I, 1993, EUR J PHARM-MOLEC PH, V245, P31, DOI 10.1016/0922-4106(93)90166-7; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MULDOON LL, 1990, CELL REGUL, V1, P379, DOI 10.1091/mbc.1.4.379; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERGEER P, 1994, REV CELL BIOL, V10, P251; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	29	1271	1300	1	77	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					557	560		10.1038/379557a0	http://dx.doi.org/10.1038/379557a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596637				2022-12-24	WOS:A1996TU69300055
J	Licht, S; Gerfen, GJ; Stubbe, JA				Licht, S; Gerfen, GJ; Stubbe, JA			Thiyl radicals in ribonucleotide reductases	SCIENCE			English	Article							ESCHERICHIA-COLI; LACTOBACILLUS-LEICHMANNII; REDUCTION; ELECTRON; COENZYME-B12; MECHANISM; COBAMIDES; STATE; DNA	The ribonucleoside triphosphate reductase (RTPR) from Lactobacillus leichmannii catalyzes adenosylcobalamin (AdoCbl)-dependent nucleotide reduction, as well as exchange of the 5' hydrogens of AdoCbl with solvent. A protein-based thiyl radical is proposed as an intermediate in both of these processes. In the presence of RTPR containing specifically deuterated cysteine residues, the electron paramagnetic resonance (EPR) spectrum of an intermediate in the exchange reaction and the reduction reaction, trapped by rapid freeze quench techniques, exhibits narrowed hyperfine features relative to the corresponding unlabeled RTPR. The spectrum was interpreted to represent a thiyl radical coupled to cob(II)alamin. Another proposed intermediate, 5'-deoxyadenosine, was detected by rapid acid quench techniques, Similarities in mechanism between RTPR and the Escherichia coli ribonucleotide reductase suggest that both enzymes require a thiyl radical for catalysis.	MIT, FRANCIS BITTER MAGNET LAB, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Licht, S (corresponding author), MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029595, R01GM029595] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00317] Funding Source: Medline; NIGMS NIH HHS [GM 29595] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES RH, 1967, J BIOL CHEM, V242, P3589; ASHLEY GW, 1986, J BIOL CHEM, V261, P3958; BOOKER S, 1994, BIOCHEMISTRY-US, V33, P12676, DOI 10.1021/bi00208a019; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; CHENG H, 1995, ARCH BIOCHEM BIOPHYS, V316, P619, DOI 10.1006/abbi.1995.1082; GERFEN GJ, UNPUB; HAMILTON JA, 1971, BIOCHEMISTRY-US, V10, P347, DOI 10.1021/bi00778a023; HIBLER DW, 1989, METHOD ENZYMOL, V177, P74; HOGANSON CW, 1994, MET IONS BIOL SYST, V30, P77; HOGENKAMP HP, 1968, J BIOL CHEM, V243, P799; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KIM ST, 1993, P NATL ACAD SCI USA, V90, P8023, DOI 10.1073/pnas.90.17.8023; MALMSTRO.BG, 1970, BIOCHIM BIOPHYS ACTA, V205, P48, DOI 10.1016/0005-2728(70)90060-5; MAWHINNEY TP, 1986, J CHROMATOGR, V358, P231, DOI 10.1016/S0021-9673(01)90333-4; NSLLOU FP, 1970, SNSL VHRM, V46, P1248; ORMEJOHNSON WH, 1974, J BIOL CHEM, V249, P2338; REICHARD P, 1993, J BIOL CHEM, V268, P8383; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SANDO GN, 1975, J BIOL CHEM, V250, P8774; SJOBERG BM, 1977, J BIOL CHEM, V252, P536; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; TAMAO Y, 1973, BIOCHEMISTRY-US, V12, P24, DOI 10.1021/bi00725a005; THELANDER L, 1974, J BIOL CHEM, V249, P4858; TSAI AL, 1995, J BIOL CHEM, V250, P1053; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WERTZ JE, 1986, ELECT SPIN RESONANCE, P498; WILLING A, 1988, EUR J BIOCHEM, V175, P167, DOI 10.1111/j.1432-1033.1988.tb14179.x	30	273	277	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 26	1996	271	5248					477	481		10.1126/science.271.5248.477	http://dx.doi.org/10.1126/science.271.5248.477			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560260				2022-12-24	WOS:A1996TR32200032
J	Pfaff, SL; Mendelsohn, M; Stewart, CL; Edlund, T; Jessell, TM				Pfaff, SL; Mendelsohn, M; Stewart, CL; Edlund, T; Jessell, TM			Requirement for LIM homeobox gene Isl1 in motor neuron generation reveals a motor neuron-dependent step in interneuron differentiation	CELL			English	Article							LARVAL FROG RETINA; CELL PATTERN; SPINAL-CORD; FLOOR PLATE; HOMEODOMAIN; EXPRESSION; NOTOCHORD; ELEGANS; LINEAGE; MOUSE	Motor neuron differentiation is accompanied by the expression of a LIM homeodomain transcription factor, Islet1 (ISL1). To assess the involvement of ISL1 in the generation of motor neurons, we analyzed cell differentiation in the neural tube of embryos in which ISL1 expression has been eliminated by gene targeting. Motor neurons are not generated without ISL1, although many other aspects of cell differentiation in the neural tube occur normally. A population of interneurons that express Engrailed1 (EN1), however, also fails to differentiate in Isl1 mutant embryos. The differentiation of EN1(+) interneurons can be induced in both wild-type and mutant neural tissue by regions of the neural tube that contain motor neurons. These results show that ISL1 is required for the generation of motor neurons and suggest that motor neuron generation is required for the subsequent differentiation of certain interneurons.	ROCHE INST MOLEC BIOL,DEPT CELL & DEV BIOL,NUTLEY,NJ 07110; UMEA UNIV,DEPT MICROBIOL,S-90187 UMEA,SWEDEN	Umea University	Pfaff, SL (corresponding author), COLUMBIA UNIV,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032, USA.							[Anonymous], 1977, HDB PHYSL NERVOUS SY; Appel B, 1995, DEVELOPMENT, V121, P4117; BARTH KA, 1995, DEVELOPMENT, V121, P1755; BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; Brown AG, 1981, ORG SPINAL CORD; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; HAMBURGER V, 1948, J COMP NEUROL, V88, P221, DOI 10.1002/cne.900880204; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LANGMAN J, 1970, J COMP NEUROL, V138, P419, DOI 10.1002/cne.901380403; LEBER SM, 1990, J NEUROSCI, V10, P2451; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LUMSDEN A, 1994, DEVELOPMENT, V120, P1581; LUNDGREN FE, 1995, DEVELOPMENT, V121, P1769; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; NEGISHI K, 1982, SCIENCE, V216, P747, DOI 10.1126/science.7079736; NOMES WO, 1978, BRAIN RES, V159, P1; REH TA, 1987, J NEUROSCI, V7, P3317; REH TA, 1986, DEV BIOL, V114, P463, DOI 10.1016/0012-1606(86)90210-1; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; SHENG H, 1996, IN PRESS SCIENCE; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; TOKUMOTO M, 1995, DEV BIOL, V171, P578, DOI 10.1006/dbio.1995.1306; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405	38	634	652	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					309	320		10.1016/S0092-8674(00)80985-X	http://dx.doi.org/10.1016/S0092-8674(00)80985-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565076	hybrid			2022-12-24	WOS:A1996TR59500017
J	Dugan, JA; Bostwick, DG; Myers, RP; Qian, JQ; Bergstralh, EJ; Oesterling, JE				Dugan, JA; Bostwick, DG; Myers, RP; Qian, JQ; Bergstralh, EJ; Oesterling, JE			The definition and preoperative prediction of clinically insignificant prostate cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLING TIME; ADENOCARCINOMA; VOLUME; CARCINOMA; ANTIGEN; PROGRESSION; PROGNOSIS	Objectives. - To define clinically insignificant prostate cancer according to cancer volume, grade, cancer doubling time, and life expectancy; and to determine how many insignificant cancers are removed by radical prostatectomy. Design and Patients. - Clinically insignificant cancer was defined as a tumor that would give rise to no more than 20 cm(3) of cancer within the prostate by the time of expected patient death (1990 life tables) and whose Gleason score was less than 4 in 40- to 49-year-olds, 5 in 50- to 59-year-olds, 6 in 60- to 69-year-olds, and 7 in 70- to 79-year-olds. Four definitions were formulated based on assumed cancer volume doubling times of 2, 3, 4, and 6 years. Using these four definitions, we reviewed 337 totally embedded prostates removed at Mayo Clinic between 1991 and 1993 for clinical stage T1c through T3 cancer to determine how many contained clinically insignificant cancer. Main Outcome Measures. - Clinically significant vs clinically insignificant prostate cancer. Results. - For cancer volume doubling time of 2, 3, 4, and 6 years, clinically insignificant cancer was identified in one (0.3%), 13 (3.9%), 25 (7.4%), and 49 (14.5%) of 337 prostatectomy specimens, respectively. Conclusions. - Clinically insignificant prostate cancer can be defined by cancer volume, grade, cancer volume doubling time, and life expectancy of the patient. According to our definitions, most men treated with radical prostatectomy have clinically significant cancer.	MAYO CLIN & MAYO FDN,DEPT UROL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PATHOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOSTAT,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic								BLACKWELL KL, 1994, J UROLOGY, V151, P1565, DOI 10.1016/S0022-5347(17)35303-X; BOSTWICK DG, 1993, UROLOGY, V41, P403, DOI 10.1016/0090-4295(93)90497-X; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CSAPO Z, 1988, J UROLOGY, V140, P1032, DOI 10.1016/S0022-5347(17)41921-5; CUPP MR, 1995, J UROLOGY, V153, P1543, DOI 10.1016/S0022-5347(01)67458-5; DAMICO AV, 1993, CANCER-AM CANCER SOC, V72, P2638, DOI 10.1002/1097-0142(19931101)72:9<2638::AID-CNCR2820720919>3.0.CO;2-N; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; FRANKS LM, 1954, J PATHOL BACTERIOL, V68, P603, DOI 10.1002/path.1700680233; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; HUMPHREY PA, 1990, HUM PATHOL, V21, P799, DOI 10.1016/0046-8177(90)90048-A; IRWIN MB, 1994, UROLOGY, V44, P862, DOI 10.1016/S0090-4295(94)80171-1; KLEE GG, 1994, J UROLOGY, V151, P94, DOI 10.1016/S0022-5347(17)34879-6; KRAMER SA, 1980, J UROLOGY, V124, P223, DOI 10.1016/S0022-5347(17)55381-1; LOWE BA, 1988, J UROLOGY, V140, P1340, DOI 10.1016/S0022-5347(17)42039-8; MCNEAL JE, 1986, LANCET, V1, P60; MCNEAL JE, 1990, CANCER, V66, P1225, DOI 10.1002/1097-0142(19900915)66:6<1225::AID-CNCR2820660624>3.0.CO;2-X; MCNEAL JE, 1992, HUM PATHOL, V23, P258, DOI 10.1016/0046-8177(92)90106-D; MCNEAL JE, 1969, CANCER, V23, P24, DOI 10.1002/1097-0142(196901)23:1<24::AID-CNCR2820230103>3.0.CO;2-1; SCHMID HP, 1993, CANCER-AM CANCER SOC, V71, P2031, DOI 10.1002/1097-0142(19930315)71:6<2031::AID-CNCR2820710618>3.0.CO;2-Q; SCHRODER FH, 1992, PROSTATE S, V4, P129; STAMEY TA, 1988, J UROLOGY, V139, P1235; STAMEY TA, 1993, CANCER, V71, P993; TERRIS MK, 1995, UROLOGY, V45, P75, DOI 10.1016/S0090-4295(95)96858-X; VILLERS AA, 1990, J UROLOGY, V143, P1183, DOI 10.1016/S0022-5347(17)40220-5; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; 1989, VITAL STATISTICS US, P22; 1981, NCI MONOGRAPH, V57; 1990, VITAL STATISTICS US, P22	28	134	136	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					288	294		10.1001/jama.275.4.288	http://dx.doi.org/10.1001/jama.275.4.288			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544268				2022-12-24	WOS:A1996TP96500024
J	Forrester, TE; Wilks, RJ; Bennett, FI; Simeon, D; Osmond, C; Allen, M; Chung, AP; Scott, P				Forrester, TE; Wilks, RJ; Bennett, FI; Simeon, D; Osmond, C; Allen, M; Chung, AP; Scott, P			Fetal growth and cardiovascular risk factors in Jamaican schoolchildren	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; ADULT LIFE; SERUM-CHOLESTEROL; CHILDHOOD; LIPOPROTEINS; CHILDREN; DISEASE; LIPIDS; HYPERTENSION; ADOLESCENCE	Objective-To determine relation between schoolchildren's blood pressure, glycated haemoglobin level, and cholesterol concentration and their anthropometry, socioeconomic status, and birth measurements. Design-Retrospective cohort study. Setting-27 schools closest to University Hospital of the West Indies, Kingston, Jamaica. Subjects-2337 children aged 6-16 years who were born at university hospital were recruited, and their birth records were recovered: 1610 had suitable records, 659 had records including birth length, and 610 of these were prepubertal. Main outcome measures-Blood pressure, haemoglobin level, serum cholesterol concentration, anthropometry at birth, current anthropometry, and socioeconomic status. Results-Multiple regression analysis showed that children's systolic blood pressure was inversely related to their birth weight (P < 0.0001) and directly related to their current weight. Glycated haemoglobin level was higher in children with thicker triceps skinfolds (P < 0.001) and who had been shorter at birth (P = 0.003). Serum cholesterol concentration was inversely related to current height (P = 0.001) and to length at birth (P = 0.09) and was directly related to triceps skinfold thickness and higher socioeconomic status (P < 0.001). Conclusions-Blood pressure in childhood was inversely related to birth weight and directly to current weight. Glycaemic control and serum cholesterol were related to short length at birth, height deficit in childhood, and childhood obesity.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Southampton	Forrester, TE (corresponding author), UNIV W INDIES,TROP METAB RES UNIT,KINGSTON 7,JAMAICA.			SIMEON, DONALD/0000-0002-6197-9369; Osmond, Clive/0000-0002-9054-4655	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDERSON AJ, 1988, ARTERIOSCLEROSIS, V8, P88, DOI 10.1161/01.ATV.8.1.88; USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; ANTIA AU, 1990, W INDIAN MED J, V24, P110; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Barker DJP, 1994, FETAL MATERNAL MED R, V6, P71, DOI DOI 10.1017/S0965539500001005; BEAGLEHOLE R, 1977, AM J EPIDEMIOL, V105, P87, DOI 10.1093/oxfordjournals.aje.a112359; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; BURNS TL, 1989, AM J EPIDEMIOL, V129, P973, DOI 10.1093/oxfordjournals.aje.a115229; CAMPOS H, 1991, ARTERIOSCLER THROMB, V11, P1077, DOI 10.1161/01.ATV.11.4.1077; CLARKE WR, 1978, CIRCULATION, V58, P626, DOI 10.1161/01.CIR.58.4.626; FREEDMAN DS, 1987, PEDIATRICS, V80, P789; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HALL PM, 1983, ANN CLIN BIOCHEM, V20, P129, DOI 10.1177/000456328302000301; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; LAUER RM, 1984, CIRCULATION, V69, P242, DOI 10.1161/01.CIR.69.2.242; LAUER RM, 1991, HYPERTENSION, V18, P74, DOI 10.1161/01.HYP.18.3_Suppl.I74; LAUER RM, 1988, PEDIATRICS, V75, P1081; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LAW CM, 1992, J EPIDEMIOL COMMUN H, V46, P184, DOI 10.1136/jech.46.3.184; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LAW CM, IN PRESS DIABET MED; LIU K, 1989, HYPERTENSION, V14, P218, DOI 10.1161/01.HYP.14.2.218; MACINTYRE S, 1991, J EPIDEMIOL COMMUN H, V45, P143, DOI 10.1136/jech.45.2.143; MARGETTS BM, 1991, INT J EPIDEMIOL, V20, P938, DOI 10.1093/ije/20.4.938; Martorell R, 1989, ANTHROPOMETRIC STAND; MILLER GJ, 1976, CLIN SCI MOL MED, V51, P475, DOI 10.1042/cs0510475; MUELLER WH, 1984, AM J PHYS ANTHROPOL, V64, P389, DOI 10.1002/ajpa.1330640404; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROSNER B, 1977, AM J EPIDEMIOL, V106, P306, DOI 10.1093/oxfordjournals.aje.a112466; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; STERN MP, 1986, ARTERIOSCLEROSIS, V6, P123, DOI 10.1161/01.ATV.6.2.123; WARD R, 1990, HYPERTENSION PATHOPH, P81; WEBBER LS, 1991, AM J EPIDEMIOL, V133, P884, DOI 10.1093/oxfordjournals.aje.a115968; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WHINCUP PH, 1992, J EPIDEMIOL COMMUNIT, V46, P1640; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L	39	175	176	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					156	160						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR325	8563535				2022-12-24	WOS:A1996TR32500023
J	Gibson, G; Hogness, DS				Gibson, G; Hogness, DS			Effect of polymorphism in the Drosophila regulatory gene Ultrabithorax on homeotic stability	SCIENCE			English	Article							BITHORAX COMPLEX; LINKAGE DISEQUILIBRIUM; MELANOGASTER; EXPRESSION; REGION; SELECTION; PRODUCTS	Development is buffered against unpredictable environmental and genetic effects. Here, a molecular genetic analysis of one type of developmental homeostasis, the establishment of thoracic segmental identity under the control of the Ultrabithorax (Ubx) gene in Drosophila melanogaster, is presented. Flies were artificially selected for differential sensitivity to the induction of bithorax phenocopies by ether vapor, The experiments demonstrated that increased sensitivity to ether correlated with a loss of expression of UBX in the third thoracic imaginal discs and that a significant proportion of the genetic variation for transcriptional stability can be attributed to polymorphism in the Ubx gene.	STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University	Gibson, G (corresponding author), UNIV MICHIGAN,DEPT BIOL,ANN ARBOR,MI 48109, USA.							AKAM ME, 1983, NATURE, V309, P635; AQUADRO CF, 1992, GENETICS, V132, P443; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BUSTURIA A, 1989, DEVELOPMENT, V107, P575; CAIZZI R, 1990, J MOL BIOL, V212, P17, DOI 10.1016/0022-2836(90)90301-2; CAPDEVILA MP, 1981, ROUX ARCH DEV BIOL, V190, P339, DOI 10.1007/BF00863271; CHARLESWORTH B, 1985, HEREDITY, V54, P71, DOI 10.1038/hdy.1985.10; DUNCAN I, 1987, ANNU REV GENET, V21, P285, DOI 10.1146/annurev.ge.21.120187.001441; FALCONER DS, 1981, INTRO QUANTITATIVE G, P272; GLOOR HANS. JU, 1947, REV SUISSE ZOOL, V54, P637; HILL W G, 1968, Theoretical and Applied Genetics, V38, P226, DOI 10.1007/BF01245622; HOGNESS DS, 1985, COLD SPRING HARB SYM, V50, P181, DOI 10.1101/SQB.1985.050.01.024; IRVINE KD, 1991, DEVELOPMENT, V111, P407; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; LAI CG, 1994, SCIENCE, V266, P1697, DOI 10.1126/science.7992053; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MACKAY TFC, 1990, NATURE, V348, P64, DOI 10.1038/348064a0; MACPHERSON JN, 1990, GENETICS, V126, P121; MORATA G, 1993, CURR OPIN GENET DEV, V3, P606, DOI 10.1016/0959-437X(93)90096-8; SIMON J, 1990, EMBO J, V9, P3945, DOI 10.1002/j.1460-2075.1990.tb07615.x; TANKSLEY SD, 1993, ANNU REV GENET, V27, P205, DOI 10.1146/annurev.ge.27.120193.001225; WADDINGTON CH, 1956, EVOLUTION, V10, P1, DOI 10.2307/2406091; YAP EPH, 1992, TRENDS GENET, V8, P49, DOI 10.1016/0168-9525(92)90339-6; ZAPATA C, 1992, EVOLUTION, V46, P1900, DOI [10.2307/2410039, 10.1111/j.1558-5646.1992.tb01177.x]; ZHIVOTOVSKY LA, 1992, THEOR POPUL BIOL, V42, P254, DOI 10.1016/0040-5809(92)90015-L	28	134	135	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					200	203		10.1126/science.271.5246.200	http://dx.doi.org/10.1126/science.271.5246.200			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539619				2022-12-24	WOS:A1996TP36400041
J	MoyaSola, S; Kohler, M				MoyaSola, S; Kohler, M			A Dryopithecus skeleton and the origins of great-ape locomotion	NATURE			English	Article							PROCONSUL-NYANZAE; SIVAPITHECUS; PROPORTIONS; EVOLUTION; PAKISTAN; HOMINIDS; MIOCENE; KENYA; SIZE	THE evolution of skeletal adaptations to orthograde postures, characteristic of extant hominoids, is of great interest as it provides the key to understanding the origins of apes and humans. We report here the recent discovery of an extraordinary partial skeleton of Dryopithiecus laietanus from Can Llobateres (Spain). It provides evidence that orthograde postures and locomotion appeared at least 9.5 million years ago(1). Our results indicate that the body structure of this Miocene ape closely resembles that of extant hominoids(2,3) and differs from the pronograde pattern of Miocene proconsulids(4,5) in a set of important morphological characters. Dryopithecus also shows more traits reflecting structural adaptations for suspension than occurs in African apes. A similar positional behaviour is inferred for Simpithecus indicus, thus strengthening previous hypotheses linking both Miocene forms with Pongo(6-9).			MoyaSola, S (corresponding author), INST PALEONTOL MIQUEL CRUSAFONT,C IND 23,E-08201 SABADELL,SPAIN.			Kohler, Meike/0000-0002-6816-6651; Moya-Sola, Salvador/0000-0001-8506-1061; Kohler, Meike/0000-0001-9228-3164				AGUSTI J, IN PRESS J HUM EVOL; ANDREWS P, 1982, NATURE, V297, P541, DOI 10.1038/297541a0; ANDREWS P, 1976, GIBBON SIAMANG, P167; Begun David R., 1994, Yearbook of Physical Anthropology, V37, P11; BEGUN DR, 1992, SCIENCE, V257, P1929, DOI 10.1126/science.1411507; ERIKSON GE, 1963, S ZOOL SOC LOND, V10, P136; HARRISON T, 1986, J HUM EVOL, V15, P541, DOI 10.1016/S0047-2484(86)80073-2; Hurzeler J., 1968, ANN PALEONT VERT, V54, P195; Jungers W.L., 1984, P146; Jungers W.L., 1985, P345; JUNGERS WL, 1987, J HUM EVOL, V16, P445, DOI 10.1016/0047-2484(87)90072-8; JUNGERS WL, 1984, YEARB PHYS ANTHROPOL, V27, P73; Jungers WL, 1990, BODY SIZE MAMMALIAN, P107; KELLEY J, 1986, COMP PRIMATE BIOL, P316; MCHENRY HM, 1992, AM J PHYS ANTHROPOL, V87, P407, DOI 10.1002/ajpa.1330870404; NAPIER JR, 1959, FORE LIMB SKELETON A, P1; PILBEAM D, 1982, NATURE, V295, P232, DOI 10.1038/295232a0; PILBEAM D, 1990, NATURE, V348, P237, DOI 10.1038/348237a0; PILBEAM D, 1971, NATURE, V229, P408; Preuschoft H., 1990, P109; ROSE MD, 1994, J HUM EVOL, V26, P387, DOI 10.1006/jhev.1994.1025; Ruff C., 1990, P119; RUFF CB, 1989, J HUM EVOL, V18, P515, DOI 10.1016/0047-2484(89)90016-X; SANDERS WJ, 1994, J HUM EVOL, V26, P203, DOI 10.1006/jhev.1994.1012; SOLA SM, 1993, NATURE, V365, P543, DOI 10.1038/365543a0; SOLA SM, 1995, J HUM EVOL, V28, P101; WARD CV, 1993, AM J PHYS ANTHROPOL, V90, P77, DOI 10.1002/ajpa.1330900106; WARD CV, 1993, AM J PHYS ANTHROPOL, V92, P291, DOI 10.1002/ajpa.1330920306; [No title captured]	29	144	144	0	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					156	159		10.1038/379156a0	http://dx.doi.org/10.1038/379156a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TP360	8538764				2022-12-24	WOS:A1996TP36000055
J	Javitt, JC; Aiello, LP				Javitt, JC; Aiello, LP			Cost-effectiveness of detecting and treating diabetic retinopathy	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			4-YEAR INCIDENCE; MELLITUS; DIAGNOSIS; AGE; PHOTOCOAGULATION; PROGRESSION; GUIDELINES; PREVALENCE; MORTALITY; SEVERITY	Objective: To determine, from the health insurer's perspective, the cost of preventing vision loss in patients with diabetes mellitus through ophthalmologic screening and treatment and to calculate the cost-effectiveness of these interventions as compared with that of other medical interventions. Design: Computer modeling, incorporating data from population-based epidemiologic studies and multicenter clinical trials. Monte Carlo simulation was used, combined with sensitivity analysis and present value analysis of cost savings. Results: Screening and treatment of eye disease in patients with diabetes mellitus costs $3190 per quality-adjusted life-year (QALY) saved. This average cost is a weighted average (based on prevalence of disease) of the cost-effectiveness of detecting and treating diabetic eye disease in those with insulin-dependent diabetes mellitus ($1996 per QALY), those with non-insulin-dependent diabetes mellitus (NIDDM) who use insulin for glycemic control ($2933 per QALY), and those with NIDDM who do not use insulin for glycemic control ($3530 per QALY). Conclusions: Our analysis indicates that prevention programs aimed at improving eye care for diabetic persons not only result in substantial federal budgetary savings but are highly cost-effective health investments for society. Ophthalmologic screening for diabetic persons is more cost-effective than many routinely provided health interventions. Because diabetic eye disease is the leading cause of new cases of blindness among working-age Americans, these results support the widespread use of screening and treatment for diabetic eye disease.	JOSLIN DIABET CTR, BEETHAM EYE INST, BOSTON, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.	Javitt, JC (corresponding author), GEORGETOWN UNIV, MED CTR, CTR SIGHT, 3800 RESERVOIR RD NW, WASHINGTON, DC 20007 USA.		Javitt, Jonathan/AAJ-5574-2021	Javitt, Jonathan/0000-0003-2371-1609	NATIONAL EYE INSTITUTE [R01EY008805, R21EY007744] Funding Source: NIH RePORTER; NEI NIH HHS [R01-EYO8805, R21-EY07744] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], 1979, Arch Ophthalmol, V97, P654; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; [Anonymous], DIABETIC RETINOPATHY; BLANKENSHIP GW, 1991, OPHTHALMOLOGY, V98, P125; BRADFORD DF, 1983, PUBLIC EXPENDITURE P, P129; BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714; BUTLER WJ, 1982, AM J EPIDEMIOL, V116, P971, DOI 10.1093/oxfordjournals.aje.a113499; CANNER JK, 1992, WIN P SIM C, V25, P1041; CHIANG YP, 1992, MILBANK Q, V70, P319, DOI 10.2307/3350062; DASBACH EJ, 1991, MED CARE, V29, P20, DOI 10.1097/00005650-199101000-00003; Davis M D, 1979, Trans Am Ophthalmol Soc, V77, P144; DETSKY AS, 1989, JAMA-J AM MED ASSOC, V262, P1795, DOI 10.1001/jama.262.13.1795; DORMAN JS, 1984, DIABETES, V33, P271, DOI 10.2337/diabetes.33.3.271; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; DRUMMOND M, 1987, CNSULTANT REPORT NAT; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; EVERHART J, 1985, NIH851468 US DEP HLT, P1; FERRIS FL, 1993, JAMA-J AM MED ASSOC, V269, P1290, DOI 10.1001/jama.269.10.1290; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; JAVITT JC, 1991, OPHTHALMOLOGY, V98, P1565; JAVITT JC, 1994, DIABETES CARE, V17, P909, DOI 10.2337/diacare.17.8.909; Johannesson M, 1992, Int J Technol Assess Health Care, V8, P359; Kenny S.J., 1995, NIH PUBLICATION, P47; KLEIN BEK, 1984, OPHTHALMOLOGY, V91, P10; KLEIN HA, 1970, US DHEW73427; KLEIN R, 1985, DIABETES CARE, V8, P71, DOI 10.2337/diacare.8.1.S71; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P244, DOI 10.1001/archopht.1989.01070010250031; KLEIN R, 1987, OPHTHALMOLOGY, V94, P747; KLEIN R, 1989, ARCH INTERN MED, V149, P266, DOI 10.1001/archinte.149.2.266; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P237, DOI 10.1001/archopht.1989.01070010243030; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KLEIN R, 1984, NIH851468 PUBLICATIO, P1; KNATTERUD GL, 1983, ISRAEL J MED SCI, V19, P424; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; MARTIN DB, 1985, NIH851468 PHS US DEP, pR24; MELTON LJ, 1983, DIABETES CARE, V6, P75, DOI 10.2337/diacare.6.1.75; MOSS SE, 1985, OPHTHALMOLOGY, V92, P62; Parsonage M, 1992, Health Econ, V1, P71, DOI 10.1002/hec.4730010110; PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015; RING A, 1991, CLIN DIABETES MELLIT, P728; SINGER DE, 1992, ANN INTERN MED, V116, P660, DOI 10.7326/0003-4819-116-8-660; SUSSMAN EJ, 1982, JAMA-J AM MED ASSOC, V247, P3231, DOI 10.1001/jama.247.23.3231; VANDER JF, 1991, OPHTHALMOLOGY, V98, P1575; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WITKIN SR, 1984, JAMA-J AM MED ASSOC, V251, P2534, DOI 10.1001/jama.251.19.2534; 1993, MMWR-MORBID MORTAL W, V42, P191; 1989, DIABETES 2000 ELIMIN; 1992, LANCET, V340, P148; 1987, VITAL STATISTICS US, V2; ANAL EARLY TREATMENT; 1980, VISION PROBLEMS US S; 1988, VITAL STATISTICS US, V1, P17; 1990, AVERAGE MEDICARE ALL	54	270	274	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				164	169		10.7326/0003-4819-124-1_Part_2-199601011-00017	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00017			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554212				2022-12-24	WOS:A1996TL94400017
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA ON THE INTERNET	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1903	1903						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568972				2022-12-24	WOS:A1995TL16900011
J	GAN, SS; AMASINO, RM				GAN, SS; AMASINO, RM			INHIBITION OF LEAF SENESCENCE BY AUTOREGULATED PRODUCTION OF CYTOKININ	SCIENCE			English	Article							TOBACCO PLANTS	Controlling expression of IPT, a gene encoding isopentenyl transferase (the enzyme that catalyzes the rate-limiting step in cytokinin biosynthesis), with a senescence-specific promoter results in the suppression of leaf senescence. Transgenic tobacco plants expressing this chimeric gene do not exhibit the developmental abnormalities usually associated with IPT expression because the system is autoregulatory. Because sufficient cytokinin is produced to retard senescence, the activity of the senescence-specific promoter is attenuated. Senescence-retarded leaves exhibit a prolonged, photosynthetically active life-span. This result demonstrates that endogenously produced cytokinin can regulate senescence and provides a system to specifically manipulate the senescence program.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								Duvick D. N., 1984, Genetic contributions to yield gains of five major crop plants. Proceedings of a symposium sponsored by Division C-1 of the Crop Science Society of America, 2 December 1981, in Atlanta, Georgia, P15; GAN S, UNPUB; GARNER RJ, 1988, GRAFTERS HDB; HEWELT A, 1994, PLANT J, V6, P879, DOI 10.1046/j.1365-313X.1994.6060879.x; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; LI Y, 1992, DEV BIOL, V153, P386, DOI 10.1016/0012-1606(92)90123-X; LOHMAN KN, 1994, PHYSIOL PLANTARUM, V92, P322, DOI 10.1111/j.1399-3054.1994.tb05343.x; MARTINEAU B, 1994, PLANT J, V5, P11, DOI 10.1046/j.1365-313X.1994.5010011.x; NOODEN LD, 1979, SCIENCE, V206, P841, DOI 10.1126/science.206.4420.841; NOODEN LD, 1978, PHYTOHORMONES RELATE, V2, P329; RICHMOND AE, 1957, SCIENCE, V125, P650, DOI 10.1126/science.125.3249.650-a; SINGH S, 1992, PHYSIOL PLANTARUM, V86, P388, DOI 10.1111/j.1399-3054.1992.tb01334.x; SMART CM, 1991, PLANT CELL, V3, P647, DOI 10.1105/tpc.3.7.647; THOMAS H, 1980, ANNU REV PLANT PHYS, V31, P83, DOI 10.1146/annurev.pp.31.060180.000503	14	774	977	9	231	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1986	1988		10.1126/science.270.5244.1986	http://dx.doi.org/10.1126/science.270.5244.1986			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8592746				2022-12-24	WOS:A1995TL42000040
J	HUDSON, TJ; STEIN, LD; GERETY, SS; MA, JL; CASTLE, AB; SILVA, J; SLONIM, DK; BAPTISTA, R; KRUGLYAK, L; XU, SH; HU, XT; COLBERT, AME; ROSENBERG, C; REEVEDALY, MP; ROZEN, S; HUI, L; WU, XY; VESTERGAARD, C; WILSON, KM; BAE, JS; MAITRA, S; GANIATSAS, S; EVANS, CA; DEANGELIS, MM; INGALLS, KA; NAHF, RW; HORTON, LT; ANDERSON, MO; COLLYMORE, AJ; YE, WJ; KOUYOUMJIAN, V; ZEMSTEVA, IS; TAM, J; DEVINE, R; COURTNEY, DF; RENAUD, MT; NGUYEN, H; OCONNOR, TJ; FIZAMES, C; FAURE, S; GYAPAY, G; DIB, C; MORISSETTE, J; ORLIN, JB; BIRREN, BW; GOODMAN, N; WEISSENBACH, J; HAWKINS, TL; FOOTE, S; PAGE, DC; LANDER, ES				HUDSON, TJ; STEIN, LD; GERETY, SS; MA, JL; CASTLE, AB; SILVA, J; SLONIM, DK; BAPTISTA, R; KRUGLYAK, L; XU, SH; HU, XT; COLBERT, AME; ROSENBERG, C; REEVEDALY, MP; ROZEN, S; HUI, L; WU, XY; VESTERGAARD, C; WILSON, KM; BAE, JS; MAITRA, S; GANIATSAS, S; EVANS, CA; DEANGELIS, MM; INGALLS, KA; NAHF, RW; HORTON, LT; ANDERSON, MO; COLLYMORE, AJ; YE, WJ; KOUYOUMJIAN, V; ZEMSTEVA, IS; TAM, J; DEVINE, R; COURTNEY, DF; RENAUD, MT; NGUYEN, H; OCONNOR, TJ; FIZAMES, C; FAURE, S; GYAPAY, G; DIB, C; MORISSETTE, J; ORLIN, JB; BIRREN, BW; GOODMAN, N; WEISSENBACH, J; HAWKINS, TL; FOOTE, S; PAGE, DC; LANDER, ES			AN STS-BASED MAP OF THE HUMAN GENOME	SCIENCE			English	Article							PHYSICAL MAP; LINKAGE MAP; HUMAN DNA; CHROMOSOMES; CLONES; POLYMORPHISMS; YEAST; STRATEGY; PANEL-2; REGION	A physical map has been constructed of the human genome containing 15,086 sequence-tagged sites (STSs), with an average spacing of 199 kilobases. The project involved assembly of a radiation hybrid map of the human genome containing 6193 loci and incorporated a genetic linkage map of the human genome containing 5264 loci. This information was combined with the results of STS-content screening of 10,850 loci against a yeast artificial chromosome library to produce an integrated map, anchored by the radiation hybrid and genetic maps. The map provides radiation hybrid coverage of 99 percent and physical coverage of 94 percent of the human genome. The map also represents an early step in an international project to generate a transcript map of the human genome, with more than 3235 expressed sequences localized. The STSs in the map provide a scaffold for initiating large-scale sequencing of the human genome.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; GENETHON SA,CNRS,URA 1922,F-91000 EVRY,FRANCE; CHU LAVAL,CTR RECH,ST FOY,PQ G1V 4G2,CANADA; MIT,ALFRED P SLOAN SCH MANAGEMENT,CAMBRIDGE,MA 02139; MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Harvard University; Brigham & Women's Hospital; Centre National de la Recherche Scientifique (CNRS); Laval University; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	HUDSON, TJ (corresponding author), WHITEHEAD MIT CTR GENOME RES,WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		Foote, Simon J/F-2802-2013; DeAngelis, e/J-7863-2015; Rozen, Steven G./J-5939-2013	Rozen, Steven G./0000-0002-4288-0056; Orlin, James/0000-0002-7488-094X; Hudson, Thomas/0000-0002-1376-4849; Slonim, Donna/0000-0003-3357-437X; Gerety, Sebastian/0000-0002-6126-5040; Fizames, Cecile/0000-0002-0551-8250; Foote, Simon/0000-0002-9142-2107	NHGRI NIH HHS [HG00017, HG00098] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ADAMS MD, 1995, NATURE, V377, pS3; ALITALO T, 1995, GENOMICS, V25, P691, DOI 10.1016/0888-7543(95)80012-B; ARRATIA R, 1991, GENOMICS, V11, P806, DOI 10.1016/0888-7543(91)90004-X; BELL CJ, 1995, HUM MOL GENET, V4, P59; BERRY R, 1995, NAT GENET, V10, P415, DOI 10.1038/ng0895-415; BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1995, NATURE, V377, pS175; COLLINS F, 1993, SCIENCE, V262, P43, DOI 10.1126/science.8211127; COLLINS JE, 1995, NATURE, V377, pS367; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; DIB C, IN PRESS NATURE; DOGGETT NA, 1995, NATURE, V377, pS335; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; DUBOIS BL, 1993, GENOMICS, V16, P315, DOI 10.1006/geno.1993.1191; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GEMMILL RM, 1995, NATURE, V377, pS299; Gijlswijk R. P. M. van, 1992, Molecular and Cellular Probes, V6, P223, DOI 10.1016/0890-8508(92)90020-X; GREEN ED, 1990, SCIENCE, V250, P94, DOI 10.1126/science.2218515; GREEN ED, 1994, HUM MOL GENET, V3, P489, DOI 10.1093/hmg/3.3.489; GYAPAY G, IN PRESS HUM MOL GEN; GYAPAY G, 1994, NAT GENET, V7, P247; HALDI M, 1994, GENOMICS, V24, P478, DOI 10.1006/geno.1994.1656; HESLOPHARRISON JS, 1989, HUM GENET, V84, P27, DOI 10.1007/BF00210666; HOULGATTE R, 1995, GENOME RES, V5, P272, DOI 10.1101/gr.5.3.272; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KRAUTER K, 1995, NATURE, V377, pS321; KRUGTYAK L, 1987, P NATL ACAD SCI USA, V84, P2363; LANDER ES, 1992, GENOMICS, V14, P604; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; Ott J., 1991, ANAL HUMAN GENETIC L; QUACKENBUSH J, 1995, GENOMICS, V29, P512, DOI 10.1006/geno.1995.9974; SACCONE S, 1992, P NATL ACAD SCI USA, V89, P4913, DOI 10.1073/pnas.89.11.4913; SELLERI L, 1992, GENOMICS, V14, P536, DOI 10.1016/S0888-7543(05)80263-0; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	45	735	771	0	26	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1945	1954		10.1126/science.270.5244.1945	http://dx.doi.org/10.1126/science.270.5244.1945			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533086				2022-12-24	WOS:A1995TL42000029
J	Livingstone, AE; Shaddick, G; Grundy, C; Elliott, P				Livingstone, AE; Shaddick, G; Grundy, C; Elliott, P			Do people living near inner city main roads have more asthma needing treatment? Case-control study	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON LONDON SCH HYG & TROP MED,ENVIRONM EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	Livingstone, AE (corresponding author), GILL ST HLTH CTR,LIMEHOUSE PRACTICE,LONDON E14 8HQ,ENGLAND.		Shaddick, Gavin B/B-3344-2011					DIGGLE PJ, 1994, J ROY STAT SOC A STA, V157, P433, DOI 10.2307/2983529; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223, DOI 10.1080/00039896.1994.9937471; WALDRON G, 1995, J PUBLIC HEALTH MED, V17, P85; WEILAND SK, 1994, ANN EPIDEMIOL, V4, P79; WJST M, 1993, BRIT MED J, V307, P596, DOI 10.1136/bmj.307.6904.596	5	65	66	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					676	677						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597735				2022-12-24	WOS:A1996UB11000025
J	Kitahata, MM; Koepsell, TD; Deyo, RA; Maxwell, CL; Dodge, WT; Wagner, EH				Kitahata, MM; Koepsell, TD; Deyo, RA; Maxwell, CL; Dodge, WT; Wagner, EH			Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; MULTICENTER AIDS COHORT; IN-HOSPITAL MORTALITY; VIRUS INFECTION; ZIDOVUDINE; PROPHYLAXIS; VOLUME; CARE; OUTCOMES; MEN	Background. Previous studies have found that patients with the acquired immunodeficiency syndrome (AIDS) who are admitted to hospitals that admit many such patients have lower mortality rates than patients in hospitals with less experience with AIDS. We examined the relation between physicians' experience with AIDS and the survival of their patients with AIDS. Methods. We studied 403 adult male patients enrolled in a staff-model health maintenance organization in whom first AIDS-defining illnesses were diagnosed from 1984 through mid-1994; we determined that these illnesses met the 1987 case definition of the Centers for Disease Control. We defined three levels of experience for the patients' 125 primary care physicians according to their experience with AIDS during residency training and the cumulative number of patients with AIDS they had cared for in their practices. Results. The median survival of the patients of physicians with the least experience in the management of AIDS was 14 months, as compared with 26 months for the patients of physicians with the most experience (P<0.001). Controlling for the severity of illness and the year of diagnosis, we found that the patients cared for by physicians with the most experience had a 31 percent lower risk of death than the patients cared for by physicians with the least experience (P<0.02). Among 244 patients with an AIDS-defining illness diagnosed from 1989 through 1994, after adjustment for the CD4+ cell count and the severity of illness, the risk of death was 43 percent lower for patients of the most experienced physicians than for patients of the least experienced (P<0.02). Conclusions. The experience of primary care physicians in the management of AIDS is significantly associated with survival among their patients.	UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; GRP HLTH COOPERAT PUGET SOUND,CTR HLTH STUDIES,SEATTLE,WA 98101	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative	Kitahata, MM (corresponding author), UNIV WASHINGTON,CTR AIDS & STD,DEPT MED,1001 BROADWAY,SUITE 215,SEATTLE,WA 98122, USA.							BENNETT CL, 1989, JAMA-J AM MED ASSOC, V261, P2975, DOI 10.1001/jama.261.20.2975; BENNETT CL, 1992, J ACQ IMMUN DEF SYND, V5, P856; BROWN BW, 1977, STATISTICS BIOMEDICA; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; COTTON DJ, 1989, JAMA-J AM MED ASSOC, V261, P3016, DOI 10.1001/jama.261.20.3016; COX DR, 1972, J R STAT SOC B, V34, P187; CURTIS JR, 1995, ARCH INTERN MED, V155, P1613, DOI 10.1001/archinte.155.15.1613; GRAHAM NM, 1994, J CLIN EPIDEMIOL, V447, P1003; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P267; HOLMBERG SD, 1993, AIDS, V7, P699, DOI 10.1097/00002030-199305000-00014; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LANG W, 1991, J ACQ IMMUN DEF SYND, V4, P713; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; LUFT HS, 1987, HEALTH SERV RES, V22, P157; LUNDGREN JD, 1994, JAMA-J AM MED ASSOC, V271, P1088, DOI 10.1001/jama.271.14.1088; MAERKI SC, 1986, MED CARE, V24, P148, DOI 10.1097/00005650-198602000-00006; MAKADON HJ, 1990, J GEN INTERN MED, V5, P446, DOI 10.1007/BF02599436; MARKSON LE, 1994, ARCH INTERN MED, V154, P1497, DOI 10.1001/archinte.154.13.1497; MUNOZ A, 1993, AM J EPIDEMIOL, V137, P423, DOI 10.1093/oxfordjournals.aje.a116691; NORTHFELT DW, 1988, ANN INTERN MED, V109, P773, DOI 10.7326/0003-4819-109-10-773; OSMOND D, 1994, JAMA-J AM MED ASSOC, V271, P1083, DOI 10.1001/jama.271.14.1083; RAMSEY PG, 1994, PRIMARY CARE PATIENT; SHAPIRO MF, 1992, JAMA-J AM MED ASSOC, V268, P2698; SMITH MD, 1991, J GEN INTERN MED S1, V16, pS56; STONE VE, 1992, JAMA-J AM MED ASSOC, V268, P2655, DOI 10.1001/jama.268.19.2655; TURNER BJ, 1991, J ACQ IMMUN DEF SYND, V4, P1059; TURNER BJ, 1992, J ACQ IMMUN DEF SYND, V5, P214; TURNER BJ, 1992, J ACQ IMMUN DEF SYND, V5, P978; VELLA S, 1994, JAMA-J AM MED ASSOC, V271, P1197, DOI 10.1001/jama.271.15.1197; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; VOLBERDING PA, 1985, ANN INTERN MED, V103, P729, DOI 10.7326/0003-4819-103-5-729; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184; 1994, LANCET, V343, P871; 1987, MMWR MORB MORTAL S1S, V36; 1992, MMWR-MORBID MORTAL W, V41, P1	40	392	396	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1996	334	11					701	706		10.1056/NEJM199603143341106	http://dx.doi.org/10.1056/NEJM199603143341106			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ528	8594430				2022-12-24	WOS:A1996TZ52800006
J	Catchpole, MA; Mercey, DE; Nicoll, A; Rogers, PA; Simms, J; Newham, J; Mahoney, A; Parry, JV; Joyce, C; Gill, ON				Catchpole, MA; Mercey, DE; Nicoll, A; Rogers, PA; Simms, J; Newham, J; Mahoney, A; Parry, JV; Joyce, C; Gill, ON			Continuing transmission of sexually transmitted diseases among patients infected with HIV-1 attending genitourinary medicine clinics in England and Wales	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether those who are aware of being infected with HIV continue to adopt behaviours that place others at risk of HIV infection. Design-Ongoing survey of current diagnosis of sexually transmitted disease and awareness of HIV infection among patients attending genitourinary medicine clinics. Setting-Six genitourinary medicine clinics in England and Wales (two in London and four outside) participating in unlinked anonymous HIV serosurveillance during 1990-3. Subjects-All attenders having blood drawn for syphilis serology for the first time during the calendar quarter of attendance. Main outcome measures-The proportion of syphilis serology specimens with antibody to HIV-1 detected by unlinked anonymous testing of the residue. The proportion of attenders infected with HIV-1 who remained clinically undetected, and the proportion who had another recently acquired sexually transmitted disease, Results-Of 85441 specimens tested, 2328 (2.7%) were positive for antibodies to HIV-1, About 30% of these specimens were from attenders whose HIV-1 infection remained clinically undetected, HIV-1 infection was found to coexist with another recently acquired sexually transmitted disease in 651 attenders, of whom 522 were homosexual or bisexual men. Of these, 245 (47%) already knew themselves to be infected with HIV-1, This proportion increased between 1990 and 1993. Conclusions-A considerable proportion of patients infected with HIV-1 are not identified by voluntary confidential HIV testing in genitourinary medicine clinics. Substantial numbers of homosexual or bisexual men attending genitourinary medicine clinics continue to practise unsafe sex despite being aware of their infection with HIV-1.	ACAD DEPT GENITOURINARY MED,MORTIMER MARKET CTR,LONDON WC 6AY,ENGLAND; PUBL HLTH LAB SERV,DIV VIRUS REFERENCE,LONDON NW9 5HT,ENGLAND	Public Health England	Catchpole, MA (corresponding author), PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND.							DAY NE, 1996, CDR REV, V6, pR1; EVANS BG, 1993, BRIT MED J, V306, P426, DOI 10.1136/bmj.306.6875.426; GILL ON, 1989, BRIT MED J, V299, P1295, DOI 10.1136/bmj.299.6711.1295; GROSECLOSE SL, 1994, SEX TRANSM DIS, V21, P31, DOI 10.1097/00007435-199401000-00007; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; *HLTH ED AUTH, 1994, HLTH UPD, V4; JONES JL, 1993, SEX TRANSM DIS, V20, P334, DOI 10.1097/00007435-199320060-00006; MILLER E, 1995, BRIT MED J, V311, P545, DOI 10.1136/bmj.311.7004.545; NARDONE A, 1995, P MED RES COUNC 9 AN; Noone A, 1992, Commun Dis Rep CDR Rev, V2, pR21; STALL R, 1994, BRIT MED J, V309, P685, DOI 10.1136/bmj.309.6956.685; TOMLINSON DR, 1991, LANCET, V337, P501, DOI 10.1016/0140-6736(91)93447-H; *UNL AN HIV SURV S, 1995, UNL AN HIV PREV MON; 1993, COMMUN DIS REP CDR R, V3, pR1; 1993, LANCET, V341, P863	15	36	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					539	542		10.1136/bmj.312.7030.539	http://dx.doi.org/10.1136/bmj.312.7030.539			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595282	Green Published			2022-12-24	WOS:A1996TY88500022
J	Sumarsono, SH; Wilson, TJ; Tymms, MJ; Venter, DJ; Corrick, CM; Kola, R; Lahoud, MH; Papas, TS; Seth, A; Kola, I				Sumarsono, SH; Wilson, TJ; Tymms, MJ; Venter, DJ; Corrick, CM; Kola, R; Lahoud, MH; Papas, TS; Seth, A; Kola, I			Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice	NATURE			English	Article							BINDING; MOUSE	EXPRESSION of Ets2, a proto-oncogene(1) and transcription factor(2-5), occurs in a variety of cell types(6), During murine development it is highly expressed in newly forming cartilage, including In the skull precursor cells and vertebral primordia(7), Ets(2) is located on human chromosome 21 (ref. 8) and is overexpressed in Down's syndrome (trisomy 21)(9), Here we generate transgenic mice to Investigate the consequences of overexpression of Ets2, We find that mice with less than 2-fold Ets2 overexpression in particular organs develop neurocranial, viscerocranial and cervical skeletal abnormalities, These abnormalities have similarities with the skeletal anomalies found in trisomy-16 mice and humans with Down's syndrome, in which the gene dosage of Ets2 is increased(10,12), Our results indicate that Ets2 has a role in skeletal development and implicate the overexpression of Ets2 in the genesis of some skeletal abnormalities that occur in Down's syndrome.	MONASH UNIV,MONASH MED CTR,INST REPROD & DEV,MOLEC GENET & DEV GRP,CLAYTON,VIC 3168,AUSTRALIA; PETER MACCALLUM CANC INST,MELBOURNE,VIC 3002,AUSTRALIA; MED UNIV S CAROLINA,HOLLINGS CANC CTR,CTR MOLEC & STRUCT BIOL,CHARLESTON,SC 29425; UNIV TORONTO,FAC MED,DEPT PATHOL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,FAC DENT,TORONTO,ON M5S 1A8,CANADA; WOMENS COLL HOSP,TORONTO,ON M5S 1A8,CANADA	Monash University; Peter Maccallum Cancer Center; Medical University of South Carolina; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital			Lahoud, Mireille/F-1299-2013; Kola, Ismail/C-5254-2013	Lahoud, Mireille/0000-0001-8472-6201; 				ASCIONE R, 1992, INT J ONCOL, V1, P631; AVRAHAM KB, 1988, CELL, V54, P823, DOI 10.1016/S0092-8674(88)91153-1; Bancroft JD, 1984, J PATH, V145, P355; CAFFEY J, 1978, PAEDIATRIC XRAY DIAG, V1, P155; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; DAVISSON MT, 1990, CYTOGENET CELL GENET, V55, P434, DOI 10.1159/000133026; Epstein L B, 1980, Ann N Y Acad Sci, V350, P171, DOI 10.1111/j.1749-6632.1980.tb20618.x; GRAUSZ H, 1991, MORPHOGENESIS DOWN S, P169; HART AH, 1995, ONCOGENE, V10, P1423; IANNELLO RC, 1994, REPROD FERT DEVELOP, V6, P599, DOI 10.1071/RD9940599; KAUFMAN MH, 1990, ATLAS MOUSE DEV, P495; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KOLA I, 1995, ADV HUMAN REPROD, P309; KORENBERG JR, 1991, MORPHOGENESIS DOWN S, P43; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; PATTERSON D, 1987, SCI AM, V257, P42; REEVES RH, 1987, MOL BRAIN RES, V2, P215, DOI 10.1016/0169-328X(87)90028-3; REEVES RH, 1985, NAT GENET, V111, P177; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; THOMAS RS, 1995, ONCOGENE, V11, P2135; Tymms M J, 1995, Methods Mol Biol, V37, P31; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0	23	168	169	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					534	537						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596630				2022-12-24	WOS:A1996TU69300048
J	Southall, DP; Ellis, J; McMaster, P; McMaster, H; Willock, A; Plunkett, M				Southall, DP; Ellis, J; McMaster, P; McMaster, H; Willock, A; Plunkett, M			Medical evacuation from Mostar	LANCET			English	Article											Southall, DP (corresponding author), KEELE UNIV,N STAFFS HOSP,ACAD DEPT PAEDIAT,STOKE ON TRENT ST4 6QG,STAFFS,ENGLAND.							[Anonymous], 1991, CONVENTION RIGHTS CH; MORLEY D, 1986, MY NAME IS TODAY; Ressler Everett M., 1992, EVACUATION CHILDREN; SOUTHALL D, IN PRESS PROGRAMME I; 1994, INTRO IOM SPECIAL ME	5	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					244	245		10.1016/S0140-6736(96)90411-0	http://dx.doi.org/10.1016/S0140-6736(96)90411-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551888				2022-12-24	WOS:A1996TT06900017
J	Okuda, T; vanDeursen, J; Hiebert, SW; Grosveld, G; Downing, JR				Okuda, T; vanDeursen, J; Hiebert, SW; Grosveld, G; Downing, JR			AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis	CELL			English	Article							ACUTE MYELOID-LEUKEMIA; EMBRYONIC STEM-CELLS; DROSOPHILA SEGMENTATION GENE; ACUTE MYELOGENOUS LEUKEMIA; SL3-3 VIRUS ENHANCER; FUSION TRANSCRIPT; RECEPTOR-DELTA; NUCLEAR FACTOR; DNA-BINDING; RUNT	The AML1-CBF beta transcription factor is the most frequent target of chromosomal rearrangements in human leukemia. To investigate its normal function, we generated mice lacking AML1. Embryos with homozygous mutations in AML1 showed normal morphogenesis and yolk sac-derived erythropoiesis, but lacked fetal liver hematopoiesis and died around E12.5. Sequentially targeted AML1(-/-) ES cells retained their capacity to differentiate into primitive erythroid cells in vitro; however, no myeloid or erythroid progenitors of definitive hematopoietic origin were detected in either the yolk sac or fetal livers of mutant embryos. Moreover, this hematopoietic defect was intrinsic to the stem cells in that AML1(-/-) ES cells failed to contribute to hematopoiesis in chimeric animals. These results suggest that AML1-regulated target genes are essential for definitive hematopoiesis of all lineages.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	Okuda, T (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT PATHOL & LAB MED, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA.		Hiebert, Scott W/C-9979-2010; Downing, James R./N-8102-2018		NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21765] Funding Source: Medline; PHS HHS [R01-64140] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAE SC, 1993, ONCOGENE, V8, P809; BORAL AL, 1989, J VIROL, V63, P76, DOI 10.1128/JVI.63.1.76-84.1989; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DOWNING JR, 1993, BLOOD, V81, P2860; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; DUFFY JB, 1991, GENE DEV, V5, P2176, DOI 10.1101/gad.5.12a.2176; ERICKSON P, 1992, BLOOD, V80, P1825; GERGEN JP, 1985, DEV BIOL, V109, P321, DOI 10.1016/0012-1606(85)90459-2; GERGEN JP, 1986, CELL, V45, P289, DOI 10.1016/0092-8674(86)90393-4; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HAJRA A, 1995, MOL CELL BIOL, V15, P4980; HAJRA A, 1995, P NATL ACAD SCI USA, V92, P1926, DOI 10.1073/pnas.92.6.1926; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; IHLE JN, 1992, CHEM IMMUNOL, V51, P65; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIESCHKE GJ, 1994, BLOOD, V84, P27; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; LOSARDO JE, 1990, J VIROL, V64, P1756, DOI 10.1128/JVI.64.4.1756-1763.1990; MANLEY NR, 1993, J VIROL, V67, P1967, DOI 10.1128/JVI.67.4.1967-1975.1993; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MEYERS S, 1996, IN PRESS CRIT REV EU; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; SHURTLEFF SA, 1995, IN PRESS LEUKEMIA; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; SONODA Y, 1990, BLOOD, V75, P1615; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; STANLEY E, 1994, P NATL ACAD SCI USA, V91, P5592, DOI 10.1073/pnas.91.12.5592; SUN WW, 1993, J VIROL, V67, P1976, DOI 10.1128/JVI.67.4.1976-1986.1993; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; VANDEURSEN J, 1992, NUCLEIC ACIDS RES, V20, P3815, DOI 10.1093/nar/20.15.3815; VANDEURSEN J, 1992, GENOMICS, V12, P340, DOI 10.1016/0888-7543(92)90383-4; VANDEURSEN J, 1991, NUCLEIC ACIDS RES, V19, P2637, DOI 10.1093/nar/19.10.2637; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WILES MV, 1991, DEVELOPMENT, V111, P259; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; ZHU X, MOL CELL BIOL, V15, P1136; ZHU XJ, 1994, MOL CELL BIOL, V14, P8051, DOI 10.1128/MCB.14.12.8051	79	1546	1584	0	45	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					321	330		10.1016/S0092-8674(00)80986-1	http://dx.doi.org/10.1016/S0092-8674(00)80986-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565077	Bronze			2022-12-24	WOS:A1996TR59500018
J	Langston, AA; Malone, KE; Thompson, JD; Daling, JR; Ostrander, EA				Langston, AA; Malone, KE; Thompson, JD; Daling, JR; Ostrander, EA			BRCA1 mutations in a population-based sample of young women with breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIAL BREAST; OVARIAN-CANCER; LINKAGE ANALYSIS	Background. Inherited mutations in the BRCA1 gene are associated with a high risk of breast and ovarian cancer in some families, However, little is known about the contribution of BRCA1 mutations to breast cancer in the general population, We analyzed DNA samples from women enrolled in a population-based study of early-onset breast cancer to assess the spectrum and frequency of germ-line BRCA1 mutations in young women with breast cancer. Methods. We studied 80 women in whom breast cancer was diagnosed before the age of 35, and who were not selected on the basis of family history. Genomic DNA was studied for BRCA1 mutations by analysis involving singlestrand conformation polymorphisms and with allele-specific assays, Alterations were defined by DNA sequencing. Results. Germ-line BRCA1 mutations were identified in 6 of the 80 women, Four additional rare sequence variants of unknown functional importance were also identified, Two of the mutations and three of the rare sequence variants were found among the 39 women who reported no family history of breast or ovarian cancer. None of the mutations and only one of the rare variants was identified in a reference population of 73 unrelated subjects. Conclusions. Alterations in BRCA1 were identified in approximately 10 percent of this cohort of young women with breast cancer, The risk of harboring a mutation was not limited to women with family histories of breast or ovarian cancer, These results represent a minimal estimate of the frequency of BRCA1 mutations in this population. Comprehensive methods of identifying BRCA1 mutations and understanding their importance will be needed before testing of women in the general population can be undertaken.	FRED HUTCHINSON CANC RES CTR, DIV CLIN RES, SEATTLE, WA 98104 USA; FRED HUTCHINSON CANC RES CTR, DIV PUBL HLTH SCI, SEATTLE, WA 98104 USA; UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle				Ostrander, Elaine/0000-0001-6075-9738	NCI NIH HHS [R01 CA63705, R01 CA41416, N01 CN 05230] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005230] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA041416, R01CA063705] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARASON A, 1993, AM J HUM GENET, V52, P711; BRINTON LA, 1983, BRIT J CANCER, V47, P757, DOI 10.1038/bjc.1983.128; BROWN MA, 1994, NATURE, V372, P733, DOI 10.1038/372733a0; BUELL P, 1973, J NATL CANCER I, V51, P1479, DOI 10.1093/jnci/51.5.1479; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLAUS EB, 1991, AM J HUM GENET, V48, P232; DALING JR, 1994, JNCI-J NATL CANCER I, V86, P1584, DOI 10.1093/jnci/86.21.1584; EASTON DF, 1993, AM J HUM GENET, V52, P678; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FRIEDMAN LS, 1995, THESIS U CALIFORNIA; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1991, LANCET, V338, P82; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PORTER DE, 1994, BRIT J SURG, V81, P1512, DOI 10.1002/bjs.1800811038; Sambrook J., 1989, MOL CLONING LAB MANU; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; TAKAHASHI H, 1995, CANCER RES, V55, P2998; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; 1995, CANCER FACTS FIGURES, P10	32	277	280	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 18	1996	334	3					137	142		10.1056/NEJM199601183340301	http://dx.doi.org/10.1056/NEJM199601183340301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ017	8531967				2022-12-24	WOS:A1996TQ01700001
J	Boismenu, R; Rhein, M; Fischer, WH; Havran, WL				Boismenu, R; Rhein, M; Fischer, WH; Havran, WL			A role for CD81 in early T cell development	SCIENCE			English	Article							RECEPTOR-BETA-CHAIN; TAPA-1; TCR; RESTORATION; CD3-EPSILON; ANTIBODY; PROTEINS; IMMATURE; SURFACE; THYMUS	Early stages of T cell development are thought to include a series of coordinated interactions between thymocytes and other cells of the thymus. A monoclonal antibody specific for mouse CD81 was identified that blocked the appearance of alpha beta but nor gamma delta T cells in fetal organ cultures initiated with day 14.5 thymus lobes. In reaggregation cultures with CD81-transfected fibroblasts, CD4(-)CD8(-) thymocytes differentiated into CD4(+)CD8(+) T cells, Thus, interactions between immature thymocytes and stromal cells expressing CD81 are required and may be sufficient to induce early events associated with T cell development.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, CLAYTON FDN LABS PEPTIDE BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Salk Institute					NIAID NIH HHS [AI32751] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032751, R29AI032751, R21AI032751] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON JP, 1982, J IMMUNOL, V129, P2293; Alschul S F, 1990, J Mol Biol, V215, P403; ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; ANDRIA ML, 1991, J IMMUNOL, V147, P1030; BOISMENU R, UNPUB; BOYD RL, 1993, IMMUNOL TODAY, V14, P445, DOI 10.1016/0167-5699(93)90248-J; DUDLEY EC, 1994, IMMUNITY, V1, P83, DOI 10.1016/1074-7613(94)90102-3; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; FISCHER WH, 1991, METHODS NEUROSCI, V6, P69; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; Jenkinson E J, 1990, Semin Immunol, V2, P51; JENKINSON EJ, 1994, CURR OPIN IMMUNOL, V6, P293, DOI 10.1016/0952-7915(94)90104-X; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KISLELOW P, 1995, ADV IMMUNOL, V58, P87; LEVELT CN, 1993, P NATL ACAD SCI USA, V90, P11401, DOI 10.1073/pnas.90.23.11401; LEVELT CN, 1993, J EXP MED, V177, P707, DOI 10.1084/jem.177.3.707; LEVY S, 1991, J BIOL CHEM, V266, P14597; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; RITTER MA, 1993, IMMUNOL TODAY, V14, P462, DOI 10.1016/0167-5699(93)90250-O; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; STEEDMAN HF, 1957, NATURE, V179, P1345, DOI 10.1038/1791345a0; WIEST DL, 1995, EMBO J, V14, P3425, DOI 10.1002/j.1460-2075.1995.tb07348.x; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4	26	92	94	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					198	200		10.1126/science.271.5246.198	http://dx.doi.org/10.1126/science.271.5246.198			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539618				2022-12-24	WOS:A1996TP36400040
J	Crossley, PH; Minowada, G; MacArthur, CA; Martin, GR				Crossley, PH; Minowada, G; MacArthur, CA; Martin, GR			Roles for FGF8 in the induction, initiation, and maintenance of chick limb development	CELL			English	Article							BUD; OUTGROWTH; GROWTH; EMBRYO; MOUSE	We provide evidence that FGF8 serves as an endogenous inducer of chick limb formation and that its expression in the intermediate mesoderm at the appropriate time and place to trigger forelimb development is directly linked to the mechanism of embryonic kidney differentiation. One function of the limb inducer is to initiate Fgf8 gene expression in the ectoderm overlying the prospective limb-forming territories. FGF8 secreted by the ectoderm then appears to initiate limb bud formation by promoting outgrowth of and Sonic hedgehog expression in the underlying lateral plate mesoderm. FGF8 also maintains mesoderm outgrowth and Sonic hedgehog expression in the established limb bud. Our data thus point to FGF8 as a key regulator of limb development that not only induces and initiates the formation of a limb bud, but also sustains its subsequent development.	UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110	University of California System; University of California San Francisco; Washington University (WUSTL)	Crossley, PH (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.							BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BURNS RK, 1955, ANAL DEV, P462; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; GEDUSPAN JS, 1992, DEV BIOL, V151, P212; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; Hinchliffe J. R., 1980, DEV VERTEBRATE LIMB; HORNBRUCH A, 1991, DEVELOPMENT, V111, P725; JOHNSON RL, 1994, CURR OPIN GENET DEV, V4, P535, DOI 10.1016/0959-437X(94)90069-F; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KIENY M, 1971, Annales d'Embryologie et de Morphogenese, V4, P281; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; MARTIN GR, 1995, NATURE, V374, P410, DOI 10.1038/374410a0; MUCHMORE WB, 1957, J EXP ZOOL, V134, P293, DOI 10.1002/jez.1401340205; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PINOT M, 1970, Journal of Embryology and Experimental Morphology, V23, P109; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SAUNDERS JW, 1974, DEV BIOL, V38, P41, DOI 10.1016/0012-1606(74)90257-7; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; SEARLS RL, 1971, DEV BIOL, V24, P198, DOI 10.1016/0012-1606(71)90095-9; STEPHENS TD, 1981, J EMBRYOL EXP MORPH, V61, P191; STRECKER TR, 1983, TERATOLOGY, V27, P159, DOI 10.1002/tera.1420270204; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; ZWILLING E, 1956, COLD SPRING HARB SYM, V21, P349, DOI 10.1101/SQB.1956.021.01.028	38	509	523	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					127	136		10.1016/S0092-8674(00)80999-X	http://dx.doi.org/10.1016/S0092-8674(00)80999-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548816	Bronze			2022-12-24	WOS:A1996TQ17000015
J	Walczak, CE; Mitchison, TJ; Desai, A				Walczak, CE; Mitchison, TJ; Desai, A			XKCM1: A Xenopus kinesin-related protein that regulates microtubule dynamics during mitotic spindle assembly	CELL			English	Article							CELL-FREE-EXTRACTS; EGG EXTRACTS; CYTOPLASMIC DYNEIN; TOPOISOMERASE-II; KINETOCHORES; INSTABILITY; ORGANIZATION; MICROSCOPY; ANAPHASE; MITOSIS	We isolated a cDNA clone encoding a kinesin-related protein, which we named XKCM1. Antibodies to XKCM1 stain mitotic centromeres and spindle poles. Immunodepletion and antibody addition experiments in an in vitro spindle assembly assay show that XKCM1 is required for both establishment and maintenance of mitotic spindles, The structures that form in the absence of XKCM1 contain abnormally long microtubules. This long microtubule defect can be rescued by the addition of purified XKCM1 protein. Analysis of microtubule dynamics in a clarified mitotic extract reveals that loss of XKCM1 function causes a 4-fold suppression in the catastrophe frequency, XKCM1 thus exhibits a novel activity for a kinesin-related protein by promoting microtubule depolymerization during mitotic spindle assembly.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Walczak, CE (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOLEC PHARMACOL,SAN FRANCISCO,CA 94143, USA.				NIGMS NIH HHS [GM39565-07] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039565, R37GM039565] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; BAJER AS, 1982, J CELL BIOL, V93, P33, DOI 10.1083/jcb.93.1.33; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; DESAI A, 1995, J CELL BIOL, V128, P1, DOI 10.1083/jcb.128.1.1; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOENGER A, 1995, NATURE, V376, P271, DOI 10.1038/376271a0; HOLY TE, 1994, P NATL ACAD SCI USA, V91, P5682, DOI 10.1073/pnas.91.12.5682; HYMAN AA, 1990, J CELL BIOL, V110, P1607, DOI 10.1083/jcb.110.5.1607; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; INOUE S, 1995, MOL BIOL CELL, P16319; KELLOGG DR, 1992, MOL BIOL CELL, V3, P1, DOI 10.1091/mbc.3.1.1; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; SALMON ED, 1984, J CELL BIOL, V99, P2165, DOI 10.1083/jcb.99.6.2165; Sambrook J., 1989, MOL CLONING LAB MANU; SAWIN KE, 1992, J CELL SCI, V101, P303; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; SMITH DB, 1988, MOL BIOCHEM PARASIT, V27, P249, DOI 10.1016/0166-6851(88)90044-8; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; VALE RD, 1991, CELL, V64, P827, DOI 10.1016/0092-8674(91)90511-V; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	44	447	469	2	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					37	47		10.1016/S0092-8674(00)80991-5	http://dx.doi.org/10.1016/S0092-8674(00)80991-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548824	Bronze			2022-12-24	WOS:A1996TQ17000007
J	Barton, K; Muthusamy, N; Chanyangam, M; Fischer, C; Clendenin, C; Leiden, JM				Barton, K; Muthusamy, N; Chanyangam, M; Fischer, C; Clendenin, C; Leiden, JM			Defective thymocyte proliferation and IL-2 production in transgenic mice expressing a dominant-negative form of CREB	NATURE			English	Article							CYCLIC-AMP; T-CELLS; TRANSCRIPTIONAL REGULATION; RESPONSE ELEMENT; NUCLEAR FACTOR; BINDING; PHOSPHORYLATION; PROTEIN; GENE; FOS	THE basic/leucine zipper (bZip) transcription factor, CREB, binds to the CRE element (TGANNTCA)(1-5). The transcriptional activity of CREB requires phosphorylation of the protein on a serine residue at position 119 (ref. 6). CREs are present in a number of T-cell genes(7,8) but the precise role of CREB in T-cell differentiation and function was unknown. Here we show that resting thymocytes contain predominantly unphosphorylated (inactive) CREB, which is rapidly activated by phosphorylation on Ser 119 following thymocyte activation. T-cell development is normal in transgenic mice that express a dominant-negative form of CREB (CREB(A119), with alanine at position 119) under the control of the T-cell-specific CD2 promoter/enhancer. In contrast, thymocytes and T cells from these animals display a profound proliferative defect characterized by markedly decreased interleukin-2 production, G1 cell-cycle arrest and subsequent apoptotic death in response to a number of different activation signals. This proliferative defect is associated with the markedly reduced induction of c-jun, c-fos, Fra-2 and FosB following activation of the CREB(A119), transgenic thymocytes. We propose that T-cell activation leads to the phosphorylation and activation of CREB, which in turn is required for normal induction of the transcription factor AP1 and subsequent interleukin-2 production and cell-cycle progression.	UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PATHOL, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago			Muthusamy, Natarajan/A-6915-2009					BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; CALAME K, 1988, ADV IMMUNOL, V43, P235; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; OTIR R, 1991, GENE EXPRESSION, V1, P55; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SMITH KA, 1992, CURR OPIN IMMUNOL, V4, P271, DOI 10.1016/0952-7915(92)90076-Q; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; VALLEJO MJ, 1994, NEUROENDOCRINOLOGY, V6, P587; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578	29	209	213	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 4	1996	379	6560					81	85		10.1038/379081a0	http://dx.doi.org/10.1038/379081a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538746				2022-12-24	WOS:A1996TN21600060
J	Takeuchi, Y; Porter, CD; Strahan, KM; Preece, AF; Gustafsson, K; Cosset, FL; Weiss, RA; Collins, MKL				Takeuchi, Y; Porter, CD; Strahan, KM; Preece, AF; Gustafsson, K; Cosset, FL; Weiss, RA; Collins, MKL			Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase	NATURE			English	Article							COMPLEMENT PATHWAY ACTIVATION; RNA TUMOR-VIRUSES; HUMAN-ANTIBODIES; LYSIS; INACTIVATION; ONCORNAVIRUSES; GLYCOPROTEINS; SPECIFICITY; RECEPTOR; ANTIGEN	MAMMALIAN C-type retroviruses are inactivated by human serum(1,2), following triggering of the classical complement cascade(3). This may have inhibited transmission to humans of C-type oncoviruses from other mammals(1). Indeed, the retroviruses human immunodeficiency virus and human T-cell leukaemia virus are resistant of human C1q, the first component of the classical pathway, by retroviral envelope proteins has been described(6). However, retroviruses produced from human cells are resistant to inactivation by human complement(7,8) and human serum is known to contain antibodies directed against carbohydrates on retroviral envelopes(9-11). Gal(alpha 1-3)Gal terminal carbohydrates are expressed by most mammals but are absent in humans, which lack a functional (alpha 1-3)galactosyltransferase gene (12,13). Here, we demonstrate that anti-Gal(alpha 1-3)Gal antibodies in human serum inactivate retroviruses produced from animal cells. Expression of porcine (alpha 1-3)galactosyltransferase(14,16) in human cells renders the cells and the retroviruses they produce sensitive to human serum.	UNIV LONDON,INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND	University of London; University College London	Takeuchi, Y (corresponding author), INST CANC RES,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND.		Cosset, François-Loïc/M-5862-2019	Cosset, François-Loïc/0000-0001-8842-3726				ALMEIDA IC, 1993, J CLIN LAB ANAL, V7, P307, DOI 10.1002/jcla.1860070603; BANAPOUR B, 1986, VIROLOGY, V152, P268, DOI 10.1016/0042-6822(86)90392-2; BARBACID M, 1979, P NATL ACAD SCI USA, V77, P1617; BARTHOLOMEW RM, 1978, J EXP MED, V147, P844, DOI 10.1084/jem.147.3.844; BATTINI JL, 1992, J VIROL, V66, P1468, DOI 10.1128/JVI.66.3.1468-1475.1992; COOPER NR, 1976, J EXP MED, V144, P970, DOI 10.1084/jem.144.4.970; COSSET FL, 1995, J VIROL, V69, P6314, DOI 10.1128/JVI.69.10.6314-6322.1995; COSSET FL, IN PRESS J VIROL; FABRE JW, 1995, NAT MED, V1, P403, DOI 10.1038/nm0595-403; GALILI U, 1993, BLOOD, V82, P2485, DOI 10.1182/blood.V82.8.2485.bloodjournal8282485; GALILI U, 1991, P NATL ACAD SCI USA, V88, P7401, DOI 10.1073/pnas.88.16.7401; GALILI U, 1988, INFECT IMMUN, V56, P1730, DOI 10.1128/IAI.56.7.1730-1737.1988; GUSTAFSSON K, 1994, IMMUNOL REV, V141, P59, DOI 10.1111/j.1600-065X.1994.tb00872.x; HAMADEH RM, 1992, J CLIN INVEST, V89, P1223, DOI 10.1172/JCI115706; HIRSCH RL, 1981, J IMMUNOL, V127, P1740; HOSHINO H, 1984, NATURE, V310, P324, DOI 10.1038/310324a0; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; LOWER J, 1981, VIROLOGY, V109, P409, DOI 10.1016/0042-6822(81)90511-0; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; MCKENZIE IF, 1968, LANCET, V2, P386; ORLOL R, 1993, TRANSPLANTATION, V56, P1433; REPIK PM, 1994, J GEN VIROL, V75, P1177, DOI 10.1099/0022-1317-75-5-1177; SANDRIN MS, 1994, IMMUNOL REV, V141, P169, DOI 10.1111/j.1600-065X.1994.tb00877.x; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; SNYDER HW, 1980, P NATL ACAD SCI-BIOL, V77, P1622, DOI 10.1073/pnas.77.3.1622; STRAHAN KM, 1995, IMMUNOGENETICS, V41, P101, DOI 10.1007/BF00182319; TAKEUCHI Y, 1994, J VIROL, V68, P8001, DOI 10.1128/JVI.68.12.8001-8007.1994; WELSH RM, 1976, VIROLOGY, V74, P432, DOI 10.1016/0042-6822(76)90349-4; WELSH RM, 1975, NATURE, V257, P612, DOI 10.1038/257612a0; WELSH RM, 1977, J IMMUNOL, V118, P348	30	237	244	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					85	88		10.1038/379085a0	http://dx.doi.org/10.1038/379085a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538747				2022-12-24	WOS:A1996TN21600061
J	Colwell, JA; Clark, CM				Colwell, JA; Clark, CM			Forum two: Unanswered research questions about metabolic control in non-insulin-dependent diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat				The participants of Forum Two addressed the unanswered research questions about metabolic control and noninsulin-dependent diabetes mellitus (NIDDM). The most compelling issue was the effect of metabolic control on both the development and progression of macrovascular disease in patients with NIDDM. Associated questions that could be answered by a well-controlled clinical trial related to the goal of blood glucose control in NIDDM in the elderly and in persons with clinical vascular disease. The specific suggestion was a trial similar to the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM. Another important research issue that was discussed was the benefit of treating other risk factors such as hypertension and hyperlipidemia in diabetic patients. Yet another area discussed was the study of health services delivery to-examine the best care-delivery methods for diabetes and other chronic diseases. Other areas of discussion centered on basic research, that is, the fundamental cause of insulin resistance and the genetics of NIDDM and the loss of protection against atherosclerosis in postmenopausal women with diabetes.	REGENSTRIEF INST HLTH CARE, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc	Colwell, JA (corresponding author), MED UNIV S CAROLINA, 171 ASHLEY AVE, CHARLESTON, SC 29401 USA.								0	14	14	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				178	179		10.7326/0003-4819-124-1_Part_2-199601011-00020	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00020			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554215				2022-12-24	WOS:A1996TL94400020
J	Jernigan, DB; Hofmann, J; Cetron, MS; Genese, CA; Nuorti, JP; Fields, BS; Benson, RF; Carter, RJ; Edelstein, PH; Guerrero, IC; Paul, SM; Lipman, HB; Breiman, RF				Jernigan, DB; Hofmann, J; Cetron, MS; Genese, CA; Nuorti, JP; Fields, BS; Benson, RF; Carter, RJ; Edelstein, PH; Guerrero, IC; Paul, SM; Lipman, HB; Breiman, RF			Outbreak of Legionnaires' disease among cruise ship passengers exposed to a contaminated whirlpool spa	LANCET			English	Article							LEGIONELLA-PNEUMOPHILA SEROGROUP-1; POLYMERASE CHAIN-REACTION; PONTIAC FEVER; PNEUMONIA	Background Outbreaks of travel-related Legionnaires' disease present a public-health challenge since rapid, sensitive, and specific diagnostic tests are not widely used and because detection of clusters of disease among travellers is difficult. We report an outbreak of Legionnaires' disease among cruise ship passengers that occurred in April, 1994, but that went unrecognised until July, 1994. Methods After rapid diagnosis of Legionnaires' disease in three passengers by urine antigen testing, we searched for additional cases of either confirmed (laboratory evidence of infection) or probable Legionnaires' disease (pneumonia of undetermined cause). A case-control study was conducted to compare exposures and activities on the ship and in ports of call between each case-passenger and two or three matched control-passengers. Water samples from the ship, from sites on Bermuda, and from the ship's water source in New York City were cultured for legionellae and examined with PCR. Findings 50 passengers with Legionnaires' disease (16 confirmed, 34 probable) were identified from nine cruises embarking between April 30 and July 9, 1994. Exposure to whirlpool spas was strongly associated with disease (odds ratio 16.2, 95% CI 2.8-351.7); risk of acquiring Legionnaires' disease increased by 64% (95% CI 12-140) for every hour spent in the spa water. Passengers spending time around the whirlpool spas, but not in the water, were also significantly more likely to have acquired infection. Legionella pneumophila serogroup 1 was isolated only from the sand filter in the ship's whirlpool spa. This isolate matched a clinical isolate from the respiratory secretions of a case-passenger as judged by monoclonal antibody subtyping and by arbitrarily primed PCR. Interpretation This investigation shows the benefit of obtaining a recent travel history, the usefulness or urine antigen testing for rapid diagnosis of legionella infection, and the need for improved surveillance for travel-related Legionnaires' disease. New strategies for whirlpool spa maintenance and decontamination may help to minimise transmission of legionellae from these aerosol-producing devices.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,BIOSTAT & INFORMAT MANAGEMENT BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,DIV FIELD EPIDEMIOL,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30333; NEW JERSEY STATE DEPT HLTH,DIV EPIDEMIOL,TRENTON,NJ; HOSP UNIV PENN,PHILADELPHIA,PA 19104; TOMS RIVER COMMUNITY MED CTR,TOMS RIVER,NJ	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; New Jersey Department of Health & Senior Services; University of Pennsylvania; Pennsylvania Medicine	Jernigan, DB (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,CHILDHOOD & RESP DIS BRANCH,MS CO9,1600 CLIFTON RD,ATLANTA,GA 30333, USA.		Paul, Steve/ABE-5400-2020; Edelstein, Paul/I-5527-2019	Edelstein, Paul/0000-0002-4069-5279				AGUEROROSENFELD ME, 1988, J CLIN MICROBIOL, V26, P1775, DOI 10.1128/JCM.26.9.1775-1778.1988; BARON PA, 1986, ENVIRON RES, V39, P8, DOI 10.1016/S0013-9351(86)80003-2; EDELSTEIN PH, 1985, MANUAL CLIN MICROBIO, P373; EDELSTEIN PH, 1992, MANUAL CLIN LAB IMMU, P459; GOLDBERG DJ, 1989, LANCET, V1, P316; GOMEZLUS P, 1993, J CLIN MICROBIOL, V31, P1940, DOI 10.1128/JCM.31.7.1940-1942.1993; GRIST NR, 1979, ANN INTERN MED, V90, P563, DOI 10.7326/0003-4819-90-4-563; HOGE CW, 1991, EPIDEMIOL REV, V13, P329, DOI 10.1093/oxfordjournals.epirev.a036076; JOLY JR, 1986, J CLIN MICROBIOL, V23, P768, DOI 10.1128/JCM.23.4.768-771.1986; Joseph C A, 1994, Commun Dis Rep CDR Rev, V4, pR109; Joseph C A, 1993, Commun Dis Rep CDR Rev, V3, pR124; KALLINGS I, 1991, TRAVEL MED, V2, P228; KAUFMANN AF, 1981, AM J EPIDEMIOL, V114, P337, DOI 10.1093/oxfordjournals.aje.a113200; KOHLER RB, 1986, DIAGN MICR INFEC DIS, V4, pS47, DOI 10.1016/S0732-8893(86)80042-6; MANGIONE EJ, 1985, JAMA-J AM MED ASSOC, V253, P535; MARSTON BJ, 1994, ARCH INTERN MED, V154, P2417, DOI 10.1001/archinte.154.21.2417; MILLER LA, 1993, J INFECT DIS, V168, P769, DOI 10.1093/infdis/168.3.769; PLOUFFE JF, 1995, CLIN INFECT DIS, V20, P1286, DOI 10.1093/clinids/20.5.1286; REINGOLD AL, 1984, J INFECT DIS, V149, P819, DOI 10.1093/infdis/149.5.819; SANDEN GN, 1993, J CLIN MICROBIOL, V31, P170, DOI 10.1128/JCM.31.1.170-172.1993; SPITALNY KC, 1984, AM J EPIDEMIOL, V120, P809, DOI 10.1093/oxfordjournals.aje.a113953; THOMAS DL, 1993, ARCH INTERN MED, V153, P2597, DOI 10.1001/archinte.153.22.2597; VOGT RL, 1987, ANN INTERN MED, V107, P596, DOI 10.7326/0003-4819-107-4-596_1; 1994, CRUISE IND OVERVIEW; 1985, US DEP HLTH HUMAN SE; 1994, COMMUNICAB DIS REP, V4, P25; 1989, US DEP HLTH HUMAN SE, P12; 1991, COMMUNICAB DIS REP, V1, P157; 1994, MMWR-MORBID MORTAL W, V43, P521; 1992, PROCEDURES RECOVERY	30	134	143	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					494	499		10.1016/S0140-6736(96)91137-X	http://dx.doi.org/10.1016/S0140-6736(96)91137-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596266	hybrid			2022-12-24	WOS:A1996TW69700008
J	Frenette, PS; Mayadas, TN; Rayburn, H; Hynes, RO; Wagner, DD				Frenette, PS; Mayadas, TN; Rayburn, H; Hynes, RO; Wagner, DD			Susceptibility to infection and altered hematopoiesis in mice deficient in both P- and E-selectins	CELL			English	Article							LEUKOCYTE ADHESION DEFICIENCY; MOUSE; EXPRESSION; MOLECULE-1; CLONING; INVIVO; RATS	We describe the phenotype of mice lacking both endothelial selectins after sequential ablation of the genes encoding P- and E-selectins. In contrast with the rather mild phenotypes observed in mice deficient in a single selectin gene, the doubly deficient mice present extreme leukocytosis, elevated cytokine levels, and alterations in hematopoiesis. Granulocytopoiesis is increased both in bone marrow and spleen, while erythropoiesis is partially translocated to the spleen. Virtual lack of leukocyte rolling and low extravasation at sites of inflammation make these animals susceptible to opportunistic bacterial infections, to which they succumb. Our results show that the absence of endothelial selectins severely affects leukocyte homeostasis and indicate that these two selectins are as important for normal leukocyte function as are the leukocyte beta 2 integrins.	HARVARD UNIV,SCH MED,CTR BLOOD RES,DEPT PATHOL,BOSTON,MA 02115; MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard Medical School			Frenette, Paul S/J-8272-2012	Frenette, Paul S/0000-0003-0862-9922	NHLBI NIH HHS [P01 HL41484, HL53756, HL41002] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL041002, R01HL053756, R01HL041002, P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; ASA D, 1995, J BIOL CHEM, V270, P11662, DOI 10.1074/jbc.270.19.11662; BAKER M, 1974, MICROVASC RES, V7, P131, DOI 10.1016/0026-2862(74)90043-0; BARTOCCI A, 1987, P NATL ACAD SCI USA, V84, P6179, DOI 10.1073/pnas.84.17.6179; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FRIES JWU, 1993, AM J PATHOL, V143, P725; FRYDMAN M, 1992, AM J MED GENET, V44, P297, DOI 10.1002/ajmg.1320440307; JOHNSON RC, 1995, BLOOD, V86, P1106; LABOW MA, 1994, IMMUNITY, V1, P709, DOI 10.1016/1074-7613(94)90041-8; LEY K, 1991, BLOOD, V77, P2553; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MOLINEUX G, 1990, BLOOD, V75, P563; ODELL TT, 1979, P SOC EXP BIOL MED, V160, P263; OLOFSSON AM, 1994, BLOOD, V84, P2749, DOI 10.1182/blood.V84.8.2749.bloodjournal8482749; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; SANDERS WE, 1992, BLOOD, V80, P795; SAWAI S, 1991, NEW BIOL, V3, P861; SCHOOLEY JC, 1972, BLOOD-J HEMATOL, V40, P662, DOI 10.1182/blood.V40.5.662.662; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; WELLER A, 1992, J BIOL CHEM, V267, P15176; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; WILSON RW, 1993, J IMMUNOL, V151, P1571; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95; YAMADA S, 1995, BLOOD, V86, P3487, DOI 10.1182/blood.V86.9.3487.bloodjournal8693487; ZANNETTINO ACW, 1995, BLOOD, V85, P3466, DOI 10.1182/blood.V85.12.3466.bloodjournal85123466	32	450	459	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					563	574		10.1016/S0092-8674(00)81032-6	http://dx.doi.org/10.1016/S0092-8674(00)81032-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598043	Bronze			2022-12-24	WOS:A1996TX17600009
J	HolgadoMadruga, M; Emlet, DR; Moscatello, DK; Godwin, AK; Wong, AJ				HolgadoMadruga, M; Emlet, DR; Moscatello, DK; Godwin, AK; Wong, AJ			A Grb2-associated docking protein in EGF- and insulin-receptor signalling	NATURE			English	Article							SUBSTRATE-1; DOMAIN; IRS-1; SH2; GRB2	THE protein Grb2 plays a central role in signalling by receptor protein-tyrosine kinases(1,2), where its SH2 domain binds to the receptor and its two SH3 domains link to effecters. One target effector is Sos, so Grb2 links receptor protein-tyrosine kinases with the Ras signalling pathway. The SH3 domains can also couple to other signalling proteins, including Vav(3), c-AbI(4) and dynamin(5), We have identified several bands in glial and medulloblastoma tumours that are recognized by Grb2 but these did not correspond to any known protein. Here we use recombinant Grb2 to isolate a complementary DNA called Gab1 (for Grb2-associated binder-1). Gab1 shares amino-acid homology and several structural features with IRS-1 (insulin-receptor substrate-1; refs 6,7), is a substate of the EGF and insulin receptors, and can act as a docking protein for several SH2-containing proteins, Overexpression of Gab1 enhances cell growth and results in transformation. We conclude that Gab1 is a new protein in EGF and insulin receptor signalling which could integrate signals from different systems.	JEFFERSON CANC INST, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19107 USA; JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA; FOX CHASE CANC CTR, DEPT MED ONCOL, PHILADELPHIA, PA 19111 USA	Jefferson University; Jefferson University; Fox Chase Cancer Center								ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; CHEN DI, 1995, MOL CELL BIOL, V15, P4711; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; LAMPHERE L, 1994, AM J PHYSIOL, V266, pE486, DOI 10.1152/ajpendo.1994.266.3.E486; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RON D, 1992, BIOTECHNIQUES, V13, P866; SCHLAEPFER DD, 1994, NATURE, V372, P786; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	30	581	589	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 8	1996	379	6565					560	564		10.1038/379560a0	http://dx.doi.org/10.1038/379560a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596638				2022-12-24	WOS:A1996TU69300056
J	Amano, M; Mukai, H; Ono, Y; Chihara, K; Matsui, T; Hamajima, Y; Okawa, K; Iwamatsu, A; Kaibuchi, K				Amano, M; Mukai, H; Ono, Y; Chihara, K; Matsui, T; Hamajima, Y; Okawa, K; Iwamatsu, A; Kaibuchi, K			Identification of a putative target for Rho as the serine-threonine kinase protein kinase N	SCIENCE			English	Article							GTP-BINDING-PROTEIN; ADP-RIBOSYLATION; MOLECULAR-WEIGHT	Rho, a Ras-like small guanosine triphosphatase, has been implicated in cytoskeletal responses to extracellular signals such as lysophosphatidic acid (LPA) to form stress fibers and focal contacts. The form of RhoA bound to guanosine triphosphate directly bound to and activated a serine-threonine kinase, protein kinase N (PKN). Activated RhoA formed a complex with PKN and activated it in COS-7 cells. PKN was phosphorylated in Swiss 3T3 cells stimulated with LPA, and this phosphorylation was blocked by treatment of cells with botulinum C3 exoenzyme. Activation of Rho may be linked directly to a serine-threonine kinase pathway.	NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,IKOMA 63001,JAPAN; KOBE UNIV,FAC SCI,DEPT BIOL,KOBE 657,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,YOKOHAMA,KANAGAWA 236,JAPAN	Nara Institute of Science & Technology; Kobe University; Kirin Brewery Company Limited			Amano, Mutsuki/M-4820-2014	Amano, Mutsuki/0000-0002-0662-1524; Mukai, Hideyuki/0000-0002-0167-8695				AMANO M, UNPUB; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KITAGAWA M, 1995, BIOCHEM J, V310, P657, DOI 10.1042/bj3100657; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; TAKAISHI K, 1994, ONCOGENE, V9, P273; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3	20	387	407	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					648	650		10.1126/science.271.5249.648	http://dx.doi.org/10.1126/science.271.5249.648			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571127				2022-12-24	WOS:A1996TT87000046
J	Brandner, S; Isenmann, S; Raeber, A; Fischer, M; Sailer, A; Kobayashi, Y; Marino, S; Weissmann, C; Aguzzi, A				Brandner, S; Isenmann, S; Raeber, A; Fischer, M; Sailer, A; Kobayashi, Y; Marino, S; Weissmann, C; Aguzzi, A			Normal host prion protein necessary for scrapie-induced neurotoxicity	NATURE			English	Article							CELL-SURFACE; PRP	ACCUMULATION of the prion protein PrPSc, a pathological and protease-resistant isoform of the normal host protein PrPC, is a feature of prion disease such as scrapie(1,2). It is still unknown whether scrapie pathology comes about by neurotoxicity of PrPSc, acute depletion of PrPC, or some other mechanism. Here we investigate this question by grafting neural tissue overexpressing PrPC into the brain of PrP-deficient mice which are scrapie-resistant and do not propagate infectivity(3-5). After intracerebral inoculation with scrapie prions, the grafts accumulated high levels of PrPSc and infectivity and developed the severe histopathological changes characteristic of scrapie. Moreover, substantial amounts of graft-derived PrPSc migrated into the host brain. Even 16 months after inoculation no pathological changes were seen in PrP-deficient tissue, not even in the immediate vicinity of the grafts. Therefore, in addition to being resistant to scrapie infection, brain tissue devoid of PrPC is not damaged by exogenous PrPSc.	UNIV ZURICH HOSP,DEPT PATHOL,INST NEUROPATHOL,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH,INST MOLEC BIOL,DEPT 1,ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital; University of Zurich			Aguzzi, Adriano/A-3351-2008; Brandner, Sebastian/J-4562-2014; Isenmann, Stefan/AAJ-3788-2020; Sailer, Andreas/M-9913-2016	Brandner, Sebastian/0000-0002-9821-0342; Marino, Silvia/0000-0002-9612-2883; Aguzzi, Adriano/0000-0002-0344-6708; Sailer, Andreas/0000-0002-9015-7946				BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; COLLINGE J, 1995, LANCET, V346, P569, DOI 10.1016/S0140-6736(95)91405-6; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; FARQUHAR CF, 1989, J VIROL METHODS, V24, P215, DOI 10.1016/0166-0934(89)90023-2; FISCHER M, IN PRESS EMBO J; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; HAYWARD PAR, 1994, NEUROPATH APPL NEURO, V20, P375, DOI 10.1111/j.1365-2990.1994.tb00983.x; ISENMANN S, IN PRESS NEUROPATHOL; JEFFREY M, 1994, BRAIN RES, V656, P329, DOI 10.1016/0006-8993(94)91477-X; JEFFREY M, 1994, NEUROSCI LETT, V174, P39, DOI 10.1016/0304-3940(94)90113-9; MANSON JC, 1994, NEURODEGENERATION, V3, P331; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; PRUISINER SBA, 1994, REV MICROBIOL, V48, P655; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; REED L. J., 1938, AMER JOUR HYG, V27, P493; SAILER A, 1994, CELL, V77, P967, DOI 10.1016/0092-8674(94)90436-7; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; Weissmann Charles, 1994, Trends in Cell Biology, V4, P10, DOI 10.1016/0962-8924(94)90032-9	23	641	659	0	40	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					339	343		10.1038/379339a0	http://dx.doi.org/10.1038/379339a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552188				2022-12-24	WOS:A1996TR32300057
J	Norris, MD; Bordow, SB; Marshall, GM; Haber, PS; Cohn, SL; Haber, M				Norris, MD; Bordow, SB; Marshall, GM; Haber, PS; Cohn, SL; Haber, M			Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PEDIATRIC-ONCOLOGY-GROUP; N-MYC ONCOGENE; POLYMERASE CHAIN-REACTION; NEURO-BLASTOMA; MDR1; AMPLIFICATION; TUMORS; CHILDHOOD; CANCER; CELLS	Background. Overexpression of the gene for the multidrug-resistance-associated protein (MRP) has been linked with resistance to chemotherapeutic agents (multidrug resistance) in vitro. The expression of MRP by neuroblastoma cells correlates with N-myc oncogene amplification, a well-established prognostic indicator in patients with neuroblastoma. Methods. To relate MRP gene expression to established prognostic markers and the clinical outcome of neuroblastoma, we analyzed MRP expression in specimens of primary tumors from 60 patients with neuroblastoma. Results. Levels of MRP gene expression were significantly higher in tumors with N-myc amplification than in tumors without such amplification (P<0.001). High levels of MRP expression were strongly associated with reductions in both survival and event-free survival (P<0.001) in the overall study population and in subgroups of patients without N-myc amplification and patients with localized disease. For the overall study population, the five-year cumulative survival rates in the groups with high and low levels of MRP expression were 57 percent (95 percent confidence interval, 37 to 78 percent) and 94 percent (95 percent confidence interval, 86 to 100 percent), respectively. In contrast, expression of the MDR1 multidrug-resistance gene was not predictive of survival or event-free survival. After adjustment by multivariate analysis for the effects of N-myc amplification and other prognostic indicators, high levels of MRP expression retained significant prognostic value for poor survival (relative hazard, 14.9; P=0.01) and poor event-free survival (relative hazard, 9.7; P=0.004), whereas N-myc amplification had no prognostic value. Conclusions. High levels of MRP gene expression in patients with neuroblastoma correlate strongly with poor outcome. The findings suggest that expression of this multidrug-resistance gene accounts for the association between N-myc amplification and reduced survival. (C) 1996, Massachusetts Medical Society.	UNIV NEW S WALES,CHILDRENS LEUKAEMIA & CANC RES CTR,SYDNEY,NSW,AUSTRALIA; PRINCE WALES CHILDRENS HOSP,DEPT GASTROENTEROL,SYDNEY,NSW,AUSTRALIA; NORTHWESTERN UNIV,SCH MED,DEPT PEDIAT,CHICAGO,IL 60611; CHILDRENS MEM HOSP,CHICAGO,IL 60614	University of New South Wales Sydney; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago			Cohn, Susan/AAB-6010-2021	Haber, Michelle/0000-0003-2036-8817; Cohn, Susan/0000-0001-5749-7650; Norris, Murray/0000-0002-0632-4589				Benard J, 1994, Prog Clin Biol Res, V385, P111; BERNARD JL, 1987, J CLIN ONCOL, V5, P1952, DOI 10.1200/JCO.1987.5.12.1952; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BORDOW SB, 1994, CANCER RES, V54, P5036; BOURHIS J, 1989, J NATL CANCER I, V81, P1401, DOI 10.1093/jnci/81.18.1401; BOWMAN LC, 1990, MED PEDIATR ONCOL, V18, P364; BRODEUR GM, 1992, CANCER-AM CANCER SOC, V70, P1685, DOI 10.1002/1097-0142(19920915)70:4+<1685::AID-CNCR2820701607>3.0.CO;2-H; BRODEUR GM, 1988, J CLIN ONCOL, V6, P1874, DOI 10.1200/JCO.1988.6.12.1874; Brodeur GM, 1993, PRINCIPLES PRACTICE, P739; CASTLEBERRY RP, 1991, J CLIN ONCOL, V9, P789, DOI 10.1200/JCO.1991.9.5.789; CASTLEBERRY RP, 1994, J CLIN ONCOL, V12, P1616, DOI 10.1200/JCO.1994.12.8.1616; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIANSEN H, 1995, EUR J CANCER, V31A, P541, DOI 10.1016/0959-8049(95)00030-M; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; CORRIAS MV, 1990, ANTICANCER RES, V10, P897; CRIST WM, 1991, NEW ENGL J MED, V324, P461, DOI 10.1056/NEJM199102143240706; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FAVROT M, 1991, BRIT J CANCER, V64, P233, DOI 10.1038/bjc.1991.282; GEKELER V, 1995, BIOCHEM BIOPH RES CO, V206, P119, DOI 10.1006/bbrc.1995.1017; GEKELER V, 1995, BIOCHEM BIOPH RES CO, V208, P345, DOI 10.1006/bbrc.1995.1344; GILBERT J, 1993, MOL CELL PROBE, V7, P227, DOI 10.1006/mcpr.1993.1033; GOLDSTEIN LJ, 1990, J CLIN ONCOL, V8, P128, DOI 10.1200/JCO.1990.8.1.128; GRANT CE, 1994, CANCER RES, V54, P357; Haber M, 1994, Prog Clin Biol Res, V385, P245; HOLZMAYER TA, 1992, J NATL CANCER I, V84, P1486, DOI 10.1093/jnci/84.19.1486; ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; JOSHI VV, 1993, CANCER-AM CANCER SOC, V71, P3173, DOI 10.1002/1097-0142(19930515)71:10<3173::AID-CNCR2820711045>3.0.CO;2-P; KRUH GD, 1994, CANCER RES, V54, P1649; LEIER I, 1994, J BIOL CHEM, V269, P27807; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; MARSHALL GM, 1995, ONCOGENE, V11, P485; MCCOWAGE GB, 1995, J CLIN ONCOL, V13, P2789, DOI 10.1200/JCO.1995.13.11.2789; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; NAKAGAWARA A, 1990, CANCER RES, V50, P3043; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NITSCHKE R, 1991, J CLIN ONCOL, V9, P1181, DOI 10.1200/JCO.1991.9.7.1181; NITSCHKE R, 1988, J CLIN ONCOL, V6, P1271, DOI 10.1200/JCO.1988.6.8.1271; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SCHWAB M, 1992, BIOCHIM BIOPHYS ACTA, V1114, P43, DOI 10.1016/0304-419X(92)90005-J; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SLOVAK ML, 1993, CANCER RES, V53, P3221; STROTHER D, 1995, J PEDIAT HEMATOL ONC, V17, P254, DOI 10.1097/00043426-199508000-00007; TELFORD DJ, 1992, J PAEDIATR CHILD H, V28, P58, DOI 10.1111/j.1440-1754.1992.tb02619.x; TEW KD, 1994, CANCER RES, V54, P4313; VERSANTVOORT CHM, 1994, BIOCHEM PHARMACOL, V48, P1129, DOI 10.1016/0006-2952(94)90149-X; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; ZHU QC, 1994, CANCER RES, V54, P4488	51	271	281	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	1996	334	4					231	238		10.1056/NEJM199601253340405	http://dx.doi.org/10.1056/NEJM199601253340405			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ755	8532000				2022-12-24	WOS:A1996TQ75500005
J	Coast, J; Inglis, A; Frankel, S				Coast, J; Inglis, A; Frankel, S			Alternatives to hospital care: What are they and who should decide?	BRITISH MEDICAL JOURNAL			English	Article							BEDS	Objective-To examine potential for alternatives to care in hospitals for acute admissions, and to compare the decisions about these alternatives made by clinicians with different backgrounds. Design-Standardised tool was used to identify patients who could potentially be treated in an alternative form of care. Information about such patients was assessed by three panels of clinicians: general practitioners without experience of general practitioner beds, general practitioners with experience of general practitioner beds, and consultants. Setting-One hospital for acute admissions in a rural area of the South and West region of England. Subjects-Of 620 patients admitted to specialties of general medicine and care of the elderly, details of 112 were assessed by panels. Main outcome measures-Proportion of hospitalised patients who could have received alternative care and identification of most appropriate alternative form of care. Results-Both general practitioner panels estimated that between 51 and 89 of the hospitalised patients could have received alternative care (equivalent to 8-14% of all admissions). Consultants estimated that between 25 and 55 patients could have had alternative care (5.5-9% of all admissions). General practitioner bed and urgent outpatient appointment were the main alternatives chosen by all three panels. Conclusion-About 10% of admissions to general hospital might be suitable for alternative forms of care. Doctors with different backgrounds made similar overall assessments of most appropriate forms of care.			Coast, J (corresponding author), UNIV BRISTOL,DEPT MED SOCIOL,BRISTOL BS8 2PR,AVON,ENGLAND.			Coast, Joanna/0000-0002-3537-5166				ANDERSON P, 1988, BRIT MED J, V297, P910, DOI 10.1136/bmj.297.6653.910; BEECH R, 1987, BRIT MED J, V294, P685, DOI 10.1136/bmj.294.6573.685; Cox DR, 1958, PLANNING EXPT; HOBBS R, 1995, BRIT MED J, V310, P207, DOI 10.1136/bmj.310.6974.207; INGLIS AL, 1995, MED CARE, V33, P952, DOI 10.1097/00005650-199509000-00006; JACOBS CM, 1992, ISD A REV SYSTEM ADU; LAURANCE J, 1993, TIMES           0111, P7; STRUMWASSER I, 1990, MED CARE, V28, P95, DOI 10.1097/00005650-199002000-00001; Torrance N, 1972, J R Coll Gen Pract, V22, P211; Victor C, 1993, Health Trends, V25, P94; VICTOR CR, 1994, J PUBLIC HEALTH MED, V16, P286; 1992, INDEPENDENT     0330, P9	12	41	41	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					162	166						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TR325	8563538				2022-12-24	WOS:A1996TR32500026
J	Gough, A; Chapman, S; Wagstaff, K; Emery, P; Elias, E				Gough, A; Chapman, S; Wagstaff, K; Emery, P; Elias, E			Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome	BRITISH MEDICAL JOURNAL			English	Article							FAILURE; ACNE	Monocycline is the most widely prescribed systemic antibiotic for acne largely because it needs to be given only once or twice a day and seems not to induce resistance. Up to April 1994 11 cases of minocycline induced systemic erythematosus and cases of hepatitis been reported to Committee on Safety of Medicines. An analysis of these cases together with seven other cases shows the severity of some of these reactions. Two patients died while taking the drug for acne and a further patient needed a liver transplant. Acne itself can induce arthritis and is often seen in association with autoimmine liver disease, but the clinical and biochemical resolution seen after withdrawal of the drug, despite deterioration of the acne, suggests a drug reaction. In five cases re-exposure led to recurrence. Because reactions may be severe early recognition is important to aid recovery and also to avoid invasive investigations and treatments such as corticosteroids and immunosuppresants. Safer alternatives should be considered for treating acne.	UNIV LEEDS,RHEUMATOL & REHABIL RES UNIT,LEEDS LS2 9NZ,W YORKSHIRE,ENGLAND; HARROGATE DIST HOSP,DEPT RHEUMATOL,HARROGATE HG2 7SX,W YORKSHIRE,ENGLAND; UNIV KEELE,DEPT PHARM POLICY & PRACTICE,KEELE ST5 5BG,STAFFS,ENGLAND; SELLY OAK HOSP,DRUG INFORMAT UNIT,BIRMINGHAM B29 6JD,W MIDLANDS,ENGLAND; QUEEN ELIZABETH HOSP,LIVER UNIT,DEPT HEPATOBILIARY MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Leeds; Keele University; University of Birmingham			emery, paul/B-3560-2013					BOCKER R, 1991, ANTIMICROB AGENTS CH, V35, P1434, DOI 10.1128/AAC.35.7.1434; BOUDREAUX JP, 1993, TRANSPLANT P, V25, P1873; BURETTE A, 1984, ARCH INTERN MED, V144, P1491, DOI 10.1001/archinte.144.7.1491; BYRNE PAC, 1994, BRIT J RHEUMATOL, V33, P674; DAVIES MG, 1989, BRIT MED J, V298, P1523, DOI 10.1136/bmj.298.6686.1523-c; DOLLERY C, 1991, THERAPEUTIC DRUGS; DOMZ CA, 1959, ANN INTERN MED, V50, P1217, DOI 10.7326/0003-4819-50-5-1217; EADY EA, 1993, BRIT MED J, V306, P555, DOI 10.1136/bmj.306.6877.555; GORARD DA, 1990, POSTGRAD MED J, V66, P404, DOI 10.1136/pgmj.66.775.404; HEALY E, 1994, BRIT MED J, V308, P831, DOI 10.1136/bmj.308.6932.831; JOHNSON PJ, 1993, HEPATOLOGY, V18, P998, DOI 10.1002/hep.1840180435; KNITZER RH, 1991, SEMIN ARTHRITIS RHEU, V20, P247, DOI 10.1016/0049-0172(91)90020-Z; MACDONALD H, 1973, CLIN PHARMACOL THER, V14, P852; MATSUURA T, 1992, LANCET, V340, P1553, DOI 10.1016/0140-6736(92)92810-3; MIN DI, 1992, PHARMACOTHERAPY, V12, P68; NELIS HJCF, 1981, LANCET, V2, P938; OTERO M, 1983, JAMA-J AM MED ASSOC, V250, P2602, DOI 10.1001/jama.1983.03340190016010; PETERS RL, 1967, AM J SURG, V113, P622, DOI 10.1016/0002-9610(67)90308-X; PUYANA J, 1990, ALLERGY, V45, P313, DOI 10.1111/j.1398-9995.1990.tb00502.x; ROBINSON MJ, 1970, AM J DIG DIS, V15, P857, DOI 10.1007/BF02236049; RUTENBURG AM, 1952, NEW ENGL J MED, V247, P797, DOI 10.1056/NEJM195211202472104; SCHULTZ JC, 1963, NEW ENGL J MED, V269, P999, DOI 10.1056/NEJM196311072691903; SOLDINGER AM, 1988, RHEUM CLIN N AM, V14, P187	23	235	235	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					169	172						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR325	8563540				2022-12-24	WOS:A1996TR32500028
J	Reichman, LB				Reichman, LB			How to ensure the continued resurgence of tuberculosis	LANCET			English	Editorial Material							NEW-YORK-CITY		UNIV MED & DENT NEW JERSEY,NATL TB CTR,DEPT PREVENT MED & COMMUNITY HLTH,NEWARK,NJ 07107	Rutgers State University New Brunswick; Rutgers State University Medical Center	Reichman, LB (corresponding author), UNIV MED & DENT NEW JERSEY,NATL TB CTR,DEPT MED,GB1,65 BERGEN ST,NEWARK,NJ 07107, USA.							BINYA T, 1992, CHINESE J ANTIBIOTIC, V7, P313; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; Comstock GW, 1993, TUBERCULOSIS COMPREH, P23; DRIVER CR, 1994, JAMA-J AM MED ASSOC, V272, P1031, DOI 10.1001/jama.272.13.1031; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P299; HORTON R, 1995, LANCET, V346, P790, DOI 10.1016/S0140-6736(95)91616-4; MOULDING T, 1995, ANN INTERN MED, V122, P951, DOI 10.7326/0003-4819-122-12-199506150-00010; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; REICHMAN LB, 1991, AM REV RESPIR DIS, V144, P741, DOI 10.1164/ajrccm/144.4.741; RIDZON R, 1995, AM J RESP CRIT CARE, V151, pA665; STARKE JR, 1992, J PEDIATR-US, V120, P839, DOI 10.1016/S0022-3476(05)81949-3; WARING JJ, 1956, JAMA-J AM MED ASSOC, V161, P1368, DOI 10.1001/jama.1956.02970140024007; 1995, MMWR-MORBID MORTAL W, V44, P387; 1993, OTR H574 US C OFF TE, P91; 1961, DHEW PHS ML784 PUBL; 1995, MMWR-MORBID MORTAL W, V44, P835; 1995, WHO TUBERCULOSIS PRO; 1995, GAOHEHS9511 US GEN A; 1993, WORLD HEALTH FORUM, V14, P438	21	33	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 20	1996	347	8995					175	177		10.1016/S0140-6736(96)90348-7	http://dx.doi.org/10.1016/S0140-6736(96)90348-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544556				2022-12-24	WOS:A1996TQ24400017
J	Volberding, PA				Volberding, PA			HIV quantification: Clinical applications	LANCET			English	Editorial Material							POLYMERASE CHAIN-REACTION				Volberding, PA (corresponding author), SAN FRANCISCO GEN HOSP,AIDS PROGRAM,SAN FRANCISCO,CA 94110, USA.							BAGNARELLI P, 1991, J MED VIROL, V34, P89, DOI 10.1002/jmv.1890340204; CAO YZ, 1995, AIDS RES HUM RETROV, V11, P353, DOI 10.1089/aid.1995.11.353; ERON J, 1995, 2ND NAT C HUM RETR R; HAVLIR D, 1995, J INFECT DIS, V172, P1379, DOI 10.1093/infdis/172.5.1379; HAVLIR D, 1995, J INFECT DIS, V171, P537, DOI 10.1093/infdis/171.3.537; HOLODNIY M, 1991, J CLIN INVEST, V88, P1755, DOI 10.1172/JCI115494; JURRIAANS S, 1995, AIDS RES HUM RETROV, V11, P473, DOI 10.1089/aid.1995.11.473; LIN HJ, 1994, J INFECT DIS, V170, P553, DOI 10.1093/infdis/170.3.553; LOVEDAY C, 1995, LANCET, V345, P790, DOI 10.1016/S0140-6736(95)90668-1; MELLORS JW, 1995, ANN INTERN MED, V122, P537; OBRIEN W, 1995, 10TH P INT C AIDS IN; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; PAXTON W, 1995, 2ND NAT C HUM RETR R; REVETS H, 1995, FEB P MOL APPR LAB D; VERHOFSTEDE C, 1994, AIDS, V8, P1421, DOI 10.1097/00002030-199410000-00008; YERLY S, 1995, AIDS, V9, P159, DOI 10.1097/00002030-199509020-00007	16	34	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					71	73		10.1016/S0140-6736(96)90205-6	http://dx.doi.org/10.1016/S0140-6736(96)90205-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538341				2022-12-24	WOS:A1996TP28100004
J	Stratmann, R; Lehner, CF				Stratmann, R; Lehner, CF			Separation of sister chromatids in mitosis requires the Drosophila pimples product, a protein degraded after the metaphase anaphase transition	CELL			English	Article							DNA TOPOISOMERASE-II; CYCLIN-A; MELANOGASTER; CHROMOSOME; GENE; MUTATIONS; SEQUENCE; EMBRYOS; PROGRESSION; SEGREGATION	Mutations in the Drosophila genes pimples and three rows result in a defect of sister chromatid separation during mitosis. As a consequence, cytokinesis is also defective. However, cell cycle progression including the mitotic degradation of cyclins A and B is not blocked by the failure of sister chromatid separation, and as a result, metaphase chromosomes with twice the normal number of chromosome arms still connected in the centromeric region are observed in the following mitosis. pimples encodes a novel protein that is rapidly degraded in mitosis. Our observations suggest that Pimples and Three rows act during mitosis to release the cohesion between sister centromeres.			Stratmann, R (corresponding author), MAX PLANCK GESELL,FRIEDRICH MIESCHER LAB,SPEMANNSTR 37-39,D-72076 TUBINGEN,GERMANY.							ABAD JP, 1992, P NATL ACAD SCI USA, V89, P4663, DOI 10.1073/pnas.89.10.4663; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CARMENA M, 1993, J CELL SCI, V105, P41; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; DANDREA RJ, 1993, MOL BIOL CELL, V4, P1161, DOI 10.1091/mbc.4.11.1161; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DAWSON IA, 1993, DEVELOPMENT, V117, P359; EARNSHAW WC, 1991, J CELL SCI, V98, P443; EDGAR BA, 1994, DEVELOPMENT, V120, P3131; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FOE VE, 1989, DEVELOPMENT, V107, P1; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; GHOSH S, 1992, EXP CELL RES, V200, P215, DOI 10.1016/S0014-4827(05)80091-6; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDSTEIN LSB, 1980, CHROMOSOMA, V78, P79, DOI 10.1007/BF00291909; GONZALEZ C, 1991, EXP CELL RES, V192, P10, DOI 10.1016/0014-4827(91)90150-S; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; GUACCI V, 1993, S QYANT BIOL, V58, P677; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HOLLOWAY SL, 1995, CURR OPIN GENET DEV, V5, P243, DOI 10.1016/0959-437X(95)80015-8; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; IMIGER S, 1995, CELL, V81, P269; KERREBROCK AW, 1992, GENETICS, V130, P827; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOSHLAND D, 1987, SCIENCE, V238, P1713, DOI 10.1126/science.3317838; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1991, COLD SH Q B, V56, P465; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MATSUMOTO K, 1994, CHROMOSOMA, V103, P338, DOI 10.1007/BF00417881; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MIYAZAKI WY, 1992, GENETICS, V132, P1047; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cellbio.1.1.289; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PHILP AV, 1993, J CELL SCI, V106, P87; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RATTNER JB, 1988, CHROMOSOMA, V96, P360, DOI 10.1007/BF00330702; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SKIBBENS RV, 1995, J CELL SCI, V108, P2537; STEM B, 1993, DEVELOPMENT, V117, P219; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652	59	116	117	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					25	35		10.1016/S0092-8674(00)80990-3	http://dx.doi.org/10.1016/S0092-8674(00)80990-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548823	Bronze			2022-12-24	WOS:A1996TQ17000006
J	Tirrell, DA				Tirrell, DA			Putting a new spin on spider silk	SCIENCE			English	Editorial Material											Tirrell, DA (corresponding author), UNIV MASSACHUSETTS,DEPT POLYMER SCI & ENGN,AMHERST,MA 01003, USA.							Byrom D., 1991, BIOMATERIALS; FOURNIER MJ, 1995, MOL BIOL BIOTECHNOLO, P714; GOSLINE JM, 1986, ENDEAVOUR, V10, P37, DOI 10.1016/0160-9327(86)90049-9; KREJCHI MT, 1994, SCIENCE, V265, P1427, DOI 10.1126/science.8073284; LEWIS RV, 1992, ACCOUNTS CHEM RES, V25, P392, DOI 10.1021/ar00021a002; PRINCE JT, 1995, BIOCHEMISTRY-US, V34, P10879, DOI 10.1021/bi00034a022; Simmons AH, 1996, SCIENCE, V271, P84, DOI 10.1126/science.271.5245.84; TERMONIA Y, 1994, MACROMOLECULES, V27, P7378, DOI 10.1021/ma00103a018	8	42	55	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 5	1996	271	5245					39	40		10.1126/science.271.5245.39	http://dx.doi.org/10.1126/science.271.5245.39			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539596				2022-12-24	WOS:A1996TP02200032
J	Henry, RR; Genuth, S				Henry, RR; Genuth, S			Forum one: Current recommendations about intensification of metabolic control in non-insulin-dependent diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			PROGRESSION; NEPHROPATHY; TRIAL	Purpose: To review issues about intensive management of non-insulin-dependent diabetes mellitus (NIDDM) and to formulate recommendations for goals and general approaches to implementation of intensive management. Method: A panel of clinical scientists and practitioners specializing in diabetes initially used a formal nominal process to identify the points of agreement on major issues. These points were further refined in a general conference discussion. Conclusions: 1) On the basis of data from intervention trials in IDDM that prove that intensive glycemic control reduces microvascular and neuropathic complications, coupled with epidemiologic and basic scientific data that support the strong likelihood of a similar benefit in NIDDM, the goal of treatment in NIDDM should be near-normal glycemia (glycohemoglobin level no higher than 1.0% above the upper normal limit); 2) glycemic targets should be adjusted individually according to clinical factors such as increased risk for hypoglycemia, advanced age, or reduced life expectancy from comorbid conditions; 3) some degree of comprehensive and repetitive instruction about diet and exercise and the use of blood glucose self-monitoring for all patients is essential to achieve the chosen targets; 4) intensive management of hyperglycemia should be instituted early and should initially emphasize diet and exercise therapy; staged introduction of oral hypoglycemic agents and finally insulin regimens of increasing complexity are recommended as needed to achieve glycemic targets; 5) comprehensive care must also include aggressive attempts to reduce cardiovascular risk factors (particularly hypertension, smoking, dyslipidemia, and obesity) as well as prevention of nephropathy and neuropathy; 6) the complex interaction among treatment regimens for hyperglycemia, dyslipidemia, obesity, and hypertension ideally requires a team approach, using a physician, diabetes educator, nurse, dietitian, and other health professionals; health insurers should make these resources available to generalists who currently care for most diabetic patients.	UNIV CALIF SAN DIEGO, DEPT MED, SAN DIEGO, CA USA; MT SINAI MED CTR, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT MED, CLEVELAND, OH USA	University of California System; University of California San Diego; Case Western Reserve University	Henry, RR (corresponding author), VET AFFAIRS MED CTR, 3350 LA JOLLA VILLAGE DR, SAN DIEGO, CA 92161 USA.							[Anonymous], 1994, Diabetes Care, V17, P616; BIERMAN EL, 1992, ARTERIOSCLER THROMB, V12, P647, DOI 10.1161/01.ATV.12.6.647; CLARK CM, 1995, NEW ENGL J MED, V332, P1210, DOI 10.1056/NEJM199505043321807; Genuth S M, 1995, Adv Intern Med, V40, P573; HERMANN LS, 1994, DIABETES CARE, V17, P1100, DOI 10.2337/diacare.17.10.1100; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; MOGENSEN CE, 1982, BRIT MED J, V285, P685, DOI 10.1136/bmj.285.6343.685; MOGENSEN CE, 1976, SCAND J CLIN LAB INV, V36, P383, DOI 10.3109/00365517609055274; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; 1994, MED MANAGEMENT NON I, P26	12	37	38	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				175	177		10.7326/0003-4819-124-1_Part_2-199601011-00019	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00019			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554214				2022-12-24	WOS:A1996TL94400019
J	Kano, M; Hashimoto, K; Chen, C; Abeliovich, A; Aiba, A; Kurihara, H; Watanabe, M; Inoue, Y; Tonegawa, S				Kano, M; Hashimoto, K; Chen, C; Abeliovich, A; Aiba, A; Kurihara, H; Watanabe, M; Inoue, Y; Tonegawa, S			Impaired synapse elimination during cerebellar development in PKC gamma mutant mice	CELL			English	Article							PROTEIN-KINASE-C; CENTRAL-NERVOUS-SYSTEM; LONG-TERM DEPRESSION; PURKINJE-CELLS; CLIMBING FIBERS; RAT-BRAIN; MULTIPLE INNERVATION; POSTNATAL-DEVELOPMENT; EXPRESSION; LOCALIZATION	PKC gamma is highly expressed in Purkinje cells (PCs) but not in other types of neurons in the cerebellum. The expression of PKC gamma changes markedly during cerebellar development, being very low at birth and reaching a peak around the third postnatal week. This temporal pattern of PKC gamma expression coincides with the developmental transition from multiple to single climbing fiber innervation onto each PC. In adult mutant mice deficient in PKC gamma, we found that 41% of PCs are still innervated by multiple climbing fibers, while other aspects of the cerebellum including the morphology and excitatory synaptic transmission of PCs appear normal. Thus, elimination of multiple climbing fiber innervation appears to be specifically impaired in the mutant cerebellum. We suggest that the developmental role of PKC gamma may be to act as a downstream element in the signal cascade necessary for the elimination of surplus climbing fiber synapses.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,CTR LEARNING & MEMORY,CAMBRIDGE,MA 02139; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HOKKAIDO UNIV,SCH MED,DEPT ANAT,SAPPORO,HOKKAIDO 606,JAPAN	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Hokkaido University	Kano, M (corresponding author), JICHI MED SCH,DEPT PHYSIOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.		WATANABE, Masahiko/A-4055-2012; Watanabe, Masahiko/S-3614-2019	WATANABE, Masahiko/0000-0001-5037-7138; Watanabe, Masahiko/0000-0001-5037-7138; Hashimoto, Kouichi/0000-0002-3884-8213; Aiba, Atsu/0000-0002-8192-0778; Kano, Masanobu/0000-0002-0725-3292	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS32925] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; ALTMAN J, 1972, J COMP NEUROL, V145, P353, DOI 10.1002/cne.901450305; ASE K, 1988, J NEUROSCI, V8, P3850; BRANDT SJ, 1987, CELL, V49, P57, DOI 10.1016/0092-8674(87)90755-0; Chen C, 1995, CELL, V83, P1233, DOI 10.1016/0092-8674(95)90148-5; CREPEL F, 1980, NATURE, V283, P483, DOI 10.1038/283483a0; CREPEL F, 1991, J PHYSIOL-LONDON, V432, P123, DOI 10.1113/jphysiol.1991.sp018380; CREPEL F, 1982, TRENDS NEUROSCI, V5, P266, DOI 10.1016/0166-2236(82)90168-0; CREPEL F, 1988, BRAIN RES, V458, P397, DOI 10.1016/0006-8993(88)90486-6; CREPEL F, 1979, J PHYSIOL-LONDON, V290, P97, DOI 10.1113/jphysiol.1979.sp012762; CREPEL F, 1976, J NEUROBIOL, V7, P579, DOI 10.1002/neu.480070610; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; GARCIASEGURA LM, 1984, BRAIN RES, V296, P75, DOI 10.1016/0006-8993(84)90512-2; HARRIS RA, 1995, P NATL ACAD SCI USA, V92, P3658, DOI 10.1073/pnas.92.9.3658; HASHIMOTO T, 1988, J NEUROSCI, V8, P1678; HEMART N, 1995, EUR J NEUROSCI, V7, P45, DOI 10.1111/j.1460-9568.1995.tb01019.x; HERMS J, 1993, NEUROREPORT, V4, P899, DOI 10.1097/00001756-199307000-00015; HIDAKA H, 1988, J BIOL CHEM, V263, P4523; HUANG FL, 1990, DEV BRAIN RES, V52, P121, DOI 10.1016/0165-3806(90)90227-P; HUANG FL, 1988, J NEUROSCI, V8, P4734; HUANG FL, 1987, J BIOL CHEM, V262, P15714; Ito M, 1984, CEREBELLUM NEURAL CO; KANO M, 1992, NATURE, V356, P601, DOI 10.1038/356601a0; Kano M., 1992, P54; KASHIWABUCHI N, 1995, CELL, V81, P245, DOI 10.1016/0092-8674(95)90334-8; KITANO T, 1987, J NEUROSCI, V7, P1520; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; KOSE A, 1988, J NEUROSCI, V8, P4262; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; LINDEN DJ, 1991, SCIENCE, V254, P1656, DOI 10.1126/science.1721243; LINDEN DJ, 1992, J NEUROSCI, V12, P3601; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; MARANI E, 1979, ACTA MORPHOL NEER SC, V17, P33; MARIANI J, 1980, J NEUROBIOL, V11, P41, DOI 10.1002/neu.480110106; MARIANI J, 1977, PHILOS T R SOC B, V281, P1, DOI 10.1098/rstb.1977.0121; MORIYA M, 1994, NEUROREPORT, V5, P929, DOI 10.1097/00001756-199404000-00019; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLEARY JL, 1971, J COMP NEUROL, V142, P377, DOI 10.1002/cne.901420307; Palay S. L., 1974, CEREBELLAR CORTEX CY; RABACCHI S, 1992, SCIENCE, V256, P1823, DOI 10.1126/science.1352066; SAITO N, 1988, J NEUROSCI, V8, P369; TANAKA C, 1992, NEUROCHEM INT, V21, P499, DOI 10.1016/0197-0186(92)90081-2; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; WATANABE M, 1994, J COMP NEUROL, V343, P513, DOI 10.1002/cne.903430402; WOODWARD DJ, 1974, J NEUROBIOL, V5, P283, DOI 10.1002/neu.480050402; YAMAKUNI T, 1984, NEUROSCI LETT, V45, P235, DOI 10.1016/0304-3940(84)90232-5; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	52	284	286	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1223	1231		10.1016/0092-8674(95)90147-7	http://dx.doi.org/10.1016/0092-8674(95)90147-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548808	Bronze			2022-12-24	WOS:A1995TM76200017
J	Zhou, QY; Palmiter, RD				Zhou, QY; Palmiter, RD			Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic	CELL			English	Article							BASAL GANGLIA; NUCLEUS-ACCUMBENS; FEEDING-BEHAVIOR; RAT NEOSTRIATUM; NEONATAL RATS; FOOD REWARD; NEURONS; LESIONS; NEUROTRANSMITTERS; RECEPTOR	Mice unable to synthesize dopamine (DA) specifically in dopaminergic neurons were created by inactivating the tyrosine hydroxylase (TH) gene then by restoring TH function in noradrenergic cells. These DA-deficient (DA(-/-)) mice were born at expected frequency but became hypoactive and stopped feeding a few weeks after birth. Midbrain dopaminergic neurons, their projections, and most characteristics of their target neurons in the striatum appeared normal. Within a few minutes of being injected with L-dihydroxyphenylalanine (L-DOPA), the product of TH, the DA(-/-) mice became more active and consumed more food than control mice. With continued administration of L-DOPA, nearly normal growth was achieved. These studies indicate that DA is essential for movement and feeding, but is not required for the development of neural circuits that control these behaviors.			Zhou, QY (corresponding author), UNIV WASHINGTON, HOWARD HUGHES MED INST, DEPT BIOCHEM, SEATTLE, WA 98195 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD009172, R01HD009172] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-09172] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ANAND BK, 1951, YALE J BIOL MED, V24, P123; ANDERSON KD, 1990, J COMP NEUROL, V295, P339, DOI 10.1002/cne.902950302; ARNT J, 1987, DOPAMINE RECEPTORS, P199; BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0; BAYER SA, 1984, INT J DEV NEUROSCI, V2, P163, DOI 10.1016/0736-5748(84)90008-X; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; BRAFF DL, 1990, ARCH GEN PSYCHIAT, V47, P181; BUNNEY BS, 1976, BRAIN RES, V117, P423, DOI 10.1016/0006-8993(76)90751-4; CARLSSON A, 1959, PHARMACOL REV, V11, P490; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; CLARK D, 1987, SYNAPSE, V1, P347, DOI 10.1002/syn.890010408; Cooper SJ, 1993, D1 D2 DOPAMINE RECEP, P203; DAHLSTROM A, 1964, ACTA PHYSIOL SCAND, V62, P1; DOURISH CT, 1993, BIOL PSYCHIAT, V7, P487; DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564; FIBIGER HC, 1973, BRAIN RES, V55, P135, DOI 10.1016/0006-8993(73)90493-9; FIBIGER HC, 1988, ANN NY ACAD SCI, V537, P206, DOI 10.1111/j.1749-6632.1988.tb42107.x; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; GROSSMAN SP, 1978, SCIENCE, V202, P537, DOI 10.1126/science.705344; HEBB DO, 1955, PSYCHOL REV, V62, P243, DOI 10.1037/h0041823; HEMMINGS HC, 1986, PROG BRAIN RES, V69, P149; HERNANDEZ L, 1988, PHYSIOL BEHAV, V44, P599, DOI 10.1016/0031-9384(88)90324-1; HERNANDEZ L, 1988, LIFE SCI, V42, P1705, DOI 10.1016/0024-3205(88)90036-7; HERNANDEZ L, 1966, PHARMACOL REV, V18, P925; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; JICHA GA, 1991, J NEUROSCI, V11, P3822; JOSEPH MH, 1990, J NEUROSCI METH, V34, P143, DOI 10.1016/0165-0270(90)90052-H; KITA H, 1988, BRAIN RES, V447, P346, DOI 10.1016/0006-8993(88)91138-9; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; KOPIN IJ, 1988, ANNU REV NEUROSCI, V11, P81, DOI 10.1146/annurev.neuro.11.1.81; LANKFORD KL, 1988, P NATL ACAD SCI USA, V85, P4567, DOI 10.1073/pnas.85.12.4567-a; LAUDER JM, 1993, TRENDS NEUROSCI, V16, P233, DOI 10.1016/0166-2236(93)90162-F; LINDVALL O, 1983, CHEM NEUROANATOMY, P229; LIU FC, 1992, J NEUROSCI, V12, P4281; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LUDECKE B, 1995, HUM GENET, V95, P123; LYTLE LD, 1978, SCIENCE, V200, P1175; MARROCCO RT, 1994, CURR OPIN NEUROBIOL, V4, P166, DOI 10.1016/0959-4388(94)90067-1; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MORGANE PJ, 1961, AM J PHYSIOL, V201, P420, DOI 10.1152/ajplegacy.1961.201.3.420; NYGAARD TG, 1995, CURR OPIN NEUROL, V8, P310, DOI 10.1097/00019052-199508000-00011; ONN SP, 1990, BRAIN RES, V518, P274, DOI 10.1016/0006-8993(90)90980-P; PARKER SW, 1967, EXP NEUROL, V17, P313, DOI 10.1016/0014-4886(67)90109-4; PHILLIPS AG, 1975, NATURE, V258, P750, DOI 10.1038/258750a0; PHILLIPSON OT, 1979, J COMP NEUROL, V187, P117, DOI 10.1002/cne.901870108; RODRIGUES PD, 1990, P NATL ACAD SCI USA, V87, P9693, DOI 10.1073/pnas.87.24.9693; ROGERS DC, 1990, EXP BRAIN RES, V80, P172; ROLLS ET, 1981, HDB HYPOTHALAMUS, V3, P439; SALAMONE JD, 1990, NEUROSCIENCE, V39, P17, DOI 10.1016/0306-4522(90)90218-S; SCHAMBRA B, 1994, NEUROSCIENCE, V62, P65, DOI 10.1016/0306-4522(94)90315-8; SCHWARZ SS, 1987, EXP BRAIN RES, V65, P449; SEEMAN P, 1993, NATURE, V365, P441, DOI 10.1038/365441a0; SKUTELLA T, 1994, NEUROSCI LETT, V167, P55, DOI 10.1016/0304-3940(94)91026-X; SMITH GP, 1988, ANN NY ACAD SCI, V537, P254, DOI 10.1111/j.1749-6632.1988.tb42111.x; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; TODD RD, 1992, BIOL PSYCHIAT, V31, P794, DOI 10.1016/0006-3223(92)90311-M; UNGERSTEDT U, 1971, ACTA PHYSIOL SCAND, P95; VANDERKOOY D, 1987, BRAIN RES, V401, P155, DOI 10.1016/0006-8993(87)91176-0; VOORN P, 1988, NEUROSCIENCE, V25, P857, DOI 10.1016/0306-4522(88)90041-3; WADDINGTON JL, 1993, D1 D2 DOPAMINE RECEP, P51; WELF DW, 1995, ANNU REV NEUROSCI, V18, P463; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WINN P, 1984, NEUROSCIENCE, V12, P225, DOI 10.1016/0306-4522(84)90149-0; WISE RA, 1992, SYNAPSE, V10, P247, DOI 10.1002/syn.890100307; WISE RA, 1978, SCIENCE, V201, P262, DOI 10.1126/science.566469; WOOLVERTON WL, 1992, TRENDS PHARMACOL SCI, V13, P193, DOI 10.1016/0165-6147(92)90063-C; WRIGHT AK, 1980, APPETITE, V1, P43, DOI 10.1016/S0195-6663(80)80007-9; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0; ZIGMOND MJ, 1989, INT REV NEUROBIOL, V31, P1; ZIGMOND MJ, 1972, SCIENCE, V177, P1211	77	575	585	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1197	1209		10.1016/0092-8674(95)90145-0	http://dx.doi.org/10.1016/0092-8674(95)90145-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548806	Bronze			2022-12-24	WOS:A1995TM76200015
J	Lehmuskallio, E; Lindholm, H; Koskenvuo, K; Sarna, S; Friberg, O; Viljanen, A				Lehmuskallio, E; Lindholm, H; Koskenvuo, K; Sarna, S; Friberg, O; Viljanen, A			Frostbite of the face and ears: Epidemiological study of risk factors in Finnish conscripts	BRITISH MEDICAL JOURNAL			English	Article							MILITARY OPERATIONS; COLD	Objective-To determine the incidence of and the risk factors for local cold injuries of the face and ears in peacetime military service. Design-Prospective, controlled epidemiological study using a questionnaire. Setting-Finnish defence forces, 1976-89. Subjects-913 young male conscripts with local frostbite of the head that needed medical attention and 2478 uninjured control conscripts. Main outcome measures-Type of activity, clothing, and other risk factors at the time of cold injury. Odds ratios were used to calculate risk. Controls were handled as one group. Results-The mean annual incidence of frostbite was 1 . 8 per 1000 conscripts. Frostbite of the ear was most common (533 conscripts (58%)), followed by frostbite of the nose (197 (22%)) and of the cheeks and other regions of the face (183 (20%)). Most conscripts (803 (88%)) had mild or superficial frostbite. Risk factors included not wearing a hat with earflaps (odds ratio 18 . 5 for frostbite of the ear); not wearing a scarf(odds ratio 2 . 1 and 3 . 8 for frostbite of the ear and cheeks respectively); using protective ointments (odds ratio 3 . 3, 4 . 5, and 5 . 6 for frostbite of the cheeks, ear, and nose respectively); being extremely sensitive to cold and having hands and feet that sweat profusely (odds ratio 3 . 5 for frostbite of the nose); and being transported in the open or in open vehicles under windy conditions (odds ratio 2 . 2 for frostbite of the cheek). Conclusions-Wearing warm clothing, including a scarf and a hat with earflaps, helps to prevent frostbite. Each person's sensitivity to cold may also be important. The routine use of protective ointments should not be recommended.	FINNISH DEF FORCES,INST MIL MED,SF-00300 HELSINKI,FINLAND; FINNISH DEF STAFF,MED SECT,SF-00101 HELSINKI,FINLAND; UNIV HELSINKI,DEPT PUBL HLTH,SF-00014 HELSINKI,FINLAND	University of Helsinki	Lehmuskallio, E (corresponding author), SANTAHAMINA MIL HLTH CTR,POB 6,SF-00861 HELSINKI,FINLAND.			Sarna, Seppo/0000-0003-3458-1627				DICK HJ, 1989, MED CORPS INT, V4, P41; FRITZ RL, 1989, CLIN SPORT MED, V8, P111; HAMLET MP, 1987, MIL MED, V152, P393; HANSON HE, 1969, MIL MED, V134, P1307; KOSKENVUO K, 1977, ANN MED MILITARIS FE, V52, P9; KOSKENVUO K, 1976, ANN MED MILITARIS FE, V51, P59; LEHMUSKALLIO E, 1993, 3RD P C EUR AC DERM, P10; LINDHOLM H, 1993, A19931 SCI COMM NAT; Siple Paul A., 1945, PROC AMER PHIL SOC, V89, P177; STEINMAN AM, 1987, MIL MED, V152, P389; TERVAHAUTA R, 1993, FIELD SURGERY MED, P461; VAUGHN PB, 1980, MIL MED, V145, P305; WILSON O, 1970, J APPL PHYSIOL, V29, P658, DOI 10.1152/jappl.1970.29.5.658	13	37	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1661	1663		10.1136/bmj.311.7021.1661	http://dx.doi.org/10.1136/bmj.311.7021.1661			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541749	Green Published			2022-12-24	WOS:A1995TL94200008
J	ZWIEBEL, LJ; SACCONE, G; ZACHAROPOULOU, A; BESANSKY, NJ; FAVIA, G; COLLINS, FH; LOUIS, C; KAFATOS, FC				ZWIEBEL, LJ; SACCONE, G; ZACHAROPOULOU, A; BESANSKY, NJ; FAVIA, G; COLLINS, FH; LOUIS, C; KAFATOS, FC			THE WHITE GENE OF CERATITIS-CAPITATA - A PHENOTYPIC MARKER FOR GERMLINE TRANSFORMATION	SCIENCE			English	Article							DROSOPHILA-MELANOGASTER; DNA; INTEGRATION; CLONING	Reliable germline transformation is required for molecular studies and ultimately for genetic control of economically important insects, such as the Mediterranean fruit fly (medfly) Ceratitis capitata. A prerequisite for the establishment and maintenance of transformant lines is selectable or phenotypically dominant markers. To this end, a complementary DNA clone derived from the medfly white gene was isolated, which showed substantial similarity to white genes in Drosophila melanogaster and other Diptera. It is correlated with a spontaneous mutation causing white eyes in the medfly and can be used to restore partial eye color in transgenic Drosophila carrying a null mutation in the endogenous white gene.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY; HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138; FORTH,INST MOLEC BIOL & BIOTECHNOL,CRETE,GREECE; UNIV NAPLES FEDERICO II,DIPARTIMENTO GENET BIOL GEN & MOLEC,NAPLES,ITALY; UNIV PATRAS,DEPT BIOL,PATRAI,GREECE; CTR DIS CONTROL & PREVENT,DIV PARASIT DIS,ATLANTA,GA 30341	European Molecular Biology Laboratory (EMBL); Harvard University; Foundation for Research & Technology - Hellas (FORTH); University of Naples Federico II; University of Patras; Centers for Disease Control & Prevention - USA			Louis, Christos/F-2527-2012; saccone, giuseppe/F-8627-2013	saccone, giuseppe/0000-0002-9835-3693; Favia, Guido/0000-0002-4420-8482; Zwiebel, Laurence/0000-0001-6686-7289				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASHBURNER M, 1989, DROSOPHILA LABORATOR; Besansky NJ, 1995, INSECT MOL BIOL, V4, P217, DOI 10.1111/j.1365-2583.1995.tb00027.x; BEVERLY S, 1984, J MOL EVOL, V12, P1; BROGNA S, UNPUB; CHRISTENSON LD, 1960, ANNU REV ENTOMOL, V5, P171, DOI 10.1146/annurev.en.05.010160.001131; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREESEN TD, 1988, MOL CELL BIOL, V8, P5206, DOI 10.1128/MCB.8.12.5206; ELIZUR A, 1990, J MOL EVOL, V30, P347, DOI 10.1007/BF02101889; FIMIANI P, 1989, FRUIT FLIES THEIR A, V3, P39; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; ISRAEL DI, 1993, NUCLEIC ACIDS RES, V21, P2627, DOI 10.1093/nar/21.11.2627; LOUKERIS TG, 1995, SCIENCE, V270, P2002, DOI 10.1126/science.270.5244.2002; Malacrida A., 1986, ATTI ASSOC GENET IT, V31, P121; MCGRANE V, 1988, AM J TROP MED HYG, V39, P502, DOI 10.4269/ajtmh.1988.39.502; MILLER LH, 1987, SCIENCE, V237, P779, DOI 10.1126/science.3039658; MORRIS AC, 1989, MED VET ENTOMOL, V3, P1, DOI 10.1111/j.1365-2915.1989.tb00467.x; OBROCHTA DA, 1994, MOL GEN GENET, V244, P9, DOI 10.1007/BF00280181; OHARE K, 1983, P NATL ACAD SCI-BIOL, V80, P6917, DOI 10.1073/pnas.80.22.6917; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING LAB MANU; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Saul S.H., 1986, Agricultural Zoology Reviews, V1, P73; SAVAKIS C, COMMUNICATION; TEARLE RG, 1989, GENETICS, V122, P595; WALKER JE, 1992, EMBO J, V1, P945; ZACHAROPOULOU A, 1992, CHROMOSOMA, V101, P448, DOI 10.1007/BF00582839; ZACHAROPOULOU A, 1990, GENOME, V33, P184, DOI 10.1139/g90-030; ZACHAROPOULOU A, UNPUB; ZIEGLER I, 1965, Z NATURFORSCH PT B, VB 20, P318, DOI 10.1515/znb-1965-0410	31	78	82	0	20	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					2005	2008		10.1126/science.270.5244.2005	http://dx.doi.org/10.1126/science.270.5244.2005			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533095				2022-12-24	WOS:A1995TL42000046
J	Pennacchio, LA; Lehesjoki, AE; Stone, NE; Willour, VL; Virtaneva, K; Miao, JM; DAmato, E; Ramirez, L; Faham, M; Koskiniemi, M; Warrington, JA; Norio, R; delaChapelle, A; Cox, DR; Myers, RM				Pennacchio, LA; Lehesjoki, AE; Stone, NE; Willour, VL; Virtaneva, K; Miao, JM; DAmato, E; Ramirez, L; Faham, M; Koskiniemi, M; Warrington, JA; Norio, R; delaChapelle, A; Cox, DR; Myers, RM			Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1)	SCIENCE			English	Article							FAMILIAL NEONATAL CONVULSIONS; CYSTEINE-PROTEINASE-INHIBITOR; CHROMOSOME-20; LOCALIZATION; EXPRESSION; LINKAGE	Progressive myoclonus epilepsy of the Unverricht-Lundborg type (EPM1) is an autosomal recessive inherited form of epilepsy, previously linked to human chromosome 21q22.3. The gene encoding cystatin B was shown to be localized to this region, and levels of messenger RNA encoded by this gene were found to be decreased in cells from affected individuals. Two mutations, a 3' splice site mutation and a stop codon mutation, were identified in the gene encoding cystatin B in EPM1 patients but were not present in unaffected individuals. These results provide evidence that mutations in the gene encoding cystatin B are responsible for the primary defect in patients with EPM1.	STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305; STANFORD UNIV,DEPT BIOL,STANFORD,CA 94305; UNIV HELSINKI,DEPT MED GENET,SF-00290 HELSINKI,FINLAND; UNIV HELSINKI,DEPT VIROL,SF-00290 HELSINKI,FINLAND; FINNISH POPULAT & FAMILY WELF FEDERAT,DEPT MED GENET,SF-00100 HELSINKI,FINLAND	Stanford University; Stanford University; University of Helsinki; University of Helsinki; Family Federation of Finland				Pennacchio, Len/0000-0002-8748-3732; Willour, Virginia/0000-0002-6639-487X	NHGRI NIH HHS [P50 HG-00206] Funding Source: Medline; NICHD NIH HHS [HD-24610] Funding Source: Medline; NIGMS NIH HHS [IF32GM17502] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024610] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG000206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017502] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSON M, 1989, HUM GENET, V82, P223, DOI 10.1007/BF00291159; BERKOVIC SF, 1986, NEW ENGL J MED, V315, P296, DOI 10.1056/NEJM198607313150506; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; ELDRIDGE R, 1983, LANCET, V2, P838, DOI 10.1016/s0140-6736(83)90749-3; FAHAM M, UNPUB; GHISO J, 1986, P NATL ACAD SCI USA, V83, P2974, DOI 10.1073/pnas.83.9.2974; GREENBERG DA, 1988, AM J MED GENET, V31, P185, DOI 10.1002/ajmg.1320310125; JARVINEN M, 1982, BIOCHIM BIOPHYS ACTA, V708, P210, DOI 10.1016/0167-4838(82)90222-9; JERALA R, 1988, FEBS LETT, V239, P41, DOI 10.1016/0014-5793(88)80541-6; JOU YS, 1994, GENOMICS, V24, P410, DOI 10.1006/geno.1994.1643; KOSKINIEMI M, 1974, EPILEPSIA, V15, P537, DOI 10.1111/j.1528-1157.1974.tb04027.x; KOSKINIEMI M, 1974, ACTA NEUROL SCAND, V50, P333; KOSKINIEMI M, 1974, ACTA NEUROL SCAND, V50, P307; LEHESJOKI AE, 1992, NEUROLOGY, V42, P1545, DOI 10.1212/WNL.42.8.1545; LEHESJOKI AE, 1993, HUM MOL GENET, V2, P1229, DOI 10.1093/hmg/2.8.1229; LEHESJOKI AE, 1991, P NATL ACAD SCI USA, V88, P3696, DOI 10.1073/pnas.88.9.3696; LEPPERT M, 1989, NATURE, V337, P647, DOI 10.1038/337647a0; LEWIS TB, 1993, AM J HUM GENET, V53, P670; LIU AW, 1995, AM J HUM GENET, V57, P68; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; LUNDBORG H, 1903, PROGR MYOCLONUS EPIL, P1; NAKAI K, 1994, GENE, V141, P171, DOI 10.1016/0378-1119(94)90567-3; NORIO R, 1979, CLIN GENET, V15, P382; OTTMAN R, 1995, NAT GENET, V10, P56, DOI 10.1038/ng0595-56; PENNACCHIO LA, UNPUB; RITONJA A, 1985, BIOCHEM BIOPH RES CO, V131, P1187, DOI 10.1016/0006-291X(85)90216-5; SCHEUER ML, 1990, NEW ENGL J MED, V323, P1468; SERRATOSA JM, 1995, HUM MOL GENET, V4, P1657; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; Stone NE, 1996, GENOME RES, V6, P218, DOI 10.1101/gr.6.3.218; TAHVANAINEN E, 1994, P NATL ACAD SCI USA, V91, P7267, DOI 10.1073/pnas.91.15.7267; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; UNVERRICHT H, 1891, MYOCLONIE, P1; Unverricht H., 1891, DTSCH Z NERVENHEILKD, V7, P32, DOI [10.1007/BF01833165, DOI 10.1007/BF01833165]; VIRTANEVA K, UNPUB	35	459	472	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1731	1734		10.1126/science.271.5256.1731	http://dx.doi.org/10.1126/science.271.5256.1731			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596935				2022-12-24	WOS:A1996UB15100048
J	Bach, JF; Chalons, S; Forier, E; Elana, G; Jouanelle, J; Kayemba, S; Delbois, D; Mosser, A; SaintAime, C; Berchel, C				Bach, JF; Chalons, S; Forier, E; Elana, G; Jouanelle, J; Kayemba, S; Delbois, D; Mosser, A; SaintAime, C; Berchel, C			10-year educational programme aimed at rheumatic fever in two French Caribbean islands	LANCET			English	Article							UNITED-STATES; RESURGENCE; DISEASE	Background In less developed countries, rheumatic fever still occurs. We started a long-term educational programme in two French Caribbean islands that was directed at the public and at health-care workers to see whether we could reduce the incidence of rheumatic fever. Methods Our 10-year programme started in 1981 in Martinique and Guadeloupe, and was based in the community and in clinics and hospitals. The programme established a registry of all cases of primary and secondary rheumatic fever (diagnosed by Jones' modified criteria), with systematic hospital admission of children. We graded carditis as severe, mild, or subclinical, and acute glomerulonephritis was defined by oedema, proteinuria, and haematuria for less than 3 months. The educational part of the programme targeted the public and healthcare workers, including doctors, with written information distributed in schools or via radio and television broadcasts or videotapes. For the public, the benign clinical presentation of the initial streptococcal infection was contrasted with the severity of later heart disease. Findings The first months of the programme led to a 10-20% increase in the number of rheumatic fever cases admitted to hospital, because of the renewed attention paid to the disease. Therefore we took 1982 as the baseline year. In 1982-83 the incidence of rheumatic fever was 19.6 per 100 000 inhabitants aged under 20 in Martinique, and 17.4 per 100 000 in Guadeloupe. In 100 Martinique children and 97 Guadeloupe children in 1982-83, 40 and 71% had carditis, respectively (severe in 10 and 32%). Rheumatic fever was preceded by symptomatic sore throat in 52 and 41% of cases, respectively. The disease was not seen in children with active streptococcal cutaneous infections. Disease frequency was highest in the poorest areas and families, a finding that persisted over time. The programme was associated with a progressive decline in the frequency of rheumatic fever: final reduction of 78% in Martinique and 74% in Guadeloupe. The frequency of carditis also fell. Apart from two outbreaks in one hospital, the frequency of acute glomerulonephritis also declined; 31% of cases had had sore throat, while 56% had shin infections, The cost of the programme during the 4 most intensive years was FFr 250 000 (US$ 44 500) in each island. The cost of childhood rheumatic fever, excluding late sequelae, was initially (in 1982) about FFr 7.8 million (US$ 1 426 000). The cost fell to an average of FFr 550 000 (US$ 100 000) per year in 1991-92. Interpretation A rapid decline in rheumatic fever incidence was achieved at modest cost. Such a programme needs to be continued because of the risk of disease resurgence.	DDASS, FORT DE FRANCE, Martinique, FRANCE; DASD, PMI, JARRYBALE MANHAULT, Guadeloupe, FRANCE; HOP PIERRE ZOBDA QUITMAN, MICROBIOL LAB, FORT DE FRANCE, Martinique, FRANCE; HOP LOUIS DOMMERGUE, LA TRINITE, Martinique, FRANCE; HOP REDOURTE, FORT DE FRANCE, Martinique, FRANCE; CHU POINTE PITRE, SERV PEDIAT, POINTE A PITRE, Guadeloupe, FRANCE	CHU Martinique; CHU Guadeloupe	Bach, JF (corresponding author), HOP NECKER ENFANTS MALAD, INSERM, U25, F-75743 PARIS 15, FRANCE.		KAYEMBA-KAY'S, SIMON/F-3503-2012; KAYEMBA-KAY'S, KABANGU/AAE-4573-2021	KAYEMBA-KAY'S, SIMON/0000-0002-5239-844X; 				AGIS F, 1985, THESIS U PARIS 5; AYOUB EM, 1992, POSTGRAD MED, V92, P133; Canterin A A, 1978, Arch Sci Med (Torino), V135, P623; CARDONA PN, 1988, REV CUBANA PEDIATR, V60, P32; DEWALS P, 1983, MED MALADIES INFECT, V13, P420, DOI 10.1016/S0399-077X(83)80022-5; DODU S R A, 1989, World Health Forum, V10, P203; EISENBERG MJ, 1993, EUR HEART J, V14, P122, DOI 10.1093/eurheartj/14.1.122; Gharagozloo R A, 1976, Acta Trop, V33, P215; GORDIS L, 1969, J CHRON DIS, V21, P655, DOI 10.1016/0021-9681(69)90037-X; KASSEM AS, 1992, PEDIATR ANN, V21, P835, DOI 10.3928/0090-4481-19921201-10; MARKOWITZ M, 1991, PEDIATR INFECT DIS J, V10, pS11, DOI 10.1097/00006454-199110001-00003; MARKOWITZ M, 1980, STREPTOCOCCAL DIS IM, P741; MASSELL BF, 1988, NEW ENGL J MED, V318, P280, DOI 10.1056/NEJM198802043180504; MONPLAISIR N, 1986, TISSUE ANTIGENS, V28, P209, DOI 10.1111/j.1399-0039.1986.tb00484.x; PATARROYO ME, 1979, NATURE, V278, P173, DOI 10.1038/278173a0; POONKING T, 1980, STREPTOCOCCAL DISEAS, P523; QUINN RW, 1978, SOUTHERN MED J, V71, P242, DOI 10.1097/00007611-197803000-00006; QUINN RW, 1980, SOUTHERN MED J, V73, P288, DOI 10.1097/00007611-198003000-00007; ROTTA J, 1980, STREPTOCOCCAL DIS IM, P751; RUTSTEIN DD, 1956, CIRCULATION, V13, P617, DOI 10.1161/01.CIR.13.4.617; Svartman M, 1980, STREPTOCOCCAL DIS IM, P669; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; VLAJINAC H, 1989, MICROBIOL IMMUNOL, V3, P471	23	85	85	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	1996	347	9002					644	648		10.1016/S0140-6736(96)91202-7	http://dx.doi.org/10.1016/S0140-6736(96)91202-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596378				2022-12-24	WOS:A1996TZ28500010
J	Blenkinsopp, A; Bradley, C				Blenkinsopp, A; Bradley, C			Over the counter drugs: Patients, society, and the increase in self medication	BRITISH MEDICAL JOURNAL			English	Article								Self medication with over the counter medicines has long been a feature of the lay health system. With the reclassification of certain drugs, the public can buy preparations that were previously available only on prescription. Sales of over the counter medicines are now equivalent to a third of the NHS drugs bill; governments throughout the world see self medication as a way of shifting some of the cost of health care onto consumers. The trend towards increased self care and with it the increasing empowerment of patients has many potential benefits; collaboration between doctors and pharmacists will be critical.	UNIV BIRMINGHAM,SCH MED,DEPT GEN PRACTICE,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	Blenkinsopp, A (corresponding author), KEELE UNIV,DEPT PHARM POLICY & PRACTICE,KEELE ST5 5BG,STAFFS,ENGLAND.			Blenkinsopp, Alison/0000-0001-8872-2769				ANDERSEN M, 1994, BRIT MED J, V309, P494; BLENKINSOPP A, 1991, BR J GEN PRACT, V41, P16; BRADLEY B, 1994, J CLIN PHARM THER, V19, P7, DOI 10.1111/j.1365-2710.1994.tb00802.x; BRANSTAD JO, 1994, SOC SCI MED, V39, P207, DOI 10.1016/0277-9536(94)90329-8; Emmerton L, 1994, INT J PHARM PRACT, V3, P27; GIBSON P, 1993, BRIT MED J, V306, P1514, DOI 10.1136/bmj.306.6891.1514; HANNAY DR, 1989, SYMPTOM ICEBERG STUD; HEATH I, 1994, BRIT MED J, V309, P623, DOI 10.1136/bmj.309.6955.623; HERXHEIMER A, 1994, BRIT J GEN PRACT, V44, P339; LAWSON D, 1995, OTC DIRECTORY 1995 9; MORLEY A, 1983, PHARM J, V231, P387; *NUFF FDN, 1986, PHARM COMM INQ APP N; PLATTEN A, 1994, MODEL STANDARDS SELF, V9; *PROPR ASS GREAT B, 1995, ANN REP; *PROPR ASS GREAT B, 1987, EVER HLTH CAR CONS S; *PROPR ASS GREAT B, 1995, OTC DIR 1995 96; RAITH H, 1992, SCRIP MAGAZINE   MAR, P20; *ROYAL PHARM SOC G, 1995, MED ETH PRACT; SMITH FJ., 1993, INT J PHARM PRACT, V2, P86; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; WHITAKER MJ, 1994, PHARM J, V253, P867; Wilson M., 1992, INT J PHARM PRACT, V1, P152; 1994, LANCET, V343, P1374	23	137	142	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					629	632						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595343				2022-12-24	WOS:A1996TZ84000034
J	Frankel, DH				Frankel, DH			Skin cancer	LANCET			English	Editorial Material																		HEANEY S, 1969, DOOR DARK, P47	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					634	634		10.1016/S0140-6736(96)91199-X	http://dx.doi.org/10.1016/S0140-6736(96)91199-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596375				2022-12-24	WOS:A1996TZ28500007
J	Ramirez, VD				Ramirez, VD			How do steroids act?	LANCET			English	Editorial Material							RAT				Ramirez, VD (corresponding author), UNIV ILLINOIS,DEPT MOLEC & INTEGRAT PHYSIOL,URBANA,IL 61801, USA.							BLACKMORE PF, 1993, CELL SIGNAL, V5, P531, DOI 10.1016/0898-6568(93)90048-Q; BRESSION D, 1986, ENDOCRINOLOGY, V119, P1048, DOI 10.1210/endo-119-3-1048; KOENIG H, 1989, CIRC RES, V64, P415, DOI 10.1161/01.RES.64.3.415; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; MCENERY MW, 1989, J BIOL CHEM, V264, P12029; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; RAMIREZ VD, IN PRESS FRONTIERS N; RAMIREZ VD, IN PRESS CELL MOL NE; SZEGO CM, 1984, INT REV CYTOL, V88, P1, DOI 10.1016/S0074-7696(08)62759-X; WEHLING M, 1995, STEROIDS, V60, P153, DOI 10.1016/0039-128X(94)00027-A; WEHLING M, 1995, GENOMIC NON GENOMIC	11	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					630	631		10.1016/S0140-6736(96)91195-2	http://dx.doi.org/10.1016/S0140-6736(96)91195-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596371				2022-12-24	WOS:A1996TZ28500003
J	Halfen, JA; Mahapatra, S; Wilkinson, EC; Kaderli, S; Young, VG; Que, L; Zuberbuhler, AD; Tolman, WB				Halfen, JA; Mahapatra, S; Wilkinson, EC; Kaderli, S; Young, VG; Que, L; Zuberbuhler, AD; Tolman, WB			Reversible cleavage and formation of the dioxygen O-O band within a dicopper complex	SCIENCE			English	Article							MONOOXYGENASE CATALYTIC CYCLE; WATER-OXIDATION; RIBONUCLEOTIDE REDUCTASE; COPPER(II) COMPLEXES; OXYGEN EVOLUTION; ACTIVE-SITES; METHANE; MODEL; HEMOCYANIN; REACTIVITY	A key step in dioxygen evolution during photosynthesis is the oxidative generation of the O-O bond from water by a manganese cluster consisting of M(2)(mu-O)(2) units (where M is manganese). The reverse reaction, reductive cleavage of the dioxygen O-O bond, is performed at a variety of dicopper and di-iron active sites in enzymes that catalyze important organic oxidations. Both processes can be envisioned to involve the interconversion of dimetal-dioxygen adducts, M(2)(O-2), and isomers having M(2)(mu-O)(2) cores. The viability of this notion has been demonstrated by the identification of an equilibrium between synthetic complexes having [Cu-2(mu-eta(2):eta(2)-O-2)](2+) and [Cu-2(mu-O)(2)](2+) cores through kinetic, spectroscopic, and crystallographic studies.	UNIV MINNESOTA, DEPT CHEM, MINNEAPOLIS, MN 55455 USA; UNIV BASEL, INST ORGAN CHEM, CH-4056 BASEL, SWITZERLAND	University of Minnesota System; University of Minnesota Twin Cities; University of Basel					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047365, R37GM047365, R01GM033162, R37GM033162] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33162, GM47365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8024, DOI 10.1021/ja00097a009; de Montellano P. R. Ortiz, 1986, CYTOCHROME P 450 STR; DONG YH, 1995, J AM CHEM SOC, V117, P2778, DOI 10.1021/ja00115a013; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; GESELOWITZ D, 1990, INORG CHEM, V29, P3894, DOI 10.1021/ic00344a048; GILBERT JA, 1985, J AM CHEM SOC, V107, P3855, DOI 10.1021/ja00299a017; Hodgson D. J., 1975, PROG INORG CHEM, V19, P173; HOUSER RP, 1995, J AM CHEM SOC, V117, P10745, DOI 10.1021/ja00148a018; KARLIN KD, 1993, J AM CHEM SOC, V115, P9506, DOI 10.1021/ja00074a015; KARLIN KD, 1988, J AM CHEM SOC, V110, P1196, DOI 10.1021/ja00212a031; KARLIN KD, 1991, J AM CHEM SOC, V113, P5868, DOI 10.1021/ja00015a054; KITAJIMA N, 1992, J AM CHEM SOC, V114, P1277, DOI 10.1021/ja00030a025; LEE SC, 1993, INORG CHEM, V32, P4745, DOI 10.1021/ic00074a016; LEE SK, 1993, J BIOL CHEM, V268, P21569; LEE SK, 1993, J AM CHEM SOC, V115, P6450, DOI 10.1021/ja00067a086; LIU KE, 1994, J AM CHEM SOC, V116, P7465, DOI 10.1021/ja00095a083; LIU KE, 1995, J AM CHEM SOC, V117, P4997, DOI 10.1021/ja00122a032; MAGNUS KA, 1994, PROTEINS, V19, P302, DOI 10.1002/prot.340190405; MAHAPATRA S, 1995, J AM CHEM SOC, V117, P8865, DOI 10.1021/ja00139a026; MAHAPATRA S, 1994, J AM CHEM SOC, V116, P9785, DOI 10.1021/ja00100a068; NARUTA Y, 1994, ANGEW CHEM INT EDIT, V33, P1839, DOI 10.1002/anie.199418391; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; PECORARO VL, 1994, CHEM REV, V94, P807, DOI 10.1021/cr00027a012; PROSERPIO DM, 1992, J AM CHEM SOC, V114, P4374, DOI 10.1021/ja00037a052; QUE L, 1990, PROG INORG CHEM, V38, P97; RAMARAJ R, 1986, ANGEW CHEM INT EDIT, V25, P825, DOI 10.1002/anie.198608252; REINAUD OM, 1994, J AM CHEM SOC, V116, P6979, DOI 10.1021/ja00094a080; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; SANCHEZFERRER A, 1995, BBA-PROTEIN STRUCT M, V1247, P1; SAUER K, 1992, MANGANESE REDOX ENZY, P141; SOLOMON EI, 1992, CHEM REV, V92, P521, DOI 10.1021/cr00012a003; SOLOMON EI, 1994, CHEM REV, V94, P827, DOI 10.1021/cr00027a013; WATKINSON M, 1994, J CHEM SOC CHEM COMM, P2141, DOI 10.1039/c39940002141; WIEGHARDT K, 1989, ANGEW CHEM INT EDIT, V28, P1153, DOI 10.1002/anie.198911531; YACHANDRA VK, 1993, SCIENCE, V260, P675, DOI 10.1126/science.8480177; ZANG Y, 1995, J AM CHEM SOC, V117, P1169, DOI 10.1021/ja00108a050	37	463	464	1	123	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 8	1996	271	5254					1397	1400		10.1126/science.271.5254.1397	http://dx.doi.org/10.1126/science.271.5254.1397			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596910				2022-12-24	WOS:A1996TY96100040
J	Hensel, WA				Hensel, WA			My living will	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					588	588		10.1001/jama.275.8.588	http://dx.doi.org/10.1001/jama.275.8.588			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594232				2022-12-24	WOS:A1996TW62700007
J	Smeal, T; Claus, J; Kennedy, B; Cole, F; Guarente, L				Smeal, T; Claus, J; Kennedy, B; Cole, F; Guarente, L			Loss of transcriptional silencing causes sterility in old mother cells of S-cerevisiae	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; TELOMERE LENGTH; HUMAN FIBROBLASTS; DNA-REPLICATION; LIFE-SPAN; GENE; ACTIVATION; AGE; RECOMBINATION; INHERITANCE	We show that sterility is an aging-specific phenotype in S. cerevisiae and, by genetic and physical means, demonstrate that this phenotype results from a loss of silencing in most old cells by the SIR complex at the HM loci. This loss of silencing is specific because transcription of genes, such as MEI4 and DCM1, normally induced by sporulation, is not observed, while transcription of HMRa is observed. These findings pinpoint the molecular cause of an aging-specific phenotype in yeast. Further, they provide direct evidence for a breakdown of silencing in old cells, as predicted from earlier findings that SIR4 is a determinant of life span in this organism.			Smeal, T (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Cole, Francesca/0000-0001-6391-2363	NIA NIH HHS [AG11119] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG011119, R01AG011119] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Ballou CE, 1982, MOL BIOL YEAST SACCH; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BERTRAND H, 1985, CELL, V41, P877, DOI 10.1016/S0092-8674(85)80068-4; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; CABIB E, 1971, J BIOL CHEM, V246, P152; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; DMELLO NP, 1991, J BACTERIOL, V173, P6709, DOI 10.1128/jb.173.21.6709-6713.1991; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; EGLIMEZ NK, 1990, J GERONTOL, V45, pB9; Finch CE, 1990, LONGEVITY SENESCENCE; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GILLEY D, 1994, P NATL ACAD SCI USA, V91, P1955, DOI 10.1073/pnas.91.5.1955; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; JAZWINSKI SM, 1989, EXP GERONTOL, V24, P423; KENNEDY BK, 1994, J CELL BIOL, V127, P1985, DOI 10.1083/jcb.127.6.1985; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; MENEES TM, 1992, MOL CELL BIOL, V12, P1340, DOI 10.1128/MCB.12.3.1340; MILLER AM, 1984, EMBO J, V3, P1061, DOI 10.1002/j.1460-2075.1984.tb01927.x; MOLNAR JA, 1986, BIOCHEM J, V240, P431, DOI 10.1042/bj2400431; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MULLER I, 1985, A VAN LEEUW J MICROB, V51, P1, DOI 10.1007/BF00444223; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; POHLEY HJ, 1987, MECH AGEING DEV, V38, P231, DOI 10.1016/0047-6374(87)90092-3; REISER KM, 1987, BIOCHIM BIOPHYS ACTA, V926, P339, DOI 10.1016/0304-4165(87)90220-0; RINE J, 1987, GENETICS, V116, P9; SCHEKMAN R, 1982, MOL BIOL YEAST SACCH; SCHWARTZ HS, 1993, CANCER GENET CYTOGEN, V71, P132, DOI 10.1016/0165-4608(93)90018-H; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; VAZIRI H, 1993, AM J HUM GENET, V52, P661; WAREHAM KA, 1987, NATURE, V327, P725, DOI 10.1038/327725a0; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WOLDRINGH CL, 1995, YEAST, V11, P361, DOI 10.1002/yea.320110409; WRIGHT RM, 1982, CELL, V29, P505, DOI 10.1016/0092-8674(82)90167-2; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	45	211	219	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					633	642		10.1016/S0092-8674(00)81038-7	http://dx.doi.org/10.1016/S0092-8674(00)81038-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598049	Bronze			2022-12-24	WOS:A1996TX17600015
J	Warriner, HE; Idziak, SHJ; Slack, NL; Davidson, P; Safinya, CR				Warriner, HE; Idziak, SHJ; Slack, NL; Davidson, P; Safinya, CR			Lamellar biogels: Fluid-membrane-based hydrogels containing polymer lipids	SCIENCE			English	Article							SYNCHROTRON X-RAY; DIBLOCK COPOLYMERS; MULTIMEMBRANE; PHASES; SEGREGATION; CURVATURE; RIGIDITY; VESICLES; SYSTEM; GELS	A class of lamellar biological hydrogels comprised of fluid membranes of lipids and surfactants with small amounts of low molecular weight poly(ethylene glycol)-derived polymer lipids (PEG-lipids) were studied by x-ray diffraction, polarized light microscopy, and rheometry, In contrast to isotropic hydrogels of polymer networks, these membrane-based birefringent liquid crystalline biogels, labeled L(alpha,g), form the gel phase when water is added to the liquid-like lamellar L(alpha) phase, which reenters a liquid-like mixed phase upon further dilution. Furthermore, gels with larger water content require less PEG-lipid to remain stable, Although concentrated (similar to 50 weight percent) mixtures of free PEG (molecular weight, 5000) and water do not gel, gelation does occur in mixtures containing as little as 0.5 weight percent PEG-lipid, A defining signature of the L(alpha,g) regime as it sets in from the fluid lamellar L(alpha) phase is the proliferation of layer-dislocalion-type defects, which are stabilized by the segregation of PEG-lipids to the defect regions of high membrane curvature that connect the membranes.	UNIV CALIF SANTA BARBARA,DEPT MAT,MAT RES LAB,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,DEPT PHYS,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,INTERDEPT BIOCHEM,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,PROGRAM MOLEC BIOL,SANTA BARBARA,CA 93106	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara			Davidson, Patrick/F-7874-2017; Davidson, Patrick/Q-6691-2019	Davidson, Patrick/0000-0002-1363-6062; Davidson, Patrick/0000-0002-1363-6062				ALEXANDER S, 1977, J PHYS-PARIS, V38, P977, DOI 10.1051/jphys:01977003808097700; ALLEN TM, 1987, FEBS LETT, V223, P42, DOI 10.1016/0014-5793(87)80506-9; ASHER SA, 1979, BIOPHYS J, V27, P393, DOI 10.1016/S0006-3495(79)85225-X; Bailey F. E., 1976, POLYETHYLENE OXIDE; BENSHAUI A, 1994, MICELLES MEMBRANES M; BOLTENHAGEN P, 1992, PHYS REV A, V46, pR1743, DOI 10.1103/PhysRevA.46.R1743; CAO BH, 1994, FARADAY DISCUSS, V98, P245, DOI 10.1039/fd9949800245; DEGENNES PG, 1980, MACROMOLECULES, V13, P1069, DOI 10.1021/ma60077a009; DEGENNES PG, 1993, PHYSICS LIQUID CRYST; DEGENNES PG, 1976, J PHYS LES ULIS, V37, P1443; GABIZON A, 1988, P NATL ACAD SCI USA, V85, P6949, DOI 10.1073/pnas.85.18.6949; HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693, DOI 10.1515/znc-1973-11-1209; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; HELFRICH W, 1985, CHEM SCR, V25, P2; HU ZB, 1995, SCIENCE, V269, P525, DOI 10.1126/science.269.5223.525; ILMAIN F, 1991, NATURE, V349, P400, DOI 10.1038/349400a0; KAWAKATSU T, 1993, J PHYS II, V3, P971, DOI 10.1051/jp2:1993177; KAWASAKI K, 1990, PHYS REV A, V42, P3664, DOI 10.1103/PhysRevA.42.3664; KEMWORTHY AK, 1995, BIOPHYS J, V68, P1921; KUHL TL, BIOPHYS J, V6619, P94; LASIC DD, 1995, SCIENCE, V267, P1275, DOI 10.1126/science.7871422; LASIC DD, 1993, LIPOSOMES PHYSICS AP; Lasic DD, 1995, STEALTH LIPOSOMES; MACKINTOSH FC, COMMUNICATION; MARSHALL E, 1995, SCIENCE, V269, P1050, DOI 10.1126/science.7652552; MATSUO ES, 1992, NATURE, V358, P482, DOI 10.1038/358482a0; MILNER ST, 1991, SCIENCE, V251, P905, DOI 10.1126/science.251.4996.905; NEEDHAM D, 1992, BIOCHIM BIOPHYS ACTA, V1108, P40, DOI 10.1016/0005-2736(92)90112-Y; OSADA Y, 1993, SCI AM, V268, P82, DOI 10.1038/scientificamerican0593-82; Osada Y., 1991, POLYM GELS FUNDAMENT; PEPPAS NA, 1994, SCIENCE, V263, P1715, DOI 10.1126/science.8134835; PINCUS P, UNPUB; ROUX D, 1988, J PHYS-PARIS, V49, P307, DOI 10.1051/jphys:01988004902030700; SAFINYA CR, 1986, PHYS REV LETT, V57, P2718, DOI 10.1103/PhysRevLett.57.2718; SAFINYA CR, 1989, PHYS REV LETT, V62, P1134, DOI 10.1103/PhysRevLett.62.1134; SCHNEIDER MB, 1984, J PHYS-PARIS, V45, P273, DOI 10.1051/jphys:01984004502027300; SEIFERT U, 1993, PHYS REV LETT, V70, P1335, DOI 10.1103/PhysRevLett.70.1335; Small D.M., 1986, HDB LIPID RES, V4; SMITH GS, 1990, J CHEM PHYS, V92, P4519, DOI 10.1063/1.457764; SMITH GS, 1988, PHYS REV LETT, V60, P813, DOI 10.1103/PhysRevLett.60.813; TARDIEU A, 1973, J MOL BIOL, V75, P711, DOI 10.1016/0022-2836(73)90303-3; WANG ZG, 1990, J PHYS-PARIS, V51, P185, DOI 10.1051/jphys:01990005102018500; WARRINER HE, UNPUB; [No title captured]	44	160	169	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					969	973		10.1126/science.271.5251.969	http://dx.doi.org/10.1126/science.271.5251.969			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584932				2022-12-24	WOS:A1996TV70400043
J	Kraemer, KH				Kraemer, KH			Xeroderma pigmentosum knockouts	LANCET			English	Editorial Material											Kraemer, KH (corresponding author), NCI,MOLEC CARCINOGENESIS LAB,BLDG 37,BETHESDA,MD 20892, USA.			Kraemer, Kenneth/0000-0002-2689-3316	Intramural NIH HHS [Z01 BC004517-31] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BOOTSMA D, 1995, PHILOS T ROY SOC B, V347, P75, DOI 10.1098/rstb.1995.0012; Cleaver J.E., 1995, METABOLIC MOL BASIS, P4393; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; GASPARI AA, 1993, J CLIN INVEST, V92, P1135, DOI 10.1172/JCI116682; HANAWALT PC, 1995, MUTAT RES-DNA REPAIR, V336, P101, DOI 10.1016/0921-8777(94)00061-A; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; LEHMANN AR, 1995, TRENDS BIOCHEM SCI, V20, P402, DOI 10.1016/S0968-0004(00)89088-X; NAKANE T, 1995, NATURE, V377, P165; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0	12	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					278	279		10.1016/S0140-6736(96)90462-6	http://dx.doi.org/10.1016/S0140-6736(96)90462-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569358	Bronze			2022-12-24	WOS:A1996TT48500005
J	Turek, FW				Turek, FW			Melatonin hype hard to swallow	NATURE			English	Editorial Material							ENTRAINMENT; RHYTHMS; SLEEP				Turek, FW (corresponding author), NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,2153 N CAMPUS DR,EVANSTON,IL 60208, USA.							Aschoff J., 1982, VERTEBRATE CIRCADIAN, P129; DOLLINS AB, 1994, P NATL ACAD SCI USA, V91, P1824, DOI 10.1073/pnas.91.5.1824; EBIHARA S, 1986, SCIENCE, V231, P491, DOI 10.1126/science.3941912; GASTON S, 1968, SCIENCE, V160, P1125, DOI 10.1126/science.160.3832.1125; HOFFMAN RA, 1965, SCIENCE, V148, P1609, DOI 10.1126/science.148.3677.1609; JAMES SP, 1987, NEUROPSYCHOPHARMACOL, V1, P41, DOI 10.1016/0893-133X(87)90008-X; MADDOX J, 1995, NATURE, V378, P435, DOI 10.1038/378435a0; Pierpaoli W, 1995, MELATONIN MIRACLE; REDMAN J, 1983, SCIENCE, V219, P1089, DOI 10.1126/science.6823571; Reiter R., 1995, MELATONIN; SACK RL, 1991, J BIOL RHYTHM, V6, P249, DOI 10.1177/074873049100600305; TAMARKIN L, 1977, SCIENCE, V198, P953, DOI 10.1126/science.563102; TUREK FW, 1976, SCIENCE, V194, P1441, DOI 10.1126/science.1006311; VANCOEVORDEN A, 1991, AM J PHYSIOL, V260, pE651, DOI 10.1152/ajpendo.1991.260.4.E651	14	40	41	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					295	296		10.1038/379295a0	http://dx.doi.org/10.1038/379295a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552179				2022-12-24	WOS:A1996TR32300027
J	Gwee, KA; Graham, JC; McKendrick, MW; Collins, SM; Marshall, JS; Walters, SJ; Read, NW				Gwee, KA; Graham, JC; McKendrick, MW; Collins, SM; Marshall, JS; Walters, SJ; Read, NW			Psychometric scores and persistence of irritable bowel after infectious diarrhoea	LANCET			English	Article							LIFE EVENTS; COMMUNITY; SYMPTOMS; ANXIETY; RAT	Background Although previous studies have shown that psychological disturbances are frequently associated with the irritable bowel syndrome (IBS), the relation was not necessarily cause and effect. The development of chronic bowel symptoms resembling IBS after an episode of acute gastroenteritis has allowed us to examine prospectively the role of psychological factors. Methods 75 patients with acute gastroenteritis completed a series of psychometric tests soon after admission to hospital. Of these, 22 had persistent symptoms compatible with IBS after the acute illness, and in 20 of these the symptoms were still present at six months. Findings At the time of their initial illness, patients who subsequently developed IBS symptoms had higher scores for anxiety, depression, somatisation, and neurotic trait than those who returned to normal bowel function. The psychometric scores had not changed when remeasured three months after the acute illness. Lactose malabsorption was not an important factor. Interpretation These results support the hypothesis that psychological factors are important in IBS.	UNIV SHEFFIELD, NO GEN HOSP, GI MOTIL UNIT, SHEFFIELD S5 7AU, S YORKSHIRE, ENGLAND; ROYAL HALLAMSHIRE HOSP, DEPT INFECT DIS & MED, SHEFFIELD S10 2JF, S YORKSHIRE, ENGLAND; MCMASTER UNIV, INTESTINAL DIS RES UNIT, HAMILTON, ON, CANADA; UNIV SHEFFIELD, SHEFFIELD CTR HLTH & RELATED RES, SHEFFIELD, S YORKSHIRE, ENGLAND	Northern General Hospital; University of Sheffield; University of Sheffield; McMaster University; University of Sheffield				Marshall, Jean S./0000-0002-5642-1379; Walters, Stephen/0000-0001-9000-8126				[Anonymous], 1992, GASTROENTEROL INT; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; CHAUDHARY NA, 1962, Q J MED, V31, P307; COLLINS SM, 1992, ANN NY ACAD SCI, V664, P415, DOI 10.1111/j.1749-6632.1992.tb39780.x; COLLINS SM, 1989, STRESS DIGESTIVE MOT, P151; CRAIG TKJ, 1984, J PSYCHOSOM RES, V28, P411, DOI 10.1016/0022-3999(84)90073-4; CREED F, 1981, LANCET, V1, P1381; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; Efron Bradley., 1994, INTRO BOOTSTRAP; ESLER MD, 1973, NEW ENGL J MED, V288, P16, DOI 10.1056/NEJM197301042880104; Eysenck H.J., 1964, MANUAL EYSENCK PERSO, DOI DOI 10.1007/SPRINGERREFERENCE_184643; GUTHRIE E, 1991, GASTROENTEROLOGY, V100, P450, DOI 10.1016/0016-5085(91)90215-7; HEATON KW, 1992, GASTROENTEROLOGY, V102, P1962, DOI 10.1016/0016-5085(92)90320-X; JIANG CG, 1990, BRAIN BEHAV IMMUN, V4, P278, DOI 10.1016/0889-1591(90)90032-L; KHAN I, 1994, GASTROENTEROLOGY, V106, pA523; MACDONALD AJ, 1980, BRIT J PSYCHIAT, V136, P276, DOI 10.1192/bjp.136.3.276; MCHUGH KJ, 1993, GASTROENTEROLOGY, V104, pA1051; MCKENDRICK MW, 1994, J INFECTION, V29, P1, DOI 10.1016/S0163-4453(94)94871-2; METZ G, 1975, LANCET, V1, P1155; PALMER RL, 1974, POSTGRAD MED J, V50, P416, DOI 10.1136/pgmj.50.585.416; Rubio C A, 1992, In Vivo, V6, P81; SAUNDERS PR, 1993, GASTROENTEROLOGY, V104, pA1061; STEWART GT, 1950, BMJ-BRIT MED J, V1, P405, DOI 10.1136/bmj.1.4650.405; TALLEY NJ, 1992, AM J EPIDEMIOL, V136, P165, DOI 10.1093/oxfordjournals.aje.a116483; TALLEY NJ, 1991, EUR J GASTROEN HEPAT, V3, P71; VALLANCE BA, 1994, GASTROENTEROLOGY, V106, pA582; WHITEHEAD WE, 1988, GASTROENTEROLOGY, V95, P709, DOI 10.1016/S0016-5085(88)80018-0; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	28	417	427	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 20	1996	347	8995					150	153		10.1016/S0140-6736(96)90341-4	http://dx.doi.org/10.1016/S0140-6736(96)90341-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544549				2022-12-24	WOS:A1996TQ24400010
J	Buhl, EH; Otis, TS; Mody, I				Buhl, EH; Otis, TS; Mody, I			Zinc-induced collapse of augmented inhibition by GABA in a temporal lobe epilepsy model	SCIENCE			English	Article							PAIRED-PULSE DEPRESSION; DENTATE GRANULE CELLS; FIBER SYNAPTIC REORGANIZATION; RAT HIPPOCAMPAL SLICES; A-RECEPTOR COMPLEX; FASCIA-DENTATA; MOSSY FIBERS; PATCH-CLAMP; GYRUS; NEURONS	In the kindling model of temporal robe epilepsy, several physiological indicators of inhibition by gamma-aminobutyric acid (GABA) in the hippocampal dentate gyrus are consistent with an augmented, rather than a diminished, inhibition. In brain slices obtained from epileptic (kindled) rats, the excitatory drive onto inhibitory interneurons was increased and was paralleled by a reduction in the presynaptic autoinhibition of GABA release. This augmented inhibition was sensitive to zinc most likely after a molecular reorganization of GABA(A) receptor subunits. Consequently, during seizures, inhibition by GABA may be diminished by the zinc released from aberrantly sprouted messy fiber terminals of granule cells, which are found in many experimental models of epilepsy and in human temporal robe epilepsy.	UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL RNRC 3131,LOS ANGELES,CA 90095; UNIV OXFORD,MRC,ANAT NEUROPHARMACOL UNIT,OXFORD OX1 3TH,ENGLAND; UNIV WISCONSIN,SCH MED,CTR MED SCI,DEPT NEUROPHYSIOL,MADISON,WI 53706	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Oxford; University of Wisconsin System; University of Wisconsin Madison					NINDS NIH HHS [NS 12151, NS 30549] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS030549, R01NS030549, P50NS012151, P01NS012151] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; AVOLI M, 1991, EPILEPSY RES, V10, P33, DOI 10.1016/0920-1211(91)90092-T; BABB TL, 1991, NEUROSCIENCE, V42, P351, DOI 10.1016/0306-4522(91)90380-7; BEKENSTEIN JW, 1993, SCIENCE, V259, P97, DOI 10.1126/science.8093417; BOWERY NG, 1980, NATURE, V283, P92, DOI 10.1038/283092a0; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; CLARK M, 1994, MOL BRAIN RES, V26, P309, DOI 10.1016/0169-328X(94)90104-X; CRONIN J, 1988, BRAIN RES, V474, P181, DOI 10.1016/0006-8993(88)90681-6; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DE KONINCK Y, 1994, J NEUROPHYSIOL, V71, P1318, DOI 10.1152/jn.1994.71.4.1318; DRAGUHN A, 1990, NEURON, V5, P781, DOI 10.1016/0896-6273(90)90337-F; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; Frederickson C. J., 1994, Biological Signals, V3, P127; FREDERICKSON CJ, COMMUNICATION; HAN ZS, 1993, EUR J NEUROSCI, V5, P395, DOI 10.1111/j.1460-9568.1993.tb00507.x; HARRISON NL, 1994, NEUROPHARMACOLOGY, V33, P935, DOI 10.1016/0028-3908(94)90152-X; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; ISOKAWA M, 1991, EPILEPSY RES, V9, P242, DOI 10.1016/0920-1211(91)90058-N; ISOKAWA M, 1993, J NEUROSCI, V13, P1511, DOI 10.1523/jneurosci.13-04-01511.1993; KAMPHUIS W, 1994, NEUROSCI LETT, V174, P5, DOI 10.1016/0304-3940(94)90105-8; KAMPHUIS W, 1992, NEUROSCI LETT, V141, P101, DOI 10.1016/0304-3940(92)90344-7; KOHR G, 1993, J NEUROSCI, V13, P3612; KOKAIA M, 1994, MOL BRAIN RES, V23, P323, DOI 10.1016/0169-328X(94)90242-9; KRAUS JE, 1994, J NEUROSCI, V14, P4196; LAMBERT NA, 1994, J NEUROPHYSIOL, V72, P121, DOI 10.1152/jn.1994.72.1.121; LEGENDRE P, 1991, MOL PHARMACOL, V39, P267; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.ne.17.030194.003033; MACONOCHIE DJ, 1994, NEURON, V12, P61, DOI 10.1016/0896-6273(94)90152-X; MCNAMARA JO, 1994, J NEUROSCI, V14, P3413; MODY I, 1987, NATURE, V326, P701, DOI 10.1038/326701a0; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; MOTT DD, 1991, SCIENCE, V252, P1718, DOI 10.1126/science.1675489; MOTT DD, 1993, J NEUROPHYSIOL, V69, P674, DOI 10.1152/jn.1993.69.3.674; OKAZAKI MM, 1995, J COMP NEUROL, V352, P515, DOI 10.1002/cne.903520404; OLIVER MW, 1985, EXP BRAIN RES, V57, P443; OTIS TS, 1993, J PHYSIOL-LONDON, V463, P391, DOI 10.1113/jphysiol.1993.sp019600; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; OTIS TS, 1991, BRAIN RES, V545, P142, DOI 10.1016/0006-8993(91)91280-E; OTIS TS, 1992, NEUROSCIENCE, V49, P13, DOI 10.1016/0306-4522(92)90073-B; Ribak C E, 1991, Hippocampus, V1, P355, DOI 10.1002/hipo.450010403; SAXENA NC, 1994, J NEUROSCI, V14, P7077; Schwartzkroin PA, 1993, EPILEPSY MODELS MECH; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; SLOVITER RS, 1994, HIPPOCAMPUS, V4, P250, DOI 10.1002/hipo.450040304; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; SMART TG, 1990, BRIT J PHARMACOL, V99, P643, DOI 10.1111/j.1476-5381.1990.tb12984.x; SMART TG, 1991, BRIT J PHARMACOL, V103, P1837, DOI 10.1111/j.1476-5381.1991.tb12337.x; SMART TG, 1994, PROG NEUROBIOL, V42, P393, DOI 10.1016/0301-0082(94)90082-5; SMART TG, 1992, J PHYSIOL-LONDON, V447, P587, DOI 10.1113/jphysiol.1992.sp019020; SOLLESZ I, 1995, NEURON, V14, P1273; SOLTESZ I, 1995, J NEUROPHYSIOL, V73, P1763, DOI 10.1152/jn.1995.73.5.1763; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; SUTULA TP, 1991, EPILEPSY RES, V10, P62, DOI 10.1016/0920-1211(91)90096-X; THOMPSON SM, 1994, PROG NEUROBIOL, V42, P575, DOI 10.1016/0301-0082(94)90044-2; THOMPSON SM, 1993, TRENDS NEUROSCI, V16, P222, DOI 10.1016/0166-2236(93)90160-N; TITULAER MNG, 1995, J NEUROCHEM, V64, P2615; TUFF LP, 1983, BRAIN RES, V277, P79, DOI 10.1016/0006-8993(83)90909-5; URNO K, 1994, HIPPOCAMPUS, V4, P583; VALDES F, 1982, P NATL ACAD SCI-BIOL, V79, P193, DOI 10.1073/pnas.79.1.193; WANG YX, 1990, PFLUG ARCH EUR J PHY, V415, P582, DOI 10.1007/BF02583509; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WHITE G, 1995, NEUROREPORT, V6, P461, DOI 10.1097/00001756-199502000-00014	66	329	333	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					369	373		10.1126/science.271.5247.369	http://dx.doi.org/10.1126/science.271.5247.369			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553076				2022-12-24	WOS:A1996TQ52800047
J	Dodds, AW; Ren, XD; Willis, AC; Law, SKA				Dodds, AW; Ren, XD; Willis, AC; Law, SKA			The reaction mechanism of the internal thioester in the human complement component C4	NATURE			English	Article							STRUCTURAL BASIS; NUCLEOPHILIC MODIFICATION; 4TH COMPONENT; 3RD COMPONENT; BINDING; C-3; SEQUENCE; SITE; C3B; IDENTIFICATION	A KEY step in the elimination of pathogens from the body is the covalent binding of complement proteins C3 and C4 to their surfaces(1-5). Proteolytic activation of these proteins results in a conformational change(6,7), and an internal thioester(8-10) is exposed which reacts with amino or hydroxyl groups on the target surface to form amide or ester bonds, or is hydrolysed(11-15). We report here that the binding of the human C4A isotype involves a direct reaction between amino-nucleophiles and the thioester. A two-step mechanism is used by the C4B isotype. The histidine at position 1,106 (aspartic acid in C4A) first attacks the thioester to form an acyl-imidazole intermediate. The released thiol then acts as a base to catalyse the transfer of the acyl group to amino- and hydroxyl-nucleophiles, including water.	UNIV OXFORD,DEPT BIOCHEM,MRC,IMMUNOCHEM UNIT,OXFORD OX1 3QU,ENGLAND	University of Oxford			Law, Alex/A-2212-2011	Dodds, Alister William/0000-0003-3396-1257				BELT KT, 1984, CELL, V36, P907; BRACIAK TA, 1988, J BIOL CHEM, V263, P3999; CAMPBELL RD, 1981, BIOCHEM J, V199, P359, DOI 10.1042/bj1990359; CARROLL MC, 1990, P NATL ACAD SCI USA, V87, P6868, DOI 10.1073/pnas.87.17.6868; CHU CT, 1994, LAB INVEST, V71, P792; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DODDS AW, 1988, COMPLEMENT INFLAMMAT, V5, P89, DOI 10.1159/000463039; DODDS AW, 1986, IMMUNOGENETICS, V24, P279, DOI 10.1007/BF00395532; DODDS AW, 1990, BIOCHEM J, V265, P494; ENGHILD JJ, 1989, J BIOL CHEM, V264, P11428; FEARON DT, 1993, CURR OPIN IMMUNOL, V5, P341, DOI 10.1016/0952-7915(93)90051-S; HOSTETTER MK, 1982, NATURE, V298, P72, DOI 10.1038/298072b0; ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4458, DOI 10.1021/bi00518a034; ISENMAN DE, 1982, BIOCHEMISTRY-US, V21, P1109, DOI 10.1021/bi00535a001; ISENMAN DE, 1984, J IMMUNOL, V132, P3019; LAW SK, 1977, P NATL ACAD SCI USA, V74, P2701, DOI 10.1073/pnas.74.7.2701; LAW SK, 1979, J IMMUNOL, V123, P1388; LAW SKA, 1984, EMBO J, V3, P1819, DOI 10.1002/j.1460-2075.1984.tb02052.x; LAW SKA, 1995, FOCUS SERIES; LEVINE RP, 1989, CURR TOP MICROBIOL I, V153, P73; NG YC, 1993, COMPLEMENT HLTH DISE, P199; PANGBURN MK, 1980, J EXP MED, V152, P1102, DOI 10.1084/jem.152.4.1102; REN XD, 1995, FEBS LETT, V368, P87, DOI 10.1016/0014-5793(95)00606-A; REN XD, 1993, IMMUNOGENETICS, V37, P120, DOI 10.1007/BF00216835; SCHWEIZER M, 1987, EUR J BIOCHEM, V164, P375, DOI 10.1111/j.1432-1033.1987.tb11068.x; SEPP A, 1993, PROTEIN SCI, V2, P706, DOI 10.1002/pro.5560020502; TACK BF, 1980, P NATL ACAD SCI-BIOL, V77, P5764, DOI 10.1073/pnas.77.10.5764; THOMAS ML, 1983, BIOCHEMISTRY-US, V22, P942, DOI 10.1021/bi00273a036; WEITZMAN JB, 1993, COMPLEMENT HLTH DISE, P269; YU CY, 1986, EMBO J, V5, P2873, DOI 10.1002/j.1460-2075.1986.tb04582.x	30	149	155	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					177	179		10.1038/379177a0	http://dx.doi.org/10.1038/379177a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538770				2022-12-24	WOS:A1996TP36000062
J	Penny, GD; Kay, GF; Sheardown, SA; Rastan, S; Brockdorff, N				Penny, GD; Kay, GF; Sheardown, SA; Rastan, S; Brockdorff, N			Requirement for Xist in X chromosome inactivation	NATURE			English	Article							STEM-CELLS; CONTROLLING ELEMENTS; MOUSE DEVELOPMENT; GENE; EXPRESSION; EMBRYOS; TRANSLOCATION; LOCATION; POSITION; CONTAINS	The Xist gene has been proposed as a candidate for the X inactivation centre the master regulatory switch locus that controls X chromosome inactivation. So far this hypothesis has been supported solely by indirect evidence. Here we describe gene targeting of Xist, and provide evidence for its absolute requirement in the process of X chromosome inactivation.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,COMPARAT MED SECT,MRC,CLIN SCI CTR,LONDON W12 0NN,ENGLAND	Imperial College London			Kay, Graham F/A-4130-2011	Brockdorff, Neil/0000-0003-4838-2653				AGULNIK AI, 1994, HUM MOL GENET, V3, P879, DOI 10.1093/hmg/3.6.879; BALL TC, 1995, BLOOD, V85, P3086, DOI 10.1182/blood.V85.11.3086.bloodjournal85113086; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, MAMM GENOME, V1, P152, DOI 10.1007/BF00351061; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1994, NATURE, V368, P154, DOI 10.1038/368154a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BUZIN CH, 1994, DEVELOPMENT, V120, P3529; CATTANACH BM, 1970, GENET RES, V15, P183, DOI 10.1017/S0016672300001518; CATTANACH BM, 1974, GENET RES, V23, P291, DOI 10.1017/S0016672300014932; CATTANACH BM, 1969, GENET RES, V14, P223, DOI 10.1017/S0016672300002068; CATTANACH BM, 1967, GENETICS, V57, P331; DUTRILLAUX B, 1974, ANN GENET-PARIS, V17, P207; GREEN MC, 1989, GENETIC VARIANTS STR, P282; GRUMBACH MM, 1963, P NATL ACAD SCI USA, V49, P581, DOI 10.1073/pnas.49.5.581; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KAY GF, 1994, CELL, V77, P639, DOI 10.1016/0092-8674(94)90049-3; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARDON G, 1990, MOL CELL BIOL, V10, P681, DOI 10.1128/MCB.10.2.681; MCCARREY JR, 1992, NAT GENET, V2, P200, DOI 10.1038/ng1192-200; MCMAHON A, 1983, GENET RES, V41, P69, DOI 10.1017/S0016672300021078; Nagy A., 1993, Gene targeting: a practical approach., P147; NORRIS DP, 1994, CELL, V77, P41, DOI 10.1016/0092-8674(94)90233-X; PAMIERI SL, 1994, DEV BIOL, V166, P259; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; RASTAN S, 1982, GENET RES, V40, P139, DOI 10.1017/S0016672300019017; RASTAN S, 1994, CURR OPIN GENET DEV, V4, P292, DOI 10.1016/S0959-437X(05)80056-5; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUSSELL LB, 1970, GENETICS, V64, P281; SALIDO EC, 1992, NAT GENET, V2, P196, DOI 10.1038/ng1192-196; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SIMMLER MC, 1993, MAMM GENOME, V4, P523, DOI 10.1007/BF00364788; Singer-Sam J, 1992, PCR Methods Appl, V1, P160; SINGERSAM J, 1992, P NATL ACAD SCI USA, V89, P10469, DOI 10.1073/pnas.89.21.10469; TADA T, 1993, DEVELOPMENT, V119, P813; TAKAGI N, 1984, DEV BIOL, V103, P425, DOI 10.1016/0012-1606(84)90330-0; TAKAGI N, 1990, DEVELOPMENT, V109, P189; WEBB S, 1992, GENET RES, V59, P205, DOI 10.1017/S0016672300030494; WU JS, 1994, NAT GENET, V7, P491, DOI 10.1038/ng0894-491; ZINN AR, 1991, GENOMICS, V11, P1097, DOI 10.1016/0888-7543(91)90037-F	46	976	1005	1	114	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					131	137		10.1038/379131a0	http://dx.doi.org/10.1038/379131a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538762				2022-12-24	WOS:A1996TP36000048
J	denHeijer, M; Koster, T; Blom, HJ; Bos, GMJ; Briet, E; Reitsma, PH; Vandenbroucke, JP; Rosendaal, FR				denHeijer, M; Koster, T; Blom, HJ; Bos, GMJ; Briet, E; Reitsma, PH; Vandenbroucke, JP; Rosendaal, FR			Hyperhomocysteinemia as a risk factor for deep-vein thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMA HOMOCYSTEINE; PROTEIN-C; HOMOCYSTINURIA; DEFICIENCY; ARTERIAL; DISEASE	Background. Previous studies have suggested that hyperhomocysteinemia may be a risk factor for venous thrombosis, To assess the risk of venous thrombosis associated with hyperhomocysteinemia, we studied plasma homocysteine levels In patients with a first episode of deep-vein thrombosis and in normal control subjects. Methods. We measured plasma homocysteine levels in 269 patients with a first, objectively diagnosed episode of deep-vein thrombosis and in 269 healthy controls matched to the patients according to age and sex, Hyperhomocysteinemia was defined as a plasma homocysteine level above the 95th percentile in the control group (18.5 mu mol per liter). Results. Of the 269 patients, 28 (10 percent) had plasma homocysteine levels above the 95th percentile for the controls, as compared with 13 of the controls (matched odds ratio, 2.5; 95 percent confidence interval, 1.2 to 5.2), The association between elevated homocysteine levels and venous thrombosis was stronger among women than among men and increased with age, The exclusion of subjects with other established risk factors for thrombosis (e.g., a deficiency of protein C, protein S, or antithrombin; resistance to activated protein C; pregnancy or recent childbirth; or oral-contraceptive use) did not materially affect the risk estimates. Conclusions. High plasma homocysteine levels are a risk factor for deep-vein thrombosis in the general population. (C) 1996, Massachusetts Medical Society.	LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT HEMATOL,2333 AA LEIDEN,NETHERLANDS; UNIV NIJMEGEN HOSP,LAB PEDIAT & NEUROL,DEPT PEDIAT,6500 HB NIJMEGEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Radboud University Nijmegen	denHeijer, M (corresponding author), MUNICIPAL HOSP LEYENBURG,DEPT HEMATOL,POB 40551,2504 LN THE HAGUE,NETHERLANDS.		Rosendaal, Frits/Q-3842-2017; Vandenbroucke, Jan/AAM-3928-2020; Martinelli, ida/J-2287-2015	Rosendaal, Frits/0000-0003-2558-7496; Vandenbroucke, Jan/0000-0001-5668-6716; Martinelli, ida/0000-0001-9218-3622; Blom, Henk/0000-0001-5202-9241				BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BIENVENU T, 1991, PRESSE MED, V20, P985; BLOM HJ, 1994, FIBRINOLYSIS, V8, P86, DOI 10.1016/0268-9499(94)90257-7; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BRATTSTROM L, 1991, HAEMOSTASIS, V21, P51; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; DENHEIJER M, 1994, FIBRINOLYSIS S2, V8, P291; ENGBERSEN AMT, 1995, AM J HUM GENET, V56, P142; FALCON CR, 1994, ARTERIOSCLER THROMB, V14, P1080, DOI 10.1161/01.ATV.14.7.1080; FISKERSTRAND T, 1993, CLIN CHEM, V39, P263; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; KOSTER T, 1995, BLOOD, V85, P2756, DOI 10.1182/blood.V85.10.2756.bloodjournal85102756; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; KOSTER T, 1995, LANCET, V345, P152, DOI 10.1016/S0140-6736(95)90166-3; MUDD SH, 1985, AM J HUM GENET, V37, P1; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; RODGERS GM, 1990, BLOOD, V75, P895; RODGERS GM, 1988, J CLIN INVEST, V81, P1911, DOI 10.1172/JCI113538; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMPFER MJ, 1995, NEW ENGL J MED, V332, P328, DOI 10.1056/NEJM199502023320511; STAMPFER MJ, 1993, JAMA-J AM MED ASSOC, V270, P2726, DOI 10.1001/jama.270.22.2726; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; Te Poele-Pothoff M. T. W. B., 1995, Annals of Clinical Biochemistry, V32, P218; UELAND PM, 1993, ATHEROSCLEROTIC CARD, P183; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0	25	881	894	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1996	334	12					759	762		10.1056/NEJM199603213341203	http://dx.doi.org/10.1056/NEJM199603213341203			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ979	8592549	Green Published			2022-12-24	WOS:A1996TZ97900003
J	Haas, GG				Haas, GG			Antisperm antibodies in infertile men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							SPERM-ASSOCIATED IMMUNOGLOBULINS; PENETRATION; BINDING; PLACEBO				Haas, GG (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEPT OBSTET & GYNECOL,SECT REPROD ENDOCRINOL INFERTIL,OKLAHOMA CITY,OK 73190, USA.							ACOSTA AA, 1994, FERTIL STERIL, V62, P826; ADEGHE AJH, 1989, INT J ANDROL, V12, P281, DOI 10.1111/j.1365-2605.1989.tb01315.x; ASCH RH, 1977, FERTIL STERIL, V28, P671; BRONSON RA, 1987, FERTIL STERIL, V48, P505; HAAS GG, 1987, FERTIL STERIL, V47, P295; HAAS GG, 1985, AM J REPROD IM MIC, V7, P109; HAAS GG, 1988, J ANDROL, V9, P190; HAAS GG, 1986, FERTIL STERIL, V46, P334; HAMILTON F, 1989, J IN VITRO FERTIL EM, V6, P342, DOI 10.1007/BF01138774; HENDRY WF, 1990, LANCET, V335, P85, DOI 10.1016/0140-6736(90)90548-J; LANSFORD B, 1990, J ANDROL, V11, P532; MAHONY MC, 1991, J REPROD IMMUNOL, V19, P287, DOI 10.1016/0165-0378(91)90041-N	12	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					885	886		10.1001/jama.275.11.885	http://dx.doi.org/10.1001/jama.275.11.885			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ971	8596228				2022-12-24	WOS:A1996TZ97100034
J	Ferradini, L; Gu, H; DeSmet, A; Rajewsky, K; Reynaud, CA; Weill, JC				Ferradini, L; Gu, H; DeSmet, A; Rajewsky, K; Reynaud, CA; Weill, JC			Rearrangement-enhancing element upstream of the mouse immunoglobulin kappa chain J cluster	SCIENCE			English	Article							REGION GENE SEGMENTS; B-CELL; V(D)J RECOMBINATION; INTRON ENHANCER; TRANSCRIPTION; MICE; EXPRESSION; HEAVY; LOCUS; DISRUPTION	Transcriptional regulatory elements have been shown to be necessary but not sufficient for the developmental regulation of immunoglobulin gene rearrangement in mouse precursor B cells. In the chicken lambda light chain locus, additional elements in the V-J intervening sequence are involved in negative and positive regulation of rearrangement. Here, mutation of the mouse homolog of a chicken element, located in the V-kappa-J(kappa) intervening sequence upstream of the J(kappa) duster, was shown to significantly decrease rearrangement. This cis-acting recombination-enhancing element affects the rearrangement process without being involved in regulating transcription.	UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY	University of Cologne	Ferradini, L (corresponding author), UNIV PARIS 05, FAC MED NECKER ENFANT MALAD,INST NECKER,INSERM, U373, 156 RUE VAUGIRARD, F-75730 PARIS 05, FRANCE.			Rajewsky, Klaus/0000-0002-6633-6370				ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; ARTELT P, 1991, GENE, V99, P249, DOI 10.1016/0378-1119(91)90134-W; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; BUCCHINI D, 1987, NATURE, V326, P409, DOI 10.1038/326409a0; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; DENG CX, 1993, MOL CELL BIOL, V13, P2134, DOI 10.1128/MCB.13.4.2134; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; Ferradini L, 1994, Semin Immunol, V6, P165, DOI 10.1006/smim.1994.1022; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; Grutzmann R., 1981, THESIS U COLOGNE COL; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LAUSTER R, 1993, EMBO J, V12, P4615, DOI 10.1002/j.1460-2075.1993.tb06150.x; LECLERCQ L, 1989, NUCLEIC ACIDS RES, V17, P6809, DOI 10.1093/nar/17.17.6809; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN DJ, 1990, MOL CELL BIOL, V10, P1950, DOI 10.1128/MCB.10.5.1950; MEDINA CA, 1993, J EXP MED, V177, P1317, DOI 10.1084/jem.177.5.1317; NELSON KJ, 1984, NUCLEIC ACIDS RES, V12, P1911, DOI 10.1093/nar/12.4.1911; NISHI M, 1985, P NATL ACAD SCI USA, V82, P6399, DOI 10.1073/pnas.82.19.6399; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; OPITZ HG, 1982, IMMUNOBIOLOGY, V160, P438, DOI 10.1016/S0171-2985(82)80007-7; RETH M, 1981, THESIS U COLOGNE COL; SAUER B, 1990, New Biologist, V2, P441; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SERWE M, 1993, EMBO J, V12, P2321, DOI 10.1002/j.1460-2075.1993.tb05886.x; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; STORB U, 1983, P NATL ACAD SCI-BIOL, V80, P6642, DOI 10.1073/pnas.80.21.6642; TAKEDA S, 1993, EMBO J, V12, P2329, DOI 10.1002/j.1460-2075.1993.tb05887.x; VANNESS BG, 1981, CELL, V27, P593, DOI 10.1016/0092-8674(81)90401-3; WEAVER D, 1987, P NATL ACAD SCI USA, V84, P1516, DOI 10.1073/pnas.84.6.1516; WOOD DL, 1984, P NATL ACAD SCI-BIOL, V81, P4756, DOI 10.1073/pnas.81.15.4756; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	41	64	66	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 8	1996	271	5254					1416	1420		10.1126/science.271.5254.1416	http://dx.doi.org/10.1126/science.271.5254.1416			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596914				2022-12-24	WOS:A1996TY96100046
J	Sewry, CA; Philpot, J; Sorokin, LM; Wilson, LA; Naom, I; Goodwin, F; DAlessandro, M; Dubowitz, V; Muntoni, F				Sewry, CA; Philpot, J; Sorokin, LM; Wilson, LA; Naom, I; Goodwin, F; DAlessandro, M; Dubowitz, V; Muntoni, F			Diagnosis of merosin (laminin-2) deficient congenital muscular dystrophy by skin biopsy	LANCET			English	Article								Background The alpha 2 chain of laminin-2 (merosin), encoded by a gene on chromosome 6q22, is deficient in about half the cases of congenital muscular dystrophy. Diagnosis of this condition has relied on immunocytochemical analysis of the alpha 2 chain in muscle biopsy specimens. We have observed that normal skin also expresses laminin alpha 2 in the basement membrane at the junction of the dermis and epidermis. Here we have investigated laminin alpha 2 deficiency in skin biopsy specimens from two patients with congenital muscular dystrophy. Participants Two patients with severe congenital muscular dystrophy gave informed consent to a shin biopsy. The girl was aged 10 and the boy was aged 7. The specimens were labelled with a commercially available mouse monoclonal antibody and a rat monoclonal antibody (4H8-2), which recognise an 80 and a 380 kDa fragment of the alpha 2 chain, respectively. The antibodies were visualised by standard methods. A muscle biopsy specimen was available for each case, and was processed with the skin biopsy samples (from the girl a few months previously, from the boy at age 14 days). Skin biopsies were done on four controls with normal expression of laminin alpha 2 on their skeletal muscle fibres. Findings We did not detect laminin alpha 2 in skin specimens from either case, although the controls were positive. The muscle biopsy specimens from the girl showed a few fibres, with traces of laminin alpha 2; those from the boy showed no laminin alpha 2. Interpretation Skin biopsy specimens will provide a useful alternative to muscle biopsy samples for the assessment of laminin-2 (merosin) status in congenital muscular dystrophy.	ROYAL POSTGRAD MED SCH,MUSCLE CELL BIOL GRP,MRC,CTR CLIN SCI,LONDON W12 0NN,ENGLAND; UNIV ERLANGEN NURNBERG,INST EXPT MED,W-8520 ERLANGEN,GERMANY	Imperial College London; University of Erlangen Nuremberg	Sewry, CA (corresponding author), ROYAL POSTGRAD MED SCH,DEPT PAEDIAT & NEONATAL MED,NEUROMUSCULAR UNIT,LONDON W12 0NN,ENGLAND.			Sorokin, Lydia/0000-0001-7704-7921				BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; DUBOWITZ V, 1985, MUSCLE BIOPSY MODERN; Dubowitz V., 1995, MUSCLE DISORDERS CHI; ENGVALL E, 1993, KIDNEY INT, V43, P2, DOI 10.1038/ki.1993.2; HELBLINGLECLERC, 1995, CR ACAD SCI PARIS LI, V318, P1245; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; HILLAIRE D, 1994, HUM MOL GENET, V3, P1657, DOI 10.1093/hmg/3.9.1657; MERCURI E, 1995, NEUROPEDIATRICS, V26, P156, DOI 10.1055/s-2007-979746; MERCURI E, 1995, NEUROPEDIATRICS, V26, P3, DOI 10.1055/s-2007-979711; MUNTONI F, 1995, LANCET, V345, P591, DOI 10.1016/S0140-6736(95)90504-9; PHILPOT J, 1995, NEUROMUSCULAR DISORD, V5, P301, DOI 10.1016/0960-8966(94)00069-L; SCHULER F, 1995, J CELL SCI, V108, P3795; SEWRY CA, 1995, NEUROMUSCULAR DISORD, V5, P307, DOI 10.1016/0960-8966(94)00072-H; SHORER Z, 1995, J CHILD NEUROL, V10, P472, DOI 10.1177/088307389501000610; TODA T, 1993, NAT GENET, V5, P283, DOI 10.1038/ng1193-283; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351	16	72	74	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					582	584		10.1016/S0140-6736(96)91274-X	http://dx.doi.org/10.1016/S0140-6736(96)91274-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596321				2022-12-24	WOS:A1996TX69400012
J	Altman, RB; Merino, JE				Altman, RB; Merino, JE			Knotted umbilical cord	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Altman, RB (corresponding author), STANFORD UNIV,SCH MED,STANFORD,CA 94305, USA.								0	2	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 29	1996	334	9					573	573		10.1056/NEJM199602293340905	http://dx.doi.org/10.1056/NEJM199602293340905			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW696	8569825				2022-12-24	WOS:A1996TW69600005
J	Pontoglio, M; Barra, J; Hadchouel, M; Doyen, A; Kress, C; Bach, JP; Babinet, C; Yaniv, M				Pontoglio, M; Barra, J; Hadchouel, M; Doyen, A; Kress, C; Bach, JP; Babinet, C; Yaniv, M			Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome	CELL			English	Article							ENRICHED TRANSCRIPTION FACTOR; DNA-BINDING; ALBUMIN GENE; EXPRESSION; PROTEIN; MOUSE; CELLS; HOMEODOMAIN; DOMAIN; HOMEOPROTEINS	HNF1 is a transcriptional activator of many hepatic genes including albumin, alpha 1-antitrypsin, and alpha- and beta-fibrinogen. It is related to the homeobox gene family and is predominantly expressed in liver and kidney. Mice lacking HNF1 fail to thrive and die around weaning after a progressive wasting syndrome with a marked liver enlargement. The transcription rate of genes like albumin and alpha 1-antitrypsin is reduced, while the gene coding for phenylalanine hydroxylase is totally silent, giving rise to phenylketonuria. Mutant mice also suffer from severe Fanconi syndrome caused by renal proximal tubular dysfunction. The resulting massive urinary glucose loss leads to energy and water wasting. HNF1-deficient mice may provide a model for human renal Fanconi syndrome.	INST PASTEUR,CTR NATL RECH SCI,URA 1960,UNITE BIOL DEV,F-75724 PARIS 15,FRANCE; HOP KREMLIN BICETRE,INSERM,U347,F-94276 LE KREMLIN BICETR,FRANCE; HOP KREMLIN BICETRE,BIOCHIM LAB,F-94276 LE KREMLIN BICETR,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP	Pontoglio, M (corresponding author), INST PASTEUR,DEPT BIOTECHNOL,CTR NATL RECH SCI,URA 1644,UNITE VIRUS ONCOGENES,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BESMOND C, 1983, BIOCHEM BIOPH RES CO, V117, P601, DOI 10.1016/0006-291X(83)91243-3; BLUMENFELD M, 1991, DEVELOPMENT, V113, P589; BRADLEY A, 1987, TETATOCARCINOMAS EMB; BRENNER BM, 1991, KIDNEY; CAMPOS JR, 1991, EMBO J, V10, P1445; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CEREGHINI S, 1992, DEVELOPMENT, V116, P783; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P120; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; CITRON BA, 1992, P NATL ACAD SCI USA, V89, P11891, DOI 10.1073/pnas.89.24.11891; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KESNER L, 1975, CLIN CHEM, V21, P353; KOEPSELL H, 1990, J MEMBRANE BIOL, V114, P113, DOI 10.1007/BF01869093; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LAZZARO D, 1992, DEVELOPMENT, V114, P469; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LONE YC, 1986, FEBS LETT, V195, P97, DOI 10.1016/0014-5793(86)80138-7; MALATHI P, 1979, BIOCHIM BIOPHYS ACTA, V554, P259, DOI 10.1016/0005-2736(79)90023-3; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCDONALD JD, 1988, J NEUROCHEM, V50, P655, DOI 10.1111/j.1471-4159.1988.tb02961.x; MCDONALD JD, 1990, P NATL ACAD SCI USA, V87, P1965, DOI 10.1073/pnas.87.5.1965; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; OTT MO, 1991, MECH DEVELOP, V36, P47, DOI 10.1016/0925-4773(91)90071-D; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROYER P, 1983, MOL CLONING; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TRONCHE F, 1989, MOL CELL BIOL, V9, P4759, DOI 10.1128/MCB.9.11.4759; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WANG YB, 1994, J BIOL CHEM, V269, P9137; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; [No title captured]	44	480	496	0	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					575	585		10.1016/S0092-8674(00)81033-8	http://dx.doi.org/10.1016/S0092-8674(00)81033-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598044	Bronze			2022-12-24	WOS:A1996TX17600010
J	Lois, C; GarciaVerdugo, JM; AlvarezBuylla, A				Lois, C; GarciaVerdugo, JM; AlvarezBuylla, A			Chain migration of neuronal precursors	SCIENCE			English	Article							DEVELOPING CEREBRAL-CORTEX; FIBRILLARY ACIDIC PROTEIN; RADIAL GLIAL FIBERS; RAT OLFACTORY-BULB; ADULT AVIAN BRAIN; CELL-MIGRATION; MONOCLONAL-ANTIBODY; SUBEPENDYMAL LAYER; GRANULE CELLS; OPTIC TECTUM	In the brain of adult mice, cells that divide in the subventricular zone of the lateral ventricle migrate up to 5 millimeters to the olfactory bulb where they differentiate into neurons. These migrating cells were found to move as chains through a well-defined pathway, the rostral migratory stream. Electron microscopic analysis of serial sections showed that these chains contained only closely apposed, elongated neuroblasts connected by membrane specializations. A second cell type, which contained glial fibrillary acidic protein, ensheathed the chains of migrating neuroblasts. Thus, during chain migration, neural precursors moved associated with each other and were not guided by radial glial or axonal fibers.	ROCKEFELLER UNIV,NEW YORK,NY 10021; UNIV VALENCIA,FAC BIOL,E-46100 VALENCIA,SPAIN	Rockefeller University; University of Valencia			García-Verdugo, José Manuel/L-8421-2017	García-Verdugo, José Manuel/0000-0001-9872-6499; Alvarez-Buylla, Arturo/0000-0003-4426-8925	NICHD NIH HHS [HD32116] Funding Source: Medline; NINDS NIH HHS [NS28478] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS028478, R01NS028478, R37NS028478] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1963, ANAT REC, V145, P573, DOI 10.1002/ar.1091450409; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ALVAREZBUYLLA A, 1988, NATURE, V335, P353, DOI 10.1038/335353a0; ALVAREZBUYLLA A, 1987, J COMP NEUROL, V264, P159, DOI 10.1002/cne.902640203; BAYER SA, 1982, SCIENCE, V216, P890, DOI 10.1126/science.7079742; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BIGNAMI A, 1974, J COMP NEUROL, V153, P27, DOI 10.1002/cne.901530104; BONFANTI L, 1994, NEUROSCIENCE, V62, P291, DOI 10.1016/0306-4522(94)90333-6; BOURRAT F, 1990, J COMP NEUROL, V294, P1, DOI 10.1002/cne.902940102; COROTTO FS, 1993, NEUROSCI LETT, V149, P111, DOI 10.1016/0304-3940(93)90748-A; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; CULICAN SM, 1990, J NEUROSCI, V10, P684; EDMONDSON JC, 1987, J NEUROSCI, V7, P1928; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FISHELL G, 1993, NATURE, V362, P636, DOI 10.1038/362636a0; GADISSEUX JF, 1992, J COMP NEUROL, V322, P246, DOI 10.1002/cne.903220210; GARCIAVERDUGO JM, 1986, J MORPHOL, V189, P189, DOI 10.1002/jmor.1051890209; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; GOODENOUGH DA, 1970, J CELL BIOL, V45, P272, DOI 10.1083/jcb.45.2.272; GRAY GE, 1988, P NATL ACAD SCI USA, V85, P7356, DOI 10.1073/pnas.85.19.7356; Herrup Karl, 1994, Current Opinion in Neurobiology, V4, P108, DOI 10.1016/0959-4388(94)90039-6; Jacobson M., 1991, DEV NEUROBIOLOGY; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; KISHI K, 1990, ARCH HISTOL CYTOL, V53, P219, DOI 10.1679/aohc.53.219; KISHI K, 1987, J COMP NEUROL, V258, P112, DOI 10.1002/cne.902580109; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOPEZGARCIA C, 1988, DEV BRAIN RES, V43, P167, DOI 10.1016/0165-3806(88)90096-X; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; MISSON JP, 1988, DEV BRAIN RES, V44, P95, DOI 10.1016/0165-3806(88)90121-6; MOODY SA, 1983, J COMP NEUROL, V213, P344, DOI 10.1002/cne.902130309; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; ONO K, 1990, ANAT EMBRYOL, V182, P11; OROURKE NA, 1992, SCIENCE, V258, P299, DOI 10.1126/science.1411527; PIXLEY SKR, 1984, DEV BRAIN RES, V15, P201, DOI 10.1016/0165-3806(84)90097-X; PUELLES L, 1977, ANAT EMBRYOL, V150, P187, DOI 10.1007/BF00316650; RAKIC P, 1981, TRENDS NEUROSCI, V4, P184, DOI 10.1016/0166-2236(81)90060-6; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1990, EXPERIENTIA, V46, P882, DOI 10.1007/BF01939380; RAYMOND PA, 1983, J NEUROSCI, V3, P1077; ROUSSELOT P, 1995, J COMP NEUROL, V351, P51, DOI 10.1002/cne.903510106; SCHMECHEL DE, 1979, ANAT EMBRYOL, V156, P115, DOI 10.1007/BF00300010; STAHELIN LA, 1974, INT REV CYTOL, V39, P191; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; VOIGT T, 1989, J COMP NEUROL, V289, P74, DOI 10.1002/cne.902890106; WALSH C, 1990, EXPERIENTIA, V46, P940, DOI 10.1007/BF01939387; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; 1970, ANAT REC, V166, P257	48	1030	1073	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					978	981		10.1126/science.271.5251.978	http://dx.doi.org/10.1126/science.271.5251.978			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584933				2022-12-24	WOS:A1996TV70400046
J	Leor, J; Poole, WK; Kloner, RA				Leor, J; Poole, WK; Kloner, RA			Sudden cardiac death triggered by an earthquake	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CIRCADIAN VARIATION; ISCHEMIC DEATH; STRESS; WAR; FREQUENCY; MORTALITY	Background. The earthquake that struck the Los Angeles area at 4:31 a.m. on January 17, 1994, was one of the strongest earthquakes ever recorded in a major city in North America. Once the life-threatening situation was over, the Northridge earthquake, so called because its epicenter was near Northridge, California, just north of Los Angeles, provided investigators an unusual opportunity to examine the relation between emotional stress and sudden cardiac death. Methods. We reviewed the records of the Department of Coroner of Los Angeles County for the week before the earthquake, the day of the earthquake, the six days after the earthquake, and corresponding control periods in 1991, 1992, and 1993. Results. On the day of the earthquake, there was a sharp increase in the number of sudden deaths from cardiac causes that were related to atherosclerotic cardiovascular disease, from a daily average (+/-SD) of 4.6+/-2.1 in the preceding week to 24 on the day of the earthquake (z=4.41, P<0.001). Sixteen victims of sudden death either died or had premonitory symptoms, usually chest pain, within the first hour after the initial tremor. Only three sudden deaths occurred during or immediately after unusual physical exertion. During the six days after the earthquake, the number of sudden deaths declined to below the base-line value, to an average of 2.7+/-1.2 per day. Conclusions. The Northridge earthquake was a significant trigger of sudden death due to cardiac causes, independently of physical exertion. This finding, along with the unusually low incidence of such deaths in the week after the earthquake, suggests that emotional stress may precipitate cardiac events in people who are predisposed to such events. (C) 1996, Massachusetts Medical Society.	UNIV SO CALIF,HOSP GOOD SAMARITAN,INST HEART,LOS ANGELES,CA 90017; RES TRIANGLE INST,RES TRIANGLE PK,NC 27709	University of Southern California; Research Triangle Institute			Kloner, Robert A/B-2971-2012; Leor, Jonathan/T-8038-2019					DANENBERG HD, 1991, ISRAEL J MED SCI, V27, P627; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DAVIES MJ, 1985, BRIT HEART J, V53, P363; DOBSON AJ, 1991, MED J AUSTRALIA, V155, P757, DOI 10.5694/j.1326-5377.1991.tb94029.x; Hall JF., 1994, NORTHRIDGE EARTHQUAK; KARK JD, 1995, JAMA-J AM MED ASSOC, V273, P2108; KATSOUYANNI K, 1986, INT J EPIDEMIOL, V15, P326, DOI 10.1093/ije/15.3.326; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P299; LEOR J, 1995, J AM COLL CARDIOL, V25, pA105; MEISEL SR, 1991, LANCET, V338, P660, DOI 10.1016/0140-6736(91)91234-L; Muller J E, 1992, Ann Epidemiol, V2, P393; MULLER JE, 1987, CIRCULATION, V75, P131, DOI 10.1161/01.CIR.75.1.131; MULLER JE, 1994, J AM COLL CARDIOL, V23, P809, DOI 10.1016/0735-1097(94)90772-2; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; MYERBURG RJ, 1992, HEART DIS TXB CARDIO, P756; NISHIYAMA Y, 1995, CIRCULATION S1, V92, P606; RIDKER PM, 1990, CIRCULATION, V82, P897, DOI 10.1161/01.CIR.82.3.897; RUMBOLDT Z, 1993, LANCET, V341, P965, DOI 10.1016/0140-6736(93)91260-S; TOFLER GH, 1987, NEW ENGL J MED, V316, P1514, DOI 10.1056/NEJM198706113162405; TOFLER GH, 1995, CIRCULATION, V92, P1203, DOI 10.1161/01.CIR.92.5.1203; TRICHOPOULOS D, 1983, LANCET, V1, P441; WILLICH SN, 1989, CIRCULATION, V80, P853, DOI 10.1161/01.CIR.80.4.853; WILLICH SN, 1993, CIRCULATION, V87, P1442, DOI 10.1161/01.CIR.87.5.1442; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7; YEUNG AC, 1991, NEW ENGL J MED, V325, P1551, DOI 10.1056/NEJM199111283252205; 1994, SCIENCE, V266, P389	26	561	573	1	26	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 15	1996	334	7					413	419		10.1056/NEJM199602153340701	http://dx.doi.org/10.1056/NEJM199602153340701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU696	8552142	Bronze			2022-12-24	WOS:A1996TU69600001
J	Bolland, S; Kleckner, N				Bolland, S; Kleckner, N			The three chemical steps of Tn10/IS10 transposition involve repeated utilization of a single active site	CELL			English	Article							DNA STRAND TRANSFER; TN10 TRANSPOSITION; TN7 TRANSPOSITION; INVITRO PROCEEDS; TARGET SITE; MU-DNA; MECHANISM; RECOMBINATION; INTERMEDIATE; CATALYSIS	Nonreplicative transposition by Tn10/IS10 involves three chemical steps at each transposon end: cleavage of the two strands plus joining of one strand to target DNA. These steps occur within a synaptic complex comprising two transposon ends and monomers of IS10 transposase. We report four transposase mutations that individually abolish each of the three chemical steps without affecting the synaptic complex. We conclude that a single constellation of residues, the ''active site,'' directly catalyzes each of the three steps. Analyses of reactions containing mixtures of wild-type and catalysis-defective transposases indicate that a single transposase monomer at each end catalyzes the cleavage of two strands and that strand transfer is carried out by the same monomers that previously catalyzed cleavage. These and other data suggest that one active site unit carries out all three reactions in succession at one transposon end.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University					NIGMS NIH HHS [R01 GM25326] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025326] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAINTON RJ, 1993, CELL, V72, P931, DOI 10.1016/0092-8674(93)90581-A; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1994, GENE DEV, V8, P2416, DOI 10.1101/gad.8.20.2416; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BENDER J, 1986, CELL, V45, P801, DOI 10.1016/0092-8674(86)90555-6; BENJAMIN HW, 1992, P NATL ACAD SCI USA, V89, P4648, DOI 10.1073/pnas.89.10.4648; BOLLAND S, 1995, P NATL ACAD SCI USA, V92, P7314; CECH TR, 1992, J BIOL CHEM, V267, P17479; CHALMERS RM, 1994, J BIOL CHEM, V269, P8029; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; COEN ES, 1989, MOBILE DNA, P227; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; Grindley NDF, 1995, CELL, V83, P1063, DOI 10.1016/0092-8674(95)90132-9; HANIFORD DB, 1991, CELL, V64, P171; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; HUISMAN O, 1989, EMBO J, V8, P2101, DOI 10.1002/j.1460-2075.1989.tb03619.x; HUISMAN O, 1987, GENETICS, V116, P185; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KAUFMAN PD, 1992, CELL, V69, P27, DOI 10.1016/0092-8674(92)90116-T; KLECKNER N, 1995, CURR TOP MICROBIOL I, V204, P49; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KWON D, 1995, P NATL ACAD SCI USA, V92, P8234, DOI 10.1073/pnas.92.18.8234; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; REZSOHAZY R, 1993, MOL MICROBIOL, V9, P1283, DOI 10.1111/j.1365-2958.1993.tb01258.x; SAKAI J, 1995, EMBO J, V14, P4374, DOI 10.1002/j.1460-2075.1995.tb00112.x; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; VANLUENEN HGAM, 1994, CELL, V79, P293, DOI 10.1016/0092-8674(94)90198-8; WAUGH DS, 1993, P NATL ACAD SCI USA, V90, P9596, DOI 10.1073/pnas.90.20.9596	38	85	86	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					223	233		10.1016/S0092-8674(00)80977-0	http://dx.doi.org/10.1016/S0092-8674(00)80977-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565068	Bronze			2022-12-24	WOS:A1996TR59500009
J	Caron, H; vanSluis, P; deKraker, J; Bokkerink, J; Egeler, M; Laureys, G; Slater, R; Westerveld, A; Voute, PA; Versteeg, R				Caron, H; vanSluis, P; deKraker, J; Bokkerink, J; Egeler, M; Laureys, G; Slater, R; Westerveld, A; Voute, PA; Versteeg, R			Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PEDIATRIC-ONCOLOGY-GROUP; CELLULAR DNA CONTENT; NEURO-BLASTOMA; CHILDHOOD NEUROBLASTOMA; MYC; HETEROZYGOSITY; ONCOGENE; TUMOR	Background. Neuroblastoma is a childhood tumor derived from cells of the neural crest, with a widely variable outcome. Differences in the behavior and prognosis of the tumor suggest that neuroblastoma can be divided into several biologic subgroups. We evaluated the most frequent genetic abnormalities in neuroblastoma to determine their prognostic value. Methods. We used Southern blot analysis to study the allelic loss of chromosomes 1p, 4p, 11q, and 14q, the duplication of chromosome 17q, and the amplification of the N-myc oncogene in 89 neuroblastomas. We also determined the nuclear DNA content of the tumor cells. Results. Allelic loss of chromosome 1p, N-myc amplification, and extra copies of chromosome 17q were significantly associated with unfavorable outcomes. In a multivariate analysis, loss of chromosome Ip was the most powerful prognostic factor. It provided strong prognostic information when it was included in multivariate models containing the prognostic factors of age and stage or serum ferritin level and stage. Among the patients with stage I, II, or IVS disease, the mean (+/-SD) three-year event-free survival was 100 percent in those without allelic loss of chromosome Ip and 34 +/- 15 percent in those with such loss; the rates of three-year event-free survival among the patients with stage III and stage IV disease were 53 +/- 10 percent and 0 percent, respectively. Conclusions. The loss of chromosome 1p is a strong prognostic factor in patients with neuroblastoma, independently of age and stage. It reliably identifies patients at high risk in stages I, II, and IVS, which are otherwise clinically favorable. More intensive therapy may be considered in these patients. Patients in stages III and IV with allelic loss of chromosome 1p have a very poor outlook, whereas those without such loss are at moderate risk. (C) 1996, Massachusetts Medical Society.	UNIV AMSTERDAM, ACAD MED CTR, INST HUMAN GENET, 1105 AZ AMSTERDAM, NETHERLANDS; UNIV NIJMEGEN, CTR PEDIAT ONCOL SE NETHERLANDS, NIJMEGEN, NETHERLANDS; ERASMUS UNIV ROTTERDAM, SOPHIA KINDERZIEKENHUIS, ROTTERDAM, NETHERLANDS; STATE UNIV GHENT HOSP, INST HUMAN GENET, GHENT, BELGIUM	University of Amsterdam; Academic Medical Center Amsterdam; Radboud University Nijmegen; Erasmus University Rotterdam; Ghent University; Ghent University Hospital	Caron, H (corresponding author), UNIV AMSTERDAM, ACAD MED CTR, EMMA KINDERZIEKENHUIS, DEPT PEDIAT ONCOL & HEMATOL, POB 22700, 1100 DE AMSTERDAM, NETHERLANDS.		laureys, genevieve/AAG-2390-2021; Bokkerink, J.P.M./L-4210-2015; Versteeg, Rogier/AAQ-1765-2020	Versteeg, Rogier/0000-0001-7172-0388				AMBROS PF, 1995, EUR J CANCER, V31A, P510, DOI 10.1016/0959-8049(95)00044-J; BERTHOLD F, 1992, AM J PEDIAT HEMATOL, V14, P207; BOURHIS J, 1991, CANCER RES, V51, P33; CAMPOS N, 1988, COMPUT METH PROG BIO, V27, P223, DOI 10.1016/0169-2607(88)90086-7; CAMPOS N, 1989, AM J EPIDEMIOL, V129, P439, DOI 10.1093/oxfordjournals.aje.a115148; CARON H, 1994, AM J HUM GENET, V55, P341; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CARON H, 1993, NAT GENET, V4, P431, DOI 10.1038/ng0893-431a; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FONG CT, 1992, CANCER RES, V52, P1780; HEDLEY DW, 1983, J HISTOCHEM CYTOCHEM, V31, P1333, DOI 10.1177/31.11.6619538; JOSHI VV, 1992, CANCER-AM CANCER SOC, V69, P2197, DOI 10.1002/1097-0142(19920415)69:8<2197::AID-CNCR2820690829>3.0.CO;2-X; LOOK AT, 1984, NEW ENGL J MED, V311, P231, DOI 10.1056/NEJM198407263110405; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SHUSTER JJ, 1992, AM J CLIN ONCOL-CANC, V15, P295, DOI 10.1097/00000421-199208000-00004; SILBER JH, 1991, CANCER RES, V51, P1426; SRIVATSAN ES, 1991, PROG CLIN BIOL RES, V366, P91; SUZUKI T, 1989, CANCER RES, V49, P1095; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; VANROY N, 1994, GENE CHROMOSOME CANC, V10, P103, DOI 10.1002/gcc.2870100205; VOUTE PA, 1992, CANCER CHILDREN CLIN	25	327	331	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 25	1996	334	4					225	230		10.1056/NEJM199601253340404	http://dx.doi.org/10.1056/NEJM199601253340404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ755	8531999	Green Published			2022-12-24	WOS:A1996TQ75500004
J	Gillis, CR; Hole, DJ				Gillis, CR; Hole, DJ			Survival outcome of care by specialist surgeons in breast cancer: A study of 3786 patients in the west of Scotland	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare survival outcome for patients with breast cancer cared for by specialist and non-specialist surgeons in a geographically defined area. Design-Retrospective study of all female patients aged under 75 years in the area treated between 1980 and June 1988 (before breast screening began). Patients were identified from the cancer registry and from pathology records of all hospitals in the area. Specialist surgeons were identified by one author. All other surgeons caring for patients from the area were considered non-specialists. Setting-A geographically defined population in urban west of Scotland. Subjects-3786 patients with histologically verified breast cancer operated on between 1 January 1980 and 30 June 1988 and followed to 31 December 1993. Main outcome measures-Five and 10 year survival rates for specialists and non-specialists; relative hazard ratios derived from Cox's proportional hazards model adjusted for prognostic factors-age, socioeconomic status, tumour size, and nodal involvement. Results-The five year survival rate was 9% higher and the 10 year survival 8% higher for patients cared for by specialist surgeons. A reduction in risk of dying of 16% (95% confidence interval 6% to 25%) was found after adjustment for age, tumour size, socioeconomic status, and nodal involvement. The benefit of specialist care was apparent for all age groups, for small and large tumours, and for tumours that did and did not affect the nodes and was consistent across all socioeconomic categories. Conclusions-Survival differences of the magnitude demonstrated have implications for the provision of services for the treatment of women with breast cancer. There is a need to improve equity in the treatment of breast cancer.			Gillis, CR (corresponding author), RUCHILL HOSP,W SCOTLAND CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,LANARK,SCOTLAND.							BASNETT I, 1992, EUR J CANCER, V28A, P1945, DOI 10.1016/0959-8049(92)90233-R; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; CARNON AG, 1994, BRIT MED J, V309, P1054, DOI 10.1136/bmj.309.6961.1054; CARSTAIRS V, 1988, DEPRIVATION HLTH SCO; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; COX DR, 1972, J R STAT SOC B, V34, P187; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; HARDING MJ, 1993, LANCET, V341, P999, DOI 10.1016/0140-6736(93)91082-W; JUNOR EJ, 1994, BRIT J CANCER, V70, P363, DOI 10.1038/bjc.1994.307; KARJALAINEN S, 1990, J EPIDEMIOL COMMUN H, V44, P210, DOI 10.1136/jech.44.3.210; OLIVOTTO IA, 1994, NEW ENGL J MED, V330, P805, DOI 10.1056/NEJM199403243301201; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; SHARP L, 1993, CANCER REGISTRATION; 1992, LANCET, V339, P71; 1986, BRIT MED J, V293, P946	15	254	257	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					145	148		10.1136/bmj.312.7024.145	http://dx.doi.org/10.1136/bmj.312.7024.145			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR325	8563532	Green Published			2022-12-24	WOS:A1996TR32500019
J	Dewji, NN; Singer, SJ				Dewji, NN; Singer, SJ			Genetic clues to Alzheimer's disease	SCIENCE			English	Editorial Material							AMYLOID PRECURSOR PROTEIN; TYROSINE-KINASE RECEPTOR; BETA-PEPTIDE; CELL-CELL; SEVENLESS; EXPRESSION; DROSOPHILA; ADHESION; LIGAND; BRIDE		UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	Dewji, NN (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.							BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; CAGAN RL, 1992, CELL, V69, P393, DOI 10.1016/0092-8674(92)90442-F; CRAS P, 1990, AM J PATHOL, V137, P241; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; KOOH PJ, 1993, DEVELOPMENT, V117, P493; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187	19	45	55	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					159	160		10.1126/science.271.5246.159	http://dx.doi.org/10.1126/science.271.5246.159			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539612				2022-12-24	WOS:A1996TP36400026
J	Lock, P; Fumagalli, S; Polakis, P; McCormick, F; Courtneidge, SA				Lock, P; Fumagalli, S; Polakis, P; McCormick, F; Courtneidge, SA			The human p62 cDNA encodes Sam68 and not the RasGAP-associated p62 protein	CELL			English	Article							DOMAINS; BINDING; GAP		ONYX PHARMACEUT,RICHMOND,CA 94806; SUGEN INC,REDWOOD CITY,CA 94063		Lock, P (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69012 HEIDELBERG,GERMANY.		FUMAGALLI, Stefano/C-2914-2019	Fumagalli, Stefano/0000-0001-5832-8680; Lock, Peter/0000-0003-4421-3609				Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OGAWA W, 1994, J BIOL CHEM, V269, P29602; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VOGEL LB, 1995, J BIOL CHEM, V270, P2506, DOI 10.1074/jbc.270.6.2506; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	11	74	75	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					23	24		10.1016/S0092-8674(00)80989-7	http://dx.doi.org/10.1016/S0092-8674(00)80989-7			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548822	Bronze			2022-12-24	WOS:A1996TQ17000005
J	Falvo, JV; Thanos, D; Maniatis, T				Falvo, JV; Thanos, D; Maniatis, T			Reversal of intrinsic DNA bends in the IFN beta gene enhancer by transcription factors and the architectural protein HMG I(Y)	CELL			English	Article							NF-KAPPA-B; CRYSTAL-STRUCTURE; TATA ELEMENT; BINDING; COMPLEX; ACTIVATION; PROMOTER; AFFINITY; ADENINE; DOMAIN	In this paper, we investigate DNA bending induced by proteins required for virus induction of the human interferon-beta (IFN beta) gene. We show that NF-kappa B-DNA complexes that are functionally distinct in the context of the IFN beta enhancer are also conformationally distinct and that two sites in the enhancer contain in-phase bends that are counteracted or reversed by the binding of NF-kappa B, ATF-2/c-Jun, and HMG I(Y). Strikingly, this modulation of intrinsic enhancer architecture results in an orientation that favors predicted protein-protein interactions in a functional nucleoprotein complex, the enhanceosome. Furthermore, the subtle modulation of DNA structure by HMG I(Y) in this process distinguishes it from other architectural factors.			Falvo, JV (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.		Thanos, Dimitris/AAE-5720-2019		NIAID NIH HHS [AI 20642] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020642, R01AI020642] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANSARI AZ, 1995, NATURE, V374, P371; BECKER JC, 1995, P NATL ACAD SCI USA, V92, P9727, DOI 10.1073/pnas.92.21.9727; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P5347, DOI 10.1021/bi00183a043; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; HAMM MK, 1995, BIOORG MED CHEM LETT, V5, P1621, DOI 10.1016/0960-894X(95)00266-V; HARAN TE, 1994, J MOL BIOL, V244, P135, DOI 10.1006/jmbi.1994.1713; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KUPRASH DV, 1995, NUCLEIC ACIDS RES, V23, P427, DOI 10.1093/nar/23.3.427; LEGER H, 1995, MOL CELL BIOL, V15, P3738; LEHN DA, 1988, BIOCHEM INT, V16, P963; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATTHEWS JR, 1995, NUCLEIC ACIDS RES, V23, P3393, DOI 10.1093/nar/23.17.3393; MEACOCK S, 1994, J BIOL CHEM, V269, P31759; MENDOZA R, 1990, BIOCHEMISTRY-US, V29, P5035, DOI 10.1021/bi00473a006; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; PAOLELLA DN, 1994, SCIENCE, V264, P1130, DOI 10.1126/science.8178171; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; THANOS D, 1993, COLD SPRING HARB SYM, V58, P73, DOI 10.1101/SQB.1993.058.01.011; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1987, PHILOS T ROY SOC B, V317, P537, DOI 10.1098/rstb.1987.0080; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WECHSLER DS, 1992, P NATL ACAD SCI USA, V89, P7635, DOI 10.1073/pnas.89.16.7635; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	63	271	273	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1101	1111		10.1016/0092-8674(95)90137-X	http://dx.doi.org/10.1016/0092-8674(95)90137-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548798	Bronze			2022-12-24	WOS:A1995TM76200007
J	Jaax, N; Jahrling, P; Geisbert, T; Geisbert, J; Steele, K; McKee, K; Nagley, D; Johnson, E; Jaax, G; Peters, C				Jaax, N; Jahrling, P; Geisbert, T; Geisbert, J; Steele, K; McKee, K; Nagley, D; Johnson, E; Jaax, G; Peters, C			Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory	LANCET			English	Note								Secondary transmission of Ebola virus infection in humans is known to be caused by direct contact with infected patients or body fluids. We report transmission of Ebola virus (Zaire strain) to two of three control rhesus monkeys (Macaca mulatta) that did not have direct contact with experimentally inoculated monkeys held in the same room. The two control monkeys died from Ebola virus infections at 10 and 11 days after the last experimentally inoculated monkey had died. The most likely route of infection of the control monkeys was aerosol, oral, or conjunctival exposure to virus-laden droplets secreted or excreted from the experimentally inoculated monkeys. These observations suggest approaches to the study of routes of transmission to and among humans.			Jaax, N (corresponding author), USA, MED RES INST INFECT DIS, FREDERICK, MD 21702 USA.							BASKERVILLE A, 1978, J PATHOL, V125, P131, DOI 10.1002/path.1711250303; BOWEN ETW, 1978, T ROY SOC TROP MED H, V72, P188, DOI 10.1016/0035-9203(78)90058-5; Breman J, 1976, EBOLA VIRUS HAEMORRH, P103; EMOND RTD, 1977, BMJ-BRIT MED J, V2, P541, DOI 10.1136/bmj.2.6086.541; GEISBERT TW, 1990, J CLIN PATHOL, V43, P813, DOI 10.1136/jcp.43.10.813; JAHRLING PB, 1990, LANCET, V335, P502, DOI 10.1016/0140-6736(90)90737-P; JOHNSON E, 1995, INT J EXP PATHOL, V76, P227; JOHNSON KM, 1981, J INFECT DIS, V143, P749, DOI 10.1093/infdis/143.5.749; PROPHET EB, 1992, LABORATORY METHODS H	9	133	144	0	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	1995	346	8991-2					1669	1671		10.1016/S0140-6736(95)92841-3	http://dx.doi.org/10.1016/S0140-6736(95)92841-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551825				2022-12-24	WOS:A1995TL42300011
J	Blackburn, H				Blackburn, H			Olestra and the FDA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Blackburn, H (corresponding author), UNIV MINNESOTA,MINNEAPOLIS,MN 55455, USA.								0	24	24	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1996	334	15					984	986		10.1056/NEJM199604113341511	http://dx.doi.org/10.1056/NEJM199604113341511			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD596	8596603				2022-12-24	WOS:A1996UD59600011
J	Kandela, P				Kandela, P			Exposing the abuse of Chinese orphans	BRITISH MEDICAL JOURNAL			English	Article																		1996, DEATH DEFAULT POLICY	1	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					495	496		10.1136/bmj.312.7029.495	http://dx.doi.org/10.1136/bmj.312.7029.495			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TX383	8597687	Green Published			2022-12-24	WOS:A1996TX38300033
J	Ifudu, O; Feldman, J; Friedman, EA				Ifudu, O; Feldman, J; Friedman, EA			The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; AMBULATORY PERITONEAL-DIALYSIS; ANEMIA; FAILURE; UREMIA	Background. Anemia (characterized by a hematocrit of 30 percent or lower) persists in 40 to 60 percent of patients treated for end-stage renal disease with maintenance hemodialysis, despite concomitant erythropoietin (epoetin) therapy. We tested the hypothesis that inadequate dialysis is a key reason for the insufficient response to erythropoietin in patients with end-stage renal disease who are receiving hemodialysis. Methods. We prospectively studied 135 randomly selected patients undergoing hemodialysis who had been receiving intravenous erythropoietin for at least four months. The adequacy of dialysis was assessed by measuring the percent reduction in the blood urea nitrogen concentration and the serum albumin concentration. The hematocrit was measured weekly for four weeks, transferrin saturation was measured, and coexisting illnesses were documented. To determine the effect of an increased level of dialysis on the hematocrit, the thrice-weekly schedule of dialysis was increased to raise the mean urea-reduction value from 60.7 to 72.0 percent for six weeks in 20 consecutive patients whose base-line urea-reduction value was less than 65 percent. The change in the hematocrit in these patients was compared with that observed in the next 20 patients who had an equivalent base-line urea-reduction value but whose level of dialysis was not altered. Results. The mean (+/-SD) hematocrit of the entire group was 29.2+/-4 percent, and the mean thrice-weekly dose of erythropoietin was 59+/-29 U per kilogram of body weight. The mean serum albumin concentration was 3.8+/-0.4 g per deciliter, the mean urea-reduction value was 62+/-4.8 percent, and the mean transferrin saturation was 20+/-9 percent. Multiple regression analysis revealed direct correlations between the hematocrit and the serum albumin concentration (P=0.009) and between the hematocrit and the urea-reduction value (P=0.012) after adjustment for other factors. A logistic-regression analysis indicated that an 11 percent increase in the urea-reduction value doubled the odds that a patient would have a hematocrit above 30 percent. After six weeks of increased intensity of dialysis in 20 patients with base-line urea-reduction values of less than 65 percent, the mean (+/-SE) hematocrit rose from 28.4+/-0.78 percent to 32.3+/-0.71 percent (P=0.002); there was no significant change in a control group of 20 patients with equivalent base-line urea-reduction values in whom the dialysis level was not altered (28.2+/-0.84 percent to 26.3+/-0.85 percent; P=0.175). Conclusions. In patients with end-stage renal disease, inadequate hemodialysis is associated with a suboptimal response to erythropoietin therapy, Increasing the intensity of dialysis in patients with anemia who are receiving inadequate dialysis results in a significant increase in the hematocrit. (C) 1996, Massachusetts Medical Society.	SUNY HLTH SCI CTR,DEPT PREVENT MED & COMMUNITY HLTH,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Ifudu, O (corresponding author), SUNY HLTH SCI CTR,DEPT MED,RENAL DIS DIV,450 CLARKSON AVE,BOX 52,BROOKLYN,NY 11203, USA.							BIA MJ, 1989, KIDNEY INT, V36, P852, DOI 10.1038/ki.1989.271; CARO J, 1979, J LAB CLIN MED, V93, P449; ESCHBACH JW, 1992, KIDNEY INT, V42, P407, DOI 10.1038/ki.1992.302; ESCHBACH JW, 1989, KIDNEY INT, V35, P134, DOI 10.1038/ki.1989.18; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; ESCHBACH JW, 1970, ARCH INTERN MED, V126, P812, DOI 10.1001/archinte.126.5.812; ESSERS U, 1974, P EUR DIAL TRANS, V11, P389; GOODNOUGH LT, 1994, CLIN NEPHROL, V41, P303; HAKIM RM, 1994, AM J KIDNEY DIS, V23, P661, DOI 10.1016/S0272-6386(12)70276-7; HELD PJ, 1994, AM J KIDNEY DIS, V24, P974, DOI 10.1016/S0272-6386(12)81108-5; IFUDU O, 1994, JAMA-J AM MED ASSOC, V271, P29, DOI 10.1001/jama.271.1.29; IFUDU O, 1995, ASAIO J, V41, pM426, DOI 10.1097/00002480-199507000-00045; IFUDU O, 1994, CLIN RES, V42, pA263; INGELFINGER JA, 1994, BIOSTATISTICS CLIN M, P166; KOCH KM, 1974, NEPHRON, V12, P405, DOI 10.1159/000180353; KOPPLE JD, 1994, AM J KIDNEY DIS, V24, P968, DOI 10.1016/S0272-6386(12)81071-7; LUNDIN AP, 1989, SEMIN NEPHROL, V9, P22; MARKSON J L, 1956, Scott Med J, V1, P320; MCGONIGLE RJS, 1984, KIDNEY INT, V25, P430, DOI 10.1038/ki.1984.35; Norusis M.J., 1993, SPSS WINDOWS ADV STA, P1; ORTEGA JA, 1977, AM J HEMATOL, V2, P299, DOI 10.1002/ajh.2830020312; POWE NR, 1992, JAMA-J AM MED ASSOC, V268, P1434, DOI 10.1001/jama.268.11.1434; POWE NR, 1993, KIDNEY INT, V43, P1125, DOI 10.1038/ki.1993.158; RADTKE HW, 1981, J CLIN INVEST, V67, P1623, DOI 10.1172/JCI110197; RAO DS, 1993, NEW ENGL J MED, V328, P171, DOI 10.1056/NEJM199301213280304; VANWYCK DB, 1989, KIDNEY INT, V35, P712, DOI 10.1038/ki.1989.43; WALLNER SF, 1981, J LAB CLIN MED, V97, P170; ZAPPACOSTA AR, 1982, AM J MED, V72, P53, DOI 10.1016/0002-9343(82)90577-0; 1992, 1992 SE KIDN COUNC A; 1994, ANN INTERN MED, V121, P62	30	230	237	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 15	1996	334	7					420	425		10.1056/NEJM199602153340702	http://dx.doi.org/10.1056/NEJM199602153340702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU696	8552143				2022-12-24	WOS:A1996TU69600002
J	Poland, GA				Poland, GA			Acellular pertussis vaccines: New vaccines for an old disease	LANCET			English	Editorial Material											Poland, GA (corresponding author), MAYO CLIN & MAYO FDN,MAYO VACCINE RES GRP,200 1ST ST SW,ROCHESTER,MN 55905, USA.							DECKER MD, 1995, PEDIATRICS, V96, P557; EDWARDS KM, 1993, JAMA-J AM MED ASSOC, V269, P53, DOI 10.1001/jama.269.1.53; EDWARDS KM, 1995, PEDIATRICS, V96, P548; EDWARDS KM, 1993, J INFECT DIS, V168, P15, DOI 10.1093/infdis/168.1.15; Folkers G, 1995, NIAID AIDS Agenda, P14; GRECO D, 1995, 35TH ANN ICAAC M, V11, pLB22; PLOTKIN SL, 1994, VACCINES, P1; Schmitt HJ, 1996, JAMA-J AM MED ASSOC, V275, P37, DOI 10.1001/jama.275.1.37; TROLLFORS B, 1995, NEW ENGL J MED, V333, P1045, DOI 10.1056/NEJM199510193331604	9	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					209	210		10.1016/S0140-6736(96)90398-0	http://dx.doi.org/10.1016/S0140-6736(96)90398-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551875				2022-12-24	WOS:A1996TT06900004
J	Dieci, G; Sentenac, A				Dieci, G; Sentenac, A			Facilitated recycling pathway for RNA polymerase III	CELL			English	Article							TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; BINDING PROTEIN; YEAST; INITIATION; COMPLEXES; INTERMEDIATE; REINITIATION; TERMINATION; CEREVISIAE	We show that the high in vitro transcription efficiency of yeast RNA poI III is mainly due to rapid recycling. Kinetic analysis shows that RNA polymerase recycling on preassembled tDNA . TFIIIC . TFIIIB complexes is much faster than the initial transcription cycle. High efficiency of RNA poI III recycling is favored at high UTP concentrations and requires termination at the natural termination signal. Runoff transcription does not allow efficient recycling. The reinitiation process shows increased resistance to heparin as compared with the primary initiation cycle, as if RNA polymerase was not released after termination. Indeed, template competition assays show that RNA poI III is committed to reinitiate on the same gene. A model is proposed where the polymerase molecule is directly transferred from the termination site to the promoter.	UNIV PARMA,IST SCI BIOCHIM,I-43100 PARMA,ITALY	University of Parma	Dieci, G (corresponding author), CEA SACLAY,SERV BIOCHIM & GENET MOLEC,F-91191 GIF SUR YVETTE,FRANCE.		Dieci, Giorgio/B-3434-2012	Dieci, Giorgio/0000-0002-8792-3961				ARNOSTI DN, 1993, EMBO J, V12, P157, DOI 10.1002/j.1460-2075.1993.tb05641.x; BAKER RE, 1984, EMBO J, V3, P2793, DOI 10.1002/j.1460-2075.1984.tb02211.x; BAKER SM, 1986, CELL, V47, P839, DOI 10.1016/0092-8674(86)90795-6; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; Burton N, 1991, Protein Expr Purif, V2, P432, DOI 10.1016/1046-5928(91)90105-R; CAMPBELL FE, 1992, MOL CELL BIOL, V12, P2260, DOI 10.1128/MCB.12.5.2260; CHAMBERLIN MJ, 1974, ENZYMES, V10, P333; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; DIECI G, 1995, EMBO J, V14, P3766, DOI 10.1002/j.1460-2075.1995.tb00046.x; DIECI G, 1995, J BIOL CHEM, V270, P13476, DOI 10.1074/jbc.270.22.13476; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GEIDUSCHEK EP, 1992, TRANSCRIPTIONAL REGU, V1, P247; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HUET J, 1985, J BIOL CHEM, V260, P5304; HUET J, 1994, NUCLEIC ACIDS RES, V22, P3433; JAHN D, 1987, J MOL BIOL, V193, P303, DOI 10.1016/0022-2836(87)90221-X; JIANG Y, 1993, MOL CELL BIOL, V13, P4572, DOI 10.1128/MCB.13.8.4572; JOAZEIRO CAP, 1994, MOL CELL BIOL, V14, P2798, DOI 10.1128/MCB.14.4.2798; JOHNSON SP, 1989, MOL CELL BIOL, V9, P4986, DOI 10.1128/MCB.9.11.4986; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1992, J MOL BIOL, V226, P47, DOI 10.1016/0022-2836(92)90123-2; KOVELMAN R, 1990, GENE DEV, V4, P646, DOI 10.1101/gad.4.4.646; LINMARQ N, 1995, J MOL BIOL, V245, P81, DOI 10.1006/jmbi.1994.0008; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; ROBERTS SGE, 1995, CURR BIOL, V5, P508, DOI 10.1016/S0960-9822(95)00103-5; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; YOO CJ, 1994, MOL CELL BIOL, V14, P5412, DOI 10.1128/MCB.14.8.5412; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	37	147	147	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					245	252		10.1016/S0092-8674(00)80979-4	http://dx.doi.org/10.1016/S0092-8674(00)80979-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565070	Bronze			2022-12-24	WOS:A1996TR59500011
J	Doolittle, RF; Feng, DF; Tsang, S; Cho, G; Little, E				Doolittle, RF; Feng, DF; Tsang, S; Cho, G; Little, E			Determining divergence times of the major kingdoms of living organisms with a protein clock	SCIENCE			English	Article							PHYLOGENETIC TREES; RIBOSOMAL-RNA; EVOLUTION; EUKARYOTES; SEQUENCE; GENE; ARCHAEBACTERIA; EUBACTERIA; ALIGNMENT; ORIGINS	Amino acid sequence data from 57 different enzymes were used to determine the divergence times of the major biological groupings. Deuterostomes and protostomes split about 670 million years ago and plants, animals, and fungi last shared a common ancestor about a billion years ago. With regard to these protein sequences, plants are slightly more similar to animals than are the fungi. In contrast, phylogenetic analysis of the same sequences indicates that fungi and animals shared a common ancestor more recently than either did with plants, the greater difference resulting from the fungal lineage changing faster than the animal and plant lines over the last 965 million years. The major protist lineages have been changing at a somewhat faster rate than other eukaryotes and split off about 1230 million years ago. If the rate of change has been approximately constant, then prokaryotes and eukaryotes last shared a common ancestor about 2 billion years ago, archaebacterial sequences being measurably more similar to eukaryotic ones than are eubacterial ones.			Doolittle, RF (corresponding author), UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA.				NHLBI NIH HHS [HL-26873] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026873, R01HL026873] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALDAUF SL, 1993, P NATL ACAD SCI USA, V90, P11558, DOI 10.1073/pnas.90.24.11558; BENTON MJ, 1990, J MOL EVOL, V30, P409, DOI 10.1007/BF02101113; Carroll RL, 1988, VERTEBRATE PALEONTOL; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; Dayhoff M.O., 1978, ATLAS PROTEIN SEQ ST; Dickerson R E., 1971, Journal Molec Evol, V1, P26, DOI 10.1007/BF01659392; DOOLITTLE RF, 1989, INT CONGR SER, V824, P73; DOOLITTLE RF, 1964, NATURE, V202, P147, DOI 10.1038/202147a0; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; DOOLITTLE RF, 1993, METHODS IN PROTEIN SEQUENCE ANALYSIS, P241; DOOLITTLE RF, UNPUB; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FENG DF, 1990, METHOD ENZYMOL, V183, P375; FITCH WM, 1994, P NATL ACAD SCI USA, V91, P6802, DOI 10.1073/pnas.91.15.6802; FITCH WM, 1970, BIOCHEM GENET, V4, P579, DOI 10.1007/BF00486096; FITCH WM, 1976, FED PROC, V35, P2092; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; Gillespie J. H., 1991, CAUSES MOL EVOLUTION; GOLDING GB, 1995, MOL BIOL EVOL, V12, P1; GONNET GH, 1992, SCIENCE, V256, P1443, DOI 10.1126/science.1604319; GUPTA RS, 1993, J MOL EVOL, V37, P573; HAN TM, 1992, SCIENCE, V257, P232, DOI 10.1126/science.1631544; HENIKOFF S, 1993, PROTEINS, V17, P49, DOI 10.1002/prot.340170108; HORI H, 1979, P NATL ACAD SCI USA, V76, P381, DOI 10.1073/pnas.76.1.381; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; JOHNSON R, 1984, ELEMENTARY STATISTIC; JUKES T H, 1969, P21; JUKES TH, 1969, SPACE LIFE SCI, V1, P469, DOI 10.1007/BF00924238; KIMURA M, 1973, NATURE-NEW BIOL, V243, P199, DOI 10.1038/newbio243199a0; KIMURA M, 1972, J MOL EVOL, V2, P87, DOI 10.1007/BF01653945; Kimura M, 1971, Journal Molec Evol, V1, P1, DOI 10.1007/BF01659390; KLOTZ LC, 1981, J THEOR BIOL, V91, P261, DOI 10.1016/0022-5193(81)90233-2; KNOLL AH, 1994, P NATL ACAD SCI USA, V91, P6743, DOI 10.1073/pnas.91.15.6743; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; LANGLEY CH, 1974, J MOL EVOL, V3, P161, DOI 10.1007/BF01797451; LOOMIS WF, 1990, P NATL ACAD SCI USA, V87, P9093, DOI 10.1073/pnas.87.23.9093; MARGOLIASH E., 1965, P221; MARSHALL CR, 1990, J MOL EVOL, V30, P400, DOI 10.1007/BF02101112; MCLAUGHLIN PJ, 1970, SCIENCE, V168, P1469, DOI 10.1126/science.168.3938.1469; MORRIS SC, 1993, NATURE, V361, P219, DOI 10.1038/361219a0; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Nei M, 1987, MOL EVOLUTIONARY GEN; OCHMAN H, 1987, J MOL EVOL, V26, P74, DOI 10.1007/BF02111283; SARICH VM, 1973, SCIENCE, V179, P1144, DOI 10.1126/science.179.4078.1144; SCHOPF JW, 1976, SCIENCE, V193, P47, DOI 10.1126/science.193.4247.47; SCHOPF JW, 1993, SCIENCE, V260, P640, DOI 10.1126/science.260.5108.640; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; SMITH MW, 1992, TRENDS BIOCHEM SCI, V17, P489, DOI 10.1016/0968-0004(92)90335-7; SOGIN ML, 1991, WIST SYMP S, V4, P175; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; WAINRIGHT PO, 1993, SCIENCE, V260, P340, DOI 10.1126/science.8469985; WOESE CR, 1991, EVOLUTION MOL MEN, P175; Zhang Zhongying, 1986, Journal of Micropalaeontology, V5, P9; ZUCKERKANDL EMILE, 1965, P97; 1987, J MOL EVOL, V26, P1; 1992, ENZYME NOMENCLATURE	57	462	484	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 26	1996	271	5248					470	477		10.1126/science.271.5248.470	http://dx.doi.org/10.1126/science.271.5248.470			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560259				2022-12-24	WOS:A1996TR32200031
J	Linnen, J; Wages, J; ZhangKeck, ZY; Fry, KE; Krawczynski, KZ; Alter, H; Koonin, E; Gallagher, M; Alter, M; Hadziyannis, S; Karayiannis, P; Fung, K; Nakatsuji, Y; Shih, JWK; Young, L; Piatak, M; Hoover, C; Fernandez, J; Chen, S; Zou, JC; Morris, T; Hyams, KC; Ismay, S; Lifson, JD; Hess, G; Foung, SKH; Thomas, H; Bradley, D; Margolis, H; Kim, JP				Linnen, J; Wages, J; ZhangKeck, ZY; Fry, KE; Krawczynski, KZ; Alter, H; Koonin, E; Gallagher, M; Alter, M; Hadziyannis, S; Karayiannis, P; Fung, K; Nakatsuji, Y; Shih, JWK; Young, L; Piatak, M; Hoover, C; Fernandez, J; Chen, S; Zou, JC; Morris, T; Hyams, KC; Ismay, S; Lifson, JD; Hess, G; Foung, SKH; Thomas, H; Bradley, D; Margolis, H; Kim, JP			Molecular cloning and disease association of hepatitis G virus: A transfusion-transmissible agent	SCIENCE			English	Article							NON-B-HEPATITIS; C VIRUS; NON-A; CDNA LIBRARIES; ANTIBODY; RNA; IDENTIFICATION; CONSTRUCTION; PROTEINASE; SEQUENCES	An RNA virus, designated hepatitis G virus (HGV), was identified from the plasma of a patient with chronic hepatitis. Extension from an immunoreactive complementary DNA clone yielded the entire genome (9392 nucleotides) encoding a polyprotein of 2873 amino acids. The virus is closely related to GB virus C (GBV-C) and distantly related to hepatitis C virus, GBV-A, and GBV-B. HGV was associated with acute and chronic hepatitis. Persistent viremia was detected for up to 9 years in patients with hepatitis. The virus is transfusion-transmissible. It has a global distribution and is present within the volunteer blood donor population in the United States.	GENELABS TECHNOL,REDWOOD CITY,CA 94063; CTR DIS CONTROL & PREVENT,HEPATITIS BRANCH,ATLANTA,GA 30333; NIH,DEPT TRANSFUS MED,BETHESDA,MD 20205; NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20894; HIPPOKRATEION HOSP,ACAD DEPT MED,ATHENS,GREECE; ST MARYS HOSP,SCH MED,DEPT MED,LONDON,ENGLAND; USN,MED RES INST,ROCKVILLE,MD 20852; NEW S WALES RED CROSS BLOOD TRANSFUS SERV,SYDNEY,NSW,AUSTRALIA; BOEHRINGER MANNHEIM GMBH,D-68305 MANNHEIM,GERMANY	Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Hippokration General Hospital; Imperial College London; Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; Australian Red Cross Blood Service			Thomas, Howard C/A-3152-2009	Karayiannis, Peter/0000-0001-5195-7863; Foung, Steven/0000-0001-7149-6160				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BENSON DA, 1994, NUCLEIC ACIDS RES, V22, P3441, DOI 10.1093/nar/22.17.3441; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; DECKER RH, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P795; DEKA N, 1994, J VIROL, V68, P7810, DOI 10.1128/JVI.68.12.7810-7815.1994; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; GRAKOUI A, 1993, P NATL ACAD SCI USA, V90, P10583, DOI 10.1073/pnas.90.22.10583; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711; HAYASHI N, 1993, J HEPATOL, V17, pS94, DOI 10.1016/S0168-8278(05)80432-5; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; KOONIN EV, 1993, CRIT REV BIOCHEM MOL, V28, P375, DOI 10.3109/10409239309078440; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Lim MY, UNPUB; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PURCELL RH, 1976, J IMMUNOL, V116, P349; REYES GR, 1991, MOL CELL PROBE, V5, P473, DOI 10.1016/S0890-8508(05)80020-9; RIZETTO M, 1980, LANCET, V1, P1215; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; WAGES J, UNPUB; WOOTTON JC, 1994, COMPUT CHEM, V18, P269, DOI 10.1016/0097-8485(94)85023-2; YARBOUGH PO, 1991, J VIROL, V65, P5790, DOI 10.1128/JVI.65.11.5790-5797.1991; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	31	1298	1395	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					505	508		10.1126/science.271.5248.505	http://dx.doi.org/10.1126/science.271.5248.505			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560265				2022-12-24	WOS:A1996TR32200042
J	Koretz, RL				Koretz, RL			Polyp surveillance in patients with limited life expectancy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Koretz, RL (corresponding author), OLIVE VIEW UCLA MED CTR,DIV GASTROENTEROL,14445 OLIVE VIEW DR,SYLMAR,CA 91342, USA.							DAY DW, 1984, SCAND J GASTROENTE S, V104, P99; KORETZ RL, 1993, ANN INTERN MED, V118, P63, DOI 10.7326/0003-4819-118-1-199301010-00011; MINAMOTO T, 1994, GASTROENTEROLOGY, V106, P1436, DOI 10.1016/0016-5085(94)90395-6; SPRATT JS, 1958, ANN SURG, V148, P682, DOI 10.1097/00000658-195810000-00014	4	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					327	327		10.1001/jama.275.4.327	http://dx.doi.org/10.1001/jama.275.4.327			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544278				2022-12-24	WOS:A1996TP96500035
J	Eckstein, MB; Brown, DWG; Foster, A; Richards, AF; Gilbert, CE; Vijayalakshmi, P				Eckstein, MB; Brown, DWG; Foster, A; Richards, AF; Gilbert, CE; Vijayalakshmi, P			Congenital rubella in south India: Diagnosis using saliva from infants with cataract	BRITISH MEDICAL JOURNAL			English	Article									PHLS VIRUS REFERENCE DIV,ENTER & RESP VIRUS LAB,LONDON NW9 5HT,ENGLAND; ARAVIND EYE HOSP,MADURAI,TAMIL NADU,INDIA; POSTGRAD INST OPHTHALMOL,MADURAI,TAMIL NADU,INDIA		Eckstein, MB (corresponding author), INST OPHTHALMOL,DEPT PREVENT OPHTHALMOL,LONDON EC1V 9EL,ENGLAND.			Foster, Allen/0000-0003-2368-4436				Banatvala JE, 1990, TOPLEY WILSONS PRINC, P502; FARACLEGAN H, 1987, J INFECT DIS, V155, P1073; PERRY KR, 1993, J MED VIROL, V40, P235, DOI 10.1002/jmv.1890400312; SETH P, 1985, REV NFECT DIS, V7, P64	4	36	39	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					161	161						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR325	8563537				2022-12-24	WOS:A1996TR32500025
J	Kessler, E; Takahara, K; Biniaminov, L; Brusel, M; Greenspan, DS				Kessler, E; Takahara, K; Biniaminov, L; Brusel, M; Greenspan, DS			Bone morphogenetic protein-1: The type I procollagen C-proteinase	SCIENCE			English	Article							POLYACRYLAMIDE GELS; MOUSE FIBROBLASTS; PURIFICATION; QUANTITIES; CLEAVAGE; SEQUENCE; PATTERN; DOMAIN; EMBRYO; BMP-1	Bone morphogenetic proteins (BMPs) are bone-derived factors capable of inducing ectopic bone formation. Unlike other BMPs, BMP-1 is not like transforming growth factor-beta (TGF-beta), but it is the prototype of a family of putative proteases implicated in pattern formation during development in diverse organisms. Although some members of this group, such as Drosophila tolloid (TLD), are postulated to activate TGF-beta-like proteins, actual substrates are unknown, Procollagen C-proteinase (PCP) cleaves the COOH-propeptides of procollagens I, II, and III to yield the major fibrous components of vertebrate extracellular matrix. Here it is shown that BMP-1 and PCP are identical. This demonstration of enzymatic activity for a BMP-1/TLD-like protein links an enzyme involved in matrix deposition to genes involved in pattern formation.	UNIV WISCONSIN, DEPT PATHOL & LAB MED, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Kessler, E (corresponding author), TEL AVIV UNIV, SACKLER FAC MED, CHAIM SHEBA MED CTR, MAURICE & GABRIELA GOLDSCHLEGER EYE RES INST, IL-52621 TEL HASHOMER, ISRAEL.			Greenspan, Daniel/0000-0001-8096-7446	NIGMS NIH HHS [GM46846] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FINELLI AL, 1994, DEVELOPMENT, V120, P861; FINELLI L, 1995, GENETICS, V141, P271; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JARVIS DL, 1992, RECOMBINANT DNA VACC, P265; KESSLER E, 1978, ANAL BIOCHEM, V86, P463, DOI 10.1016/0003-2697(78)90770-4; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; KESSLER EM, UNPUB; KUHN K, 1987, STRUCTURE FUNCTION C, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE ST, 1990, J BIOL CHEM, V265, P21992; LEPAGE T, 1992, DEVELOPMENT, V114, P147; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NGUYEN T, 1994, DEV BIOL, V166, P569, DOI 10.1006/dbio.1994.1338; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; REYNOLDS SD, 1992, DEVELOPMENT, V114, P769; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	30	436	459	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	1996	271	5247					360	362		10.1126/science.271.5247.360	http://dx.doi.org/10.1126/science.271.5247.360			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553073				2022-12-24	WOS:A1996TQ52800044
J	Krek, W; Xu, GF; Livingston, DM				Krek, W; Xu, GF; Livingston, DM			Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint	CELL			English	Article							TRANSCRIPTION FACTOR E2F; CELL-CYCLE; COMPLEX-FORMATION; GENE-PRODUCT; PROTEIN; IDENTIFICATION; EXPRESSION; TRANSACTIVATION; REPLICATION; COMPONENT	Commitment of mammalian cells to enter S phase enables the transcription factor E2F-1 to activate certain genes whose products mediate cell cycle advance. In S phase, E2F-1 forms stable complexes with cyclin A-kinase, which in turn eliminates E2F-1 DNA binding function. Here, we show that suppression of E2F-1 DNA-binding activity by cyclin A-kinase is linked to orderly S phase progression. Disruption of this linkage resulted in S phase delay/arrest followed by regrowth or apoptosis, depending upon whether the DNA-bound E2F-1 could transactivate. Hence, the unscheduled presence of E2F-1 on specific DNA sequences during S phase can activate a specific S phase checkpoint, thereby linking transcription, DNA replication, and cell cycle control.	DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School								BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NEVINS JR, 1992, SCIENCE, V258, P424; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SELLERS WR, 1995, IN PRESS P NATL ACAD; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	43	312	322	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1149	1158		10.1016/0092-8674(95)90141-8	http://dx.doi.org/10.1016/0092-8674(95)90141-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548802	Bronze			2022-12-24	WOS:A1995TM76200011
J	Wilson, ME				Wilson, ME			Infectious diseases: An ecological perspective	BRITISH MEDICAL JOURNAL			English	Article							ENVIRONMENTAL-CHANGES		HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health	Wilson, ME (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT POPULAT & INT HLTH,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.							[Anonymous], 1993, MANAGING GLOBAL GENE; CARLTON JT, 1993, SCIENCE, V261, P78, DOI 10.1126/science.261.5117.78; Chivian E., 1993, CRITICAL CONDITION H; Crosby A., 1989, AM FORGOTTEN PANDEMI; Crosby A., 1972, COLUMBIAN EXCHANGE B; Dubos Rene, 1987, WHITE PLAGUE TUBERCU; ELTON CS, 1972, ECOLOGY INVASIONS AN; FISHERHOCH SP, 1995, BRIT MED J, V311, P857, DOI 10.1136/bmj.311.7009.857; GRIST NR, 1993, LANCET, V339, P1363; GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55; HOMERDIXON TF, 1991, INT SECURITY, V16, P76, DOI 10.2307/2539061; KOHN MA, 1995, J INFECT DIS, V172, P246, DOI 10.1093/infdis/172.1.246; KOOPMAN JS, 1991, AM J EPIDEMIOL, V133, P1168, DOI 10.1093/oxfordjournals.aje.a115829; LEAF A, 1989, NEW ENGL J MED, V321, P1577, DOI 10.1056/NEJM198912073212305; Lederberg J., 1992, EMERGING INFECTIONS; LOEVINSOHN ME, 1994, LANCET, V343, P714, DOI 10.1016/S0140-6736(94)91586-5; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MCCARTHY SA, 1994, APPL ENVIRON MICROB, V60, P2597, DOI 10.1128/AEM.60.7.2597-2601.1994; McMichael A J, 1993, PLANETARY OVERLOAD G; McNeill W.H., 1976, PLAGUES PEOPLES, V1st ed.; MOORE PS, 1989, LANCET, V2, P260; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; RAEBURN P, 1995, LAST HARVEST GENETIC; REEVES WC, 1995, J MED ENTOMOL, V31, P323; ROOT TL, 1995, SCIENCE, V269, P334, DOI 10.1126/science.269.5222.334; SCHWARTZ B, 1989, CLIN MICROBIOL REV, V2, pS118, DOI 10.1128/CMR.2.Suppl.S118-S124.1989; SHOPE R, 1991, ENVIRON HEALTH PERSP, V96, P171, DOI 10.2307/3431227; Snow J., 1849, MODE COMMUNICATION C; SUN L, 1995, NAT MED, V1, P661, DOI 10.1038/nm0795-661; TESH RB, 1994, DISEASE EVOLUTION GL; TICKELL C, 1993, PARASITOLOGY, V106, pS5, DOI 10.1017/S0031182000086078; Toole M. J., 1994, MED GLOBAL SURVIVAL, V1, P200; WATTS DM, 1987, AM J TROP MED HYG, V36, P143, DOI 10.4269/ajtmh.1987.36.143; Weiner J., 1994, BEAK FINCH STORY EVO; WILSON ME, 1995, EMERG INFECT DIS, V1, P39, DOI 10.3201/eid0102.950201; WILSON ME, 1995, EPIDEMIOLOGY, V6, P458, DOI 10.1097/00001648-199507000-00027; WILSON ME, 1994, DISEASE EVOLUTION GL; WINKELSTEIN W, 1995, AM J EPIDEMIOL, V142, pS3, DOI 10.1093/aje/142.Supplement_9.S3; 1995, WHO1995 WORLD HLTH R; 1991, MMWR-MORBID MORTAL W, V40, P838; 1993, 1993 WORLD DEV REP; 1995, MMWR-MORBID MORTAL W, V44, P468; 1995, MMWR-MORBID MORTAL W, V44, P243; IN PRESS POLICY MAKE; 1995, MMWR-MORBID MORTAL W, V44, P237; 1995, LANCET, V345, P339; 1995, MMWR-MORBID MORTAL W, V44, P475	48	66	70	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1681	1684		10.1136/bmj.311.7021.1681	http://dx.doi.org/10.1136/bmj.311.7021.1681			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541756	Green Published			2022-12-24	WOS:A1995TL94200016
J	Lambe, M; Ekbom, A				Lambe, M; Ekbom, A			Cancers coinciding with childbearing: Delayed diagnosis during pregnancy?	BRITISH MEDICAL JOURNAL			English	Article											Lambe, M (corresponding author), UNIV UPPSALA HOSP,DEPT CANC EPIDEMIOL,S-75185 UPPSALA,SWEDEN.			Lambe, Mats/0000-0002-4624-3767				HAAS JF, 1984, INT J CANCER, V34, P229, DOI 10.1002/ijc.2910340214; JOHANSSON I, 1993, FERTILITY SWEDISH WO; MUSEY VC, 1986, J CLIN ENDOCR METAB, V64, P111; WALLACE N, 1983, FEDERAL RESERVE BANK, V7, P1; 1993, CANCER INCIDENCE SWE	5	47	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 16	1995	311	7020					1607	1608		10.1136/bmj.311.7020.1607	http://dx.doi.org/10.1136/bmj.311.7020.1607			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL422	8555804	Green Published			2022-12-24	WOS:A1995TL42200021
J	Schumacher, TNM; Mayr, LM; Minor, DL; Milhollen, MA; Burgess, MW; Kim, PS				Schumacher, TNM; Mayr, LM; Minor, DL; Milhollen, MA; Burgess, MW; Kim, PS			Identification of D-peptide ligands through mirror-image phage display	SCIENCE			English	Article							EPITOPE LIBRARY; N-15 NMR; PROTEINS; MOLECULES; SELECTION; DOMAIN; BIND; SRC; H-1	Genetically encoded libraries of peptides and oligonucleotides are well suited for the identification of ligands for many macromolecules. A major drawback of these techniques is that the resultant ligands are subject to degradation by naturally occurring enzymes. Here, a method is described that uses a biologically encoded library for the identification of D-peptide ligands, which should be resistant to proteolytic degradation, In this approach, a protein is synthesized in the D-amino acid configuration and used to select peptides from a phage display library expressing random L-amino acid peptides, For reasons of symmetry, the mirror images of these phage-displayed peptides interact with the target protein of the natural handedness, The value of this approach was demonstrated by the identification of a cyclic D-peptide that interacts with the Src homology 3 domain of c-Src. Nuclear magnetic resonance studies indicate that the binding site for this D-peptide partially overlaps the site for the physiological ligands of this domain.	MIT, HOWARD HUGHES MED INST, WHITEHEAD INST BIOMED RES, DEPT CHEM, CAMBRIDGE, MA 02142 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute	Schumacher, TNM (corresponding author), MIT, HOWARD HUGHES MED INST, WHITEHEAD INST BIOMED RES, DEPT BIOL, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Schumacher, Ton/Y-2432-2019; Ueno, Hiroshi/C-3301-2009	Schumacher, Ton/0000-0003-0517-8804; 				BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BOREK F, 1965, BIOCHEM J, V96, P577, DOI 10.1042/bj0960577; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BUNIN BA, 1994, P NATL ACAD SCI USA, V91, P4708, DOI 10.1073/pnas.91.11.4708; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CULL MG, 1992, P NATL ACAD SCI USA, V89, P1865, DOI 10.1073/pnas.89.5.1865; CUNNINGHAM BC, 1994, EMBO J, V13, P2508, DOI 10.1002/j.1460-2075.1994.tb06540.x; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DINTZIS HM, 1993, PROTEINS, V16, P306, DOI 10.1002/prot.340160309; DOOLEY CT, 1994, SCIENCE, V266, P2019, DOI 10.1126/science.7801131; DOOLITTLE RF, 1993, SCI AM, V269, P50, DOI 10.1038/scientificamerican1093-50; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EFIMOV AV, 1994, FEBS LETT, V355, P213, DOI 10.1016/0014-5793(94)01194-X; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; GILL TJ, 1963, NATURE, V197, P746, DOI 10.1038/197746a0; GOMEZ FA, 1994, J ORG CHEM, V59, P2885, DOI 10.1021/jo00089a038; GORDON EM, 1994, J MED CHEM, V37, P1385, DOI 10.1021/jm00036a001; JANEWAY CA, 1967, IMMUNOLOGY, V13, P29; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; MATTHEAKIS LC, 1994, P NATL ACAD SCI USA, V91, P9022, DOI 10.1073/pnas.91.19.9022; MAUER PH, 1965, J EXP MED, V121, P339; MCINTOSH LP, 1990, BIOCHEMISTRY-US, V29, P6341, DOI 10.1021/bi00479a003; MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MUIR TW, 1995, STRUCTURE, V3, P649, DOI 10.1016/S0969-2126(01)00200-3; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; PASTEUR ML, 1860, RECHERCHES DISSYMETR; PRELOG V, 1976, SCIENCE, V193, P17, DOI 10.1126/science.935852; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHUMACHER TNM, UNPUB; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SEYMOUR JF, 1995, SCI MED, V2, P48; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; STALEY JP, 1994, PROTEIN SCI, V3, P1822, DOI 10.1002/pro.5560031021; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YU H, 1993, FEBS LETT, V324, P87, DOI 10.1016/0014-5793(93)81538-B; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZAWADZKE LE, 1993, PROTEINS, V16, P301, DOI 10.1002/prot.340160308; ZAWADZKE LE, 1992, J AM CHEM SOC, V114, P4002, DOI 10.1021/ja00036a073	51	283	328	3	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1996	271	5257					1854	1857		10.1126/science.271.5257.1854	http://dx.doi.org/10.1126/science.271.5257.1854			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596952				2022-12-24	WOS:A1996UC77800043
J	Friedman, LN; Williams, MT; Singh, TP; Frieden, TR				Friedman, LN; Williams, MT; Singh, TP; Frieden, TR			Tuberculosis, aids, and death among substance abusers on welfare in New York City	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MENS SHELTER; INFECTION; RISK; HIV; PROGRESSION	Background. In New York City, the incidence of tuberculosis has more than doubled during the past decade. We examined the incidence of tuberculosis and the acquired immunodeficiency syndrome (AIDS) and the rate of death from all causes in a very-high-risk group - indigent subjects who abuse drugs, alcohol, or both. Methods. In 1984 we began to study prospectively a cohort of welfare applicants and recipients 18 to 64 years of age who abused drugs or alcohol. The incidence rates of tuberculosis, AIDS, and death for this group were ascertained through vital records and New York City's tuberculosis and AIDS registries. Results. The cohort was followed for eight years. Of the 858 subjects, tuberculosis developed in 47 (5.5 percent), 84 (9.8 percent) were given a diagnosis of AIDS, and 183 (21.3 percent) died. The rates of incidence per 100,000 person-years were 744 for tuberculosis, 1323 for AIDS, and 2842 for death. In this group of welfare clients, the rate of newly diagnosed tuberculosis was 14.8 times that of the age-matched general population of New York City; the rate of AIDS was 10.0 times as high; and the death rate was 5.2 times as high. There was no significant difference in the rate of new cases of tuberculosis between subjects with positive skin tests and those with negative skin tests at examination in 1984. Conclusions. Among indigent alcohol and drug abusers in New York City, the rates of tuberculosis, AIDS, and death are extremely high. In this population, a single positive or negative skin test does not predict the development of tuberculosis, probably because both anergy and new infections are common. If programs to control tuberculosis and AIDS are to be effective in groups of indigent substance abusers, health services must be integrated into the welfare delivery system. (C) 1996, Massachusetts Medical Society.	MILFORD HOSP,DEPT QUAL MANAGEMENT,MILFORD,CT 06460; YALE UNIV,SCH MED,PULM & CRIT CARE SECT,NEW HAVEN,CT; NEW YORK CITY DEPT HLTH,BUR TB CONTROL,NEW YORK,NY 10013; NEW YORK CITY DEPT HLTH,OFF AIDS SURVEILLANCE,NEW YORK,NY 10013; CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,ATLANTA,GA 30341	Yale University; New York City Department of Health & Mental Hygiene; New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA	Friedman, LN (corresponding author), MILFORD HOSP,DEPT INTENS CARE,2047 BRIDGEPORT AVE,MILFORD,CT 06460, USA.							ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; AVINS AL, 1994, JAMA-J AM MED ASSOC, V271, P515, DOI 10.1001/jama.271.7.515; BALLA AK, 1994, ALCOHOL, V11, P99, DOI 10.1016/0741-8329(94)90050-7; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; *BUR TUB CONTR, 1993, TUB NEW YORK CIT 199; CONCATO J, 1994, ARCH INTERN MED, V154, P2069, DOI 10.1001/archinte.154.18.2069; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; *DEP HLTH HUM SERV, 1994, REP TUB US 1993; Diem K., 1970, SCI TABLES, VSeventh; *DIV SUBST AB SERV, 1985, STAT COMPR 5 YEAR PL; FONG IW, 1994, CLIN INFECT DIS, V19, P337, DOI 10.1093/clinids/19.2.337; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDMAN LN, 1987, AM REV RESPIR DIS, V136, P1188, DOI 10.1164/ajrccm/136.5.1188; *HUM RES ADM, 1984, 9 HUM RES ADM MONTHL, V45; *HUM RES ADM CIT N, 1994, HRA FACTS DEC 1994; JORDAN TJ, 1991, JAMA-J AM MED ASSOC, V265, P2987, DOI 10.1001/jama.265.22.2987; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P104; MAHLER J, 1994, AM J PSYCHIAT, V151, P439; MCADAM JM, 1991, CHEST, V99, P792, DOI 10.1378/chest.99.3.792-c; MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; MORENO S, 1993, ANN INTERN MED, V119, P194, DOI 10.7326/0003-4819-119-3-199308010-00003; *OFF VIT STAT EP, 1990, SUMM VIT STAT 1990 C; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; PAUL EA, 1993, AM J PUBLIC HEALTH, V83, P1743, DOI 10.2105/AJPH.83.12.1743; REICHMAN LB, 1991, AM REV RESPIR DIS, V144, P741, DOI 10.1164/ajrccm/144.4.741; REICHMAN LB, 1979, ARCH INTERN MED, V139, P337, DOI 10.1001/archinte.139.3.337; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P3434; ZOLOPA AR, 1994, JAMA-J AM MED ASSOC, V272, P455, DOI 10.1001/jama.272.6.455; 1992, MMWR-MORBID MORTAL W, V41, P13; 1990, MMWR-MORBID MORTAL W, V39, P561; 1987, MMWR MORB MORTAL S1S, V36, pS3; 1986, MMWR-MORBID MORTAL W, V35, P74; 1991, MMWR-MORBID MORTAL W, V40, P485; 1987, MMWR-MORBID MORTAL W, V36, P785; 1992, MMWR-MORBID MORTAL W, V41, P1	38	92	95	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1996	334	13					828	833		10.1056/NEJM199603283341304	http://dx.doi.org/10.1056/NEJM199603283341304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB950	8596549				2022-12-24	WOS:A1996UB95000004
J	Mandel, H; Brenner, B; Berant, M; Rosenberg, N; Lanir, N; Jakobs, C; Fowler, B; Seligsohn, U				Mandel, H; Brenner, B; Berant, M; Rosenberg, N; Lanir, N; Jakobs, C; Fowler, B; Seligsohn, U			Coexistence of hereditary homocystinuria and Factor V Leiden - Effect on thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METHYLENETETRAHYDROFOLATE REDUCTASE DEFICIENCY; PROTEIN-C ACTIVATION; CULTURED HUMAN-CELLS; VASCULAR-DISEASE; HOMOCYSTEINE	Background. Venous and arterial thromboembolism occurs in only about one third of patients homozygous for homocystinuria, which suggests that other, contributory factors are necessary for the development of thrombosis in these patients, Factor V Leiden, an R506Q mutation in the gene coding for factor V, is the most common cause of familial thrombosis and could be a potentiating factor. Methods. We determined activated partial-thromboplastin times in the presence and absence of activated protein C and tested for the factor V Leiden mutation in 45 members of seven unrelated consanguineous kindreds in which at least 1 member was homozygous for homocystinuria. Results. Thrombosis (venous, arterial, or both) occurred in 6 of 11 patients with homocystinuria (age, 0.2 to 8 years), All six also had the factor V Leiden mutation. One patient with prenatally diagnosed homocystinuria who was also heterozygous for factor V Leiden has received warfarin therapy since birth and has not had thrombosis (age, 18 months), Of four patients with homocystinuria who did not have factor V Leiden, none had thrombosis (ages at this writing, 1 to 17 years). Three women who were heterozygous for both homocystinuria and factor V Leiden had recurrent fetal loss and placental infarctions. Conclusions. Patients with concurrent homocystinuria and factor V Leiden can have an increased risk of thrombosis, Screening for factor V Leiden may be indicated in patients with homocystinuria and their family members. (C) 1996, Massachusetts Medical Society.	TECHNION ISRAEL INST TECHNOL,FAC MED,RAMBAM MED CTR,THROMBOSIS & HEMOSTASIS UNIT,IL-31096 HAIFA,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,INST THROMBOSIS & HEMOSTASIS,DEPT HEMATOL,SHEBA MED CTR,IL-69978 TEL AVIV,ISRAEL; FREE UNIV AMSTERDAM HOSP,DEPT PEDIAT,1081 HV AMSTERDAM,NETHERLANDS; UNIV BASEL,CHILDRENS HOSP,BASEL,SWITZERLAND	Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Basel	Mandel, H (corresponding author), TECHNION ISRAEL INST TECHNOL,FAC MED,RAMBAM MED CTR,DEPT PEDIAT,IL-31096 HAIFA,ISRAEL.							BAUER KA, 1995, THROMB HAEMOSTASIS, V74, P94; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOSS GR, 1985, J CLIN INVEST, V76, P213, DOI 10.1172/JCI111948; BURKE G, 1994, NEW ENGL J MED, V326, P69; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; CUTZ E, 1989, NEW ENGL J MED, V320, P646, DOI 10.1056/NEJM198903093201006; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; FALCON CR, 1994, ARTERIOSCLER THROMB, V14, P1080, DOI 10.1161/01.ATV.14.7.1080; Fenton W. A., 1995, METABOLIC MOL BASES, P3129; FOWLER B, 1994, ENZYME PROTEIN, V47, P180; GANDRILLE S, 1995, BLOOD, V86, P219, DOI 10.1182/blood.V86.1.219.bloodjournal861219; GRASBECK R, 1972, NEW ENGL J MED, V287, P358; GREENGARD JS, 1994, NEW ENGL J MED, V331, P1559, DOI 10.1056/NEJM199412083312305; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; HOLME E, 1989, ARCH DIS CHILD, V64, P1061, DOI 10.1136/adc.64.7.1061; KOELEMAN BPC, 1995, THROMB HAEMOSTASIS, V74, P580; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; LINDBLAD B, 1994, LANCET, V343, P917, DOI 10.1016/S0140-6736(94)90035-3; MUDD SH, 1985, AM J HUM GENET, V37, P1; MUDD SH, 1995, METABOLIC MOL BASES, V1, P1279; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; RODGERS GM, 1990, BLOOD, V75, P895; ROSENBLATT DS, 1977, PEDIATR RES, V11, P1141, DOI 10.1203/00006450-197711000-00005; ROSENBLATT DS, 1979, J CLIN INVEST, V63, P1019, DOI 10.1172/JCI109370; ROSENBLATT DS, 1987, AM J MED GENET, V26, P377, DOI 10.1002/ajmg.1320260216; Rosenblatt DS., 1995, METABOLIC MOL BASES, VSeventh, P3111; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; Sweetman L, 1991, TECHNIQUES DIAGNOSTI, P143; TRIPLETT DA, 1989, AM J REPROD IMMUNOL, V20, P52, DOI 10.1111/j.1600-0897.1989.tb00639.x; UBBINK JB, 1991, J CHROMATOGR-BIOMED, V565, P441, DOI 10.1016/0378-4347(91)80407-4; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; UHLENDORF BW, 1968, SCIENCE, V160, P1007, DOI 10.1126/science.160.3831.1007; VANBOVEN HH, 1995, THROMB HAEMOSTASIS, V73, P1256; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; ZOLLER B, 1995, BLOOD, V85, P3518, DOI 10.1182/blood.V85.12.3518.bloodjournal85123518	42	245	255	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1996	334	12					763	768		10.1056/NEJM199603213341204	http://dx.doi.org/10.1056/NEJM199603213341204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ979	8592550				2022-12-24	WOS:A1996TZ97900004
J	Rensch, MJ; Merenich, JA; Lieberman, M; Long, BD; Davis, DR; McNally, PR				Rensch, MJ; Merenich, JA; Lieberman, M; Long, BD; Davis, DR; McNally, PR			Gluten-sensitive enteropathy in patients with insulin-dependent diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article							CELIAC-DISEASE; ANTIBODIES; RELATIVES; CHILDREN; GLIADIN	Objective: To determine the prevalence of celiac disease in a cohort of patients with insulin-dependent diabetes mellitus and to describe the clinical characteristics of patients with coexistent disease. Design: Prospective cohort study. Setting: U.S. Army medical center. Patients: 47 patients with insulin-dependent diabetes mellitus. Measurements: Antiendomysial antibody testing was used to screen for celiac disease. The diagnosis of celiac disease required histologic evidence of villous atrophy and crypt hyperplasia and a positive antiendomysial antibody test result. In patients identified as having coexistent disease, complete blood counts, multiphasic biochemical testing, D-xylose absorption testing, and bone mineral density estimates were done. Results: 3 of 47 patients with insulin-dependent diabetes mellitus (6.4%; 95% Cl, 1.4% to 17.5%) had positive antiendomysial antibody test results and small-bowel biopsy specimens consistent with celiac disease. The 95% Ci lies entirely above the estimated prevalence of celiac disease expected in the general U.S. population, which ranges from 0.02% to 0.1%. Mean bone mineral densities were 0.8 and 1.1 SD below age-, ethnicity-, and sex matched controls in each of the 2 antiendomysial anti body-positive patients tested. Small-bowel absorption was abnormal in 1 of the 2 patients tested by D-xylose. Anemia and hypoalbuminemia were not detected in any of the patients with coexistent disease. Only 1 of the 3 patients had symptoms of diarrhea. All patients were at or above their ideal body weights. Conclusions: Celiac disease appears to be more common among patients with insulin-dependent diabetes mellitus than in the general U.S. population (P < 0.001). Two of the three patients with coexistent disease in this study had subclinical or latent celiac disease.	FITZSIMONS ARMY MED CTR, DEPT MED, SERV GASTROENTEROL, AURORA, CO 80045 USA; FITZSIMONS ARMY MED CTR, DEPT CLIN INVEST, AURORA, CO 80045 USA; UNIV COLORADO, HLTH SCI CTR, DENVER, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BARERA G, 1991, ARCH DIS CHILD, V66, P491, DOI 10.1136/adc.66.4.491; CATASSI C, 1994, LANCET, V343, P200, DOI 10.1016/S0140-6736(94)90989-X; COLLIN P, 1989, SCAND J GASTROENTERO, V24, P81, DOI 10.3109/00365528909092243; CONGIA M, 1994, HUM IMMUNOL, V40, P138, DOI 10.1016/0198-8859(94)90059-0; CORAZZA G, 1992, GASTROENTEROLOGY, V103, P1517, DOI 10.1016/0016-5085(92)91172-Z; FERREIRA M, 1992, GUT, V33, P1633, DOI 10.1136/gut.33.12.1633; Kahn CR, 1994, JOSLINS DIABETES MEL; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KNUDTZON J, 1991, J PEDIATR GASTR NUTR, V12, P190, DOI 10.1097/00005176-199102000-00009; LINDH E, 1992, J INTERN MED, V231, P403, DOI 10.1111/j.1365-2796.1992.tb00951.x; MAKI M, 1995, GUT, V36, P239, DOI 10.1136/gut.36.2.239; MAKI M, 1991, LANCET, V337, P763, DOI 10.1016/0140-6736(91)91375-5; RUBIN CE, 1960, GASTROENTEROLOGY, V38, P28; SAVILAHTI E, 1986, J PEDIATR-US, V108, P690, DOI 10.1016/S0022-3476(86)81042-3; STROBER W, 1992, OXFORD MONOGRAPHS ME, V20, P279; TALLEY NJ, 1994, AM J GASTROENTEROL, V89, P843; VOLTA U, 1991, DIGEST DIS SCI, V36, P752, DOI 10.1007/BF01311232; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909; WATSON RG, 1994, GUT, V35, pW14	19	77	77	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1996	124	6					564	567		10.7326/0003-4819-124-6-199603150-00004	http://dx.doi.org/10.7326/0003-4819-124-6-199603150-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ529	8597319				2022-12-24	WOS:A1996TZ52900004
J	Celenza, A; Fothergill, J; Kupek, E; Shaw, RJ				Celenza, A; Fothergill, J; Kupek, E; Shaw, RJ			Thunderstorm associated asthma: A detailed analysis of environmental factors	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SOYBEAN DUST; WEATHER; POLLEN	Objectives-To seek meteorological factors, pollutants or pollen, and an asthma epidemic which occurred in London on 24 and 25 June 1994 after a thunderstorm. Design-Retrospective study of patients' accident and emergency department records, with bivariate and multivariate analysis of environmental factors and data collection for the two months surrounding the epidemic. Setting-The accident and emergency department of St Mary's Hospital in west central London. Subjects-148 patients presenting with asthma between 1 June and 31 July 1994, of whom 40 presented in the 24 hours after the storm. Results-The asthma epidemic was significantly associated with a drop in air temperature six hours previously and a high grass pollen concentration nine hours previously. Non-epidemic asthma was significantly associated with lightning strikes, increase in humidity or sulphur dioxide concentration, a drop in temperature or high rainfall the previous day, and a decrease in maximum air pressure or changes in grass pollen counts over the previous two days. Conclusions-New episodes of asthma during the epidemic on 24 and 25 June 1994 were associated with a fall in air temperature and a rise in grass pollen concentration. Non-epidemic asthma was significantly associated with a greater number of environmental changes. This may indicate that the patients with thunderstorm associated asthma were a separate population, sensitive to different environmental stimuli.	ST MARYS HOSP, LONDON W2 1NY, ENGLAND	Imperial College London								ACEVES M, 1991, J ALLERGY CLIN IMMUN, V88, P124, DOI 10.1016/0091-6749(91)90309-C; ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; AYRES J, 1994, BRIT MED J, V309, P619, DOI 10.1136/bmj.309.6955.619; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834, DOI 10.5694/j.1326-5377.1992.tb136994.x; BROWN HM, 1983, LANCET, V2, P630; CAMPBELLHEWSON G, 1994, BRIT MED J, V309, P1086, DOI 10.1136/bmj.309.6961.1086a; EGAN P, 1985, MED J AUSTRALIA, V142, P330, DOI 10.5694/j.1326-5377.1985.tb113389.x; Ito S, 1989, Arerugi, V38, P1077; Lim T O, 1991, Med J Malaysia, V46, P230; LOGAN WPD, 1953, LANCET, V264, P336; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MONTEALEGRE F, 1993, J ASTHMA, V30, P219, DOI 10.3109/02770909309054520; MORRISON I, 1960, Med J Aust, V47(1), P850; MURRAY V, 1994, BRIT MED J, V309, P131, DOI 10.1136/bmj.309.6947.131c; PACKE GE, 1985, LANCET, V2, P199; ROSSI OVJ, 1993, THORAX, V48, P244, DOI 10.1136/thx.48.3.244; *SAS I, 1995, P243 SAS I; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; WALTERS S, 1994, THORAX, V49, P133, DOI 10.1136/thx.49.2.133	19	151	154	1	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 9	1996	312	7031					604	607						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595333				2022-12-24	WOS:A1996TZ84000023
J	Zuckerman, AJ				Zuckerman, AJ			Alphabet of hepatitis viruses	LANCET			English	Editorial Material											Zuckerman, AJ (corresponding author), ROYAL FREE HOSP, SCH MED, WHO, COLLABORATING CTR REFERENCE & RES VIRAL DIS, LONDON, ENGLAND.							Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; MUERHOFF AS, 1995, J VIROL, V69, P5621, DOI 10.1128/JVI.69.9.5621-5630.1995; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7; ZUCKERMAN AJ, 1995, LANCET, V345, P1453, DOI 10.1016/S0140-6736(95)91032-8	7	173	174	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 2	1996	347	9001					558	559		10.1016/S0140-6736(96)91267-2	http://dx.doi.org/10.1016/S0140-6736(96)91267-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596314				2022-12-24	WOS:A1996TX69400005
J	Hugot, JP; LaurentPuig, P; GowerRousseau, C; Olson, JM; Lee, JC; Beaugerie, L; Naom, I; Dupas, JL; VanGossum, A; Orholm, M; BonaitiPellie, C; Weissenbach, J; Mathew, CG; LennardJones, JE; Cortot, A; Colombel, JF; Thomas, G				Hugot, JP; LaurentPuig, P; GowerRousseau, C; Olson, JM; Lee, JC; Beaugerie, L; Naom, I; Dupas, JL; VanGossum, A; Orholm, M; BonaitiPellie, C; Weissenbach, J; Mathew, CG; LennardJones, JE; Cortot, A; Colombel, JF; Thomas, G			Mapping of a susceptibility locus for Crohn's disease on chromosome 16	NATURE			English	Article							INFLAMMATORY BOWEL-DISEASE; COMPLEX SEGREGATION ANALYSIS; LINKAGE ANALYSIS; EPIDEMIOLOGY	Crohn's disease (CD) and ulcerative colitis are the major forms of chronic inflammatory bowel diseases in the western world, and occur in young adults with an estimated prevalence of more than one per thousand inhabitants'. The causes of inflammatory bowel diseases remain unknown, but genetic epidemiology studies(2-5) suggest that inherited factors may contribute in part to variation in individual susceptibility to Crohn's disease. A genome-wide search performed on two consecutive and independent panels of families with multiple affected members, using a non-parametric two-point sibling-pair linkage method, identified a putative CD-susceptibility locus on chromosome 16 (P < 0.01 for each panel). The localization was centred around loci D16S409 and D16S419 by using multipoint sibpair analysis (ref. 6, and J.M.O., manuscript submitted) (P < 1.5 x 10(-5)). This region of the genome contains candidate genes which may be relevant to the pathogenic mechanism of inflammatory bowel diseases.	INST CURIE,LAB GENET TUMEURS,INSERM,U434,F-75231 PARIS,FRANCE; CTR HOSP REG & UNIV LILLE,REGISTRE MALAD INFLAMMATOIRES TUBE DIGEST NORD QU,F-59037 LILLE,FRANCE; CASE WESTERN RESERVE UNIV,DEPT EPIDEMIOL & BIOSTAT,CLEVELAND,OH 44109; ST MARKS HOSP,LONDON EC1V 2PS,ENGLAND; HOP ROTHSCHILD,SERV GASTROENTEROL & HEPTAOL,F-75571 PARIS,FRANCE; UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,DIV MED & MOLEC GENET,LONDON SE1 9RT,ENGLAND; HOP NORD AMIENS,SERV HEPATOGASTROENTEROL,F-80054 AMIENS,FRANCE; HOP ERASME,SERV GASTROENTEROL & HEPATOPANCREATOL,B-1070 BRUSSELS,BELGIUM; GRP ETUD THERAPEUT AFFECT INFLAMMATORIES DIGEST,F-75012 PARIS,FRANCE; HERLEV HOSP,DEPT MED GASTROENTEROL,COPENHAGEN,DENMARK; INST GUSTAVE ROUSSY,CANC EPIDEMIOL UNIT,F-94805 VILLEJUIF,FRANCE; GENETHON,CNRS,URA 1922,F-91002 EVRY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite de Lille - ISITE; CHU Lille; Case Western Reserve University; Imperial College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; Universite Libre de Bruxelles; University of Copenhagen; Herlev & Gentofte Hospital; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS)			Mathew, Christopher G/G-3434-2015; laurent-puig, pierre/B-2226-2013; CORTOT, ANTOINE/I-7739-2016; Gower-Rousseau, Corinne/I-2553-2018; CORTOT, Antoine/I-5796-2015; Hugot, Jean-Pierre/F-6594-2012; Laurent-Puig, Pierre/K-3641-2019	Mathew, Christopher G/0000-0003-4178-1838; laurent-puig, pierre/0000-0001-8475-5459; CORTOT, ANTOINE/0000-0002-1067-8996; Gower-Rousseau, Corinne/0000-0002-3925-5364; Laurent-Puig, Pierre/0000-0001-8475-5459; Hugot, Jean-Pierre/0000-0002-8446-6056				BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; CALKINS BM, 1986, EPIDEMIOL REV, V8, P60, DOI 10.1093/oxfordjournals.epirev.a036296; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DOGGETT NA, 1995, NATURE, V377, P335; GOWERROUSSEAU C, 1994, GUT, V35, P1433, DOI 10.1136/gut.35.10.1433; GREEN P, 1992, CYTOGENET CELL GENET, V59, P122, DOI 10.1159/000133221; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HASHIMOTO L, 1994, NATURE, V371, P161, DOI 10.1038/371161a0; HETLAND G, 1994, IMMUNOLOGY, V82, P445; HODGE S E, 1984, Genetic Epidemiology, V1, P109, DOI 10.1002/gepi.1370010203; HUGOT JP, 1994, AM J MED GENET, V52, P207, DOI 10.1002/ajmg.1320520216; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; KUSTER W, 1989, AM J MED GENET, V32, P105, DOI 10.1002/ajmg.1320320122; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LATHROP GM, 1985, AM J HUM GENET, V37, P482; MALONEY MD, 1994, J EXP MED, V180, P191, DOI 10.1084/jem.180.1.191; MANJUNATH N, 1993, J IMMUNOL, V151, P1528; ORHOLM M, 1993, BRIT MED J, V306, P20, DOI 10.1136/bmj.306.6869.20; ORHOLM M, 1991, NEW ENGL J MED, V324, P84, DOI 10.1056/NEJM199101103240203; OTT J, 1989, P NATL ACAD SCI USA, V86, P4175, DOI 10.1073/pnas.86.11.4175; RISCH N, 1987, AM J HUM GENET, V40, P1; RISH N, 1990, AM J HUM GENET, V46, P229; SCHREIBER S, 1995, GASTROENTEROLOGY, V108, P21, DOI 10.1016/0016-5085(95)90004-7; SONNENBERG A, 1991, GASTROENTEROLOGY, V101, P122, DOI 10.1016/0016-5085(91)90468-Z; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990; WHITE H, 1982, ECONOMETRICA, V50, P1, DOI 10.2307/1912526; 1994, STATISTICAL ANAL GEN	27	791	826	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					821	823		10.1038/379821a0	http://dx.doi.org/10.1038/379821a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587604				2022-12-24	WOS:A1996TX50100057
J	Wragg, M; Hutton, M; Talbot, C; Busfield, F; Han, SW; Lendon, C; Clark, RF; Morris, JC; Edwards, D; Goate, A; Pfeiffer, E; Crook, R; Prihar, G; Phillips, H; Baker, M; Hardy, J; Rossor, M; Houlden, H; Karran, E; Roberts, G; Craddock, N				Wragg, M; Hutton, M; Talbot, C; Busfield, F; Han, SW; Lendon, C; Clark, RF; Morris, JC; Edwards, D; Goate, A; Pfeiffer, E; Crook, R; Prihar, G; Phillips, H; Baker, M; Hardy, J; Rossor, M; Houlden, H; Karran, E; Roberts, G; Craddock, N			Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease	LANCET			English	Article								Background Mutations in the presenilin-1 (PS-1) gene are associated with early-onset Alzheimer's disease. 40-50% of the risk for late-onset disease has been attributed to alleles at the apolipoprotein E (ApoE) locus. We have looked for an association between PS-1 and late-onset disease. Methods We collected blood samples from 208 white cases of dementia of the Alzheimer type and from 185 age matched controls (mean ages 76.9 and 76.2 years, respectively; 58% female in each series). Clinical diagnostic accuracy for Alzheimer's disease in our patients is 96%. We also studied 29 African-American patients with dementia of the Alzheimer type and 50 age-matched controls (cases vs controls, 77.2 vs 72.0 years; 72 vs 77% female). We used PCR to test for an association between Alzheimer's disease and a polymorphism within the intron 3' to exon 8 of the PS-1 gene. The ApoE genotype of most of the cases and controls was known from previous investigations. Findings Homozygosity of the 1 allele in the PS-1 gene was associated with a doubling of the risk for late-onset Alzheimer's disease compared with the [12]/[22] genotype (odds ratio 1.97, 95% CI 1.29-3.00). The proportion of Alzheimer's disease cases in the white population that could be attributed to homozygosity at this locus, as estimated by the attributable fraction, was 0.22. This compares with 0.35 for a single copy of ApoE4 and 0.15 for two copies. The smaller African-American series showed similar distribution of PS-1 genotype between cases and controls. Interpretation In our white series of cases, PS-1 accounted for about half as much of the risk for late-onset Alzheimer's disease as did ApoE4.	WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63100; UNIV S FLORIDA,GERONTOL CTR,TAMPA,FL; WASHINGTON UNIV,SCH MED,DEPT NEUROL & OCCUPAT THERAPY,ST LOUIS,MO 63100; UNIV S FLORIDA,SUNCOAST ALZHEIMERS DIS LABS,DEPT PSYCHIAT,TAMPA,FL; UNIV S FLORIDA,SUNCOAST ALZHEIMERS DIS LABS,DEPT PHARMACOL,TAMPA,FL; UNIV S FLORIDA,SUNCOAST ALZHEIMERS DIS LABS,DEPT BIOCHEM,TAMPA,FL; UNIV S FLORIDA,SUNCOAST ALZHEIMERS DIS LABS,DEPT NEUROL,TAMPA,FL; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT NEUROL,LONDON W2,ENGLAND; SMITHKLINE BEECHAM,DEPT MOL NEUROPATHOL,HARLOW,ESSEX,ENGLAND; UNIV WALES COLL CARDIFF,COLL MED,DEPT PSYCHOL MED,CARDIFF,S GLAM,WALES	Washington University (WUSTL); State University System of Florida; University of South Florida; Washington University (WUSTL); State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Imperial College London; GlaxoSmithKline; Cardiff University			Morris, John C/A-1686-2012; Rossor, Martin/C-1598-2008; Hardy, John/C-2451-2009; Houlden, Henry J/C-1532-2008	Hardy, John/0000-0002-3122-0423; Houlden, Henry J/0000-0002-2866-7777; Phillips, Helen Margaret/0000-0003-4513-9148; Rossor, Martin/0000-0001-8215-3120; Clark, Robert/0000-0001-5091-8280; Goate, Alison/0000-0002-0576-2472; Talbot, Christopher/0000-0001-7406-8962	NIA NIH HHS [AG00634, AG11871, AG12028] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012028, R01AG011871] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Berg Leonard, 1994, P9; CLARK RF, 1995, NAT GENET, V11, P219, DOI 10.1038/ng1095-219; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CRUTS M, 1995, HUM MOL GENET, V4, P2363, DOI 10.1093/hmg/4.12.2363; HOULDEN H, 1993, NEURODEGENERATION, V2, P283; HUTTON M, IN PRESS NEUROREPORT; KAMBOH MI, 1995, NAT GENET, V10, P486, DOI 10.1038/ng0895-486; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; PEREZTUR J, IN PRESS NEUROREPORT; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SCHELLENBERG GD, 1993, AM J HUM GENET, V53, P619; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; TALBOT C, 1994, LANCET, V343, P1432, DOI 10.1016/S0140-6736(94)92557-7; TALBOT CJ, IN PRESS NEUROREPORT; WASCO W, 1995, NAT MED, V1, P848, DOI 10.1038/nm0995-848a; WISNIEWSKI T, 1995, LANCET, V346, P1366, DOI 10.1016/S0140-6736(95)92379-9	17	230	242	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					509	512		10.1016/S0140-6736(96)91140-X	http://dx.doi.org/10.1016/S0140-6736(96)91140-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596269				2022-12-24	WOS:A1996TW69700011
J	Grubmuller, H; Heymann, B; Tavan, P				Grubmuller, H; Heymann, B; Tavan, P			Ligand binding: Molecular mechanics calculation of the streptavidin biotin rupture force	SCIENCE			English	Article							DYNAMICS; PROTEIN; PROGRAM; ENERGY	The force required to rupture the streptavidin-biotin complex was calculated here by computer simulations. The computed force agrees well with that obtained by recent single molecule atomic force microscope experiments. These simulations suggest a detailed multiple-pathway rupture mechanism involving five major unbinding steps. Binding forces and specificity are attributed to a hydrogen bond network between the biotin ligand and residues within the binding pocket of streptavidin. During rupture, additional water bridges substantially enhance the stability of the complex and even dominate the binding interactions. In contrast, steric restraints do not appear to contribute to the binding forces, although conformational motions were observed.			Grubmuller, H (corresponding author), UNIV MUNICH,INST MED OPT,THERESIENSTR 37,D-80333 MUNICH,GERMANY.							BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROOKS CL, 1983, J CHEM PHYS, V79, P6312, DOI 10.1063/1.445724; Brunger A.T., 1988, X PLOR; EICHINGER M, UNPUB; EICHINGER M, 1995, E COMMUNICATION; ELBER R, IN PRESS NEW DEV THE; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FRAUENFELDER H, 1979, NATURE, V280, P558, DOI 10.1038/280558a0; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; GRUBMULLER H, 1995, PHYS REV E, V52, P2893, DOI 10.1103/PhysRevE.52.2893; Heller H, 1990, MOL SIMULAT, V5, P133, DOI 10.1080/08927029008022127; JORGENSON WL, 1983, J CHEM PHYS, V79, P927; KITAO A, 1993, J PHYS CHEM-US, V97, P10223, DOI 10.1021/j100141a052; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; MCCAMMON JA, 1977, NATURE, V267, P585, DOI 10.1038/267585a0; MIYAMOTO S, 1993, PROTEINS, V16, P226, DOI 10.1002/prot.340160303; MOY VT, 1994, SCIENCE, V266, P257, DOI 10.1126/science.7939660; NIEDERMEIER C, 1994, J CHEM PHYS, V101, P734, DOI 10.1063/1.468129; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; WEBER PC, 1992, J AM CHEM SOC, V114, P3197, DOI 10.1021/ja00035a004; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722	23	739	744	15	209	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					997	999		10.1126/science.271.5251.997	http://dx.doi.org/10.1126/science.271.5251.997			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584939	Green Submitted			2022-12-24	WOS:A1996TV70400052
J	Bradbury, AW; Ruckley, CV				Bradbury, AW; Ruckley, CV			Angioplasty for lower-limb ischaemia: Time for randomised controlled trials	LANCET			English	Editorial Material									UNIV EDINBURGH,VASC SURG OFF,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh	Bradbury, AW (corresponding author), ST MARYS HOSP,PRAED ST,LONDON,ENGLAND.							BAKER SR, 1995, AUST NZ J SURG, V65, P166, DOI 10.1111/j.1445-2197.1995.tb00600.x; BUCKENHAM TM, 1993, EUR J VASCULAR SURG, V7, P21, DOI 10.1016/S0950-821X(05)80538-9; Creasy T S, 1990, Eur J Vasc Surg, V4, P135, DOI 10.1016/S0950-821X(05)80427-X; CURRIE IC, 1994, BRIT J SURG, V81, P191, DOI 10.1002/bjs.1800810209; DOTTER CT, 1964, CIRCULATION, V30, P654, DOI 10.1161/01.CIR.30.5.654; HUNINK MGM, 1994, ADV VASC SURG, V2, P135; LONDON NJM, 1994, EUR J VASCULAR SURG, V8, P148, DOI 10.1016/S0950-821X(05)80450-5; LONDON NJM, 1995, BRIT J SURG, V82, P1232, DOI 10.1002/bjs.1800820925; Pell J P, 1995, Health Bull (Edinb), V53, P34; PELL JP, 1994, BRIT J SURG, V81, P832, DOI 10.1002/bjs.1800810613; PORTER JM, 1995, J VASC SURG, V21, P995, DOI 10.1016/S0741-5214(95)70229-6; RAY SA, 1995, BRIT J SURG, V82, P1217, DOI 10.1002/bjs.1800820921; SACKETT DL, 1989, CHEST, V95, pS2, DOI 10.1378/chest.95.2.2S; VROEGINDEWEIJ D, 1995, EUR J VASC ENDOVASC, V10, P40, DOI 10.1016/S1078-5884(05)80197-2; WHITE GH, 1995, J VASC SURG, V21, P270, DOI 10.1016/S0741-5214(95)70268-7; WHYMAN MR, 1991, BRIT J SURG, V78, P643, DOI 10.1002/bjs.1800780603	16	31	31	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					277	278		10.1016/S0140-6736(96)90460-2	http://dx.doi.org/10.1016/S0140-6736(96)90460-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569356	Bronze			2022-12-24	WOS:A1996TT48500003
J	Lee, MA; Nelson, HD; Tilden, VP; Ganzini, L; Schmidt, TA; Tolle, SW				Lee, MA; Nelson, HD; Tilden, VP; Ganzini, L; Schmidt, TA; Tolle, SW			Legalizing assisted suicide - Views of physicians in Oregon	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EUTHANASIA; LIFE; DEPRESSION; ATTITUDES; AID	Background. Since the Oregon Death with Dignity Act was passed in November 1994, physicians in Oregon have faced the prospect of legalized physician-assisted suicide. We studied the attitudes and current practices of Oregon physicians in relation to assisted suicide. Methods. From March to June 1995, we conducted a cross-sectional mailed survey of all physicians who might be eligible to prescribe a lethal dose of medication if the Oregon law is upheld, Physicians were asked to complete and return a confidential 56-item questionnaire. Results. Of the 3944 eligible physicians who received the questionnaire, 2761 (70 percent) responded. Sixty percent of the respondents thought physician-assisted suicide should be legal in some cases, and nearly half (46 percent) might be willing to prescribe a lethal dose of medication if it were legal to do so; 31 percent of the respondents would be unwilling to do so on moral grounds. Twenty-one percent of the respondents have previously received requests for assisted suicide, and 7 percent have complied. Half the respondents were not sure what to prescribe for this purpose, and 83 percent cited financial pressure as a possible reason for such requests. The respondents also expressed concern about complications of suicide attempts and doubts about their ability to predict survival at six months accurately. Conclusions. Oregon physicians have a more favorable attitude toward legalized physician-assisted suicide, are more willing to participate, and are currently participating in greater numbers than other surveyed groups of physicians in the United States. A sizable minority of physicians in Oregon objects to legalization and participation on moral grounds. Regardless of their attitudes, physicians had a number of reservations about the practical applications of the act. (C) 1996, Massachusetts Medical Society.	OREGON HLTH SCI UNIV,SCH MED,DEPT MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,SCH MED,DEPT PSYCHIAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,SCH MED,DEPT EMERGENCY MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,SCH NURSING,RES OFF,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,CTR BIOMED INFORMAT COMMUN,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Lee, MA (corresponding author), OREGON HLTH SCI UNIV,CTR ETH HLTH CARE L101,PORTLAND,OR 97201, USA.							ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; BATTIN MP, 1991, J PAIN SYMPTOM MANAG, V6, P298, DOI 10.1016/0885-3924(91)90053-7; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; CARALIS PV, 1992, CRIT CARE MED, V20, P683, DOI 10.1097/00003246-199205000-00023; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; CROSBY C, 1992, INTERNIST, V31, P10; DUBERSEIN PR, 1995, J AM GERIATR SOC, V43, P395, DOI 10.1111/j.1532-5415.1995.tb05814.x; EMANUEL EJ, 1994, ANN INTERN MED, V121, P793, DOI 10.7326/0003-4819-121-10-199411150-00010; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; GATES V, 1995, OREGON HLTH PLAN REP, P71; HEILIG S, 1989, SF MED, V61, P24; KEISLING P, 1995, OREGON BLUE BOOK, P296; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KOENIG HG, 1988, ARCH INTERN MED, V148, P1929, DOI 10.1001/archinte.148.9.1929; KRUSE JA, 1988, JAMA-J AM MED ASSOC, V260, P1739, DOI 10.1001/jama.260.12.1739; MEIER D, 1993, SURVEY END LIFE PRAC; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; NIELSEN AC, 1980, ARCH GEN PSYCHIAT, V37, P999; OVERMYER M, 1991, PHYSICIANS MANAGE, V31, P40; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; TENO JM, 1994, J AM GERIATR SOC, V42, P1202, DOI 10.1111/j.1532-5415.1994.tb06990.x; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; 1992, JAMA-J AM MED ASSOC, V267, P2229; 1995, ACAD MED, V70, P583; 1995, J AM GERIATR SOC, V42, P579; 1994, POISITON STATEMENT A; 1994, OREGON VOTERS PAMPHL; 1991, INITATIVE 119 WSMA M	29	208	208	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					310	315		10.1056/NEJM199602013340507	http://dx.doi.org/10.1056/NEJM199602013340507			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV695	8532028				2022-12-24	WOS:A1996TV69500007
J	Collier, J				Collier, J			Medicines mismatch	LANCET			English	Editorial Material							DRUG				Collier, J (corresponding author), ST GEORGE HOSP,SCH MED,DEPT CLIN PHARMACOL,CRANMER TERRACE,LONDON,ENGLAND.							CHANDRA S, 1995, OCT NAT MED DRUG POL; GREENHALGH T, 1987, SOC SCI MED, V25, P307, DOI 10.1016/0277-9536(87)90233-4; KRISHNASWAMY K, 1985, EUR J CLIN PHARMACOL, V29, P363, DOI 10.1007/BF00544095; PHADKE A, 1995, STUDY SUPPLY USE PHA, P152	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					212	212		10.1016/S0140-6736(96)90400-6	http://dx.doi.org/10.1016/S0140-6736(96)90400-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TT069	8551877				2022-12-24	WOS:A1996TT06900006
J	Phillips, AN				Phillips, AN			Reduction of HIV concentration during acute infection: Independence from a specific immune response	SCIENCE			English	Article							VIRUS TYPE-1 INFECTION; DYNAMICS; VIREMIA; PLASMA	After infection with the human immunodeficiency virus (HIV), the concentration of the virus in the person's plasma increases. The subsequent decrease in concentration a few weeks later was thought to result from an HIV-specific immune response. This purported causal relation is investigated with a model of the dynamics of early HIV infection that incorporates no increase in the rate of removal of free virions or virus-infected cells. A pattern of changes in virus concentration similar to that observed in patients is predicted by the model. Thus, the reduction in virus concentration during acute infection may not reflect the ability of the HIV-specific immune response to control virus replication.			Phillips, AN (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PRIMARY CARE & POPULAT SCI,HIV RES UNIT,ROWLAND HILL ST,LONDON NW3 2PF,ENGLAND.		Phillips, Andrew N/B-4427-2008	Phillips, Andrew N/0000-0003-2384-4807				BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; GOWDA SD, 1989, J IMMUNOL, V142, P773; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KATZENSTEIN TL, UNPUB; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P40; KOUP RA, 1994, NATURE, V370, P416, DOI 10.1038/370416a0; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LUZURIAGA K, 1993, J INFECT DIS, V167, P1008, DOI 10.1093/infdis/167.5.1008; MCLEAN AR, 1991, AIDS, V5, P485, DOI 10.1097/00002030-199105000-00002; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; PAUL WE, 1985, FUNDAMENTAL IMMUNOLO; PEAKMAN M, 1995, CELL ACTIVATION APOP; PERELSON AS, 1993, MATH BIOSCI, V114, P81, DOI 10.1016/0025-5564(93)90043-A; PERELSON AS, 1989, LECTURE NOTES BIOMAT, V82, P350; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; SAFRIT JT, 1994, J EXP MED, V179, P463, DOI 10.1084/jem.179.2.463; SAFRIT JT, 1994, J IMMUNOL, V153, P3822; SHENZLE D, 1994, STAT MED, V13, P2067; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	22	255	260	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					497	499		10.1126/science.271.5248.497	http://dx.doi.org/10.1126/science.271.5248.497			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560262				2022-12-24	WOS:A1996TR32200039
J	McPherson, PS; Garcia, EP; Slepnev, VI; David, C; Zhang, XM; Grabs, D; Sossin, WS; Bauerfeind, R; Nemoto, Y; DeCamilli, P				McPherson, PS; Garcia, EP; Slepnev, VI; David, C; Zhang, XM; Grabs, D; Sossin, WS; Bauerfeind, R; Nemoto, Y; DeCamilli, P			A presynaptic inositol-5-phosphatase	NATURE			English	Article							PHOSPHOLIPID TRANSFER PROTEIN; INOSITOL POLYPHOSPHATE-5-PHOSPHATASE; YEAST GOLGI; IDENTIFICATION; MUTATIONS	SYNAPTOJANIN is a nerve terminal protein of relative molecular mass 145,000 which appears to participate with dynamin in synaptic vesicle recycling(1,2). The central region of synaptojanin defines it as a member of the inositol-5-phosphatase family, which includes the product of the gene that is defective in the oculocerebrorenal syndrome of Lowe(3-7). Synaptojanin has 5-phosphatase activity and its amino-terminal domain is homologous with the yeast protein Sac1 (Rsd1), which is genetically implicated in phospholipid metabolism and in the function of the actin cytoskeleton(8-10). The carboxy terminus, which is of different lengths in adult and developing neurons owing to the alternative use of two termination sites, is proline-rich, consistent,vith the reported interaction of synaptojanin with the SH3 domains of Grb2 (refs 1, 2), Synaptojanin is the only other major brain protein besides dynamin that binds the SH3 domain of amphiphysin, a presynaptic protein with a putative function in endocytosis(11-14). Our results suggest a link between phosphoinositide metabolism and synaptic vesicle recycling.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; MCGILL UNIV,MONTREAL NEUROL INST,DEPT NEUROL & NEUROSURG,MONTREAL,PQ H3A 2B4,CANADA	Yale University; Howard Hughes Medical Institute; Yale University; McGill University								ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; DAVID C, IN PRESS P NATN ACAD; GAIDAROV IO, 1995, MOL BIOL CELL, V6, P407; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; NOVICK P, 1989, GENETICS, V121, P659; ROSS TS, 1991, J BIOL CHEM, V266, P20283; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; SZABO G, 1994, MOL CELL BIOL, V14, P7535, DOI 10.1128/MCB.14.11.7535; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	30	482	491	2	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					353	357		10.1038/379353a0	http://dx.doi.org/10.1038/379353a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552192				2022-12-24	WOS:A1996TR32300061
J	Nightingale, SL				Nightingale, SL			Guidance on industry dissemination of textbooks and reprints	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					273	273						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544255				2022-12-24	WOS:A1996TP96500006
J	Furukawa, K; Barger, SW; Blalock, EM; Mattson, MP				Furukawa, K; Barger, SW; Blalock, EM; Mattson, MP			Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein	NATURE			English	Article							POTASSIUM CHANNEL; ALZHEIMERS-DISEASE; RAT; MODULATION; GENE	THE Alzheimer's beta-amyloid precursor protein (beta-APP) is widely expressed in neural cells, and in neurons secreted forms of beta-APP (sAPPs) are released from membrane-spanning holo-beta APP in an activity-dependent manner(1,2). Secreted APPs can modulate neurite outgrowth, synaptogenesis, synaptic plasticity and cell survival(3,9); a signal transduction mechanism of sAPPs may involve modulation of intracellular calcium levels ([Ca2+](i))(4,10). Here we use whole-cell perforated patch and single-channel patch-clamp analysis of hippocampal neurons to demonstrate that sAPPs suppress action potentials and hyperpolarize neurons by activating high-conductance, charybdotoxin-sensitive K+ channels. Activation of K+ channels by sAPPs was mimicked by a cyclic GMP analogue and sodium nitroprusside and blocked by an antagonist of cGMP-dependent kinase and a phosphatase inhibitor, suggesting that the effect is mediated by cGMP and protein dephosphorylation. Calcium imaging studies indicate that activation of K+ channels mediates the ability of sAPPs to decrease [Ca-2](i). Modulation of neuronal excitability may be a major mechanism by which beta-APP regulates developmental and synaptic plasticity in the nervous system.	UNIV KENTUCKY,SANDERS BROWN RES CTR AGING,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT PHARMACOL,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT ANAT & NEUROBIOL,LEXINGTON,KY 40536	University of Kentucky; University of Kentucky; University of Kentucky			Mattson, Mark P/F-6038-2012	Barger, Steven/0000-0001-6049-6480				AKON DL, 1991, BRAIN RES REV, V16, P193; ARCHER SL, 1994, P NATL ACAD SCI USA, V91, P7583, DOI 10.1073/pnas.91.16.7583; BARGER SW, 1995, J NEUROCHEM, V64, P2087; BARGER SW, 1995, BIOCHEM J, V311, P45, DOI 10.1042/bj3110045; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; CRITZ SD, 1992, J NEUROPHYSIOL, V68, P1079, DOI 10.1152/jn.1992.68.4.1079; EGAN TM, 1993, J NEUROPHYSIOL, V69, P1433, DOI 10.1152/jn.1993.69.5.1433; ETCHEBERRIGARAY R, 1993, P NATL ACAD SCI USA, V90, P8209, DOI 10.1073/pnas.90.17.8209; Firestein Stuart, 1994, Seminars in Cell Biology, V5, P39, DOI 10.1006/scel.1994.1006; HAYDON PG, 1995, TRENDS NEUROSCI, V18, P196, DOI 10.1016/0166-2236(95)93901-9; HUBER G, 1993, BRAIN RES, V603, P348, DOI 10.1016/0006-8993(93)91261-P; KATER SB, 1988, TRENDS NEUROSCI, V11, P315, DOI 10.1016/0166-2236(88)90094-X; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; LUO LQ, 1992, NEURON, V9, P595, DOI 10.1016/0896-6273(92)90024-8; MARK RJ, 1995, J NEUROSCI, V15, P6239; MATTSON MP, 1994, J NEUROBIOL, V25, P439, DOI 10.1002/neu.480250409; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; NITSCH RM, 1993, P NATL ACAD SCI USA, V90, P5191, DOI 10.1073/pnas.90.11.5191; PONGS O, 1992, TRENDS PHARMACOL SCI, V13, P359, DOI 10.1016/0165-6147(92)90109-J; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; Sperelakis N, 1994, Adv Pharmacol, V26, P217, DOI 10.1016/S1054-3589(08)60056-3; WAKAMORI M, 1993, J PHYSIOL-LONDON, V463, P585, DOI 10.1113/jphysiol.1993.sp019612; WANN KT, 1994, EUR J NEUROSCI, V6, P607, DOI 10.1111/j.1460-9568.1994.tb00305.x; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0	29	289	294	2	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					74	78		10.1038/379074a0	http://dx.doi.org/10.1038/379074a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538744				2022-12-24	WOS:A1996TN21600058
J	Tartaglia, LA; Dembski, M; Weng, X; Deng, NH; Culpepper, J; Devos, R; Richards, GJ; Campfield, LA; Clark, FT; Deeds, J; Muir, C; Sanker, S; Moriarty, A; Moore, KJ; Smutko, JS; Mays, GG; Woolf, EA; Monroe, CA; Tepper, RI				Tartaglia, LA; Dembski, M; Weng, X; Deng, NH; Culpepper, J; Devos, R; Richards, GJ; Campfield, LA; Clark, FT; Deeds, J; Muir, C; Sanker, S; Moriarty, A; Moore, KJ; Smutko, JS; Mays, GG; Woolf, EA; Monroe, CA; Tepper, RI			Identification and expression cloning of a leptin receptor, OB-R	CELL			English	Article							COLONY-STIMULATING FACTOR; LEUKEMIA-INHIBITORY FACTOR; SIGNAL TRANSDUCER; MOLECULAR-CLONING; GP130; EFFICIENT; OBESITY; DOMAINS; MICE	The ob gene product, leptin, is an important circulating signal for the regulation of body weight. To identify high affinity leptin-binding sites, we generated a series of leptin-alkaline phosphatase (AP) fusion proteins as well as [I-125]leptin. After a binding survey of cell lines and tissues, we identified leptin-binding sites in the mouse choroid plexus. A cDNA expression library was prepared from mouse choroid plexus and screened with a leptin-AP fusion protein to identify a leptin receptor (OB-R). OB-R is a single membrane-spanning receptor most related to the gp130 signal-transducing component of the IL-6 receptor, the G-CSF receptor, and the LIF receptor. OB-R mRNA is expressed not only in choroid plexus, but also in several other tissues, including hypothalamus. Genetic mapping of the gene encoding OB-R shows that it is within the 5.1 cM interval of mouse chromosome 4 that contains the db locus.	ROCHE RES GENT, B-9000 GHENT, BELGIUM; F HOFFMANN LA ROCHE & CO LTD, CH-4002 BASEL, SWITZERLAND; HOFFMANN LA ROCHE INC, DEPT METAB DIS, NUTLEY, NJ 07110 USA	Roche Holding; Roche Holding	Tartaglia, LA (corresponding author), MILLENNIUM PHARMACEUT INC, 640 MEM DR, CAMBRIDGE, MA 02139 USA.		sheng, jian/E-9474-2012					BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; DEBONS AF, 1977, FED PROC, V36, P143; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; GOUGH NM, 1988, P NATL ACAD SCI USA, V85, P2623, DOI 10.1073/pnas.85.8.2623; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMILTON BS, 1995, NAT MED, V1, P953, DOI 10.1038/nm0995-953; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HUMMEL KP, 1966, SCIENCE, V153, P1127, DOI 10.1126/science.153.3740.1127; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SAITO M, 1992, J IMMUNOL, V148, P4066; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; SPECTOR R, 1989, SCI AM, V261, P68, DOI 10.1038/scientificamerican1189-68; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	36	2933	3139	1	147	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1263	1271		10.1016/0092-8674(95)90151-5	http://dx.doi.org/10.1016/0092-8674(95)90151-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548812	Bronze			2022-12-24	WOS:A1995TM76200021
J	Qizilbash, N; Lewington, S; Duffy, S; Peto, R; Smith, T; Spiegelhalter, D; Iso, H; Shimamoto, T; Komachi, Y; Iida, M; Doyle, J; Strogatz, D; Ebrahim, S; Wannamethee, G; Whincup, P; Burke, V; Cullen, K; Knuiman, M; Welborn, T; Bainton, D; Baker, I; Elwood, P; Sweetnam, P; Yarnell, J; Keil, J; Sutherland, S; Hames, C; Tyroler, H; DAgostino, R; Kannel, W; Wolf, P; Aromaa, A; Knekt, P; Maatela, J; Reunanen, A; Puska, P; Sarti, C; Tamminen, M; Tuomilehto, J; Vartiainen, E; Bengtsson, C; Bjorkelund, C; Lissner, L; Kodama, K; Shimizu, Y; Kagan, A; Popper, J; Reed, D; Yano, K; Goldbourt, U; Medalie, J; Yaari, S; Criqui, M; Davis, C; Blackburn, H; Jacobs, D; Leupker, R; Harris, T; Madans, J; Ofstedal, M; Bjartveit, K; Stensvold, I; Tverdal, A; Garrow, K; Meade, T; Ruddock, V; Haheim, L; Hjermann, I; Holme, I; Leren, P; Cambien, F; Ducimetiere, P; Richard, J; Assmann, G; BarrettConnor, E; Langer, R; Gillis, C; Hart, C; Hawthorne, V; Hole, D; Isles, C; Lever, A; Smith, GD; Aravanis, C; Blackburn, H; Buzina, R; Dontas, A; Fidanza, F; Giampaoli, S; Karvonen, M; Keys, A; Kromhout, D; Lanti, M; Menotti, A; Mohacek, I; Nedeljkovic, S; Nissinen, A; Punsar, S; Seccareccia, F; Toshima, H; Chen, Z; Collins, R; Li, W; Lu, J; Date, C; Nakayama, T; Tanaka, H; Yokoyama, T; Yoshiike, N; Brown, C; TunstallPedoe, H; Higgins, M; Keller, J; Carstensen, J; Tornberg, S; Marmot, M; Shipley, M				Qizilbash, N; Lewington, S; Duffy, S; Peto, R; Smith, T; Spiegelhalter, D; Iso, H; Shimamoto, T; Komachi, Y; Iida, M; Doyle, J; Strogatz, D; Ebrahim, S; Wannamethee, G; Whincup, P; Burke, V; Cullen, K; Knuiman, M; Welborn, T; Bainton, D; Baker, I; Elwood, P; Sweetnam, P; Yarnell, J; Keil, J; Sutherland, S; Hames, C; Tyroler, H; DAgostino, R; Kannel, W; Wolf, P; Aromaa, A; Knekt, P; Maatela, J; Reunanen, A; Puska, P; Sarti, C; Tamminen, M; Tuomilehto, J; Vartiainen, E; Bengtsson, C; Bjorkelund, C; Lissner, L; Kodama, K; Shimizu, Y; Kagan, A; Popper, J; Reed, D; Yano, K; Goldbourt, U; Medalie, J; Yaari, S; Criqui, M; Davis, C; Blackburn, H; Jacobs, D; Leupker, R; Harris, T; Madans, J; Ofstedal, M; Bjartveit, K; Stensvold, I; Tverdal, A; Garrow, K; Meade, T; Ruddock, V; Haheim, L; Hjermann, I; Holme, I; Leren, P; Cambien, F; Ducimetiere, P; Richard, J; Assmann, G; BarrettConnor, E; Langer, R; Gillis, C; Hart, C; Hawthorne, V; Hole, D; Isles, C; Lever, A; Smith, GD; Aravanis, C; Blackburn, H; Buzina, R; Dontas, A; Fidanza, F; Giampaoli, S; Karvonen, M; Keys, A; Kromhout, D; Lanti, M; Menotti, A; Mohacek, I; Nedeljkovic, S; Nissinen, A; Punsar, S; Seccareccia, F; Toshima, H; Chen, Z; Collins, R; Li, W; Lu, J; Date, C; Nakayama, T; Tanaka, H; Yokoyama, T; Yoshiike, N; Brown, C; TunstallPedoe, H; Higgins, M; Keller, J; Carstensen, J; Tornberg, S; Marmot, M; Shipley, M			Cholesterol, diastolic blood pressure, and stroke: 13000 strokes in 450000 people in 45 prospective cohorts	LANCET			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; SERUM-CHOLESTEROL; CARDIOVASCULAR-DISEASE; CEREBRAL INFARCTION; CIVIL-SERVANTS; BRITISH MEN; FOLLOW-UP; MORTALITY; POPULATION	Individual studies of stroke have not clearly answered two questions: on the relation, if any, between total blood cholesterol and stroke; and on how the strength of the relation between diastolic blood pressure and stroke varies with age. The associations of blood cholesterol and diastolic blood pressure with subsequent stroke rates were investigated by review of 45 prospective observational cohorts involving 450 000 individuals with 5-30 years of follow-up (mean 16 years, total 7 . 3 million person-years of observation), during which 13 397 participants were recorded as having had a stroke. Most of these were fatal strokes in studies that recorded only mortality and not incidence, but about one-quarter were from studies that recorded both fatal and non-fatal strokes. After standardisation for age, there was no association between blood cholesterol and stroke except, perhaps, in those under 45 years of age when screened. This lack of association was not influenced by adjustment for sex, diastolic blood pressure, history of coronary heart disease, or ethnicity (Asian or non-Asian). However, because the types of the strokes were not centrally available, the lack of any overall relation might conceal a positive association with ischaemic stroke together with a negative association with haemorrhagic stroke. When the highest and the lowest of the six blood pressure categories were compared, the difference in usual diastolic blood pressure was 27 mm Hg (102 vs 75 mm Hg), and there was a fivefold difference in stroke risk. This fivefold difference was seen both in those with a preexisting history of coronary heart disease and in those without it. The proportional difference stroke risk, was more extreme in middle in old age. Among those aged <45, 45-64, and 65+ when screened, the differences in the relative risks of stroke (between the highest diastolic blood pressure category and a combination of the lowest two categories) were tenfold, fivefold, and twofold, respectively. However, because the absolute stroke risks are greater in old age, the absolute differences in the annual stroke rates showed an opposite pattern, being 2, 5, and 8 per thousand, respectively. This suggests that the effects of therapeutic blood pressure reductions should be assessed separately in middle age and in old age.	GOTHENBURG WOMEN, GOTHENBURG, SWEDEN; HONOLULU HEART PROGRAM, HONOLULU, HI USA		Qizilbash, N (corresponding author), UNIV OXFORD, RADCLIFFE INFIRM, DEPT CLIN GERATOL, OXFORD OX2 6HE, ENGLAND.		Knuiman, Matthew W/I-5549-2013; Davey Smith, George/A-7407-2013; Kromhout, Daan/A-8566-2014; Marmot, M G/Y-3920-2019	Davey Smith, George/0000-0002-1407-8314; Marmot, M G/0000-0002-2431-6419; Carstensen, John/0000-0003-2256-8089; Seccareccia, Fulvia/0000-0003-4135-2806	Medical Research Council [G8802774] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		ATKINS D, 1993, ANN INTERN MED, V119, P136, DOI 10.7326/0003-4819-119-2-199307150-00008; BAINTON D, 1992, BRIT HEART J, V68, P60; BALKAU B, 1993, BRIT MED J, V307, P295, DOI 10.1136/bmj.307.6899.295; BENGTSSON C, 1989, SCAND J SOC MED, V17, P141, DOI 10.1177/140349488901700203; Bjartveit K, 1979, Acta Med Scand Suppl, V634, P1; BOLTONSMITH C, 1993, BRIT J NUTR, V69, P315, DOI 10.1079/BJN19930036; Breslow N. E., 1987, STATISTICAL METHODS, VII; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COX CS, 1992, VITAL HLTH STAT, P27; CRIQUI MH, 1978, AM J EPIDEMIOL, V108, P367, DOI 10.1093/oxfordjournals.aje.a112633; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; GARDNER MJ, 1973, J CHRON DIS, V26, P781, DOI 10.1016/0021-9681(73)90013-1; GILKS WR, 1993, J R STAT SOC B, V55, P39; GOLDBOURT U, 1993, CARDIOLOGY, V82, P100, DOI 10.1159/000175862; GORDON T, 1987, AM J EPIDEMIOL, V125, P263, DOI 10.1093/oxfordjournals.aje.a114525; HAHEIM LL, 1993, STROKE, V24, P1484, DOI 10.1161/01.STR.24.10.1484; HAWTHORNE VM, 1978, J EPIDEMIOL COMMUN H, V32, P260, DOI 10.1136/jech.32.4.260; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; Heyman A, 1971, STROKE, V2, P509, DOI 10.1161/01.STR.2.6.509; Higgins M, 1992, Ann Epidemiol, V2, P69, DOI 10.1016/1047-2797(92)90039-S; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; KAGAN A, 1980, STROKE, V11, P14, DOI 10.1161/01.STR.11.1.14; Keil J E, 1992, Ann Epidemiol, V2, P93; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KNEKT P, 1991, J CLIN EPIDEMIOL, V44, P933, DOI 10.1016/0895-4356(91)90056-F; KNUIMAN MW, 1994, AUST J PUBLIC HEALTH, V18, P129; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; LIN CH, 1984, STROKE, V15, P653, DOI 10.1161/01.STR.15.4.653; LINDENSTROM E, 1994, BMJ-BRIT MED J, V309, P11, DOI 10.1136/bmj.309.6946.11; LUEPKER RV, 1994, AM J PUBLIC HEALTH, V84, P1383, DOI 10.2105/AJPH.84.9.1383; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MCGOVERN PG, 1992, JAMA-J AM MED ASSOC, V268, P753; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; MENOTTI A, 1990, INT J EPIDEMIOL, V19, P309, DOI 10.1093/ije/19.2.309; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; NEATON JD, 1995, HYPERTENSION PATHOPH, V1, P127; PEDERSEN TR, 1994, LANCET, V344, P1383; PSATY BM, 1990, J CLIN EPIDEMIOL, V43, P961, DOI 10.1016/0895-4356(90)90079-5; PUSKA P, 1983, BRIT MED J, V287, P1840, DOI 10.1136/bmj.287.6408.1840; REID DD, 1974, LANCET, V1, P469; SHAPER AG, 1991, BRIT MED J, V302, P1111, DOI 10.1136/bmj.302.6785.1111; SHIMAMOTO T, 1989, CIRCULATION, V79, P503, DOI 10.1161/01.CIR.79.3.503; Spearman C, 1904, AM J PSYCHOL, V15, P72, DOI 10.2307/1412159; Speizer, 1976, NATURAL HIST CHRONIC, P218; SZATROWSKI TP, 1984, J CHRON DIS, V37, P569, DOI 10.1016/0021-9681(84)90007-9; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; TANAKA H, 1985, STROKE, V16, P773, DOI 10.1161/01.STR.16.5.773; TORNBERG SA, 1989, JNCI-J NATL CANCER I, V81, P1917, DOI 10.1093/jnci/81.24.1917; TUOMILEHTO J, 1991, STROKE, V22, P7, DOI 10.1161/01.STR.22.1.7; Wolf P A, 1983, Neurol Clin, V1, P317; YANO K, 1989, STROKE, V20, P1460, DOI 10.1161/01.STR.20.11.1460	53	706	729	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	1995	346	8991-2					1647	1653						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551820				2022-12-24	WOS:A1995TL42300006
J	SEO, S; OKAMOTO, N; SETO, H; ISHIZUKA, K; SANO, H; OHASHI, Y				SEO, S; OKAMOTO, N; SETO, H; ISHIZUKA, K; SANO, H; OHASHI, Y			TOBACCO MAP KINASE - A POSSIBLE MEDIATOR IN WOUND SIGNAL-TRANSDUCTION PATHWAYS	SCIENCE			English	Article							PATHOGENESIS-RELATED PROTEINS; INHIBITOR-INDUCING FACTOR; JASMONIC ACID; GENE-EXPRESSION; ACQUIRED-RESISTANCE; VIRUS-INFECTION; SALICYLIC-ACID; PHOSPHORYLATION; PLANTS; INDUCTION	A complementary DNA encoding a mitogen-activated protein (MAP) kinase homolog has been isolated from tobacco plants. Transcripts of the corresponding gene were not observed in healthy tobacco leaves but began to accumulate 1 minute after mechanical wounding. In tobacco plants transformed with the cloned complementary DNA, trans inactivation of the endogenous homologous gene occurred, and both production of wound-induced jasmonic acid and accumulation of wound-inducible gene transcripts were inhibited. In contrast, the levels of salicylic acid and transcripts for pathogen-inducible, acidic pathogenesis-related proteins were increased upon wounding. These results indicate that this MAP kinase is part of the initial response of higher plants to mechanical wounding.	NATL INST AGROBIOL RESOURCES,DEPT MOLEC BIOL,TSUKUBA,IBARAKI 305,JAPAN; NARA INST SCI & TECHNOL,IKOMA,NARA 63001,JAPAN; INST PHYS & CHEM RES,WAKO,SAITAMA 35101,JAPAN; TOAGOUSEI CORP LTD,TSUKUBA INST,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN	National Institute of Agrobiological Sciences - Japan; Nara Institute of Science & Technology; RIKEN; RIKEN; University of Tsukuba				Seo, Shigemi/0000-0003-4940-288X				ANDERBERG RJ, 1992, P NATL ACAD SCI USA, V89, P10183, DOI 10.1073/pnas.89.21.10183; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BALANDIN T, 1995, PLANT MOL BIOL, V27, P1197, DOI 10.1007/BF00020893; BLECHERT S, 1995, P NATL ACAD SCI USA, V92, P4099, DOI 10.1073/pnas.92.10.4099; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREDERODE FT, 1991, PLANT MOL BIOL, V17, P1117, DOI 10.1007/BF00028729; CREELMAN RA, 1992, P NATL ACAD SCI USA, V89, P4938, DOI 10.1073/pnas.89.11.4938; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIETRICH A, 1990, J BIOL CHEM, V265, P6360; DUERR B, 1993, PLANT CELL, V5, P87, DOI 10.1105/tpc.5.1.87; EYAL Y, 1992, PLANT MOL BIOL, V19, P589, DOI 10.1007/BF00026785; FARMER EE, 1991, J BIOL CHEM, V266, P3140; FARMER EE, 1992, PLANT CELL, V4, P129, DOI 10.1105/tpc.4.2.129; FARMER EE, 1994, PLANT MOL BIOL, V26, P1423, DOI 10.1007/BF00016483; FARMER EE, 1989, P NATL ACAD SCI USA, V86, P1539, DOI 10.1073/pnas.86.5.1539; FELIX G, 1991, P NATL ACAD SCI USA, V88, P8831, DOI 10.1073/pnas.88.19.8831; FELIX G, 1994, P NATL ACAD SCI USA, V91, P952, DOI 10.1073/pnas.91.3.952; FLAVELL RB, 1994, P NATL ACAD SCI USA, V91, P3490, DOI 10.1073/pnas.91.9.3490; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HAHLBROCK K, 1995, P NATL ACAD SCI USA, V92, P4150, DOI 10.1073/pnas.92.10.4150; HAMBERG M, 1992, BIOCHIM BIOPHYS ACTA, V1165, P1, DOI 10.1016/0005-2760(92)90069-8; KLESSIG DF, 1994, PLANT MOL BIOL, V26, P1349; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LINTHORST HJM, 1990, P NATL ACAD SCI USA, V87, P8756, DOI 10.1073/pnas.87.22.8756; MACKINTOSH C, 1994, PLANT J, V5, P137, DOI 10.1046/j.1365-313X.1994.5010137.x; MALAMY J, 1992, PLANT CELL, V4, P359, DOI 10.1105/tpc.4.3.359; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MALAMY J, 1992, PLANT J, V2, P642; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MATSUOKA M, 1987, PLANT PHYSIOL, V85, P942, DOI 10.1104/pp.85.4.942; MATZKE M, 1993, ANNU REV PLANT PHYS, V44, P53, DOI 10.1146/annurev.pp.44.060193.000413; MEMELINK J, 1990, PLANT MOL BIOL, V14, P119, DOI 10.1007/BF00018553; MIZOGUCHI T, 1994, PLANT J, V5, P111, DOI 10.1046/j.1365-313X.1994.5010111.x; NAGY F, 1988, PLANT MOL BIOL MANUA; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; NOJIRI H, 1992, PLANT CELL PHYSIOL, V33, P1225; OHSHIMA M, 1990, PLANT CELL, V2, P95, DOI 10.1105/tpc.2.2.95; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PENACORTES H, 1993, PLANTA, V191, P123, DOI 10.1007/BF00240903; RYAN CA, 1992, PLANT MOL BIOL, V19, P123, DOI 10.1007/BF00015610; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; Sambrook J., 1989, MOL CLONING LAB MANU; SANO H, 1995, P NATL ACAD SCI USA, V92, P4138, DOI 10.1073/pnas.92.10.4138; SANO H, 1994, P NATL ACAD SCI USA, V91, P10556, DOI 10.1073/pnas.91.22.10556; SANO H, 1994, P NATL ACAD SCI USA, V91, P2582, DOI 10.1073/pnas.91.7.2582; SHEN WJ, 1989, NUCLEIC ACIDS RES, V17, P8385, DOI 10.1093/nar/17.20.8385; SHIH MC, 1986, CELL, V47, P73, DOI 10.1016/0092-8674(86)90367-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; SUZUKI K, 1995, PLANT CELL, V7, P639, DOI 10.1105/tpc.7.5.639; URANO T, 1994, MOL GEN GENET, V244, P331; USAMI S, 1995, P NATL ACAD SCI USA, V92, P8660, DOI 10.1073/pnas.92.19.8660; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; XU Y, 1994, PLANT CELL, V6, P1077, DOI 10.1105/tpc.6.8.1077	58	433	464	2	29	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1988	1992		10.1126/science.270.5244.1988	http://dx.doi.org/10.1126/science.270.5244.1988			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533090				2022-12-24	WOS:A1995TL42000041
J	Bevec, D; Jaksche, H; Oft, M; Wohl, T; Himmelspach, M; Pacher, A; Schebesta, M; Koettnitz, K; Dobrovnik, M; Csonga, R; Lottspeich, F; Hauber, J				Bevec, D; Jaksche, H; Oft, M; Wohl, T; Himmelspach, M; Pacher, A; Schebesta, M; Koettnitz, K; Dobrovnik, M; Csonga, R; Lottspeich, F; Hauber, J			Inhibition of HIV-1 replication in lymphocytes by mutants of the Rev cofactor eIF-5A	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; EUKARYOTIC INITIATION FACTOR-5A; GENE-EXPRESSION REQUIRES; HUMAN T-CELLS; TRANS-ACTIVATOR; RESPONSIVE ELEMENT; REGULATORY GENES; CARBOXY-TERMINUS; TARGET SEQUENCE; MESSENGER-RNA	Eukaryotic initiation factor 5A (eIF-5A) is a cellular cofactor required for the function of the human immunodeficiency virus type-1 (HIV-1) Rev trans-activator protein. The majority of a set of eIF-5A mutants did not support growth of yeast cells having an inactivated genomic copy of eIF-5A, indicating that the introduced mutation eliminated eIF-5A activity. Two nonfunctional mutants, eIF-5AM13 and eIF-5AM14, retained their binding capacity for the HIV-1 Rev response element:Rev complex. Both mutants were constitutively expressed in human T cells. When these T cells were infected with replication-competent HIV-1, virus replication was inhibited. The eIF-5AM13 and eIF-5AM14 proteins blocked Rev trans-activation and Rev-mediated nuclear export.	SANDOZ GMBH,RES INST,DEPT IMMUNODERMATOL,A-1235 VIENNA,AUSTRIA; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Novartis; Sandoz; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Max Planck Society			Schebesta, Michael/B-5891-2008					ANSORGE W, 1982, EXP CELL RES, V140, P31, DOI 10.1016/0014-4827(82)90152-5; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BEVEC D, 1992, P NATL ACAD SCI USA, V89, P9870, DOI 10.1073/pnas.89.20.9870; BEVEC D, 1994, HUM GENE THER, V5, P193, DOI 10.1089/hum.1994.5.2-193; BEVEC D, UNPUB; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; COCHRANE AW, 1990, P NATL ACAD SCI USA, V87, P1198, DOI 10.1073/pnas.87.3.1198; DALY TJ, 1993, BIOCHEMISTRY-US, V32, P10497, DOI 10.1021/bi00090a028; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DALY TJ, 1993, BIOCHEMISTRY-US, V32, P8945, DOI 10.1021/bi00085a028; DOBROVNIK M, UNPUB; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; HAMMERSCHMID M, 1994, J VIROL, V68, P7329, DOI 10.1128/JVI.68.11.7329-7335.1994; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KANG HA, 1994, J BIOL CHEM, V269, P3934; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; MAGDOLEN V, 1994, MOL GEN GENET, V244, P646, DOI 10.1007/BF00282755; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MALIM MH, 1992, J EXP MED, V176, P1197, DOI 10.1084/jem.176.4.1197; MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; Pacher A, UNPUB; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PARK MH, 1993, BIOFACTORS, V4, P95; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; SADAIE MR, 1988, SCIENCE, V239, P910, DOI 10.1126/science.3277284; SCHWELBERGER HG, 1993, J BIOL CHEM, V268, P14018; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; TERWILLIGER E, 1988, J VIROL, V62, P655, DOI 10.1128/JVI.62.2.655-658.1988; VENKATESH LK, 1990, VIROLOGY, V178, P327, DOI 10.1016/0042-6822(90)90414-M; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WOHL T, 1993, MOL GEN GENET, V241, P305; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	45	174	185	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1858	1860		10.1126/science.271.5257.1858	http://dx.doi.org/10.1126/science.271.5257.1858			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596953				2022-12-24	WOS:A1996UC77800044
J	Reuss, ML; Paneth, N; PintoMartin, JA; Lorenz, JM; Susser, M				Reuss, ML; Paneth, N; PintoMartin, JA; Lorenz, JM; Susser, M			The relation of transient hypothyroxinemia in preterm infants to neurologic development at two years of age	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISTRESS SYNDROME; WEIGHT PREMATURE-INFANTS; THYROID-FUNCTION; BIRTH-WEIGHT; TRIIODOTHYRONINE CONCENTRATIONS; FREE-THYROXINE; THYROTROPIN; REPLACEMENT; DEFICIENCY; LESS	Background. Transient hypothyroxinemia, a common finding in premature infants, is not thought to have long-term sequelae or to require treatment. We investigated whether hypothyroxinemia in premature infants is a cause of subsequent motor and cognitive abnormalities. Methods. In this historical cohort study, we retrieved blood thyroxine values, obtained on routine screening in the first week of life, from state screening records of children who weighed 2000 g or less at birth, who were born at 33 weeks' gestation or earlier, and who were enrolled in a population-based study of the late sequelae of neonatal brain hemorrhage. We investigated the relation of these values to the odds for disabling cerebral palsy among 463 subjects for whom data were available and to the mental-development score on the Bayley Scales of Infant Development or the Stanford-Binet Intelligence Scales for Children at the age of two years in 400 subjects. The effects of severe hypothyroxinemia, defined as a blood thyroxine value more than 2.6 SD below the mean for New Jersey newborns, were assessed before and after adjustment for gestational age and potentially confounding variables. Results. In analyses adjusted for gestational age, infants with severe hypothyroxinemia had a risk of disabling cerebral palsy that was nearly 11 times that of infants without hypothyroxinemia (odds ratio, 10.8; 95 percent confidence interval, 3.0 to 39.3) and a mean mental-development score at the age of two that was 15.4 points lower (95 percent confidence interval, 8.1 to 22.6 points) than the mean score of children with normal neonatal blood thyroxine concentrations. After adjustment for gestational age and multiple prenatal, perinatal, and early and late neonatal variables, severe hypothyroxinemia was still associated with an increased risk of disabling cerebral palsy (odds ratio, 4.4; 95 percent confidence interval, 1.0 to 18.6) and a reduction of nearly 7 points (95 percent confidence interval, 0.3 to 13.2 points) in the mental-development score. Conclusions. Severe hypothyroxinemia in preterm infants may be an important cause of problems in neurologic and mental development detected at the age of two years. (C) 1996, Massachusetts Medical Society.	COLUMBIA UNIV, SERGIEVSKY CTR, NEW YORK, NY USA; COLUMBIA UNIV, DEPT OBSTET & GYNECOL, NEW YORK, NY USA; MICHIGAN STATE UNIV, COLL HUMAN MED, PROGRAM EPIDEMIOL, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, COLL HUMAN MED, DEPT PEDIAT & HUMAN GENET, E LANSING, MI 48824 USA; UNIV PENN, SCH NURSING, PHILADELPHIA, PA 19104 USA	Columbia University; Columbia University; Michigan State University; Michigan State University College of Human Medicine; Michigan State University; Michigan State University College of Human Medicine; University of Pennsylvania			Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X	NICHD NIH HHS [HD-30278] Funding Source: Medline; NINDS NIH HHS [NS-20713] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020713] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMATO M, 1989, HORM RES, V32, P213, DOI 10.1159/000181292; Bayley N., 1969, BAYLEY SCALES INFANT; BURROW GN, 1994, NEW ENGL J MED, V331, P1072; CHOWDHRY P, 1984, PEDIATRICS, V73, P301; CUESTAS RA, 1979, J PEDIATR-US, V94, P643, DOI 10.1016/S0022-3476(79)80042-6; Delong G. Robeert, 1993, American Journal of Clinical Nutrition, V57, p286S, DOI 10.1093/ajcn/57.2.286S; DESCORBAR GM, 1987, HORM RES, V26, P12; EGGERMONT E, 1984, HELV PAEDIATR ACTA, V39, P209; ETLING N, 1984, HELV PAEDIATR ACTA, V39, P223; FABRIS N, 1987, J CLIN ENDOCR METAB, V65, P247, DOI 10.1210/jcem-65-2-247; FISHER DA, 1990, PEDIATR CLIN N AM, V37, P1297; FISHER DA, 1981, P SERONO S, V40, P225; FRANKLIN RC, 1986, ARCH DIS CHILD, V61, P589, DOI 10.1136/adc.61.6.589; FUSE Y, 1990, J DEV PHYSIOL, V14, P17; HACK M, 1994, NEW ENGL J MED, V331, P753, DOI 10.1056/NEJM199409223311201; HADEED AJ, 1981, PEDIATRICS, V68, P494; Harkavy K L, 1991, J Perinatol, V11, P117; HENNEMANN G, 1988, Acta Medica Austriaca, V15, P42; HETZEL BS, 1989, J NUTR, V119, P145, DOI 10.1093/jn/119.2.145; JOHN R, 1987, ANN CLIN BIOCHEM, V24, P461, DOI 10.1177/000456328702400506; KARNA P, 1991, AM J PERINAT, V8, P288, DOI 10.1055/s-2007-999399; KLEIN AH, 1979, PEDIATRICS, V63, P380; KOK JH, 1995, PEDIATR RES, V37, pA218; KOOISTRA L, 1994, J PEDIATR-US, V124, P903, DOI 10.1016/S0022-3476(05)83178-6; LEVITON A, 1990, EARLY HUM DEV, V24, P1, DOI 10.1016/0378-3782(90)90002-Z; LUCAS A, 1988, ARCH DIS CHILD, V63, P1201, DOI 10.1136/adc.63.10.1201; MEIJER WJ, 1992, ARCH DIS CHILD, V67, P944, DOI 10.1136/adc.67.7.944; MERCADO M, 1987, CLIN PEDIATR, V26, P343, DOI 10.1177/000992288702600704; MERCADO M, 1988, EARLY HUM DEV, V16, P131, DOI 10.1016/0378-3782(88)90093-X; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; OUDEN ALD, 1996, PEDIATR RES, V39, P142; PHAROAH P, 1981, DEV MED CHILD NEUROL, V23, P76; Pinto-Martin J, 1992, Paediatr Perinat Epidemiol, V6, P273, DOI 10.1111/j.1365-3016.1992.tb00767.x; PINTOMARTIN JA, 1995, PEDIATRICS, V95, P249; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; ROBERTSON CMT, 1992, PEDIATRICS, V90, P750; ROVET J, 1987, J PEDIATR-US, V110, P700, DOI 10.1016/S0022-3476(87)80005-7; SCHONBERGER W, 1981, EUR J PEDIATR, V135, P245, DOI 10.1007/BF00442098; STEIN SA, 1991, ADV EXP MED BIOL, V299, P47; TERM LM, 1972, STANFORD BINET INTEL; TILLOTSON SL, 1994, BRIT MED J, V309, P440, DOI 10.1136/bmj.309.6952.440; VANWASSENAER AG, 1993, ACTA ENDOCRINOL-COP, V129, P139, DOI 10.1530/acta.0.1290139; YUDKIN PL, 1987, EARLY HUM DEV, V15, P45, DOI 10.1016/0378-3782(87)90099-5	43	276	285	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1996	334	13					821	827		10.1056/NEJM199603283341303	http://dx.doi.org/10.1056/NEJM199603283341303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB950	8596548	Bronze			2022-12-24	WOS:A1996UB95000003
J	Macgregor, SH; Hamley, JG; Dunbar, JA; Dodd, TRP; Cromarty, JA				Macgregor, SH; Hamley, JG; Dunbar, JA; Dodd, TRP; Cromarty, JA			Evaluation of a primary care anticoagulant clinic managed by a pharmacist	BRITISH MEDICAL JOURNAL			English	Article									TAYSIDE HLTH BOARD,DUNDEE DD1 9NL,SCOTLAND; ROBERT GORDON UNIV,ABERDEEN AB1 1FR,SCOTLAND	Robert Gordon University	Macgregor, SH (corresponding author), DOWNFIELD SURG,DUNDEE DD3 8NE,SCOTLAND.		Dunbar, James A/G-3034-2012					HALL J, 1994, PHARM J, V252, P230; JENNINGS I, 1991, J CLIN PATHOL, V44, P950, DOI 10.1136/jcp.44.11.950; RADLEY AS, 1995, J CLIN PATHOL, V48, P545, DOI 10.1136/jcp.48.6.545; RADLEY AS, 1994, PHARM J, V252, P91; 1990, J CLIN PATHOL, V43, P177	5	29	31	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					560	560		10.1136/bmj.312.7030.560	http://dx.doi.org/10.1136/bmj.312.7030.560			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595288	Green Published			2022-12-24	WOS:A1996TY88500031
J	Monaghan, G; Ryan, M; Seddon, R; Hume, R; Burchell, B				Monaghan, G; Ryan, M; Seddon, R; Hume, R; Burchell, B			Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome	LANCET			English	Article							CRIGLER-NAJJAR SYNDROME; DRUG-METABOLISM; GLUCURONIDATION; POPULATION; TYPE-2; LIVER	Background The genetic basis of Gilbert's syndrome is ill-defined. This common mild hyperbilirubinaemia sometimes presents as an intermittent jaundice, A reduced hepatic bilirubin UDP-glucuronosyltransferase (UGT) is associated with this syndrome, We have examined variation in the gene encoding the UGT1*1 enzyme and serum bilirubin levels in a Scottish population. Methods Blood was collected from 12 patients with confirmed or suspected Gilbert's syndrome, from 6 members of a family with 4 Gilbert members, and from 77 non-smoking, alcohol-free, drug-free volunteers recruited from the staff of a teaching hospital in Dundee. Polymerase chain reaction amplification was used to examine sequence variation of the promoter upstream of the UGT1*1 exon I, Genotypes were assigned as follows: 6/6 (homozygous for a common allele bearing the sequence [TA](6)TAA), 7/7 (homozygous for a rarer allele with the sequence [TA](7)TAA), and 6/7 (heterozygous with one of each allele). Findings Individuals in the population with the 7/7 genotype had significantly higher bilirubin concentrations than those who had the 6/7 or 6/6 genotype, 14 volunteers underwent a 24 h fasting test to see if they had Gilbert's syndrome, and all four positives had the 7/7 genotype. One confirmed Gilbert's patient, two recurrent jaundice patients (with suspected Gilbert's syndrome), and nine clinically diagnosed cases had the 7/7 genotype. Segregation of the 7/7 genotype with the Gilbert phenotype was also demonstrated in the family with four affected members. The frequency of the 7/7 genotype in this eastern Scottish population was 10-13%. Interpretation In a healthy population there was an association between;variation in bilirubin concentration and a mutation within the gene encoding the enzyme bilirubin UGT, This and other findings suggest the existence of a mild and a more severe form of Gilbert's syndrome, depending on whether the gene defect lies in the promoter sequence upstream of UGT1*I exon I, as here (mild), or in the coding sequence (severe) of the gene.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT CHILD HLTH & OBSTET & GYNAECOL, DUNDEE DD1 9SY, SCOTLAND; N DEVON DIST HOSP, DEPT CHEM PATHOL, BARNSTAPLE, DEVON, ENGLAND	University of Dundee	Monaghan, G (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT BIOCHEM MED, DUNDEE DD1 9SY, SCOTLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AONO S, 1995, LANCET, V345, P958, DOI 10.1016/S0140-6736(95)90702-5; BAILEY A, 1977, LANCET, V1, P931; BOSMA P, 1994, HEPATOLOGY       OCT, pA226; CARULLI N, 1976, GUT, V17, P581, DOI 10.1136/gut.17.8.581; DEMORAIS SMF, 1992, GASTROENTEROLOGY, V102, P577, DOI 10.1016/0016-5085(92)90106-9; EBNER T, 1993, MOL PHARMACOL, V43, P649; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; FEVERY J, 1981, EUR J CLIN INVEST, V11, P417, DOI 10.1111/j.1365-2362.1981.tb02006.x; GOLLAN JL, 1975, GASTROENTEROLOGY, V68, P1543; IDEO G, 1971, EXPERIENTIA, V27, P24, DOI 10.1007/BF02137719; KOIWAI O, 1995, HUM MOL GENET, V4, P1183, DOI 10.1093/hmg/4.7.1183; LASCELLES PT, 1989, DIAGNOSTIC FUNCTION, P24; MACKLON AF, 1979, CLIN PHARMACOKINET, V4, P223, DOI 10.2165/00003088-197904030-00004; MOGHRABI N, 1993, GENOMICS, V18, P171, DOI 10.1006/geno.1993.1451; MOHRABI NN, 1994, THESIS U DUNDEE; OWENS D, 1973, BRIT MED J, V3, P559, DOI 10.1136/bmj.3.5880.559; OWENS D, 1975, J MED GENET, V12, P152, DOI 10.1136/jmg.12.2.152; REAVEN GM, 1994, J INTERN MED, V236, P13; ROSMA PJ, 1995, NEW ENGL J MED, V333, P1171; SUTHERLAND L, 1993, BIOCHEM PHARMACOL, V45, P295, DOI 10.1016/0006-2952(93)90064-4; Thompson R.P.H., 1981, FAMILIAL HYPERBILIRU, P91; WATSON KJR, 1989, BAILLIERE CLIN GASTR, V3, P337, DOI 10.1016/0950-3528(89)90004-3	22	507	528	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 2	1996	347	9001					578	581		10.1016/S0140-6736(96)91273-8	http://dx.doi.org/10.1016/S0140-6736(96)91273-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596320				2022-12-24	WOS:A1996TX69400011
J	Kimura, T; Yokoi, H; Nakagawa, Y; Tamura, T; Kaburagi, S; Sawada, Y; Sato, Y; Yokoi, H; Hamasaki, N; Nosaka, H; Nobuyoshi, M				Kimura, T; Yokoi, H; Nakagawa, Y; Tamura, T; Kaburagi, S; Sawada, Y; Sato, Y; Yokoi, H; Hamasaki, N; Nosaka, H; Nobuyoshi, M			Three-year follow-up after implantation of metallic coronary-artery stents	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BALLOON ANGIOPLASTY; RESTENOSIS; EXPERIENCE; MULTICENTER; OCCLUSION	Background. Coronary-artery stents are known to reduce rates of restenosis after coronary angioplasty, but it is uncertain how long this benefit is maintained. Methods. We evaluated clinical and angiographic follow-up information for up to three years after the implantation of Palmaz-Schatz metallic coronary-artery stents in 143 patients with 147 lesions of native coronary arteries. Results, The rate of survival free of myocardial infarction, bypass surgery, and repeated coronary angioplasty for stented lesions was 74.6 percent at three years. After 14 months, revascularization of the stented lesion was necessary in only three patients (2.1 percent), In contrast, coronary angioplasty for a new lesion was required in 11 patients (7.7 percent), Follow-up coronary angiography of 137 lesions at six months, 114 lesions at one year, and 72 lesions at three years revealed a decrease in minimal luminal diameter from 2.54+/-0.44 mm immediately after stent implantation to 1.87+/-0.56 mm at six months, but no further decrease in diameter at one year (in patients with paired angiograms, 1.95+/-0.49 mm at both six months and one year), Significant late improvement in luminal diameter was observed at three years (in patients with paired angiograms, 1.94+/-0.48 mm at six months and 2.09+/-0.48 mm at three years; P<0.001). Conclusions. Clinical and angiographic outcomes up to three years after coronary-artery stenting were favorable, with a low rate of revascularization of the stented lesions. Late improvement in luminal diameter appears to occur between six months and three years.	KOKURA MEM HOSP,DEPT CARDIOL,KOKURAKITA KU,KITAKYUSHU,FUKUOKA 802,JAPAN	Kokura Memorial Hospital								CARROZZA JP, 1992, J AM COLL CARDIOL, V20, P328, DOI 10.1016/0735-1097(92)90098-8; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; DETRE KM, 1990, CIRCULATION, V82, P739, DOI 10.1161/01.CIR.82.3.739; ELLIOTT JM, 1995, CIRCULATION, V91, P2158, DOI 10.1161/01.CIR.91.8.2158; ELLIS SG, 1992, CIRCULATION, V86, P1836, DOI 10.1161/01.CIR.86.6.1836; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; GORDON PC, 1994, AM J CARDIOL, V74, P26, DOI 10.1016/0002-9149(94)90486-3; HERNANDEZ RA, 1992, J AM COLL CARDIOL, V19, P1402, DOI 10.1016/0735-1097(92)90594-D; HERRMANN HC, 1992, CIRCULATION, V86, P812, DOI 10.1161/01.CIR.86.3.812; KASTRATI A, 1993, CIRCULATION, V87, P1498, DOI 10.1161/01.CIR.87.5.1498; KIMURA T, 1993, J AM COLL CARDIOL, V21, P1557, DOI 10.1016/0735-1097(93)90368-B; King SB, 1993, J AM COLL CARDIOL, V22, P353, DOI 10.1016/0735-1097(93)90037-2; MATTHEWS DE, 1988, USING UNDERSTANDING; MINTZ GS, 1995, J AM COLL CARDIOL, V25, pA36; NAKAMURA S, 1994, CIRCULATION, V89, P2026, DOI 10.1161/01.CIR.89.5.2026; NOBUYOSHI M, 1991, J AM COLL CARDIOL, V17, P433, DOI 10.1016/S0735-1097(10)80111-1; NOBUYOSHI M, 1988, J AM COLL CARDIOL, V12, P616, DOI 10.1016/S0735-1097(88)80046-9; PAINTER JA, 1994, CIRCULATION, V90, P163; ROUBIN GS, 1992, CIRCULATION, V85, P916, DOI 10.1161/01.CIR.85.3.916; SAVAGE MP, 1994, J AM COLL CARDIOL, V24, P1207, DOI 10.1016/0735-1097(94)90099-X; SCHATZ RA, 1991, CIRCULATION, V83, P148, DOI 10.1161/01.CIR.83.1.148; SCHATZ RA, 1987, CIRCULATION, V76, P450, DOI 10.1161/01.CIR.76.2.450; SCHOMIG A, 1994, CIRCULATION, V90, P2716, DOI 10.1161/01.CIR.90.6.2716; Serruys P.W., 1994, QUANTITATIVE CORONAR; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; TOPOL EJ, 1994, NEW ENGL J MED, V331, P539, DOI 10.1056/NEJM199408253310811; WHITE CJ, 1992, J AM COLL CARDIOL, V19, P870, DOI 10.1016/0735-1097(92)90534-T; 1985, NEW ENGL J MED, V312, P932	29	431	445	1	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 29	1996	334	9					561	566		10.1056/NEJM199602293340903	http://dx.doi.org/10.1056/NEJM199602293340903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW696	8569823				2022-12-24	WOS:A1996TW69600003
J	Stiell, IG; Greenberg, GH; Wells, GA; McDowell, I; Cwinn, AA; Smith, NA; Cacciotti, TF; Sivilotti, MLA				Stiell, IG; Greenberg, GH; Wells, GA; McDowell, I; Cwinn, AA; Smith, NA; Cacciotti, TF; Sivilotti, MLA			Prospective validation of a decision rule for the use of radiography in acute knee injuries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE ANKLE INJURIES; RECURSIVE PARTITION; PREDICTION RULES; SURVIVAL-DATA; EMERGENCY; FRACTURE; AVULSION; PROGRAM	Objective. - To validate a previously derived decision rule for the use of radiography in patients with acute knee injury. Design. - Prospectively administered survey. Setting. - Emergency departments of two university hospitals serving adults. Patients. - Convenience sample of 1096 of 1251 eligible adults with acute knee injuries; 124 patients were examined by two physicians. Main Outcome Measures. - Attending emergency physicians assessed each patient for standardized clinical variables and determined the need for radiography according to the decision rule. Patients who did not have radiography underwent a structured telephone interview at day 14 to determine the possibility of a fracture. The rule was assessed for ability to correctly identify the criterion standard, fracture of the knee, An attempt was made to refine the rule by means of univariate and recursive partitioning analyses. Results. - The decision rule had a sensitivity of 1.0 (95% confidence interval [CI], 0.94 to 1.0) for identifying 63 clinically important fractures. Physicians correctly interpreted the rule in 96% of cases, and the kappa value for interpretation was 0.77 (95% CI, 0.65 to 0.89). The potential relative reduction in use of radiography was estimated to be 28%, The probability of fracture, if the decision rule were ''negative, is estimated to be 0% (95% CI, 0% to 0.4%). Attempts to refine the rule led to a model with improved specificity but with an unacceptable loss of sensitivity. Conclusion. - Prospective validation has shown this decision rule to be 100% sensitive for identifying fractures of the knee, to be reliable and acceptable, and to have the potential to allow physicians to reduce the use of radiography in patients with acute knee injury.	UNIV OTTAWA,FAC MED,DEPT EMERGENCY MED,OTTAWA,ON,CANADA; UNIV OTTAWA,FAC MED,DEPT EPIDEMIOL & COMMUNITY MED,OTTAWA,ON,CANADA; UNIV OTTAWA,FAC MED,DEPT MED,OTTAWA,ON,CANADA; UNIV OTTAWA,FAC MED,CLIN EPIDEMIOL UNIT,OTTAWA,ON,CANADA	University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa			Sivilotti, Marco L.A./AAR-8892-2020	Sivilotti, Marco L.A./0000-0001-6641-1118; Stiell, Ian/0000-0002-2583-6408				ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; ANIS AH, 1995, ANN EMERG MED, V26, P422, DOI 10.1016/S0196-0644(95)70108-7; Bauer Steven J., 1995, Journal of Emergency Medicine, V13, P611, DOI 10.1016/0736-4679(95)00064-H; Baugher W H, 1984, Emerg Med Clin North Am, V2, P347; CALLAHAM ML, 1987, CURRENT THERAPY EMER; CHARLSON ME, 1987, ARCH INTERN MED, V147, P2155, DOI 10.1001/archinte.147.12.2155; CIAMPI A, 1988, COMPUT METH PROG BIO, V26, P239, DOI 10.1016/0169-2607(88)90004-1; CIAMPI A, 1986, COMPUT STAT DATA AN, V4, P185, DOI 10.1016/0167-9473(86)90033-2; CIAMPI A, 1987, TIME SERIES ECONOMET, V5, P23; DIAMOND GA, 1989, AM J CARDIOL, V63, P99, DOI 10.1016/0002-9149(89)91084-9; DIETZ GW, 1986, RADIOLOGY, V159, P467, DOI 10.1148/radiology.159.2.3961179; FAIRCLOUGH JA, 1988, INJURY, V19, P79, DOI 10.1016/0020-1383(88)90077-0; FEINSTEIN AR, 1985, ARCH INTERN MED, V145, P1257, DOI 10.1001/archinte.145.7.1257; Feinstein AR, 1987, CLINIMETRICS; Fleiss JL, 1981, STAT METHODS RATES P; FRIEDMAN JH, 1977, IEEE T COMPUT, V16, P404; GLEADHILL DNS, 1987, BRIT MED J, V294, P943, DOI 10.1136/bmj.294.6577.943; GOLDMAN AB, 1988, AM J ROENTGENOL, V151, P1163, DOI 10.2214/ajr.151.6.1163; GRATTON MC, 1990, ANN EMERG MED, V19, P497, DOI 10.1016/S0196-0644(05)82175-4; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARWOODNUSS A, 1991, CLIN PRACTICE EMERGE; KOOPMAN PAR, 1984, BIOMETRICS, V40, P513, DOI 10.2307/2531405; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEE TH, 1990, J GEN INTERN MED, V5, P528, DOI 10.1007/BF02600886; LLOYD S, 1986, CAN MED ASSOC J, V135, P973; Long A E, 1985, Emerg Med Clin North Am, V3, P437; MATTHEWS MG, 1986, BRIT MED J, V293, P959; McCaig L F, 1994, Adv Data, P1; MCCONNOCHIE KM, 1990, PEDIATRICS, V86, P45; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; MOLONEY TW, 1979, NEW ENGL J MED, V301, P1413, DOI 10.1056/NEJM197912273012603; ROSEN P, 1992, EMERGENCY MED CONCEP; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SAXENA AC, 1992, ANN EMERG MED, V21, P658; SEABERG DC, 1994, AM J EMERG MED, V12, P541, DOI 10.1016/0735-6757(94)90274-7; SIMON RR, 1995, EMERGENCY ORTHOPEDIC; Sox HC, 1988, MED DECISION MAKING; STIELL I, 1995, BRIT MED J, V311, P594, DOI 10.1136/bmj.311.7005.594; STIELL IG, 1992, CAN MED ASSOC J, V147, P1671; STIELL IG, 1993, JAMA-J AM MED ASSOC, V269, P1127, DOI 10.1001/jama.269.9.1127; STIELL IG, 1995, ACAD EMERG MED, V2, P966, DOI 10.1111/j.1553-2712.1995.tb03123.x; STIELL IG, 1994, JAMA-J AM MED ASSOC, V271, P827, DOI 10.1001/jama.271.11.827; STIELL IG, 1995, ANN EMERG MED, V26, P405, DOI 10.1016/S0196-0644(95)70106-0; SVENSON J, 1988, LANCET, V1, P244; TINTINALLI JE, 1992, EMERGENCY MED COMPRE; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WEBER JE, 1995, ANN EMERG MED, V26, P429, DOI 10.1016/S0196-0644(95)70109-5; 1994, NATL HOSPITAL AMBULA; 1992, 1991 92 ONT MIN HLTH	50	167	167	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					611	615		10.1001/jama.275.8.611	http://dx.doi.org/10.1001/jama.275.8.611			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594242				2022-12-24	WOS:A1996TW62700021
J	Bujan, L; Mansat, A; Pontonnier, F; Mieusset, R				Bujan, L; Mansat, A; Pontonnier, F; Mieusset, R			Time series analysis of sperm concentration in fertile men in Toulouse, France between 1977 and 1992	BRITISH MEDICAL JOURNAL			English	Article							SEMEN CHARACTERISTICS	Objectives-To investigate whether sperm production has changed during the past 16 years in the Toulouse area of France. Design-Time series analysis of sperm donors' specimens between 1977 and 1992. Setting-Sperm bank of university hospital in Toulouse, France. Subjects-302 healthy fertile men candidate sperm donors more than 20 and up to 45 years old and without any infertile brothers. Main outcome measure-Spermatozoa concentration. Results-Donors' mean age at time of donation was 34.05 (SD 5.13), but this increased significantly (P<0.001) during the study, from 32.4 in 1977 to 36 in 1992. Mean sperm count of samples was 83.12 x 10(6)/ml (SD 68.42 x 10(6)/ml). Sperm concentration was positively linked to the year of donation (Pearson's coefficient r = 0.12, P < 0.05), but this correlation disappeared after adjustment for age of donors (r = 0.09, P > 0.05). Conclusion-Sperm concentration has not changed with time in the Toulouse area.	CHU LA GRAVE,CTR STERILITE MASCULINE,F-31052 TOULOUSE,FRANCE; CHU LA GRAVE,CECOS MIDI PYRENEES,F-31052 TOULOUSE,FRANCE	CHU de Toulouse; CHU de Toulouse				Bujan, Louis/0000-0003-1540-0536; Mieusset, Roger/0000-0001-9057-630X				ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; [Anonymous], 1992, ARCH DIS CHILD, V67, P892; AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; COUZET P, 1994, ENV FRANCE EDITION 1, P9; DELAMASSA JP, 1994, DG 13 TELECOMMUNICAT, P5; GINSBURG J, 1994, LANCET, V343, P230, DOI 10.1016/S0140-6736(94)91012-X; JOUANNET P, 1981, INT J ANDROL, V4, P440, DOI 10.1111/j.1365-2605.1981.tb00728.x; LAVOUX T, 1994, ENV FRANCE EDITION 1, P216; MICHAL F, 1993, ENVIRON HEALTH PERSP, V101, P159, DOI 10.2307/3431390; MIEUSSET R, 1987, FERTIL STERIL, V48, P1006; MIEUSSET R, 1995, INT J ANDROL, V18, P169, DOI 10.1111/j.1365-2605.1995.tb00408.x; MOLLER H, 1993, EUR UROL, V23, P8; SCHWARTZ D, 1983, FERTIL STERIL, V39, P530; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; STEENO OP, 1984, ANDROLOGIA, V16, P5; TOPPARI J, 1995, MALE REPROD HLTH ENV	17	183	192	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					471	472		10.1136/bmj.312.7029.471	http://dx.doi.org/10.1136/bmj.312.7029.471			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597677	Green Published			2022-12-24	WOS:A1996TX38300021
J	Needleman, HL; Riess, JA; Tobin, MJ; Biesecker, GE; Greenhouse, JB				Needleman, HL; Riess, JA; Tobin, MJ; Biesecker, GE; Greenhouse, JB			Bone lead levels and delinquent behavior	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPOSURE	Objective.-To evaluate the association between body lead burden and social adjustment. Design.-Retrospective cohort study. Setting.-Public school community. Participants.-From a population of 850 boys in the first grade at public schools, 503 were selected on the basis of a risk scale for antisocial behavior. All of the 850 boys who scored in the upper 30th percentile of the distribution on a self-reported antisocial behavior scale were matched with an equal number drawn by lot from the lower 70% of the distribution. From this sample, 301 students accepted the invitation to participate. Exposure Measure.-K x-ray fluorescence spectroscopy of tibia at subjects' age of 12 years. Main Outcome Measures.-Child Behavior Checklist (CBCL), teachers' and parents' reports, and subjects' self-report of antisocial behavior and delinquency at 7 and 11 years of age. Results.-Subjects, teachers, and parents were blind to the bone lead measurements. At 7 years of age, borderline associations between teachers' aggression, delinquency, and externalizing scores and lead levels were observed after adjustment for covariates. At 11 years of age, parents reported a significant lead-related association with the following CBCL cluster scores: somatic complaints and delinquent, aggressive, internalizing, and externalizing behavior. Teachers reported significant associations of lead with somatic complaints, anxious/depressed behavior, social problems, attention problems, and delinquent, aggressive, internalizing, and externalizing behavior. High-lead subjects reported; higher scores in subjects' self-reports of delinquency at 11 years. High-lead subjects were more likely to obtain worse scores on all items of the CBCL during the 4-year period of observation. High bone lead levels were associated with an increased risk of exceeding the clinical score (T>70) for attention, aggression, and delinquency. Conclusion.-Lead exposure is associated with increased risk for antisocial and delinquent behavior, and the effect follows a developmental course.	UNIV PITTSBURGH,SCH MED,DEPT PSYCHIAT,PITTSBURGH,PA; UNIV PITTSBURGH,GRAD SCH PUBL HLTH,PITTSBURGH,PA; CARNEGIE MELLON UNIV,DEPT STAT,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University			Greenhouse, Joel/W-2132-2019; Klishevych, Nataliia/ABB-2500-2021	Greenhouse, Joel/0000-0001-5087-9648; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005015] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES 05015-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ACHENBACH TM, 1995, J AM ACAD CHILD PSY, V34, P488, DOI 10.1097/00004583-199504000-00016; ACHENBACH TM, 1991, MANUAL CHILD BEHAVIO; [Anonymous], 1988, NATURE EXTENT LEAD P; BELLINGER D, 1994, ENVIRON RES, V66, P12, DOI 10.1006/enrs.1994.1041; Byers RK, 1943, AM J DIS CHILD, V66, P471; DENNO DW, 1990, BIOL VIOLENCE; FARRINGTON DP, 1991, DEV TREATMENT CHILDH, P189; FERGUSSON DM, 1993, J CHILD PSYCHOL PSYC, V34, P215, DOI 10.1111/j.1469-7610.1993.tb00980.x; GOLDSTEIN GW, 1992, HUMAN LEAD EXPOSURE; HATZAKIS A, 1987, INT C HEAVY METALS E, P204; Hollingshead August B., 1958, SOCIAL CLASS MENTAL; LANSDOWN R, 1983, LEAD VERSUS HLTH; LANTHONY P, 1987, J FR OPHTALMOL, V10, P579; LAUGHLIN NK, 1991, NEUROTOXICOL TERATOL, V13, P429, DOI 10.1016/0892-0362(91)90092-B; Letz R, 1988, NES2 NEUROBEHAVIORAL; LOEBER R, 1991, J CRIM LAW CRIM, V82, P36; LOEBER R, 1983, PSYCHOL BULL, V94, P68, DOI 10.1037/0033-2909.94.1.68; LOEBER R, 1989, CROSS NATIONAL RES S; MIRSKY AF, 1987, ENVIRON HEALTH PERSP, V74, P191, DOI 10.2307/3430449; MOFFITT TE, 1990, CRIME JUSTICE, V12, P99, DOI 10.1086/449165; NEEDLEMAN HL, 1990, NEW ENGL J MED, V322, P83, DOI 10.1056/NEJM199001113220203; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; OFFORD DR, 1979, J NERV MENT DIS, V167, P734, DOI 10.1097/00005053-197912000-00003; PIRKLE JL, 1994, JAMA-J AM MED ASSOC, V272, P284, DOI 10.1001/jama.272.4.284; Raven JC, 1988, MANUAL RAVENS PROGR; REYNOLDS CR, 1990, HDB PSYCHOL ED ASSES, P370; RICE DC, 1993, NEUROTOXICOLOGY, V14, P167; SATTERFIELD JH, 1987, CAUSES CRIME; SCIARILLO WG, 1992, AM J PUBLIC HEALTH, V82, P1356, DOI 10.2105/AJPH.82.10.1356; TAYLOR D, 1978, J PHARMACOL EXP THER, V206, P371; THOMSON GOB, 1989, J CHILD PSYCHOL PSYC, V30, P515, DOI 10.1111/j.1469-7610.1989.tb00265.x; TODD AC, 1991, ENVIRON RES, V57, P117; Tonry ML, 1991, HUMAN DEV CRIMINAL B, DOI DOI 10.1007/978-1-4613-9055-8; WATKINS CE, 1986, PROF PSYCHOL-RES PR, V17, P36; Wilson James, 1986, CRIME HUMAN NATURE	35	444	459	0	39	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					363	369		10.1001/jama.275.5.363	http://dx.doi.org/10.1001/jama.275.5.363			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TT303	8569015				2022-12-24	WOS:A1996TT30300029
J	Dacey, DM; Lee, BB; Stafford, DK; Pokorny, J; Smith, VC				Dacey, DM; Lee, BB; Stafford, DK; Pokorny, J; Smith, VC			Horizontal cells of the primate retina: Cone specificity without spectral opponency	SCIENCE			English	Article							MACAQUE GANGLION-CELLS; MONKEY RETINA; PHOTORECEPTORS; SENSITIVITY; CONNECTIONS; RESPONSES	The chromatic dimensions of human color vision have a neural basis in the retina. Ganglion cells, the output neurons of the retina, exhibit spectral opponency; they are excited by some wavelengths and inhibited by others. The hypothesis that the opponent circuitry emerges from selective connections between horizontal cell interneurons and cone photoreceptors sensitive to long, middle, and short wavelengths (L-, M-, and S-cones) was tested by physiologically and anatomically characterizing cone connections of horizontal cell mosaics in macaque monkeys. H1 horizontal cells received input only from L- and M-cones, whereas H2 horizontal cells received a strong input from S-cones and a weaker input from L- and M-cones. All cone inputs were the same sign, and both horizontal cell types lacked opponency. Despite cone type selectivity, the horizontal cell cannot be the locus of an opponent transformation in primates, including humans.	MAX PLANCK INST BIOPHYS CHEM,D-37077 GOTTINGEN,GERMANY; UNIV CHICAGO,CTR VISUAL SCI,CHICAGO,IL 60637	Max Planck Society; University of Chicago	Dacey, DM (corresponding author), UNIV WASHINGTON,DEPT BIOL STRUCT,BOX 357420,SEATTLE,WA 98195, USA.			Dacey, Dennis/0000-0001-8476-5585				AHNELT P, 1994, J COMP NEUROL, V343, P406, DOI 10.1002/cne.903430306; [Anonymous], 1991, COMPUTATIONAL MODELS, DOI [10.7551/mitpress/2002.003.0010, DOI 10.7551/MITPRESS/2002.003.0010]; BOYCOTT BB, 1987, PROC R SOC SER B-BIO, V229, P345, DOI 10.1098/rspb.1987.0001; BURKHARDT DA, 1993, VISUAL NEUROSCI, V10, P981, DOI 10.1017/S0952523800010087; CURCIO CA, 1991, J COMP NEUROL, V312, P610, DOI 10.1002/cne.903120411; DACEY DM, 1994, NATURE, V367, P731, DOI 10.1038/367731a0; DACHEUX RF, 1990, PROC R SOC SER B-BIO, V239, P213, DOI 10.1098/rspb.1990.0014; DEVALOIS RL, 1964, SCIENCE, V146, P1184, DOI 10.1126/science.146.3648.1184; DEVALOIS RL, 1958, SCIENCE, V127, P238, DOI 10.1126/science.127.3292.238; Goodchild A. K., 1995, Society for Neuroscience Abstracts, V21, P1645; GOURAS P, 1968, J PHYSIOL-LONDON, V199, P533, DOI 10.1113/jphysiol.1968.sp008667; KAMERMANS M, 1995, PROG RETIN EYE RES, V14, P313, DOI 10.1016/1350-9462(94)00003-2; KOLB H, 1980, J COMP NEUROL, V189, P31; LEE BB, 1995, COLOR VISION DEFICIE, V11, P177; MANGEL SC, 1991, J PHYSIOL-LONDON, V442, P211, DOI 10.1113/jphysiol.1991.sp018790; REID RC, 1992, NATURE, V356, P716, DOI 10.1038/356716a0; SCHNAPF JL, 1987, NATURE, V325, P439, DOI 10.1038/325439a0; SCHNEEWEIS DM, 1995, SCIENCE, V268, P1053, DOI 10.1126/science.7754386; SMITH RG, 1995, VISUAL NEUROSCI, V12, P545, DOI 10.1017/S0952523800008440; SMITH VC, 1975, VISION RES, V15, P161, DOI 10.1016/0042-6989(75)90203-5; SMITH VC, 1992, J PHYSIOL-LONDON, V458, P191, DOI 10.1113/jphysiol.1992.sp019413; SMITH VC, 1995, J OPT SOC AM A, V12, P241, DOI 10.1364/JOSAA.12.000241; SWANSON WH, 1987, J OPT SOC AM A, V4, P1992, DOI 10.1364/JOSAA.4.001992; VALBERG A, 1992, J PHYSIOL-LONDON, V458, P579, DOI 10.1113/jphysiol.1992.sp019435; VANEY DI, 1994, PROG RETIN EYE RES, V13, P301, DOI 10.1016/1350-9462(94)90014-0; WASSLE H, 1989, EUR J NEUROSCI, V1, P421, DOI 10.1111/j.1460-9568.1989.tb00350.x; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P1115, DOI 10.1152/jn.1966.29.6.1115; Wyszecki G., 1982, COLOR SCI	28	184	187	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					656	659		10.1126/science.271.5249.656	http://dx.doi.org/10.1126/science.271.5249.656			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571130				2022-12-24	WOS:A1996TT87000049
J	Gurwitz, JH; Gore, JM; Goldberg, RJ; Rubison, M; Chandra, N; Rogers, WJ				Gurwitz, JH; Gore, JM; Goldberg, RJ; Rubison, M; Chandra, N; Rogers, WJ			Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article							ELDERLY PATIENTS; MORTALITY; PROGNOSIS; OUTCOMES; WOMEN; CARE	Objective: To examine recent trends in the use of thrombolytic therapy in elderly patients who have had acute myocardial infarction and to determine whether failure to meet time-to-hospital presentation and electrocardiographic criteria might explain age-related differences in the use of thrombolytic therapy. Design: A national registry of patients who have had acute myocardial infarction. Setting: 1249 U.S. hospitals. Patients: 350 755 patients who had an acute myocardial infarction from 1 July 1990 to 30 September 1994. Measurements: Trends in the proportions of patients who received thrombolytic therapy were examined according to age and sex. The association between age and treatment with a thrombolytic agent was determined by crude and multivariable-adjusted analyses. Results: Use of a thrombolytic agent was inversely related to patient age: Almost 51% of patients younger than age 55 years received a thrombolytic agent during hospitalization for acute myocardial infarction; this proportion decreased to 43.6% for patients aged 55 to 64 years, 33.0% for those aged 65 to 74 years, 19.0% for those aged 75 to 84 years, and 7.4% for those aged 85 years or older. However, relative increases in the use of thrombolytic therapy over time were greatest for patients in the oldest age groups. Between 1 July 1990 and 30 June 1991, 16.0% of patients aged 75 to 84 years received a thrombolytic agent compared with 21.4% between 1 June 1993 and 30 September 1994 (a 33.8% relative increase in use). Among persons aged 85 years or older, the proportion of treated patients increased from 5.3% to 9.1% over this same period (a 71.7% relative increase in use). Increases in thrombolytic use were most prominent for older women. After adjustment for sex, diagnosis by initial electrocardiogram, electrocardiogram-based infarction description, time from symptom onset to hospital presentation, and period of the acute myocardial infarction, the odds of receiving a thrombolytic agent were significantly reduced for patients in the older age groups compared with the odds for patients younger than age 55 years (for patients aged 75 to 84 years, the adjusted odds ratio was 0.27 [95% CI, 0.26 to 0.28]; for patients aged 85 years or older, the odds ratio was 0.09 [CI, 0.08 to 0.10]). Conclusions: Although older patients who have had acute myocardial infarction less commonly receive a thrombolytic agent, use of thrombolytic therapy in this population is expanding. However, substantial differences across age groups persist in the likelihood of receiving treatment, even after adjustment for potentially confounding factors. Age-related differences in thrombolytic use may not be completely explained by the degree to which older patients do not meet conventional eligibility criteria for thrombolytic therapy.	UNIV MASSACHUSETTS, MED CTR, DEPT MED, WORCESTER, MA 01655 USA; CLINTRIALS RES INC, LEXINGTON, KY 40504 USA; JOHNS HOPKINS UNIV, BAYVIEW MED CTR, DIV CARDIOL, BALTIMORE, MD 21224 USA; UNIV ALABAMA, MED CTR, BIRMINGHAM, AL 35294 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV MASSACHUSETTS, SCH MED, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Johns Hopkins University; University of Alabama System; University of Alabama Birmingham; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	Gurwitz, JH (corresponding author), BRIGHAM & WOMENS HOSP, PROGRAM ANAL CLIN STRATEGIES, 221 LONGWOOD AVE, SUITE 341, BOSTON, MA 02115 USA.				NIA NIH HHS [K08 AG00510] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K08AG000510] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; CHAMBERLAIN DA, 1988, LANCET, V1, P545; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; GOLDBERG RJ, 1992, AM J CARDIOL, V70, P421, DOI 10.1016/0002-9149(92)91183-5; Gunnar R M, 1990, Circulation, V82, P664; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; GURWITZ JH, 1992, AM J MED, V93, P605, DOI 10.1016/0002-9343(92)90192-E; GURWITZ JH, 1994, ARCH INTERN MED, V154, P2202; GURWITZ JH, 1993, INCLUSION ELDERLY IN, P205; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KLINKENBERGKNOL EC, 1987, LANCET, V1, P349; KRUMHOLZ HM, 1994, J AM GERIATR SOC, V42, P127, DOI 10.1111/j.1532-5415.1994.tb04938.x; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; MAGGIONI AP, 1993, NEW ENGL J MED, V329, P1442, DOI 10.1056/NEJM199311113292002; MEDALIE JH, 1976, ANN INTERN MED, V84, P526, DOI 10.7326/0003-4819-84-5-526; MEEHAN TP, 1995, ANN INTERN MED, V122, P928, DOI 10.7326/0003-4819-122-12-199506150-00007; NADELMANN J, 1990, AM J CARDIOL, V66, P533, DOI 10.1016/0002-9149(90)90477-I; PASHOS CL, 1993, JAMA-J AM MED ASSOC, V270, P1832, DOI 10.1001/jama.270.15.1832; PASHOS CL, 1994, J AM COLL CARDIOL, V23, P1023, DOI 10.1016/0735-1097(94)90585-1; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; ROGERS WJ, 1995, AM J MED, V99, P195, DOI 10.1016/S0002-9343(99)80140-5; SIGURDSSON E, 1995, ANN INTERN MED, V122, P96, DOI 10.7326/0003-4819-122-2-199501150-00003; SIMOONS ML, 1993, LANCET, V342, P1523, DOI 10.1016/S0140-6736(05)80089-3; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1992, NEW ENGL J MED, V327, P45, DOI 10.1056/NEJM199207023270109; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WILCOX RG, 1988, LANCET, V2, P525; YARZEBSKI J, 1994, AM HEART J, V128, P255, DOI 10.1016/0002-8703(94)90477-4; 1992, CARDIOLOGY, V21, P5	37	118	121	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					283	+		10.7326/0003-4819-124-3-199602010-00001	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554222				2022-12-24	WOS:A1996TR59600001
J	Peters, RK; Kjos, SL; Xiang, A; Buchanan, TA				Peters, RK; Kjos, SL; Xiang, A; Buchanan, TA			Long-term diabetogenic effect of single pregnancy in women with previous gestational diabetes mellitus	LANCET			English	Article							IMPAIRED GLUCOSE-TOLERANCE; INSULIN-RESISTANCE; PIMA-INDIANS; FOLLOW-UP; PARITY; CELL	Background Pregnancy is associated with marked insulin resistance that seems to have little, if any, impact on the long-term risk of non-insulin-dependent diabetes mellitus (NIDDM) in the general population. The aim of this study was to test whether pregnancy would alter the risk of NIDDM among women with a high prevalence of pancreatic beta-cell dysfunction, as indicated by a history of gestational diabetes mellitus. Methods The cohort consisted of 666 Latino women with gestational diabetes attending a high-risk family planning clinic. They were followed up for up to 7.5 years, during which lime they were weighed and underwent an oral glucose-tolerance test annually. The effect of an additional pregnancy, and of other risk factors for diabetes, was examined. Findings 87 (13%) of the women completed an additional pregnancy. 80 of those women did not have NIDDM immediately after the additional pregnancy and their subsequent annual incidence rate of NIDDM was 30.9% (95% CI 12.7-49.1), more than 2.5 times the annual incidence rate of NIDDM in the cohort overall (11.9%; 95% CI 10.0-13.8). Proportional hazards regression analysis using the presence or absence of an additional pregnancy as a time-dependent variable confirmed that an additional pregnancy increased the rate ratio of NIDDM to 3.34(95% CI 1.80-6.19), compared with women without an additional pregnancy after adjustment for other potential diabetes risk factors during the index pregnancy (antepartum oral glucose tolerance, highest fasting glucose, gestational age at diagnosis of gestational diabetes) and during follow-up (postpartum body mass index [BMI], and glucose tolerance, weight change, breast feeding, and months of contraceptive use). Weight gain also was independently associated with an increased risk of NIDDM; the rate ratio was 1.95 (95% CI 1.63-2.33) for each 10 lb (4.5 kg) gained during follow-up after adjustment for the additional pregnancy and the other potential risk factors. Interpretation The study showed that a single pregnancy, independent of the well-known effect of weight gain, accelerated the development of NIDDM in a group of women with a high prevalence of pancreatic beta-cell dysfunction. This finding implies that episodes of insulin resistance may contribute to the decline in beta-cell function that leads to NIDDM in many high-risk individuals.	UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT OBSTET & GYNECOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MED,LOS ANGELES,CA 90033	University of Southern California; University of Southern California; University of Southern California					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046374] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR-43] Funding Source: Medline; NIDDK NIH HHS [R01-DK-46374] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; BERAL V, 1985, J EPIDEMIOL COMMUN H, V39, P343, DOI 10.1136/jech.39.4.343; BLEICHER SJ, 1964, NEW ENGL J MED, V271, P866, DOI 10.1056/NEJM196410222711702; BUCHANAN TA, 1990, AM J OBSTET GYNECOL, V162, P1008, DOI 10.1016/0002-9378(90)91306-W; CATALANO PM, 1991, AM J OBSTET GYNECOL, V165, P1667, DOI 10.1016/0002-9378(91)90012-G; CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; COX DR, 1972, J R STAT SOC B, V34, P187; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DONG ZG, 1993, AUST NZ J OBSTET GYN, V33, P350, DOI 10.1111/j.1479-828X.1993.tb02107.x; FOSSATI P, 1982, CLIN CHEM, V28, P2077; GAUDIER FL, 1992, OBSTET GYNECOL, V80, P755; GRANT PT, 1986, AUST NZ J OBSTET GYN, V26, P17, DOI 10.1111/j.1479-828X.1986.tb01521.x; HANSON RL, 1995, DIABETES, V43, P261; KJOS SL, 1995, DIABETES, V44, P586, DOI 10.2337/diabetes.44.5.586; KRITZSILVERSTEIN D, 1989, NEW ENGL J MED, V321, P1214, DOI 10.1056/NEJM198911023211802; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; MANSON JE, 1992, AM J MED, V93, P13, DOI 10.1016/0002-9343(92)90674-Z; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; PYKE DA, 1956, LANCET, V270, P818; RYAN EA, 1985, DIABETES, V34, P380, DOI 10.2337/diabetes.34.4.380; RYAN EA, 1995, DIABETES, V44, P506, DOI 10.2337/diabetes.44.5.506; SAAD MF, 1988, NEW ENGL J MED, V319, P1500, DOI 10.1056/NEJM198812083192302; SPELLACY WN, 1963, NEW ENGL J MED, V268, P988, DOI 10.1056/NEJM196305022681805; WARD WK, 1985, DIABETES, V34, P861, DOI 10.2337/diabetes.34.9.861; WEST KM, 1978, EPIDEMIOLOGY DIABETE, P221; 1979, DIABETES, V29, P1039	27	201	207	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					227	230		10.1016/S0140-6736(96)90405-5	http://dx.doi.org/10.1016/S0140-6736(96)90405-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551882				2022-12-24	WOS:A1996TT06900011
J	Sabin, CA; Phillips, AN; Lee, CA				Sabin, CA; Phillips, AN; Lee, CA			Arguments contradict the ''foreign protein-zidovudine'' hypothesis - Response	BRITISH MEDICAL JOURNAL			English	Editorial Material									ROYAL FREE HOSP,HAEMOPHILIA CTR,DEPT HAEMATOL,LONDON NW3 2PF,ENGLAND; ROYAL FREE HOSP,HAEMOSTASIS UNIT,DEPT HAEMATOL,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Sabin, CA (corresponding author), ROYAL FREE HOSP,SCH MED,HIV RES UNIT,DEPT PUBL HLTH,LONDON NW3 2PF,ENGLAND.		Phillips, Andrew N/B-4427-2008; Sabin, Caroline/C-2464-2008	Phillips, Andrew N/0000-0003-2384-4807; Sabin, Caroline/0000-0001-5173-2760				BOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243, DOI 10.1111/j.1365-2249.1992.tb03068.x; DARBY SC, 1995, NATURE, V377, P79, DOI 10.1038/377079a0; DUESBERG P, 1996, BMJ, V312; DUESBERG PH, 1991, P NATL ACAD SCI USA, V88, P1575, DOI 10.1073/pnas.88.4.1575; GOEDERT JJ, 1994, LANCET, V344, P791, DOI 10.1016/S0140-6736(94)92345-0; MONTORO JB, 1995, BLOOD, V86, P2213, DOI 10.1182/blood.V86.6.2213.bloodjournal8662213; Sabin CA, 1996, BMJ-BRIT MED J, V312, P207, DOI 10.1136/bmj.312.7025.207; SEREMETIS SV, 1993, LANCET, V342, P700, DOI 10.1016/0140-6736(93)91706-R; 1994, HIV AIDS SURVEILLANC, V6, P1	9	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					211	212						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563584				2022-12-24	WOS:A1996TT48600023
J	Siniossoglou, S; Wimmer, C; Rieger, M; Doye, V; Tekotte, H; Weise, C; Emig, S; Segref, A; Hurt, EC				Siniossoglou, S; Wimmer, C; Rieger, M; Doye, V; Tekotte, H; Weise, C; Emig, S; Segref, A; Hurt, EC			A novel complex of nucleoporins, which includes Sec13p and a Sec13p homolog, is essential for normal nuclear pores	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSPORT; RECONSTITUTION; PROTEINS; INVITRO; MUTANT; NSP1	In a genetic screen for nucleoporin-interacting components, a novel nuclear pore protein Nup84p, which exhibits homology to mammalian Nup107p, was isolated. Nup84p forms a complex with five proteins, of which Nup120p, Nup85p, Sec13p, and a Sec13p homolog were identified. Upon isolation of Sec13p-ProtA, nucleoporins were still associated, but the major copurifying band was a 150 kDa protein, showing that Sec13p occurs in two complexes. Disruption of any of the genes encoding Nup84p, Nup85p, or Nup120p caused defects in nuclear membrane and nuclear pore complex organization, as well as in poly(A)(+) RNA transport. Thus, the Nup84p complex in conjunction with Sec13-type proteins is required for correct nuclear pore biogenesis.	EUROPEAN MOLEC BIOL LAB, D-69115 HEIDELBERG, GERMANY; FREE UNIV BERLIN, INST BIOCHEM, D-14195 BERLIN, GERMANY; GENOTYPE GMBH, D-69259 WILHELMSFELD, GERMANY; INST CURIE, CNRS UMR 144, SECT RECH, F-75231 PARIS, FRANCE	European Molecular Biology Laboratory (EMBL); Free University of Berlin; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Segref, Alexandra/C-8325-2011; Ed Hurt, Dr./AAE-8874-2019	Ed Hurt, Dr./0000-0002-4535-8255; Tekotte, Hille/0000-0003-2164-7412; Segref, Alexandra/0000-0001-8095-4469				AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BOGERD AM, 1994, J CELL BIOL, V127, P319, DOI 10.1083/jcb.127.2.319; DABAUVALLE MC, 1990, CHROMOSOMA, V100, P56, DOI 10.1007/BF00337603; DOYE V, 1995, TRENDS GENET, V11, P235, DOI 10.1016/S0168-9525(00)89057-5; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; GRANDI P, 1993, EMBO J, V12, P3061, DOI 10.1002/j.1460-2075.1993.tb05975.x; GRANDI P, 1995, J CELL BIOL, V130, P1263, DOI 10.1083/jcb.130.6.1263; GRANDI P, 1995, EMBO J, V14, P76, DOI 10.1002/j.1460-2075.1995.tb06977.x; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; JORDAN EG, 1977, EXP CELL RES, V104, P446, DOI 10.1016/0014-4827(77)90114-8; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; LI O, 1995, MOL BIOL CELL, V6, P401, DOI 10.1091/mbc.6.4.401; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEHRBASS U, 1993, EUR J CELL BIOL, V62, P1; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; PRINGLE JR, 1981, MOL BIOL YEAST SACCH; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1994, J BIOL CHEM, V269, P17600; RASMUSSEN SW, 1994, YEAST, V10, pS63, DOI 10.1002/yea.320100008; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMOS G, 1995, FEBS LETT, V369, P107, DOI 10.1016/0014-5793(95)00674-X; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; WOZNIAK RW, 1989, J CELL BIOL, V108, P2083, DOI 10.1083/jcb.108.6.2083	33	267	277	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					265	275		10.1016/S0092-8674(00)80981-2	http://dx.doi.org/10.1016/S0092-8674(00)80981-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565072	Bronze			2022-12-24	WOS:A1996TR59500013
J	Brocke, S; Gijbels, K; Allegretta, M; Ferber, I; Piercy, C; Blankenstein, T; Martin, R; Utz, U; Karin, N; Mitchell, D; Veromaa, T; Waisman, A; Gaur, A; Conlon, P; Ling, N; Fairchild, PJ; Wraith, DC; OGarra, A; Fathman, CG; Steinman, L				Brocke, S; Gijbels, K; Allegretta, M; Ferber, I; Piercy, C; Blankenstein, T; Martin, R; Utz, U; Karin, N; Mitchell, D; Veromaa, T; Waisman, A; Gaur, A; Conlon, P; Ling, N; Fairchild, PJ; Wraith, DC; OGarra, A; Fathman, CG; Steinman, L			Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein	NATURE			English	Article							T-CELL RECEPTOR; TUMOR NECROSIS FACTOR; MULTIPLE-SCLEROSIS	FOLLOWING induction of experimental encephalomyelitis with a T-cell clone, L10C1, that is specific for the myelin basic protein epitope p87-99, the inflammatory infiltrate in the central nervous system contains a diverse collection of T cells with heterogeneous receptors. We show here that when clone L10C1 is tolerized in vivo with an analogue of p87-99, established paralysis is reversed, inflammatory infiltrates regress, and the heterogeneous T-cell infiltrate disappears from the brain, with only the T-cell clones that incited disease remaining in the original lesions. We found that antibody raised against interleukin-4 reversed the tolerance induced by the altered peptide ligand. Treatment,vith this altered peptide ligand selectively silences pathogenic T cells and actively signals for the efflux of other T cells recruited to the site of disease as a result of the production of interleukin-4 and the reduction of tumour-necrosis factor-alpha in the lesion.	STANFORD UNIV,MED CTR,DEPT NEUROL & NEUROL SCI,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT MED,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT PATHOL,STANFORD,CA 94305; MAX DELBRUCK CTR MOLEC MED,D-13125 BERLIN,GERMANY; NINCDS,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892; WEIZMANN INST SCI,DEPT IMMUNOL,IL-76100 REHOVOT,ISRAEL; NEUROCRINE BIOSCI,LA JOLLA,CA 92121; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB1 1QP,ENGLAND; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94305	Stanford University; Stanford University; Stanford University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Weizmann Institute of Science; Neurocrine Biosciences; University of Cambridge; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Waisman, Ari/C-7383-2015	Waisman, Ari/0000-0003-4304-8234; Wraith, David/0000-0003-2147-5614; O'Garra, Anne/0000-0001-9845-6134; Steinman, Lawrence/0000-0002-2437-2250	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELL RB, 1993, J IMMUNOL, V150, P4085; BROCKE S, 1993, NATURE, V365, P642, DOI 10.1038/365642a0; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; GOLD DP, 1992, J IMMUNOL, V148, P1712; KARIN N, 1994, J EXP MED, V180, P2227, DOI 10.1084/jem.180.6.2227; KOOP BF, 1992, GENOMICS, V13, P1209, DOI 10.1016/0888-7543(92)90039-U; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MARTIN R, 1991, J EXP MED, V173, P19, DOI 10.1084/jem.173.1.19; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; PLATZER C, 1992, EUR J IMMUNOL, V22, P1179, DOI 10.1002/eji.1830220511; POWELL MB, 1990, INT IMMUNOL, V2, P539, DOI 10.1093/intimm/2.6.539; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; RAINE CS, 1995, NAT MED, V1, P211, DOI 10.1038/nm0395-211; SELMAJ KW, 1990, J IMMUNOL, V144, P129; STEINMAN L, 1994, BEHRING I MITT, V94, P148; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VOGT AB, 1994, J IMMUNOL, V153, P1665; WRAITH DC, 1989, CELL, V57, P709, DOI 10.1016/0092-8674(89)90786-1; WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279	21	361	379	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					343	346		10.1038/379343a0	http://dx.doi.org/10.1038/379343a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552189				2022-12-24	WOS:A1996TR32300058
J	Palevsky, PM; Bhagrath, R; Greenberg, A				Palevsky, PM; Bhagrath, R; Greenberg, A			Hypernatremia in hospitalized patients	ANNALS OF INTERNAL MEDICINE			English	Article						hypernatremia; hospitalization; sodium; fluid therapy; water-electrolyte balance	HYPONATREMIA; DEHYDRATION	Objective: To determine the incidence, clinical characteristics, and outcome for general medical-surgical hospital patients with hypernatremia. Design: A prospective cohort study. Setting: A 942-bed urban university hospital. Patients: All patients who developed a serum sodium concentration of 150 mmol/L or greater during a 3-month observation period. Measurements: Daily fluid balance, mental status, and serum and urine electrolytes and osmolality. Results: 103 patients were identified. Eighteen patients were hypernatremic on hospital admission, and 85 developed hypernatremia during hospitalization. Patients who developed hypernatremia during hospitalization were younger than patients who developed hypernatremia before hospital admission (mean age +/- SD, 58.9 +/- 19.2 years compared with 76.6 +/- 16.6 years; P < 0.01) but did not differ in age from the patients of the general hospitalized population. Eighty-nine percent of patients who developed hypernatremia during hospitalization had urine concentrating defects, primarily as the result of the use of diuretics or of solute diuresis, whereas only 50% of patients who were hypernatremic on admission could be shown to have concentrating defects (P < 0.01). Fifty-five percent of all hypernatremic patients had increased insensible water losses, and 35% had increased enteral water losses. Eighty-six percent of patients with hospital-acquired hypernatremia lacked free access to water, 74% had enteral water intake of less than 1 L/d, and 94% received less than 1 L of intravenous electrolyte-free water per day during the development of hypernatremia. No supplemental electrolyte-free water was prescribed during the first 24 hours of hypernatremia in 49% of patients. The duration of hypernatremia was shorter in patients who were hypernatremic on admission (median duration, 3 days) than in patients with hospital-acquired hypernatremia (median duration, 5 days; P < 0.05). Mortality was 41% for all patients, but hypernatremia was judged to have contributed to mortality in only 16% of patients. Conclusions: Although the development of hypernatremia before hospital admission occurs primarily in geriatric patients, hospital-acquired hypernatremia was more common in our cohort and had an age distribution similar to that of the general hospitalized population. Hospital-acquired hypernatremia was primarily iatrogenic, resulting from inadequate and inappropriate prescription of fluids to patients with predictably increased water losses and impaired thirst or restricted free water intake or both. Treatment of hypernatremia is often inadequate or delayed. Efforts to manage hypernatremia better and altogether avoid hospital-acquired hypernatremia should focus on both physician education and the development of hospital systems to prevent errors in fluid prescription.	VET AFFAIRS MED CTR, MED SERV, PITTSBURGH, PA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Palevsky, PM (corresponding author), UNIV PITTSBURGH, SCH MED, DIV RENAL ELECTROLYTE, A919 SCAIFE HALL, 3550 TERRACE ST, PITTSBURGH, PA 15261 USA.		Palevsky, Paul M./Q-1491-2019	Palevsky, Paul M./0000-0002-7334-5400; Greenberg, Arthur/0000-0002-2838-8401				ANDERSON RJ, 1985, ANN INTERN MED, V102, P164, DOI 10.7326/0003-4819-102-2-164; BECK LH, 1987, ANN INTERN MED, V107, P768, DOI 10.7326/0003-4819-107-5-768; BRENNAN J, 1990, J CRIT ILLNESS, V5, P330; DAGGETT P, 1979, BRIT MED J, V1, P1177, DOI 10.1136/bmj.1.6172.1177; FITZSIMONS JT, 1976, KIDNEY INT, V10, P3, DOI 10.1038/ki.1976.74; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.me.44.020193.001445; HIMMELSTEIN DU, 1983, J AM GERIATR SOC, V31, P466, DOI 10.1111/j.1532-5415.1983.tb05118.x; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LONG CA, 1991, POSTGRAD MED J, V67, P643, DOI 10.1136/pgmj.67.789.643; MACDONALD NJ, 1989, BRIT MED J, V299, P1426, DOI 10.1136/bmj.299.6713.1426; MAHOWALD JM, 1981, J AM GERIATR SOC, V29, P177, DOI 10.1111/j.1532-5415.1981.tb01761.x; PALEVSKY PM, 1992, CURRENT THERAPY NEPH; Plum F, 1966, DIAGNOSIS STUPOR COM, V1st; SNYDER NA, 1987, ANN INTERN MED, V107, P309, DOI 10.7326/0003-4819-107-2-309; TIERNEY WM, 1986, J GEN INTERN MED, V1, P380, DOI 10.1007/BF02596422	16	213	227	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					197	+		10.7326/0003-4819-124-2-199601150-00002	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ016	8533994				2022-12-24	WOS:A1996TQ01600002
J	Desenclos, JC; Bouvet, P; BenzLemoine, E; Grimont, F; Desqueyroux, H; Rebiere, I; Grimont, PA				Desenclos, JC; Bouvet, P; BenzLemoine, E; Grimont, F; Desqueyroux, H; Rebiere, I; Grimont, PA			Large outbreak of Salmonella enterica serotype paratyphi B infection caused by a goats' milk cheese, France, 1993: A case finding and epidemiological study	BRITISH MEDICAL JOURNAL			English	Article							CAMPYLOBACTER ENTERITIS	Objective-To assess the magnitude of a nationwide outbreak of infection with Salmonella enterica serotype paratyphi B and identify the vehicle and source of infection. Design - A case finding study of S paratyphi B infection between 15 August and 30 November 1993; a pair matched case-control study; an environmental investigation at a processing plant that produced a raw goats' milk cheese incriminated in the outbreak; phage typing and genotyping of food and human Sparatyphi B isolates. Setting - France, 15 August to 30 November 1993. Subjects - 273 patients with S paratyphi B infection; 59 pairs of cases and controls matched for age, sex, and city of residence. Main outcome measures - Numbers of cases and incidence rates by region of residence and age; matched odds ratios for dairy food preferences. Results - Among the 273 cases there was one death; 203 (78%) strains belonged to phage type 1 var 3. The incidence of infection was greatest in the region where goats) milk cheese is commonly produced. Comparison of cases and controls showed a 12-fold greater risk of illness (95% confidence interval 1.6 to 92.3) from eating brand A unpasteurised goats' milk cheese. Sparatyphi B isolates of phage type 1 var 3 were recovered from cheese A, goats' milk at the plant processing cheese A, and goats' milk supplied to the plant by a single farm. Genotypic IS 200 typing of food and human 1 var 3 phage type isolates showed a common IS 200 pattern. Conclusion - This outbreak emphasises the potential health hazards of widely distributed unpasteurised milk products in France and the need for their close bacterial monitoring.	INST PASTEUR, CTR NATL REFERENCE SALMONELLA SHIGELLA, PARIS, FRANCE; DIRECT DEPT AFFAIRES SANIT & SOCIALES DEUX SEVRES, NIORT, FRANCE; INST PASTEUR, CTR NATL REFERENCE TYPAGE MOLEC ENTER, PARIS, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Desenclos, JC (corresponding author), RESEAU NATL SANTE PUBL, F-94415 ST MAURICE, FRANCE.							Benenson AS, 1990, CONTROL COMMUNICABLE, V15th; BILLE J, 1990, T IND MICR, P71; CAZENAVE DJC, 1993, B EPIDEMIOLOGIQUE HE, V48, P222; CHAUVIN P, 1993, B EPIDEMIOLOGIQUE HE, V21, P93; EZQUERRA E, 1993, J GEN MICROBIOL, V139, P2409, DOI 10.1099/00221287-139-10-2409; FELIX A, 1951, LANCET, V2, P10; GRIMONT PAD, 1991, B EPIDEMIOLOGIQUE HE, V25, P102; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; POTELON JL, 1989, B EPIDEMIOLOGIQUE HE, V24, P98; ROBINSON DA, 1981, BRIT MED J, V282, P1374, DOI 10.1136/bmj.282.6273.1374; ROBINSON DA, 1979, BRIT MED J, V1, P1171, DOI 10.1136/bmj.1.6172.1171; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Talbot J C, 1967, Public Health, V81, P191, DOI 10.1016/S0033-3506(67)80185-9; WRIGHT EP, 1983, J HYG-CAMBRIDGE, V91, P227, DOI 10.1017/S002217240006023X; 1993, GUIDELINES APPLICATI; 1991, RECENSEMENT GENERRAL	16	57	59	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					91	94						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555937	Green Published			2022-12-24	WOS:A1996TQ16800024
J	Klein, R; Klein, BEK; Moss, SE				Klein, R; Klein, BEK; Moss, SE			Relation of glycemic control to diabetic microvascular complications in diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			STAGE RENAL-DISEASE; GROSS PROTEINURIA; METABOLIC CONTROL; 4-YEAR INCIDENCE; PLASMA-GLUCOSE; BLOOD-PRESSURE; PIMA-INDIANS; RETINOPATHY; NEPHROPATHY; POPULATION	Objective: To describe the relation between glycated hemoglobin and the incidence or progression, or both, of diabetic microvascular complications in persons with insulin-dependent (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM). Design: Population-based cohort study. Setting: An 11-county area in southern Wisconsin. Patients: All persons with IDDM diagnosed before age 30 and taking insulin (n = 996) and a probability sample (based on duration of disease) of persons diagnosed with diabetes at age 30 or older who were either taking insulin (n = 674) or not taking insulin (n = 696) and who participated in a baseline examination from 1980 to 1982. Survivors of the cohort were re-examined again in 1984 to 1986 and 1990 to 1992. Measurements: The incidence and progression of diabetic retinopathy was determined by masked grading of stereoscopic color fundus photographs using the modified Early Treatment Diabetic Retinopathy Study severity scale. Gross proteinuria was determined using a dipstick. Ten-year incidence of renal dialysis or transplantation or loss of tactile sensation or of temperature sensitivity was based on self-reported history. Results: The glycated hemoglobin level at baseline was strongly related to the incidence or progression, or both, of diabetic retinopathy, the incidence of gross proteinuria, and the incidence of loss of tactile sensation or temperature sensitivity in persons with either IDDM or NIDDM. Conclusions: These prospective epidemiologic data suggest that glycemic control is similarly related to the incidence and progression of diabetic microvascular complications in both IDDM and NIDDM. However, further evidence from clinical trials in persons with NIDDM is necessary to assess the risks and benefits of such treatment in preventing these complications.			Klein, R (corresponding author), UNIV WISCONSIN, SCH MED, DEPT OPHTHALMOL & VISUAL SCI, 610 N WALNUT ST, 460 WARF, MADISON, WI 53705 USA.				NEI NIH HHS [EYO-3083] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY003083] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BALLARD DJ, 1988, DIABETES, V37, P405, DOI 10.2337/diabetes.37.4.405; BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; DYCK PJ, 1985, ADV EXP MED BIOL, V189, P305; DYCK PJ, 1993, NEUROLOGY, V43, P817, DOI 10.1212/WNL.43.4.817; FABRE J, 1982, KIDNEY INT, V21, P730, DOI 10.1038/ki.1982.90; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FERRIS FL, 1993, JAMA-J AM MED ASSOC, V269, P1290, DOI 10.1001/jama.269.10.1290; HASSLACHER C, 1985, DIABETOLOGIA, V28, P6, DOI 10.1007/BF00276992; HASSLACHER C, 1989, NEPHROL DIAL TRANSPL, V4, P859, DOI 10.1093/ndt/4.10.859; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HUMPHREY LL, 1989, ANN INTERN MED, V111, P788, DOI 10.7326/0003-4819-111-10-788; KLEIN R, 1993, DIABETES, V42, P381, DOI 10.2337/diabetes.42.3.381; KLEIN R, 1987, DIABETES CARE, V10, P633, DOI 10.2337/diacare.10.5.633; KLEIN R, 1991, ARCH INTERN MED, V151, P1344, DOI 10.1001/archinte.151.7.1344; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P244, DOI 10.1001/archopht.1989.01070010250031; KLEIN R, 1984, OPHTHALMOLOGY, V91, P1; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1994, ARCH INTERN MED, V154, P2169, DOI 10.1001/archinte.154.19.2169; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P237, DOI 10.1001/archopht.1989.01070010243030; KLEIN R, 1985, ADV EXP MED BIOL, V189, P321; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1217, DOI 10.1001/archopht.1994.01090210105023; KOHNER EM, 1987, PRACT CARDIOL, V13, P70; KROLEWSKI AS, 1986, DIABETES CARE, V9, P443, DOI 10.2337/diacare.9.5.443; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; LEE ET, 1992, DIABETES CARE, V15, P1620, DOI 10.2337/diacare.15.11.1620; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MAUER SM, 1985, ADV EXP MED BIOL, V189, P299; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; NELSON RG, 1988, DIABETOLOGIA, V31, P730, DOI 10.1007/BF00274774; ORCHARD TJ, 1994, DIABETES CARE, V17, P326, DOI 10.2337/diacare.17.4.326; PETTITT DJ, 1980, LANCET, V2, P1050; PUGH JA, 1993, DIABETOLOGIA, V36, P1094, DOI 10.1007/BF02374504; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TEUSCHER A, 1988, DIABETES CARE, V11, P246, DOI 10.2337/diacare.11.3.246; WITKIN SR, 1984, JAMA-J AM MED ASSOC, V251, P2534, DOI 10.1001/jama.251.19.2534; WU MS, 1990, DIABETES CARE, V13, P1, DOI 10.2337/diacare.13.1.1; YOUNG MJ, 1993, DIABETOLOGIA, V36, P150, DOI 10.1007/BF00400697; 1976, PREV MED, V5, P207; 1981, INVEST OPHTH VIS SCI, V21, P210; 1981, FAST HEMOGLOBIN TEST, P1; PB85223006AS	43	197	211	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				90	96		10.7326/0003-4819-124-1_Part_2-199601011-00003	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554220				2022-12-24	WOS:A1996TL94400003
J	Lee, CG; Parikh, V; Itsukaichi, T; Bae, K; Edery, I				Lee, CG; Parikh, V; Itsukaichi, T; Bae, K; Edery, I			Resetting the Drosophila clock by photic regulation of PER and a PER-TIM complex	SCIENCE			English	Article							MESSENGER-RNA LEVELS; CIRCADIAN CLOCK; SUPRACHIASMATIC NUCLEUS; PROTEIN-SYNTHESIS; MOSAIC ANALYSIS; VISUAL-SYSTEM; GENE-PRODUCT; RHYTHMS; LIGHT; MELANOGASTER	Circadian clocks can be reset by light stimulation. To investigate the mechanism of this phase shifting, the effects of light pulses on the protein and messenger RNA products of the Drosophila clock gene period (per) were measured. Photic stimuli perturbed the timing of the PER protein and messenger RNA cycles in a manner consistent with the direction and magnitude of the phase shift. In addition, the recently identified clock protein TIM (for timeless) interacted with PER in vivo, and this association was rapidly decreased by light. This disruption of the PER-TIM complex in the cytoplasm was accompanied by a delay in PER phosphorylation and nuclear entry and disruption in the nucleus by an advance in PER phosphorylation and disappearance. These results suggest a mechanism for how a unidirectional environmental signal elicits a bidirectional clock response.	RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,DEPT MOLEC BIOL & BIOCHEM,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,GRAD PROGRAM MOLEC GENET & MICROBIOL,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,DEPT BIOL SCI,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick								ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; DUNLAP JC, 1988, P NATL ACAD SCI USA, V85, P1096, DOI 10.1073/pnas.85.4.1096; DUSHAY MS, 1990, GENETICS, V125, P557; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EWER J, 1992, J NEUROSCI, V12, P3321; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; HALL JC, 1987, TRENDS GENET, V3, P185, DOI 10.1016/0168-9525(87)90231-9; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HSTINGS JW, 1991, NEURAL INTEGRATIVE A, P435; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; KHALSA SBS, 1992, P NATL ACAD SCI USA, V89, P10862, DOI 10.1073/pnas.89.22.10862; KONOPKA R, 1983, MOL GEN GENET, V190, P284, DOI 10.1007/BF00330652; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; Lee C., UNPUB; LEVINE JD, 1994, NEURON, V13, P967, DOI 10.1016/0896-6273(94)90262-3; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; RUTILA JE, 1992, J NEUROGENET, V8, P101, DOI 10.3109/01677069209084155; SAUNDERS DS, 1994, J INSECT PHYSL, V40, P947; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; Takahashi J S, 1991, Curr Opin Neurobiol, V1, P556, DOI 10.1016/S0959-4388(05)80028-5; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; YOUNG MW, 1989, NEURONAL CELLULAR OS, P529; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZERR DM, 1990, J NEUROSCI, V10, P2749	39	229	236	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1740	1744		10.1126/science.271.5256.1740	http://dx.doi.org/10.1126/science.271.5256.1740			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596938				2022-12-24	WOS:A1996UB15100051
J	Palmer, SR; Biffin, AH; Craig, PS; Walters, TM				Palmer, SR; Biffin, AH; Craig, PS; Walters, TM			Control of hydatid disease in Wales	BRITISH MEDICAL JOURNAL			English	Article							ECHINOCOCCUS-GRANULOSUS; CONTROL SCHEME; DOGS	Objectives-To evaluate the success of the south Powys hydatid control progamme by analysis of trends in cystic disease in humans and sheep and dog infestation. Design-A review of hospital admissions for human hydatid disease in 1984-90, abattoir prevalence surveys of hydatid cysts in adult sheep, arecoline acetarsol and coproantigen surveys of prevalence of Echinococcus infestation in dogs. Setting-All hospitals in England and Wales, three abattoirs, and dog populations in mid and south east Wales. Subjects-Residents of England and Wales admitted to hospital between 1984 and 1990 with a new diagnosis of human hydatid disease (International Classification of Diseases (ICD), ninth revision, code 122) acquired in the United Kingdom. Results-The average annual incidence of human hydatid disease in Powys, mid-Wales, fell from 3.9x10(-5) in 1974-83 to 2.3x10(-5) in 1984-90. Age specific incidence rates in Wales declined over this period only in children, and no cases occurred in children (<15 years) in Powys. Two Welsh children who lived in Gwent and mid-Glamorgan were infected. Prevalence of hydatid cysts in old sheep from south Wales declined during the control period, but in 1993 prevalence of cysts was 13%. Prevalence of E granulosus infestation was zero in the control area in 1993, but it was 2.4% in Powys dogs outside the control area in 1989 and 9.2% in dogs in Gwent in 1991. Conclusions-Human hydatid disease has been successfully controlled in south Powys but cystic echinococcosis is still endemic in sheep in mid-Wales, and there is a focus of infection in humans, sheep, and dogs in the bordering areas of Gwent and mid-Glamorgan. There is considerable potential for an upsurge in human cases if control measures are relaxed.	UNIV SALFORD,DEPT BIOL SCI,SALFORD M5 4WT,LANCS,ENGLAND; HLTH PROMOT UNIT,POWYS HLTH PROMOT,BRECON LD3 0LS,POWYS,WALES	University of Salford	Palmer, SR (corresponding author), CTR COMMUNICABLE DIS SURVEILLANCE,WELSH UNIT,PUBL HLTH LAB SERV,ABTON HOUSE,CARDIFF CF4 3QX,S GLAM,WALES.							ALLAN JC, 1992, PARASITOLOGY, V104, P347, DOI 10.1017/S0031182000061801; BARONET D, 1994, ANN TROP MED PARASIT, V88, P482; CRAIG PS, 1995, VET PARASITOL, V56, P293, DOI 10.1016/0304-4017(94)00680-B; FRNACIS B, 1993, GLIM SYSTEM RELEASE; GEMMELL MA, 1981, FAO UNEP WHO GUIDELI; LLOYD S, 1991, VET REC, V129, P73, DOI 10.1136/vr.129.4.73; PALMER SR, 1987, EPIDEMIOL INFECT, V99, P693, DOI 10.1017/S0950268800066553; SWAN AV, 1991, OXFORD TXB PUBLIC HL, V2; THOMAS TDL, 1966, THESIS LIVERPOOL U; WALTERS TMH, 1986, J SMALL ANIM PRACT, V27, P693, DOI 10.1111/j.1748-5827.1986.tb03769.x; WALTERS TMH, 1992, VET REC, V131, P39, DOI 10.1136/vr.131.2.39; WALTERS TMH, 1978, VET REC, V102, P257, DOI 10.1136/vr.102.12.257; WALTERS TMH, 1980, VET PARASITOL, V7, P185, DOI 10.1016/0304-4017(80)90022-9	13	32	33	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					674	675						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597734	Green Published			2022-12-24	WOS:A1996UB11000024
J	Feher, MD; Simms, JP; Lant, AF				Feher, MD; Simms, JP; Lant, AF			History of chickenpox and steroid cards: A new warning?	BRITISH MEDICAL JOURNAL			English	Article									CHELSEA & WESTMINSTER HOSP,DEPT PHARM,LONDON SW10 9NH,ENGLAND; UNIV LONDON KINGS COLL HOSP,DEPT PHARM,LONDON SW3 6LX,ENGLAND	Imperial College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Feher, MD (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT CLIN PHARMACOL & THERAPEUT,LONDON SW10 9NH,ENGLAND.							*COMM SAF MED, 1994, CURR PROBL PHARM, V20; *DEP HLTH, 1994, CORT VAR ZOST VIR CM; DOWELL SF, 1993, PEDIATRICS, V92, P223; RICE P, 1994, BRIT MED J, V309, P1069, DOI 10.1136/bmj.309.6961.1069	4	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					542	543		10.1136/bmj.312.7030.542	http://dx.doi.org/10.1136/bmj.312.7030.542			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595283	Green Published			2022-12-24	WOS:A1996TY88500023
J	Hurtley, SM				Hurtley, SM			Lysosomal degradation of ubiquitin-tagged receptors	SCIENCE			English	Editorial Material																		GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6	4	3	3	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					617	617		10.1126/science.271.5249.617	http://dx.doi.org/10.1126/science.271.5249.617			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571124				2022-12-24	WOS:A1996TT87000035
J	Bouhnik, Y; Lemann, M; Mary, JY; Scemama, G; Tai, R; Matuchansky, C; Modigliani, R; Rambaud, JC				Bouhnik, Y; Lemann, M; Mary, JY; Scemama, G; Tai, R; Matuchansky, C; Modigliani, R; Rambaud, JC			Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; EXPERIENCE; PREGNANCY; TOXICITY	Background Crohn's ulcerative gastrointestinal disease is presently managed through a variety of medical interventions, including-according to severity of illness-anti-inflammatory, immunosuppressive, and corticosteroid agents; and with remedial surgery to correct anatomical abnormalities caused by disease processes. The immunosuppressant azathioprine (or its metabolite, 6-mercaptopurine) is considered an efficient maintenance therapy for Crohn's, but there is always concern about bone-marrow suppression, liver damage, and other adverse effects. For how long persons with this disease should be given these drugs has not been determined. Methods Patients who were treated with azathioprine or 6-mercaptopurine for more than 6 months, and who were in prolonged clinical remission (>6 months without steroids) were followed. The time-to-relapse was analysed in those on treatment, in those who stopped treatment for reasons other than a relapse, and in the whole sample, taking into account that they could be treated with the drugs or not, as a function of time. The influence of concomitant variables on time-to-relapse rate was examined using the Cox proportional hazard model. Findings In the 157 patients who continued to take the therapy, cumulative probabilities of relapse al 1 and 5 years were 11% and 32% respectively. Female gender, younger age, and a time for achieving remission more than 6 months were associated with a higher risk of relapse. In 42 patients who stopped therapy, probabilities of relapse at 1 and 5 years were 38% and 75%, respectively. Male gender, younger age and duration of remisson less than 4 years were associated with a higher risk of relapse. After 4 years of remission on these drugs, the risk of relapse appeared to be similar, whether the therapy was maintained or stopped. Interpretation Taking into account the potential risks of long-term immunosuppressive therapy, the usefulness of maintaining azathioprine or 6-mercaptopurine in patients who have been in remission for more than 4 years is questionable.	HOP ST LOUIS,SERV GASTROENTEROL,F-75010 PARIS,FRANCE; HOP ST LAZARE,SERV GASTROENTEROL,F-75475 PARIS,FRANCE; UNIV PARIS 07,INSERM,U263,CTR BIOINFORMAT,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite								ALSTEAD EM, 1990, GASTROENTEROLOGY, V99, P443, DOI 10.1016/0016-5085(90)91027-4; ALTMAN DG, 1994, STAT MED, V13, P201; BYAR DP, 1988, CANCER CLIN TRIALS, P382; CONNELL WR, 1994, LANCET, V343, P1249, DOI 10.1016/S0140-6736(94)92150-4; CONNELL WR, 1993, GUT, V34, P1081, DOI 10.1136/gut.34.8.1081; COTTONE M, 1994, GASTROENTEROLOGY, V106, P643, DOI 10.1016/0016-5085(94)90697-1; EWE K, 1993, GASTROENTEROLOGY, V105, P367, DOI 10.1016/0016-5085(93)90709-L; GAUDIER FL, 1988, SURG GYNECOL OBSTET, V167, P533; HARVEY RF, 1980, LANCET, V1, P514; KINLEN LJ, 1985, AM J MED, V78, P44, DOI 10.1016/0002-9343(85)90245-1; KORELITZ BI, 1993, AM J GASTROENTEROL, V88, P1198; LARVOL L, 1994, NEW ENGL J MED, V331, P883, DOI 10.1056/NEJM199409293311321; LEB DE, 1971, ARCH INTERN MED, V128, P441, DOI 10.1001/archinte.128.3.441; LEMANN M, 1990, GASTROEN CLIN BIOL, V14, P548; LENNARDJONES JE, 1981, DIGEST DIS SCI, V77, P364; LILLEYMAN JS, 1994, LANCET, V343, P1188, DOI 10.1016/S0140-6736(94)92400-7; MARKOWITZ J, 1990, GASTROENTEROLOGY, V99, P1347, DOI 10.1016/0016-5085(90)91160-8; NYMAN M, 1985, SCAND J GASTROENTERO, V20, P1197, DOI 10.3109/00365528509089276; OBRIEN JJ, 1991, GASTROENTEROLOGY, V101, P39, DOI 10.1016/0016-5085(91)90457-V; ODONOGHUE DP, 1978, LANCET, V2, P944; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PRESENT DH, 1980, NEW ENGL J MED, V302, P981, DOI 10.1056/NEJM198005013021801; PRESENT DH, 1989, ANN INTERN MED, V111, P641, DOI 10.7326/0003-4819-111-8-641; REIMERS TJ, 1978, SCIENCE, V201, P65, DOI 10.1126/science.663638; SINGLETON JW, 1979, GASTROENTEROLOGY, V77, P870; SUMMERS RW, 1979, GASTROENTEROLOGY, V77, P847; TUCHMANNDUPLESS.H, 1966, CR SOC BIOL, V166, P501	27	405	412	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					215	219		10.1016/S0140-6736(96)90402-X	http://dx.doi.org/10.1016/S0140-6736(96)90402-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551879				2022-12-24	WOS:A1996TT06900008
J	Lambright, DG; Sondek, J; Bohm, A; Skiba, NP; Hamm, HE; Sigler, PB				Lambright, DG; Sondek, J; Bohm, A; Skiba, NP; Hamm, HE; Sigler, PB			The 2.0 angstrom crystal structure of a heterotrimeric G protein	NATURE			English	Article							GAMMA SUBUNITS CONTAIN; ROD OUTER SEGMENTS; ALPHA-SUBUNIT; BETA-GAMMA; SIGNAL TRANSDUCTION; LIPID MODIFICATIONS; AMINO TERMINUS; GTP-BINDING; PHOSPHODIESTERASE; IDENTIFICATION	The structure of a heterotrimeric G protein reveals the mechanism of the nucleotide-dependent engagement of the alpha and beta gamma subunits that regulates their interaction with receptor and effector molecules. The interaction involves two distinct interfaces and dramatically alters the conformation of the alpha but not of the beta gamma subunits. The location of the known sites for post-translational modification and receptor coupling suggest a plausible orientation with respect to the membrane surface and an activated heptahelical receptor.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60680	Yale University; Howard Hughes Medical Institute; Yale University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Hamm, Heidi E/G-2374-2014	Sondek, John/0000-0002-1127-8310				BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; BRUNGER A, 1993, X PLOR VERSION 3 1 M; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GarciaHiguera I, 1996, J BIOL CHEM, V271, P528, DOI 10.1074/jbc.271.1.528; GRAF R, 1992, J BIOL CHEM, V267, P24307; GRISHIN AV, 1994, MOL CELL BIOL, V14, P4571, DOI 10.1128/MCB.14.7.4571; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIRSCH JP, 1991, GENE DEV, V5, P467, DOI 10.1101/gad.5.3.467; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEE E, 1992, J BIOL CHEM, V267, P1212; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MAZZONI MR, 1989, BIOCHEMISTRY-US, V28, P9873, DOI 10.1021/bi00451a047; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PFISTER C, 1993, CELL SIGNAL, V5, P235, DOI 10.1016/0898-6568(93)90015-E; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STRYER L, 1983, METHOD ENZYMOL, V96, P617; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WEST RE, 1985, J BIOL CHEM, V260, P4428; WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	56	1006	1028	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					311	319		10.1038/379311a0	http://dx.doi.org/10.1038/379311a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552184				2022-12-24	WOS:A1996TR32300049
J	Vescovi, EG; Soncini, FC; Groisman, EA				Vescovi, EG; Soncini, FC; Groisman, EA			Mg2+ as an extracellular signal: Environmental regulation of Salmonella virulence	CELL			English	Article							ESCHERICHIA-COLI; MAGNESIUM-METABOLISM; EPITHELIAL-CELLS; TYPHIMURIUM; EXPRESSION; TRANSPORT; PROTEINS; BACTERIA; GENE; MACROPHAGES	Ions are not traditionally thought to act as first messengers in signal transduction cascades. However, while searching for genes regulated by the PhoP/PhoQ virulence regulatory system of Salmonella typhimurium, we recovered two loci whose expression is controlled by the concentration of Mg2+. To determine whether Mg2+ is the signal modulating the whole PhoP/ phoQ system, we evaluated the gene expression pattern of six PhoP-activated genes. Growth in physiological concentrations of divalent cations repressed transcription of PhoP-activated genes and rendered wild-type Salmonella phenotypically PhoP(-). Mg2+ changed the conformation of the periplasmic domain of phoQ, identifying this protein as a Mg2+ sensor. A mutation in the sensing domain of phoQ altered the set point for Mg2+ and rendered Salmonella avirulent.			Vescovi, EG (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA.			Soncini, Fernando/0000-0002-8925-7763; Garcia Vescovi, Eleonora/0000-0002-4431-8606	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029554] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIBA H, 1983, CELL, V32, P141, DOI 10.1016/0092-8674(83)90504-4; ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; ALPUCHEARANDA CM, 1994, J EXP MED, V179, P601, DOI 10.1084/jem.179.2.601; ARANDA CMA, 1992, P NATL ACAD SCI USA, V89, P10079, DOI 10.1073/pnas.89.21.10079; BEHLAU I, 1993, J BACTERIOL, V175, P4475, DOI 10.1128/JB.175.14.4475-4484.1993; Bergmeyer H. U., 1974, METHODS ENZYMATIC AN; Brown Edward M., 1994, P15; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Davis R., 1980, ADV BACTERIAL GENETI; DZIEJMAN M, 1995, 2 COMPONENT SIGNAL T, P305; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FOSTER JW, 1990, J BACTERIOL, V172, P771, DOI 10.1128/jb.172.2.771-778.1990; GARCIADELPORTILLO F, 1992, MOL MICROBIOL, V6, P3289, DOI 10.1111/j.1365-2958.1992.tb02197.x; GROISMAN EA, 1992, J BACTERIOL, V174, P486, DOI 10.1128/jb.174.2.486-491.1992; GROISMAN EA, 1992, P NATL ACAD SCI USA, V89, P11939, DOI 10.1073/pnas.89.24.11939; GROISMAN EA, 1995, 2 COMPONENT SIGNAL T, P319, DOI DOI 10.1128/9781555818319; HEBERT SC, 1995, CURR OPIN CELL BIOL, V7, P484, DOI 10.1016/0955-0674(95)80004-2; KIER LD, 1979, J BACTERIOL, V138, P155, DOI 10.1128/JB.138.1.155-161.1979; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; Miller JH, 1972, EXPT MOL GENETICS; MILLER SI, 1990, J BACTERIOL, V172, P2485, DOI 10.1128/jb.172.5.2485-2490.1990; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; NEEDHAM JV, 1993, BIOCHEMISTRY-US, V32, P3363, DOI 10.1021/bi00064a020; NORRIS V, 1991, MOL MICROBIOL, V5, P775, DOI 10.1111/j.1365-2958.1991.tb00748.x; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; POLLACK C, 1986, NATURE, V322, P834, DOI 10.1038/322834a0; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; RATHMAN M, 1995, 95TH GEN M WASH; REINHART RA, 1988, ARCH INTERN MED, V148, P2415, DOI 10.1001/archinte.148.11.2415; ROOF SK, 1994, J AM COLL NUTR, V13, P424; Sambrook J., 1989, MOL CLONING LAB MANU; SANDERSON KE, 1995, MICROBIOL REV, V59, P241, DOI 10.1128/MMBR.59.2.241-303.1995; SILVER S, 1971, J BIOL CHEM, V246, P569; SMITH DL, 1993, MINER ELECTROL METAB, V19, P266; SNAVELY MD, 1991, J BIOL CHEM, V266, P824; SONCINI FC, 1995, J BACTERIOL, V177, P4364, DOI 10.1128/jb.177.15.4364-4371.1995; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; STRALEY SC, 1993, MOL MICROBIOL, V8, P1005, DOI 10.1111/j.1365-2958.1993.tb01644.x; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; VESCOVI EG, 1994, RES MICROBIOL, V145, P473, DOI 10.1016/0923-2508(94)90096-5; VOLZ K, 1991, J BIOL CHEM, V266, P15511; WICK MJ, 1995, MOL MICROBIOL, V16, P465, DOI 10.1111/j.1365-2958.1995.tb02411.x	47	628	641	2	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	1996	84	1					165	174		10.1016/S0092-8674(00)81003-X	http://dx.doi.org/10.1016/S0092-8674(00)81003-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548821	Bronze			2022-12-24	WOS:A1996TQ17000019
J	Billups, B; Attwell, D				Billups, B; Attwell, D			Modulation of non-vesicular glutamate release by pH	NATURE			English	Article							RAT-BRAIN; GLIAL-CELLS; TRANSPORTER; ASPARTATE; SALAMANDER; ISCHEMIA; RETINA; HIPPOCAMPUS; EXPRESSION; MEMBRANE	GLUTAMATE uptake into glial cells helps to keep the brain extracellular glutamate concentration, [glu](0), below levels that kill neurons. Uptake is powered(1-4) by the transmembrane gradients of Na+, K+ and pH. When the extracellular [K+] rises in brain ischaemia, uptake reverses, releasing glutamate into the extracellular space(5,6). Here we show, by monitoring glutamate transport electrically and detecting released glutamate with ion channels in neurons placed outside glial cells, that a raised [Hf] inhibits both forward and reversed glutamate uptake. No electroneutral reversed uptake was detected, contradicting the idea(7) that forward and reversed uptake differ fundamentally. Suppression of reversed uptake by the low pH occurring in ischaemia(8,9) will slow the Ca2+-independent release of glutamate(10) which can raise [glu], to a neurotoxic level(11,12), and will thus protect the brain during a transient loss of blood supply.			Billups, B (corresponding author), UCL, DEPT PHYSIOL, GOWER ST, LONDON WC1E 6BT, ENGLAND.		Attwell, David/ABE-6750-2020	Billups, Brian/0000-0001-5378-2809	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Attwell David, 1994, Current Opinion in Neurobiology, V4, P353, DOI 10.1016/0959-4388(94)90096-5; BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; ELIASOF S, 1993, J NEUROSCI, V13, P402; ERECINSKA M, 1983, J BIOL CHEM, V258, P9069; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; IKEDA M, 1989, NEUROSCI LETT, V96, P202, DOI 10.1016/0304-3940(89)90058-X; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; LORD RSA, 1990, AUST NZ J OPHTHALMOL, V18, P299, DOI 10.1111/j.1442-9071.1990.tb00624.x; MADL JE, 1993, J NEUROSCI, V13, P4429; MOBBS P, 1988, BRAIN RES, V460, P235, DOI 10.1016/0006-8993(88)90368-X; MUTCH WAC, 1984, J CEREBR BLOOD F MET, V4, P17, DOI 10.1038/jcbfm.1984.3; NADEAU SE, 1994, J FAM PRACTICE, V38, P495; NELSON PJ, 1983, BIOCHEMISTRY-US, V22, P5459, DOI 10.1021/bi00292a030; NEWMAN EA, 1984, J NEUROPHYSIOL, V51, P164, DOI 10.1152/jn.1984.51.1.164; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; SARANTIS M, 1988, NATURE, V332, P451, DOI 10.1038/332451a0; SCHWARTZ EA, 1990, J PHYSIOL-LONDON, V426, P43, DOI 10.1113/jphysiol.1990.sp018126; SCHWARTZ EA, 1993, NEURON, V10, P1141, DOI 10.1016/0896-6273(93)90062-V; SILVER IA, 1992, J CEREBR BLOOD F MET, V12, P759, DOI 10.1038/jcbfm.1992.107; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; TRAYNELIS SF, 1990, NATURE, V345, P347, DOI 10.1038/345347a0; YAMADA KA, 1993, J NEUROSCI, V13, P3904	30	128	132	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	1996	379	6561					171	174		10.1038/379171a0	http://dx.doi.org/10.1038/379171a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538768				2022-12-24	WOS:A1996TP36000060
J	Pier, GB; Grout, M; Zaidi, TS; Olsen, JC; Johnson, LG; Yankaskas, JR; Goldberg, JB				Pier, GB; Grout, M; Zaidi, TS; Olsen, JC; Johnson, LG; Yankaskas, JR; Goldberg, JB			Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections	SCIENCE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; AERUGINOSA STRAIN PAO; PSEUDOMONAS-AERUGINOSA; DEFECTIVE-MUTANTS; EPITHELIAL-CELLS; LIPOPOLYSACCHARIDE; SURFACE; LOCALIZATION; POLYSACCHARIDE	Cystic fibrosis (CF) patients are hypersusceptible to chronic Pseudomonas aeruginosa lung infections. Cultured human airway epithelial cells expressing the Delta F508 allele of the cystic fibrosis transmembrane conductance regulator (CFTR) were defective in uptake of P. aeruginosa compared with cells expressing the wild-type allele. Pseudomonas aeruginosa lipopolysaccharide (LPS)-core oligosaccharide was identified as the bacterial ligand for epithelial cell ingestion; exogenous oligosaccharide inhibited bacterial ingestion in a neonatal mouse model, resulting In Increased amounts of bacteria in the lungs. CFTR may contribute to a host-defense mechanism that is important for clearance of P. aeruginosa from the respiratory tract.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; UNIV N CAROLINA,DEPT MED,DIV PULM DIS,CHAPEL HILL,NC 27599	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill	Pier, GB (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CHANNING LAB,180 LONGWOOD AVE,BOSTON,MA 02115, USA.		Pier, Gerald/AAO-2692-2021	Pier, Gerald/0000-0002-9112-2331	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042384, R01HL058398] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022806, R01AI035674] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42384, R01 HL058398] Funding Source: Medline; NIAID NIH HHS [AI35674, AI22806] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARONSON M, 1988, INFECT IMMUN, V56, P1615, DOI 10.1128/IAI.56.6.1615-1617.1988; BALTIMORE RS, 1989, AM REV RESPIR DIS, V140, P1650, DOI 10.1164/ajrccm/140.6.1650; CERVIN MA, 1994, MICROB PATHOGENESIS, V17, P291, DOI 10.1006/mpat.1994.1075; COYNE MJ, 1994, J BACTERIOL, V176, P3500, DOI 10.1128/JB.176.12.3500-3507.1994; DALAL E, 1994, INFECT IMMUN, V62, P5505, DOI 10.1128/IAI.62.12.5505-5510.1994; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; EVANS DJ, 1994, MOL MICROBIOL, V13, P427, DOI 10.1111/j.1365-2958.1994.tb00437.x; FLEISZIG SMJ, 1995, INFECT IMMUN, V63, P4072, DOI 10.1128/IAI.63.10.4072-4077.1995; GOLDBERG JB, 1992, P NATL ACAD SCI USA, V89, P10716, DOI 10.1073/pnas.89.22.10716; GROUT M, UNPUB; HANCOCK REW, 1983, INFECT IMMUN, V42, P170, DOI 10.1128/IAI.42.1.170-177.1983; IMUNDO L, 1995, P NATL ACAD SCI USA, V92, P3019, DOI 10.1073/pnas.92.7.3019; JARRELL K, 1977, MICROBIOS, V19, P103; JEFFERY PK, 1988, SCANNING MICROSCOPY, V2, P553; KOVAL SF, 1977, J GEN MICROBIOL, V98, P387, DOI 10.1099/00221287-98-2-387; KROPINSKI AM, 1979, CAN J MICROBIOL, V25, P390, DOI 10.1139/m79-060; LAM J, 1980, INFECT IMMUN, V28, P546; MAHENTHIRALINGAM E, 1994, INFECT IMMUN, V62, P596, DOI 10.1128/IAI.62.2.596-605.1994; NELSON JW, 1990, INFECT IMMUN, V58, P1489, DOI 10.1128/IAI.58.6.1489-1495.1990; OHMAN DE, 1990, PSEUDOMONAS : BIOTRANSFORMATIONS, PATHOGENESIS, AND EVOLVING BIOTECHNOLOGY, P28; OLSEN JC, 1992, HUM GENE THER, V3, P253, DOI 10.1089/hum.1992.3.3-253; ORIKASA S, 1977, INVEST UROL, V15, P185; PENKETH A, 1983, AM REV RESPIR DIS, V127, P605, DOI 10.1164/arrd.1983.127.5.605; PIER GB, 1978, INFECT IMMUN, V22, P908, DOI 10.1128/IAI.22.3.908-918.1978; PIER GB, 1986, J CLIN MICROBIOL, V24, P189, DOI 10.1128/JCM.24.2.189-196.1986; PLOTKOWSKI MC, 1992, J MED MICROBIOL, V36, P104, DOI 10.1099/00222615-36-2-104; ROWE PSN, 1983, EUR J BIOCHEM, V132, P329, DOI 10.1111/j.1432-1033.1983.tb07366.x; SAIMAN L, 1993, J CLIN INVEST, V92, P1875, DOI 10.1172/JCI116779; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SCHWAN ET, 1995, MOL MICROBIOL, V15, P267, DOI 10.1111/j.1365-2958.1995.tb02241.x; TANG H, 1995, INFECT IMMUN, V63, P1278, DOI 10.1128/IAI.63.4.1278-1285.1995; ZAR H, 1995, J PEDIATR-US, V126, P230, DOI 10.1016/S0022-3476(95)70549-X	34	322	334	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 5	1996	271	5245					64	67		10.1126/science.271.5245.64	http://dx.doi.org/10.1126/science.271.5245.64			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539601	Green Submitted, Green Accepted			2022-12-24	WOS:A1996TP02200043
J	Hiss, RG; Greenfield, S				Hiss, RG; Greenfield, S			Forum three: Changes in the US health care system that would facilitate improved care for non-insulin-dependent diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat				At the conclusion of the conference detailed in this supplement, conference attendees participated in one of three fora to discuss an assigned topic and incorporate conference presentations into the discussion. Forum Three, the results of which are reported here, addressed the challenging question of what changes in the U.S. health care system would facilitate improved care for patients with non-insulin-dependent diabetes mellitus (NIDDM). Using the nominal group process-a discussion technique designed to obtain a rank-ordered list of responses to the challenge question from a group of informed persons-forum Three made the following priority recommendations: 1) Establish universal access to the comprehensive preventive services necessary to optimally manage the estimated 16 million Americans with NIDDM; 2) create a system of co-management between primary and specialty care services; and 3) modify the current health care system to include a program for increased patient and public awareness of the seriousness of NIDDM, special training for primary care residents and practicing physicians in this area, development of standards of care, creation of a central coordinating agency for all aspects of diabetes care, and development of outcome-based goals for patients and providers.	TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA; UNIV MICHIGAN, MED CTR, ANN ARBOR, MI USA	Tufts Medical Center; University of Michigan System; University of Michigan				Greenfield, Sheldon/0000-0003-4628-1998				BARONDESS JA, 1993, ANN INTERN MED, V119, P153, DOI 10.7326/0003-4819-119-2-199307150-00010; DELBECQ AL, 1971, J APPL BEHAV SCI, V7, P466, DOI 10.1177/002188637100700404; FISHER EB, 1994, NIH943773 NAT I DIAB, P101; GREENFIELD S, 1995, MED CARE, V33, pAS47; GREENFIELD S, IN PRESS JAMA; HISS RG, 1994, DIABETES REV, V2, P310; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; 1989, NIH892925 US DEP HLT; 1976, DHEW781086 NAT HEART; 1976, DHEW761018 US DEP HL; 1995, DIABETES CARE S1, V18, P1	11	14	14	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				180	183		10.7326/0003-4819-124-1_Part_2-199601011-00021	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00021			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554216				2022-12-24	WOS:A1996TL94400021
J	Thanos, D; Maniatis, T				Thanos, D; Maniatis, T			Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome	CELL			English	Article							FACTOR-BINDING-SITES; NF-KAPPA-B; REGULATORY ELEMENTS; INTERFERON GENE; ACTIVATION; PROMOTER; IRF-1; TRANSCRIPTION; DOMAINS; CELLS	We present evidence that transcriptional activation of the human interferon-beta (IFN beta) gene requires the assembly of a higher order transcription enhancer complex (enhanceosome). This multicomponent complex includes at least three distinct transcription factors and the high mobility group protein HMG I(Y). Both the in vitro assembly and in vivo transcriptional activity of this complex require a precise helical relationship between individual transcription factor-binding sites. In addition, HMG I(Y), which binds specifically to three sites within the enhancer, promotes cooperative binding of transcription factors in vitro and is required for transcriptional synergy between these factors in vivo. Thus, HMG I(Y) plays an essential role in the assembly and function of the IFN beta gene enhanceosome.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University			Li, Yapeng/N-1042-2017; Thanos, Dimitris/AAE-5720-2019	Li, Yapeng/0000-0002-5042-6881; 	NIAID NIH HHS [AI20642] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020642, R37AI020642] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABEL T, 1992, GENE DEV, V6, P466, DOI 10.1101/gad.6.3.466; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CORBIN V, 1990, GENETICS, V124, P637; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GONZALEZCRESPO S, 1994, SCIENCE, V264, P255, DOI 10.1126/science.8146656; GOODBOURN S, 1985, CELL, V41, P509, DOI 10.1016/S0092-8674(85)80024-6; GOTO T, 1989, CELL, V57, P413, DOI 10.1016/0092-8674(89)90916-1; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MCKINIGHT SL, 1982, TRANSCRIPTIONAL REGU; MCKNIGHT SL, 1982, CELL, V31, P355, DOI 10.1016/0092-8674(82)90129-5; MEACOCK S, 1994, J BIOL CHEM, V269, P31756; Miller J.H., 1972, EXPT MOL GENETICS; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; ONDEK B, 1988, NATURE, V333, P42; PEREZMARTIN J, 1994, MICROBIOL REV, V58, P268; PTASHNE M, 1992, GENETIC SWITCH GENE; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SZYMANSKI K, 1995, EMBO J, V10, P2229; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THANOS D, 1993, COLD SPRING HARB SYM, V58, P733; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WINDLE JJ, 1986, MOL CELL BIOL, V6, P4585, DOI 10.1128/MCB.6.12.4585; WU L, 1988, GENE DEV, V2, P403, DOI 10.1101/gad.2.4.403; XIE WQ, 1992, MOL CELL BIOL, V12, P1266, DOI 10.1128/MCB.12.3.1266	53	846	853	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1091	1100		10.1016/0092-8674(95)90136-1	http://dx.doi.org/10.1016/0092-8674(95)90136-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548797	Bronze			2022-12-24	WOS:A1995TM76200006
J	LOUKERIS, TG; LIVADARAS, I; ARCA, B; ZABALOU, S; SAVAKIS, C				LOUKERIS, TG; LIVADARAS, I; ARCA, B; ZABALOU, S; SAVAKIS, C			GENE-TRANSFER INTO THE MEDFLY, CERATITIS-CAPITATA, WITH A DROSOPHILA-HYDEI TRANSPOSABLE ELEMENT	SCIENCE			English	Article							MEDITERRANEAN FRUIT-FLY; TRANSFORMATION; GENOME	Exogenous functional DNA was introduced into the germline chromosomes of the Mediterranean fruit fly (medfly) Ceratitis capitata with a germline transformation system based on the transposable element Mines from Drosophila hydei. Transformants were identified as phenotypic revertants of a white-eyed mutation carried by the recipient strain. Clusters of transformants were detected among the progeny of 390 individuals screened for germline transformation. Five independent and phenotypically active integration events were identified, in each of which a single copy of the transposon was inserted into a different site of the medfly genome. Molecular analysis indicates that they represent transposase-mediated insertions of the transposon into medfly chromosomes.	FDN RES & TECHNOL HELLAS,INST MOLEC BIOL & BIOTECHNOL,GR-71110 CRETE,GREECE; UNIV CRETE,SCH MED,DIV BASIC MED SCI,CRETE,GREECE	Foundation for Research & Technology - Hellas (FORTH); University of Crete			Savakis, Babis/D-3633-2009; Arca, Bruno/C-8383-2012	Arca, Bruno/0000-0002-4029-0984				ARCA B, UNPUB; BLACKMAN RK, 1989, EMBO J, V8, P211, DOI 10.1002/j.1460-2075.1989.tb03366.x; CAREY JR, 1991, SCIENCE, V253, P1369, DOI 10.1126/science.1896848; FINNEGAN DJ, 1989, TRENDS GENET, V5, P103, DOI 10.1016/0168-9525(89)90039-5; FRANZ G, 1991, NUCLEIC ACIDS RES, V19, P6646, DOI 10.1093/nar/19.23.6646; FRANZ G, 1994, P NATL ACAD SCI USA, V91, P4746, DOI 10.1073/pnas.91.11.4746; KNIPLING EF, 1959, SCIENCE, V130, P902, DOI 10.1126/science.130.3380.902; LIDHOLM DA, 1993, GENETICS, V134, P859; LIVADARAS I, UNPUB; LOUIS C, 1987, FRUITFLIES, P47; LOUKERIS TG, 1995, P NATL ACAD SCI USA, V92, P9485, DOI 10.1073/pnas.92.21.9485; LOUKERIS TG, UNPUB; MILLER LH, 1987, SCIENCE, V237, P779, DOI 10.1126/science.3039658; MINTZAS AC, 1983, DEV BIOL, V95, P492, DOI 10.1016/0012-1606(83)90051-9; MORRIS AC, 1989, MED VET ENTOMOL, V3, P1, DOI 10.1111/j.1365-2915.1989.tb00467.x; OBROCHTA DA, 1994, MOL GEN GENET, V244, P9, DOI 10.1007/BF00280181; Robertson H.M., 1993, Insect Molecular Biology, V2, P125, DOI 10.1111/j.1365-2583.1993.tb00132.x; ROBERTSON HM, 1995, ANNU REV ENTOMOL, V40, P333, DOI 10.1146/annurev.en.40.010195.002001; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; ZACHAROPOULOU A, 1992, CHROMOSOMA, V101, P448, DOI 10.1007/BF00582839; ZACHAROPOULOU A, 1990, GENOME, V33, P184, DOI 10.1139/g90-030; ZWIEBEL LJ, 1995, SCIENCE, V270, P2005, DOI 10.1126/science.270.5244.2005	22	241	269	1	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					2002	2005		10.1126/science.270.5244.2002	http://dx.doi.org/10.1126/science.270.5244.2002			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533094				2022-12-24	WOS:A1995TL42000045
J	Allen, K; Blascovich, J				Allen, K; Blascovich, J			The value of service dogs for people with severe ambulatory disabilities - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SOCIAL ACKNOWLEDGMENTS; DEPRESSION; STRESS; CHILDREN; SUPPORT	Objective.-To assess the value of service dogs for people with ambulatory disabilities. Design.-Randomized, controlled clinical trial. Setting.-Environments of study participants. Participants.-Forty-eight individuals with severe and chronic ambulatory disabilities requiring use of wheelchairs who were recruited from advocacy and support groups for persons with muscular dystrophy, multiple sclerosis, traumatic brain injury, and spinal cord injury. Participants were matched on age, sex, marital status, race, and the nature and severity of the disability in order to create 24 pairs. Within each pair, participants were randomly assigned to either the experimental group or a wait-list control group. Intervention.-Experimental group members received trained-service dogs 1 month after the study began, and subjects in the wait-list control group received dogs in month 13 of the study. Main Outcome Measures.-Dependent variables evaluated were self-reported assessments of psychological well-being, internal locus of control, community integration, school attendance, part-time work status, self-esteem, marital status, living arrangements, and number of biweekly paid and unpaid assistance hours. Data collection occurred every 6 months over a 2-year period, resulting in five data collection points for all subjects. Results.-Significant positive changes in all but two dependent measures were associated with the presence of a service dog both between and within groups (P<.001). Psychologically, all participants showed substantial improvements in self-esteem, internal locus of control, and psychological well-being within 6 months after receiving their service dog. Socially, all participants showed similar improvements in community integration. Demographically, all participants showed increases in school attendance and/or part-time employment. Economically, all participants showed dramatic decreases in the number of both paid and unpaid assistance hours. Conclusions.-Trained service dogs can be highly beneficial and potentially cost-effective components of independent living for people with physical disabilities.	SUNY BUFFALO,DEPT MED,BUFFALO,NY; UNIV CALIF SANTA BARBARA,DEPT PSYCHOL,SANTA BARBARA,CA 93106	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of California System; University of California Santa Barbara								ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; ALLEN KM, 1991, J PERS SOC PSYCHOL, V61, P582, DOI 10.1037/0022-3514.61.4.582; Americans with Disabilities Act, SPRINGER REFERENCE, DOI [10.1007/springerreference_44126, DOI 10.1007/SPRINGERREFERENCE_44126]; BATAVIA AI, 1991, J HEALTH POLIT POLIC, V16, P523, DOI 10.1215/03616878-16-3-523; Bradburn NM, 1969, STRUCTURE PSYCHOL WE; *CAN COMP IND, 1994, CAN COMP IND PROGR I; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; EATON L, 1994, NY TIMES        0911, P1; EDDY J, 1988, J PSYCHOL, V122, P39, DOI 10.1080/00223980.1988.10542941; EISENBERG MG, 1982, DISABLED PEOPLE 2 CL; FITZPATRICK R, 1991, SOC SCI MED, V33, P605, DOI 10.1016/0277-9536(91)90218-2; FRIEDLAND J, 1992, SOC SCI MED, V34, P395, DOI 10.1016/0277-9536(92)90299-6; HARTMANN C, 1988, Biofactors, V1, P41; KEENAN MP, 1989, CHANGING NEEDS LONG; KINNEY WB, 1992, ARCH PHYS MED REHAB, V73, P863; Kirk R.E., 2012, EXPT DESIGN PROCEDUR, P23; LAPLANTE MP, 1989, 1 U CAL I HLTH AG; LITVAK SIMI, 1987, ATTENDING AM PERSONA; MADER B, 1989, CHILD DEV, V60, P1529, DOI 10.1111/j.1467-8624.1989.tb04023.x; MARINELLI RP, 1977, PSYCHOL SOCIAL IMPAC; PAULHUS D, 1983, J PERS SOC PSYCHOL, V44, P1253, DOI 10.1037/0022-3514.44.6.1253; Rosenberg M., 1965, MEASUREMENT SELF EST, DOI [10.1515/9781400876136, DOI 10.1515/9781400876136]; TURNER RJ, 1990, J NERV MENT DIS, V178, P343, DOI 10.1097/00005053-199006000-00001; VALENTINE DP, 1993, SOC WORK HEALTH CARE, V19, P109, DOI 10.1300/J010v19n01_07; VARNI JW, 1991, ARCH PHYS MED REHAB, V72, P1053; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; *WORLD I DIS, 1988, REP NAT COUNC HAND M	27	106	107	1	53	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					1001	1006		10.1001/jama.275.13.1001	http://dx.doi.org/10.1001/jama.275.13.1001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UC123	8596231				2022-12-24	WOS:A1996UC12300027
J	Riddington, DW; Venkatesh, B; Boivin, CM; Bonser, RS; Elliot, TSJ; Marshall, T; Mountford, PJ; Bion, JF				Riddington, DW; Venkatesh, B; Boivin, CM; Bonser, RS; Elliot, TSJ; Marshall, T; Mountford, PJ; Bion, JF			Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFLAMMATORY BOWEL-DISEASE; TUMOR NECROSIS FACTOR; GASTROINTESTINAL COMPLICATIONS; CARDIAC OPERATIONS; INTRAMURAL PH; LUNG INJURY; MULTIPLE; ISCHEMIA; HYPOPERFUSION; ABSORPTION	Objective.-To examine the relationship between gastric intramucosal pH, intestinal permeability, endotoxemia, and oxygen delivery in patients undergoing cardiopulmonary bypass (CPB). Design.-Prospective, observational study. Setting.-Tertiary care center. Patients.-Fifty patients undergoing elective cardiac surgery and 10 patients awaiting elective cardiac surgery. Interventions.-Patients received chromium 51-labeled ethylenediaminetetraacetic acid (Cr-51-EDTA) as a marker of intestinal permeability; insertion of a nasogastric tonometer to measure intramucosal pH (pHi); insertion of a pulmonary artery catheter to measure systemic oxygen delivery and consumption variables; arterial blood sampling for plasma endotoxin by the Limulus amebocyte lysate assay; and blood and urine sampling for measurement of Cr-51-EDTA. Main Outcome Measures.-Systemic oxygen delivery, duration of gastric mucosal acidosis, absorption of Cr-51-EDTA, appearance of systemic endotoxemia, renal dysfunction, and duration of hospital stay. Results.-Median (range) 24-hour urinary recovery of Cr-51-EDTA in patients was 10.6% (2.1% to 40.2%) while that in controls was 1.2% (0.7% to 2.0%, P<.001). Intestinal permeability increased during CPB. The median (range) for the lowest pHi after bypass was 6.98 (6.74 to 7.17). The pHi did not decline until CPB was discontinued and the heart took over the load of the circulation. Endotoxin was detectable (>0.2 endotoxin unit per milliliter) in the plasma of 21 patients (42%) during the study, most of whom were endotoxemic by the end of CPB. There was no evident relationship between the degree of gut permeability, endotoxemia, gut ischemia, or systemic oxygen dynamics. Conclusions.-Cardiopulmonary bypass is associated with increases in gut permeability, which precede gut mucosal ischemia. In cardiac surgical patients, a low pHi is not necessarily indicative of an adverse clinical outcome. Endotoxemia as measured by the Limulus amebocyte lysate assay is common. The increased intestinal absorption of Cr-51-EDTA and gastric mucosal acidosis occur as independent phenomena and are not related in severity or time of onset.	UNIV BIRMINGHAM, DEPT ANAESTHESIA & INTENS CARE MED, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; QUEEN ELIZABETH HOSP, DEPT NUCL MED, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND; QUEEN ELIZABETH HOSP, DEPT MED MICROBIOL, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND; QUEEN ELIZABETH HOSP, CARDIOTHORAC SURG UNIT, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND	University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham			Venkatesh, Bala/F-4700-2010	Bion, Julian/0000-0003-0344-5403; Venkatesh, Bala/0000-0002-3234-5244				AABAKKEN L, 1989, SCAND J GASTROENTERO, V24, P351, DOI 10.3109/00365528909093059; Altman DG, 1991, PRACTICAL STAT MED R, P426; ANDERSEN LW, 1987, J THORAC CARDIOV SUR, V93, P115; BAUE AE, 1975, ARCH SURG-CHICAGO, V110, P779; BERTHIAUME F, 1994, CRIT CARE MED, V22, P455, DOI 10.1097/00003246-199403000-00016; BION JF, 1994, CRIT CARE MED, V22, P40, DOI 10.1097/00003246-199401000-00011; BJARNASON I, 1983, GASTROENTEROLOGY, V85, P318; CARRICO CJ, 1986, ARCH SURG-CHICAGO, V121, P196; DEITCH EA, 1990, ARCH SURG-CHICAGO, V125, P403; DINARELLO CA, 1986, J CLIN INVEST, V77, P1734, DOI 10.1172/JCI112495; ELIA M, 1987, CLIN SCI, V73, P197, DOI 10.1042/cs0730197; FIDDIANGREEN RG, 1987, CRIT CARE MED, V15, P153, DOI 10.1097/00003246-198702000-00015; FIDDIANGREEN RG, 1986, ARCH SURG-CHICAGO, V121, P654; FINE J, 1967, GASTROENTEROLOGY, V52, P454; FINK MP, 1991, ARCH SURG-CHICAGO, V126, P211; FONG YM, 1989, J IMMUNOL, V142, P2321; GIRAUD GD, 1984, J PHARMACOL EXP THER, V230, P214; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K; HEARD SO, 1991, CRIT CARE MED, V19, P271, DOI 10.1097/00003246-199102000-00025; HOWDEN CW, 1991, AM J GASTROENTEROL, V86, P1445; KOIKE K, 1992, SURGERY, V112, P173; MARIK PE, 1993, CHEST, V104, P225, DOI 10.1378/chest.104.1.225; MARTINEZPELLUS AE, 1993, CRIT CARE MED, V21, P1684, DOI 10.1097/00003246-199311000-00017; METCHNIKOFF E, 1908, STUDIES OPPORTUNISTI, P309; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MONETA GL, 1985, AM J SURG, V149, P648, DOI 10.1016/S0002-9610(85)80148-3; NATANSON C, 1989, J EXP MED, V169, P823, DOI 10.1084/jem.169.3.823; OHRI SK, 1991, ANN THORAC SURG, V52, P826, DOI 10.1016/0003-4975(91)91219-L; OHRI SK, 1994, GASTROENTEROLOGY, V106, P318, DOI 10.1016/0016-5085(94)90588-6; PAPA M, 1983, J SURG RES, V35, P264, DOI 10.1016/S0022-4804(83)80013-4; PARSONNET V, 1989, CIRCULATION, V79, P3; PRINS JM, 1994, ANTIMICROB AGENTS CH, V38, P1211, DOI 10.1128/AAC.38.6.1211; RIDDINGTON D, 1994, CRIT CARE MED, V22, P96, DOI 10.1097/00003246-199401000-00019; RIDDINGTON D, 1992, LANCET, V340, P547, DOI 10.1016/0140-6736(92)91742-Q; RIDDINGTON DW, 1994, NUCL MED COMMUN, V15, P257; SOONG CV, 1995, BRIT J SURG, V82, P912, DOI 10.1002/bjs.1800820718; STJOHN RC, 1993, J APPL PHYSIOL, V74, P1994, DOI 10.1152/jappl.1993.74.4.1994; VANDERHULST RRWJ, 1993, LANCET, V341, P1363, DOI 10.1016/0140-6736(93)90939-E; WELLING RE, 1986, ARCH SURG-CHICAGO, V121, P1178; WYATT J, 1993, LANCET, V341, P1437, DOI 10.1016/0140-6736(93)90882-H	40	197	203	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					1007	1012		10.1001/jama.275.13.1007	http://dx.doi.org/10.1001/jama.275.13.1007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC123	8596232				2022-12-24	WOS:A1996UC12300028
J	Skaggs, WE; McNaughton, BL				Skaggs, WE; McNaughton, BL			Replay of neuronal firing sequences in rat hippocampus during sleep following spatial experience	SCIENCE			English	Article							LONG-TERM POTENTIATION; RABBIT FOLLOWING STIMULATION; COMPLEX-SPIKE CELLS; FREELY-MOVING RAT; LASTING POTENTIATION; SYNAPTIC TRANSMISSION; PERFORANT PATH; UNIT-ACTIVITY; THETA-RHYTHM; DENTATE GYRUS	The correlated activity of rat hippocampal pyramidal cells during sleep reflects the activity of those cells during earlier spatial exploration. Now the patterns of activity during sleep have also been found to reflect the order in which the cells fired during spatial exploration. this relation was reliably stronger for sleep after the behavioral session than before it; thus, the activity during sleep reflects changes produced by experience, This memory for temporal order of neuronal firing could be produced by an interaction between the temporal integration properties of long-term potentiation and the phase shifting of spike activity with respect to the hippocampal theta rhythm.			Skaggs, WE (corresponding author), UNIV ARIZONA, ARIZONA RES LABS, DIV NEURAL SYST MEMORY & AGING, TUCSON, AZ 85724 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH046823, R37MH046823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012609, R37AG012609] Funding Source: NIH RePORTER; NIA NIH HHS [AG12609] Funding Source: Medline; NIMH NIH HHS [MH46823] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSEN P, 1977, NATURE, V266, P736, DOI 10.1038/266736a0; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BROWN TH, 1991, LONG TERM POTENTIATI, P357; BUZSAKI G, 1986, BRAIN RES, V398, P242, DOI 10.1016/0006-8993(86)91483-6; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; Cohen NJ, 1993, MEMORY AMNESIA HIPPO; COLINO A, 1992, J NEUROSCI, V12, P180; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; DOUGLAS RM, 1975, BRAIN RES, V86, P205, DOI 10.1016/0006-8993(75)90697-6; FOX SE, 1981, EXP BRAIN RES, V41, P399; GREENSTEIN YJ, 1988, BRAIN RES, V438, P331, DOI 10.1016/0006-8993(88)91358-3; GUSTAFSSON B, 1986, J NEUROSCI, V6, P1575; LARSON J, 1989, BRAIN RES, V489, P49, DOI 10.1016/0006-8993(89)90007-3; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; LEVY WB, 1979, BRAIN RES, V175, P233, DOI 10.1016/0006-8993(79)91003-5; LEVY WB, 1983, NEUROSCIENCE, V8, P791, DOI 10.1016/0306-4522(83)90010-6; LOMO T, 1966, ACTA PHYSIOL SCAND, VS 68, P128; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MCNAUGHTON BL, 1983, EXP BRAIN RES, V52, P41; MULLER RU, 1987, J NEUROSCI, V7, P1935; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE J, 1979, PROG NEUROBIOL, V13, P419, DOI 10.1016/0301-0082(79)90005-4; OKEEFE J, 1976, EXP NEUROL, V51, P78, DOI 10.1016/0014-4886(76)90055-8; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; OLTON DS, 1978, EXP NEUROL, V58, P387, DOI 10.1016/0014-4886(78)90096-1; PAVLIDES C, 1989, J NEUROSCI, V9, P2907; PAVLIDES C, 1988, BRAIN RES, V439, P383, DOI 10.1016/0006-8993(88)91499-0; RANCK JB, 1973, EXP NEUROL, V41, P462, DOI 10.1016/0014-4886(73)90290-2; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SKAGGS WE, IN PRESS HIPPOCAMPUS; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUZUKI SS, 1987, ELECTROENCEPHALOGR C, V69, P541; TEYLER TJ, 1986, BEHAV NEUROSCI, V100, P147, DOI 10.1037/0735-7044.100.2.147; TREVES A, 1994, HIPPOCAMPUS, V4, P374, DOI 10.1002/hipo.450040319; WILSON MA, 1994, SCIENCE, V265, P676, DOI 10.1126/science.8036517; YLINEN A, 1995, J NEUROSCI, V15, P30	43	709	715	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1996	271	5257					1870	1873		10.1126/science.271.5257.1870	http://dx.doi.org/10.1126/science.271.5257.1870			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596957				2022-12-24	WOS:A1996UC77800048
J	Ramachandran, VS; Tyler, CW; Gregory, RL; RogersRamachandran, D; Duensing, S; Pillsbury, C; Ramachandran, C				Ramachandran, VS; Tyler, CW; Gregory, RL; RogersRamachandran, D; Duensing, S; Pillsbury, C; Ramachandran, C			Rapid adaptive camouflage in tropical flounders	NATURE			English	Article								Despite the commonly held view that flatfish can change their surface markings to match their background pattern(1), there have been few systematic studies(2,3) and it has recently been claimed(4) that their capacity for such adaptive changes is minimal. Here we show that the tropical flatfish Bothus ocellatus can achieve pattern-matching with surprising fidelity. By adjusting the contrast of different sets of 'splotches' of different grain size (or spatial frequency) on the skin, the fish can blend into a wide range of background textures in just 2-8 seconds.			Ramachandran, VS (corresponding author), UNIV CALIF SAN DIEGO,BRAIN & PERCEPT LAB,0109,,LA JOLLA,CA 92093, USA.							BOMFORD L, 1992, CAMOUFLAGE COLOR; Mast S. O., 1916, Bulletin of the Bureau of Fisheries Washington, V34; PACKARD A, 1995, CEPHALOPOD NEUROBIOL, P231; SAIDEL WM, 1988, SENSORY BIOL AQUATIC; SAIDEL WM, 1977, THESIS MIT CAMBRIDGE; Sumner F. B., 1911, Journal of Experimental Zoology Philadelphia, V10, DOI 10.1002/jez.1400100405	6	89	98	3	58	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					815	818		10.1038/379815a0	http://dx.doi.org/10.1038/379815a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587602				2022-12-24	WOS:A1996TX50100055
J	Clark, DA				Clark, DA			Red-cell antibodies in pregnancy: Evidence overturned	LANCET			English	Editorial Material							NEWBORN; PATIENT				Clark, DA (corresponding author), MCMASTER UNIV,HAMILTON,ON,CANADA.							Dickersin K, 1993, ANN NY ACAD SCI, V703, P145; ENGELFRIET CP, 1994, TRANSFUSION, V34, P627; FROEHLICH P, 1995, LANCET, V346, P1039, DOI 10.1016/S0140-6736(95)91722-5; HADLEY AG, 1992, VOX SANG, V63, P291, DOI 10.1111/j.1423-0410.1992.tb01242.x; JUDD WJ, 1990, TRANSFUSION, V30, P175, DOI 10.1046/j.1537-2995.1990.30290162907.x; SOCOL ML, 1992, PRINCIPLES PRACTICE, P1046; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; VANDIJK BA, 1995, TRANSFUSION MED, V4, P199; 1992, JAMA-J AM MED ASSOC, V268, P2420; 1994, AM J REPROD IMMUNOL, V32, P55	10	4	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					485	486		10.1016/S0140-6736(96)91133-2	http://dx.doi.org/10.1016/S0140-6736(96)91133-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596262				2022-12-24	WOS:A1996TW69700004
J	Griffiths, C; Naish, J; Sturdy, P; Pereira, F				Griffiths, C; Naish, J; Sturdy, P; Pereira, F			Prescribing and hospital admissions for asthma in east London	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON QUEEN MARY & WESTFIELD COLL,DEPT EPIDEMIOL & MED STAT,LONDON,ENGLAND	University of London; Queen Mary University London	Griffiths, C (corresponding author), UNIV LONDON QUEEN MARY & WESTFIELD COLL,ST BARTHOLOMEWS & ROYAL LONDON SCH MED & DENT,LONDON E1 4NS,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CAMPBELL M, 1995, BRIT MED J, V310, P1069, DOI 10.1136/bmj.310.6986.1069b; NAISH J, 1995, BRIT MED J, V310, P97, DOI 10.1136/bmj.310.6972.97; SHINE C, 1995, BRIT MED J, V310, P1070, DOI 10.1136/bmj.310.6986.1070a; STURDY P, 1995, BRIT MED J, V311, P1547, DOI 10.1136/bmj.311.7019.1547; 1994, HLTH E ANN PUBLIC HL	5	37	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					481	482		10.1136/bmj.312.7029.481	http://dx.doi.org/10.1136/bmj.312.7029.481			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597680	Green Published			2022-12-24	WOS:A1996TX38300024
J	Baukrowitz, T; Yellen, G				Baukrowitz, T; Yellen, G			Use-dependent blockers and exit rate of the last ion from the multi-ion pore of a K+ channel	SCIENCE			English	Article							POTASSIUM CHANNELS; MOLECULAR MECHANISMS; LOCAL-ANESTHETICS; CALCIUM CHANNELS; INACTIVATION	Quaternary ammonium blockers inhibit many voltage-activated potassium (K+) channels from the intracellular side. When applied to Drosophila Shaker potassium channels expressed in mammalian cells, these rapidly reversible blockers produced use-dependent inhibition through an unusual mechanism-they promoted an intrinsic conformational change known as C-type inactivation, from which recovery is slow. The blockers did so by cutting off potassium ion flow to a site in the pore, which then emptied at a rate of 10(5) ions per second. This slow rate probably reflected the departure of the last ion from the multi-ion pore: Permeation of ions (at 10(7) per second) occurs rapidly because of ion-ion repulsion, but the last ion to leave would experience no such repulsion.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02114	Harvard University; Harvard Medical School				Baukrowitz, Thomas/0000-0003-4562-0505; Yellen, Gary/0000-0003-4228-7866	NINDS NIH HHS [NS29693, R01 NS029693] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029693] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; BAUKROWITZ T, 1995, NEURON, V15, P951, DOI 10.1016/0896-6273(95)90185-X; BAUKROWITZ T, UNPUB; BIGGER JT, 1985, PHARM BASIS THERAPEU, pCH31; BUTTERWORTH JF, 1990, ANESTHESIOLOGY, V72, P711, DOI 10.1097/00000542-199004000-00022; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; COLATSKY TJ, 1990, CIRCULATION, V82, P2235, DOI 10.1161/01.CIR.82.6.2235; Crank J., 1975, MATH DIFFUSION; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HILLE B, 1977, J GEN PHYSIOL, V69, P497, DOI 10.1085/jgp.69.4.497; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; HILLE B, 1992, IONIC CHANNELS EXCIT, pCH11; HODGKIN AL, 1955, J PHYSIOL-LONDON, V128, P61, DOI 10.1113/jphysiol.1955.sp005291; HONDEGHEM LM, 1990, CIRCULATION, V81, P686, DOI 10.1161/01.CIR.81.2.686; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; LABARCA P, 1992, Biophysical Journal, V61, pA378; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; MACDONALD RL, 1989, EPILEPSIA, V30, pS19, DOI 10.1111/j.1528-1157.1989.tb05810.x; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; STARMER CF, 1984, BIOPHYS J, V46, P15, DOI 10.1016/S0006-3495(84)83994-6; YELLEN G, 1984, J GEN PHYSIOL, V84, P187, DOI 10.1085/jgp.84.2.187; YELLEN G, 1994, BIOPHYS J, V66, P1068, DOI 10.1016/S0006-3495(94)80888-4	28	194	195	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					653	656		10.1126/science.271.5249.653	http://dx.doi.org/10.1126/science.271.5249.653			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571129				2022-12-24	WOS:A1996TT87000048
J	Hotamisligil, GS; Peraldi, P; Budavari, A; Ellis, R; White, MF; Spiegelman, BM				Hotamisligil, GS; Peraldi, P; Budavari, A; Ellis, R; White, MF; Spiegelman, BM			IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; CELLS; IRS-1	Tumor necrosis factor-alpha (TNF-alpha) is an important mediator of insulin resistance in obesity and diabetes through its ability to decrease the tyrosine kinase activity of the insulin receptor (IR). Treatment of cultured murine adipocytes with TNF-alpha was shown to induce serine phosphorylation of insulin receptor substrate 1 (IRS-1) and convert IRS-1 into an inhibitor of the IR tyrosine kinase activity in vitro. Myeloid 32D cells, which lack endogenous IRS-1, were resistant to TNF-alpha-mediated inhibition of IR signaling, whereas transfected 32D cells that express IRS-1 were very sensitive to this effect of TNF-alpha. An inhibitory form of IRS-1 was observed in muscle and fat tissues from obese rats. These results indicate that TNF-alpha induces insulin resistance through an unexpected action of IRS-1 to attenuate insulin receptor signaling.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT MOLEC & CELLULAR BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, JOSLIN DIABET CTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Robles-Sardin, Alma E/M-7714-2015; Peraldi, Pascal/O-4592-2016	Robles-Sardin, Alma E/0000-0003-2044-7793; Peraldi, Pascal/0000-0003-0205-9252	NIDDK NIH HHS [DK 42539] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042539] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1993, J BIOL CHEM, V268, P8204; BEGUM N, 1995, DIABETES, V44, pA140; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DOUGLAS RG, 1991, AM J PHYSIOL, V261, pE606, DOI 10.1152/ajpendo.1991.261.5.E606; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; HOTAMISLIGIL GS, UNPUB; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; KRODER G, 1995, DIABETES, V44, pA264; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; Moller DE, 1993, INSULIN RESISTANCE; Olefsky JM, 1990, DIABETES MELLITUS TH, P121; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TANTI JF, 1994, J BIOL CHEM, V269, P6051; VANDERPOLL T, 1991, AM J PHYSIOL, V261, pE457, DOI 10.1152/ajpendo.1991.261.4.E457; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 1994, J BIOL CHEM, V269, P1	27	2023	2109	6	149	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 2	1996	271	5249					665	668		10.1126/science.271.5249.665	http://dx.doi.org/10.1126/science.271.5249.665			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571133				2022-12-24	WOS:A1996TT87000052
J	Klein, MG; Cheng, H; Santana, LF; Jiang, YH; Lederer, WJ; Schneider, MF				Klein, MG; Cheng, H; Santana, LF; Jiang, YH; Lederer, WJ; Schneider, MF			Two mechanisms of quantized calcium release in skeletal muscle	NATURE			English	Article							FROG TWITCH FIBERS; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; ANTIPYRYLAZO-III; CHARGE MOVEMENT; CHANNEL; PURIFICATION; SIGNALS	SKELETAL muscle uses voltage sensors in the transverse tubular membrane(1-3) that are linked by protein-protein interactions(4-6) to intracellular ryanodine receptors(7-10), which gate the release of calcium from the sarcoplasmic reticulum. Here we show, by using voltage-clamped single fibres and confocal imaging, that sto chastic calcium-release events, visualized as Ca2+ sparks, occur in skeletal muscle and originate at the tried. Unitary triadic Ca2+-release events are initiated by the voltage sensor in a steeply voltage-dependent manner, or occur spontaneously by a mechanism independent of the voltage sensor. Large amplitude events also occur during depolarization and consist of two or more unitary events. We propose a 'dual-control' model for discrete Ca2+ release events from the sacroplasmic reticulum that unifies diverse observations about Ca2+-signalling in frog skeletal muscle, and that may be applicable to other excitable cells.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore			Santana, Luis/AAF-9298-2019; Heping, Cheng/AAE-2680-2019; Lederer, William/B-1285-2010	Santana, Luis/0000-0002-4297-8029; Heping, Cheng/0000-0002-9604-6702; 				BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CHANDLER WK, 1976, J PHYSIOL-LONDON, V254, P285, DOI 10.1113/jphysiol.1976.sp011233; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; ENDO M, 1966, J PHYSIOL-LONDON, V185, P224, DOI 10.1113/jphysiol.1966.sp007983; ESCOBAR AL, 1994, NATURE, V367, P739, DOI 10.1038/367739a0; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIAMSTRON.C, 1994, REV PHYSL, V56, P509; HARKINS AB, 1993, BIOPHYS J, V65, P865, DOI 10.1016/S0006-3495(93)81112-3; HUXLEY AF, 1958, J PHYSIOL-LONDON, V144, P426, DOI 10.1113/jphysiol.1958.sp006111; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; IRVING M, 1987, J GEN PHYSIOL, V89, P1, DOI 10.1085/jgp.89.1.1; KLEIN MG, 1990, J PHYSIOL-LONDON, V425, P599, DOI 10.1113/jphysiol.1990.sp018120; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MAYLIE J, 1987, J GEN PHYSIOL, V89, P83, DOI 10.1085/jgp.89.1.83; MAYLIE J, 1991, J PHYSIOL-LONDON, V442, P551, DOI 10.1113/jphysiol.1991.sp018808; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MINTA A, 1989, J BIOL CHEM, V264, P8171; PIZARRO G, 1991, J GEN PHYSIOL, V97, P913, DOI 10.1085/jgp.97.5.913; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RIOS E, 1988, NEWS PHYSIOL SCI, V3, P223, DOI 10.1152/physiologyonline.1988.3.6.223; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SCHNEIDER MF, 1988, J PHYSIOL-LONDON, V405, P747; SIMON BJ, 1991, J GEN PHYSIOL, V97, P437, DOI 10.1085/jgp.97.3.437; STEM MD, 1992, BIOPHYS J, V63, P497; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TSUGORKA A, 1995, SCIENCE, V269, P1723, DOI 10.1126/science.7569901	31	273	282	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					455	458		10.1038/379455a0	http://dx.doi.org/10.1038/379455a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559251				2022-12-24	WOS:A1996TT30400061
J	Mirenowicz, J; Schultz, W				Mirenowicz, J; Schultz, W			Preferential activation of midbrain dopamine neurons by appetitive rather than aversive stimuli	NATURE			English	Article							NUCLEUS-ACCUMBENS; VENTRAL STRIATUM; MONKEY; RESPONSES; REWARD; INVIVO; MICRODIALYSIS; AMYGDALA; PRIMATE; COMPLEX	MIDBRAIN dopamine systems are crucially involved in motivational processes underlying the learning and execution of goal-directed behaviour(1-5). Dopamine neurons in monkeys are uniformly activated by unpredicted appetitive stimuli such as food and liquid rewards and conditioned, reward-predicting stimuli. By contrast, fully predicted stimuli are ineffective(6-8), and the omission of predicted reward depresses their activity(9). These characteristics follow associative-learning rules(10,11), suggesting that dopamine responses report an error in reward prediction(12). Accordingly, neural network models are efficiently trained using a dopamine-like reinforcement signal(13,14). However, it is unknown whether the responses to environmental stimuli concern specific motivational attributes or reflect more general stimulus salience(4,15). To resolve this, we have compared dopamine impulse responses to motivationally opposing appetitive and aversive stimuli. In contrast to appetitive events, primary and conditioned non-noxious aversive stimuli either failed to activate dopamine neurons or, in cases of close resemblance with appetitive stimuli, induced weaker responses than appetitive stimuli. Thus, dopamine neurons preferentially report environmental stimuli with appetitive rather than aversive motivational value.	UNIV FRIBOURG,INST PHYSIOL,CH-1700 FRIBOURG,SWITZERLAND	University of Fribourg								ABERCROMBIE ED, 1989, J NEUROCHEM, V52, P1655, DOI 10.1111/j.1471-4159.1989.tb09224.x; [Anonymous], 1992, SEMIN NEUROSCI; BENINGER RJ, 1983, SCIENCE, V220, P1304, DOI 10.1126/science.6857251; CADOR M, 1989, NEUROSCIENCE, V30, P77, DOI 10.1016/0306-4522(89)90354-0; CHERGUI K, 1994, NEUROSCIENCE, V62, P641, DOI 10.1016/0306-4522(94)90465-0; CHURCH WH, 1987, BRAIN RES, V412, P397, DOI 10.1016/0006-8993(87)91150-4; DELONG MR, 1983, J NEUROSCI, V3, P1599; Dickinson A., 1980, CONT ANIMAL LEARNING; FREUND TF, 1984, NEUROSCIENCE, V13, P1189, DOI 10.1016/0306-4522(84)90294-X; FRISTON KJ, 1994, NEUROSCIENCE, V59, P229, DOI 10.1016/0306-4522(94)90592-4; GAFFAN D, 1987, J NEUROSCI, V7, P2285; GARRIS PA, 1994, NEUROSCIENCE, V59, P417, DOI 10.1016/0306-4522(94)90606-8; GOLDMANRAKIC PS, 1989, P NATL ACAD SCI USA, V86, P9015, DOI 10.1073/pnas.86.22.9015; LJUNGBERG T, 1992, J NEUROPHYSIOL, V67, P145, DOI 10.1152/jn.1992.67.1.145; LOUILOT A, 1986, BRAIN RES, V397, P395, DOI 10.1016/0006-8993(86)90646-3; MIRENOWICZ J, 1994, J NEUROPHYSIOL, V72, P1024, DOI 10.1152/jn.1994.72.2.1024; NISHIJO H, 1988, J NEUROSCI, V8, P3570; Rescorla RA, 1972, CLASSICAL CONDITION, P64, DOI DOI 10.1101/GR.110528.110; ROBBINS TW, 1992, SEMIN NEUROSCI, V4, P119; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; ROMO R, 1990, J NEUROPHYSIOL, V63, P592, DOI 10.1152/jn.1990.63.3.592; SCHULTZ W, 1993, J NEUROSCI, V13, P900; SCHULTZ W, 1987, J NEUROPHYSIOL, V57, P201, DOI 10.1152/jn.1987.57.1.201; SCHULTZ W, 1983, EXP BRAIN RES S, V7, P171; SUTTON RS, 1981, PSYCHOL REV, V88, P135, DOI 10.1037/0033-295X.88.2.135; WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203; YOUNG AMJ, 1992, NEUROSCIENCE, V48, P871, DOI 10.1016/0306-4522(92)90275-7; YUNG KKL, 1995, NEUROSCIENCE, V65, P709, DOI 10.1016/0306-4522(94)00536-E; [No title captured]; [No title captured]	30	620	630	0	55	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					449	451		10.1038/379449a0	http://dx.doi.org/10.1038/379449a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559249				2022-12-24	WOS:A1996TT30400059
J	Godecke, I; Bonhoeffer, T				Godecke, I; Bonhoeffer, T			Development of identical orientation maps for two eyes without common visual experience	NATURE			English	Article							CROSS-CORRELATION; STRIATE CORTEX; ORGANIZATION; SELECTIVITY; POTENTIALS; DOMAINS; AREA-18; CELLS	IN the mammalian visual cortex, many neurons are driven binocularly and response properties such as orientation preference or spatial frequency tuning are virtually identical for the two eyes(1). A precise match of orientation is essential in order to detect disparity and is therefore a prerequisite for stereoscopic vision. It is not clear whether this match is accomplished by activity-dependent mechanisms together wit the common visual experience normally received by the eyes(2,3), or whether the visual system relies on other, perhaps even innate, cues to achieve this task(4-7). Here we test whether visual experience is responsible for the match in a reverse-suturing experiment in which kittens were raised so that both eyes were never able to see at the same time. A comparison of the layout of the two maps formed under these conditions showed them to be virtually identical. Considering that the two eyes never had common visual experience, this indicates that correlated visual input is not required for the alignment of orientation preference maps.	MAX PLANCK INST PSYCHIAT,D-82152 MUNICH,GERMANY	Max Planck Society			Bonhoeffer, Tobias/B-9481-2009	Bonhoeffer, Tobias/0000-0001-7897-6634				ALBUS K, 1984, J PHYSIOL-LONDON, V348, P153, DOI 10.1113/jphysiol.1984.sp015104; BARLOW HB, 1971, J PHYSIOL-LONDON, V218, P98; BLAKEMORE C, 1975, J PHYSIOL-LONDON, V248, P663, DOI 10.1113/jphysiol.1975.sp010995; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; BONHOEFFER T, 1995, CHALLENGES PERSPECTI, P117; BRAASTAD BO, 1985, J NEUROPHYSIOL, V53, P1158, DOI 10.1152/jn.1985.53.5.1158; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; CROOK JM, 1992, J NEUROSCI, V12, P1816; FERSTER D, 1986, J NEUROSCI, V6, P1284; FITZPATRICK D, 1993, SOC NEUR ABSTR, V19; HUBEL DH, 1963, J NEUROPHYSIOL, V26, P994, DOI 10.1152/jn.1963.26.6.994; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; IMBERT M, 1975, EXP BRAIN RES, V22, P25; KIM DS, 1994, NATURE, V370, P370, DOI 10.1038/370370a0; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MOVSHON JA, 1976, J PHYSIOL-LONDON, V261, P125, DOI 10.1113/jphysiol.1976.sp011551; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; SCHWARZ C, 1991, J NEUROSCI, V11, P2995; SILLITO AM, 1980, BRAIN RES, V194, P517, DOI 10.1016/0006-8993(80)91234-2; TANAKA K, 1983, J NEUROPHYSIOL, V49, P1303, DOI 10.1152/jn.1983.49.6.1303; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; WIESEL TN, 1974, J COMP NEUROL, V158, P307, DOI 10.1002/cne.901580306	25	127	128	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					251	254		10.1038/379251a0	http://dx.doi.org/10.1038/379251a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538789				2022-12-24	WOS:A1996TQ16900045
J	Last, EC				Last, EC			For Corrie	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					271	272		10.7326/0003-4819-124-2-199601150-00016	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ016	8534008				2022-12-24	WOS:A1996TQ01600016
J	GlucksmannKuis, MA; Dai, X; Markiewicz, P; RothmanDenes, LB				GlucksmannKuis, MA; Dai, X; Markiewicz, P; RothmanDenes, LB			E-coli SSB activates N4 virion RNA polymerase promoters by stabilizing a DNA hairpin required for promoter recognition	CELL			English	Article							SINGLE-STRANDED-DNA; BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATOR; PURIFICATION; REPLICATION; INITIATION	Bacteriophage N4 virion RNA polymerase transcription of double-stranded promoter-containing DNAs requires supercoiled template and E. coli single-stranded DNA-binding protein (EcoSSB); other single-stranded DNA-binding proteins cannot substitute. The DNA determinants of virion RNA polymerase binding at the promoter comprise a small template-strand hairpin. The requirement for EcoSSB is surprising, since single-stranded DNA-binding proteins destabilize hairpin structures. DNA footprinting of EcoSSB on wild-type and mutant promoters indicates that EcoSSB stabilizes the template-strand hairpin owing to the hairpin-loop sequences. Other single-stranded DNA-binding proteins destabilize the promoter hairpin, explaining the specificity of EcoSSB activation. We conclude that EcoSSB activates transcription by providing the appropriate DNA structure for polymerase binding. The existence of small hairpins stable to single-stranded protein binding suggests a novel mechanism that provides structural determinants for specific recognition in single-stranded DNA transactions by an otherwise nonspecific DNA-binding protein.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	University of Chicago	GlucksmannKuis, MA (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007099, R01AI012575] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI12575, 5T32 AI 07099] Funding Source: Medline; NIGMS NIH HHS [GM08369] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; ANSARI AZ, 1995, NATURE, V374, P371; BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; BENZ EW, 1983, MECHANISTIC STUDIES, P279; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CHASE JW, 1983, P NATL ACAD SCI-BIOL, V80, P5480, DOI 10.1073/pnas.80.18.5480; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P130; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; FALCO SC, 1980, J BIOL CHEM, V255, P4339; FALCO SC, 1977, P NATL ACAD SCI USA, V74, P520, DOI 10.1073/pnas.74.2.520; FALCO SC, 1978, P NATL ACAD SCI USA, V75, P320; GLUCKSMANN MA, 1992, CELL, V70, P491, DOI 10.1016/0092-8674(92)90173-A; HAYNES LL, 1985, CELL, V41, P597, DOI 10.1016/S0092-8674(85)80032-5; HIRAO I, 1994, NUCLEIC ACIDS RES, V22, P576, DOI 10.1093/nar/22.4.576; HIRAO I, 1990, BIOCHIM BIOPHYS ACTA, V1087, P199, DOI 10.1016/0167-4781(90)90205-G; HOESS RH, 1984, P NATL ACAD SCI-BIOL, V81, P1026, DOI 10.1073/pnas.81.4.1026; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; KIM YT, 1992, J BIOL CHEM, V267, P15022; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; LAVOIE BD, 1993, GENE DEV, V7, P2510, DOI 10.1101/gad.7.12b.2510; LINDBERG G, 1989, J BIOL CHEM, V264, P12700; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; LONBERG N, 1981, J MOL BIOL, V145, P122; MARKIEWICZ P, 1992, GENE DEV, V6, P2010, DOI 10.1101/gad.6.10.2010; Maxam A M, 1980, Methods Enzymol, V65, P499; POOM R, 1977, BIOCHEMISTRY-US, V16, P486; SIMS J, 1980, P NATL ACAD SCI-BIOL, V77, P900, DOI 10.1073/pnas.77.2.900; SUN W, 1994, J BIOL CHEM, V268, P8026; VOLOGODSKII A, 1992, TOPOLOGY PHYSICS CIR, P105; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167	32	57	59	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					147	154		10.1016/S0092-8674(00)81001-6	http://dx.doi.org/10.1016/S0092-8674(00)81001-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548819	Bronze			2022-12-24	WOS:A1996TQ17000017
J	Koelle, MR; Horvitz, HR				Koelle, MR; Horvitz, HR			EGL-10 regulates G protein signaling in the C-elegans nervous system and shares a conserved domain with many mammalian proteins	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; ALPHA-FACTOR PHEROMONES; SACCHAROMYCES-CEREVISIAE; GENETIC-ANALYSIS; MOTOR NEURONS; A-FACTOR; MUTANTS; RECEPTOR; TRANSDUCIN; PHOSDUCIN	The frequencies of certain periodic behaviors of the nematode C. elegans are regulated in a dose-dependent manner by the activity of the gene egl-10. These behaviors are modulated oppositely by the activity of the G protein alpha subunit gene goa-1, suggesting that egl-10 may regulate a G protein signaling pathway in a dose-dependent fashion. egl-10 encodes a protein similar to Sst2p, a negative regulator of G protein signaling in yeast. EGL-10 protein is localized in neural processes, where it may function in neurotransmitter signaling. Two previously known and 13 newly identified mammalian genes have similarity to egl-10 and SST2, and we propose that members of this family regulate many G protein signaling pathways.			Koelle, MR (corresponding author), MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139, USA.				NIGMS NIH HHS [GM24663] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024663, R01GM024663] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; BAILEY CH, 1994, ADV SEC MESS PHOSPH, V29, P529; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BLINDER D, 1989, MOL CELL BIOL, V9, P3720, DOI 10.1128/MCB.9.9.3720; BRENNER S, 1974, GENETICS, V77, P71; Catty D., 1988, ANTIBODIES PRACTICAL; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; CROLL NA, 1975, J ZOOL, V176, P159, DOI 10.1111/j.1469-7998.1975.tb03191.x; DESAI C, 1989, GENETICS, V121, P703; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; Hille B., 1992, IONIC CHANNELS EXCIT; HONG JX, 1993, J IMMUNOL, V150, P3895; HORVITZ HR, 1982, SCIENCE, V216, P1012, DOI 10.1126/science.6805073; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KURJAN J, 1993, ANNU REV GENET, V27, P147; LEE BN, 1994, MOL MICROBIOL, V14, P323, DOI 10.1111/j.1365-2958.1994.tb01293.x; LEE RH, 1992, J BIOL CHEM, V267, P25104; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; MURPHY JJ, 1990, BIOCHIM BIOPHYS ACTA, V1049, P261; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEWTON JS, 1993, BIOCHIM BIOPHYS ACTA, V1216, P314, DOI 10.1016/0167-4781(93)90163-8; OTTOBRUC A, 1994, BIOCHEMISTRY-US, V33, P15215, DOI 10.1021/bi00255a001; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; RIMM DL, 1989, GENE, V75, P323, DOI 10.1016/0378-1119(89)90278-3; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; Sambrook J., 1989, MOL CLONING LAB MANU; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; SPRAGUE GF, 1992, MOL CELLULAR BIOL YE, V2, P657; THOMAS JH, 1990, GENETICS, V124, P855; TRENT C, 1983, GENETICS, V104, P619; Trent C, 1983, THESIS MIT; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wood WB, 1988, NEMATODE CAENORHABDI	47	491	509	1	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					115	125		10.1016/S0092-8674(00)80998-8	http://dx.doi.org/10.1016/S0092-8674(00)80998-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548815	Bronze			2022-12-24	WOS:A1996TQ17000014
J	Gohdes, D; RithNajarian, S; Acton, K; Shields, R				Gohdes, D; RithNajarian, S; Acton, K; Shields, R			Improving diabetes care in the primary health setting - The Indian Health Service experience	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			AMERICAN-INDIANS; COMPLICATIONS; PREVALENCE; MELLITUS; TRIAL	Purpose: To identify key systems issues from the Indian Health Service (IHS) experience that must be addressed to improve metabolic control among patients with noninsulin-dependent diabetes mellitus (NIDDM) who were followed in primary care settings. Data Sources: Records of diabetic patients seen in IHS facilities in specific geographic regions from 1987 to 1994. Study Selection: A representative-sample of charts from each facility was reviewed yearly to measure key variables. The sampling frame was the number of diabetic patients currently active on the registry and the sample size calculated to measure a 10% change in selected practices at each facility. Extraction: Regional diabetes coordinators reviewed charts or trained local providers to sample and extract data in a standard format. Results: Regional data were examined to show trends in the performance of immunizations and foot examinations and in other variables such as hypertension and metabolic control. The percentage of diabetic patients who received a single dose of pneumococcal vaccine improved from 24% in 1987 to 1988 to 57% in 1994 (P < 0.01 for trend) among diabetic patients in Minnesota, Wisconsin, and Michigan. Rates of yearly comprehensive foot examination increased from 36% to 58% (P < 0.01 for trend) over the same period. In Montana and Wyoming, the percentage of diabetic patients with uncontrolled hypertension (defined as the mean of three systolic blood pressure measurements of greater than or equal to 140 mm Hg or diastolic pressure measurements greater than or equal to 90 mm Hg, or both, during the previous year) decreased from 36% in 1992 to 25% in 1993 after the regional diabetes coordinator emphasized hypertension control. In 1994, when less emphasis was placed on hypertension, 33% of the diabetic patients had uncontrolled hypertension. Estimates of metabolic control from records of diabetic patients in Washington, Oregon, and Idaho in 1994 showed that 29% of patients had excellent metabolic control (a hemoglobin A(1c) [HbA(1c)] level less than or equal to 7.5% or mean blood glucose level less than or equal to 9.2 mmol/L) within the past year; only 9% experienced poor control (a HbA(1c) level > 12% or mean blood glucose level > 18.9 mmol/L). Conclusions: The IHS experience shows that standard, ongoing monitoring of key variables allows facilities to improve diabetes care. Simple, reliable methods of defining metabolic control combined with a feedback system in the primary care setting are needed to improve metabolic control in patients with NIDDM.	BEMIDJI AREA INDIAN HLTH SERV, BEMIDJI, MN 56601 USA; TRIBAL HLTH & HUMAN SERV, BILLINGS AREA DIABET PROGRAM, ST IGNATIUS, MT 59865 USA; PORTLAND AREA DIABET PROGRAM, BELLINGHAM, WA 98225 USA		Gohdes, D (corresponding author), INDIAN HLTH SERV, DIABET PROGRAM, 5300 HOMESTEAD RD NE, ALBUQUERQUE, NM 87110 USA.							ACTON K, 1993, DIABETES CARE, V16, P372, DOI 10.2337/diacare.16.1.372; BIRKE JA, 1986, LEPROSY REV, V57, P261; CAPUTO GM, 1994, NEW ENGL J MED, V331, P854, DOI 10.1056/NEJM199409293311307; Centers for Disease Control (CDC), 1989, MMWR Morb Mortal Wkly Rep, V38, P64; DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715; DEAN AG, 1991, AM J PREV MED, V7, P178, DOI 10.1016/S0749-3797(18)30936-X; DUMAS J, 1994, DIABETES CARE, V17, P1227, DOI 10.2337/diacare.17.10.1227; FIELD M, 1992, I MED GUIDELINES CLI; GOHDES D, 1995, NEW ENGL J MED, V332, P269; GOHDES DM, 1986, DIABETES CARE, V9, P609, DOI 10.2337/diacare.9.6.609; KING H, 1993, DIABETES CARE, V16, P157, DOI 10.2337/diacare.16.1.157; LITTLE RR, 1992, CLIN CHEM, V38, P2472; LITTLE RR, 1991, CLIN CHEM, V37, P1725; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; MAYFIELD JA, 1994, DIABETES CARE, V17, P918, DOI 10.2337/diacare.17.8.918; NAGAFUCHI S, 1993, DIABETES CARE, V16, P1408, DOI 10.2337/diacare.16.10.1408; NATHAN DM, 1984, NEW ENGL J MED, V310, P341, DOI 10.1056/NEJM198402093100602; NATHAN DM, 1994, DIABETES CARE, V17, P1228, DOI 10.2337/diacare.17.10.1228; RITHNAJARIAN SJ, 1992, DIABETES CARE, V15, P1386, DOI 10.2337/diacare.15.10.1386; SANTIAGO JV, 1993, DIABETES, V42, P1549, DOI 10.2337/diab.42.11.1549; SANTIAGO JV, 1994, DIABETES CARE, V17, P1229, DOI 10.2337/diacare.17.10.1229; SCHRAER C, 1995, DIABETES, V44, pA121; SCHRAER CD, 1993, DIABETES CARE, V16, P257, DOI 10.2337/diacare.16.1.257; 1989, MMWR-MORBID MORTAL W, V38, P73; 1994, NIH943530 US DEP HLT; 1994, GUIDE ADULT IMMUNIZA, P107; 1994, TRENDS INDIAN HLTH 1	27	23	23	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				149	152		10.7326/0003-4819-124-1_Part_2-199601011-00013	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554208				2022-12-24	WOS:A1996TL94400013
J	Quickel, KE				Quickel, KE			Diabetes in a managed care system	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			SERVICE; OUTCOMES; SETTINGS; PROGRAM; FEE	Health care expenditures account for over 14% of the gross domestic product in the United States. Managed care has evolved to control these costs. Because diabetes accounts for nearly 15% of health care expenditures, the strategies used by managed care organizations are expected to have a particular effect on diabetes. Managed care organizations have two primary goals: to control costs and to provide care of sufficient quality to attract and satisfy enrollees. Managed care organizations have designed strategies to meet these goals. Four primary managed care strategies and their effects on diabetes care are discussed: 1) payment incentives rewarding desired provider practice patterns; 2) designation of providers who possess desirable practice behaviors; 3) coverage policies that control the services paid for; and 4) traditional insurance strategies that determine who is eligible for insurance and what premiums are to be paid. The few direct studies of the effects of each strategy on the care of diabetic persons are discussed. The conclusion is that although managed care organizations have the potential to provide excellent care for diabetic persons, little evidence exists that they have improved either the quality or the cost-effectiveness of diabetes care. Recommendations to guide the development of cost-effective care for diabetic persons are presented.			Quickel, KE (corresponding author), JOSLIN DIABET CTR, 1 JOSLIN PL, BOSTON, MA 02215 USA.							CARTLAND JDC, 1992, PEDIATRICS, V89, P183; Corrigan J M, 1993, Jt Comm J Qual Improv, V19, P566; GEFFNER DL, 1992, DIABETES CARE, V15, P44, DOI 10.2337/diacare.15.1.S44; IGLEHART JK, 1994, NEW ENGL J MED, V331, P63, DOI 10.1056/NEJM199407073310129; IGLEHART JK, 1992, NEW ENGL J MED, V327, P742, DOI 10.1056/NEJM199209033271029; KERTESZ L, 1995, MODERN HEALTHCA 0417, P17; LANGWELL K, 1992, CBO STAFF MEMORANDUM; LEVETAN CS, 1995, AM J MED, V99, P22, DOI 10.1016/S0002-9343(99)80100-4; LYTTLE C, 1989, ANN INTERN MED, V111, P604, DOI 10.7326/0003-4819-111-7-604; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; MUHLHAUSER I, 1983, DIABETOLOGIA, V25, P470; MUHLHAUSER I, 1987, DIABETOLOGIA, V30, P681, DOI 10.1007/BF00296989; PRASHKER MJ, 1991, ANN INTERN MED, V115, P715, DOI 10.7326/0003-4819-115-9-715; REDHEAD J, 1993, DIABETIC MED, V10, P672, DOI 10.1111/j.1464-5491.1993.tb00143.x; RETCHIN SM, 1991, ARCH INTERN MED, V151, P2244, DOI 10.1001/archinte.151.11.2244; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; RUBIN RJ, 1994, J CLIN ENDOCR METAB, V78, pA809, DOI 10.1210/jcem.78.4.8157701; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SINNOCK P, 1986, J INSURANCE MED, V18, P24; SLEE VN, 1991, HLTH CARE TERMS; STARFIELD B, 1994, DIABETES CARE, V17, P12; STARR B, 1995, BUSINESS HLTH MAG SC, V13, P56; TAYLOR AK, 1987, DIABETES CARE, V10, P87, DOI 10.2337/diacare.10.1.87; TUTTLEMAN M, 1993, DIABETES CARE, V16, P765, DOI 10.2337/diacare.16.5.765; UDVARHELYI IS, 1991, ANN INTERN MED, V115, P394, DOI 10.7326/0003-4819-115-5-394; VAUGHAN NJA, 1994, DIABETIC MED, V11, P418; WEINBERGER M, 1988, MED CARE, V26, P77, DOI 10.1097/00005650-198801000-00008; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WENNBERG JE, 1993, HEALTH AFFAIR, V12, P89, DOI 10.1377/hlthaff.12.2.89; YELIN EH, 1986, MED CARE, V24, P236, DOI 10.1097/00005650-198603000-00006; 1987, 3RD PARTY REIMBURSEM, V6, P1; 1992, CBO STUDY PROJECTION; 1994, DIABETES CARE S1, V2, P1555; 1993, DIRECT INDIRECT COST	34	27	27	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				160	163		10.7326/0003-4819-124-1_Part_2-199601011-00016	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00016			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554211				2022-12-24	WOS:A1996TL94400016
J	HELZLSOUER, KJ; ALBERG, AJ; GORDON, GB; LONGCOPE, C; BUSH, TL; HOFFMAN, SC; COMSTOCK, GW				HELZLSOUER, KJ; ALBERG, AJ; GORDON, GB; LONGCOPE, C; BUSH, TL; HOFFMAN, SC; COMSTOCK, GW			SERUM GONADOTROPINS AND STEROID-HORMONES AND THE DEVELOPMENT OF OVARIAN-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEHYDROEPIANDROSTERONE SULFATE; POSTMENOPAUSAL WOMEN; BREAST-CANCER; ANDROGEN; GROWTH; RISK; DIETARY	Objective.-To prospectively examine the association between endogenous hormones and development of ovarian cancer. Design.-Nested case-control study. Setting.-A population-based serum bank in Washington County, Maryland. Participants.-Serum samples were collected in 1974 from 20 305 county residents and stored at - 70 degrees C. From 1975 through 1989, a total of 31 cases of ovarian cancer were identified in women who were not taking hormones at the time of blood collection. These cases were matched to 62 controls on age, menopausal status, and, for premenopausal women, number of days from the beginning of the last menstrual period. Main Outcome Measure.-Prediagnostic endogenous hormone levels of cases and controls were compared. Results.-Mean follicle-stimulating hormone levels were lower among cases (43.3 IU/L) compared with controls (54.4 IU/L) (P=.04), and increasing levels were associated with significantly lower risk (P for trend=.01), particularly among postmenopausal women. Luteinizing hormone levels were 9% lower among cases than controls, but the difference was not statistically significant (P=.39). Compared with controls, cases had higher androstenedione levels (4.5 nmol/L vs 3.3 nmol; P=.03) and higher dehydroepiandrosterone (DHEA) levels (15.9 nmol/L vs 9.7 nmol/L; P=.02). The risk of ovarian cancer increased with higher levels of androstenedione and DHEA sulfate (P for trend=.008 and .11, respectively). These associations were not materially different between premenopausal and postmenopausal women. Conclusion.-The results suggest that women with low serum gonadotropin levels or high androgen levels have an increased risk of ovarian cancer. These findings do not support the hypothesis that pituitary gonadotropins increase the risk of ovarian cancer. Replication of the study in other populations is highly desirable.	JOHNS HOPKINS UNIV, SCH MED, DEPT ONCOL, BALTIMORE, MD 21205 USA; UNIV MASSACHUSETTS, MED CTR, DEPT OBSTET & GYNECOL, WORCESTER, MA USA	Johns Hopkins University; University of Massachusetts System; University of Massachusetts Worcester	HELZLSOUER, KJ (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, 615 N WOLFE ST, BALTIMORE, MD 21205 USA.				NATIONAL CANCER INSTITUTE [R01CA036390, R01CA047503, R55CA036390] Funding Source: NIH RePORTER; NCI NIH HHS [CA01522, CA36390, CA47503] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Breslow N, 1980, STAT METHODS CANC RE, P248; BYERS T, 1983, JNCI-J NATL CANCER I, V71, P681; CARLSTROM K, 1985, ACTA OBSTET GYN SCAN, V64, P267, DOI 10.3109/00016348509155126; CRAMER DW, 1984, OBSTET GYNECOL, V63, P833; CUZICK J, 1983, INT J CANCER, V32, P723, DOI 10.1002/ijc.2910320611; FARROW DC, 1989, AM J EPIDEMIOL, V129, P1300, DOI 10.1093/oxfordjournals.aje.a115249; GARDNER WU, 1961, J NATL CANCER I, V26, P829; GODWIN AK, 1992, HEMATOL ONCOL CLIN N, V6, P829; HEINONEN PK, 1982, BRIT J OBSTET GYNAEC, V89, P84, DOI 10.1111/j.1471-0528.1982.tb04643.x; HEINONEN PK, 1986, GYNECOL ONCOL, V25, P1, DOI 10.1016/0090-8258(86)90058-2; HELZLSOUER KJ, 1992, CANCER RES, V52, P1; HSING AW, 1989, CLIN CHEM, V35, P2145; LONGCOPE C, 1986, MATURITAS, V8, P189, DOI 10.1016/0378-5122(86)90025-3; LUCISANO A, 1986, MATURITAS, V8, P57, DOI 10.1016/0378-5122(86)90008-3; MAHLCK CG, 1986, ACTA OBSTET GYN SCAN, P1; MANGO D, 1985, J ENDOCRINOL INVEST, V8, P359, DOI 10.1007/BF03348514; RAO BR, 1991, ENDOCR REV, V12, P14, DOI 10.1210/edrv-12-1-14; RODRIGUEZ C, 1995, AM J EPIDEMIOL, V141, P828, DOI 10.1093/oxfordjournals.aje.a117518; ROSSING MA, 1994, NEW ENGL J MED, V331, P771, DOI 10.1056/NEJM199409223311204; SAWADA M, 1990, INT J CANCER, V45, P359, DOI 10.1002/ijc.2910450225; SIMON WE, 1983, J NATL CANCER I, V70, P839; SLOTMAN BJ, 1989, CANCER LETT, V45, P213, DOI 10.1016/0304-3835(89)90080-3; SPICER DV, 1993, CONTRACEPTION, V47, P427, DOI 10.1016/0010-7824(93)90095-O; Stadel B V, 1975, Am J Obstet Gynecol, V123, P772; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; 1988, NCI NIH882789 PUBL H	26	210	225	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1926	1930		10.1001/jama.274.24.1926	http://dx.doi.org/10.1001/jama.274.24.1926			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568986				2022-12-24	WOS:A1995TL16900034
J	Watura, R; Lloyd, DCF; Chawda, S				Watura, R; Lloyd, DCF; Chawda, S			Magnetic resonance imaging of the knee: Direct access for general practitioners	BRITISH MEDICAL JOURNAL			English	Article									CARDIFF ROYAL INFIRM,DEPT RADIOL,CARDIFF CF2 1SZ,S GLAM,WALES	Cardiff Royal Infirmary								BOEREE NR, 1991, INJURY, V22, P291, DOI 10.1016/0020-1383(91)90008-3; MAIR WJ, 1974, BMJ-BRIT MED J, V3, P732, DOI 10.1136/bmj.3.5933.732; POLLY DW, 1988, J BONE JOINT SURG AM, V70A, P192, DOI 10.2106/00004623-198870020-00005; Smith G L, 1979, J R Coll Gen Pract, V29, P539; WRIGHT HJ, 1979, J ROY SOC MED, V72, P88	5	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 16	1995	311	7020					1614	1614		10.1136/bmj.311.7020.1614	http://dx.doi.org/10.1136/bmj.311.7020.1614			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL422	8555806	Green Published			2022-12-24	WOS:A1995TL42200025
J	Goldman, M				Goldman, M			Cancer risk of low-level exposure	SCIENCE			English	Editorial Material											Goldman, M (corresponding author), UNIV CALIF DAVIS,DEPT SURG & RADIOL SCI,DAVIS,CA 95616, USA.							AMES BN, 1993, ENVIRON HEALTH PERSP, V101, P35, DOI 10.2307/3431840; [Anonymous], 1994, SOURC EFF ION RAD, P16; COHEN BL, 1995, HEALTH PHYS, V68, P157, DOI 10.1097/00004032-199502000-00002; EVANS R, 1974, HEALTH PHYS, V17, P497; GOLDMAN M, 1971, RADIAT RES, V47, P305; KITCHIN KT, 1994, TOXICOLOGY, V88, P31, DOI 10.1016/0300-483X(94)90109-0; Kondo S., 1993, HLTH EFFECTS LOW LEV; LEWIS EB, 1957, SCIENCE, V125, P965, DOI 10.1126/science.125.3255.965; Muller H J, 1927, Science, V66, P84, DOI 10.1126/science.66.1699.84; *NATL RES COUNC, 1990, HLTH EFF EXP LOW LEV; ROSENBLATT LS, 1971, HEALTH PHYS, V21, P869; WOLFF S, 1988, INT J RADIAT BIOL, V53, P39, DOI 10.1080/09553008814550401	12	56	59	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1821	1822		10.1126/science.271.5257.1821	http://dx.doi.org/10.1126/science.271.5257.1821			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596947				2022-12-24	WOS:A1996UC77800031
J	Reddy, MM; Quinton, PM; Haws, C; Wine, JJ; Grygorczyk, R; Tabcharani, JA; Hanrahan, JW; Gunderson, KL; Kopito, RR				Reddy, MM; Quinton, PM; Haws, C; Wine, JJ; Grygorczyk, R; Tabcharani, JA; Hanrahan, JW; Gunderson, KL; Kopito, RR			Failure of the cystic fibrosis transmembrane conductance regulator to conduct ATP	SCIENCE			English	Article							GENE; CFTR; IDENTIFICATION; SELECTIVITY; CHANNEL; CELLS	The cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride ion channel regulated by protein kinase A and adenosine triphosphate (ATP). Loss of CFTR-mediated chloride ion conductance from the apical plasma membrane of epithelial cells is a primary physiological lesion in cystic fibrosis. CFTR has also been suggested to function as an ATP channel, although the size of the ATP anion is much larger than the estimated size of the CFTR pore. ATP was not conducted through CFTR in intact organs, polarized human lung cell lines, stably transfected mammalian cell lines, or planar lipid bilayers reconstituted with CFTR protein. These findings suggest that ATP permeation through the CFTR is unlikely to contribute to the normal function of CFTR or to the pathogenesis of cystic fibrosis.	STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA; UNIV CALIF RIVERSIDE, DIV BIOMED SCI, RIVERSIDE, CA 92521 USA; STANFORD UNIV, DEPT PSYCHOL, CYST FIBROSIS RES LAB, STANFORD, CA 94305 USA; MCGILL UNIV, DEPT PHYSIOL, MONTREAL, PQ H3G 1Y6, CANADA	Stanford University; University of California System; University of California Riverside; Stanford University; McGill University			Hanrahan, John/AGG-1926-2022	Hanrahan, John/0000-0001-9080-2039; Grygorczyk, Ryszard/0000-0002-9798-7651	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045913, R01DK043994] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42368] Funding Source: Medline; NIDDK NIH HHS [DK45913, DK43994] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BULL HB, 1972, INTRO PHYSICAL BIOCH; GREGER R, 1981, PFLUG ARCH EUR J PHY, V390, P30, DOI 10.1007/BF00582707; GRYGORCZYK R, IN PRESS J MEMBR BIO; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; GUNDERSON KL, UNPUB; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanrahan John W., 1993, P93; HAWS C, 1994, AM J PHYSIOL, V266, pL502, DOI 10.1152/ajplung.1994.266.5.L502; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; NEHER E, 1992, METHOD ENZYMOL, V207, P123; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; QUINTON PM, 1982, FLUID ELECTROLYTE AB, P53; REDDY MM, 1994, AM J PHYSIOL-CELL PH, V267, pC1136, DOI 10.1152/ajpcell.1994.267.4.C1136; REISIN IL, 1994, J BIOL CHEM, V269, P20584; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698	25	165	166	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1996	271	5257					1876	1879		10.1126/science.271.5257.1876	http://dx.doi.org/10.1126/science.271.5257.1876			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596959				2022-12-24	WOS:A1996UC77800050
J	Fagon, JY; Chastre, J; Vuagnat, A; Trouillet, JL; Novara, A; Gibert, C				Fagon, JY; Chastre, J; Vuagnat, A; Trouillet, JL; Novara, A; Gibert, C			Nosocomial pneumonia and mortality among patients in intensive care units	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTINUOUS MECHANICAL VENTILATION; PROTECTED SPECIMEN BRUSH; ATTRIBUTABLE MORTALITY; INFECTION; RISK; FATALITY; FAILURE; DEATHS; SYSTEM; STAY	Objective.-To evaluate the role that nosocomial pneumonia plays in the outcome of intensive care unit (ICU) patients. Design.-Cohort study. Setting.-Medical ICU, Hospital Bichat, Paris, France, an academic tertiary care center. Patients.-A total of 1978 consecutive patients admitted to the ICU for at least 48 hours. Main Outcome Measures.-Various parameters known to be strongly associated with death of ICU patients were recorded: age, location before admission to the ICU, diagnostic categories, Acute Physiology and Chronic Health Evaluation (APACHE) II score, Simplified Acute Physiologic Score, McCabe score, number and type of dysfunctional organs, and the development of nosocomial bacteremia and nosocomial urinary tract infection. These variables and the presence or absence of nosocomial pneumonia were compared between survivors and nonsurvivors and entered into a stepwise logistic regression model to evaluate their independent prognostic roles. Results.-Nosocomial pneumonia developed in 328 patients (16.6%) whose mortality rate was 52.4% compared with 22.4% for patients without ICU-acquired pneumonia (P<.001). APACHE II score (odds ratio [OR]=1.08; 95% confidence interval [CI], 1.06 to 1.10; P<.001), number of dysfunctional organs (OR=1.54; 95% CI, 1.36 to 1.74; P<.001), nosocomial pneumonia (OR=2.08; 95% CI, 1.55 to 2.80; P<.001), nosocomial bacteremia (OR=2.51; 95% CI, 1.78 to 3.55; P<.001), ultimately or rapidly fatal underlying disease (OR=1.76; 95% CI, 1.38 to 2.25; P<.001), and admission from another ICU (OR=1.30; 95% CI, 1.01 to 1.68; P=.04) were significantly associated with mortality. Conclusion.-These data suggest that, in addition to the severity of underlying medical conditions and nosocomial bacteremia, nosocomial pneumonia independently contributes to ICU patient mortality.			Fagon, JY (corresponding author), HOP BICHAT,SERV REANIMAT MED,46 RUE HENRI HUCHARD,F-75877 PARIS 18,FRANCE.							BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BUENOCAVANILLAS A, 1994, CRIT CARE MED, V22, P55, DOI 10.1097/00003246-199401000-00013; CHASTRE J, 1994, AM J RESP CRIT CARE, V150, P570, DOI 10.1164/ajrccm.150.2.8049850; CHASTRE J, 1995, AM J RESP CRIT CARE, V152, P231, DOI 10.1164/ajrccm.152.1.7599829; CHASTRE J, 1988, AM J MED, V85, P499; CRAIG CP, 1984, AM J INFECT CONTROL, V12, P233, DOI 10.1016/0196-6553(84)90114-7; CRAVEN DE, 1988, ARCH INTERN MED, V148, P1161, DOI 10.1001/archinte.148.5.1161; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; FAGON JY, 1993, INTENS CARE MED, V19, P137, DOI 10.1007/BF01720528; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FAGON JY, 1993, CHEST, V103, P547, DOI 10.1378/chest.103.2.547; GROSS PA, 1983, AM J MED, V75, P658, DOI 10.1016/0002-9343(83)90453-9; GROSS PA, 1980, AM J MED, V68, P219, DOI 10.1016/0002-9343(80)90357-5; HALEY RW, 1985, AM J EPIDEMIOL, V121, P159, DOI 10.1093/oxfordjournals.aje.a113988; HURLEY JC, 1995, ANTIMICROB AGENTS CH, V39, P941, DOI 10.1128/AAC.39.4.941; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LEU HS, 1989, AM J EPIDEMIOL, V129, P1258, DOI 10.1093/oxfordjournals.aje.a115245; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; MEDURI GU, 1990, CHEST, V97, P1208, DOI 10.1378/chest.97.5.1208; NIEDERMAN MS, 1994, AM J RESP CRIT CARE, V150, P565, DOI 10.1164/ajrccm.150.2.8049849; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; SPILKER B, 1991, GUIDE CLIN TRIALS, P134; TEASDALE G, 1974, LANCET, V2, P81; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523	28	333	349	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					866	869		10.1001/jama.275.11.866	http://dx.doi.org/10.1001/jama.275.11.866			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ971	8596225				2022-12-24	WOS:A1996TZ97100030
J	Schieber, RA; Switzer, DW				Schieber, RA; Switzer, DW			Injuries from propane gas grills	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									US CONSUMER PROD SAFETY COMMISS,BETHESDA,MD		Schieber, RA (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,ATLANTA,GA 30341, USA.							*US CONS PROD SAF, 1992, NEISS SAMPL DES IMPL	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					886	886		10.1001/jama.275.11.886	http://dx.doi.org/10.1001/jama.275.11.886			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ971	8596229				2022-12-24	WOS:A1996TZ97100035
J	Tappero, JW; Khan, AS; Pinner, RW; Wenger, JD; Graber, JM; Armstrong, LR; Holman, RC; Ksiazek, TG; Khabbaz, RF				Tappero, JW; Khan, AS; Pinner, RW; Wenger, JD; Graber, JM; Armstrong, LR; Holman, RC; Ksiazek, TG; Khabbaz, RF			Utility of emergency, telephone-based national surveillance for Hantavirus pulmonary syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								On May 27, 1993, in response to the outbreak investigation of newly recognized Hantavirus pulmonary syndrome (HPS) in the Four Corners states (New Mexico, Arizona, Utah, and Colorado), the Centers for Disease Control and Prevention established a national surveillance case definition for severe, unexplained respiratory disease to determine the extent of HPS throughout the United States, A toll-free telephone hotline number was instituted to provide updated information about unexplained respiratory illness and to serve as a passive mechanism for reporting suspected cases. Clinical information was obtained from callers reporting suspected cases, and diagnostic specimens and medical record reviews were requested from health care providers, From June 3 through December 31, 1993, the hotline received 21 443 telephone inquiries; callers identified 280 suspected cases living outside the Four Comers states with at least one specimen available for diagnostic testing. By December 31, 1993, 21 confirmed cases (age range, 14 to 58 years) residing in 11 states outside the Four Corners region had been identified, This passive surveillance system was successful in rapidly identifying the widespread sporadic geographic distribution for HPS cases throughout the United States and could serve as a model for similar emergencies, Expanding and coordinating surveillance systems for the early detection, tracking, and evaluation of emerging infections is a critical component of disease prevention.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,CHILDHOOD & RESP DIS BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,BIOMETR ACTIV,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; Berkelman RL, 1996, JAMA-J AM MED ASSOC, V275, P315, DOI 10.1001/jama.275.4.315; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BUTLER JC, 1994, CLIN INFECT DIS, V19, P387, DOI 10.1093/clinids/19.3.387; Carleton M.D., 1989, P7; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; CHAPMAN LE, 1994, INFECT AGENT DIS, V3, P234; CHILDS JE, 1994, J INFECT DIS, V169, P1271, DOI 10.1093/infdis/169.6.1271; DUCHIN JS, 1994, NEW ENGL J MED, V330, P949, DOI 10.1056/NEJM199404073301401; ELLIOTT LH, 1994, AM J TROP MED HYG, V51, P102, DOI 10.4269/ajtmh.1994.51.102; FELDMANN H, 1993, VIRUS RES, V30, P351, DOI 10.1016/0168-1702(93)90101-R; HJELLE B, 1994, J VIROL, V68, P592, DOI 10.1128/JVI.68.2.592-596.1994; HUGHES JM, 1993, SCIENCE, V262, P850, DOI 10.1126/science.8235607; KHAN AS, IN PRESS J INFECT DI; KSAIZEK TG, 1995, AM J TROP MED HYG, V52, P117; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; ROLLIN PE, 1995, J MED VIROL, V46, P35, DOI 10.1002/jmv.1890460108; SHEFER AM, 1994, CLIN INFECT DIS, V19, P1105, DOI 10.1093/clinids/19.6.1105; SPIROPOULOU CF, 1994, VIROLOGY, V200, P715, DOI 10.1006/viro.1994.1235; TAPPERO JW, 1995, JAMA-J AM MED ASSOC, V273, P1118, DOI 10.1001/jama.273.14.1118; THACKER SB, 1983, JAMA-J AM MED ASSOC, V249, P1181; ZAKI SR, 1995, AM J PATHOL, V146, P552; ZAKI SR, IN PRESS ARCH PATHOL; ZEITZ PS, 1995, J INFECT DIS, V171, P864, DOI 10.1093/infdis/171.4.864; 1993, MMWR-MORBID MORTAL W, V42, P612; 1992, EMERGING INFECTIONS; 1994, MMWR-MORBID MORTAL W, V43, P99; 1993, MMWR-MORBID MORTAL W, V42, P441; 1993, MMWR-MORBID MORTAL W, V42, P421; 1994, MMWR-MORBID MORTAL W, V43, P105; 1993, MMWR-MORBID MORTAL W, V42, P816; 1994, MMWR-MORBID MORTAL W, V43, P45	32	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					398	400		10.1001/jama.275.5.398	http://dx.doi.org/10.1001/jama.275.5.398			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8569020				2022-12-24	WOS:A1996TT30300034
J	Zahn, R; Perrett, S; Stenberg, G; Fersht, AR				Zahn, R; Perrett, S; Stenberg, G; Fersht, AR			Catalysis of amide proton exchange by the molecular chaperones GroEL and SecB	SCIENCE			English	Article							HYDROGEN-EXCHANGE; ESCHERICHIA-COLI; PROTEIN; BARNASE; STABILITY; BINDING; SURFACE; PATHWAY	Hydrogen-deuterium exchange of 39 amide protons of Bacillus amyloliquefaciens ribonuclease (barnase) was analyzed by two-dimensional nuclear magnetic resonance in the presence of micromolar concentrations of the molecular chaperones GroEL and SecB. Both chaperones bound to native barnase under physiological conditions and catalyzed exchange of deeply buried amide protons with solvent. Such exchange required complete unfolding of barnase, which occurred in the complex with the chaperones. Subsequent collapse of unfolded barnase to the exchange-protected folding intermediate was markedly slowed in the presence of GroEL or SecB. Thus, both chaperones have the potential to correct misfolding in proteins by annealing.	UNIV CAMBRIDGE,MRC,UNIT PROT FUNCT & DESIGN,DEPT CHEM,CAMBRIDGE CB2 1EW,ENGLAND	University of Cambridge			Perrett, Sarah/AAS-9483-2020; Fersht, Alan R/B-2189-2008	Perrett, Sarah/0000-0003-0137-0997; 				AGARD DA, 1993, SCIENCE, V260, P1903, DOI 10.1126/science.8100365; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CLARKE J, 1993, P NATL ACAD SCI USA, V90, P9837, DOI 10.1073/pnas.90.21.9837; CORRALES F, UNPUB; CORRALES FJ, 1995, P NATL ACAD SCI USA, V92, P5326, DOI 10.1073/pnas.92.12.5326; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; DIAMOND DL, 1995, PROTEIN SCI, V4, P1118, DOI 10.1002/pro.5560040610; ELLIS RJ, 1994, CURR OPIN STRUC BIOL, V4, P117, DOI 10.1016/S0959-440X(94)90069-8; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FERSHT AR, 1993, FEBS LETT, V325, P5, DOI 10.1016/0014-5793(93)81405-O; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLASOE PK, 1960, J PHYS CHEM-US, V64, P188, DOI 10.1021/j100830a521; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1993, EMBO J, V12, P4145, DOI 10.1002/j.1460-2075.1993.tb06098.x; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HUBBARD TJP, 1991, PROTEIN ENG, V4, P711, DOI 10.1093/protein/4.7.711; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LILIE H, 1995, P NATL ACAD SCI USA, V92, P8100, DOI 10.1073/pnas.92.18.8100; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; PERRETT S, 1995, BIOCHEMISTRY-US, V34, P9288, DOI 10.1021/bi00029a003; PERRETT S, UNPUB; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; RODER H, 1985, BIOCHEMISTRY-US, V24, P7396, DOI 10.1021/bi00346a055; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; STENBERG G, UNPUB; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TOPPING TB, 1994, PROTEIN SCI, V3, P760; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P2728, DOI 10.1073/pnas.86.8.2728; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029; ZAHN R, 1994, THESIS U MUNICH	46	134	135	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					642	645		10.1126/science.271.5249.642	http://dx.doi.org/10.1126/science.271.5249.642			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571125				2022-12-24	WOS:A1996TT87000044
J	Michallet, M; Archimbaud, E; Bandini, G; Rowlings, PA; Deeg, HJ; Gahrton, G; Montserrat, E; Rozman, C; Gratwohl, A; Gale, RP				Michallet, M; Archimbaud, E; Bandini, G; Rowlings, PA; Deeg, HJ; Gahrton, G; Montserrat, E; Rozman, C; Gratwohl, A; Gale, RP			HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia	ANNALS OF INTERNAL MEDICINE			English	Article							MULTIVARIATE SURVIVAL ANALYSIS; PROGNOSIS; FLUDARABINE; ADULTS	Objective: To characterize in detail the outcomes of HLA-identical sibling bone marrow transplantation for chronic lymphocytic leukemia (CLL) in patients Lounger than 60 years of age. Design: Retrospective cohort study. Setting: 30 centers for bone marrow transplantation worldwide, which reported data on outcome of HLA-identical sibling bone marrow transplantation for CLL to the European Group for Blood and Marrow Transplantation or the International Bone Marrow Transplant Registry between 1984 and 1992. Patients: 54 patients diagnosed with CLL (median age, 41 years; range, 21 to 58 years). The median interval from diagnosis to transplantation was 37 months (range, 5 to 130 months). At the time of transplantation, 3 patients were at Rai stage 0; 10 were at stage 1; 10 were at stage 2; 7 were at stage 3; and 22 were at stage 4. Intervention: Transplant regimens varied. Most patients received high-dose cyclophosphamide and total body irradiation, followed by infusion of bone marrow from an HLA-identical sibling. After transplantation, immune suppression with cyclosporine or methotrexate or both was generally used to prevent graft-versus-host disease. Measurements: The primary outcome was survival. We also studied hematologic remission, defined as normalization of the leukocyte count, hemoglobin level, and platelet count, and absence of lymphadenopathy and splenomegaly. Results: 38 patients (70%) achieved hematologic remission. Twenty-four (44%) remain alive a median of 27 months (range, 5 to 80 months) after transplantation. Three-year survival probability was 46% (95% CI, 32% to 60%). Three patients who received transplants at Rai stage 0 remain alive 21, 32, and 45 months after transplantation. Three-year survival probabilities were as follows: 68% (CI, 38% to 98%) in 10 patients who received transplants at Rai stage 1, 30% (CI, 2% to 58%) in 10 patients who received transplants at Rai stage 2, 57% (CI, 21% to 93%) in 7 patients who received transplants at Rai stage 3, and 34% (CI, 12% to 56%) in 22 patients who received transplants at Rai stage 4 CLL. Five patients (9%) died of progressive leukemia and 25 (46%) of treatment-related complications. Conclusions: Bone marrow transplants from HLA-identical siblings can result in hematologic remission and survival in persons with CLL, but it is uncertain how these results compare with those of conventional therapies.	MED COLL WISCONSIN, INT BONE MARROW TRANSPLANT REGISTRY, HLTH POLICY INST, MILWAUKEE, WI 53226 USA; SAN ORSOLA HOSP, BOLOGNA, ITALY; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; KAROLINSKA INST, HUDDINGE HOSP, DEPT MED, S-14186 HUDDINGE, SWEDEN; KAROLINSKA INST, HUDDINGE, SWEDEN; SALICK HLTH CARE INC, LOS ANGELES, CA USA; HOP EDOUARD HERRIOT, HOP LYON, F-69437 LYON 03, FRANCE; HOP EDOUARD HERRIOT, SERV HEMATOL, F-69437 LYON 03, FRANCE; HUDDINGE HOSP, KAROLINSKA INST, DEPT MED, S-14186 HUDDINGE, SWEDEN; ST VINCENTS HOSP, DEPT HEMATOL, SYDNEY, NSW, AUSTRALIA; ROYAL POSTGRAD MED SCH, DEPT HEMATOL, LONDON, ENGLAND; CLAUDE HURIEZ HOSP, DEPT HEMATOL, LILLE, FRANCE; LONG ISL JEWISH MED CTR, NEW HYDE PK, NY 11042 USA; UNIV HOSP, DIV HEMATOL, DEPT INTERNAL MED, BASEL, SWITZERLAND; HOSP CLIN BARCELONA, BARCELONA, SPAIN	Medical College of Wisconsin; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Fred Hutchinson Cancer Center; Karolinska Institutet; Karolinska Institutet; CHU Lyon; CHU Lyon; Karolinska Institutet; St Vincents Hospital Sydney; Imperial College London; Universite de Lille - ISITE; CHU Lille; Northwell Health; University of Barcelona; Hospital Clinic de Barcelona					NATIONAL CANCER INSTITUTE [P01CA040053] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA-40053] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANDINI G, 1991, BONE MARROW TRANSPL, V7, P251; BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V; BORTIN MM, 1992, ANN INTERN MED, V116, P505, DOI 10.7326/0003-4819-116-6-505; FOON KA, 1990, ANN INTERN MED, V113, P525, DOI 10.7326/0003-4819-113-7-525; GAJEWSKI JL, 1996, IN PRESS J CLIN ONCO; GALE RP, 1993, BAILLIERE CLIN HAEM, V6, P879, DOI 10.1016/S0950-3536(05)80181-7; GALE RP, 1996, IN PRESS LEUKEMIA; HOROWITZ MM, 1991, ANN INTERN MED, V115, P13, DOI 10.7326/0003-4819-115-1-13; JULIUSSON G, 1992, NEW ENGL J MED, V327, P1056, DOI 10.1056/NEJM199210083271504; JULIUSSON G, 1993, CHRONIC LYMPHOCYTIC, P83; KEATING MJ, 1993, BLOOD, V81, P2878; KHOURI IF, 1994, J CLIN ONCOL, V12, P748, DOI 10.1200/JCO.1994.12.4.748; LEE JS, 1987, BLOOD, V69, P929; MICHALLET M, 1991, BONE MARROW TRANSPL, V7, P275; MONTSERRAT E, 1989, ANN INTERN MED, V110, P236; MONTSERRAT E, 1991, BLOOD, V78, P1545; MONTSERRAT E, 1986, BRIT J HAEMATOL, V62, P567, DOI 10.1111/j.1365-2141.1986.tb02969.x; RABINOWE SN, 1993, BLOOD, V82, P1366; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; ROZMAN C, 1984, BLOOD, V64, P642	20	204	207	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					311	315		10.7326/0003-4819-124-3-199602010-00005	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554226				2022-12-24	WOS:A1996TR59600005
J	Shaper, AG				Shaper, AG			Reflections on the seven countries study	LANCET			English	Editorial Material											Shaper, AG (corresponding author), ROYAL FREE HOSP,SCH MED,LONDON,ENGLAND.							BLACKBURN H, 1995, TRAIL HEART ATTACKS, P148; Kromhout D., 1994, 7 COUNTRIES STUDY SC, P219; TOSHIMA H, 1994, LESSONS SCI 7 COUNTR, P243	3	7	7	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					208	208		10.1016/S0140-6736(96)90396-7	http://dx.doi.org/10.1016/S0140-6736(96)90396-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551873				2022-12-24	WOS:A1996TT06900002
J	Savage, B; Saldivar, E; Ruggeri, ZM				Savage, B; Saldivar, E; Ruggeri, ZM			Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor	CELL			English	Article							VONWILLEBRAND-FACTOR-BINDING; CORONARY-ARTERY THROMBOSIS; MEMBRANE GLYCOPROTEIN-IB; IIB-IIIA COMPLEX; SHEAR-STRESS; MONOCLONAL-ANTIBODIES; ALPHA-CHAIN; DOMAIN; AGGREGATION; DISEASE	We have identified two distinct mechanisms initiating the adhesion of flowing platelets to thrombogenic surfaces. The integrin alpha(IIb)beta(3) promotes immediate arrest onto fibrinogen but is fully efficient only at wall shear rates below 600-900 s(-1), perhaps because of a relatively slow rate of bond formation or low resistance to tensile stress. In contrast, glycoprotein Ib alpha binding to immobilized von Willebrand factor (vWF) appears to have fast association and dissociation rates as well as high resistance to tensile stress, supporting slow movement of platelets in continuous contact with the surface even at shear rates in excess of 6000 s(-1). This eventually allows activated alpha(IIb)beta(3) to arrest platelets onto vWF under conditions not permissive of direct binding to fibrinogen. The coupling of these different functions may be crucial for thrombogenesis.	SCRIPPS RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	Savage, B (corresponding author), SCRIPPS RES INST, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.		Pieper, Maja/AAN-8539-2020		NHLBI NIH HHS [HL-31950, HL-48728, HL-42846] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042846, P01HL031950, P01HL048728, R37HL042846] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEVRIADOU BR, 1993, BLOOD, V81, P1263; ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; BACK LD, 1977, J BIOMECH, V10, P339, DOI 10.1016/0021-9290(77)90006-9; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BELLINGER DA, 1987, P NATL ACAD SCI USA, V84, P8100, DOI 10.1073/pnas.84.22.8100; BENNETT JS, 1982, J BIOL CHEM, V257, P8049; COLLER BS, 1980, BLOOD, V55, P169; DISE CA, 1982, J BIOL CHEM, V257, P4701; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FOWLER WE, 1985, J CLIN INVEST, V76, P1491, DOI 10.1172/JCI112129; FRENETTE PS, 1995, P NATL ACAD SCI USA, V92, P7450, DOI 10.1073/pnas.92.16.7450; FUJIMURA Y, 1991, BLOOD, V77, P113; Fung YC., 1981, BIOMECHANICS; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GIBSON CM, 1993, ARTERIOSCLER THROMB, V13, P310, DOI 10.1161/01.ATV.13.2.310; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; GOGSTAD GO, 1982, BLOOD, V60, P663; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4; HANDA M, 1986, J BIOL CHEM, V261, P2579; HUBER W, 1995, EUR J BIOCHEM, V227, P647, DOI 10.1111/j.1432-1033.1995.tb20184.x; IKEDA Y, 1993, THROMB HAEMOSTASIS, V69, P496; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; KAZAL LA, 1963, P SOC EXP BIOL MED, V113, P989; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; MCKEE PA, 1966, ARCH BIOCHEM BIOPHYS, V116, P271, DOI 10.1016/0003-9861(66)90033-6; MOAKE JL, 1988, BLOOD, V71, P1366; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MUSTARD JF, 1978, BLOOD, V52, P453; NACHMAN RL, 1982, J CLIN INVEST, V69, P263, DOI 10.1172/JCI110448; NICHOLS TC, 1991, CIRCULATION, V83, P56; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; NIIYA K, 1987, BLOOD, V70, P475; PARHAM P, 1982, J IMMUNOL METHODS, V53, P133, DOI 10.1016/0022-1759(82)90137-5; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; Ruggeri ZM, 1993, CURR OPIN CELL BIOL, V5, P898, DOI 10.1016/0955-0674(93)90041-N; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; SAVAGE B, 1990, J BIOL CHEM, V265, P11766; SAVAGE B, 1995, J BIOL CHEM, V270, P28812, DOI 10.1074/jbc.270.48.28812; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SIXMA JJ, 1977, SEMIN HEMATOL, V14, P265; STRONY J, 1990, CIRCULATION, V81, P1106, DOI 10.1161/01.CIR.81.3.1106; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; SUGIMOTO M, 1993, J BIOL CHEM, V268, P12185; TANGELDER GJ, 1988, AM J PHYSIOL, V254, pH1059, DOI 10.1152/ajpheart.1988.254.6.H1059; TEMPELMAN LA, 1994, BIOPHYS J, V66, P1231, DOI 10.1016/S0006-3495(94)80907-5; TOZEREN A, 1992, BIOPHYS J, V63, P700, DOI 10.1016/S0006-3495(92)81660-0; TSCHOPP TB, 1974, J LAB CLIN MED, V83, P296; USAMI S, 1993, ANN BIOMED ENG, V21, P77, DOI 10.1007/BF02368167; VICENTE V, 1988, J BIOL CHEM, V263, P18473; VICENTE V, 1990, J BIOL CHEM, V265, P274; WEISS HJ, 1975, NEW ENGL J MED, V293, P531, DOI 10.1056/NEJM197509112931105; WEISS HJ, 1975, NEW ENGL J MED, V293, P580, DOI 10.1056/NEJM197509182931204; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WEISS HJ, 1971, NEW ENGL J MED, V285, P369, DOI 10.1056/NEJM197108122850703; WEISS HJ, 1993, J LAB CLIN MED, V122, P324; Whitmore R. L., 1968, RHEOLOGY CIRCULATION	57	944	974	3	65	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					289	297		10.1016/S0092-8674(00)80983-6	http://dx.doi.org/10.1016/S0092-8674(00)80983-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565074	Bronze			2022-12-24	WOS:A1996TR59500015
J	Parrington, J; Swann, K; Shevchenko, VI; Sesay, AK; Lai, FA				Parrington, J; Swann, K; Shevchenko, VI; Sesay, AK; Lai, FA			Calcium oscillations in mammalian eggs triggered by a soluble sperm protein	NATURE			English	Article							SEA-URCHIN EGGS; FERTILIZATION; ACTIVATION; OOCYTES; FUSION	AT fertilization in mammals, the sperm induces a characteristic series of Ca2+ oscillations in the egg which serve as the essential trigger for egg activation and early development of the embryo(1-3). It is not known how the sperm initiates this fundamental process, however(4-6), nor has any pathway linking sperm-egg membrane-receptor binding with intracellular Ca2+ release been demonstrated(7-11). Microinjection of sperm extracts into mammalian eggs elicits Ca2+ oscillations identical to those occurring at fertilization(12-14), which suggests that sperm may introduce a Ca2+ oscillation-inducing factor into the egg on gamete membrane fusion(12,15-18). Here we identify a soluble sperm protein that exhibits Ca2+ oscillation-inducing ('oscillogen') activity in eggs, Sperm oscillogen exists as an oligomer with a subunit of M(r) 33K and a specific intracellular localization at the equatorial segment of the sperm head. Cloning of the 33K oscillogen complementary DNA indicates similarity with a hexose phosphate isomerase found in prokaryotes. This sperm-derived oscillogen, termed oscillin, may represent the physiological trigger for development in mammals.	NATL INST MED RES, MRC, LONDON NW7 1AA, ENGLAND; ST GEORGE HOSP, SCH MED, MRC, EXPTL EMBRYOL & TERATOL UNIT, LONDON SW17 0RE, ENGLAND; UCL, DEPT ANAT & DEV BIOL, LONDON WC1E 6BT, ENGLAND	MRC National Institute for Medical Research; St Georges University London; University of London; University College London			Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051; Lai, Tony/0000-0003-2852-8547; Swann, Karl/0000-0002-4355-1449				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berrie CP, 1996, BIOCHEM J, V313, P369, DOI 10.1042/bj3130369; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; CUTHBERTSON KSR, 1985, NATURE, V316, P541, DOI 10.1038/316541a0; DALE B, 1985, EXPERIENTIA, V41, P1068, DOI 10.1007/BF01952148; DOZORTSEV D, 1995, HUM REPROD, V10, P403, DOI 10.1093/oxfordjournals.humrep.a135952; Foltz KR, 1993, ZYGOTE, V1, P276, DOI 10.1017/S0967199400001593; HARLOW E, 1988, ANTIBODIES LABORATOR; HOMA ST, 1994, HUM REPROD, V9, P2356, DOI 10.1093/oxfordjournals.humrep.a138452; KLINE D, 1992, DEV BIOL, V149, P80, DOI 10.1016/0012-1606(92)90265-I; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; MYLES DG, 1993, DEV BIOL, V158, P35, DOI 10.1006/dbio.1993.1166; NUCCITELLI R, 1991, CURR TOP DEV BIOL, V25, P1; OHLENDIECK K, 1995, TRENDS BIOCHEM SCI, V20, P29, DOI 10.1016/S0968-0004(00)88947-1; Shen SS, 1992, CURR OPIN GENET DEV, V2, P642, DOI 10.1016/S0959-437X(05)80185-6; STICE SL, 1990, MOL REPROD DEV, V25, P272, DOI 10.1002/mrd.1080250309; SWANN K, 1990, DEVELOPMENT, V110, P1295; SWANN K, 1994, CELL CALCIUM, V15, P331, DOI 10.1016/0143-4160(94)90072-8; SWANN K, 1994, INT REV CYTOL, V152, P183, DOI 10.1016/S0074-7696(08)62557-7; Swann K, 1993, ZYGOTE, V1, P273, DOI 10.1017/S0967199400001581; TESARIK J, 1994, HUM REPROD, V9, P511, DOI 10.1093/oxfordjournals.humrep.a138537; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; WHITAKER M, 1993, DEVELOPMENT, V117, P1; Yanagimachi R., 1988, P135	26	339	346	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	1996	379	6563					364	368		10.1038/379364a0	http://dx.doi.org/10.1038/379364a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552195				2022-12-24	WOS:A1996TR32300064
J	LeDuc, JW				LeDuc, JW			World Health Organization strategy for emerging infectious diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LeDuc, JW (corresponding author), WHO,DIV EMERGING & OTHER COMMUNICABLE DIS SURVEILLANC,CH-1211 GENEVA 27,SWITZERLAND.							[Anonymous], 1995, WKLY EPIDEMIOL REC, V5, P35; BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; GLASS RI, 1991, LANCET, V338, P791, DOI 10.1016/0140-6736(91)90673-D; Lederberg J., 1992, EMERGING INFECTIONS; MURRAY K, 1995, SCIENCE, V268, P94, DOI 10.1126/science.7701348; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; OBRIEN TF, 1995, EMERG INFECT DIS, V1, P66, DOI 10.3201/eid0102.950209; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; 1994, B WORLD HEALTH ORGAN, V72, P845; 1995, WHOCDSBVI952 PUBL; 1995, REPORT NATIONAL SCI	12	29	29	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					318	320		10.1001/jama.275.4.318	http://dx.doi.org/10.1001/jama.275.4.318			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544274				2022-12-24	WOS:A1996TP96500030
J	AlChalabi, A; Enayat, ZE; Bakker, MC; Sham, PC; Ball, DM; Shaw, CE; Lloyd, CM; Powell, JF; Leigh, PN				AlChalabi, A; Enayat, ZE; Bakker, MC; Sham, PC; Ball, DM; Shaw, CE; Lloyd, CM; Powell, JF; Leigh, PN			Association of apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease	LANCET			English	Article							SPORADIC ALZHEIMERS-DISEASE	Background Variants of the apolipoprotein E (APOE) gene influence the age of onset of Alzheimer's disease. APOE may influence the presentation of other neurological diseases. We investigated the relationship between the allelic variants of apolipoprotein E and clinical presentation in motor neuron disease. Methods 123 patients with motor neuron disease and 121 controls were studied. Diagnosis, location of onset and date of onset were recorded prospectively. Genotyping was performed blind to clinical information. Findings Possession of at least one epsilon 4 allele was significantly more common in patients with bulbar onset motor neuron disease (14/33, 42%) than in limb onset patients (20/90, 22%) and controls (26/121, 21%) (chi(2)=4.93, p=0.026 and chi(2)=5.91, p=0.015, respectively). Interpretation These results suggest that the apolipoprotein E epsilon 4 allele may influence the pattern of motor neuron loss in motor neuron disease and that it may affect neuronal function in ways unrelated to the deposition of beta-amyloid or accumulation of neurofibrillary tangles.	INST PSYCHIAT,DEPT CLIN NEUROSCI,LONDON SE5 8AF,ENGLAND; INST PSYCHIAT,KINGS MND CARE & RES CTR,LONDON SE5 8AF,ENGLAND; INST PSYCHIAT,DEPT PSYCHOL,LONDON SE5 8AF,ENGLAND; INST PSYCHIAT,DEPT NEUROSCI,LONDON SE5 8AF,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,LONDON SE5 8AF,ENGLAND	University of London; King's College London; University of London; King's College London; University of London; King's College London; University of London; King's College London; University of London; King's College London			Powell, John F/G-4412-2011; Al-Chalabi, Ammar/E-5361-2010; Leigh, Peter/AAD-5638-2019	Powell, John F/0000-0001-6124-439X; Al-Chalabi, Ammar/0000-0002-4924-7712; 				ABRAHAMS S, 1995, J NEUROL SCI, V129, P54, DOI 10.1016/0022-510X(95)00063-8; HAVERKAMP LJ, 1995, BRAIN, V118, P707, DOI 10.1093/brain/118.3.707; MUI S, 1995, ANN NEUROL, V38, P460, DOI 10.1002/ana.410380318; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NORRIS F, 1993, J NEUROL SCI, V118, P48, DOI 10.1016/0022-510X(93)90245-T; REBECK GW, 1993, NEURON, V11, P575; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHNEIDER JA, 1995, ANN NEUROL, V38, P131, DOI 10.1002/ana.410380122; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; WHENHAM PR, 1991, LANCET, V337, P1158	10	83	84	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 20	1996	347	8995					159	160		10.1016/S0140-6736(96)90343-8	http://dx.doi.org/10.1016/S0140-6736(96)90343-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544551				2022-12-24	WOS:A1996TQ24400012
J	Bednarek, SY; Ravazzola, M; Hosobuchi, M; Amherdt, M; Perrelet, A; Schekman, R; Orci, L				Bednarek, SY; Ravazzola, M; Hosobuchi, M; Amherdt, M; Perrelet, A; Schekman, R; Orci, L			COPI- and COPII-coated vesicles bud directly from the endoplasmic reticulum in yeast	CELL			English	Article							ADP-RIBOSYLATION FACTOR; BREFELDIN-A; TRANSPORT VESICLES; GOLGI-COMPLEX; GUANINE-NUCLEOTIDE; PROTEIN-TRANSPORT; BETA-COP; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; MEMBRANE-PROTEIN	The cytosolic yeast proteins Sec13p-Sec31p, Sec23p-Sec24p, and the small GTP-binding protein Sar1p generate protein transport vesicles by forming the membrane coat termed COPII. We demonstrate by thin section and immunoelectron microscopy that purified COPII components form transport vesicles directly from the outer membrane of isolated yeast nuclei. Another set of yeast cytosolic proteins, coatomer and Arf1p (COPI), also form coated buds and vesicles from the nuclear envelope. Formation of COPI-coated, but not COPII-coated, buds and vesicles on the nuclear envelope is inhibited by the fungal metabolite brefeldin A. The two vesicle populations are distinct. However, both vesicle types are devoid of endoplasmic reticulum (ER) resident proteins, and each contains targeting proteins necessary for docking at the Golgi complex. Our data suggest that COPI and COPII mediate separate vesicular transport pathways from the ER.	UNIV GENEVA, SCH MED, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva	Bednarek, SY (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.							ARIS JP, 1991, METHOD ENZYMOL, V194, P735; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BLOOM H, 1987, ELECTROPHORESIS, V8, P93; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DAUM G, 1982, J BIOL CHEM, V257, P3028; DENFERT C, 1992, EMBO J, V11, P4205, DOI 10.1002/j.1460-2075.1992.tb05514.x; DOERING TL, 1996, IN PRESS EMBO J; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUDEN R, 1994, J BIOL CHEM, V269, P24486; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GRAHAM TR, 1993, EMBO J, V12, P869, DOI 10.1002/j.1460-2075.1993.tb05727.x; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HARDWICK KG, 1992, EMBO J, V11, P4187, DOI 10.1002/j.1460-2075.1992.tb05512.x; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; OPRINS A, 1994, J CELL BIOL, V124, P725; ORCI L, 1994, P NATL ACAD SCI USA, V91, P11924, DOI 10.1073/pnas.91.25.11924; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; ORCI L, 1993, P NATL ACAD SCI USA, V90, P11089, DOI 10.1073/pnas.90.23.11089; ORCI L, 1991, CELL, V64, P1183; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; PREUSS D, 1991, YEAST, V7, P891, DOI 10.1002/yea.320070902; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMA NR, 1995, CURR OPIN CELL BIOL, V7, P536, DOI 10.1016/0955-0674(95)80011-5; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SEGAARD M, 1994, CELL, V8, P937; SHAYWITZ DA, 1995, J CELL BIOL, V128, P769, DOI 10.1083/jcb.128.5.769; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TANDLER B, 1990, J ELECTRON MICR TECH, V16, P81, DOI 10.1002/jemt.1060160110; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOGEL JP, 1993, J BIOL CHEM, V268, P3040; WUESTEHUBE LJ, 1992, METHOD ENZYMOL, V219, P124; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	60	234	242	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1183	1196		10.1016/0092-8674(95)90144-2	http://dx.doi.org/10.1016/0092-8674(95)90144-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548805	Bronze			2022-12-24	WOS:A1995TM76200014
J	Grieco, D; Porcellini, A; Avvedimento, EV; Gottesman, ME				Grieco, D; Porcellini, A; Avvedimento, EV; Gottesman, ME			Requirement for cAMP-PKA pathway activation by M phase-promoting factor in the transition from mitosis to interphase	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; XENOPUS-LAEVIS-OOCYTES; CELL-CYCLE; CATALYTIC SUBUNIT; AMPHIBIAN EGGS; CDC2; DEGRADATION; EXTRACTS; MPF; INACTIVATION	Cell cycle progression in cycling Xenopus egg extracts is accompanied by fluctuations in the concentration of adenosine 3',5'-monophosphate (cAMP) and in the activity of the cAMP-dependent protein kinase (PKA). The concentration of cAMP and the activity of PKA decrease at the onset of mitosis and increase at the transition between mitosis and interphase. Blocking the activation of PKA at metaphase prevented the transition into interphase; the activity of M phase-promoting factor (MPF; the cyclin B-p34(cdc2) complex) remained high, and mitotic cyclins were not degraded. The arrest in mitosis was reversed by the reactivation of PKA. The inhibition of protein synthesis prevented the accumulation of cyclin and the oscillations of MPF, PKA, and cAMP. Addition of recombinant nondegradable cyclin B activated p34(cdc2) and PKA and induced the degradation of full-length cyclin B. Addition of cyclin A activated p34(cdc2) but not PKA, nor did it induce the degradation of full-length cyclin B. These findings suggest that cyclin degradation and exit from mitosis require MPF-dependent activation of the cAMP-PKA pathway.	UNIV NAPLES,SCH MED 2,CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; COLUMBIA UNIV,INST CANC RES,NEW YORK,NY 10032; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE,SCH MED,CATANZARO,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Columbia University; Universita Mediterranea di Reggio Calabria	Grieco, D (corresponding author), UNIV NAPLES,SCH MED 2,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC L CAL,VIA S PANSINI 5,I-80131 NAPLES,ITALY.		Porcellini, Antonio/AAC-6097-2019; Porcellini, Antonio/E-1900-2011	Porcellini, Antonio/0000-0001-6882-9518; GRIECO, Domenico/0000-0002-7131-5742				CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; COSTA M, 1976, J BIOL CHEM, V251, P3313; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FINIDORILEPICARD J, 1981, NATURE, V292, P255, DOI 10.1038/292255a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRIECO D, 1994, P NATL ACAD SCI USA, V91, P9896, DOI 10.1073/pnas.91.21.9896; GRIECO D, UNPUB; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LORCA T, 1992, J CELL SCI, V102, P55; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MALLER JL, 1977, J BIOL CHEM, V252, P1712; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PORCELLINI A, UNPUB; SCHORDERETSLATKINE S, 1978, CELL, V15, P1269, DOI 10.1016/0092-8674(78)90052-1; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682	31	127	131	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1718	1723		10.1126/science.271.5256.1718	http://dx.doi.org/10.1126/science.271.5256.1718			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596931				2022-12-24	WOS:A1996UB15100044
J	Ridge, JP; Fuchs, EJ; Matzinger, P				Ridge, JP; Fuchs, EJ; Matzinger, P			Neonatal tolerance revisited: Turning on newborn T cells with dendritic cells	SCIENCE			English	Article							ANTIGEN-PRESENTING FUNCTION; SMALL B-CELLS; TRANSPLANTATION TOLERANCE; SELF-TOLERANCE; PROTEIN ANTIGENS; IMMUNE-SYSTEM; LYMPHOCYTE-T; INDUCTION; MICE; INVIVO	For some time it has been thought that antigenic challenge in neonatal life is a tolerogenic rather than immunogenic event. Reexamination of the classic neonatal tolerance experiments of Billingham, Brent, and Medawar showed that tolerance is not an intrinsic property of the newborn immune system, but that the nature of the antigen-presenting cell determines whether the outcome is neonatal tolerance or immunization.			Ridge, JP (corresponding author), NIAID,CELLULAR & MOLEC IMMUNOL LAB,SECT T CELL TOLERANCE & MEMORY,GHOST LAB,BETHESDA,MD 20892, USA.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257				ARNOLD B, 1991, ANNU REV IMMUNOL, V9, P297, DOI 10.1146/annurev.iy.09.040191.001501; BAL V, 1990, EUR J IMMUNOL, V20, P1893, DOI 10.1002/eji.1830200904; BANDEIRA A, 1989, P NATL ACAD SCI USA, V86, P272, DOI 10.1073/pnas.86.1.272; BELLGRAU D, 1981, J EXP MED, V153, P1660, DOI 10.1084/jem.153.6.1660; BILLINGHAM R, 1956, P ROY SOC LONDON, V239, P44; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BILLINGHAM RE, 1960, J IMMUNOL, V85, P14; BONNEY EA, UNPUB; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BURNET FM, 1950, AUST J EXP BIOL MED, V28, P291, DOI 10.1038/icb.1950.29; Burnet FM, 1949, PRODUCTION ANTIBODIE; BURNET FM, 1959, CLONAL SELECTION THE; BUSKER AE, 1990, CELL IMMUNOL, V125, P225, DOI 10.1016/0008-8749(90)90076-4; CHEN NX, 1995, TRANSPLANTATION, V59, P933, DOI 10.1097/00007890-199504150-00002; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHIAK J, 1978, IMMUNOLOGY, V34, P265; COBBOLD SP, 1990, EUR J IMMUNOL, V20, P2747, DOI 10.1002/eji.1830201232; DONOHOE JA, 1983, TRANSPLANTATION, V35, P62, DOI 10.1097/00007890-198301000-00012; EYNON EE, 1991, TRANSPLANT P, V23, P729; EYNON EE, 1992, J EXP MED, V175, P131, DOI 10.1084/jem.175.1.131; FINKLEMAN F, UNPUB; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; GERSHON RK, 1971, IMMUNOLOGY, V21, P903; GOLLOB KJ, 1993, J IMMUNOL, V150, P3705; GUERDER S, 1992, J EXP MED, V176, P553, DOI 10.1084/jem.176.2.553; GUERDER S, 1989, COLD SPRING HARB SYM, V54, P799; HOFFMAN PM, 1984, J VIROL, V52, P734, DOI 10.1128/JVI.52.3.734-738.1984; INABA M, 1991, J EXP MED, V173, P549, DOI 10.1084/jem.173.3.549; ISHIZAKA ST, 1986, J IMMUNOL, V137, P2093; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JOHNSON LL, 1988, TRANSPLANTATION, V46, P167; JOHNSON LL, 1988, TRANSPLANTATION, V46, P170; Lafferty K J, 1986, Prog Clin Biol Res, V224, P87; LAFFERTY KJ, 1975, AUST J EXP BIOL MED, V53, P27, DOI 10.1038/icb.1975.3; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LASSILA O, 1988, NATURE, V334, P253, DOI 10.1038/334253a0; LAUCHART W, 1980, TRANSPLANTATION, V29, P259, DOI 10.1097/00007890-198003000-00020; LECHLER RI, 1982, J EXP MED, V156, P1835, DOI 10.1084/jem.156.6.1835; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LU CY, 1979, NATURE, V282, P327, DOI 10.1038/282327a0; MACATONIA SE, 1989, J EXP MED, V169, P1255, DOI 10.1084/jem.169.4.1255; MARKMANN J, 1988, NATURE, V336, P476, DOI 10.1038/336476a0; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MILLER A, 1994, EUR J IMMUNOL, V24, P1026, DOI 10.1002/eji.1830240503; MORRISSEY PJ, 1983, J EXP MED, V158, P365, DOI 10.1084/jem.158.2.365; NOSSAL G. J. V., 1957, AUSTRALIAN JOUR EXPTL BIOL AND MED SCI, V35, P549, DOI 10.1038/icb.1957.57; POWELL TJ, 1990, J IMMUNOL, V144, P854; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; RAMMENSEE HG, 1984, J IMMUNOL, V133, P2390; REES MA, 1990, P NATL ACAD SCI USA, V87, P2765, DOI 10.1073/pnas.87.7.2765; RIDGE JP, UNPUB; ROSER BJ, 1989, IMMUNOL REV, V107, P179, DOI 10.1111/j.1600-065X.1989.tb00009.x; Sarzotti M, 1996, SCIENCE, V271, P1726, DOI 10.1126/science.271.5256.1726; SCHURMANS S, 1990, J IMMUNOL, V145, P2465; SHEHADEH NN, 1993, SPRINGER SEMIN IMMUN, V14, P203; STROBEL S, 1984, PEDIATR RES, V18, P588, DOI 10.1203/00006450-198407000-00004; UMLAUF SW, 1993, IMMUNOL REV, V133, P177, DOI 10.1111/j.1600-065X.1993.tb01516.x	62	638	659	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1723	1726		10.1126/science.271.5256.1723	http://dx.doi.org/10.1126/science.271.5256.1723			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596932	Green Submitted			2022-12-24	WOS:A1996UB15100045
J	Keiler, KC; Waller, PRH; Sauer, RT				Keiler, KC; Waller, PRH; Sauer, RT			Role of a peptide tagging system in degradation of proteins synthesized from damaged messenger RNA	SCIENCE			English	Article							N-END RULE; ESCHERICHIA-COLI; TRANSCRIPTION TERMINATION; STABLE RNA; CLONING	Variants of lambda repressor and cytochrome b(562) translated from messenger RNAs without stop codons were modified by carboxyl terminal addition of an ssrA-encoded peptide tag and subsequently degraded by carboxyl terminal-specific proteases present in both the cytoplasm and periplasm of Escherichia coli, The tag appears to be added to the carboxyl terminus of the nascent polypeptide chain by cotranslational switching of the ribosome from the damaged messenger RNA to ssrA RNA.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)				Keiler, Kenneth/0000-0001-8753-335X; Sauer, Robert/0000-0002-1719-5399	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016892, R01AI015706, R37AI015706] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-16892, AI-15706] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTONOV VK, 1993, CHEM PROTEOLYSIS, P36; BALZI E, 1990, J BIOL CHEM, V265, P7464; Bass S, 1996, J BACTERIOL, V178, P1154, DOI 10.1128/jb.178.4.1154-1161.1996; CAUSTON H, 1994, MOL MICROBIOL, V14, P731, DOI 10.1111/j.1365-2958.1994.tb01310.x; Clechanover A., 1994, CELL, V79, P13; FARNHAM PJ, 1980, CELL, V20, P739, DOI 10.1016/0092-8674(80)90320-7; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HAJNSDORF E, 1994, EMBO J, V13, P3368, DOI 10.1002/j.1460-2075.1994.tb06639.x; HERSHEY JWB, 1987, CELLULAR MOL BIOL, P613; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUANG WM, 1988, SCIENCE, V239, P1005, DOI 10.1126/science.2830666; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KEILER KC, 1995, J BIOL CHEM, V270, P28864, DOI 10.1074/jbc.270.48.28864; KEILER KC, 1995, PROTEIN SCI, V4, P1507, DOI 10.1002/pro.5560040808; KELLER KC, 1996, J BIOL CHEM, V281, P2589; KIRBY JE, 1994, J BACTERIOL, V176, P2068, DOI 10.1128/jb.176.7.2068-2081.1994; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; NIKKILA H, 1991, EUR J BIOCHEM, V202, P309, DOI 10.1111/j.1432-1033.1991.tb16377.x; OH BK, 1991, MOL GEN GENET, V229, P52, DOI 10.1007/BF00264212; PARSELL DA, 1990, GENE DEV, V4, P277, DOI 10.1101/gad.4.2.277; RAY BK, 1979, MOL GEN GENET, V174, P25, DOI 10.1007/BF00433301; RETALLACK DM, 1994, J BACTERIOL, V176, P2082, DOI 10.1128/jb.176.7.2082-2089.1994; RETALLACK DM, 1995, CELL, V83, P227, DOI 10.1016/0092-8674(95)90164-7; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; SHRADER TE, 1993, J BACTERIOL, V175, P4364, DOI 10.1128/JB.175.14.4364-4374.1993; SILBER KR, 1992, P NATL ACAD SCI USA, V89, P295, DOI 10.1073/pnas.89.1.295; SILBER KR, 1994, MOL GEN GENET, V242, P237, DOI 10.1007/BF00391018; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; USHIDA C, 1994, NUCLEIC ACIDS RES, V22, P3392, DOI 10.1093/nar/22.16.3392	30	858	896	0	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					990	993		10.1126/science.271.5251.990	http://dx.doi.org/10.1126/science.271.5251.990			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584937				2022-12-24	WOS:A1996TV70400050
J	Kawashima, T; BerthetColominas, C; Wulff, M; Cusack, S; Leberman, R				Kawashima, T; BerthetColominas, C; Wulff, M; Cusack, S; Leberman, R			The structure of the Escherichia coli EF-Tu center dot EF-Ts complex at 2.5 angstrom resolution	NATURE			English	Article							POLYPEPTIDE ELONGATION-FACTOR; QBETA-REPLICASE; PURIFICATION; SEQUENCE; DOMAIN; RAS	The crystal structure of the EF-Tu . EF-Ts complex from Escherichia coli has been determined to a resolution of 2.5 Angstrom. The complex contains two subunits of each of the elongation factors. The two EF-Ts molecules form a tight dimer, but there is little contact between the two EF-Tu molecules. The interaction of EF-Ts with EF-Tu results principally in the disruption of the Mg2+ ion binding site, thereby reducing the affinity of EF-Tu for guanine nucleotides.	EUROPEAN MOLEC BIOL LAB, GRENOBLE OUTSTN, F-38042 GRENOBLE, FRANCE; EUROPEAN SYNCHROTRON RADIAT FACIL, F-38043 GRENOBLE, FRANCE	European Molecular Biology Laboratory (EMBL); European Synchrotron Radiation Facility (ESRF)				Cusack, Stephen/0000-0002-9324-0796				AN G, 1981, NUCLEIC ACIDS RES, V9, P4163, DOI 10.1093/nar/9.16.4163; ARAI KI, 1972, J BIOL CHEM, V247, P7029; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BLUMENTHAL T, 1972, P NATL ACAD SCI USA, V69, P1313, DOI 10.1073/pnas.69.5.1313; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; ERTEL R, 1968, ARCH BIOCHEM BIOPHYS, V128, P331, DOI 10.1016/0003-9861(68)90039-8; JANSSEN GMC, 1994, J BIOL CHEM, V269, P31410; JOHN J, 1993, J BIOL CHEM, V268, P923; JONES MD, 1980, EUR J BIOCHEM, V108, P507, DOI 10.1111/j.1432-1033.1980.tb04748.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jones TA, 1992, MOL REPLACEMENT, P92; KABSCH W, 1977, J MOL BIOL, V117, P999, DOI 10.1016/S0022-2836(77)80009-0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAWASHIMA T, IN PRESS ACTA CRYSTA; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEBERMAN R, 1980, ANAL BIOCHEM, V104, P29, DOI 10.1016/0003-2697(80)90272-9; LEBERMAN R, 1981, FEBS LETT, V124, P279, DOI 10.1016/0014-5793(81)80155-X; LESLIE AGW, 1987, P CCP4 STUD WEEK SER, P39; LUCUSLENARD J, 1966, P NATN ACAD SCIUS, V55, P1562; MILLER DL, 1970, ARCH BIOCHEM BIOPHYS, V141, P26, DOI 10.1016/0003-9861(70)90102-5; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; SCHICK B, 1994, ACTA CRYSTALLOGR D, V50, P563, DOI 10.1107/S0907444994001976; SCHNEIDER U, 1983, THESIS U FREIBURG GE; WEISSBACH H, 1970, ARCH BIOCHEM BIOPHYS, V137, P262, DOI 10.1016/0003-9861(70)90433-9; 1979, SERC4 DAR LAB COLL C	30	276	283	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 8	1996	379	6565					511	518		10.1038/379511a0	http://dx.doi.org/10.1038/379511a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596629				2022-12-24	WOS:A1996TU69300041
J	Tycowski, KT; Shu, MD; Steitz, JA				Tycowski, KT; Shu, MD; Steitz, JA			A mammalian gene with introns instead of exons generating stable RNA products	NATURE			English	Article							SMALL NUCLEOLAR RNAS	THE nucleoli of eukaryotic cells are the sites of ribosomal RNA transcription and processing and of ribosomal subunit assembly. They contain multiple small nucleolar RNAs (snoRNAs), several of which are essential for rRNA maturation(1). The U3, U8 and U13 snoRNA genes are transcribed independently, whereas U14-U24, as well as E3, are located within introns of protein-coding genes, most of whose functions are linked to translation. These snoRNAs are co-transcribed with their host pre-mRNAs and released by processing from excised introns(1,2). Here we show that, in addition to U22, seven novel fibrillarin-associated snoRNAs, named U25-U31, are encoded within different introns of the unusually compact mammalian U22 host gene (UHG). All seven RNAs exhibit extensive (12-15 nucleotides) complementarity to different segments of the mature rRNAs, followed by a C/AUGA ('U-turn') sequence. The spliced UHG RNA, although it is associated with polysomes, has little potential for protein coding, is short-lived, and is poorly conserved between human and mouse. Thus, the introns rather than the exons specify the functional products of UHG.			Tycowski, KT (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,295 CONGRESS AVE,NEW HAVEN,CT 06536, USA.							BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; GEYER PK, 1982, MOL CELL BIOL, V2, P685, DOI 10.1128/MCB.2.6.685; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; MAGER WH, 1988, BIOCHIM BIOPHYS ACTA, V949, P1, DOI 10.1016/0167-4781(88)90048-6; MAQUAT LE, 1995, RNA, V1, P453; MATTICK JS, 1994, CURR OPIN GENET DEV, V4, P823, DOI 10.1016/0959-437X(94)90066-3; MAXWELL ES, 1995, A REV BIOCH, V35, P899; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; PELLIZZONI L, 1994, NUCLEIC ACIDS RES, V22, P4607, DOI 10.1093/nar/22.22.4607; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; RIMOLDI OJ, 1993, MOL CELL BIOL, V13, P4382, DOI 10.1128/MCB.13.7.4382; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SOLLNERWEBB B, 1993, CELL, V75, P403, DOI 10.1016/0092-8674(93)90374-Y; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; TYCOWSKI KT, 1994, SCIENCE, V266, P1558, DOI 10.1126/science.7985025	16	247	258	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					464	466		10.1038/379464a0	http://dx.doi.org/10.1038/379464a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559254				2022-12-24	WOS:A1996TT30400064
J	Berkelman, RL; Pinner, RW; Hughes, JM				Berkelman, RL; Pinner, RW; Hughes, JM			Addressing emerging microbial threats in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Berkelman, RL (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,1600 CLIFTON RD NE,MAILSTOP C12,ATLANTA,GA 30333, USA.							BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; CAMPBELL GL, 1995, ANN INTERN MED, V122, P151, DOI 10.7326/0003-4819-122-2-199501150-00014; Cassel GH, 1994, ASM NEWS, V60, P251; COX NJ, 1994, EUR J EPIDEMIOL, V10, P467, DOI 10.1007/BF01719678; DOWDLE WR, 1993, ANNU REV PUBL HEALTH, V14, P649; DUMLER JS, 1995, CLIN INFECT DIS, V20, P1102, DOI 10.1093/clinids/20.5.1102; GAYNES RP, 1991, AM J MED, V91, P1165; KAPLAN JE, 1995, CLIN INFECT DIS   S1, V21, P12; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; LEDERBERG J, 1993, ASM NEWS, V59, P162; LeDuc JW, 1996, JAMA-J AM MED ASSOC, V275, P318, DOI 10.1001/jama.275.4.318; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; Morse Stephen S., 1993, EMERGING VIRUSES; STACHE RD, 1995, EMERGING INFECT DIS, V1, P1; 1995, MMWR-MORBID MORTAL W, V44, P1; 1995, EMERGING INFECT J, V1, P105; 1995, REPORT NSTC COMMITTE; 1994, MMWR-MORBID MORTAL W, V43, P740; 1992, EMERGING INFECTIONS; 1994, MMWR-MORBID MORTAL W, V43, P421; 1991, ADDRESSING EMERGING; 1995, MMWR-MORBID MORTAL W, V44, P121; 1994, CAN COMMUN DIS REP, V20, P1; 1995, MMWR-MORBID MORTAL W, V44, P535	24	22	22	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					315	317		10.1001/jama.275.4.315	http://dx.doi.org/10.1001/jama.275.4.315			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544273				2022-12-24	WOS:A1996TP96500029
J	Sorrell, VL; Davis, MJ; Bove, AA				Sorrell, VL; Davis, MJ; Bove, AA			Origins of coronary artery ectasia	LANCET			English	Editorial Material									UNIV TEXAS, MED BRANCH, GALVESTON, TX 77550 USA; TEMPLE UNIV HOSP & MED SCH, PHILADELPHIA, PA 19140 USA	University of Texas System; University of Texas Medical Branch Galveston; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Sorrell, VL (corresponding author), E CAROLINA UNIV, SCH MED, 4S-22 BRODY, GREENVILLE, NC 27834 USA.							CARMICHAEL P, 1963, ARCH ENVIRON HEALTH, V7, P424, DOI 10.1080/00039896.1963.10663561; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P113; England JF., 1981, MED J AUSTRALIA, V68, P260; ENGLAND JF, 1981, MED J AUSTRALIA, V2, P140; HARTNELL GG, 1985, BRIT HEART J, V54, P392; LANGE RL, 1972, CIRCULATION, V46, P666, DOI 10.1161/01.CIR.46.4.666; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; PROUDFIT WL, 1966, CIRCULATION, V33, P901, DOI 10.1161/01.CIR.33.6.901; QUYYUMI AA, 1995, J CLIN INVEST, V95, P1747, DOI 10.1172/JCI117852; VANHOUTTE PM, 1989, HYPERTENSION, V13, P658, DOI 10.1161/01.HYP.13.6.658	10	37	39	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 20	1996	347	8995					136	137		10.1016/S0140-6736(96)90335-9	http://dx.doi.org/10.1016/S0140-6736(96)90335-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544543				2022-12-24	WOS:A1996TQ24400004
J	Akopian, AN; Sivilotti, L; Wood, JN				Akopian, AN; Sivilotti, L; Wood, JN			A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons	NATURE			English	Article							ROOT GANGLION NEURONS; NERVOUS-SYSTEM; RAT; CURRENTS; CELLS	DORSAL root ganglion sensory neurons associated with C-fibres, many of which are activated by tissue-damage, express an unusual voltage-gated sodium channel that is resistant to tetrodotoxin(1-9). We report here that we have identified a 1,957 aminoacid sodium channel in these cells that shows 65% identity with the rat cardiac tetrodotoxin-insensitive sodium channel(10), and is not expressed in other peripheral and central neurons, glia or non-neuronal tissues. In situ hybridization shows that the channel is expressed only by small-diameter sensory neurons in neonatal and adult dorsal root and trigeminal ganglia. The channel is resistant to tetrodotoxin when expressed in Xenopus oocytes. The electrophysiological and pharmacological properties of the expressed channel are similar to those described for the small-diameter sensory neuron tetrodotoxin-resistant sodium channels. As some noxious input into the spinal cord is resistant to tetrodotoxin(8,11,12), block of expression or function of such a C-fibre-restricted sodium channel may have a selective analgesic effect.	UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,LONDON WC1E 6BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT PHARMACOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London; University of London; University College London			Sivilotti, Lucia/D-8919-2011	Sivilotti, Lucia/0000-0003-2510-8424	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKOPIAN AN, 1995, J BIOL CHEM, V270, P21264, DOI 10.1074/jbc.270.36.21264; BECKH S, 1990, FEBS LETT, V262, P317, DOI 10.1016/0014-5793(90)80218-8; CAFFREY JM, 1992, BRAIN RES, V592, P283, DOI 10.1016/0006-8993(92)91687-A; CARRIER GO, 1992, PFLUG ARCH EUR J PHY, V421, P7, DOI 10.1007/BF00374726; CHABAL C, 1989, PAIN, V38, P333, DOI 10.1016/0304-3959(89)90220-0; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Cohen S A, 1993, Int Rev Cytol, V137C, P55; DELBIANCO E, 1994, NEUROSCI LETT, V170, P163, DOI 10.1016/0304-3940(94)90264-X; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ELLIOTT AA, 1993, J PHYSIOL-LONDON, V463, P39, DOI 10.1113/jphysiol.1993.sp019583; GAUTRON S, 1992, P NATL ACAD SCI USA, V89, P7272, DOI 10.1073/pnas.89.15.7272; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; JEFTINIJA S, 1994, BRAIN RES, V665, P69, DOI 10.1016/0006-8993(94)91153-3; JEFTINIJA S, 1994, BRAIN RES, V639, P125, DOI 10.1016/0006-8993(94)91772-8; KOSTYUK PG, 1981, NEUROSCIENCE, V6, P2423, DOI 10.1016/0306-4522(81)90088-9; LEBEAU MC, 1991, NUCLEIC ACIDS RES, V19, P1337, DOI 10.1093/nar/19.6.1337; Mandel G, 1993, Curr Opin Neurobiol, V3, P278, DOI 10.1016/0959-4388(93)90118-I; MATSUDA Y, 1978, BRAIN RES, V154, P69, DOI 10.1016/0006-8993(78)91052-1; MATZNER O, 1994, J NEUROPHYSIOL, V72, P349, DOI 10.1152/jn.1994.72.1.349; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; NOWYCKY M, 1993, SENSORY NEURONS, P97; OH YS, 1994, NEUROSCI LETT, V176, P119, DOI 10.1016/0304-3940(94)90885-0; RAJ PP, 1988, NEURAL BLOCKADE CLIN, P899; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; ROY ML, 1992, J NEUROSCI, V12, P2104; SATIN J, 1992, SCIENCE, V256, P1205; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHALLER KL, 1995, J NEUROSCI, V15, P3231; WAXMAN SG, 1994, J NEUROPHYSIOL, V72, P466, DOI 10.1152/jn.1994.72.1.466; WILLIS WD, 1994, 7TH P WORLD C PAIN, P301	30	842	889	2	62	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					257	262		10.1038/379257a0	http://dx.doi.org/10.1038/379257a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538791				2022-12-24	WOS:A1996TQ16900047
J	Laakso, M				Laakso, M			Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus - The Finnish studies	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			GLUCOSE	Purpose: To review population-based studies that investigated the association and nature of association between glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus (NIDDM). Data Sources: Study 1 included 133 newly diagnosed patients with NIDDM from eastern Finland, who were 45 to 64 years of age at baseline. These patients were followed up to 10 years for cardiovascular mortality. Study 2 included 229 newly or previously diagnosed patients with NIDDM from eastern Finland, aged 65 to 74 years at baseline. These patients were followed up to 3.5 years for coronary heart disease mortality and all coronary heart disease events (mortality or nonfatal myocardial infarction). Study Selection: Prospective, population-based studies that included indicators of glycemic control and the evaluation of coronary heart disease and cardiovascular risk. Results: Study 1 : 10-year cardiovascular mortality was significantly and linearly associated with glycemic control (fasting blood glucose and glycated hemoglobin A(1) levels) independently of the mode of treatment. A high fasting blood glucose level significantly predicted cardiovascular mortality in multiple logistic regression analysis independently of other risk factors. Study 2: Glycated hemoglobin A(1c) was the most important single risk factor associated with coronary heart disease death or all coronary heart disease events. In multiple logistic regression analysis, glycated hemoglobin A(1c) was significantly associated with coronary heart disease death after adjustment for other cardiovascular risk factors. Conclusions: Two prospective, population-based studies from Finland give evidence for the linear association of glycemic control with the risk for coronary heart disease in middle-aged and elderly patients with NIDDM.			Laakso, M (corresponding author), KUOPIO UNIV, DEPT MED, SF-70210 KUOPIO, FINLAND.							BIERMAN EL, 1992, ARTERIOSCLER THROMB, V12, P647, DOI 10.1161/01.ATV.12.6.647; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; LYONS TJ, 1992, DIABETES, V41, P67, DOI 10.2337/diab.41.2.S67; MYKKANEN L, 1990, DIABETES CARE, V13, P1099, DOI 10.2337/diacare.13.11.1099; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TURNER RC, 1985, DIABETES, V34, P793; UUSITUPA MIJ, 1993, DIABETOLOGIA, V36, P1175, DOI 10.1007/BF00401063; WELBORN TA, 1984, DIABETOLOGIA, V27, P568, DOI 10.1007/BF00276969; WEST KM, 1983, DIABETES CARE, V6, P361, DOI 10.2337/diacare.6.4.361; 1985, TECHNICAL REPORT SER, V727; 1990, MONICA MANUAL	12	124	129	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				127	130		10.7326/0003-4819-124-1_Part_2-199601011-00009	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554204				2022-12-24	WOS:A1996TL94400009
J	Economou, A; Pogliano, JA; Beckwith, J; Oliver, DB; Wickner, W				Economou, A; Pogliano, JA; Beckwith, J; Oliver, DB; Wickner, W			SecA membrane cycling at SecYEG is driven by distinct ATP binding and hydrolysis events and is regulated by SecD and SecF	CELL			English	Article							COLI PLASMA-MEMBRANE; PROTON MOTIVE FORCE; PRECURSOR PROTEIN TRANSLOCATION; ESCHERICHIA-COLI; CYTOPLASMIC MEMBRANE; INNER MEMBRANE; TRIGGER FACTOR; PREPROTEIN TRANSLOCASE; PRESECRETORY PROTEINS; SECRETORY PROTEINS	The SecA subunit of E. coli preprotein translocase promotes protein secretion during cycles of membrane insertion and deinsertion at SecYEG. This process is regulated both by nucleotide binding and hydrolysis and by the SecD and SecF proteins. In the presence of associated preprotein, the energy of ATP binding at nucleotide-binding domain 1 (NBD1) drives membrane insertion of a 30 kDa domain of SecA, while deinsertion of SecA requires the hydrolysis of this ATP. SecD and SecF stabilize the inserted state of SecA. ATP binding at NBD2, though needed for preprotein translocation, is not needed for SecA insertion or deinsertion.	UNIV CRETE, DEPT BIOL, GR-71110 IRAKLION, GREECE; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; WESLEYAN UNIV, DEPT MOLEC BIOL & BIOCHEM, MIDDLETOWN, CT 06459 USA	University of Crete; Harvard University; Harvard Medical School; Wesleyan University	Economou, A (corresponding author), DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA.		Economou, Anastassios/P-8292-2017	Economou, Anastassios/0000-0002-1770-507X				AKITA M, 1990, J BIOL CHEM, V265, P8164; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; ARKOWITZ RA, 1994, EMBO J, V13, P954, DOI 10.1002/j.1460-2075.1994.tb06340.x; ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; BASSILANA M, 1993, BIOCHEMISTRY-US, V32, P2626, DOI 10.1021/bi00061a021; BIEKERBRADY K, 1992, EMBO J, V11, P3165, DOI 10.1002/j.1460-2075.1992.tb05393.x; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DOUVILLE K, 1994, J BIOL CHEM, V269, P18705; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; GARDEL C, 1987, J BACTERIOL, V169, P1286, DOI 10.1128/jb.169.3.1286-1290.1987; GARDEL C, 1990, EMBO J, V9, P4205, DOI 10.1002/j.1460-2075.1990.tb07645.x; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GRUNDERSON KL, 1995, CELL, V82, P231; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; ITO K, 1980, J BIOL CHEM, V255, P2123; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KIM YJ, 1994, CELL, V78, P845; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1993, MOL MICROBIOL, V7, P159, DOI 10.1111/j.1365-2958.1993.tb01107.x; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; POGLIANO KJ, 1993, GENETICS, V133, P763; POGLIANO KJ, 1994, J BACTERIOL, V176, P804, DOI 10.1128/jb.176.3.804-814.1994; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; RENSING SA, 1994, MOL PHYLOGENET EVOL, V3, P187, DOI 10.1006/mpev.1994.1021; SAGARA K, 1994, J BACTERIOL, V176, P4111, DOI 10.1128/JB.176.13.4111-4116.1994; Sambrook J., 1989, MOL CLONING LAB MANU; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; SILHAVY TJ, 1984, EXPT GENE FUSIONS, pR11; TANI K, 1989, J BIOL CHEM, V264, P18582; UEGUCHI C, 1990, J BACTERIOL, V172, P5643, DOI 10.1128/jb.172.10.5643-5649.1990; VANDERWOLK J, 1993, MOL MICROBIOL, V8, P31; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; YAMADA H, 1989, J BIOL CHEM, V264, P18577	56	271	274	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1171	1181		10.1016/0092-8674(95)90143-4	http://dx.doi.org/10.1016/0092-8674(95)90143-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548804	hybrid			2022-12-24	WOS:A1995TM76200013
J	NIGHTINGALE, S				NIGHTINGALE, S			NEW INFORMATION SHEETS FOR IRBS AND CLINICAL INVESTIGATORS AVAILABLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, S (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1994, JAMA-J AM MED ASSOC, V272, P582	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1903	1903						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568972				2022-12-24	WOS:A1995TL16900009
J	Cairns, JA				Cairns, JA			Medical management of unstable angina	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CLINICAL-TRIALS; ACUTE CORONARY SYNDROMES; ARTERY DISEASE; HEART-DISEASE; DOUBLE-BLIND; ASPIRIN; NIFEDIPINE; DILTIAZEM; PATHOGENESIS				Cairns, JA (corresponding author), MCMASTER UNIV,DEPT MED,HAMILTON,ON,CANADA.		Cairns, John/AAI-8744-2021					ANDREFOUET X, 1983, EUR HEART J, V4, P691, DOI 10.1093/oxfordjournals.eurheartj.a061380; BRAUNWALD E, 1994, 940602 US DEP HLTH H; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; COHEN M, 1994, CIRCULATION, V89, P81, DOI 10.1161/01.CIR.89.1.81; FANG ZY, 1991, AM J CARDIOL, V68, pC42; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GERSTENBLITH G, 1982, NEW ENGL J MED, V306, P885, DOI 10.1056/NEJM198204153061501; GOTTLIEB SO, 1986, NEW ENGL J MED, V314, P121; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; LUBSEN J, 1987, AM J CARDIOL, V60, pA18; MULLER JE, 1984, CIRCULATION, V69, P740, DOI 10.1161/01.CIR.69.4.740; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; THEROUX P, 1985, J AM COLL CARDIOL, V5, P717, DOI 10.1016/S0735-1097(85)80400-9; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2259, DOI 10.1001/jama.260.15.2259; 1990, LANCET, V336, P827; 1994, CIRCULATION, V89, P1545	18	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1644	1645		10.1016/S0140-6736(95)92834-0	http://dx.doi.org/10.1016/S0140-6736(95)92834-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551818				2022-12-24	WOS:A1995TL42300004
J	Fukasawa, K; Choi, T; Kuriyama, R; Rulong, S; VandeVoude, GF				Fukasawa, K; Choi, T; Kuriyama, R; Rulong, S; VandeVoude, GF			Abnormal centrosome amplification in the absence of p53	SCIENCE			English	Article							WILD-TYPE P53; HAMSTER OVARY CELLS; GENE AMPLIFICATION; FRIEND-VIRUS; CYCLE; EXPRESSION; TRANSCRIPTION; PROTEIN; BINDING; CANCER	The centrosome plays a vital role in mitotic fidelity, ensuring establishment of bipolar spindles and balanced chromosome segregation. Centrosome duplication occurs only once during the cell cycle and is therefore highly regulated. Here, it is shown that in mouse embryonic fibroblasts (MEFs) lacking the p53 tumor suppressor protein, multiple copies of functionally competent centrosomes are generated during a single cell cycle. In contrast, MEFs prepared from normal mice or mice deficient in the retinoblastoma tumor suppressor gene product do not display these abnormalities. The abnormally amplified centrosomes profoundly affect mitotic fidelity, resulting in unequal segregation of chromosomes. These observations implicate p53 in the regulation of centrosome duplication and suggest one possible mechanism by which the loss of p53 may cause genetic instability.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; UNIV MINNESOTA,SCH MED,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Minnesota System; University of Minnesota Twin Cities								AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BLAIRZAJDEL ME, 1988, ONCOGENE, V2, P579; BOMENS M, 1992, CENTROSOME, P1; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; CALARCO PD, 1983, J CELL BIOL, V101, P319; CARDER P, 1993, ONCOGENE, V8, P1397; CLAYTON L, 1985, CELL, V35, P621; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FUKASAWA K, 1995, ONCOGENE, V10, P1; FUKASAWA K, UNPUB; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, ONCOGENE, V8, P2457; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOSHI HC, 1994, CURR OPIN CELL BIOL, V6, P55, DOI 10.1016/0955-0674(94)90116-3; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KURIYAMA R, 1986, CELL MOTIL CYTOSKEL, V6, P355, DOI 10.1002/cm.970060402; KURIYAMA R, 1981, J CELL BIOL, V91, P814, DOI 10.1083/jcb.91.3.814; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE JM, 1994, ONCOGENE, V9, P3731; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE DS, 1991, P NATL ACAD SCI USA, V88, P6427, DOI 10.1073/pnas.88.15.6427; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MANIOTIS A, 1991, CELL, V67, P495, DOI 10.1016/0092-8674(91)90524-3; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Oakley B R, 1992, Trends Cell Biol, V2, P1, DOI 10.1016/0962-8924(92)90125-7; ORREN DK, 1995, MOL CELL BIOL, V15, P3722; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROBBINS E, 1968, J CELL BIOL, V36, P329, DOI 10.1083/jcb.36.2.329; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHAEFER DI, 1993, CANCER RES, V53, P4946; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TUFFANELLI DL, 1983, ARCH DERMATOL, V119, P560, DOI 10.1001/archderm.119.7.560; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	57	722	743	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1744	1747		10.1126/science.271.5256.1744	http://dx.doi.org/10.1126/science.271.5256.1744			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596939	Green Submitted			2022-12-24	WOS:A1996UB15100052
J	Leach, DR; Krummel, MF; Allison, JP				Leach, DR; Krummel, MF; Allison, JP			Enhancement of antitumor immunity by CTLA-4 blockade	SCIENCE			English	Article							RECEPTOR; CELLS; CD28; MOLECULES; MOUSE; COSTIMULATION; EXPRESSION; REJECTION; ANTIGEN	One reason for the poor immunogenicity of many tumors may be that they cannot provide signals for CD28-mediated costimulation necessary to fully activate T cells. It has recently become apparent that CTLA-4, a second counterreceptor for the B7 family of costimulatory molecules, is a negative regulator of T cell activation. Here, in vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors. Furthermore, this rejection resulted in immunity to a secondary exposure to tumor cells. These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune responses against tumor cells.	UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley				Allison, James/0000-0001-8980-5697	NATIONAL CANCER INSTITUTE [R01CA057986, T32CA009179, R01CA040041, R37CA040041] Funding Source: NIH RePORTER; NCI NIH HHS [CA57986, CA09179, CA40041] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON JP, 1995, CURR OPIN IMMUNOL, V7, P682, DOI 10.1016/0952-7915(95)80077-8; ALLISON JP, 1995, SCIENCE, V270, P932, DOI 10.1126/science.270.5238.932; ALLISON JP, 1994, CURR OPIN IMMUNOL, V6, P414, DOI 10.1016/0952-7915(94)90120-1; BASKAR S, 1993, P NATL ACAD SCI USA, V90, P5687, DOI 10.1073/pnas.90.12.5687; BASKAR S, 1995, J EXP MED, V181, P619, DOI 10.1084/jem.181.2.619; BLUESTONE JA, 1995, IMMUNITY, V2, P555, DOI 10.1016/1074-7613(95)90000-4; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FLAMAND V, 1994, EUR J IMMUNOL, V24, P605, DOI 10.1002/eji.1830240317; GRABBE S, 1995, IMMUNOL TODAY, V16, P117, DOI 10.1016/0167-5699(95)80125-1; GRIBBEN JG, 1995, P NATL ACAD SCI USA, V92, P811, DOI 10.1073/pnas.92.3.811; GROSS JA, 1992, J IMMUNOL, V149, P380; HARPER K, 1991, J IMMUNOL, V147, P1037; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; JENKINS MK, 1994, IMMUNITY, V1, P443, DOI 10.1016/1074-7613(94)90086-8; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KEARNEY ER, 1995, J IMMUNOL, V155, P1033; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; KRUMMEL MF, IN PRESS INT IMMUNOL; LEACH DR, 1995, J IMMUNOL, V154, P738; LEACH DRF, UNPUB; LEVITSKY HI, 1994, J EXP MED, V179, P1215, DOI 10.1084/jem.179.4.1215; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1995, J EXP MED, V182, P289, DOI 10.1084/jem.182.2.289; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; OSTRANDROSENBERG S, 1990, J IMMUNOL, V144, P4068; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TOWNSEND SE, 1994, CANCER RES, V54, P6477; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985	33	2500	2689	24	401	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1734	1736		10.1126/science.271.5256.1734	http://dx.doi.org/10.1126/science.271.5256.1734			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596936				2022-12-24	WOS:A1996UB15100049
J	Bindels, PJE; Krol, A; vanAmeijden, E; MulderFolkerts, DKF; vandenHoek, JAR; vanGriensven, GPJ; Coutinho, RA				Bindels, PJE; Krol, A; vanAmeijden, E; MulderFolkerts, DKF; vandenHoek, JAR; vanGriensven, GPJ; Coutinho, RA			Euthanasia and physician-assisted suicide in homosexual men with AIDS	LANCET			English	Article							IMMUNODEFICIENCY-SYNDROME AIDS; LONGITUDINAL DATA-ANALYSIS; RESPONSIVENESS; SURVIVAL	Background In the Netherlands a nationwide study has shown that, in 38% of deaths, there have been medical decisions concerning the end of life (MDEL); 2.1% of all deaths were brought about by euthanasia or physician-assisted suicide (PAS). We investigated the incidence of MDEL in homosexual men with AIDS, suspecting that it might be higher, and studied the effect of euthanasia/PAS on survival time. Methods The patients were 131 male homosexual participants in a cohort study in Amsterdam, diagnosed between 1985 and 1992 as having AIDS; all had died before Jan 1, 1995. Clinical and laboratory data and information on mode of death were obtained from their physicians and by review of hospital records. Those who died by euthanasia/PAS or in whom there had been other MDEL were then compared with those who died naturally. Findings 29 men (22%) had died by euthanasia/PAS and in 17 (13%) another MDEL had been made; thus, more than one-third of these men had made medical decisions concerning the end of life. The greatest difference between the groups was in age at time of diagnosis-72% aged 40 or more in the euthanasia/PAS group compared with 38% in the natural death group. The likelihood (relative risk) of euthanasia/PAS increased with duration of survival after AIDS diagnosis. Comparison of the groups in terms of three laboratory markers (CD4+ and CD8+ cells and phytohaemagglutinin responses) in the two years before death, and estimates of these markers at the time of death, did not indicate any substantial shortening of life by euthanasia/PAS; in the judgment of the physicians, most of these patients would have died naturally within one month. Interpretation A possible reason for the high incidence of MDEL in this cohort was a good knowledge of the characteristics of AIDS acquired through long-term awareness of HIV infection. The higher rate of euthanasia in those with long survival from AIDS diagnosis could reflect either additional suffering or the greater opportunity to discuss this option with friends and physicians. Our findings indicate that euthanasia and other MDEL did little to shorten life; rather, they were an extreme form of palliation, applied in the terminal phase of a lethal disease.			Bindels, PJE (corresponding author), DEPT PUBL HLTH,MUNICIPAL HLTH SERV,NIEUWE ACHTERGRACHT 100,POB 20244,1000 HE AMSTERDAM,NETHERLANDS.							Anderson PK, 1993, STAT MODELS BASED CO; BINDELS PJE, 1995, J INFECT DIS, V172, P97, DOI 10.1093/infdis/172.1.97; BLOEMENA E, 1989, J IMMUNOL METHODS, V122, P161, DOI 10.1016/0022-1759(89)90260-3; CHANG HGH, 1993, AM J EPIDEMIOL, V138, P341, DOI 10.1093/oxfordjournals.aje.a116864; FAHEY JL, 1989, NEW ENGL J MED, V321, P673; GRIENSVEN GP, 1987, AM J EPIDEMIOL, V125, P1048; JACOBSON LP, 1993, AM J EPIDEMIOL, V138, P952, DOI 10.1093/oxfordjournals.aje.a116815; KEET IPM, 1993, AIDS, V7, P51, DOI 10.1097/00002030-199301000-00008; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; LUNDGREN JD, 1994, BMJ-BRIT MED J, V308, P1068, DOI 10.1136/bmj.308.6936.1068; PIJNENBORG L, 1995, END LIFE DECISIONS M; SCHELLEKENS PTA, 1990, J CLIN IMMUNOL, V10, P121, DOI 10.1007/BF00918194; SEAGE GR, 1993, AM J PUBLIC HEALTH, V83, P72, DOI 10.2105/AJPH.83.1.72; SORGDRAGER W, 1995, MED CONTACT, V50, P381; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; VANDERWAL G, 1991, MED CONTACT, V46, P174; VANLIER RAW, 1987, J IMMUNOL, V139, P2873; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1987, MMWR-MORBID M      S, V36, pS1	21	27	27	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					499	504		10.1016/S0140-6736(96)91138-1	http://dx.doi.org/10.1016/S0140-6736(96)91138-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TW697	8596267				2022-12-24	WOS:A1996TW69700009
J	Little, P; Smith, L; Cantrell, T; Chapman, J; Langridge, J; Pickering, R				Little, P; Smith, L; Cantrell, T; Chapman, J; Langridge, J; Pickering, R			General practitioners' management of acute back pain: A survey of reported practice compared with clinical guidelines	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SPINAL MANIPULATION; CONTROLLED TRIAL; EXERCISE; PHYSIOTHERAPY; THERAPY; REST	Objective-To compare general practitioners' reported management of acute back pain with ''evidence based'' guidelines for its management. Design-Confidential postal questionnaire. Setting-One health district in the South and West region. Subjects-236 general practitioners; 166 (70%) responded. Outcome measures-Examination routinely performed, ''danger'' symptoms and signs warranting urgent referral, advice given, and satisfaction with management. Results-A minority of general practitioners do not examine reflexes routinely (27%, 95% confidence interval 20% to 34%), and a majority do not examine routinely for muscle weakness or sensation. Although most would refer patients with danger signs, some would not seek urgent advice for saddle anaesthesia (6%, 3% to 11%), extensor plantar response (45%, 37% to 53%), or neurological signs at multiple levels (15%, 10% to 21%). A minority do not give advice about back exercises (42%, 34% to 49%), fitness (34%, 26% to 41%), or everyday activities. A minority performed manipulation (20%) or acupuncture (6%). One third rated their satisfaction with management of back pain as 4 out of 10 or less. Conclusions-The management of back pain by general practitioners does not match the guidelines, but there is little evidence from general practice for many of the recommendations, including routine examination, activity modification, educational advice, and back exercises. General practitioners need to be more aware of danger symptoms and of the benefits of early mobilisation and possibly of manipulation for persisting symptoms. Guidelines should reference each recommendation and discuss study methodology and the setting of evidence.	SOUTHAMPTON HOSP, NHS TRUST, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND; UNIV SOUTHAMPTON, SCH OCCUPAT THERAPY & PHYSIOTHERAPY, SOUTHAMPTON SO17 1BJ, HANTS, ENGLAND; UNIV SOUTHAMPTON, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND	University of Southampton; University of Southampton	Little, P (corresponding author), UNIV SOUTHAMPTON, FAC MED HLTH & BIOL SCI, SOUTHAMPTON SO16 5ST, HANTS, ENGLAND.			Little, Paul/0000-0003-3664-1873	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERGQUISTULLMAN M, 1977, ACTA ORTHOP SCAND S1, V70, P1; CAREY TS, 1995, NEW ENGL J MED, V333, P913, DOI 10.1056/NEJM199510053331406; CHOLER U, 1985, ONT RUGGEN FORSCH ME; COSTE J, 1994, BRIT MED J, V308, P577, DOI 10.1136/bmj.308.6928.577; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; DEYO RA, 1992, JAMA-J AM MED ASSOC, V268, P760, DOI 10.1001/jama.268.6.760; FAAS A, 1995, SPINE, V20, P941, DOI 10.1097/00007632-199504150-00012; FAAS A, 1993, SPINE, V18, P1388; FEDER G, 1994, BRIT MED J, V309, P1457, DOI 10.1136/bmj.309.6967.1457; FRANK A, 1993, BMJ-BRIT MED J, V306, P901, DOI 10.1136/bmj.306.6882.901; FROST H, 1995, BRIT MED J, V310, P151, DOI 10.1136/bmj.310.6973.151; GARDNER SB, 1989, CIA CONFIDENCE INTER; GILBERT JR, 1985, BRIT MED J, V291, P791, DOI 10.1136/bmj.291.6498.791; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GUNDEWALL B, 1993, SPINE, V18, P587, DOI 10.1097/00007632-199304000-00011; JONES SL, 1988, SPINE, V13, P553, DOI 10.1097/00007632-198805000-00020; KELLETT KM, 1991, PHYS THER, V71, P283, DOI 10.1093/ptj/71.4.283; KOES BW, 1992, BRIT MED J, V304, P601, DOI 10.1136/bmj.304.6827.601; KOES BW, 1995, SPINE, V20, P228, DOI 10.1097/00007632-199501150-00021; KOES BW, 1991, BRIT MED J, V303, P1298, DOI 10.1136/bmj.303.6813.1298; KOES BW, 1991, BRIT MED J, V302, P1572, DOI 10.1136/bmj.302.6792.1572; LINDSTROM I, 1992, PHYS THER, V72, P279, DOI 10.1093/ptj/72.4.279; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; Management of cancer pain, 1994, AGENCY HLTH CARE POL; MANNICHE C, 1991, PAIN, V47, P53, DOI 10.1016/0304-3959(91)90011-L; MEADE TW, 1992, BRIT MED J, V304, P1310, DOI 10.1136/bmj.304.6837.1310; Morrell D C, 1976, J R Coll Gen Pract, V26, P398; Postacchini F, 1988, NEURO-ORTHOPEDICS, V6, P28; ROLAND M, 1989, J ROY COLL GEN PRACT, V39, P244; ROLAND MO, 1983, BRIT MED J, V286, P523, DOI 10.1136/bmj.286.6364.523; ROLAND MO, 1983, PRACTITIONER, V227, P1119; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; STUBBS DA, 1983, ERGONOMICS, V26, P767, DOI 10.1080/00140138308963398; VALAT JP, 1994, RHEUMATOLOGY EUROPE, V23, P55; WADDELL G, 1993, ANN RHEUM DIS, V52, P317, DOI 10.1136/ard.52.5.317; WADDELL G, 1992, BAILLIERE CLIN RHEUM, V6, P523, DOI 10.1016/S0950-3579(05)80126-8; WADSWORTH MEJ, 1971, HLTH SICKNESS CHOICE; 1994, MANAGEMENT GUIDELINE; 1994, EFFECTIVE HLTH CARE, P8; 1987, SPINE, V12, pS9; 1993, BETTER LIVING BETTER; 1994, GUIDE MANAGEMENT LOW	42	61	61	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 24	1996	312	7029					485	488		10.1136/bmj.312.7029.485	http://dx.doi.org/10.1136/bmj.312.7029.485			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597683	Green Published			2022-12-24	WOS:A1996TX38300028
J	Kelner, KL				Kelner, KL			Ion channels: Opening the gate	SCIENCE			English	Editorial Material							SODIUM											ARMSTRONG CM, 1973, NATURE, V242, P459, DOI 10.1038/242459a0; LARSSON HP, IN PRESS NEURON; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8	5	2	4	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					615	615		10.1126/science.271.5249.615	http://dx.doi.org/10.1126/science.271.5249.615			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571122				2022-12-24	WOS:A1996TT87000033
J	Goulmy, E; Schipper, R; Pool, J; Blokland, E; Falkenburg, JHF; Vossen, J; Gratwohl, A; Vogelsang, GB; vanHouwelingen, HC; vanRood, JJ				Goulmy, E; Schipper, R; Pool, J; Blokland, E; Falkenburg, JHF; Vossen, J; Gratwohl, A; Vogelsang, GB; vanHouwelingen, HC; vanRood, JJ			Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TISSUE DISTRIBUTION; LYMPHOCYTES; TOLERANCE; LEUKEMIA; CELLS	Background. Graft-versus-host disease (GVHD) can be a major complication of allogeneic bone marrow transplantation even when the donor and recipient are siblings and share identical major histocompatibility antigens. The explanation may be a mismatch of minor histocompatibility antigens. We previously characterized five minor histocompatibility antigens, HA-1, 2, 3, 4, and 5, that are recognized by T cells in association with the major histocompatibility antigens HLA-A1 and A2. Methods. We collected peripheral-blood leukocytes from 148 bone marrow recipients and their sibling donors, who were genotypically HLA identical. Fifty pairs were positive for HLA-A1, 117 were positive for HLA-A2, and 19 were positive for both. The pairs were typed with cytotoxic-T-cell clones specific for minor histocompatibility antigens HA-1, 2, 3, 4, and 5. Results. Mismatches of HA-3 were equally distributed among recipients in whom GVHD developed and those in whom it did not. By contrast, a mismatch of only HA-1 was significantly correlated with GVHD of grade II or higher (odds ratio, infinity; P = 0.02) in adults. One or more mismatches of HA-1, 2, 4, and 5 were also significantly associated with GVHD (odds ratio, infinity; P = 0.006) in adults. These associations were not observed in children. Conclusions. A mismatch of minor histocompatibility antigen HA-1 can cause GVHD in adult recipients of allogeneic bone marrow from HLA-identical donors. Prospective HA-1 typing may improve donor selection and identify recipients who are at high risk for GVHD. (C) 1996, Massachusetts Medical Society.	UNIV LEIDEN HOSP,DEPT HEMATOL,2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,DEPT PEDIAT,2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,DEPT MED STAT,2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,EUROPDONOR FDN,2300 RC LEIDEN,NETHERLANDS; KANTONSSPITAL,DIV HEMATOL,DEPT RES,CH-4031 BASEL,SWITZERLAND; JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Kantonsspital Aarau AG (KSA); University of Basel; Johns Hopkins University; Johns Hopkins Medicine	Goulmy, E (corresponding author), UNIV LEIDEN HOSP,DEPT IMMUNOHEMATOL & BLOOD BANK,2300 RC LEIDEN,NETHERLANDS.		van houwelingen, hans c/C-1872-2008	van houwelingen, hans c/0000-0002-0494-4637				ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; BEATTY PG, 1990, GRAFT VERSUS HOST DI, V12, P415; BORTIN MM, 1991, TRANSPLANT P, V23, P61; BRESOW NE, 1980, IARC SCI PUBLICATION, V32; DEBUEGER M, 1992, J IMMUNOL, V149, P1788; DEBUEGER M, 1992, INT IMMUNOL, V4, P53, DOI 10.1093/intimm/4.1.53; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; ELKINS WL, 1987, BONE MARROW TRANSPL, V1, P397; GOULMY E, 1983, NATURE, V302, P159, DOI 10.1038/302159a0; GOULMY E, 1982, HLA TYPING METHODOLO, V2, P105; GOULMY E, 1988, TRANSPLANT REV, V2, P29, DOI DOI 10.1016/S0955-470X(88)80005-3; IRLE C, 1985, TRANSPLANTATION, V40, P329, DOI 10.1097/00007890-198509000-00021; IRSCHICK EU, 1992, BLOOD, V79, P1622; MARTIN PJ, 1991, BONE MARROW TRANSPL, V8, P217; NIEDERWIESER D, 1993, BLOOD, V81, P2200; RAMSAY NKC, 1982, NEW ENGL J MED, V306, P392, DOI 10.1056/NEJM198202183060703; SCHREUDER GMT, 1993, IMMUNOGENETICS, V38, P98, DOI 10.1007/BF00190897; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; THOMAS ED, 1975, NEW ENGL J MED, V292, P832, DOI 10.1056/NEJM197504172921605; TSOI MS, 1983, TRANSPLANT P, V15, P1484; TSOI MS, 1980, J IMMUNOL, V125, P2258; VANELS CACM, 1992, IMMUNOGENETICS, V35, P161, DOI 10.1007/BF00185109; VANELS CACM, 1990, TRANSPLANTATION, V50, P62, DOI 10.1097/00007890-199007000-00011; VANLOCHEM E, IN PRESS TRANSPLANT; VOSSEN JM, 1990, GRAFT VERSUS HOST DI, V12, P403; WANG W, 1995, SCIENCE, V269, P1588, DOI 10.1126/science.7667640; ZELEN M, 1971, BIOMETRIKA, V58, P129, DOI 10.1093/biomet/58.1.129; 1989, BONE MARROW TRANSPL, V4, P221	28	445	458	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					281	285		10.1056/NEJM199602013340501	http://dx.doi.org/10.1056/NEJM199602013340501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV695	8532022				2022-12-24	WOS:A1996TV69500001
J	OBrien, CP; McLellan, AT				OBrien, CP; McLellan, AT			Myths about the treatment of addiction	LANCET			English	Article							ALCOHOL DEPENDENCE; HYPERTENSION; NALTREXONE				OBrien, CP (corresponding author), UNIV PENN,VA MED CTR,DEPT PSYCHIAT,3900 CHESTNUT ST,PHILADELPHIA,PA 19104, USA.				NIDA NIH HHS [P50-DA-05186] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA005186] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALTERMAN AI, 1991, J NERV MENT DIS, V179, P401, DOI 10.1097/00005053-199107000-00003; Armor D. J., 1976, ALCOHOLISM TREATMENT; Ball J.C., 2012, EFFECTIVENESS METHAD; CLARK LT, 1991, AM HEART J, V121, P664, DOI 10.1016/0002-8703(91)90443-L; DEKKER FW, 1993, EUR RESPIR J, V6, P886; DELEON G, 1994, 841286 NAT I DRUG AB; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; FULLER RK, 1986, JAMA-J AM MED ASSOC, V256, P1449, DOI 10.1001/jama.256.11.1449; GERSTEIN DR, 1979, AM J DRUG ALCOHOL AB, V6, P1, DOI 10.3109/00952997909007029; GERSTEIN DR, 1990, TREATING DRUG PROBLE, V1; GERSTEIN DR, 1994, ADP94628 CAL DEP ALC; GORLIN R, 1991, AM HEART J, V121, P658, DOI 10.1016/0002-8703(91)90442-K; GRABER AL, 1992, DIABETES CARE, V15, P1477, DOI 10.2337/diacare.15.11.1477; Harrison W. H., 1993, INTERNAL MED; HAVASSY BE, 1995, ADDICTION, V90, P699, DOI 10.1046/j.1360-0443.1995.90569911.x; Herman W. H., 1985, DIABETIC RENAL DISOR; HIGGINS ST, 1994, ARCH GEN PSYCHIAT, V51, P568; HOROWITZ RI, 1990, LANCET, V336, P542; Hubbard RL, 1989, DRUG ABUSE TREATMENT; Kurtz S M, 1990, Diabetes Educ, V16, P50, DOI 10.1177/014572179001600112; Mattick RP, 1996, LANCET, V347, P97, DOI 10.1016/S0140-6736(96)90215-9; MCLELLAN AT, 1980, DRUG ALCOHOL DEPEN, V5, P189, DOI 10.1016/0376-8716(80)90179-9; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; Miller WR, 1986, TREATING ADDICTIVE B; Moos R, 1990, ALCOHOLISM TREATMENT; OBRIEN CP, 1986, PHILADELPHIA MED, V82, P442; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; SCHAUB AF, 1993, CLIN EXP HYPERTENS, V15, P1121, DOI 10.3109/10641969309037099; SCHUCKIT MA, 1994, AM J PSYCHIAT, V151, P184; SIMPSON DD, 1980, ARCH GEN PSYCHIAT, V37, P896; SINNOCK P, 1955, HOSPITALIZATION DIAB; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; 1989, PUBLIC USE DATATAPE; 1989, PREVENTION TREATMENT	34	343	349	1	20	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					237	240		10.1016/S0140-6736(96)90409-2	http://dx.doi.org/10.1016/S0140-6736(96)90409-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TT069	8551886	hybrid			2022-12-24	WOS:A1996TT06900015
J	Chandrasekharan, UM; Sanker, S; Glynias, MJ; Karnik, SS; Husain, A				Chandrasekharan, UM; Sanker, S; Glynias, MJ; Karnik, SS; Husain, A			Angiotensin II-forming activity in a reconstructed ancestral chymase	SCIENCE			English	Article							SUBSTRATE-SPECIFICITY; SUBSTANCE-P; HUMAN HEART; MAST-CELLS; PEPTIDE; ENZYME; GENE; RAT	The current model of serine protease diversity theorizes that the earliest protease molecules were simple digestive enzymes that gained complex regulatory functions and restricted substrate specificities through evolution. Among the chymase group of serine proteases are enzymes that convert angiotensin I to angiotensin II, as well as others that simply degrade angiotensins. An ancestral chymase reconstructed with the use of phylogenetic inference, total gene synthesis, and protein expression had efficient and specific angiotensin II-forming activity (turnover number, about 700 per second). Thus, angiotensin II-forming activity is the more primitive state for chymases, and the loss of such activity occurred later in the evolution of some of these serine proteases.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC CARDIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Husain, Ahsan/J-6861-2012; Karnik, Sadashiva/Y-2477-2019	Husain, Ahsan/0000-0003-3426-3469; Karnik, Sadashiva/0000-0003-0746-2753	NHLBI NIH HHS [HL44201, R01 HL057470, HL33713] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL033713, R01HL044201] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRAIN SD, 1988, NATURE, V335, P73, DOI 10.1038/335073a0; CAUGHEY GH, 1988, J PHARMACOL EXP THER, V244, P133; ERDOS EG, 1985, BIOCHEM SOC T, V13, P42, DOI 10.1042/bst0130042; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; HAKANSON R, 1986, HISTOCHEMISTRY, V86, P5, DOI 10.1007/BF00492340; HENDERSON IW, 1981, ADV ANIMAL COMP PHYS, P355; HILLIS DM, 1992, SCIENCE, V255, P589, DOI 10.1126/science.1736360; HOIT BD, 1995, J CLIN INVEST, V95, P1519, DOI 10.1172/JCI117824; JERMANN TM, 1995, NATURE, V374, P57, DOI 10.1038/374057a0; KHORANA HG, 1979, SCIENCE, V203, P614, DOI 10.1126/science.366749; KINOSHITA A, 1991, J BIOL CHEM, V266, P19192; LETRONG H, 1987, P NATL ACAD SCI USA, V84, P364; MURAKAMI M, 1995, J BIOL CHEM, V270, P2218, DOI 10.1074/jbc.270.5.2218; PASTOR LM, 1988, J SUBMICR CYTOL PATH, V20, P25; REILLY CF, 1982, J BIOL CHEM, V257, P8619; REMMINGTON SJ, 1988, BIOCHEMISTRY-US, V27, P8097; SWOFFORD DL, 1992, PAUP PHYLOGENETIC AN; URATA H, 1990, J BIOL CHEM, V265, P22348; URATA H, 1993, J CLIN INVEST, V91, P1269, DOI 10.1172/JCI116325; WOODBURY RG, 1984, NATURE, V312, P450, DOI 10.1038/312450a0	20	166	170	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					502	505		10.1126/science.271.5248.502	http://dx.doi.org/10.1126/science.271.5248.502			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560264				2022-12-24	WOS:A1996TR32200041
J	Barnes, PF; ElHajj, H; PrestonMartin, S; Cave, MD; Jones, BE; Otaya, M; Pogoda, J; Eisenach, KD				Barnes, PF; ElHajj, H; PrestonMartin, S; Cave, MD; Jones, BE; Otaya, M; Pogoda, J; Eisenach, KD			Transmission of tuberculosis among the urban homeless	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYCOBACTERIUM-TUBERCULOSIS; COMPLEX; ELEMENT; IS6110; TOOL	Objective. - To determine the relative frequencies of primary and reactivation tuberculosis in the urban homeless. Design. - Prospective evaluation of homeless tuberculosis patients. Setting. - Central Los Angeles, Calif. Patients. - Thirty-four homeless patients with culture-proven tuberculosis. Interventions. - IS61 10-based restriction fragment length polymorphism (RFLP) analysis was performed on Mycobacterium tuberculosis isolates. If results were inconclusive, pTBN12-based RFLP analysis was performed. Main Outcome Measure. - Clustering of M tuberculosis isolates. A cluster consisted of two or more isolates with indistinguishable RFLP patterns. Results. - Twenty-four of 34 homeless patients had clustered isolates in six clusters. Conclusions. - The minimum percentage of cases due to primary tuberculosis in the homeless was estimated to be 53%, compared with the traditional estimate of 10% in the general population. The results suggest that primary tuberculosis caused the majority of tuberculosis cases in this population of the urban homeless in central Los Angeles.	UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA 90033; UNIV ARKANSAS MED SCI HOSP,DEPT PATHOL,LITTLE ROCK,AR 72205; UNIV ARKANSAS MED SCI HOSP,DEPT ANAT,LITTLE ROCK,AR 72205; MCLELLAN MEM VET HOSP,MED RES SERV,LITTLE ROCK,AR; STATOLOGY,TAHOE PARADISE,CA	University of Southern California; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Barnes, PF (corresponding author), UNIV SO CALIF,SCH MED,DEPT MED,DIV INFECT DIS,HMR 904,2025 ZONAL AVE,LOS ANGELES,CA 90033, USA.				NIAID NIH HHS [AI35265, AI35222] Funding Source: Medline; PHS HHS [CCU901877] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035265, R01AI035222] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; BERMUDEZ LE, 1991, J INFECT DIS, V163, P1286, DOI 10.1093/infdis/163.6.1286; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; COUSINS DV, 1993, VET MICROBIOL, V37, P1, DOI 10.1016/0378-1135(93)90178-A; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; KLIMAS NG, 1991, AM J MED, V90, P163, DOI 10.1016/0002-9343(91)80155-F; KLINE SE, 1995, NEW ENGL J MED, V333, P222, DOI 10.1056/NEJM199507273330404; MAZUREK GH, 1991, J CLIN MICROBIOL, V29, P2030, DOI 10.1128/JCM.29.9.2030-2033.1991; MCMURRAY DN, 1992, J NUTR, V122, P738, DOI 10.1093/jn/122.suppl_3.738; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; ROSSI PH, 1987, SCIENCE, V235, P1336, DOI 10.1126/science.2950592; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; ZOLOPA AR, 1994, JAMA-J AM MED ASSOC, V272, P455, DOI 10.1001/jama.272.6.455; 1992, MMWR-MORBID MORTAL W, V41, P13; 1990, MMWR-MORBID MORTAL W, V39, P9	17	120	123	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					305	307		10.1001/jama.275.4.305	http://dx.doi.org/10.1001/jama.275.4.305			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544271				2022-12-24	WOS:A1996TP96500027
J	Ferguson, SSG; Downey, WE; Colapietro, AM; Barak, LS; Menard, L; Caron, MG				Ferguson, SSG; Downey, WE; Colapietro, AM; Barak, LS; Menard, L; Caron, MG			Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization	SCIENCE			English	Article							ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; DESENSITIZATION; RHODOPSIN; KINASE; MECHANISM; PATHWAYS; BINDING	beta-Arrestins are proteins that bind phosphorylated heterotrimeric GTP-binding protein (G protein)-coupled receptors (GPCRs) and contribute to the desensitization of GPCRs by uncoupling the signal transduction process. Resensitization of GPCR responsiveness involves agonist-mediated receptor sequestration. Overexpression of beta-arrestins in human embryonic kidney cells rescued the sequestration of beta(2)-adrenergic receptor (beta(2)AR) mutants defective in their ability to sequester, an effect enhanced by simultaneous overexpression of beta-adrenergic receptor kinase 1, Wild-type beta(2)AR sequestration was inhibited by the overexpression of two beta-arrestin mutants. These findings suggest that beta-arrestins play an integral role in GPCR internalization and thus serve a dual role in the regulation of GPCR function.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST LABS,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University; Duke University; Duke University					NINDS NIH HHS [NS 19576] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1992, J NEUROSCI, V12, P4045; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; SCHWINN DA, 1992, HEART CARDIOVASCULAR, P1657; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; TSUGA H, 1994, J BIOL CHEM, V269, P32522; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; YU SS, 1993, J BIOL CHEM, V268, P337	28	799	815	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					363	366		10.1126/science.271.5247.363	http://dx.doi.org/10.1126/science.271.5247.363			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553074				2022-12-24	WOS:A1996TQ52800045
J	Yeh, SR; Fricke, RA; Edwards, DH				Yeh, SR; Fricke, RA; Edwards, DH			The effect of social experience on serotonergic modulation of the escape circuit of crayfish	SCIENCE			English	Article							BEHAVIOR; RECEPTORS; AGGRESSION; OCTOPAMINE; LOBSTERS	The neuromodulator serotonin has widespread effects in the nervous systems of many animals, often influencing aggression;and dominance status. In crayfish, the effect of serotonin on the neural circuit for tailflip escape behavior was found to depend on the animal's social experience. Serotonin reversibly enhanced the response to sensory stimuli of the lateral giant (LG) tailflip command neuron in socially dominant crayfish, reversibly inhibited it in subordinate animals, and persistently enhanced it in socially isolated crayfish, Serotonin receptor agonists had opposing effects: A vertebrate serotonin type 1 receptor agonist inhibited the LG neurons in dominant and subordinate crayfish and had no effect in isolates, whereas a vertebrate serotonin type 2 receptor agonist enhanced the LG neurons' responses in all three types of crayfish. The LG neurons appear to have at ]east two populations of serotonin receptors that differ in efficacy in dominant, subordinate, and socially isolate crayfish.	GEORGIA STATE UNIV,DEPT BIOL,ATLANTA,GA 30302; EMORY UNIV,DEPT ANAT & CELL BIOL,ATLANTA,GA 30322	University System of Georgia; Georgia State University; Emory University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026457] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS26457] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOVBJERG RV, 1953, PHYSIOL ZOOL, V26, P173, DOI 10.1086/physzool.26.2.30154514; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; COCCARO EF, 1992, INT CLIN PSYCHOPHARM, V7, P3, DOI 10.1097/00004850-199200710-00001; EDWARDS DH, 1991, J NEUROSCI, V11, P2117; GLANZMAN DL, 1983, J NEUROSCI, V3, P2263; GLENNON RA, 1987, J MED CHEM, V30, P1, DOI 10.1021/jm00384a001; HUMPHREY PPA, 1993, TRENDS PHARMACOL SCI, V14, P233, DOI 10.1016/0165-6147(93)90016-D; KRASNE FB, 1969, J EXP BIOL, V50, P29; KRAVITZ EA, 1988, SCIENCE, V241, P1775, DOI 10.1126/science.2902685; LEONARD BE, 1992, INT CLIN PSYCHOPHARM, V7, P13, DOI 10.1097/00004850-199200710-00002; LINNOILA VMI, 1992, J CLIN PSYCHIAT, V53, P46; LIVINGSTONE MS, 1980, SCIENCE, V208, P76, DOI 10.1126/science.208.4439.76; REAL D, 1990, BRAIN RES, V521, P203, DOI 10.1016/0006-8993(90)91544-Q; STEKLIS HD, 1986, AM J PRIMATOL, V11, P133, DOI 10.1002/ajp.1350110206; Van Harreveld A, 1936, P SOC EXP BIOL MED, V34, P428; VU ET, 1993, J NEUROSCI, V13, P4379; WINBERG S, 1992, J COMP PHYSIOL A, V170, P93; Wine J.J., 1982, P241; YEH SC, UNPUB; ZHANG B, 1994, J EXP BIOL, V190, P55; ZUCKER RS, 1972, J NEUROPHYSIOL, V35, P599, DOI 10.1152/jn.1972.35.5.599	21	217	218	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					366	369		10.1126/science.271.5247.366	http://dx.doi.org/10.1126/science.271.5247.366			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553075	Green Submitted			2022-12-24	WOS:A1996TQ52800046
J	Finger, EB; Puri, KD; Alon, R; Lawrence, MB; vonAndrian, UH; Springer, TA				Finger, EB; Puri, KD; Alon, R; Lawrence, MB; vonAndrian, UH; Springer, TA			Adhesion through L-selectin requires a threshold hydrodynamic shear	NATURE			English	Article							NODE HOMING RECEPTOR; HUMAN NEUTROPHILS; LECAM-1; IDENTIFICATION; LEUKOCYTES; SURFACE; GMP-140; MAC-1; RATES; FLOW	SELECTINS are cell adhesion molecules that bind carbohydrate ligands and promote interaction between leukocytes and the vessel wall in vascular shear flow(1,2). Selectin-ligand bonds have high mechanical strength, allowing initial tethering to the vessel wall through one or few bonds, and have fast on and off rates, permitting rolling in response to hydrodynamic drag(3). The L-selectin molecule on leukocytes binds to peripheral node addressin on high endothelial venules of lymph nodes to mediate leukocyte rolling(4,5) and binds to a ligand on neutrophils to mediate rolling of leukocytes over one another(6). Here we describe a surprising mechanism for regulation of these interactions, both in vitro and in vivo. Shear above a critical threshold is required to promote and maintain rolling interactions through L-selectin, but not through E-selectin, P-selectin or VCAM-1. The shear threshold requirement for L-selectin may be physiologically important in low shear to prevent inappropriate aggregation of leukocytes and interaction with the vessel wall.	HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; UNIV VIRGINIA,DEPT BIOMED ENGN,CHARLOTTESVILLE,VA 22903	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; University of Virginia			Finger, Erik/AFP-0406-2022; ALON, RONEN/GRX-6987-2022; von Andrian, Ulrich H/A-5775-2008	Finger, Erik/0000-0003-3899-6985; Alon, Ronen/0000-0001-9161-6369				ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; ALON R, 1995, J IMMUNOL, V154, P5356; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; ERLANDSEN SL, 1993, J HISTOCHEM CYTOCHEM, V41, P327, DOI 10.1177/41.3.7679125; GLABE CG, 1983, ANAL BIOCHEM, V130, P287, DOI 10.1016/0003-2697(83)90590-0; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4; KAPLANSKI G, 1993, BIOPHYS J, V64, P1922, DOI 10.1016/S0006-3495(93)81563-7; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; LAWRENCE MB, 1994, IMMUNITY, V1, P137, DOI 10.1016/1074-7613(94)90107-4; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; MILLER LJ, 1987, J CLIN INVEST, V80, P535, DOI 10.1172/JCI113102; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; PEPINSKY B, 1992, J BIOL CHEM, V267, P17820; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; PURI KD, 1995, J CELL BIOL, V131, P261, DOI 10.1083/jcb.131.1.261; ROCHON YP, 1994, J IMMUNOL, V152, P1385; SCHMIDSCHONBEIN GW, 1980, MICROVASC RES, V19, P45, DOI 10.1016/0026-2862(80)90083-7; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; SPRINGER TA, 1995, TRAFFIC SIGNALS ROLL; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699	29	392	403	3	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					266	269		10.1038/379266a0	http://dx.doi.org/10.1038/379266a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538793				2022-12-24	WOS:A1996TQ16900049
J	Sherin, JE; Shiromani, PJ; McCarley, RW; Saper, CB				Sherin, JE; Shiromani, PJ; McCarley, RW; Saper, CB			Activation of ventrolateral preoptic neurons during sleep	SCIENCE			English	Article							FOS-LIKE IMMUNOREACTIVITY; RAT-BRAIN; C-FOS; BASAL FOREBRAIN; POSTERIOR HYPOTHALAMUS; WAKING DISCHARGE; UNIT-ACTIVITY; CAT; AREA; MICROINJECTION	The rostral hypothalamus and adjacent basal forebrain participate in the generation of sleep, but the neuronal circuitry involved in this process remains poorly characterized. Immunocytochemistry was used to identify the FOS protein, an immediate-early gene product, in a group of ventrolateral preoptic neurons that is specifically activated during deep. The retrograde tracer cholera toxin B, in combination with FOS immunocytochemistry, was used to show that sleep-activated ventrolateral preoptic neurons innervate the tuberomammillary nucleus, a posterior hypothalamic cell group thought to participate in the modulation of arousal. This monosynaptic pathway in the hypothalamus may play a key role in determining sleep-wake states.	HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, PROGRAM NEUROSCI, BOSTON, MA 02115 USA; HARVARD UNIV, BROCKTON VET ADM HOSP, SCH MED, DEPT PSYCHIAT, BROCKTON, MA 02401 USA; UNIV CHICAGO, COMM NEUROBIOL, CHICAGO, IL 60637 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; University of Chicago			Saper, Clifford/L-3815-2019; Shenton, Martha/V-8780-2019; McCarley, Robert W/N-5562-2014	McCarley, Robert W/0000-0001-5705-7495	NIMH NIH HHS [MH10709] Funding Source: Medline; NINDS NIH HHS [NS22835, NS30140] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH010709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022835, R01NS030140] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALAM MN, IN PRESS AM J PHYSL; BENTIVOGLIO M, 1993, SLEEP RES, V22, P475; BOBERLY AA, 1985, BRAIN MECHANISMS SLE, P35; CIRELLI C, 1993, ARCH ITAL BIOL, V131, P327; DETARI L, 1984, ELECTROEN CLIN NEURO, V58, P362, DOI 10.1016/0013-4694(84)90062-2; DRAGUNOW M, 1989, J NEUROSCI METH, V29, P261, DOI 10.1016/0165-0270(89)90150-7; Economo CV, 1930, J NERV MENT DIS, V71, P249, DOI 10.1097/00005053-193003000-00001; ELMQUIST JK, 1993, ENDOCRINOLOGY, V133, P3054, DOI 10.1210/en.133.6.3054; ERICSON H, 1991, J COMP NEUROL, V305, P462, DOI 10.1002/cne.903050309; FINDLAY ALR, 1969, J PHYSIOL-LONDON, V201, P237, DOI 10.1113/jphysiol.1969.sp008753; GARCIAARRARAS JE, 1983, J NEUROPHYSIOL, V49, P528, DOI 10.1152/jn.1983.49.2.528; GRASSIZUCCONI G, 1994, J PHYSIOLOGY-PARIS, V88, P91, DOI 10.1016/0928-4257(94)90096-5; GRASSIZUCCONI G, 1993, SLEEP RES, V22, P478; GRITTI I, 1994, J COMP NEUROL, V339, P251, DOI 10.1002/cne.903390206; HOFFMAN GE, 1993, FRONT NEUROENDOCRIN, V14, P173, DOI 10.1006/frne.1993.1006; KAADA BR, 1951, ACTA PHYSL SCAND, V24, P200; KAITIN KI, 1984, EXP NEUROL, V83, P347, DOI 10.1016/0014-4886(84)90103-1; KONONEN J, 1990, NEUROSCI LETT, V120, P105, DOI 10.1016/0304-3940(90)90179-D; KOYAMA Y, 1994, BRAIN RES BULL, V33, P367, DOI 10.1016/0361-9230(94)90278-X; KRILOWICZ BL, 1994, BRAIN RES, V668, P30, DOI 10.1016/0006-8993(94)90507-X; LIN JS, 1988, NEUROPHARMACOLOGY, V27, P111, DOI 10.1016/0028-3908(88)90159-1; LIN JS, 1989, BRAIN RES, V479, P225, DOI 10.1016/0006-8993(89)91623-5; LUCAS EA, 1975, EXP NEUROL, V46, P368, DOI 10.1016/0014-4886(75)90142-9; MALLICK BN, 1983, EXP NEUROL, V81, P586, DOI 10.1016/0014-4886(83)90328-X; MATSUMURA H, 1994, P NATL ACAD SCI USA, V91, P11998, DOI 10.1073/pnas.91.25.11998; Mauthner L, 1890, WIEN MED WSCHR, V40, P961; MCGINTY D, 1994, BRAIN RES, V667, P273, DOI 10.1016/0006-8993(94)91506-7; MCGINTY DJ, 1968, SCIENCE, V160, P1253, DOI 10.1126/science.160.3833.1253; MENDELSON WB, 1989, NEUROPSYCHOPHARMACOL, V2, P61, DOI 10.1016/0893-133X(89)90008-0; MONTI JM, 1993, LIFE SCI, V53, P1331, DOI 10.1016/0024-3205(93)90592-Q; NAUTA WJH, 1946, J NEUROPHYSIOL, V9, P285, DOI 10.1152/jn.1946.9.4.285; NITZ DN, 1995, SLEEP RES, V24, P12; OGAWA Y, 1988, BRAIN RES BULL, V20, P897, DOI 10.1016/0361-9230(88)90108-6; PANULA P, 1984, P NATL ACAD SCI-BIOL, V81, P2572, DOI 10.1073/pnas.81.8.2572; POMPEIANO M, 1994, J SLEEP RES, V3, P80, DOI 10.1111/j.1365-2869.1994.tb00111.x; ROBERTS WW, 1969, EXP NEUROL, V25, P282, DOI 10.1016/0014-4886(69)90051-X; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SALLANON M, 1989, NEUROSCIENCE, V32, P669, DOI 10.1016/0306-4522(89)90289-3; SCHWARTZ JC, 1991, PHYSIOL REV, V71, P1, DOI 10.1152/physrev.1991.71.1.1; SENBA E, 1985, J NEUROSCI, V5, P3393; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHERIN JE, 1993, SOC NEUR ABSTR, V19, P31; SHERIN JE, UNPUB; SHIROMANI PJ, 1995, MOL BRAIN RES, V29, P163, DOI 10.1016/0169-328X(94)00242-7; Snedecor GW., 1989, STAT METHODS, P177; STERIADE M, 1987, J NEUROPHYSIOL, V57, P260, DOI 10.1152/jn.1987.57.1.260; STERMAN MB, 1962, EXP NEUROL, V6, P91, DOI 10.1016/0014-4886(62)90080-8; Sterman MB, 1985, BRAIN MECHANISMS SLE, P277; SWETT CP, 1968, ARCH ITAL BIOL, V106, P283; SZYMUSIAK R, 1989, BRAIN RES BULL, V23, P111, DOI 10.1016/0361-9230(89)90169-X; SZYMUSIAK R, 1989, BRAIN RES, V498, P355, DOI 10.1016/0006-8993(89)91116-5; SZYMUSIAK R, 1986, BRAIN RES, V370, P82, DOI 10.1016/0006-8993(86)91107-8; SZYMUSIAK R, 1986, EXP NEUROL, V94, P598, DOI 10.1016/0014-4886(86)90240-2; UENO R, 1982, BIOCHEM BIOPH RES CO, V109, P576, DOI 10.1016/0006-291X(82)91760-0; VANHULZEN ZJM, 1980, PHYSIOL BEHAV, V25, P807, DOI 10.1016/0031-9384(80)90298-X; VANNIMERCIER G, 1984, CR ACAD SCI III-VIE, V298, P195; WATANABE T, 1983, NEUROSCI LETT, V39, P249, DOI 10.1016/0304-3940(83)90308-7; WILCOX BJ, 1982, NEUROSCI LETT, V29, P105, DOI 10.1016/0304-3940(82)90337-8; YANG OZ, 1994, SOC NEUR ABSTR, V20, P346	59	721	755	0	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	1996	271	5246					216	219		10.1126/science.271.5246.216	http://dx.doi.org/10.1126/science.271.5246.216			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539624				2022-12-24	WOS:A1996TP36400046
J	Sobol, RW; Horton, JK; Kuhn, R; Gu, H; Singhal, RK; Prasad, R; Rajewsky, K; Wilson, SH				Sobol, RW; Horton, JK; Kuhn, R; Gu, H; Singhal, RK; Prasad, R; Rajewsky, K; Wilson, SH			Requirement of mammalian DNA polymerase-beta in base-excision repair	NATURE			English	Article							CELLS; AGENTS	SYNTHESIS Of DNA by DNA polymerase-beta is distributive on single-stranded DNA templates, but short DNA gaps with a 5' PO4 in the gap are filled processively to completion(1,2). In vitro studies have suggested a role of beta-polymerase in different types of DNA repair(3-9). However, the significance of these studies to the in vivo role of beta-polymerase has remained unclear. Because genetic studies are essential for determining the physiological role of a gene, we established embryonic fibroblast cell lines homozygous for a deletion mutation in the gene encoding DNA polymerase-beta. Extracts from these cell lines were found to be defective in uracil-initiated base-excision repair. The beta-polymerase-deleted cells are normal in viability and growth characteristics, although they exhibit increased sensitivity to monofunctional DNA-alkylating agents, but not to other DNA-damaging agents. Both the deficiency in base-excision repair and hypersensitivity to DNA-alkylating agents are rescued following stable transfection with a wild-type beta-polymerase minitransgene. These studies demonstrate that beta-polymerase functions specifically in base-excision repair in vivo.	UNIV COLOGNE,INST GENET,D-50931 COLOGNE,GERMANY	University of Cologne	Sobol, RW (corresponding author), UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,CELL BIOL LAB,GALVESTON,TX 77555, USA.		Wilson, Samuel H/E-6644-2019; Sobol, Robert W./E-4125-2013; Kühn, Ralf/U-1278-2017	Wilson, Samuel H/0000-0002-1702-5293; Sobol, Robert W./0000-0001-7385-3563; Kühn, Ralf/0000-0003-1694-9803; Rajewsky, Klaus/0000-0002-6633-6370				BUTLER WB, 1984, ANAL BIOCHEM, V141, P70, DOI 10.1016/0003-2697(84)90426-3; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DOLAN ME, 1990, P NATL ACAD SCI USA, V87, P5368, DOI 10.1073/pnas.87.14.5368; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; KOMBERG A, 1991, DNA REPLICATION; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P211; KRIEGLER M, 1995, CURRENT PROTOCOLS MO; MATSUMOTO Y, 1991, MOL CELL BIOL, V11, P4441, DOI 10.1128/MCB.11.9.4441; PRASAD R, 1994, J BIOL CHEM, V269, P18096; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P49; SRIVASTAVA DK, 1995, J BIOL CHEM, V270, P1; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199	17	748	770	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					183	186		10.1038/379183a0	http://dx.doi.org/10.1038/379183a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538772				2022-12-24	WOS:A1996TP36000064
J	Chittajallu, R; Vignes, M; Dev, KK; Barnes, JM; Collingridge, GL; Henley, JM				Chittajallu, R; Vignes, M; Dev, KK; Barnes, JM; Collingridge, GL; Henley, JM			Regulation of glutamate release by presynaptic kainate receptors in the hippocampus	NATURE			English	Article							NEURONS; RAT; AMPA; 2,3-BENZODIAZEPINE; DESENSITIZATION; CYCLOTHIAZIDE; TRANSMISSION; ACTIVATION; ANTAGONIST; CHANNELS	MOST reported actions of kainate are mediated by AMPA (alpha-amino-3-hydroxy-5-methyl 3-isosazolepropionate) receptors(1,2). Here we report that, unlike AMPA which stimulates, kainate elicits a dose-dependent decrease in L-glutamate release from rat hippocampal synaptosomes and also depresses glutamatergic synaptic transmission. Brief exposure to kainate inhibited Ca2+-dependent [H-3]L-glutamate release by up to 80%. Inhibition was reversed by kainate antagonists but not by the AMPA-selective noncompetitive antagonist 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3- benzodiazepine (GYKI 52466)(3-7). A corresponding reversible kainate-evoked depression of NMDA (N-methyl-D-aspartate) receptor-mediated excitatory postsynaptic currents (e.p.s.cs) was observed when AMPA receptors were blocked by GYKI 52466. The synaptic depression was preceded by a brief period of enhanced release and a small inward current was also observed. The effects of kainate were unaffected by metabotropic glutamate (mGlu), GABA(A), GABA(B), glycine and adenosine receptor antagonists. These results indicate that glutamate release can be modulated directly by kainate autoreceptors.	UNIV BRISTOL,SCH MED SCI,DEPT ANAT,BRISTOL BS8 1TD,AVON,ENGLAND; UNIV BIRMINGHAM,SCH MED,DEPT PHARMACOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Bristol; University of Birmingham			collingridge, graham/AAI-8362-2020; Collingridge, Graham L/C-4605-2015; Vignes, Michel/AAA-7693-2019; Chittajallu, Ramesh/AAX-3749-2020; Henley, Jeremy M/A-2776-2009	Collingridge, Graham L/0000-0002-9572-5359; Vignes, Michel/0000-0003-0969-2966; Chittajallu, Ramesh/0000-0002-9794-0052; Henley, Jeremy/0000-0003-3589-8335; Dev, Kumlesh/0000-0003-4274-9119	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGRAWAL SG, 1986, BRIT J PHARMACOL, V87, P345, DOI 10.1111/j.1476-5381.1986.tb10823.x; BAHN S, 1994, J NEUROSCI, V14, P5525; BARNES JM, 1994, BRIT J PHARMACOL, V113, P339, DOI 10.1111/j.1476-5381.1994.tb16902.x; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; COLLINGRIDGE G, 1994, NMDA RECEPTOR; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DONEVAN SD, 1993, NEURON, V10, P51, DOI 10.1016/0896-6273(93)90241-I; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; JOHANSEN TH, 1993, EUR J PHARM-MOLEC PH, V246, P195, DOI 10.1016/0922-4106(93)90031-4; LEGENDRE P, 1993, J NEUROSCI, V13, P674; LERMA J, 1993, P NATL ACAD SCI USA, V90, P11688, DOI 10.1073/pnas.90.24.11688; MALVA JO, 1995, NEUROSCI LETT, V185, P83, DOI 10.1016/0304-3940(94)11230-G; MARTIN D, 1991, J NEUROCHEM, V56, P1647, DOI 10.1111/j.1471-4159.1991.tb02063.x; NISTRI A, 1991, J PHYSIOL-LONDON, V435, P465, DOI 10.1113/jphysiol.1991.sp018519; PALMER AJ, 1993, EUR J PHARM-MOLEC PH, V244, P193, DOI 10.1016/0922-4106(93)90027-7; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; PATNEAU DK, 1991, NEURON, V6, P785, DOI 10.1016/0896-6273(91)90175-Y; RENARD A, 1995, NEUROPHARMACOLOGY, V34, P335, DOI 10.1016/0028-3908(94)00165-O; RUANO D, 1995, J NEURON, V14, P1009; SAWADA S, 1985, EXP BRAIN RES, V60, P323; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; TAMAWA I, 1990, AMINO ACIDS CHEM BIO, P538; VERDOORN TA, 1994, EUR J PHARM-MOLEC PH, V269, P43, DOI 10.1016/0922-4106(94)90024-8; WONG LA, 1993, MOL PHARMACOL, V44, P504; ZEMAN S, 1992, BRIT J PHARMACOL, V106, P367, DOI 10.1111/j.1476-5381.1992.tb14342.x; ZHOU M, 1995, J NEUROCHEM, V64, P1556; ZORUMSKI CF, 1993, NEURON, V10, P61, DOI 10.1016/0896-6273(93)90242-J	30	338	342	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					78	81		10.1038/379078a0	http://dx.doi.org/10.1038/379078a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538745				2022-12-24	WOS:A1996TN21600059
J	Mok, A; Nelson, EAS				Mok, A; Nelson, EAS			Children on hunger strike: Child abuse or legitimate protest?	BRITISH MEDICAL JOURNAL			English	Article								The issue of children on hunger strike (voluntary total fasting) has not been reported before. The World Medical Association Declaration of Tokyo 1975 and the Declaration of Malta 1991 (revised 1992) provide clinicians with guidelines for the management of adult patients on hunger strike(12) but do not mention children. We report the management of 14 Vietnamese children, aged 1 to 12 years, who took part in a hunger strike at a refugee detention centre in Hong Kong.	CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT PAEDIAT,SHA TIN,HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital			Nelson, E Anthony S/ABF-4238-2020	Nelson, E Anthony S/0000-0002-2521-3403				[Anonymous], 1989, CONV RIGHTS CHILD 20; DEVEREUX JA, 1993, BRIT MED J, V306, P1459, DOI 10.1136/bmj.306.6890.1459; KALK WJ, 1991, LANCET, V337, P660, DOI 10.1016/0140-6736(91)92465-E; SHIELD JP, 1994, BRIT MED J, V308, P1182, DOI 10.1136/bmj.308.6938.1182; 1994, S CHINA MORNING 0914; 1975, WORLD MED J, V22, P87; 1992, 44 WORLD MED ASS MAR; 1991, 43 WORLD MED ASS MAL	8	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					501	502		10.1136/bmj.312.7029.501	http://dx.doi.org/10.1136/bmj.312.7029.501			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597690	Green Published			2022-12-24	WOS:A1996TX38300037
J	VanDaele, PLA; Seibel, MJ; Burger, H; Hofman, A; Grobbee, DE; VanLeeuwen, JPTM; Birkenhager, JC; Pols, HAP				VanDaele, PLA; Seibel, MJ; Burger, H; Hofman, A; Grobbee, DE; VanLeeuwen, JPTM; Birkenhager, JC; Pols, HAP			Case-control analysis of bone resorption markers, disability, and hip fracture risk: The Rotterdam study	BRITISH MEDICAL JOURNAL			English	Article									ERASMUS UNIV ROTTERDAM,SCH MED,DEPT INTERNAL MED 3,3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS; UNIV HEIDELBERG,DEPT ENDOCRINOL & METAB,HEIDELBERG,GERMANY	Erasmus University Rotterdam; Erasmus University Rotterdam; Ruprecht Karls University Heidelberg			Grobbee, Diederick/C-7651-2014; van Leeuwen, Johannes/D-5015-2014	Grobbee, Diederick/0000-0003-4472-4468; van Leeuwen, Johannes/0000-0002-2282-4006; Seibel, Markus J/0000-0002-2701-378X				CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; JOHNSTON CC, 1994, OSTEOPOROSIS INT, V4, P43; LIPS P, 1990, BONE MINER, V9, P49, DOI 10.1016/0169-6009(90)90099-2; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107	5	154	156	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					482	483		10.1136/bmj.312.7029.482	http://dx.doi.org/10.1136/bmj.312.7029.482			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597681	Green Submitted, Green Published			2022-12-24	WOS:A1996TX38300025
J	Daltry, JC; Wuster, W; Thorpe, RS				Daltry, JC; Wuster, W; Thorpe, RS			Diet and snake venom evolution	NATURE			English	Article							RATTLESNAKE VENOM; RUSSELL VIPER; ISLAND; PREY	VENOM composition within snake species can show considerable geographical variation(1), an important consideration because bites by conspecific populations may differ in symptomatology and require different treatments(2-5). The underlying causes of this phenomenon have never been explained, Here we present evidence that the variation in the venom of the pitviper Calloselasma rhodostoma (Serpentes: Viperidae) is closely associated with its diet, We also evaluated other possible causes of geographic variation in venom using partial Mantel tests(6-10) and independent contrasts(11), but rejected both contemporary gene flow (estimated from geographical proximity) and the phylogenetic relationships (assessed by analysis of mitochondrial DNA) among populations as important influences upon venom evolution, As the primary function of viperid venom is to immobilize and digest prey(12-14) and prey animals vary in their susceptibility to venom(15,16), we suggest that geographical variation in venom composition reflects natural selection for feeding on local prey.	UNIV COLL N WALES, SCH BIOL SCI, BANGOR LL57 2UW, GWYNEDD, WALES	Bangor University			Wuster, Wolfgang/B-2879-2008	Wuster, Wolfgang/0000-0002-4890-4311; Daltry, Jennifer C./0000-0003-0364-9465				BARRIO AVELINO, 1951, ACTA PHYSIOL LATINOAMER, V1, P291; BOCHE J, 1981, B SOC PATHOL EXOT, V74, P356; BROWN RP, 1991, NATURE, V352, P60, DOI 10.1038/352060a0; CASTELLANO S, 1994, BIOL J LINN SOC, V52, P365, DOI 10.1006/bijl.1994.1057; CHEN YC, 1984, TOXICON, V22, P53, DOI 10.1016/0041-0101(84)90138-7; CHIPPAUX JP, 1991, TOXICON, V29, P1279, DOI 10.1016/0041-0101(91)90116-9; ELLIOTT WB, 1978, BIOL REPTILIA, V8, P163; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FELSENSTEIN J, 1990, PHYLIP VERSION 3 3; FOOTE R, 1977, COMP BIOCHEM PHYS B, V57, P235, DOI 10.1016/0305-0491(77)90150-X; GREGORYDWYER VM, 1986, TOXICON, V24, P995, DOI 10.1016/0041-0101(86)90005-X; HAYES WK, 1991, TOXICON, V29, P867, DOI 10.1016/0041-0101(91)90223-E; JAYANTHI GP, 1988, TOXICON, V26, P257, DOI 10.1016/0041-0101(88)90216-4; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; MACKESSY SP, 1988, COPEIA, P92, DOI 10.2307/1445927; MCELROY D, 1992, RESTRICTION ENZYME A; Minton S. A., 1969, VENOMOUS REPTILES; MORITZ C, 1992, SYST BIOL, V41, P273, DOI 10.2307/2992567; POUGH FH, 1983, AM ZOOL, V23, P443; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x; Tan N.-H., 1991, Tropical Biomedicine, V8, P91; THOMAS RG, 1979, TOXICON, V17, P221, DOI 10.1016/0041-0101(79)90211-3; Thorpe R.S., 1994, Linnean Society Symposium Series, V17, P189; THORPE RS, 1995, PHILOS T ROY SOC B, V349, P61, DOI 10.1098/rstb.1995.0091; THORPE RS, 1993, BIOL J LINN SOC, V48, P75, DOI 10.1111/j.1095-8312.1993.tb00878.x; TU AT, 1978, J HERPETOL, V12, P105, DOI 10.2307/1563515; TU AT, 1968, NATURE, V217, P761; WARRELL DA, 1986, NATURAL TOXINS ANIMA, P00025; WUSTER W, 1992, BIOL J LINN SOC, V47, P97, DOI 10.1111/j.1095-8312.1992.tb00658.x	29	486	498	1	149	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					537	540		10.1038/379537a0	http://dx.doi.org/10.1038/379537a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596631				2022-12-24	WOS:A1996TU69300049
J	Considine, RV; Sinha, MK; Heiman, ML; Kriauciunas, A; Stephens, TW; Nyce, MR; Ohannesian, JP; Marco, CC; McKee, LJ; Bauer, TL; Caro, JF				Considine, RV; Sinha, MK; Heiman, ML; Kriauciunas, A; Stephens, TW; Nyce, MR; Ohannesian, JP; Marco, CC; McKee, LJ; Bauer, TL; Caro, JF			Serum immunoreactive leptin concentrations in normal-weight and obese humans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. Leptin, the product of the ob gene, is a hormone secreted by adipocytes, Animals with mutations in the ob gene are obese and lose weight when given leptin, but little is known about the physiologic actions of leptin in humans. Methods. Using a newly developed radioimmunoassay, we measured serum concentrations of leptin in 136 normal-weight subjects and 139 obese subjects (body-mass index, greater than or equal to 27.3 for men and greater than or equal to 27.8 for women; the body-mass index was defined as the weight in kilograms divided by the square of the height in meters). The measurements were repeated in seven obese subjects after weight loss and during maintenance of the lower weight. The ob messenger RNA (mRNA) content of adipocytes was determined in 27 normal-weight and 27 obese subjects. Results. The mean (+/-SD) serum leptin concentrations were 31.3+/-24.1 ng per milliliter in the obese subjects and 7.5+/-9.3 ng per milliliter in the normal-weight subjects (P < 0.001). There was a strong positive correlation between serum leptin concentrations and the percentage of body fat (r = 0.85, P < 0.001). The ob mRNA content of adipocytes was about twice as high in the obese subjects as in the normal-weight subjects (P = 0.005) and was correlated with the percentage of body fat (r = 0.68, P < 0.001) in the 54 subjects in whom it was measured. In the seven obese subjects studied after weight loss, both serum leptin concentrations and ob mRNA content of adipocytes declined, but these measures increased again during the maintenance of the lower weight. Conclusions. Serum leptin concentrations are correlated with the percentage of body fat, suggesting that most obese persons are insensitive to endogenous leptin production. (C) 1996, Massachusetts Medical Society.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT CLIN PHARMACOL,BIOSTAT SECT,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT SURG,PHILADELPHIA,PA 19107; ELI LILLY & CO,LILLY RES LABS,INDIANAPOLIS,IN 46285	Jefferson University; Jefferson University; Jefferson University; Eli Lilly	Considine, RV (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DIV ENDOCRINOL & METAB,1025 WALNUT ST,813 COLL BLDG,PHILADELPHIA,PA 19107, USA.		sheng, jian/E-9474-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045592] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK45592] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; DEVOS P, 1995, J BIOL CHEM, V270, P15958, DOI 10.1074/jbc.270.27.15958; FUNAHASHI T, 1995, BIOCHEM BIOPH RES CO, V211, P469, DOI 10.1006/bbrc.1995.1837; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMILTON BS, 1995, NAT MED, V1, P953, DOI 10.1038/nm0995-953; JEBB SA, 1993, INT J OBESITY, V17, P611; KOLACZYNSKI JW, 1994, INT J OBESITY, V18, P161; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; MASUZAKI H, 1995, DIABETES, V44, P855, DOI 10.2337/diabetes.44.7.855; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; NIH Technology Assessment Conference Panel, 1992, ANN INTERN MED, V116, P942; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; ZHANG YY, 1995, NATURE, V374, P479, DOI 10.1038/374479a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	20	5077	5244	4	283	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					292	295		10.1056/NEJM199602013340503	http://dx.doi.org/10.1056/NEJM199602013340503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV695	8532024	Bronze			2022-12-24	WOS:A1996TV69500003
J	Pisetsky, DS				Pisetsky, DS			The breakthrough	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Pisetsky, DS (corresponding author), DUKE UNIV, MED CTR,VET AFFAIRS MED CTR,BOX 151G,ROOM E-1008, 508 FULTON ST, DURHAM, NC 27705 USA.								0	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					345	347		10.7326/0003-4819-124-3-199602010-00013	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00013			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554234				2022-12-24	WOS:A1996TR59600013
J	Ryan, CJ; Kaye, M				Ryan, CJ; Kaye, M			Euthanasia in Australia - The Northern Territory rights of the terminally ill act	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									UNIV SYDNEY,SYDNEY,NSW 2000,AUSTRALIA	University of Sydney	Ryan, CJ (corresponding author), WESTMEAD HOSP,SYDNEY,NSW 2145,AUSTRALIA.		Ryan, Christopher/B-4095-2010	Kaye, Miranda/0000-0003-4484-1904; Ryan, Christopher/0000-0003-2158-9427				BATTIN MP, 1994, LEAST WORST DEATH, P123; BAUME P, 1994, MED J AUSTRALIA, V161, P137, DOI 10.5694/j.1326-5377.1994.tb127345.x; BAUME P, 1994, MED J AUSTRALIA, V161, P142; BAUME P, 1994, MED J AUSTRALIA, V161, P140; GLOVER J, 1988, CAUSING DEATH SAVING, P188; Griffiths John, 1994, Med Law Int, V1, P137; KUHSE H, 1988, MED J AUSTRALIA, V148, P623, DOI 10.5694/j.1326-5377.1988.tb116334.x; OGILVIE AD, 1994, BRIT MED J, V309, P492, DOI 10.1136/bmj.309.6953.492; Ryan CJ, 1995, AUST NZ J PSYCHIAT, V29, P580, DOI 10.3109/00048679509064970; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; 1995, NO TERRITORY RIGHTS	11	46	46	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					326	328		10.1056/NEJM199602013340512	http://dx.doi.org/10.1056/NEJM199602013340512			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV695	8532033				2022-12-24	WOS:A1996TV69500012
J	Thadhani, R; Pascual, M; Nickeleit, V; TolkoffRubin, N; Colvin, R				Thadhani, R; Pascual, M; Nickeleit, V; TolkoffRubin, N; Colvin, R			Preliminary description of focal segmental glomerulosclerosis in patients with renovascular disease	LANCET			English	Article							PROTEINURIA	Background Primary and secondary forms of focal segmental glomerulosclerosis (FSGS) are common causes of glomerular proteinuria. Secondary forms of FSGS seem to be the result of adaptive changes that follow a reduction in renal mass. We saw an elderly patient with severe bilateral renal vascular disease (RVD) who had FSGS on percutaneous biopsy. To find out whether elderly patients with atherosclerotic RVD are predisposed to the development of FSGS, we reviewed all cases of FSGS at our institution between 1990 and 1995. Methods We identified 59 cases of biopsy-proven FSGS and examined clinical, histological, and radiographic records. Findings Of the 59 patients, 24 were older than 50 years; eight of these had RVD. No patient under the age of 50 had RVD. Seven of the eight patients with RVD and FSGS had substantial proteinuria at presentation. All had typical glomerular lesions with focal segmental tuft collapse and synechiae; other glomeruli were hypertrophic. All patients showed further decline in renal function on follow-up. Interpretation The association of FSGS and RVD may represent an under-recognised aetiology of significant proteinuria in elderly patients.	MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital				Pascual, Manuel A./0000-0001-7747-1693				ARTERO M, 1992, AM J MED, V92, P375, DOI 10.1016/0002-9343(92)90267-F; DAGATI V, 1994, KIDNEY INT, V46, P1223, DOI 10.1038/ki.1994.388; DANTAL J, 1994, NEW ENGL J MED, V330, P7, DOI 10.1056/NEJM199401063300102; FREEDMAN BI, 1995, AM J KIDNEY DIS, V25, P207, DOI 10.1016/0272-6386(95)90001-2; GEPHARDT GN, 1984, CLEVELAND CLIN Q, V51, P371, DOI 10.3949/ccjm.51.2.371; HARVEY JM, 1992, LANCET, V340, P1435, DOI 10.1016/0140-6736(92)92624-O; KUMAR A, 1980, ARCH INTERN MED, V140, P1631, DOI 10.1001/archinte.140.12.1631; MCLACHLAN M, 1981, BRIT J RADIOL, V54, P488, DOI 10.1259/0007-1285-54-642-488; PICKERING TG, 1993, DISEASES KIDNEY, P1451; RENNKE HG, 1989, AM J KIDNEY DIS, V13, P443, DOI 10.1016/S0272-6386(89)80001-0	10	61	61	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					231	233		10.1016/S0140-6736(96)90406-7	http://dx.doi.org/10.1016/S0140-6736(96)90406-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551883				2022-12-24	WOS:A1996TT06900012
J	Acton, S; Rigotti, A; Landschulz, KT; Xu, SZ; Hobbs, HH; Krieger, M				Acton, S; Rigotti, A; Landschulz, KT; Xu, SZ; Hobbs, HH; Krieger, M			Identification of scavenger receptor SR-BI as a high density lipoprotein receptor	SCIENCE			English	Article							CHOLESTERYL LINOLEYL ETHER; APOPROTEIN-A-I; SELECTIVE UPTAKE; MEDIATED ENDOCYTOSIS; HEPATOMA-CELLS; ADRENAL-GLAND; RAT; ESTERS; METABOLISM; HEPATOCYTES	High density lipoprotein (HDL) and low density lipoprotein (LDL) are cholesterol transport particles whose plasma concentrations are directly (LDL) and inversely (HDL) correlated with risk for atherosclerosis. LDL catabolism involves cellular uptake and degradation of the entire particle by a well-characterized receptor. HDL, in contrast, selectively delivers its cholesterol, but not protein, to cells by unknown receptors. Here it is shown that the class B scavenger receptor SR-BI is an HDL receptor. SR-BI binds HDL with high affinity, is expressed primarily in liver and nonplacental steroidogenic tissues, and mediates selective cholesterol uptake by a mechanism distinct from the classic LDL receptor pathway.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	Massachusetts Institute of Technology (MIT); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Eckhardt, Erik/G-1567-2010; Girelli, Domenico/B-1183-2008	Girelli, Domenico/0000-0001-9684-1899	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009047, P01HL041484, R01HL052212] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52212, HL41484, HL09047] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACTON SL, 1994, J BIOL CHEM, V269, P21003; ANDERSEN JM, 1981, J BIOL CHEM, V256, P7362; ARBEENY CM, 1987, BIOCHIM BIOPHYS ACTA, V917, P9, DOI 10.1016/0005-2760(87)90277-3; ASSRNAN G, 1995, METABOLIC MOL BASES, P2053; BABITT J, UNPUB; BRESLOW JL, 1995, METABOLIC MOL BASES, P2031; Brown M S, 1979, Recent Prog Horm Res, V35, P215; CALVO D, 1993, J BIOL CHEM, V268, P18929; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; Converse CA, 1992, LIPOPROTEIN ANAL PRA; DELAMATRE JG, 1991, J CELL PHYSIOL, V146, P18, DOI 10.1002/jcp.1041460104; FIELDING CJ, 1995, J LIPID RES, V36, P211; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2849, DOI 10.1001/jama.256.20.2849; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; JACKLE S, 1993, HEPATOLOGY, V17, P455, DOI 10.1016/0270-9139(93)90058-U; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KNECHT TP, 1989, BIOCHIM BIOPHYS ACTA, V1002, P365, DOI 10.1016/0005-2760(89)90351-2; KOVANEN PT, 1979, J BIOL CHEM, V254, P5498; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; KRIEGER M, 1979, J SUPRAMOL STR CELL, V10, P467, DOI 10.1002/jss.400100409; LEITERSDORF E, 1986, BIOCHIM BIOPHYS ACTA, V878, P320, DOI 10.1016/0005-2760(86)90239-0; MACKINNON M, 1986, J BIOL CHEM, V261, P2548; MURPHY BD, 1985, ENDOCRINOLOGY, V116, P1587, DOI 10.1210/endo-116-4-1587; PAGANO RE, 1985, SCIENCE, V229, P1051, DOI 10.1126/science.4035344; PIETERS MN, 1994, BBA-MOL BASIS DIS, V1225, P125, DOI 10.1016/0925-4439(94)90069-8; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; REAVEN E, 1995, J LIPID RES, V36, P1602; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; RINNINGER F, 1993, BIOCHIM BIOPHYS ACTA, V1166, P275, DOI 10.1016/0005-2760(93)90108-L; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; SCHOUTEN D, 1990, ARTERIOSCLEROSIS, V10, P1127, DOI 10.1161/01.ATV.10.6.1127; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; WISHART R, 1990, BIOCHIM BIOPHYS ACTA, V1044, P375, DOI 10.1016/0005-2760(90)90083-A	43	1933	2048	1	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					518	520		10.1126/science.271.5248.518	http://dx.doi.org/10.1126/science.271.5248.518			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560269				2022-12-24	WOS:A1996TR32200046
J	Dempsey, PW; Allison, MED; Akkaraju, S; Goodnow, CC; Fearon, DT				Dempsey, PW; Allison, MED; Akkaraju, S; Goodnow, CC; Fearon, DT			C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity	SCIENCE			English	Article							RAPID PURIFICATION; MOUSE COMPLEMENT; LYMPHOCYTES-B; RECEPTOR; SYSTEM; ANTIBODY; PROTEINS; INVIVO; SELF	An optimal immune response should differentiate between harmful and innocuous antigens. Primitive systems of innate immunity, such as the complement system, may play a role in this distinction. When activated, the C3 component of complement attaches to potential antigens on microorganisms. To determine whether this alters acquired immune recognition, mice were immunized with a recombinant model antigen, hen egg lysozyme (HEL), fused to murine C3d. HEL bearing two and three copies of C3d was 1000- and 10,000-fold more immunogenic, respectively, than HEL alone. Thus, C3d is a molecular adjuvant of innate immunity that profoundly influences an acquired immune response.	UNIV CAMBRIDGE,SCH MED,DEPT MED,WELLCOME TRUST IMMUNOL UNIT,CAMBRIDGE CB2 2SP,ENGLAND; STANFORD UNIV,SCH MED,PROGRAM IMMUNOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	University of Cambridge; Stanford University; Howard Hughes Medical Institute; Stanford University			Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155; Allison, Michael/0000-0003-3677-3294	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI019512] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07247, AI19512] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		DOMDEY H, 1982, P NATL ACAD SCI-BIOL, V79, P7619, DOI 10.1073/pnas.79.24.7619; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FEARON DT, 1980, NEW ENGL J MED, V303, P259, DOI 10.1056/NEJM198007313030505; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; HEYMAN B, 1990, J EXP MED, V172, P665, DOI 10.1084/jem.172.2.665; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; KINOSHITA T, 1988, J IMMUNOL, V140, P3066; KROP I, IN PRESS EUR J IMMUN; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; PEPYS MB, 1974, J EXP MED, V140, P126, DOI 10.1084/jem.140.1.126; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; SMITHGILL SJ, 1982, J IMMUNOL, V128, P314; TAYLOR ME, 1991, BIOCHEM J, V274, P575, DOI 10.1042/bj2740575; TEDDER TE, 1994, IMMUNOL TODAY, V15, P437, DOI 10.1016/0167-5699(94)90274-7; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; WENG WK, 1994, J BIOL CHEM, V269, P32514	21	943	1042	4	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					348	350		10.1126/science.271.5247.348	http://dx.doi.org/10.1126/science.271.5247.348			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553069				2022-12-24	WOS:A1996TQ52800040
J	Hahn, SA; Schutte, M; Hoque, ATMS; Moskaluk, CA; daCosta, LT; Rozenblum, E; Weinstein, CL; Fischer, A; Yeo, CJ; Hruban, RH; Kern, SE				Hahn, SA; Schutte, M; Hoque, ATMS; Moskaluk, CA; daCosta, LT; Rozenblum, E; Weinstein, CL; Fischer, A; Yeo, CJ; Hruban, RH; Kern, SE			DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1	SCIENCE			English	Article							CANCER; CARCINOMAS; PANCREAS	About 90 percent of human pancreatic carcinomas show allelic loss at chromosome 18q. To identify candidate tumor suppressor genes on 18q, a panel of pancreatic carcinomas were analyzed for convergent sites of homboygous deletion. Twenty-five of 84 tumors had homozygous deletions at 18q21.1, a site that excludes DCC (a candidate suppressor gene for colorectal cancer) and includes DPC4, a gene similar in sequence to a Drosophila melanogaster gene (Mad) implicated in a transforming growth factor-beta (TGF-beta)-like signaling pathway. Potentially inactivating mutations in DPC4 were identified in six of 27 pancreatic carcinomas that did not have homozygous deletions at 18q21.1. These results identify DPC4 as a candidate tumor suppressor gene whose inactivation may play a role in pancreatic and possibly other human cancers.	JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT SURG,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,GRAD PROGRAM HUMAN GENET & MOLEC BIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Hahn, Stephan A./AAV-6062-2021; Hahn, Stephan/E-3880-2010	Hahn, Stephan A./0000-0003-0855-9741; Hahn, Stephan/0000-0003-0855-9741	NATIONAL CANCER INSTITUTE [P50CA062924] Funding Source: NIH RePORTER; NCI NIH HHS [CA62924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CONE D, 1993, NATURE, V366, P698; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRANCKE U, 1994, CYTOGENET CELL GENET, V66, P196, DOI 10.1159/000133697; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; HAHN S, UNPUB; HAHN SA, 1995, CANCER RES, V55, P4670; HAHN SA, IN PRESS CANCER RES; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HRUBAN RH, 1993, AM J PATHOL, V143, P545; HURSH DA, 1993, DEVELOPMENT, V117, P1211; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1985, CANCER RES, V45, P1437; Leach Francis, COMMUNICATION; LIU YG, 1995, GENOMICS, V25, P674, DOI 10.1016/0888-7543(95)80010-J; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; REDSTON MS, 1994, CANCER RES, V54, P3025; SCHUTTE M, 1995, P NATL ACAD SCI USA, V92, P5950, DOI 10.1073/pnas.92.13.5950; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SILVERMAN GA, 1993, PCR METH APPL, V3, P141; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	27	2054	2165	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					350	353		10.1126/science.271.5247.350	http://dx.doi.org/10.1126/science.271.5247.350			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553070				2022-12-24	WOS:A1996TQ52800041
J	Slotnick, RN; Abuhamad, AZ				Slotnick, RN; Abuhamad, AZ			Prognostic implications of fetal echogenic bowel	LANCET			English	Article							DENSITOMETRY; DISEASE	Background An increased frequency of hyperechogenic bowel on ultrasound has been reported in fetuses with cystic fibrosis (CF) and trisomy-21. However, the diagnostic application of this observation has been hampered by the absence of a means of measuring echogenicity. Methods We devised an ultrasonic grading system in which echogenicity was quantified by linear gain reduction and comparison with fetal iliac crest. From 7400 second-trimester ultrasound referrals, 145 patients were identified as having a fetus with abnormally echogenic bowel. They were offered genetic counselling, parental and (if appropriate) CF carrier testing, and amniocentesis for karyotype and CF status if parents were informative. Follow-up was to 4 months of age. Findings Of 40 fetuses with mild increase in bowel sonodensity (grade 1), none had CF or aneuploidy. Of 81 patients identified with a moderate increase (grade 2), 2 had trisomy 21 and 2 had CF. And of 24 pregnancies with a pronounced increase (grade 3), 5 had CF and 6 had trisomy-21. Interpretation Parental CF carrier testing and amniocentesis to identify aneuploidy or fetal CF status has a high positive ascertainment rate in fetuses with echogenic bowel grades 2 and 3.			Slotnick, RN (corresponding author), EASTERN VIRGINIA MED SCH,DEPT OBSTET & GYNECOL,DIV MATERNAL FETAL MED,NORFOLK,VA 23507, USA.							BEAUDET AL, 1990, NEW ENGL J MED, V323, P70; BLICKSTEIN I, 1994, J ULTRAS MED, V13, P675, DOI 10.7863/jum.1994.13.9.675; BLICKSTEIN I, 1993, J ULTRAS MED, V12, P567; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CASPI B, 1992, GYNECOL OBSTET INVES, V33, P26, DOI 10.1159/000294842; CASPI B, 1988, PRENATAL DIAG, V8, P379, DOI 10.1002/pd.1970080508; CHALUBINSKI K, 1992, PRENATAL DIAG, V12, P631, DOI 10.1002/pd.1970120802; DICKE JM, 1992, OBSTET GYNECOL, V80, P778; FOROUZAN I, 1992, OBSTET GYNECOL, V80, P535; NYBERG DA, 1990, OBSTET GYNECOL, V76, P370; NYBERG DA, 1993, RADIOLOGY, V188, P527, DOI 10.1148/radiology.188.2.8327709; PLATT JF, 1988, AM J ROENTGENOL, V151, P317, DOI 10.2214/ajr.151.2.317; SCIOSCIA AL, 1992, AM J OBSTET GYNECOL, V167, P889, DOI 10.1016/S0002-9378(12)80007-X; WEINER CP, 1993, AM J OBSTET GYNECOL, V68, P6	14	94	98	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					85	87		10.1016/S0140-6736(96)90210-X	http://dx.doi.org/10.1016/S0140-6736(96)90210-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538346				2022-12-24	WOS:A1996TP28100009
J	Mortier, E; Pouchot, J; Girard, L; Boussougant, Y; Vinceneux, P				Mortier, E; Pouchot, J; Girard, L; Boussougant, Y; Vinceneux, P			Assessment of urine analysis for the diagnosis of tuberculosis	BRITISH MEDICAL JOURNAL			English	Article									UNIV PARIS 07,HOP LOUIS MOURIER,DEPT MICROBIOL,F-92700 COLOMBES,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite	Mortier, E (corresponding author), UNIV PARIS 07,HOP LOUIS MOURIER,DEPT INTERNAL MED,F-92700 COLOMBES,FRANCE.							BARBEZAT C, 1981, SCHWEIZ RUNDSCH MED, V70, P241; BASS JB, 1990, AM REV RESPIR DIS, V142, P725; BENTZ RR, 1975, AM REV RESPIR DIS, V111, P647; FAVEZ G, 1972, SCHWEIZ MED WSCHR, V102, P877; GARCIARODRIGUEZ JA, 1994, CLIN INFECT DIS, V18, P557, DOI 10.1093/clinids/18.4.557	5	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	1996	312	7022					27	28		10.1136/bmj.312.7022.27	http://dx.doi.org/10.1136/bmj.312.7022.27			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555854	Green Published			2022-12-24	WOS:A1996TP20900020
J	Torgerson, DJ; Spencer, A				Torgerson, DJ; Spencer, A			Marginal costs and benefits	BRITISH MEDICAL JOURNAL			English	Article								Decision makers are interested in measuring the costs and benefits of various interventions, and sometimes they are presented with the average costs and benefits of alternative interventions and asked to compare these. Usually a newer intervention is being compared with an existing one, and the most appropriate comparison is not of average costs (and benefits) but of the extra-or marginal-costs (and benefits) of the new intervention. Reanalysis of the cost effectiveness ratio of biochemical screening of all women for Down's syndrome compared with age based screening shows that the marginal cost effectiveness of biochemical screening is pound 47 786, compared with an average cost effectiveness of pound 37 591. It may sometimes be difficult or costly to calculate marginal costs and benefits, but this should be done whenever possible.	UNIV YORK,DEPT ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK	Torgerson, DJ (corresponding author), UNIV YORK,CTR HLTH ECON,NATL PRIMARY CARE RES & DEV,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275; Spencer, Anne/0000-0002-8163-3103				HOLLINGWORTH W, 1993, BRIT MED J, V307, P903, DOI 10.1136/bmj.307.6909.903; MCGHEE SM, 1994, BRIT J GEN PRACT, V44, P441; NEUHAUSER D, 1975, NEW ENGL J MED, V293, P226, DOI 10.1056/NEJM197507312930504; Piggott M, 1994, J Med Screen, V1, P45; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; WHYNES DK, 1995, HEALTH ECON, V4, P31, DOI 10.1002/hec.4730040104; WILLIAMS A, 1974, BRIT MED BULL, V30, P252, DOI 10.1093/oxfordjournals.bmb.a071211	7	37	37	2	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	1996	312	7022					35	36		10.1136/bmj.312.7022.35	http://dx.doi.org/10.1136/bmj.312.7022.35			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555859	Green Published			2022-12-24	WOS:A1996TP20900025
J	Zinner, E				Zinner, E			Stardust in the laboratory	SCIENCE			English	Editorial Material							INTERSTELLAR GRAINS; METEORITES; GRAPHITE		WASHINGTON UNIV,DEPT PHYS,ST LOUIS,MO 63130; WASHINGTON UNIV,DEPT EARTH & PLANETARY SCI,ST LOUIS,MO 63130	Washington University (WUSTL); Washington University (WUSTL)	Zinner, E (corresponding author), WASHINGTON UNIV,MCDONNELL CTR SPACE SCI,ST LOUIS,MO 63130, USA.							ALEXANDER CMO, 1993, GEOCHIM COSMOCHIM AC, V57, P2869, DOI 10.1016/0016-7037(93)90395-D; AMARI S, 1990, NATURE, V345, P238, DOI 10.1038/345238a0; ANDERS E, 1993, METEORITICS, V28, P490, DOI 10.1111/j.1945-5100.1993.tb00274.x; BERNATOWICZ T, 1987, NATURE, V330, P728, DOI 10.1038/330728a0; BERNATOWICZ T, UNPUB; BOOTHROYD AI, 1994, ASTROPHYS J, V430, pL77, DOI 10.1086/187442; BURBIDGE EM, 1957, REV MOD PHYS, V29, P547, DOI 10.1103/RevModPhys.29.547; CAMERON AGW, 1995, ASTROPHYS J, V447, pL53, DOI 10.1086/309554; CAMERON AGW, 1957, 1CRL41 AT EN CAN REP; EBISUZAKI T, 1989, ASTROPHYS J, V344, pL65, DOI 10.1086/185532; GALLINO R, 1994, ASTROPHYS J, V430, P858, DOI 10.1086/174457; HOPPE P, 1994, ASTROPHYS J, V430, P870, DOI 10.1086/174458; HUSS GR, 1994, ASTROPHYS J, V430, pL81, DOI 10.1086/187443; LEWIS RS, 1987, NATURE, V326, P160, DOI 10.1038/326160a0; MACPHERSON GJ, 1995, METEORITICS, V30, P365, DOI 10.1111/j.1945-5100.1995.tb01141.x; NITTLER L, 1995, NUCLEI COSMOS, V3, P585; NITTLER LR, 1994, NATURE, V370, P443, DOI 10.1038/370443a0; NITTLER LR, 1995, ASTROPHYS J, V453, pL25, DOI 10.1086/309743; OTT U, 1993, NATURE, V364, P25, DOI 10.1038/364025a0; SRINIVASAN G, 1994, ASTROPHYS J, V431, pL67, DOI 10.1086/187474; WASSERBURG GJ, 1995, ASTROPHYS J, V440, pL101, DOI 10.1086/187771; WOOSLEY SE, 1995, ASTROPHYS J SUPPL S, V101, P181, DOI 10.1086/192237; ZINNER E, 1995, LUNAR PLANET SCI, V26, P1561; ZINNER E, 1995, NUCLEI COSMOS, V3, P567	24	7	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 5	1996	271	5245					41	42		10.1126/science.271.5245.41	http://dx.doi.org/10.1126/science.271.5245.41			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539598				2022-12-24	WOS:A1996TP02200034
J	Hunt, JF; Weaver, AJ; Landry, SJ; Gierasch, L; Deisenhofer, J				Hunt, JF; Weaver, AJ; Landry, SJ; Gierasch, L; Deisenhofer, J			The crystal structure of the GroES co-chaperonin at 2.8 angstrom resolution	NATURE			English	Article							PROTEIN STRUCTURES; SURFACE; COOPERATIVITY; HYDROLYSIS; INTERFACES; BINDING; CYCLE	The GroES heptamer forms a dome, approximately 75 Angstrom in diameter and 30 Angstrom high, with an 8 Angstrom orifice in the centre of its roof. The 'mobile loop' segment, previously identified as a GroEL binding determinant, is disordered in the crystal structure in six subunits; the single well-ordered copy extends from the bottom outer rim of the GroES dome, suggesting that the cavity within the dome is continuous with the polypeptide binding chamber of GroEL in the chaperonin complex.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hunt, JF (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235, USA.		Landry, Samuel/AAK-5778-2020; Gierasch, Lila M/D-1494-2009	Landry, Samuel/0000-0002-4082-0543; 				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; Drenth J, 1994, PRINCIPLES PROTEIN X; ELLIS RJ, 1994, CURR BIOL, V4, P633; ELLIS RJ, 1994, CURR BIOL, V2, P1125; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HERZBERG O, 1991, PROTEINS, V11, P223, DOI 10.1002/prot.340110307; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; LORIMER GH, 1994, STRUCTURE, V2, P1125, DOI 10.1016/S0969-2126(94)00114-6; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MERNITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869; Nicholls A., 1992, GRASP GRAPHICAL REPR; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; Seale JW, 1995, J BIOL CHEM, V270, P30268, DOI 10.1074/jbc.270.51.30268; STEIGERMANN W, 1991, INT UNION CRYSTALLOG, V5, P115; TILLY K, 1982, J BACTERIOL, V149, P1082, DOI 10.1128/JB.149.3.1082-1088.1982; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VELLIEUX FMDAP, 1995, J APPL CRYSTALLOGR, V28, P347, DOI 10.1107/S0021889894012355; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; ZONDLO J, 1995, BIOCHEMISTRY-US, V34, P10334, DOI 10.1021/bi00033a003	53	388	394	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					37	45		10.1038/379037a0	http://dx.doi.org/10.1038/379037a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538739				2022-12-24	WOS:A1996TN21600047
J	Thomas, DHV; Noyce, PR				Thomas, DHV; Noyce, PR			Over the counter drugs - The interface between self medication and the NHS	BRITISH MEDICAL JOURNAL			English	Article								Cost and convenience seem to be major factors in determining whether, given the choice, patients purchase a medicine over the counter or obtain it on prescription. With current arrangements, exemption from prescription charges provides an incentive to continue to obtain products on NHS prescription even when they are available over the counter. There is therefore no simple relation between the availability of over the counter medicines and the level of prescribing of deregulated products. The appropriate use of over the counter medicines-particularly those that have only recently been deregulated-places a burden of care on community pharmacists and calls for closer working relationships with general practitioners. In particular, systems for referral and for recording details of both prescribed and over the counter medicines need to be developed, and a direct route needs to be established for community pharmacists to report adverse drug reactions to over the counter products.	UNIV MANCHESTER,DEPT PHARM,MANCHESTER M13 9PL,LANCS,ENGLAND; ST JOHNS HLTH CTR,WOKING GU21 1TD,SURREY,ENGLAND	University of Manchester								BAHRA MS, 1994, PHARM J, V253, pR10; BLENKINSOPP A, 1991, BRIT J GEN PRACT, V41, P116; BRADLEY C, 1995, PRESCRIBER      0305, P75; *BRIT MARK RES BUR, 1987, EVERYDAY HLTH CARE C; COLWELL J, 1993, PHARM J, V251, P194; Consumers' Association, 1991, WHICH WAY HLTH, P191; HEAD S, 1994, BRIT MED J, V309, P957, DOI 10.1136/bmj.309.6959.957a; HEATH I, 1994, BRIT MED J, V309, P623, DOI 10.1136/bmj.309.6955.623; NOYCE PR, 1992, INT J PHARM PRACT, V1, P122; NOYCE PR, 1995, PARLIAMENTARY BREIF, V3, P85; *PROPR ASS GREAT B, 1995, OTC DIR 1995 6; Rogers PJ, 1994, INT J PHARM PRACT, V3, P6; ROGERS PJ, 1992, PHARM J, V248, P193; RYAN M, 1990, HEALTH POLICY, V16, P233, DOI 10.1016/0168-8510(90)90424-C; SCHAFHEUTLE EL, 1994, THESIS U MANCHESTER; TERMIN P, 1983, J HLTH EC, V2, P187; THOM C, 1994, PHARM J, V253, P616; 1994, OTG BUSINESS NE 0706, P13; 1994, READERS DIGEST	19	31	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					688	691						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597739				2022-12-24	WOS:A1996UB11000032
J	Nordlee, JA; Taylor, SL; Townsend, JA; Thomas, LA; Bush, RK				Nordlee, JA; Taylor, SL; Townsend, JA; Thomas, LA; Bush, RK			Identification of a Brazil-nut allergen in transgenic soybeans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BERTHOLLETIA-EXCELSA; RICH PROTEIN; METHIONINE; EXPRESSION; ALBUMIN	Background The nutritional qulaity of soybeans (Glycine maul is compromised by a relative deficiency of methionine in the protein fraction of the seeds. To improve the nutritional quality, methionine-rich 2S albumin from the Brazil nut (Bertholletia excelsa) has been introduced into transgenic soybeans. Since the Brazil nut is a known allergenic food, we assessed the allergenicity of the 2S albumin. Methods. The ability of proteins in transgenic and nontransgenic soybeans, Brazil nuts, and purified 25 albumin to bind to IgE in serum from subjects allergic to Brazil nuts was determined by radioallergosorbent tests (four subjects) and sodium dodecyl sulfate-polyacrylamide-gel electrophoresis (nine subjects) with immunoblotting and autoradiography. Three subjects also underwent skin-prick testing with extracts of soybean, transgenic soybean, and Brazil nut. Results On radioallergosorbent testing of pooled serum from four subjects allergic to Brazil nuts, protein extracts of transgenic soybean inhibited binding of IgE to Brazil-nut proteins. On immunoblotting, serum IgE from eight of nine subjects bound to purified 2S albumin from the Brazil nut and to proteins of similar molecular weight in the Brazil nut and the transgenic soybean. On skin-prick testing, three subjects had positive reactions to extracts of Brazil nut and transgenic soybean and negative reactions to soybean extract. Conclusions. The 2S albumin is probably a major Brazil-nut allergen, and the transgenic soybeans analyzed in this study contain this protein. Our study shows that an allergen from a food known to be allergenic can be transferred into another food by genetic engineering.	PIONEER HI BRED INT INC,RES & PROD DEV,JOHNSTON,IA; UNIV WISCONSIN,DEPT MED,MADISON,WI; UNIV WISCONSIN,FOOD RES INST,MADISON,WI 53706; WILLIAM S MIDDLETON MEM VET AFFAIRS HOSP,MADISON,WI	DuPont; Pioneer Hi-Bred International, Inc.; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Nordlee, JA (corresponding author), UNIV NEBRASKA,DEPT FOOD SCI & TECHNOL,LINCOLN,NE 68583, USA.		Taylor, Steve L./V-1341-2019					ALDOPHSON CR, 1986, MANUAL CLIN LAB IMMU, P652; ALTENBACH SB, 1987, PLANT MOL BIOL, V8, P239, DOI 10.1007/BF00015032; ALTENBACH SB, 1989, PLANT MOL BIOL, V13, P513, DOI 10.1007/BF00027311; ALTENBACH SB, 1992, PLANT MOL BIOL, V18, P235, DOI 10.1007/BF00034952; ARAGAO FJL, 1992, PLANT MOL BIOL, V20, P357, DOI 10.1007/BF00014508; ARSHAD SH, 1991, CLIN EXP ALLERGY, V21, P373, DOI 10.1111/j.1365-2222.1991.tb01671.x; AUKRUST L, 1978, INT ARCH ALLER A IMM, V57, P253, DOI 10.1159/000232110; BARNETT D, 1983, J ALLERGY CLIN IMMUN, V72, P61, DOI 10.1016/0091-6749(83)90053-2; CAREY B, 1993, HEALTH, V7, P24; FOX JL, 1994, BIO-TECHNOL, V12, P568; GUERCHE P, 1990, MOL GEN GENET, V221, P306, DOI 10.1007/BF00259393; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; HERIAN AM, 1990, INT ARCH ALLER A IMM, V92, P193, DOI 10.1159/000235213; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; LEHRER SB, 1986, ANN ALLERGY, V57, P267; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Melo Vania Maria Maciel, 1994, Food and Agricultural Immunology, V6, P185, DOI 10.1080/09540109409354829; NORDLEE JA, 1981, J ALLERGY CLIN IMMUN, V68, P376, DOI 10.1016/0091-6749(81)90136-6; Norman P, 1986, MANUAL CLIN LABORATO, P660; SAALBACH I, 1994, MOL GEN GENET, V242, P226, DOI 10.1007/BF00391017; SNYDER J, 1992, LONGEVITY, V4, P52; SUN SSM, 1987, J AGR FOOD CHEM, V35, P232, DOI 10.1021/jf00074a016; TAYLOR SL, 1992, FOOD TECHNOL-CHICAGO, V46, P146; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWNSEND JA, 1994, J CELL BIOCH SA, V18, P78; Utsumi S, 1992, Adv Food Nutr Res, V36, P89, DOI 10.1016/S1043-4526(08)60105-9; 1992, FED REGISTER, V57, P22984	27	438	494	4	135	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1996	334	11					688	692		10.1056/NEJM199603143341103	http://dx.doi.org/10.1056/NEJM199603143341103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ528	8594427	Green Published			2022-12-24	WOS:A1996TZ52800003
J	Friedmann, PD; Brett, AS; MayoSmith, MF				Friedmann, PD; Brett, AS; MayoSmith, MF			Differences in generalists' and cardiologists' perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease	ANNALS OF INTERNAL MEDICINE			English	Article						cardiology; physicians, family; outcome and process; assessment (health care); risk; health promotion	CORONARY-ARTERY DISEASE; DECISION-MAKING; PHYSICIANS; PROBABILITY; SURVIVAL; JUDGMENT; SURGERY; TRIAL; CARE	Objective: To compare generalists' and cardiologists' estimates of baseline cardiovascular risk and the outcomes of preventive therapy. Design: Cross-sectional mail survey using written case simulations of typical patients from primary prevention trials for hypercholesterolemia and isolated systolic hypertension, and tertiary prevention studies of coronary artery bypass surgery for chronic stable angina with left main coronary stenosis, Participants: Nationally representative sample of 599 practicing family physicians, general internists, and cardiologists selected from the American Medical Association masterfile. Among eligible physicians, 84 (44%) of 191 family physicians, 77 (40%) of 194 general internists, and 66 (34%) of 194 cardiologists responded. Measurements: Estimates of risk at baseline and after therapy, and whether therapy generally would be recommended. Results: For both primary prevention case simulations (scenarios), cardiologists provided lower, more accurate estimates of baseline cardiovascular risk and of absolute therapeutic benefit than either family physicians or general internists. The range of the generalists' estimates was extremely wide. Perceptions of relative risk reduction and treatment recommendations for the primary prevention scenarios did not differ among specialties. Overall, generalists who would not recommend primary preventive therapy in these scenarios appeared to give more accurate estimates than did generalists who would recommend such therapy. Conclusions: Many generalists have inflated perceptions of cardiovascular risk without treatment and of the benefit of risk-modifying medical treatment. Further study should assess the reasons for these misperceptions and their effect on counseling about primary preventive therapy.	DEACONESS HOSP, BOSTON, MA USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; VET AFFAIRS MED CTR, MANCHESTER, NH USA	Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA)								[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1991, MINITAB REFERENCE MA; ASCH DA, 1995, ANN INTERN MED, V122, P846, DOI 10.7326/0003-4819-122-11-199506010-00007; AYANIAN JZ, 1991, MED DECIS MAKING, V11, P154, DOI 10.1177/0272989X9101100302; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; BERWICK DM, 1981, AM J MED, V71, P991, DOI 10.1016/0002-9343(81)90325-9; BOBBIO M, 1994, LANCET, V343, P1209, DOI 10.1016/S0140-6736(94)92407-4; BRETT AS, 1989, NEW ENGL J MED, V321, P676, DOI 10.1056/NEJM198909073211009; BUCHER HC, 1994, BRIT MED J, V309, P761, DOI 10.1136/bmj.309.6957.761; Bursztajn HJ, 1981, MED CHOICES MED CHAN; CHAITMAN BR, 1981, AM J CARDIOL, V48, P765, DOI 10.1016/0002-9149(81)90156-9; CHRISTENSENSZALANSKI JJJ, 1981, J EXP PSYCHOL HUMAN, V7, P928, DOI 10.1037/0096-1523.7.4.928; DAWSON NV, 1987, J GEN INTERN MED, V2, P183, DOI 10.1007/BF02596149; DOLAN JG, 1986, MED DECIS MAKING, V6, P216, DOI 10.1177/0272989X8600600406; ENGEL W, 1989, MED CARE, V27, P306, DOI 10.1097/00005650-198903000-00009; FORROW L, 1992, AM J MED, V92, P121, DOI 10.1016/0002-9343(92)90100-P; FORROW L, 1988, JAMA-J AM MED ASSOC, V259, P3161, DOI 10.1001/jama.259.21.3161; FREIDSON E, 1975, PROFESSION MED; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GOLDMAN L, 1995, J GEN INTERN MED, V10, P147, DOI 10.1007/BF02599671; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GRELBE J, 1977, BRIT MED J, V2, P1572; JONES TV, 1990, J CLIN EPIDEMIOL, V43, P805, DOI 10.1016/0895-4356(90)90241-G; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1895, DOI 10.1056/NEJM199406303302611; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1151, DOI 10.1056/NEJM199410273311709; KONG A, 1986, NEW ENGL J MED, V315, P740, DOI 10.1056/NEJM198609183151206; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LEWIS C E, 1988, American Journal of Preventive Medicine, V4, P9; MANU P, 1984, MED CARE, V22, P366, DOI 10.1097/00005650-198404000-00008; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MARTIN BC, 1974, DONT SURVEY PHYSICIA; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; PICKERING TG, 1983, JAMA-J AM MED ASSOC, V249, P399, DOI 10.1001/jama.249.3.399; POSES RM, 1991, MED DECIS MAKING, V11, P159, DOI 10.1177/0272989X9101100303; POSES RM, 1985, JAMA-J AM MED ASSOC, V254, P925, DOI 10.1001/jama.254.7.925; RAJAGOPAL S, 1994, J CLIN ONCOL, V12, P1296, DOI 10.1200/JCO.1994.12.6.1296; REDELMEIER DA, 1991, MED DECIS MAKING, V11, P169, DOI 10.1177/0272989X9101100304; REDELMEIER DA, 1990, NEW ENGL J MED, V322, P1162, DOI 10.1056/NEJM199004193221620; REED WW, 1993, J GEN INTERN MED, V8, P591, DOI 10.1007/BF02599710; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; Roback G, 1994, PHYSICIAN CHARACTERI; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SCHWARTZ S, 1986, MED THINKING PSYCHOL, P162; TAKARO T, 1982, CIRCULATION, V66, P14, DOI 10.1161/01.CIR.66.1.14; TAMBOR ES, 1993, AM J PUBLIC HEALTH, V83, P1599, DOI 10.2105/AJPH.83.11.1599; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; WARD MM, 1993, ARCH INTERN MED, V153, P2229, DOI 10.1001/archinte.153.19.2229; 1990, SAS STAT USERS GUIDE; 1989, GUIDE CLIN PREVENTIV, pR28	51	107	107	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1996	124	4					414	+		10.7326/0003-4819-124-4-199602150-00005	http://dx.doi.org/10.7326/0003-4819-124-4-199602150-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV220	8554250				2022-12-24	WOS:A1996TV22000005
J	Watanabe, G; Saito, Y; Madaule, P; Ishizaki, T; Fujisawa, K; Morii, N; Mukai, H; Ono, Y; Kakizuka, A; Narumiya, S				Watanabe, G; Saito, Y; Madaule, P; Ishizaki, T; Fujisawa, K; Morii, N; Mukai, H; Ono, Y; Kakizuka, A; Narumiya, S			Protein kinase N (PKN) and PKN-related protein rhophilin as targets of small GTPase Rho	SCIENCE			English	Article							BOTULINUM C3 EXOENZYME; SWISS 3T3 CELLS; ADP-RIBOSYLATION; GENE-PRODUCT; ACTIVATION; REQUIRES; P21	The Rho guanosine 5'-triphosphatase (GTPase) cycles between the active guanosine triphosphate (GTP)-bound form and the inactive guanosine diphosphate-bound form and regulates cell adhesion and cytokinesis, but how it exerts these actions is unknown. The yeast two-hybrid system was used to clone a complementary DNA for a protein (designated Rhophilin) that specifically bound to GTP-Rho. The Rho-binding domain of this protein has 40 percent identity with a putative regulatory domain of a protein kinase, PKN. PKN itself bound to GTP-Rho and was activated by this binding both in vitro and in vivo. This study indicates that a serine-threonine protein kinase is a Rho effector and presents an amino acid sequence motif for binding to GTP-Rho that may be shared by a family of Rho target proteins.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN; KOBE UNIV,FAC SCI,DEPT BIOL,KOBE 657,JAPAN	Kyoto University; Kobe University				Mukai, Hideyuki/0000-0002-0167-8695				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATA K, 1992, J BIOL CHEM, V267, P8719; ISHIZAKI T, IN PRESS EMBO J; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; KUMAGAI N, 1995, FEBS LETT, V366, P11, DOI 10.1016/0014-5793(95)00478-R; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORII N, 1993, J BIOL CHEM, V268, P27160; MORII N, 1992, J BIOL CHEM, V267, P20921; MORII N, 1995, METHOD ENZYMOL, V256, P196; MUKAI H, 1995, BBA-GENE STRUCT EXPR, V1261, P296, DOI 10.1016/0167-4781(95)00030-K; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WATANABE G, UNPUB, P55215; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	33	352	375	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					645	648		10.1126/science.271.5249.645	http://dx.doi.org/10.1126/science.271.5249.645			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571126				2022-12-24	WOS:A1996TT87000045
J	Vito, P; Lacana, E; DAdamio, L				Vito, P; Lacana, E; DAdamio, L			Interfering with apoptosis: Ca2+-binding protein ALG-2 and Alzheimer's disease gene ALG-3	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; T-CELL HYBRIDOMAS; DNA FRAGMENTATION; ENDONUCLEASE ACTIVATION; THYMOCYTE APOPTOSIS; IMMATURE THYMOCYTES; SUICIDE PROCESS; MESSENGER-RNA; DEATH; INITIATION	Two apoptosis-linked genes, named ALG-2 and ALG-3, were identified by means of a functional selection strategy. ALG-2 codes for a Ca2+-binding protein required for T cell receptor-, Fas-, and glucocorticoid-induced cell death. ALG-3, a partial complementary DNA that is homologous to the familial Alzheimer's disease gene STM2, rescues a T cell hybridoma from T cell receptor- and Fas-induced apoptosis. These findings suggest that ALG-2 may mediate Ca2+-regulated signals along the death pathway and that cell death may play a role in Alzheimer's disease.	NIAID,CELLULAR & MOLEC IMMUNOL LAB,T CELL MOLEC BIOL UNIT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			vito, pasquale/ABF-5505-2020	D'Adamio, Luciano/0000-0002-2204-9441; D'Adamio, Luciano/0000-0002-9820-4882; vito, pasquale/0000-0002-5721-7716				ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BROWN KS, UNPUB; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CIFONE MG, 1993, J EXP MED, V177, P1547; COHEN JJ, 1984, J IMMUNOL, V132, P38; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; CURRAN J, 1988, EMBO J, V7, P245, DOI 10.1002/j.1460-2075.1988.tb02806.x; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GABIG TG, 1994, J BIOL CHEM, V269, P29515; GSCHWIND M, 1995, J NEUROCHEM, V65, P292; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAGEYAMA H, 1989, BIOCHIM BIOPHYS ACTA, V1008, P255, DOI 10.1016/0167-4781(80)90018-4; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIZAKI H, 1989, J IMMUNOL, V143, P1790; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LACANA E, UNPUB; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LASSMANN H, 1995, ACTA NEUROPATHOL, V89, P35, DOI 10.1007/BF00294257; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OSHIMI Y, 1995, J IMMUNOL, V154, P599; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SARIN A, 1995, J IMMUNOL, V154, P5806; SHI YF, 1990, J IMMUNOL, V144, P3326; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; VANDERBILT JN, 1982, J BIOL CHEM, V257, P3009; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; VITO P, UNPUB; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037	55	459	477	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					521	525		10.1126/science.271.5248.521	http://dx.doi.org/10.1126/science.271.5248.521			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560270	Green Submitted			2022-12-24	WOS:A1996TR32200047
J	Wilson, CJ; Chao, DM; Imbalzano, AN; Schnitzler, GR; Kingston, RE; Young, RA				Wilson, CJ; Chao, DM; Imbalzano, AN; Schnitzler, GR; Kingston, RE; Young, RA			RNA polymerase II holoenzyme contains SWI/SNF regulators involved in chromatin remodeling	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATORS; NEGATIVE REGULATOR; SNF6 PROTEINS; YEAST; GENES; EXPRESSION; SNF2/SWI2; DNA	The RNA polymerase II holoenzyme contains RNA polymerase II, a subset of general transcription factors and SRB regulatory proteins. We report here that SWI and SNF gene products, previously identified as global gene regulators whose functions include remodeling chromatin, are also integral components of the yeast RNA polymerase II holoenzyme. The SWI/SNF proteins are components of the SRB complex, also known as the mediator, which is tightly associated with the RNA polymerase II C-terminal repeat domain. The SWI/SNF components provide the holoenzyme with the capacity to disrupt nucleosomal DNA and thus facilitate stable binding of various components of the transcription initiation complex at promoters.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Wilson, CJ (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Wilson, Christopher/0000-0002-9146-522X; Chao, David/0000-0001-9198-337X				ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CAREY MF, 1995, CURR BIOL, V5, P1003, DOI 10.1016/S0960-9822(95)00201-6; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; EMILI A, 1995, CURR OPIN GENET DEV, V5, P204, DOI 10.1016/0959-437X(95)80009-3; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; HAPPEL AM, 1991, GENETICS, V128, P69; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1996, IN PRESS METH ENZYMO; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, GENE DEV, V6, P2233; LAURENT BC, 1990, MOL CELL BIOL, V11, P5615; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LORCH Y, 1988, CELL, V55, P743, DOI 10.1016/0092-8674(88)90128-6; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NEIGEBORN L, 1984, GENETICS, V108, P845; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SHELDON M, 1995, CURR BIOL, V5, P423; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; TAGUCHI AKW, 1987, GENETICS, V116, P523; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TREICH I, 1995, MOL CELL BIOL, V15, P4240; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	57	336	339	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					235	244		10.1016/S0092-8674(00)80978-2	http://dx.doi.org/10.1016/S0092-8674(00)80978-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565069	Bronze			2022-12-24	WOS:A1996TR59500010
J	Davis, CE				Davis, CE			Fresh vs preserved stool specimens for detection of parasites	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Davis, CE (corresponding author), UNIV CALIF SAN DIEGO,DEPT PATHOL,SAN DIEGO,CA 92103, USA.							BRONSDON MA, 1984, J CLIN MICROBIOL, V19, P952, DOI 10.1128/JCM.19.6.952-953.1984; DAVIS CE, 1994, HARRISONS PRINCIPLES, P872; Garcia Lynne S., 1995, P1145; SMITH JW, 1979, AM J CLIN PATHOL, V72, P371; WEBER R, 1992, NEW ENGL J MED, V326, P161, DOI 10.1056/NEJM199201163260304	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					326	327						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544277				2022-12-24	WOS:A1996TP96500034
J	Nightingale, SL				Nightingale, SL			First protease inhibitor approved for treatment of HIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					273	273						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544255				2022-12-24	WOS:A1996TP96500005
J	Naktinis, V; Turner, J; ODonnell, M				Naktinis, V; Turner, J; ODonnell, M			Molecular switch in a replication machine defined by an internal competition for protein rings	CELL			English	Article							POLYMERASE-III HOLOENZYME; CELL NUCLEAR ANTIGEN; PRIMER-TEMPLATE JUNCTION; ACCESSORY PROTEINS; ESCHERICHIA-COLI; FACTOR-C; DNA; COMPLEX; BACTERIOPHAGE-T4; SUBUNIT	Replication machines use ring-shaped clamps that encircle DNA to tether the polymerase to the chromosome. The clamp is assembled on DNA by a clamp loader. This report shows that the polymerase and clamp loader coordinate their actions with the clamp by competing for it through overlapping binding sites. The competition is modulated by DNA. In the absence of DNA, the clamp associates with the clamp loader. But after the clamp is placed on DNA, the polymerase develops a tight grip on the clamp and out-competes the clamp loader. After replication of the template, the polymerase looses affinity for the clamp. Now the clamp loader regains access to the clamp and removes it from DNA thus recycling it for future use.	CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Cornell University; Howard Hughes Medical Institute	Naktinis, V (corresponding author), CORNELL UNIV,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021, USA.							BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; HANAI R, 1994, P NATL ACAD SCI USA, V91, P11904, DOI 10.1073/pnas.91.25.11904; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; HEYDUK E, 1994, BIOCHEMISTRY-US, V33, P9643, DOI 10.1021/bi00198a033; JUE RA, 1985, BIOCHEMISTRY-US, V24, P162, DOI 10.1021/bi00322a023; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE SH, 1991, J BIOL CHEM, V266, P594; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; MUNN MM, 1991, J BIOL CHEM, V266, P20034; MUNN MM, 1991, J BIOL CHEM, V266, P20024; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; REEMS JA, 1995, J BIOL CHEM, V270, P5606, DOI 10.1074/jbc.270.10.5606; REEMS JA, 1994, J BIOL CHEM, V269, P33091; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SINHA NK, 1980, J BIOL CHEM, V263, P6561; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; STUKENBERG PT, 1995, J BIOL CHEM, V270, P13384, DOI 10.1074/jbc.270.22.13384; TINKER RL, 1994, EMBO J, V13, P5330, DOI 10.1002/j.1460-2075.1994.tb06867.x; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TURNER J, 1994, METHOD ENZYMOL, V262, P442; XIAO H, 1993, J BIOL CHEM, V268, P11773; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001; ZHONG M, 1995, P NATL ACAD SCI USA, V92, P2111, DOI 10.1073/pnas.92.6.2111	41	128	131	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					137	145		10.1016/S0092-8674(00)81000-4	http://dx.doi.org/10.1016/S0092-8674(00)81000-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548818	Bronze			2022-12-24	WOS:A1996TQ17000016
J	Copeland, JWR; Nasiadka, A; Dietrich, BH; Krause, HM				Copeland, JWR; Nasiadka, A; Dietrich, BH; Krause, HM			Patterning of the Drosophila embryo by a homeodomain-deleted Ftz polypeptide	NATURE			English	Article							FUSHI-TARAZU; DNA-BINDING; GENE; EXPRESSION; PROTEIN; SEGMENTATION; DOMAIN; ESTABLISHMENT; MAINTENANCE; ACTIVATION	HOMEODOMAIN proteins regulate diverse developmental processes in a wide range of organisms, yet bind in vitro to DNA sequences that are remarkably similar(1). This has raised the fundamental question of how target gene specificity is achieved in vivo. The Drosophila fushi tarazu protein (Ftz) contains a homeodomain(2) and is required for the formation of alternate segments(3). We have shown previously that a homeodomain-deleted Ftz polypeptide (Ftz Delta HD), incapable of binding DNA in vitro, could regulate endogenous ftz gene expression(4). Here we test Ftz Delta HD activities in a ftz mutant background and find that, surprisingly, Ftz Delta HD can directly regulate ftz-dependent segmentation, suggesting that it can control target gene expression through interactions with other proteins. A likely candidate is the pair-rule protein Paired (Prd). Ftz Delta HD bound directly to Prd in vitro and required Prd to repress wingless in vivo. These results emphasize the pivotal importance of protein-protein interactions in homeodomain protein function.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; DEPT MED & MOLEC GENET,TORONTO,ON M5G 1L6,CANADA	University of Toronto				Krause, Henry/0000-0002-6182-7074				ANANTHAN J, 1993, MOL CELL BIOL, V13, P1599, DOI 10.1128/MCB.13.3.1599; BAUMGARTNER S, 1991, MECH DEVELOP, V33, P1; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FURUKUBOTOKUNAGA K, 1992, GENE DEV, V6, P1082, DOI 10.1101/gad.6.6.1082; GALLAGHER SR, 1993, CURRENT PROTOCOLS MO; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; INGHAM PW, 1988, NATURE, V331, P73, DOI 10.1038/331073a0; ISHHOROWICZ D, 1989, CELL, V57, P223, DOI 10.1016/0092-8674(89)90960-4; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; KRAUSE HM, 1988, GENE DEV, V2, P1021, DOI 10.1101/gad.2.8.1021; LI XL, 1993, EMBO J, V12, P4499, DOI 10.1002/j.1460-2075.1993.tb06139.x; LI XL, 1993, EMBO J, V12, P1427, DOI 10.1002/j.1460-2075.1993.tb05786.x; MANOUKIAN AS, 1992, GENE DEV, V6, P1740, DOI 10.1101/gad.6.9.1740; SCHIER AF, 1992, NATURE, V356, P804, DOI 10.1038/356804a0; SHEPHERD JCW, 1984, NATURE, V310, P70, DOI 10.1038/310070a0; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; WAKIMOTO BT, 1981, DEV BIOL, V81, P51, DOI 10.1016/0012-1606(81)90347-X	22	79	79	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					162	165		10.1038/379162a0	http://dx.doi.org/10.1038/379162a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538765				2022-12-24	WOS:A1996TP36000057
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CHLORZOXAZONE WARNING ON HEPATOTOXICITY IS STRENGTHENED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1903	1903						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568972				2022-12-24	WOS:A1995TL16900012
J	Lee, A; Thomas, P; Cupidore, L; Serjeant, B; Serjeant, G				Lee, A; Thomas, P; Cupidore, L; Serjeant, B; Serjeant, G			Improved survival in homozygous sickle cell disease: Lessons from a cohort study	BRITISH MEDICAL JOURNAL			English	Article							BONE-MARROW TRANSPLANTATION; CHEST SYNDROME; ANEMIA; CHILDREN; TRANSFUSION; SEPTICEMIA	Objective-To examine whether simple interventions in a sickle cell clinic improve survival in sickle cell disease. Design-Survival curve analysis and hazard ratios in a cohort study followed from birth. Setting-MRC Laboratories (Jamaica) at the University of the West Indies, and Victoria Jubilee Hospital, Kingston, Jamaica. Subject-315 patients with homozygous sickle cell disease detected during the screening of 100 000 consecutive non-operative deliveries between June 1973 and December 1981 at the main government maternity hospital, Kingston, Jamaica. Interventions-Prophylactic penicillin to prevent pneumococcal septicaemia, parental education in early diagnosis of acute splenic sequestration, close monitoring in sickle cell clinic, Main outcome measures-Survival. Results-Survival appeared to improve, the log rank test for trend comparing the first, second, and last third of the study reaching borderline significance (P=0.05). Combined deaths from acute splenic sequestration and pneumococcal septicaemia-meningitis declined significantly (test for trend, P=0 . 02). Conclusion-Early diagnosis and simple prophylactic measures significantly reduce deaths associated with homozygous sickle cell disease.	UNIV W INDIES,MRC LABS,KINGSTON 7,JAMAICA	University West Indies Mona Jamaica				Thomas, Peter/0000-0003-2478-4324				BEUTLER E, 1991, SEMIN HEMATOL, V28, P263; DAVIES SC, 1984, LANCET, V1, P36; EMOND AM, 1985, J PEDIATR-US, V107, P201, DOI 10.1016/S0022-3476(85)80125-6; FERSTER A, 1992, BRIT J HAEMATOL, V80, P102, DOI 10.1111/j.1365-2141.1992.tb06407.x; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; JOHN AB, 1984, BRIT MED J, V288, P1567, DOI 10.1136/bmj.288.6430.1567; MALLOUH AA, 1988, AM J DIS CHILD, V142, P178, DOI 10.1001/archpedi.1988.02150020080034; MENTZER WC, 1994, AM J PEDIAT HEMATOL, V16, P27; POWARS D, 1983, PEDIATRICS, V71, P927; POWARS D, 1981, JAMA-J AM MED ASSOC, V245, P1839, DOI 10.1001/jama.245.18.1839; RUSSELL MO, 1984, BLOOD, V63, P162; SERJEANT BE, 1974, CLIN CHEM, V20, P666; SERJEANT GR, 1981, LANCET, V2, P595; STEVENS MCG, 1986, PEDIATRICS, V78, P124; THOMAS AN, 1982, BRIT MED J, V285, P633, DOI 10.1136/bmj.285.6342.633; VERMYLEN C, 1991, ARCH DIS CHILD, V66, P1195, DOI 10.1136/adc.66.10.1195	16	131	133	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 16	1995	311	7020					1600	1602		10.1136/bmj.311.7020.1600	http://dx.doi.org/10.1136/bmj.311.7020.1600			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL422	8555802	Green Published			2022-12-24	WOS:A1995TL42200019
J	Shilatifard, A; Lane, WS; Jackson, KW; Conaway, RC; Conaway, JW				Shilatifard, A; Lane, WS; Jackson, KW; Conaway, RC; Conaway, JW			An RNA polymerase II elongation factor encoded by the human ELL gene	SCIENCE			English	Article							ACUTE LEUKEMIAS; CHROMOSOMAL TRANSLOCATIONS; DROSOPHILA-TRITHORAX; TRANSCRIPTION FACTOR; SEQUENCE	The human ELL gene on chromosome 19 undergoes frequent translocations with the trithorax-like MLL gene on chromosome 11 in acute myeloid leukemias. Here, ELL was shown to encode a previously uncharacterized elongation factor that can increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by polymerase at multiple sites along the DNA. Functionally, ELL resembles Elongin (SIII), a transcription elongation factor regulated by the product of the von Hippel-Lindau (VHL) tumor suppressor gene. The discovery of a second elongation factor implicated in oncogenesis provides further support for a close connection between the regulation of transcription elongation and cell growth.	OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,OKLAHOMA CITY,OK 73104; HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138; UNIV OKLAHOMA,HLTH SCI CTR,WILLIAM K WARREN MED RES INST,OKLAHOMA CITY,OK 73190	Oklahoma Medical Research Foundation; Harvard University; University of Oklahoma System; University of Oklahoma Health Sciences Center				Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; BERNARD OA, 1994, ONCOGENE, V9, P1039; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; PRASAD R, 1993, CANCER RES, V53, P5624; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SHILATIFARD A, UNPUB; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; TAN SY, 1994, BIOTECHNIQUES, V16, P824; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9	25	288	294	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1873	1876		10.1126/science.271.5257.1873	http://dx.doi.org/10.1126/science.271.5257.1873			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596958				2022-12-24	WOS:A1996UC77800049
J	Hull, HF; Lee, JW				Hull, HF; Lee, JW			Sabin, Salk, or sequential?	LANCET			English	Editorial Material											Hull, HF (corresponding author), WHO,CH-1211 GENEVA,SWITZERLAND.							ANDRUS JK, 1995, B WORLD HEALTH ORGAN, V73, P33; BART KJ, IN PRESS B WHO; FRANKEL DH, 1995, LANCET, V346, P1151, DOI 10.1016/S0140-6736(95)91812-4; GHENDON Y, 1994, B WORLD HEALTH ORGAN, V72, P973; HEYMANN DL, 1987, B WORLD HEALTH ORGAN, V65, P495; HULL HF, 1994, LANCET, V343, P1331, DOI 10.1016/S0140-6736(94)92472-4; WARD NA, 1995, LANCET, V345, P318, DOI 10.1016/S0140-6736(95)90305-4; 1995, WEEKLY EPIDEMIOL REC, V70, P169; 1994, WEEKLY EPIDEMIOL REC, V69, P293; 1995, WEEKLY EPIDEMIOL REC, V70, P341; 1995, WEEKLY EPIDEMIOL REC, V79, P325; 1994, WEEKLY EPIDEMIOL REC, V69, P377	12	14	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					630	630		10.1016/S0140-6736(96)91194-0	http://dx.doi.org/10.1016/S0140-6736(96)91194-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596370				2022-12-24	WOS:A1996TZ28500002
J	Froster, UG; Jackson, L				Froster, UG; Jackson, L			Limb defects and chorionic villus sampling: Results from an international registry, 1992-94	LANCET			English	Article							PRENATAL-DIAGNOSIS; CONGENITAL-DEFECTS; REDUCTION DEFECTS; ABNORMALITIES; POPULATION; CVS; MALFORMATIONS; ANOMALIES; AMNIOCENTESIS	Background Several reports of limb defects occurring among infants exposed to chorionic villus sampling (CVS) during pregnancy resulted in concern about the safety of this procedure for prenatal diagnosis. To avoid publication bias and evaluate the true risk of limb defects in a CVS cohort, the World Health Organization initiated international registration of post-CVS limb defects in 1992. Methods From May, 1992, to May, 1994, 77 infants or fetuses with limb defects from 138 996 pregnancies having CVS were reported to the WHO CVS Registry. These cases were analysed by standardised methods-ie, exclusion of syndromes, inherited disorders, and defects occurring in previable fetuses. The included limb deficiencies were studied by pattern analysis. Findings Defects of the upper limbs were reported in 64.6%, of the lower limbs in 12.5%, and of both upper and lower limbs in 20.8% of cases, These figures are in agreement with the distribution of limb defects in several large population-based studies. Transverse limb defects occurred in 40.8% and longitudinal defects in 59.2%, compared with 42.7% and 57.3% in an unexposed population. Interpretation The analysis of this cohort did not show any differences from the background population in the overall frequency or pattern distribution of limb deficiencies. There was also no correlation between gestational age at CVS and severity of defects. Therefore these results do not indicate any increased risk of limb defects after CVS.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DIV MED GENET,PHILADELPHIA,PA 19107	Jefferson University	Froster, UG (corresponding author), UNIV SPITAL ZURICH,KLIN & POLIKLIN GEBURTSHILFE,DEPT FRAUENHEILKUNDE,FRAUENKLIN STR 10,CH-8091 ZURICH,SWITZERLAND.							[Anonymous], 1991, LANCET, V337, P1491; ARO T, 1982, INT J EPIDEMIOL, V3, P239; BAMFORTH JS, 1992, AM J MED GENET, V44, P281; BRAMBATI B, 1983, LANCET, V1, P586; BRAMBATI B, 1992, PRENATAL DIAG, V12, P789, DOI 10.1002/pd.1970121004; BURTON BK, 1992, OBSTET GYNECOL, V79, P726; BURTON BK, 1993, PEDIATRICS, V91, P989; Canadian Collaborative CVS-Amniocentesis Clinical Trial Group, 1989, LANCET, V1, P1; DOLK H, 1992, LANCET, V339, P876, DOI 10.1016/0140-6736(92)90325-W; FIRTH HV, 1994, LANCET, V343, P1069, DOI 10.1016/S0140-6736(94)90182-1; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; FROSTER UG, 1993, AM J MED GENET, V45, P60, DOI 10.1002/ajmg.1320450116; FROSTER UG, 1993, AM J MED GENET, V46, P479, DOI 10.1002/ajmg.1320460502; FROSTER UG, 1993, AM J MED GENET, V46, P497, DOI 10.1002/ajmg.1320460507; FROSTER UG, 1992, LANCET, V339, P66, DOI 10.1016/0140-6736(92)90198-C; FROSTERISKENIUS UG, 1990, TERATOLOGY, V41, P23, DOI 10.1002/tera.1420410104; FROSTERISKENIUS UG, 1989, TERATOLOGY, V39, P127, DOI 10.1002/tera.1420390205; GOLBUS MT, 1992, PRENATAL DIAG, V12, P313, DOI 10.1002/pd.1970120502; HOLZGREVE W, 1990, GYNAKOLOGE, V23, P261; HSIEH FJ, 1991, LANCET, V337, P1091; JAHODA MGJ, 1991, PRENATAL DIAG, V11, P559, DOI 10.1002/pd.1970110811; KALLEN B, 1984, TERATOLOGY, V29, P73, DOI 10.1002/tera.1420290109; KAPLAN P, 1990, AM J MED GENET, V37, P366, DOI 10.1002/ajmg.1320370315; KULIEV AM, 1993, PRENATAL DIAG, V13, P197, DOI 10.1002/pd.1970130307; KULIEV AM, 1992, LANCET, V340, P668, DOI 10.1016/0140-6736(92)92197-N; KULIEV AM, 1992, J ASSIST REPROD GEN, V9, P299, DOI 10.1007/BF01203947; LIN SP, 1992, J MED GENET, V51, pA261; LIPPMAN A, 1992, PRENATAL DIAG, V12, P385, DOI 10.1002/pd.1970120508; MAHONEY MJ, 1991, LANCET, V337, P1422, DOI 10.1016/0140-6736(91)93117-R; MASTROIACOVO P, 1992, AM J MED GENET, V44, P856, DOI 10.1002/ajmg.1320440639; MONNI G, 1991, LANCET, V337, P1091; OLNEY RS, 1995, TERATOLOGY, V51, P20, DOI 10.1002/tera.1420510104; RHOADS GG, 1989, NEW ENGL J MED, V320, P609, DOI 10.1056/NEJM198903093201001; SCHLOO R, 1992, AM J MED GENET, V42, P404, DOI 10.1002/ajmg.1320420338; Stoll C, 1992, Paediatr Perinat Epidemiol, V6, P323, DOI 10.1111/j.1365-3016.1992.tb00773.x; Wapner R., 1996, American Journal of Obstetrics and Gynecology, V174, P310; 1993, PRENATAL DIAG, V13, P1051	37	69	71	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					489	494		10.1016/S0140-6736(96)91136-8	http://dx.doi.org/10.1016/S0140-6736(96)91136-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596265				2022-12-24	WOS:A1996TW69700007
J	Miyazaki, T; Wolf, P; Tourne, S; Waltzinger, C; Dierich, A; Barois, N; Ploegh, H; Benoist, C; Mathis, D				Miyazaki, T; Wolf, P; Tourne, S; Waltzinger, C; Dierich, A; Barois, N; Ploegh, H; Benoist, C; Mathis, D			Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway	CELL			English	Article							ANTIGEN-PROCESSING MUTANT; MAJOR HISTOCOMPATIBILITY COMPLEX; INVARIANT CHAIN PEPTIDES; HLA-DR MOLECULES; SELECTION; GENES; EXPRESSION	We have generated mice lacking H2-M complexes, critical facilitators of peptide loading onto major histocompatibility complex class II molecules. Ab molecules in these mice matured into stable complexes and were efficiently expressed at the cell surface. Most carried a single peptide derived from the class II-associated invariant chain; the diverse array of peptides normally displayed by class II molecules was absent. Cells from mutant mice presented both whole proteins and short peptides very poorly. Surprisingly, positive selection of CD4(+) T cells was quite efficient, yielding a large and broad repertoire. Peripheral T cells reacted strongly to splenocytes from syngeneic wild-type mice, no doubt reflecting the unique peptide complement carried by class II molecules in mutant animals.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; CTR IMMUNOL MARSEILLE LUMINY,F-13288 MARSEILLE 9,FRANCE	Massachusetts Institute of Technology (MIT); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Miyazaki, T (corresponding author), UNIV STRASBOURG 1,INSERM,CNRS,INST GENET & BIOL MOL & CELLULAIRE,CU STRASBOURG,F-67404 ILLKIRCH GRAFFENS,FRANCE.				NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NCI NIH HHS [2-P30-CA14051-24] Funding Source: Medline; PHS HHS [5-R01-AL34893, T32-AL07463] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BROOKS AG, 1994, J IMMUNOL, V153, P5382; CEMAN S, 1992, J IMMUNOL, V149, P754; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; CHO SG, 1991, P NATL ACAD SCI USA, V88, P5197, DOI 10.1073/pnas.88.12.5197; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; EASTMAN S, 1996, IN PRESS EUR J IMMUN; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; KROPSHOFER H, 1995, SCIENCE, V270, P1357, DOI 10.1126/science.270.5240.1357; LANDAIS D, 1986, J IMMUNOL, V137, P3002; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LIANG MN, 1995, INT IMMUNOL, V7, P1397, DOI 10.1093/intimm/7.9.1397; MALCHEREK G, 1995, J EXP MED, V181, P527, DOI 10.1084/jem.181.2.527; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MIYAZAKI T, 1996, IN PRESS SCIENCE; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NAUJOKAS MF, 1995, IMMUNITY, V3, P359, DOI 10.1016/1074-7613(95)90120-5; RADLEY E, 1994, J BIOL CHEM, V269, P18834; REGNIERVIGOUROX A, 1988, J IMMUNOL, V140, P1069; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SETTE A, 1995, J EXP MED, V181, P677, DOI 10.1084/jem.181.2.677; SHACHAR I, 1995, IMMUNITY, V3, P373, DOI 10.1016/1074-7613(95)90121-3; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; TOUME S, 1995, EUR J IMMUNOL, V25, P1851; URBAN RG, 1995, J EXP MED, V180, P1851; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WHITE J, 1989, J IMMUNOL, V143, P1822; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411	44	300	305	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					531	541		10.1016/S0092-8674(00)81029-6	http://dx.doi.org/10.1016/S0092-8674(00)81029-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598040	Bronze			2022-12-24	WOS:A1996TX17600006
J	Guler, ML; Gorham, JD; Hsieh, CS; Mackey, AJ; Steen, RG; Dietrich, WF; Murphy, KM				Guler, ML; Gorham, JD; Hsieh, CS; Mackey, AJ; Steen, RG; Dietrich, WF; Murphy, KM			Genetic susceptibility to Leishmania: IL-12 responsiveness in T(H)1 cell development	SCIENCE			English	Article							CD4+ T-CELLS; CUTANEOUS LEISHMANIASIS; INTERFERON-GAMMA; IFN-GAMMA; IMMUNOLOGICAL REGULATION; MURINE LEISHMANIASIS; MICE; INTERLEUKIN-4; INVITRO; RESISTANCE	The genetic background of T lymphocytes influences development of the T helper (T-H) phenotype, resulting in either resistance or susceptibility of certain mouse strains to pathogens such as Leishmania major. With an in vitro model system, a difference in maintenance of responsiveness of T cells to interleukin-12 (IL-12) was detected between BALB/c and B10.D2 mice, Although naive T cells from both strains initially responded to IL-12, BALB/c T cells lost IL-12 responsiveness after stimulation with antigen in vitro, even when cocultured with B10.D2 T cells, Thus, susceptibility of BALB/c mice to infection with L. major may derive from the loss of the ability to generate IL-12-induced T(H)1 responses rather than from an IL-4-induced T(H)2 response.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02139 USA	Washington University (WUSTL); Massachusetts Institute of Technology (MIT); Whitehead Institute					NIAID NIH HHS [AI31238, AI34580] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI031238, U19AI034580, U01AI034580] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELOSEVIC M, 1989, J IMMUNOL, V143, P266; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; CHATELAIN R, 1992, J IMMUNOL, V148, P1182; GORHAM J, UNPUB; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HOWARD JG, 1981, J EXP MED, V153, P557, DOI 10.1084/jem.153.3.557; HOWARD JG, 1986, INT REV EXP PATHOL, V28, P79; HSIEH CS, 1995, J EXP MED, V181, P713, DOI 10.1084/jem.181.2.713; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LOCKSLEY RM, 1991, IMMUNOPARASITOL TOD, pA58, DOI 10.1016/S0167-5699(05)80017-9; MAGGI E, 1992, J IMMUNOL, V148, P2142; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; ROBERTS M, 1993, EUR J IMMUNOGENET, V20, P349, DOI 10.1111/j.1744-313X.1993.tb00154.x; SADICK MD, 1986, J IMMUNOL, V136, P655; SADICK MD, 1987, J IMMUNOL, V139, P1303; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SCHARTON TM, 1993, J EXP MED, V178, P567, DOI 10.1084/jem.178.2.567; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SCOTT P, 1991, J IMMUNOL, V147, P3149; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188; SHANKAR AH, 1995, J EXP MED, V181, P845, DOI 10.1084/jem.181.3.845; SWAIN SL, 1991, J IMMUNOL, V147, P2991; SWAIN SL, 1990, J IMMUNOL, V145, P3796; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; TITUS RG, 1985, J IMMUNOL, V135, P2108; YANAGIDA T, 1994, J IMMUNOL, V152, P4919	33	331	334	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 16	1996	271	5251					984	987						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584935				2022-12-24	WOS:A1996TV70400048
J	Clemens, J; Brenner, R; Rao, M; Tafari, N; Lowe, C				Clemens, J; Brenner, R; Rao, M; Tafari, N; Lowe, C			Evaluating new vaccines for developing countries - Efficacy or effectiveness?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VI-CAPSULAR POLYSACCHARIDE; BOVINE ROTAVIRUS VACCINE; ENTERIC-COATED CAPSULES; TITER MEASLES-VACCINES; CONTROLLED FIELD TRIAL; ORAL CHOLERA VACCINES; CHILDHOOD TUBERCULOSIS; CONJUGATE VACCINE; TYPHOID VACCINE; ANTIBODY-RESPONSE	Despite the profusion of promising new vaccines against illnesses prevalent in developing countries, uncertainties about the balance between costs and benefits of new vaccines have retarded their use in public health practice. Conventional prelicensure trials of vaccine protection exacerbate these uncertainties by focusing on measurement of vaccine efficacy-the performance of a vaccine under idealized conditions. Vaccine effectiveness trials provide a more pragmatic perspective by addressing the performance of a vaccine under the ordinary conditions of a public health program, by capturing direct as well as indirect effects of vaccination, and by comprehensively addressing outcomes of public health concern. The use of effectiveness trials should enable more rational triaging of new vaccines for developing countries and may accelerate the introduction of new vaccines into public health practice by resolving speculative debates about practical costs and benefits.	NICHHD, DIV EPIDEMIOL STAT & PREVENT RES, BETHESDA, MD 20892 USA; NICHHD, OFF DIRECTOR, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								AABY P, 1993, AM J EPIDEMIOL, V138, P746, DOI 10.1093/oxfordjournals.aje.a116912; AABY P, 1988, LANCET, V2, P809; ACHARYA IL, 1987, NEW ENGL J MED, V317, P1101, DOI 10.1056/NEJM198710293171801; [Anonymous], 1981, Int J Epidemiol, V10, P73; [Anonymous], 1993, WORLD DEV REPORT INV; [Anonymous], 1992, WKLY EPIDEMIOL REC, V67, P357; BASCH PF, 1994, VACCINES WORLD HLTH, P95; BEGG N, 1990, VACCINE, V8, P180, DOI 10.1016/0264-410X(90)90042-K; BINKIN N, 1982, LANCET, V2, P315; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; BLOK L, 1994, LANCET, V344, P1022; BOOY R, 1994, LANCET, V344, P362, DOI 10.1016/S0140-6736(94)91400-1; CLEMENS J, 1990, PROSPECTS PUBLIC HLT, P131; CLEMENS JD, 1992, AM J EPIDEMIOL, V135, P865, DOI 10.1093/oxfordjournals.aje.a116382; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; CLEMENS JD, 1990, AM J EPIDEMIOL, V131, P400, DOI 10.1093/oxfordjournals.aje.a115515; CLEMENS JD, 1984, REV INFECT DIS, V6, P589; CLEMENS JD, 1988, LANCET, V1, P1375; CLEMENS JD, 1990, NEW GENERATION VACCI, P51; Clemens John, 1994, P425; COMSTOCK GW, 1990, AM J EPIDEMIOL, V131, P205, DOI 10.1093/oxfordjournals.aje.a115490; COMSTOCK GW, 1994, EPIDEMIOL REV, V16, P77, DOI 10.1093/oxfordjournals.epirev.a036147; DEMING MS, 1992, AM J EPIDEMIOL, V135, P393, DOI 10.1093/oxfordjournals.aje.a116300; DEMOL P, 1986, LANCET, V2, P108; DONNER A, 1984, STAT MED, V3, P199, DOI 10.1002/sim.4780030302; DRUMMOND MF, 1987, HEALTH POLICY, V7, P309, DOI 10.1016/0168-8510(87)90072-8; EGAN W, 1995, JAMA-J AM MED ASSOC, V273, P888; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; FEDSON DS, 1990, PROSPECTS PUBLIC HLT, P131; FERRECCIO C, 1989, J INFECT DIS, V159, P766, DOI 10.1093/infdis/159.4.766; FINE PEM, 1993, EPIDEMIOL REV, V15, P265, DOI 10.1093/oxfordjournals.epirev.a036121; GARENNE M, 1993, AM J EPIDEMIOL, V138, P182, DOI 10.1093/oxfordjournals.aje.a116844; GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L; GLASS RI, 1991, LANCET, V338, P791, DOI 10.1016/0140-6736(91)90673-D; Greenwood M, 1915, Proc R Soc Med, V8, P113; HALL AJ, 1989, LANCET, V1, P1057; HALL AJ, 1990, INT J EPIDEMIOL, V19, P777, DOI 10.1093/ije/19.4.777; HALLORAN ME, 1991, EPIDEMIOLOGY, V2, P331, DOI 10.1097/00001648-199109000-00004; HALLORAN ME, 1991, AM J EPIDEMIOL, V133, P323, DOI 10.1093/oxfordjournals.aje.a115884; HANLON P, 1987, LANCET, V1, P1342; HARRINGTON D, 1990, NEW GENERATION VACCI, P43; HENDRICKSE RG, 1975, T ROY SOC TROP MED H, V69, P31, DOI 10.1016/0035-9203(75)90007-3; HLADY WG, 1992, AM J PUBLIC HEALTH, V82, P1365, DOI 10.2105/AJPH.82.10.1365; HULL HF, 1983, LANCET, V1, P972; IVANOFF B, 1994, B WORLD HEALTH ORGAN, V72, P957; KLUGMAN KP, 1987, LANCET, V2, P1165; KOENIG MA, 1990, B WORLD HEALTH ORGAN, V68, P441; LAGOS R, IN PRESS PEDIATR INF; LANATA CF, 1989, J INFECT DIS, V159, P452, DOI 10.1093/infdis/159.3.452; LEE JW, 1994, SCIENCE, V266, P527, DOI 10.1126/science.7939695; LEVINE MM, 1987, LANCET, V1, P1049; LEVINE MM, 1990, LANCET, V336, P891; Markowitz LE, 1994, VACCINES, P229; MCINTYRE RC, 1982, B WORLD HEALTH ORGAN, V60, P767; MELNICK JL, 1994, VACCINES, P155; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055; osmer D. W, 1989, APPL LOGISTIC REGRES, P38; PADUNGCHAN S, 1986, B WORLD HEALTH ORGAN, V64, P247; PAPPAIOANOU M, 1986, NEW ENGL J MED, V314, P280, DOI 10.1056/NEJM198601303140504; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; PICHICHERO ME, 1990, J INFECT DIS, V162, P753, DOI 10.1093/infdis/162.3.753; PIERCE NF, 1994, LANCET, V344, P1022, DOI 10.1016/S0140-6736(94)91682-9; REINGOLD AL, 1985, LANCET, V2, P114; ROBBINS A, 1993, PEDIATR INFECT DIS J, V12, P523, DOI 10.1097/00006454-199306000-00012; SACK DA, 1994, LANCET, V344, P616, DOI 10.1016/S0140-6736(94)92003-6; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SACKETT DL, 1983, CLIN TRIALS, P65; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; SCHWARTZ D, 1980, CLIN TRIALS; SHAPIRO C, 1985, INT J EPIDEMIOL, V14, P441, DOI 10.1093/ije/14.3.441; SIMANJUNTAK CH, 1991, LANCET, V338, P1055, DOI 10.1016/0140-6736(91)91910-M; SMITH PG, 1982, TUBERCLE, V63, P23, DOI 10.1016/S0041-3879(82)80006-8; SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87; STANFORD JL, 1987, TUBERCLE, V68, P169, DOI 10.1016/0041-3879(87)90052-3; SWERDLOW DL, 1994, LANCET, V344, P1302, DOI 10.1016/S0140-6736(94)90793-5; TIDJANI O, 1986, TUBERCLE, V67, P269, DOI 10.1016/0041-3879(86)90016-4; VADHEIM CM, 1994, ARCH PEDIAT ADOL MED, V148, P51, DOI 10.1001/archpedi.1994.02170010053011; VESIKARI T, 1984, LANCET, V1, P977; WAHDAN MH, 1982, J INFECT DIS, V145, P292, DOI 10.1093/infdis/145.3.292; WARD J, 1990, NEW ENGL J MED, V323, P1393, DOI 10.1056/NEJM199011153232006; Weinstein M. C., 1980, CLIN DECISION ANAL, P228; WHITTLE H, 1988, LANCET, V2, P811; 1985, EXPANDED PROGRAMME I, V7, P1; 1991, WKLY EPIDEMIOL REC, V66, P259; 1994, MMWR-MORBID MORTAL W, V43, P144; 1990, WIKLY EPIDEMIOL REC, V65, P2	87	135	139	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					390	397		10.1001/jama.275.5.390	http://dx.doi.org/10.1001/jama.275.5.390			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8569019				2022-12-24	WOS:A1996TT30300033
J	Kizer, KW				Kizer, KW			Nasopharyngeal radium treatment of veterans	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Kizer, KW (corresponding author), DEPT VET AFFAIRS,OFF PUBL HLTH & ENVIRONM HAZARDS,810 VERMONT AVE NW,WASHINGTON,DC 20420, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					351	351						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8569001				2022-12-24	WOS:A1996TT30300007
J	Dewsnup, DH; Galgiani, JN; Graybill, JR; Diaz, M; Rendon, A; Cloud, GA; Stevens, DA				Dewsnup, DH; Galgiani, JN; Graybill, JR; Diaz, M; Rendon, A; Cloud, GA; Stevens, DA			Is it ever safe to stop azole therapy for Coccidioides immitis meningitis?	ANNALS OF INTERNAL MEDICINE			English	Article						coccidioidomycosis; meningitis, fungal; azoles; triazoles; recurrence	ITRACONAZOLE THERAPY; FLUCONAZOLE THERAPY; KETOCONAZOLE; ANTIFUNGAL; MYCOSES	Objective: To determine 1) whether patients with coccidioidal meningitis who had achieved remission with oral azole therapy were cured and 2) when oral atole therapy could be discontinued in these patients. Design: Data were gathered on patients with coccidioidal meningitis who had successfully responded to atole therapy in previous clinical trials. Setting: Referral centers, including university, county, and veterans' hospitals and clinics. Patients: 18 patients in whom atole therapy for meningitis had been discontinued, usually because of a presumption of cure. Main Outcome Measures: Clinical and cerebrospinal fluid relapse. Results: 14 of 18 patients (78% [95% CI, 52% to 94%]) had relapse with disseminated disease after discontinuation of therapy, for a total of 1 nonmeningeal and 15 meningeal relapses to date. Relapse occurred both soon and late (range, 0.5 to 30 months) after therapy was discontinued. The characteristics of patients who did not have relapse, including the particular atole used, the duration of therapy, the reason therapy was discontinued, and the cerebrospinal fluid indices before discontinuation, were similar to the characteristics of patients who had relapse. Relapse had serious consequences in some patients; 3 patients died. Conclusion: Our data suggest 1) that disease is only suppressed in patients with meningitis who achieve remission while receiving atole therapy and 2) that discontinuing atole therapy is unsafe. The alternative is lifelong treatment with azoles; this appears to be acceptable, because toxicity is uncommon with triazole therapy, even longterm triazole therapy.	SANTA CLARA VALLEY MED CTR, DEPT MED, DIV INFECT DIS, SAN JOSE, CA 95128 USA; VET AFFAIRS MED CTR, DEPT MED, DIV INFECT DIS, TUCSON, AZ 85723 USA; UNIV TEXAS, HLTH SCI CTR, DEPT INFECT DIS, AUDIE MURPHY VET AFFAIRS HOSP, SAN ANTONIO, TX 78284 USA; UNIV ALABAMA, MED CTR, TUMOR INST, BIRMINGHAM, AL 35294 USA; CALIF INST MED RES, SAN JOSE, CA 95128 USA; STANFORD UNIV, SCH MED, STANFORD, CA 94305 USA; NIAID, MYCOSES STUDY GRP, BETHESDA, MD USA; UNIV ARIZONA, TUCSON, AZ USA; AUDIE L MURPHY MEM VET ADM MED CTR, SAN ANTONIO, TX 78284 USA; UNIV AUTONOMA NUEVO LEON, MONTERREY, MEXICO; UNIV HOSP, MONTERREY, MEXICO	Santa Clara Valley Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System; University of Texas System; University of Texas Health San Antonio; University of Alabama System; University of Alabama Birmingham; Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Arizona; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Universidad Autonoma de Nuevo Leon; Universidad Autonoma de Nuevo Leon; University Hospital Autonomous University of Nuevo Leon			Rendon, Adrian/S-1531-2017; Galgiani, John/GLT-7012-2022; A., Rendon/AAE-5931-2021	Rendon, Adrian/0000-0001-8973-4024; A., Rendon/0000-0001-8973-4024	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015082] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-15082] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENNETT J, 1990, FLUCONAZOLE OVERVIEW, P1; BORELLI D, 1979, POSTGRAD MED J, V55, P657, DOI 10.1136/pgmj.55.647.657; CAUWENBERGH G, 1990, J AM ACAD DERMATOL, V23, P549; DENNING DW, 1990, MYCOSES IN AIDS PATIENTS, P305; DEWSNUP DH, 1991, 31ST INT C ANT AG CH, P1156; DIAZ M, 1992, CLIN INFECT DIS, V14, pS68, DOI 10.1093/clinids/14.Supplement_1.S68; DUPONT B, 1988, 10TH P C INT SOC HUM, P197; EINSTEIN HE, 1961, CALIF MED, V94, P339; GALGIANI JN, 1993, ANN INTERN MED, V119, P28, DOI 10.7326/0003-4819-119-1-199307010-00005; GALGIANI JN, 1990, ANN INTERN MED, V113, P177, DOI 10.7326/0003-4819-113-3-177; GRANT SM, 1989, DRUGS, V37, P310, DOI 10.2165/00003495-198937030-00003; Graybill J R, 1988, Ann N Y Acad Sci, V544, P488, DOI 10.1111/j.1749-6632.1988.tb40446.x; GRAYBILL JR, 1990, AM J MED, V89, P282, DOI 10.1016/0002-9343(90)90339-F; Kelly P.C., 1980, COCCIDIOIDOMYCOSIS T, P163, DOI [10.1007/978-1-4757-1712-9_11, DOI 10.1007/978-1-4757-1712-9_11]; PAPPAGIANIS D, 1990, CLIN MICROBIOL REV, V3, P247, DOI 10.1128/CMR.3.3.247-268.1990; RESTREPO A, 1980, REV INFECT DIS, V2, P519; SAAG MS, 1992, NEW ENGL J MED, V326, P83, DOI 10.1056/NEJM199201093260202; STEVENS DA, 1983, DRUGS, V26, P347, DOI 10.2165/00003495-198326040-00004; STEVENS DA, 1986, INFECTIOUS DISEASES; TUCKER RM, 1990, J AM ACAD DERMATOL, V23, P593, DOI 10.1016/0190-9622(90)70261-F; TUCKER RM, 1990, REV INFECT DIS, V12, pS380; TUCKER RM, 1990, ANN INTERN MED, V112, P108, DOI 10.7326/0003-4819-112-2-108; 1993, MMWR-MORBID MORTAL W, V42, P21	23	130	135	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					305	+		10.7326/0003-4819-124-3-199602010-00004	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554225				2022-12-24	WOS:A1996TR59600004
J	Steegmans, PHA; Fekkes, D; Hoes, AW; Bak, AAA; vanderDoes, E; Grobbee, DE				Steegmans, PHA; Fekkes, D; Hoes, AW; Bak, AAA; vanderDoes, E; Grobbee, DE			Low serum cholesterol concentration and serotonin metabolism in men	BRITISH MEDICAL JOURNAL			English	Article									ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,SCH MED,SECT PATHOPHYSIOL BEHAV,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam			Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				BROWN SL, 1994, BRIT MED J, V308, P1328, DOI 10.1136/bmj.308.6940.1328; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; KAPLAN JR, 1994, PSYCHOSOM MED, V56, P479, DOI 10.1097/00006842-199411000-00001; LINDBERG G, 1992, BRIT MED J, V305, P277, DOI 10.1136/bmj.305.6848.277; SALTER M, 1992, LANCET, V339, P1169	5	109	111	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					221	221						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563588	Green Published			2022-12-24	WOS:A1996TT48600028
J	WiedauPazos, M; Goto, JJ; Rabizadeh, S; Gralla, EB; Roe, JA; Lee, MK; Valentine, JS; Bredesen, DE				WiedauPazos, M; Goto, JJ; Rabizadeh, S; Gralla, EB; Roe, JA; Lee, MK; Valentine, JS; Bredesen, DE			Altered reactivity of superoxide dismutase in farmilial amyotrophic lateral sclerosis	SCIENCE			English	Article							HYDROGEN-PEROXIDE; COPPER; ENZYME	A subset of individuals with familiar amyotrophic lateral sclerosis (FALS) possesses dominantly inherited mutations in the gene that encodes copper-zinc superoxide dismutase (CuZnSOD). A4V and G93A, two of the mutant enzymes associated with FALS, were shown to catalyze the oxidation of a model substrate (spin trap 5,5'-dimethyl-1-pyrroline N-oxide) by hydrogen peroxide at a higher rate than that seen with the wild-type enzyme. Catalysis of this reaction by A4V and G93A was more sensitive to inhibition by the copper chelators diethyldithiocarbamate and penicillamine than was catalysis by wild-type CuZnSOD. The same two chelators reversed the apoptosis-inducing effect of mutant enzymes expressed in a neural cell line. These results suggest that oxidative reactions catalyzed by mutant CuZnSOD enzymes initiate the neuropathologic changes in FALS.	UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, INTERDEPARTMENTAL PROGRAM NEUROSCI, LOS ANGELES, CA 90095 USA; LA JOLLA CANC RES FDN, PROGRAM AGING, LA JOLLA, CA 92037 USA; LOYOLA MARYMOUNT UNIV, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90045 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21218 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Sanford Burnham Prebys Medical Discovery Institute; Loyola Marymount University; Johns Hopkins University			Lee, Michael K/D-9491-2013; Valentine, Joan S/B-6665-2008	Lee, Michael K/0000-0001-5865-9682; Valentine, Joan S/0000-0002-7174-925X	NIA NIH HHS [AG12282] Funding Source: Medline; NIDDK NIH HHS [DK46828] Funding Source: Medline; NIGMS NIH HHS [GM28222] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012282] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BROWN RH, CELL, V687, P95; BUETTNER GR, 1978, BIOCHEM BIOPH RES CO, V83, P69, DOI 10.1016/0006-291X(78)90398-4; CABELLI DE, 1989, J BIOL CHEM, V264, P9967; DAMANI LA, 1989, SULPHUR CONTAINING D, V3; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DURAND M M, 1990, Society for Neuroscience Abstracts, V16, P40; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; GANDARA DR, 1995, J CLIN ONCOL, V13, P490, DOI 10.1200/JCO.1995.13.2.490; GOTO JJ, UNPUB; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HEIKKILA RE, 1976, ANAL BIOCHEM, V75, P356, DOI 10.1016/0003-2697(76)90089-0; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; JOYCE DA, 1993, AGENT ACTION SUPPL, V44, P203; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MISRA HP, 1979, J BIOL CHEM, V254, P1623; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; REINKE LA, 1994, FREE RADICAL RES, V21, P213, DOI 10.3109/10715769409056573; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SARAFIAN TA, 1994, FREE RADICAL RES, V21, P1, DOI 10.3109/10715769409056549; YIM MB, 1993, J BIOL CHEM, V268, P4099; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	28	639	650	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					515	518		10.1126/science.271.5248.515	http://dx.doi.org/10.1126/science.271.5248.515			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560268				2022-12-24	WOS:A1996TR32200045
J	Brock, DJH				Brock, DJH			Prenatal screening for cystic fibrosis: 5 years' experience reviewed	LANCET			English	Article							CARRIERS; CARE	Background Although several programmes of prenatal screening for cystic fibrosis have been completed and reported, there are still uncertainties about rates of take up and also about the action of parents identified as having a one-in-four risk of an affected child. I report 5 years' experience with the two-step and couple models of prenatal screening of cystic fibrosis. Methods Screening has been available at two antenatal clinics in Edinburgh, UK, since January, 1992, first on a research basis and then routinely. 25 000 couples have been screened. Findings Take-up rates for the two-step and couple models of delivery are very similar at about 70%. Take-up rates did not change when screening moved from a research to a routine service. Of 22 high-risk couples identified entirely through screening, 20 (91%) opted for prenatal diagnosis. Four couples returned for second and two for third monitored pregnancies. In all eight cases where affected fetuses were identified, pregnancy was terminated. Interpretation These data remove one of the few remaining obstacles to a general implementation of prenatal screening for cystic fibrosis.			Brock, DJH (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; BOWMAN JE, 1991, AM J HUM GENET, V48, P433; BROCK D, 1990, AM J HUM GENET, V47, P164; DOHERTY RA, 1994, LANCET, V343, P172, DOI 10.1016/S0140-6736(94)90961-X; KABACK MM, 1977, TAY SACHS DISEASE SC, P13; LIVINGSTONE J, 1993, CLIN GENET, V43, P57, DOI 10.1111/j.1399-0004.1993.tb04427.x; LIVINGSTONE J, 1994, BRIT MED J, V308, P1459, DOI 10.1136/bmj.308.6942.1459; MENNIE ME, 1992, LANCET, V340, P214, DOI 10.1016/0140-6736(92)90476-J; MENNIE ME, 1993, J MED GENET, V30, P543, DOI 10.1136/jmg.30.7.543; MODELL B, 1984, CLIN APPROACH THALAS, P354; Morris J K, 1995, J Med Screen, V2, P22; TAMBOR ES, 1994, AM J HUM GENET, V55, P626; WALD NJ, 1993, LANCET, V342, P1307, DOI 10.1016/0140-6736(93)92403-G; WALD NJ, 1991, LANCET, V338, P1318, DOI 10.1016/0140-6736(91)92605-2; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504; 1988, BRIT MED J, V297, P1599	16	55	55	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 20	1996	347	8995					148	150		10.1016/S0140-6736(96)90340-2	http://dx.doi.org/10.1016/S0140-6736(96)90340-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544548				2022-12-24	WOS:A1996TQ24400009
J	Gabriel, K; Schneider, J; McClain, WH				Gabriel, K; Schneider, J; McClain, WH			Functional evidence for indirect recognition of G center dot U in tRNA(Ala) by alanyl-tRNA synthetase	SCIENCE			English	Article							TRANSFER-RNA; ESCHERICHIA-COLI; IDENTITY; SPECIFICITY; DETERMINES; END	The structural features of the G . U wobble pair in Escherichia coli alanine transfer RNA (tRNA(Ala)) that are associated with aminoacylation by alanyl-tRNA synthetase (AlaRS) were investigated in vivo for wild-type tRNA(Ala) and mutant tRNAs with G . U substitutions. tRNA(Ala) with G . U, C . A, or G . A gave similar amounts of charged tRNA(Ala) and supported viability of E. coli lacking chromosomal tRNA(Ala) genes. tRNA(Ala) With G . C was inactive. Recognition of G . U by AlaRS thus requires more than the functional groups on G . U in a regular helix and may involve detection of a helical distortion.	UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM42123] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042123] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAIN FHT, 1995, J MOL BIOL, V250, P333, DOI 10.1006/jmbi.1995.0381; ALLAIN FHT, 1995, NUCLEIC ACIDS RES, V23, P341, DOI 10.1093/nar/23.3.341; BLUM P, 1989, J BACTERIOL, V171, P538, DOI 10.1128/jb.171.1.538-546.1989; BRUN YV, 1990, J MOL BIOL, V214, P825, DOI 10.1016/0022-2836(90)90339-N; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, P1410; CONDON C, 1993, EMBO J, V12, P4305, DOI 10.1002/j.1460-2075.1993.tb06115.x; DOUDNA JA, 1989, P NATL ACAD SCI USA, V86, P7402, DOI 10.1073/pnas.86.19.7402; GABRIEL K, UNPUB; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; LIMMER S, 1993, P NATL ACAD SCI USA, V90, P6199, DOI 10.1073/pnas.90.13.6199; MCCLAIN WH, 1988, SCIENCE, V242, P1681, DOI 10.1126/science.2462282; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MCCLAIN WH, 1994, NUCLEIC ACIDS RES, V22, P522, DOI 10.1093/nar/22.3.522; MCCLAIN WH, 1988, J MOL BIOL, V202, P697, DOI 10.1016/0022-2836(88)90551-7; MUSIERFORSYTH K, 1991, SCIENCE, V253, P784, DOI 10.1126/science.1876835; STROBEL SA, 1995, SCIENCE, V267, P675, DOI 10.1126/science.7839142; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712	21	106	106	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	1996	271	5246					195	197		10.1126/science.271.5246.195	http://dx.doi.org/10.1126/science.271.5246.195			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539617				2022-12-24	WOS:A1996TP36400039
J	Gravholt, CH; Juul, S; Naeraa, RW; Hansen, J				Gravholt, CH; Juul, S; Naeraa, RW; Hansen, J			Prenatal and postnatal prevalence of Turner's syndrome: A registry study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHROMOSOMAL MOSAICISM; 45,X/46,XY MOSAICISM; MATERNAL AGE; MONOSOMY-X; ABNORMALITIES; AMNIOCENTESIS; DIAGNOSIS; PREGNANCY; CHILDREN; ORIGIN	Objective-To study prevalence of Turner's syndrome in Denmark and to assess validity of prenatal diagnosis. Design-Study of data on prenatal and postnatal Turner's syndrome in Danish Cytogenetic Central Register. Subjects-All registered Turner's syndrome karyotypes (100 prenatal cases and 215 postnatal cases) during 1970-93. Main outcome measures-Prevalence of Turner's syndrome karyotypes among prenatally tested fetuses and Turner's syndrome among liveborn infants. Results-Among infant girls, prevalence of Turner's syndrome was 32/100000. Among female fetuses tested by amniocentesis, prevalence of Turner's syndrome karyotypes was 176/100000 (relative risk of syndrome, 6.74 compared with prevalence among untested pregnancies). Among female fetuses tested by chorion villus sampling, prevalence of syndrome karyotypes was 392/100000 (relative risk, 16.8). We excluded prenatal tests referred because of results of ultrasound scanning: among fetuses tested by amniocentesis revised relative risk was 5.68, while revised relative risk among fetuses tested by chorion villus sampling was 13.3. For 29 fetuses with prenatal diagnosis of possible Turner's syndrome, pregnancy was allowed to continue and 24 children were live born. Thirteen of these children were karyotyped postnatally, and diagnosis of Turner's syndrome had to be revised for eight, seven being normal girls and one boy, This gives tentative predictive value of amniocentesis in diagnosing Turner's syndrome of betmeen 21% and 67%. There was no significant relation between mother's age and risk of Turner's syndrome. Conclusions-Discrepancy between prenatal and postnatal prevalence of Turner's syndrome challenges specificity of prenatal examination in diagnosing Turner's syndrome.	AARHUS UNIV, DEPT EPIDEMIOL & SOCIAL MED, AARHUS, DENMARK; AARHUS UNIV HOSP, AARHUS KOMMUNEHOSP, PAEDIAT DEPT A, DK-8000 AARHUS C, DENMARK; AARHUS UNIV HOSP, AARHUS PSYCHIAT HOSP, DANISH CYTOGENET CENT REGISTER, DK-8000 AARHUS C, DENMARK	Aarhus University; Aarhus University; Aarhus University	Gravholt, CH (corresponding author), AARHUS UNIV HOSP, AARHUS KOMMUNEHOSP, MED DEPT M ENDOCRINOL & DIABET, DK-8000 AARHUS C, DENMARK.		Gravholt, Claus H./Z-1435-2018	Gravholt, Claus H./0000-0001-5924-1720				BERNASCONI S, 1994, ACTA PAEDIATR, V83, P292, DOI 10.1111/j.1651-2227.1994.tb18097.x; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; CAROTHERS AD, 1980, ANN HUM GENET, V43, P355, DOI 10.1111/j.1469-1809.1980.tb01570.x; CHANG HJ, 1990, AM J HUM GENET, V46, P156; CONNOR JM, 1989, ACTA PAEDIATR SCAND, P77; GRAVHOLT CH, 1991, HUM GENET, V88, P49, DOI 10.1007/BF00204928; HASSOLD T, 1988, AM J HUM GENET, V42, P534; HELD KR, 1992, HUM GENET, V88, P288; HOOK EB, 1983, HUM GENET, V64, P24, DOI 10.1007/BF00289473; HOOK EB, 1989, AM J HUM GENET, V45, P855; IMAIZUMI K, 1993, INT CONGR SER, V1014, P3; JACOBS PA, 1974, ANN HUM GENET, V37, P359, DOI 10.1111/j.1469-1809.1974.tb01843.x; JACOBS PA, 1990, ANN HUM GENET, V54, P209, DOI 10.1111/j.1469-1809.1990.tb00379.x; KAJII T, 1979, HUM GENET, V51, P147, DOI 10.1007/BF00287168; KEIDING N, 1994, BRIT MED J, V309, P131, DOI 10.1136/bmj.309.6947.131b; KULKARNI R, 1989, PRENATAL DIAG, V9, P439, DOI 10.1002/pd.1970090610; LARSEN T, 1995, CLIN GENET, V48, P6; LIPPE B, 1991, ENDOCRIN METAB CLIN, V20, P121, DOI 10.1016/S0889-8529(18)30284-6; LORDASANCHEZ I, 1992, AM J MED GENET, V42, P487, DOI 10.1002/ajmg.1320420414; LOUGHLIN SAR, 1991, J MED GENET, V28, P156, DOI 10.1136/jmg.28.3.156; MARTIN RH, 1987, AM J HUM GENET, V41, P484; MIKKELSEN M, 1992, PRAENATALE UNDERSOGE, P1; MINY P, 1991, PRENATAL DIAG, V11, P581, DOI 10.1002/pd.1970110815; NIELSEN J, 1991, HUM GENET, V87, P81, DOI 10.1007/BF01213097; NISANI R, 1989, PRENATAL DIAG, V9, P223, DOI 10.1002/pd.1970090402; ROLAND B, 1990, PRENATAL DIAG, V10, P333, DOI 10.1002/pd.1970100509; SCHWINGER E, 1989, PRENATAL DIAG, V9, P639, DOI 10.1002/pd.1970090907; THARAPEL AT, 1989, PRENATAL DIAG, V9, P467, DOI 10.1002/pd.1970090703; TOMKINS DJ, 1989, PRENATAL DIAG, V9, P139, DOI 10.1002/pd.1970090210; VILLAMAR M, 1990, ANN GENET-PARIS, V33, P29; WARBURTON D, 1980, LANCET, V1, P167; WHEELER M, 1988, AM J MED GENET, V29, P565, DOI 10.1002/ajmg.1320290314	32	120	129	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 6	1996	312	7022					16	21		10.1136/bmj.312.7022.16	http://dx.doi.org/10.1136/bmj.312.7022.16			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555850	Green Published			2022-12-24	WOS:A1996TP20900017
J	Zitnan, D; Kingan, TG; Hermesman, JL; Adams, ME				Zitnan, D; Kingan, TG; Hermesman, JL; Adams, ME			Identification of ecdysis-triggering hormone from an epitracheal endocrine system	SCIENCE			English	Article							MANDUCA-SEXTA; ECLOSION HORMONE; MOTOR PATTERN; CARDIOACTIVE PEPTIDE; NEURAL ORGANIZATION; TOBACCO HORNWORM; NERVOUS-SYSTEM; METAMORPHOSIS; ANTIBODIES; DROSOPHILA	Developing insects repeatedly shed their cuticle by means of a stereotyped behavior called ecdysis, thought to be initiated by the brain peptide eclosion hormone. Here an ecdysis-triggering hormone, Mas-ETH, is described from the tobacco hornworm Manduca sexta. Mas-ETH contains 26 amino acids and is produced by a segmentally distributed endocrine system of epitracheal glands (EGs). The EGs undergo a marked reduction in volume, appearance, and immunohistochemical staining during ecdysis, at which time Mas-ETH is found in the hemolymph. Injection of EGs extract or synthetic Mas-ETH into pharate larvae, pupae,or adults initiates preecdysis within 2 to 10 minutes, followed by ecdysis. Sensitivity to injected Mas-ETH appears much earlier before ecdysis and occurs with shorter latency than that reported for eclosion hormone. The isolated central nervous system responds to Mas-ETH, but not to eclosion hormone, with patterned motor bursting corresponding to in vivo preecdysis and ecdysis. Mas-ETH may be an immediate blood-borne trigger for ecdysis through a direct action on the nervous system.	UNIV CALIF RIVERSIDE,DEPT ENTOMOL,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,AGR EXPT STN,RIVERSIDE,CA 92521; USDA ARS,INSECT NEUROBIOL & HORMONE LAB,BELTSVILLE,MD 20705; UNIV MARYLAND,DEPT BIOL SCI,BALTIMORE,MD 21228	University of California System; University of California Riverside; University of California System; University of California Riverside; United States Department of Agriculture (USDA); University System of Maryland; University of Maryland Baltimore			Adams, Michael/ABF-6728-2020	Adams, Michael/0000-0003-0519-6113				AKAI H, 1992, Cytologia (Tokyo), V57, P195; COPENHAVER PF, 1982, J INSECT PHYSIOL, V28, P695, DOI 10.1016/0022-1910(82)90148-2; CURTIS AT, 1984, J INSECT PHYSIOL, V30, P597, DOI 10.1016/0022-1910(84)90043-X; EWER J, 1994, J NEUROSCI, V14, P7704; HEWES RS, 1991, J COMP PHYSIOL A, V168, P697; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; Keilin D., 1944, PARASITOLOGY, V36, P1, DOI 10.1017/S0031182000011975; MASINOVSKY B, 1988, J COMP NEUROL, V273, P500, DOI 10.1002/cne.902730406; MILES CI, 1991, J COMP PHYSIOL A, V168, P179, DOI 10.1007/BF00218410; MORRIS HR, 1982, NATURE, V300, P643, DOI 10.1038/300643a0; REYNOLDS SE, 1979, J EXP BIOL, V78, P77; Truman J.W., 1985, P381; TRUMAN JW, 1992, PROG BRAIN RES, V92, P361, DOI 10.1016/S0079-6123(08)61189-9; TRUMAN JW, 1978, J EXP BIOL, V74, P151; TRUMAN JW, 1980, J EXP BIOL, V88, P327; TRUMAN JW, 1994, INSECT NEUROCHEMISTRY AND NEUROPHYSIOLOGY 1993, P39; TRUMAN JW, 1983, NEURAL CONTROL RHYTH, V37, P223; WEEKS JC, 1984, J COMP PHYSIOL, V155, P407, DOI 10.1007/BF00610594; WEEKS JC, 1984, J COMP PHYSIOL, V155, P423, DOI 10.1007/BF00610595; ZITNAN D, 1993, DEV BIOL, V156, P117, DOI 10.1006/dbio.1993.1063; ZITNAN D, 1989, THESIS SLOVAK ACADEM; ZITNAN D, 1995, J COMP NEUROL, V355, P1; ZITNAN D, UNPUB	23	188	195	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 5	1996	271	5245					88	91						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539606				2022-12-24	WOS:A1996TP02200050
J	Molkentin, JD; Black, BL; Martin, JF; Olson, EN				Molkentin, JD; Black, BL; Martin, JF; Olson, EN			Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins	CELL			English	Article							HELIX-LOOP-HELIX; ENHANCER-BINDING-FACTOR; TRANSCRIPTION FACTORS; BASIC REGION; MYOD FAMILY; FACTOR-II; OLIGOMERIZATION; MYOBLASTS; COMPLEXES; PRODUCTS	Members of the myocyte enhancer factor-2 (MEF2) family of MADS domain transcription factors cannot induce myogenesis in transfected fibroblasts, but when coexpressed with the myogenic basic-helix-loop-helix (bHLH) proteins MyoD or myogenin they dramatically increase the extent of myogenic conversion above that seen with either myogenic bHLH factor alone. This cooperativity required direct interactions between the DNA-binding domains of MEF2 and the myogenic bHLH factors, but only one of the factors needed a transactivation domain, and only one of the factors needed to be bound to DNA. These interactions allow either factor to activate transcription through the other's binding site and reveal a novel mechanism for indirect activation of gene expression via protein-protein interactions between the DNA-binding domains of heterologous classes of transcription factors.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center				Molkentin, Jeffery/0000-0002-3558-6529; Black, Brian/0000-0002-6664-8913	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040339] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLACK BL, 1995, J BIOL CHEM, V270, P2889, DOI 10.1074/jbc.270.7.2889; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; BUCHBERGER A, 1994, J BIOL CHEM, V269, P17289; CHAKRABORTY T, 1992, J BIOL CHEM, V267, P17498; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CHAMBERS AE, 1994, GENE DEV, V8, P1324, DOI 10.1101/gad.8.11.1324; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EMERSON CP, 1993, CURR OPIN GENET DEV, V3, P265, DOI 10.1016/0959-437X(93)90033-L; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRAYSON J, 1995, MOL CELL BIOL, V15, P1870; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; TAYLOR MV, 1995, MECH DEVELOP, V50, P29, DOI 10.1016/0925-4773(94)00323-F; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	56	684	707	1	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1125	1136		10.1016/0092-8674(95)90139-6	http://dx.doi.org/10.1016/0092-8674(95)90139-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548800	Bronze			2022-12-24	WOS:A1995TM76200009
J	MacLennan, AH; Wilson, DH; Taylor, AW				MacLennan, AH; Wilson, DH; Taylor, AW			Prevalence and cost of alternative medicine in Australia	LANCET			English	Article								Background To determine the prevalence and cost of alternative medicines and alternative practitioner use in an Australian population. Methods We conducted a representative population survey of persons aged 15 or older living in South Australia, which required 3004 personal interviews, We assessed the rates of use and types of alternative medicine and therapists used by this population in 1993, and correlations with other demographic and medical variables. Findings The overall use of at least one non-medically prescribed alternative medicine (excluding calcium, iron and prescribed vitamins) was 48.5%. The users were more likely to be perimenopausal females, better educated, have a higher alcohol intake, be of normal weight and more likely to be employed than non-users, 20.3% of respondents had visited at least one alternative practitioner, most commonly chiropractors (15%). The users of alternative practitioners were more likely to be younger, live in the country and be overweight, Women were more likely to consult naturopaths, iridiologists, and reflexologists than men. Interpretation Extrapolation of the costs to the Australian population gives a natural expenditure in 1993, for alternative medicines, of $621 million (Australian dollars) and for alternative therapists of $AU309 million per annum. This compares to the $AU360 million of patient contributions for all classes of pharmaceutical drugs purchased in Australia in 1992/93, The public health and economic ramifications of these huge costs are questioned in view of the paucity of sound safety and efficacy data for many of the therapies and products of the alternative medicine industry.	S AUSTRALIAN HLTH COMMISS,PUBL & ENVIRONM HLTH SERV,ADELAIDE,SA,AUSTRALIA		MacLennan, AH (corresponding author), UNIV ADELAIDE,DEPT OBSTET & GYNAECOL,ADELAIDE,SA 5000,AUSTRALIA.		Taylor, Anne w/F-5708-2010	Taylor, Anne w/0000-0002-4422-7974				CHENOY R, 1994, BRIT MED J, V308, P501, DOI 10.1136/bmj.308.6927.501; CUI J, 1994, LANCET, V344, P134, DOI 10.1016/S0140-6736(94)91322-6; DESMET PAGM, 1995, BRIT MED J, V310, P1023, DOI 10.1136/bmj.310.6986.1023; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; ERNST E, 1993, LANCET, V341, P1626, DOI 10.1016/0140-6736(93)90763-7; KELLY JL, 1988, USING ASCO SOCIO EC; LLOYD P, 1993, AUST J PUBLIC HEALTH, V17, P135; LOHR SL, 1994, J QUANT CRIMINOL, V10, P343, DOI 10.1007/BF02221280; MOULDS RFW, 1988, MED J AUSTRALIA, V149, P572, DOI 10.5694/j.1326-5377.1988.tb120789.x; ONEILL A, 1994, SOC SCI MED, V38, P497, DOI 10.1016/0277-9536(94)90246-1; PERHARIC L, 1993, LANCET, V342, P180, DOI 10.1016/0140-6736(93)91389-4; STARK DJ, 1981, MED J AUSTRALIA, V2, P676, DOI 10.5694/j.1326-5377.1981.tb113049.x; SWAYNE JMD, 1989, J ROY COLL GEN PRACT, V39, P503; TORO T, 1992, NEW SCI, V1831, P10; WIESNER D, 1995, AUSTR DOCT       MAR, P44; 1994, AUSTR HLTH; 1990, 12220 AUSTR BUR STAT; 1986, INQUIRY ALTERNATIVE; 1990, 27100 AUSTR BUR STAT	19	664	672	0	29	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					569	573		10.1016/S0140-6736(96)91271-4	http://dx.doi.org/10.1016/S0140-6736(96)91271-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596318				2022-12-24	WOS:A1996TX69400009
J	NostenBertrand, M; Errington, ML; Murphy, KPSJ; Tokugawa, Y; Barboni, E; Kozlova, E; Michalovich, D; Morris, RGM; Silver, J; Stewart, CL; Bliss, TVP; Morris, RJ				NostenBertrand, M; Errington, ML; Murphy, KPSJ; Tokugawa, Y; Barboni, E; Kozlova, E; Michalovich, D; Morris, RGM; Silver, J; Stewart, CL; Bliss, TVP; Morris, RJ			Normal spatial learning despite regional inhibition of LTP in mice lacking Thy-1	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL GRANULE CELLS; DENTATE GYRUS INVITRO; II MUTANT MICE; MEMORY; MODULATION; LESIONS; RAT	The process of learning involves stable changes in synaptic efficacy for which long-term potentiation (LTP)(1) provides a widely adopted mammalian model. Synaptic modification induced by learning or LTP may involve the action of cell adhesion molecules(2-4). One such candidate is the ubiquitous neuronal glycoprotein Thy-1 (refs 5, 6). In mice in which the gene encoding Thy-1 has been inactivated, we find a regionally selective impairment of LTP in vivo in the hippocampal formation: LTP is normal in area CA1 but strongly inhibited in the dentate gyrus. Spatial learning by Thy-1-deficient mice, as assessed in the watermaze(7), is unimpaired. Thus LTP in the cortical input to the dentate gyrus seems not to be required for spatial learning.	NATL INST MED RES, DEPT NEUROBIOL, LONDON NW7 1AA, ENGLAND; NATL INST MED RES, DEPT NEUROPHYSIOL, LONDON NW7 1AA, ENGLAND; CORNELL UNIV, COLL MED, N SHORE UNIV HOSP, DIV MOLEC MED, NEW YORK, NY 11030 USA; UNIV ROMA LA SAPIENZA, DEPT HUMAN BIOPATHOL, I-00100 ROME, ITALY; ERASMUS UNIV ROTTERDAM, DEPT CELL BIOL & GENET, 3000 DR ROTTERDAM, NETHERLANDS; UNIV EDINBURGH, CTR NEUROSCI, EDINBURGH EH8 9LE, MIDLOTHIAN, SCOTLAND; ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA; UNITED MED & DENT SCH, GUYS HOSP, DEPT EXPTL PATHOL, LONDON SE1 9RT, ENGLAND	MRC National Institute for Medical Research; MRC National Institute for Medical Research; Cornell University; Northwell Health; North Shore University Hospital; Sapienza University Rome; Erasmus University Rotterdam; University of Edinburgh; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			Murphy, Kerry/H-1934-2012; Morris, Richard G M/C-9982-2013	Michalovich, David/0000-0003-4452-5776; Kozlova, Elena/0000-0002-2234-0079				ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; CHO YH, 1995, NEUROBIOL LEARN MEM, V64, P285, DOI 10.1006/nlme.1995.0011; CONRAD CD, 1993, J NEUROSCI, V13, P2582, DOI 10.1523/JNEUROSCI.13-06-02582.1993; FAZELI MS, 1994, NEUROSCI LETT, V169, P77, DOI 10.1016/0304-3940(94)90360-3; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; GORDON JA, 1994, SOC NEUR ABSTR, V20; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HALASY K, 1993, EUR J NEUROSCI, V5, P411, DOI 10.1111/j.1460-9568.1993.tb00508.x; HANSE E, 1992, EUR J NEUROSCI, V4, P1191, DOI 10.1111/j.1460-9568.1992.tb00144.x; LUTHI A, 1994, NATURE, V372, P777, DOI 10.1038/372777a0; MAYFORD M, 1995, CURR OPIN NEUROBIOL, V5, P141, DOI 10.1016/0959-4388(95)80019-0; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; MCNAMARA RK, 1993, BRAIN RES REV, V18, P33, DOI 10.1016/0165-0173(93)90006-L; MCNAUGHTON BL, 1989, EXP BRAIN RES, V76, P485, DOI 10.1007/BF00248904; MORRIS R, 1992, BIOESSAYS, V14, P715, DOI 10.1002/bies.950141014; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MURPHY KPSJ, 1994, NEUROPHARMACOLOGY, V33, P1375, DOI 10.1016/0028-3908(94)90039-6; Naquet P, 1989, Immunol Ser, V45, P99; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; SCHENK F, 1985, EXP BRAIN RES, V58, P11; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SLOVITER RS, 1995, J NEUROSCI, V15, P811; Swanson LW, 1987, HDB CHEM NEUROANATOM, P125; TIVERON MC, 1992, NATURE, V355, P745, DOI 10.1038/355745a0; WHISHAW IQ, 1987, BEHAV BRAIN RES, V24, P59, DOI 10.1016/0166-4328(87)90036-2; WIGSTROM H, 1983, BRAIN RES, V275, P153, DOI 10.1016/0006-8993(83)90428-6	30	204	211	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 29	1996	379	6568					826	829		10.1038/379826a0	http://dx.doi.org/10.1038/379826a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587606				2022-12-24	WOS:A1996TX50100059
J	Amakawa, R; Hakem, A; Kundig, TM; Matsuyama, T; Simard, JJL; Timms, E; Wakeham, A; Mittruecker, HW; Griesser, H; Takimoto, H; Schmits, R; Shahinian, A; Ohashi, PS; Penninger, JM; Mak, TW				Amakawa, R; Hakem, A; Kundig, TM; Matsuyama, T; Simard, JJL; Timms, E; Wakeham, A; Mittruecker, HW; Griesser, H; Takimoto, H; Schmits, R; Shahinian, A; Ohashi, PS; Penninger, JM; Mak, TW			Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice	CELL			English	Article							VESICULAR STOMATITIS-VIRUS; X-LINKED IMMUNODEFICIENCY; NECROSIS-FACTOR RECEPTOR; STERNBERG-REED CELLS; HYPER-IGM SYNDROME; KI-1 ANTIGEN; CD40 LIGAND; CD30 ANTIGEN; SELF-TOLERANCE; LYMPHOID-CELLS	CD30 is found on Reed-Sternberg cells of Hodgkin's disease and on a variety of non-Hodgkin's lymphoma cells and is up-regulated on cells after Epstein-Barr virus, human T cell leukemia virus, and HIV infections. We report here that the thymus in CD30-deficient mice contains elevated numbers of thymocytes. Activation-induced death of thymocytes after CD3 cross-linking is impaired both in vitro and in vivo. Breeding the CD30 mutation separately into alpha beta TCR- or gamma delta TCR-transgenic mice revealed a gross defect in negative but not positive selection. Thus, like TNF-receptors and Fas/Apo-1, the CD30 receptor is involved in cell death signaling. It is also an important coreceptor that participates in thymic deletion.	UNIV TORONTO, AMGEN INST, TORONTO, ON M5G 2C1, CANADA; UNIV TORONTO, ONTARIO CANC INST, DEPT MED BIOPHYS, TORONTO, ON M5G 2C1, CANADA; UNIV TORONTO, ONTARIO CANC INST, DEPT IMMUNOL, TORONTO, ON M5G 2C1, CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto			Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777; Ohashi, Pamela S./0000-0003-2915-9317				ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ALZONA M, 1994, J IMMUNOL, V153, P2861; ANDREESEN R, 1984, BLOOD, V63, P1299; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BACHMANN MF, 1994, CURR OPIN IMMUNOL, V6, P320, DOI 10.1016/0952-7915(94)90108-2; BINDER D, 1991, J IMMUNOL, V146, P4301; BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; CALIGARISCAPPIO F, 1995, CLIN EXP RHEUMATOL, V13, P339; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DELPRETE G, 1995, FASEB J, V9, P81, DOI 10.1096/fasebj.9.1.7821763; DENT AL, 1990, NATURE, V343, P714, DOI 10.1038/343714a0; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ELLIS TM, 1993, J IMMUNOL, V151, P2380; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FONATSCH C, 1992, GENOMICS, V14, P825, DOI 10.1016/S0888-7543(05)80203-4; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FOY TM, 1995, J EXP MED, V182, P1377, DOI 10.1084/jem.182.5.1377; FROESE P, 1987, J IMMUNOL, V139, P2081; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GAUSE A, 1991, BLOOD, V77, P1983; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; GRUSS HJ, 1994, BLOOD, V83, P2045; KEMPER O, 1991, HUM GENET, V87, P623; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KUNDIG TM, 1993, J VIROL, V67, P3680; KUNDIG TM, 1993, J IMMUNOL, V150, P4450; LATZA U, 1994, EUR J IMMUNOL, V24, P677, DOI 10.1002/eji.1830240329; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MAGGI E, 1994, J EXP MED, V180, P489, DOI 10.1084/jem.180.2.489; MANETTI R, 1994, J EXP MED, V180, P2407, DOI 10.1084/jem.180.6.2407; MCDONALD PP, 1995, EUR J IMMUNOL, V25, P2870, DOI 10.1002/eji.1830251024; MECHTERSHEIMER G, 1990, CANCER, V66, P1732, DOI 10.1002/1097-0142(19901015)66:8<1732::AID-CNCR2820660815>3.0.CO;2-5; Merkenschlager M, 1989, Int Immunol, V1, P450, DOI 10.1093/intimm/1.4.450; NAWROCKI JF, 1988, J IMMUNOL, V141, P672; PALLESEN G, 1990, HISTOPATHOLOGY, V16, P409, DOI 10.1111/j.1365-2559.1990.tb01151.x; PALLESEN G, 1988, AM J PATHOL, V133, P446; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PIRIS M, 1990, HISTOPATHOLOGY, V17, P211, DOI 10.1111/j.1365-2559.1990.tb00709.x; PIZZOLO G, 1990, BRIT J HAEMATOL, V75, P282, DOI 10.1111/j.1365-2141.1990.tb02664.x; PIZZOLO G, 1994, AIDS, V8, P741, DOI 10.1097/00002030-199406000-00003; PUDDINGTON L, 1986, J VIROL, V60, P708, DOI 10.1128/JVI.60.2.708-717.1986; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SCHUURMAN HJ, 1989, THYMUS, V14, P43; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; SCHWARTING R, 1989, BLOOD, V74, P1678; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SHI YF, 1991, J IMMUNOL, V146, P3340; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SKEEN MJ, 1993, J EXP MED, V178, P971, DOI 10.1084/jem.178.3.971; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPRENT J, 1988, IMMUNOL REV, V101, P173, DOI 10.1111/j.1600-065X.1988.tb00737.x; SPRENT J, 1995, CURR OPIN IMMUNOL, V7, P196, DOI 10.1016/0952-7915(95)80004-2; STEIN H, 1982, INT J CANCER, V30, P445, DOI 10.1002/ijc.2910300411; STEIN H, 1985, BLOOD, V66, P848; SUCHI T, 1987, J CLIN PATHOL, V40, P995, DOI 10.1136/jcp.40.9.995; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TATSUMI Y, 1993, J IMMUNOL, V151, P3030; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WALLACE VA, 1992, J EXP MED, V176, P1657, DOI 10.1084/jem.176.6.1657; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	74	284	295	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 23	1996	84	4					551	562		10.1016/S0092-8674(00)81031-4	http://dx.doi.org/10.1016/S0092-8674(00)81031-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598042	Bronze			2022-12-24	WOS:A1996TX17600008
J	Leopold, DA; Logothetis, NK				Leopold, DA; Logothetis, NK			Activity changes in early visual cortex reflect monkeys' percepts during binocular rivalry	NATURE			English	Article								WHEN the two eyes view dissimilar images, we experience binocular rivalry, in which one eye's view dominates for several seconds and is then replaced by that of the other eye(1,2). What causes these perceptual changes in the absence of any change in the stimulus? We showed previously that some neurons in monkey cortical area MT show changes in activity during motion rivalry that reflect the perceived direction of motion(3). To determine whether perception-related modulation of activity occurs in other visual cortical areas, we recorded from individual neurons in V1, V2 and V4 while monkeys reported the perceived orientation of rival gratings of two orthogonal orientations. Many cells, particularly in V4, showed patterns of activity that correlated with the perceptual dominance and suppression of one stimulus. The majority were orientation-selective and could be driven equally well from either eye. It has been previously suggested that binocular rivalry involves reciprocal inhibition between monocular neurons within V1 (for example, see ref, 4), but our results do not support this view; rather, we propose that binocular rivalry arises through interactions between binocular neurons at several levels in the visual pathways, and that similar mechanisms may underlie other multistable perceptual states that occur when viewing ambiguous images.	BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine			Logothetis, Nikos/U-9282-2019	Leopold, David/0000-0002-1345-6360				BLAKE R, 1989, PSYCHOL REV, V96, P145, DOI 10.1037/0033-295X.96.1.145; BLAKE R, 1974, NATURE, V249, P488, DOI 10.1038/249488a0; BORSELLINO A, 1972, KYBERNETIK, V10, P139, DOI 10.1007/BF00290512; Breese BB., 1899, PSYCHOL REV-MONOGR S, V3, DOI [10.1037/h0092990, DOI 10.1037/H0092990]; CAMPBELL FW, 1972, J PHYSIOL-LONDON, V225, pP19; FOX R, 1967, PERCEPT PSYCHOPHYS, V2, P432, DOI 10.3758/BF03208783; Helmholtz H.von., 1924, PHYSL OPTICS; Levelt W., 1965, BINOCULAR RIVALRY; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; LOGOTHETIS NK, 1995, CURR BIOL, V5, P552, DOI 10.1016/S0960-9822(95)00108-4; WALKER P, 1975, PERCEPT PSYCHOPHYS, V18, P467, DOI 10.3758/BF03204122; WHITTLE P, 1968, PERCEPT PSYCHOPHYS, V4, P183, DOI 10.3758/BF03210465	12	646	652	2	61	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					549	553		10.1038/379549a0	http://dx.doi.org/10.1038/379549a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TU693	8596635				2022-12-24	WOS:A1996TU69300053
J	Nathanielsz, PW				Nathanielsz, PW			Fetal and neonatal environment has influence on brain development	LANCET			English	News Item														Nathanielsz, Peter/0000-0001-8410-6280					0	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					314	314		10.1016/S0140-6736(96)90479-1	http://dx.doi.org/10.1016/S0140-6736(96)90479-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569370	Bronze			2022-12-24	WOS:A1996TT48500020
J	Weber, GF; Ashkar, S; Glimcher, MJ; Cantor, H				Weber, GF; Ashkar, S; Glimcher, MJ; Cantor, H			Receptor-ligand interaction between CD44 and osteopontin (Eta-1)	SCIENCE			English	Article							T-CELL ACTIVATION; SECRETED PHOSPHOPROTEIN; OSTEO-SARCOMA; BONE; LINES; IMMUNOLOCALIZATION; ANTIBODIES; DEFINITION; EXPRESSION; PROTEIN	The CD44 family of surface receptors regulates adhesion, movement, and activation of normal and neoplastic cells. The cytokine osteopontin (Eta-1), which regulates similar cellular functions, was found to be a protein ligand of CD44. Osteopontin induces cellular chemotaxis but not homotypic aggregation, whereas the inverse is true for the interaction between CD44 and a carbohydrate ligand, hyaluronate. The different responses of cells after CD44 ligation by either osteopontin or hyaluronate may account for the independent effects of CD44 on cell migration and growth. This mechanism may also be exploited by tumor cells to promote metastasis formation.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT ORTHOPED RES,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School	Weber, GF (corresponding author), HARVARD UNIV,SCH MED,DEPT PATHOL,DANA FARBER CANC INST,DIV IMMUNOPATHOL,BOSTON,MA 02115, USA.		Eckhardt, Erik/G-1567-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012184, R01AI013600, R37AI012184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR034078] Funding Source: NIH RePORTER; NIAID NIH HHS [AI13600, AI12184] Funding Source: Medline; NIAMS NIH HHS [P01 AR34078] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANTHER UG, 1991, CELL, V65, P13; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARESU O, 1991, INVAS METAST, V11, P2; ASHKAR S, 1995, ANN NY ACAD SCI, V760, P296, DOI 10.1111/j.1749-6632.1995.tb44639.x; ASHKAR S, 1993, BIOCHEM BIOPH RES CO, V191, P126, DOI 10.1006/bbrc.1993.1193; BEHREND EI, 1994, CANCER RES, V54, P832; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DENNING SM, 1990, J IMMUNOL, V144, P7; HU MCT, 1992, COLD SPRING HARB SYM, V57, P291, DOI 10.1101/SQB.1992.057.01.034; HUET S, 1989, J IMMUNOL, V143, P798; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; MCKEE MD, 1990, ANAT REC, V228, P77, DOI 10.1002/ar.1092280112; MCKEE MD, 1992, ANAT REC, V234, P479, DOI 10.1002/ar.1092340404; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; PATARCA R, 1993, CRIT REV IMMUNOL, V13, P225; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; RODAN GA, 1995, ANN NY ACAD SCI, V760, P1, DOI 10.1111/j.1749-6632.1995.tb44614.x; ROTHMAN BL, 1991, J IMMUNOL, V147, P2493; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; SCHMIDT J, 1988, DIFFERENTIATION, V39, P151, DOI 10.1111/j.1432-0436.1988.tb00090.x; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; SENGER DR, 1989, ANTICANCER RES, V9, P1291; SINGH RP, 1990, J EXP MED, V171, P1931, DOI 10.1084/jem.171.6.1931; SPINELLA DG, 1987, J IMMUNOL, V138, P3991; VANDIJK S, 1993, J BONE MINER RES, V8, P1499; WASS JA, 1981, J NATL CANCER I, V66, P927; WEBER GF, 1995, IMMUNITY, V2, P363, DOI 10.1016/1074-7613(95)90144-2; YUE TL, 1994, EXP CELL RES, V214, P459, DOI 10.1006/excr.1994.1282	37	744	779	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					509	512		10.1126/science.271.5248.509	http://dx.doi.org/10.1126/science.271.5248.509			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560266				2022-12-24	WOS:A1996TR32200043
J	Evens, RG				Evens, RG			Appropriateness of routine chest radiography	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Evens, RG (corresponding author), WASHINGTON UNIV,DEPT RADIOL,ST LOUIS,MO 63130, USA.							FENGOLD AO, 1975, PUBLIC HLTH REP, V90, P544; RUCKER L, 1983, JAMA-J AM MED ASSOC, V250, P3209, DOI 10.1001/jama.250.23.3209; SAGEL SS, 1974, NEW ENGL J MED, V291, P1001, DOI 10.1056/NEJM197411072911904; 1993, ACR STANDARD ADULT C; 1983, HHS FDA838204 US DEP	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					326	326						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544276				2022-12-24	WOS:A1996TP96500033
J	Bickmore, WA; Oghene, K				Bickmore, WA; Oghene, K			Visualizing the spatial relationships between defined DNA sequences and the axial region of extracted metaphase chromosomes	CELL			English	Article							SCAFFOLD ATTACHMENT; NUCLEAR SCAFFOLD; REPLICATION; KINETOCHORE; LOOP; ORGANIZATION; GENOME; GENES; SITES; SIZE	Using fluorescence in situ hybridization to extracted metaphase chromosomes, we present visual evidence that specific human DNA sequences occupy distinctive positions with respect to the axial region of chromosomes and that the DNA is organized into loops emanating from this region. In a stretch of unique DNA on chromosome 11, large loops of DNA can be traced and one specific region associated with the axial region of the chromosome. Within rDNA, nontranscribed spacer sequences are more closely apposed to the chromosome axis than are rRNA genes. Heterochromatic and euchromatic DNAs appear to be organized into loops of similar size. We could not detect loops at centromeres; most alphoid DNA appears to remain close to the axial region.			Bickmore, WA (corresponding author), WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, CREWE RD, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		Bickmore, Wendy A/C-7314-2013	Bickmore, Wendy A/0000-0001-6660-7735				AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BAUMGARTNER M, 1991, CELL, V64, P761, DOI 10.1016/0092-8674(91)90505-S; BICKMORE WA, 1995, J CELL SCI, V108, P2801; BLUMENTHAL AB, 1979, J CELL BIOL, V81, P255, DOI 10.1083/jcb.81.1.255; BUONGIORNONARDELLI M, 1982, NATURE, V298, P100, DOI 10.1038/298100a0; CALLAN HG, 1982, PROC R SOC SER B-BIO, V214, P417, DOI 10.1098/rspb.1982.0020; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; COOK PR, 1994, BIOESSAYS, V16, P425, DOI 10.1002/bies.950160611; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; COOKE CA, 1993, J CELL BIOL, V120, P1083, DOI 10.1083/jcb.120.5.1083; COOKE H, 1976, NATURE, V262, P182, DOI 10.1038/262182a0; CREMISI F, 1988, CHROMOSOMA, V97, P204, DOI 10.1007/BF00292962; DIJKWEL PA, 1988, BIOESSAYS, V9, P147; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; EARNSHAW WC, 1984, J CELL BIOL, V98, P352, DOI 10.1083/jcb.98.1.352; EARNSHAW WC, 1983, J CELL BIOL, V96, P84, DOI 10.1083/jcb.96.1.84; FANTES J, 1995, HUM MOL GENET, V4, P415, DOI 10.1093/hmg/4.3.415; FANTES JA, 1995, GENOMICS, V25, P447, DOI 10.1016/0888-7543(95)80045-N; GASSER SM, 1989, INT REV CYTOL, V119, P57; GERDES MG, 1994, J CELL BIOL, V126, P289, DOI 10.1083/jcb.126.2.289; JACKSON DA, 1990, EMBO J, V9, P567, DOI 10.1002/j.1460-2075.1990.tb08144.x; JEPPESEN P, 1985, J CELL SCI, V73, P245; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; MARSDEN MPF, 1979, CELL, V17, P849, DOI 10.1016/0092-8674(79)90325-8; MIRKOVITCH J, 1988, J MOL BIOL, V200, P101, DOI 10.1016/0022-2836(88)90336-1; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MOENS PB, 1990, CHROMOSOMA, V100, P8, DOI 10.1007/BF00337598; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; RAZIN SV, 1993, COLD SPRING HARB SYM, V58, P25, DOI 10.1101/SQB.1993.058.01.006; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; SATYAPRAKASH KL, 1980, CHROMOSOMA, V81, P1, DOI 10.1007/BF00292418; TRASK BJ, 1991, AM J HUM GENET, V48, P1; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; YOON Y, 1995, MOL CELL BIOL, V15, P2482	37	63	65	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	1996	84	1					95	104		10.1016/S0092-8674(00)80996-4	http://dx.doi.org/10.1016/S0092-8674(00)80996-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548831	Bronze			2022-12-24	WOS:A1996TQ17000012
J	Trachtenberg, JT; Thompson, WJ				Trachtenberg, JT; Thompson, WJ			Schwann cell apoptosis at developing neuromuscular junctions is regulated by glial growth factor	NATURE			English	Article							NERVOUS-SYSTEM; MOTOR UNITS; MUSCLE; IDENTIFICATION; BIRTH; DEATH	DENERVATED adult mammalian muscle fibres are reinnervated by regenerating axons and, in the case of partially denervated muscles, by sprouts extended from remaining, intact axons(1,3). Recent experiments suggest that Schwann cells (SCs) regulate these events, inducing and guiding axonal outgrowth through the processes they extend(4,5). In contrast to adults, reinnervation of denervated neonatal muscles is deficient and axonal sprouting is absent(6-9). In light of the proposed roles for SCs in these processes, we examined whether SCs in neonatal muscles exhibit altered responses to denervation. We report here that neonatal denervation leads to the rapid, apoptotic death of SCs at rat neuromuscular junctions. Injection of glial growth factor, a member of the neuregulin family of trophic factors present in developing sensory and motor neurons(10), prevents this apoptosis in vivo. These results provide further evidence for the importance of SCs in regulating nerve grow,vth and suggest that axon-Schwann cell trophic interactions play a role in the normal development of the neuromuscular system.			Trachtenberg, JT (corresponding author), UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712, USA.							ASTROW SH, 1994, J NEUROBIOL, V25, P937, DOI 10.1002/neu.480250804; BETZ WJ, 1980, J PHYSIOL-LONDON, V303, P265, DOI 10.1113/jphysiol.1980.sp013284; BROWN MC, 1981, A REV NEUROSCI, V4, P57; DENNIS MJ, 1980, DEV BIOL, V74, P173, DOI 10.1016/0012-1606(80)90059-7; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MCARDLE JJ, 1977, J PHYSIOL-LONDON, V271, P567, DOI 10.1113/jphysiol.1977.sp012015; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; SON YJ, 1995, NEURON, V14, P125, DOI 10.1016/0896-6273(95)90246-5; SON YJ, 1995, NEURON, V14, P133, DOI 10.1016/0896-6273(95)90247-3; THOMPSON W, 1977, NEUROSCIENCE, V2, P523, DOI 10.1016/0306-4522(77)90049-5; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WERNIG A, 1986, PROG NEUROBIOL, V27, P251, DOI 10.1016/0301-0082(86)90023-7	18	250	254	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					174	177		10.1038/379174a0	http://dx.doi.org/10.1038/379174a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538769				2022-12-24	WOS:A1996TP36000061
J	YAMAGUCHI, K; SHIRAKABE, T; SHIBUYA, H; IRIE, K; OISHI, I; UENO, N; TANIGUCHI, T; NISHIDA, E; MATSUMOTO, K				YAMAGUCHI, K; SHIRAKABE, T; SHIBUYA, H; IRIE, K; OISHI, I; UENO, N; TANIGUCHI, T; NISHIDA, E; MATSUMOTO, K			IDENTIFICATION OF A MEMBER OF THE MAPKKK FAMILY AS A POTENTIAL MEDIATOR OF TGF-BETA SIGNAL-TRANSDUCTION	SCIENCE			English	Article							GROWTH-FACTOR-BETA; KINASE; GENE; EXPRESSION; CELLS; RAF	The mitogen-activated protein kinase (MAPK) pathway is a conserved beta eukaryotic signaling module that converts receptor signals into various outputs. MAPK is activated through phosphorylation by MAPK kinase (MAPKK), which is first activated by MAPKK kinase (MAPKKK). A genetic selection based on a MAPK pathway in yeast was used to identify a mouse protein kinase (TAK1) distinct from other members of the MAPKKK family. TAK1 was shown to participate in regulation of transcription by transforming growth factor-beta (TGF-beta). Furthermore, kinase activity of TAK1 was stimulated in response to TGF-beta and bone morphogenetic protein. These results suggest that TAK1 functions as a mediator in the signaling pathway of TGF-beta superfamily members.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,SAPPORO,HOKKAIDO 060,JAPAN; NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; KYOTO UNIV,INST VIRUS RES,DEPT GENET & MOLEC BIOL,SAKYO KU,KYOTO 60601,JAPAN; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	Hokkaido University; Nagoya University; Kyoto University; Osaka University			Oishi, Isao/L-8639-2018	Oishi, Isao/0000-0003-3682-5349; Ueno, Naoto/0000-0002-8375-2317				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIRAI R, COMMUNICATION; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; IRIE K, UNPUB; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OHTA S, 1992, FEBS LETT, V314, P356, DOI 10.1016/0014-5793(92)81505-G; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; SHIBUYA H, UNPUB; Shibuya K., UNPUB; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738	28	1158	1201	2	43	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					2008	2011		10.1126/science.270.5244.2008	http://dx.doi.org/10.1126/science.270.5244.2008			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533096				2022-12-24	WOS:A1995TL42000047
J	Hvass, U; Juliard, JM; Assayag, P; Laperche, T; Pansard, Y; Chatel, D				Hvass, U; Juliard, JM; Assayag, P; Laperche, T; Pansard, Y; Chatel, D			Tricuspid autograft for mitral-valve repair	LANCET			English	Article							REPLACEMENT	Background Transferring the posterior leaflet of the patient's own tricuspid Valve with its subvalvular apparatus to the mitral valve is a new technique that allows a conservative approach to mitral-valve repair. The technique is based on the knowledge that the tricuspid valve can be remodelled from tricuspid to bicuspid, with a very low risk of significant dysfunction. Methods We describe six patients (age range 20-70 years) with mitral insufficiency in whom we have used the technique. Findings All patients survived the operation and were in sinus rhythm. Transoesophageal echocardiography before discharge showed trivial or no regurgitation at the site of mitral repair. Before operation, all patients were in New York Heart Association class Ill-IV; at follow-up after 6-13 months all patients were in class I-II Interpretation Compared with using segments of mitral homografts in similar situations, the intraoperative availability of the tricuspid's viable natural chordae and valvular leaflet means that there are no immunological disadvantages to the procedure. With this new operation, the patient is his own tissue bank.	HOP BEAUJON, DEPT CARDIOL, CLICHY, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Hvass, U (corresponding author), HOP BICHAT, DEPT CARDIOL, F-75018 PARIS, FRANCE.		Assayag, Patrick/GPS-4910-2022	Assayag, Patrick/0000-0001-9406-4555				ACAR C, 1994, ANN THORAC SURG, V57, P746, DOI 10.1016/0003-4975(94)90582-7; CARPENTIER A, 1983, J THORAC CARDIOV SUR, V86, P323; CHAUVAUD S, 1991, J THORAC CARDIOV SUR, V102, P171; DAVID TE, 1991, J THORAC CARDIOV SUR, V101, P495; ELKINS RC, 1995, ANN THORAC SURG, V59, P269, DOI 10.1016/0003-4975(94)00974-C; Horskotte D, 1993, J Heart Valve Dis, V2, P150; HVASS U, 1986, ARCH MAL COEUR VAISS, V79, P103; KIRKLIN JW, 1993, CARDIAC SURG, P589; MATSUKI O, 1988, J THORAC CARDIOV SUR, V95, P705; OKADA Y, 1995, ANN THORAC SURG, V59, P658, DOI 10.1016/0003-4975(94)01008-0; 1967, LANCET, V2, P956	11	9	11	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	1996	347	9002					659	661		10.1016/S0140-6736(96)91206-4	http://dx.doi.org/10.1016/S0140-6736(96)91206-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596382				2022-12-24	WOS:A1996TZ28500014
J	McMillan, TJ				McMillan, TJ			Gene manipulation in radiotherapy	LANCET			English	Editorial Material											McMillan, TJ (corresponding author), UNIV LANCASTER,INST ENVIRONM & BIOL SCI,DIV BIOL SCI,LANCASTER LA1 4YQ,ENGLAND.							HALLAHAN DE, 1994, NATURE MED, V1, P85; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SURESH A, 1994, CANCER GENE THER, V1, P85; VILE RG, 1993, CANCER RES, V53, P962; WEISCHELBAUM RR, 1991, EUR J CANCER, V27, P405	6	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					632	632		10.1016/S0140-6736(96)91196-4	http://dx.doi.org/10.1016/S0140-6736(96)91196-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596372				2022-12-24	WOS:A1996TZ28500004
J	Wang, YK; Schnegelsberg, PNJ; Dausman, J; Jaenisch, R				Wang, YK; Schnegelsberg, PNJ; Dausman, J; Jaenisch, R			Functional redundancy of the muscle-specific transcription factors Myf5 and myogenin	NATURE			English	Article							REGULATORY GENE; EXPRESSION; MYOD; INACTIVATION; LETHALITY	The myogenic basic helix-loop-helix transcription factors, Myf5, MyoD, myogenin and MRF4, play key roles in skeletal muscle development(1,2). All of them induce myogenic differentiation in cultured non-muscle cells, suggesting that they might be functionally redundant. But the genes are expressed at different times during embryogenesis(3-6) and mice carrying a mutation in any of the genes have different phenotypes(7-13). A rib cage defect was observed in Myf5-deficient mice, which die perinatally(7). We investigated whether the rib cage defect was due to the failure of the early activation of the gene or to the unique interactions of Myf5 with specific downstream targets. For this we inserted a myogenin complementary DNA into the Myf5 locus by homologous recombination ,which simultaneously disrupted Myf5 function. We report here that mice homozygous for this myogenin gene knock-in (ki) developed a normal rib cage and were viable, therefore demonstrating functional redundancy of Myf5 and myogenin for rib formation.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT)	Wang, YK (corresponding author), MIT, WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.							BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1995, EMBO J, V14, P1176, DOI 10.1002/j.1460-2075.1995.tb07101.x; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OTT MO, 1991, DEVELOPMENT, V111, P1097; PATAPOUTIAN A, 1995, DEVELOPMENT, V121, P3347; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; TAJBAKHSH S, 1994, P NATL ACAD SCI USA, V91, P747, DOI 10.1073/pnas.91.2.747; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	21	126	134	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 29	1996	379	6568					823	825		10.1038/379823a0	http://dx.doi.org/10.1038/379823a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587605				2022-12-24	WOS:A1996TX50100058
J	Hennekens, CH; Lee, IM; Cook, NR; Hebert, PR; Karlson, EW; LaMotte, F; Manson, JE; Buring, JE				Hennekens, CH; Lee, IM; Cook, NR; Hebert, PR; Karlson, EW; LaMotte, F; Manson, JE; Buring, JE			Self-reported breast implants and connective-tissue diseases in female health professionals - A retrospective cohort study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WOMEN	Objective. - To evaluate the association of breast implants with connective-tissue diseases. Design and Participants. - Retrospective cohort study of 395 543 female health professionals who completed mailed questionnaires for potential participation in the Women's Health Study. A total of 10 830 women reported breast implants and 11 805 reported connective-tissue diseases between 1962 and 1991. Cox proportional hazards regression models were used in analyses. Main Outcome Measure. - Self-reported connective-tissue diseases. Results. - Compared with women who did not report breast implants, the relative risk (RR) of the combined end point of any connective-tissue disease among those who reported breast implants was 1.24 (95% confidence interval, 1.08 to 1.41, P=.0015). With respect to the individual diseases, the finding for other connective-tissue diseases (including mixed) was statistically significant (P=.017), the findings for rheumatoid arthritis, Sjogren's syndrome, dermatomyositis or polymyositis, or scleroderma were of borderline statistical significance (.05<P<.10), and the finding for systemic lupus erythematosus was not statistically significant (P=.44). There were no clear trends in RR with increasing duration of breast implants. Conclusion. - These self-reported data from female health professionals are compatible with prior reports from other cohort studies that exclude a large hazard, but do suggest small increased risks of connective-tissue diseases among women with breast implants. The very large sample size makes chance an unlikely explanation for the results, but bias due to differential overreporting of connective-tissue diseases or selective participation by affected women with breast implants remains a plausible alternative explanation. The major contribution of this and other observational analytic studies has been to exclude large risks of connective-tissue diseases following breast implants.	HARVARD UNIV,SCH MED,DIV PREVENT MED,BOSTON,MA; HARVARD UNIV,SCH MED,DIV RHEUMATOL IMMUNOL,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Hennekens, CH (corresponding author), BRIGHAM & WOMENS HOSP,DIV PREVENT MED,900 COMMONWEALTH AVE E,BOSTON,MA 02215, USA.		Lee, I-Min/ABD-5409-2021		NCI NIH HHS [CA-34944, CA-40360] Funding Source: Medline; NHLBI NIH HHS [HL-26490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGELL M, 1992, NEW ENGL J MED, V326, P1695, DOI 10.1056/NEJM199206183262510; BARTON TJ, 1983, ORGANOMETALLICS, V2, P1, DOI 10.1021/om00073a001; BORENSTEIN D, 1994, SEMIN ARTHRITIS RHEU, V24, P1, DOI 10.1016/0049-0172(94)90102-3; BRIDGES AJ, 1994, LANCET, V344, P1451, DOI 10.1016/S0140-6736(94)90284-4; BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; BUSCH H, 1994, SEMIN ARTHRITIS RHEU, V24, P11, DOI 10.1016/0049-0172(94)90104-X; CHOW HY, 1995, ARTHRITIS RHEUM, V38, P264; COOK RR, 1995, J CLIN EPIDEMIOL, V48, P519, DOI 10.1016/0895-4356(94)00208-8; COOK RR, 1994, ARTHRITIS RHEUM, V37, P153, DOI 10.1002/art.1780370202; COX DR, 1972, J R STAT SOC B, V34, P187; DUGOWSON CE, 1991, ARTHRITIS RHEUM-US, V34, P1502; DUGOWSON CE, 1992, ARTHRITIS RHEUM S192, V35, pS566; ENGLERT HJ, 1994, AUST NZ J MED, V24, P74, DOI 10.1111/j.1445-5994.1994.tb04439.x; FISHER JC, 1992, NEW ENGL J MED, V326, P1696, DOI 10.1056/NEJM199206183262511; FOREMAN J, 1992, BOSTON GLOBE    0125, P1; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; GILTAY EJ, 1994, ANN RHEUM DIS, V53, P194, DOI 10.1136/ard.53.3.194; GOLDMAN JA, 1995, J CLIN EPIDEMIOL, V48, P571, DOI 10.1016/0895-4356(94)00215-C; Hennekens CH, 1987, EPIDEMIOLOGY MED, P101; Hochberg M. C., 1994, Arthritis and Rheumatism, V37, pS369; Hochberg MC, 1995, LUPUS, V4, P454, DOI 10.1177/096120339500400606; KESSLER DA, 1992, NEW ENGL J MED, V326, P1713, DOI 10.1056/NEJM199206183262525; Kolata Gina, 1995, N Y Times Web, P6; KOSSOVSKY N, 1994, SEMIN ARTHRITIS RHEU, V24, P18, DOI 10.1016/0049-0172(94)90105-8; KUMAGAI Y, 1984, ARTHRITIS RHEUM-US, V27, P1, DOI 10.1002/art.1780270101; LITTLE R, 1987, STATISTICAL ANAL MIS; MCLAUGHLIN JK, 1994, J NATL CANCER I, V86, P1424, DOI 10.1093/jnci/86.18.1424; MICHET CJ, 1985, MAYO CLIN PROC, V60, P105, DOI 10.1016/S0025-6196(12)60294-8; ODDIS CV, 1990, J RHEUMATOL, V17, P1329; SANCHEZGUERRERO J, 1995, ANN INTERN MED, V122, P430, DOI 10.7326/0003-4819-122-6-199503150-00005; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; SCHUSTERMAN MA, 1993, ANN PLAS SURG, V31, P1; SILMAN A, 1988, BRIT J RHEUMATOL, V27, P286; STAR VL, 1993, ARTHRITIS RHEUM, V36, P510; STROM BL, 1994, J CLIN EPIDEMIOL, V47, P1211, DOI 10.1016/0895-4356(94)90109-0; SWAN SH, 1995, LANCET, V345, P319, DOI 10.1016/S0140-6736(95)90307-0; VASSEY FB, 1994, SEMIN ARTHRITIS RHEU, V24, P22; WELLS KE, 1994, PLAST RECONSTR SURG, V93, P907, DOI 10.1097/00006534-199404001-00002	39	205	210	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					616	621		10.1001/jama.275.8.616	http://dx.doi.org/10.1001/jama.275.8.616			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594243				2022-12-24	WOS:A1996TW62700022
J	Ammala, C; Moorhouse, A; Gribble, F; Ashfield, R; Proks, P; Smith, PA; Sakura, H; Coles, B; Ashcroft, SJH; Ashcroft, FM				Ammala, C; Moorhouse, A; Gribble, F; Ashfield, R; Proks, P; Smith, PA; Sakura, H; Coles, B; Ashcroft, SJH; Ashcroft, FM			Promiscuous coupling between the sulphonylurea receptor and inwardly rectifying potassium channels	NATURE			English	Article							K+ CHANNEL; ATP	SULPHONYLUREAS are a class of drugs widely used to treat non-insulin-dependent diabetes mellitus. These drugs act by binding to a sulphonylurea receptor (SUR) in the pancreatic beta-cell membrane which inhibits an ATP-sensitive potassium (K-ATP) channel and thereby stimulates insulin secretion. There has been much debate as to whether SUR and the K-ATP channel are the same or separate proteins, whether SUR confers ATP-sensitivity on an ATP-insensitive pore-forming subunit, and whether sulphonylureas can also modulate other types of K-channel. We show here that SUR itself does not possess intrinsic channel activity but that it endows sulphonylurea sensitivity on several types of inwardly-rectifying K-channels. It does not necessarily confer ATP-sensitivity on these channels.	UNIV OXFORD,PHYSIOL LAB,OXFORD OX1 3PT,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN BIOCHEM,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford			Moorhouse, Andrew J/B-8526-2011	Moorhouse, Andrew J/0000-0001-7957-2498; Proks, Peter/0000-0001-6097-3646; Smith, Paul/0000-0002-8710-6830; Gribble, Fiona/0000-0002-4232-2898	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT SJH, 1992, BIOCHIM BIOPHYS ACTA, V1175, P45, DOI 10.1016/0167-4889(92)90008-Y; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; THOMAS PM, 1995, SCIENCE, V268, P425; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; TSUCHIYA K, 1992, P NATL ACAD SCI USA, V89, P6418, DOI 10.1073/pnas.89.14.6418; ZUNCKLER BJ, 1988, N-S ARCH PHARMACOL, V337, P225	14	152	158	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					545	548		10.1038/379545a0	http://dx.doi.org/10.1038/379545a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596634				2022-12-24	WOS:A1996TU69300052
J	Krumholz, HM; Radford, MJ; Ellerbeck, EF; Hennen, J; Meehan, TP; Petrillo, M; Wang, Y; Jencks, SF				Krumholz, HM; Radford, MJ; Ellerbeck, EF; Hennen, J; Meehan, TP; Petrillo, M; Wang, Y; Jencks, SF			Aspirin for secondary prevention after acute myocardial infarction in the elderly: Prescribed use and outcomes	ANNALS OF INTERNAL MEDICINE			English	Article						aspirin; myocardial infarction; age factors; patient care characteristics; patient care planning	AGE; TRIALS	Objectives: To determine how often aspirin was prescribed as a discharge medication to eligible patients 65 years of age and older who were hospitalized with an acute myocardial infarction; to identify patient characteristics associated with the decision to use aspirin; and to evaluate the association between prescription of aspirin at discharge and 6-month survival. Design: Observational study. Setting: All 352 nongovernment, acute care hospitals in Alabama, Connecticut, Iowa, and Wisconsin. Patients: 5490 consecutive Medicare beneficiaries who survived an acute myocardial infarction, were hospitalized between June 1992 and February 1993, and did not have a contraindication to aspirin. Measurements: Medical charts were reviewed to obtain information on the prescription of aspirin at discharge, contraindications, patient demographic characteristics, and clinical factors. Results: 4149 patients (76%) were prescribed aspirin at hospital discharge. In a multivariable analysis, an increased prescribed use of aspirin at discharge was correlated with several indicators of better overall health status (better left ventricular ejection fraction, absence of diabetes, shorter length of hospital stay, higher albumin level, and discharge to the patient's home). The prescribed use of aspirin at discharge was also associated with several specific patterns of care, including the use of cardiac procedures, p-blocker therapy at discharge, and aspirin during the hospitalization. The prescribed use of aspirin at discharge was associated with a lower mortality rate 6 months after discharge compared with no prescribed aspirin (odds ratio, 0.77; 95% CI, 0.61 to 0.98), even after adjustment for baseline differences in demographic, clinical, and treatment characteristics between the two groups. Conclusions: Aspirin was not prescribed at discharge to 24% of elderly patients who were hospitalized with an acute myocardial infarction and did not have a contraindication to aspirin. Several patient characteristics were associated with a higher risk for not being prescribed aspirin. Increasing the prescription of aspirin for these patients may provide an excellent opportunity to improve their care.	UNIV CONNECTICUT, CTR HLTH, FARMINGTON, CT 06030 USA; CONNECTICUT PEER REVIEW ORG, MIDDLETOWN, CT 06457 USA; US HLTH CARE FINANCING ADM, BALTIMORE, MD 21207 USA; UNIV CONNECTICUT, SCH MED, FARMINGTON, CT 06030 USA	University of Connecticut; University of Connecticut	Krumholz, HM (corresponding author), YALE UNIV, SCH MED, CARDIOVASC SECT, 333 CEDAR ST, POB 208107, NEW HAVEN, CT 06520 USA.		Ellerbeck, Edward/I-8438-2014; , Harlan/AAI-2875-2020	Ellerbeck, Edward/0000-0002-7774-2729; Radford, Martha/0000-0001-7503-9557				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; AUDET AM, 1993, ANN INTERN MED, V119, P1209, DOI 10.7326/0003-4819-119-12-199312150-00008; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; GOLDBERG RJ, 1989, AM HEART J, V117, P543, DOI 10.1016/0002-8703(89)90727-8; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; KRUMHOLZ HM, 1995, CIRCULATION, V92, P2841, DOI 10.1161/01.CIR.92.10.2841; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; LANDWEHR JM, 1984, J AM STAT ASSOC, V79, P61, DOI 10.2307/2288334; MAGGIONI AP, 1993, NEW ENGL J MED, V329, P1442, DOI 10.1056/NEJM199311113292002; MEEHAN TP, 1995, ANN INTERN MED, V122, P928, DOI 10.7326/0003-4819-122-12-199506150-00007; MOORE JG, 1991, GASTROENTEROLOGY, V100, P1626, DOI 10.1016/0016-5085(91)90661-4; RODERICK PJ, 1993, BRIT J CLIN PHARMACO, V35, P219, DOI 10.1111/j.1365-2125.1993.tb05689.x; SILAGY CA, 1993, CLIN PHARMACOL THER, V54, P84, DOI 10.1038/clpt.1993.115	16	169	176	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					292	+		10.7326/0003-4819-124-3-199602010-00002	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554223				2022-12-24	WOS:A1996TR59600002
J	Leatherwood, J; LopezGirona, A; Russell, P				Leatherwood, J; LopezGirona, A; Russell, P			Interaction of Cdc2 and Cdc18 with a fission yeast ORC2-like protein	NATURE			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; S-PHASE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; SEQUENCE-ANALYSIS; CELL-CYCLE; MITOSIS; GENE; SYSTEM	IN fission yeast, Cdc2 kinase has both positive and negative roles in regulating DNA replication, being first necessary for the transition from G(1) to S phase and later required to prevent the re-initiation of DNA replication during G(2)(1-3). We report here that Cdc2 interacts with Orp2, a protein similar to the Orc2 replication factor subunit of Saccharomyces cerevisiae origin recognition complex (ORC). ORC binds chromosomal origins and is essential for chromosomal replication initiation(4-6). Fission yeast Orp2 is required for DNA replication and interacts with the rate-limiting replication activator Cdc18. Cells lacking Orp2 undergo aberrant mitosis, indicating that Orp2 is involved in generating a checkpoint signal, These findings suggest that ORC functions are conserved among eukaryotes and provide evidence that Cdc2 controls DNA replication initiation by acting directly at chromosomal origins.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute								ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MAIER E, 1992, NAT GENET, V1, P273, DOI 10.1038/ng0792-273; MAUNDRELL K, 1985, NUCLEIC ACIDS RES, V13, P3711, DOI 10.1093/nar/13.10.3711; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAUNDRELL K, 1988, EMBO J, V7, P2203, DOI 10.1002/j.1460-2075.1988.tb03059.x; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; ZHOU C, 1989, J BIOL CHEM, V264, P9022	28	109	114	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					360	363		10.1038/379360a0	http://dx.doi.org/10.1038/379360a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552194				2022-12-24	WOS:A1996TR32300063
J	Sondek, J; Bohm, A; Lambright, DG; Hamm, HE; Sigler, PB				Sondek, J; Bohm, A; Lambright, DG; Hamm, HE; Sigler, PB			Crystal structure of a G(A) protein beta gamma dimer at 2.1 angstrom resolution	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SUBUNIT; PHEROMONE	MANY signalling cascades use seven-helical transmembrane receptors coupled to heterotrimeric G proteins (G(alpha beta gamma)) to convert extracellular signals into intracellular responses(1). Upon nucleotide exchange catalysed by activated receptors, heterotrimers dissociate into GTP-bound G(alpha) subunits and G(beta gamma) dimers, either of which can modulate many downstream effectors(2,3). Here we use multiwavelength anomalous diffraction data to solve the crystal structure of the beta gamma dimer of the G protein transducin. The beta-subunit is primarily a seven-bladed beta-propeller that is partially encircled by an extended gamma-subunit. The beta-propeller, which contains seven structurally similar WD repeats, defines the stereochemistry of the WD repeat and the probable architecture of all WD-repeat-containing domains. The structure details interactions between G protein beta- and gamma-subunits and highlights regions implicated in effector modulation for the conserved family of G protein beta gamma dimers.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60612	Yale University; Howard Hughes Medical Institute; Yale University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Hamm, Heidi E/G-2374-2014	Sondek, John/0000-0002-1127-8310				BIGAY J, 1994, METHOD ENZYMOL, V237, P139; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GAMISTEN A, 1993, P NATL ACAD SCI USA, V90, P7706; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GRISHIN AV, 1994, MOL CELL BIOL, V14, P4571, DOI 10.1128/MCB.14.7.4571; GRISHIN AV, 1994, GENETICS, V138, P1081; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KATZ A, 1995, P NATL ACAD SCI USA, V92, P1998, DOI 10.1073/pnas.92.6.1998; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE CH, 1995, J BIOL CHEM, V270, P8779, DOI 10.1074/jbc.270.15.8779; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MURZIN AG, 1992, PROTEINS, V14, P191, DOI 10.1002/prot.340140206; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; UEDA N, 1994, J BIOL CHEM, V269, P4388; VANDERVOOM L, 1992, FEBS LETT, V30, P131; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223	32	688	705	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					369	374		10.1038/379369a0	http://dx.doi.org/10.1038/379369a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552196				2022-12-24	WOS:A1996TR32300065
J	Livingston, G; Manela, M; Katona, C				Livingston, G; Manela, M; Katona, C			Depression and other psychiatric morbidity in carers of elderly people living at home	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE RATES; COMMUNITY; DEMENTIA; RELATIVES	Objective-To describe the mental health of a community sample of carers of elderly people with dementia, depression, or physical disability and to compare that with the mental health of other adults living in the household and of those living alone. Design-Assessment of psychiatric morbidity and physical disability with standardised questionnaire in randomly selected enumeration districts; subjects were interviewed at home. Setting-London Borough of Islington. Subjects-700 people aged greater than or equal to 65 and other co-residents. Main outcome measure-Depression measured with standardised interview. Results-The prevalence of depression was not significantly higher in carers overall (15%) than in coresidents (11%). Being a woman carer was a significant predictor of psychiatric illness. Depression was more common in the carers of people with a psychiatric disorder than in coresidents (24% v 11%, P < 0.05) and in those living alone (19%). Depression was most common (47%) in women carers of people with dementia. Conclusion-The increase in psychiatric morbidity reported in carers of people with psychiatric disorders may reflect the lack of a confiding relationship.			Livingston, G (corresponding author), UCL, SCH MED, DEPT PSYCHIAT, MORTIMER ST, LONDON W1N 8AA, ENGLAND.		Livingston, G/C-7081-2008	Katona, Cornelius/0000-0001-7451-0167; Livingston, Gill/0000-0001-6741-5516				[Anonymous], 1993, ICD 10 CLASSIFICATIO; BERGMANN K, 1983, ELDERLY PEOPLE COMMU; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; COLLINS C, 1992, RECENT ADV PSYCHOGER, P153; COPELAND JRM, 1987, BRIT J PSYCHIAT, V150, P815, DOI 10.1192/bjp.150.6.815; EAGLES JM, 1987, BRIT J PSYCHIAT, V150, P293, DOI 10.1192/bjp.150.3.293; Foulds G. A, 1976, HIERARCHICAL NATURE; GEORGE LK, 1986, GERONTOLOGIST, V26, P253, DOI 10.1093/geront/26.3.253; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GURLAND B, 1984, J GERONTOL, V39, P166, DOI 10.1093/geronj/39.2.166; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; KAY DWK, 1985, PSYCHOL MED, V15, P771, DOI 10.1017/S0033291700005006; LEVIN E, 1989, FAMILIES SERVICES CO; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; LINDESAY J, 1989, BRIT J PSYCHIAT, V155, P317, DOI 10.1192/bjp.155.3.317; LIVINGSTON G, 1990, PSYCHOL MED, V20, P137, DOI 10.1017/S0033291700013313; MANELA M, IN PRESS INT J GERIA; Murray J., 1995, PREVENTION ANXIETY D; NORUSIS MJ, SPSSPC4; OCONNOR DW, 1990, BRIT J PSYCHIAT, V156, P835, DOI 10.1192/bjp.156.6.835; PARKER G, DHSS715 U YORK SOC P; WADE DT, 1986, BRIT MED J, V293, P418, DOI 10.1136/bmj.293.6544.418; WING JK, 1976, PSYCHOL MED, V6, P665; 1987, GENERAL HOUSEHOLD SU	24	111	111	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					153	156						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TR325	8563534				2022-12-24	WOS:A1996TR32500022
J	MacLean, JD; Arthur, JR; Ward, BJ; Gyorkos, TW; Curtis, MA; Kokoskin, E				MacLean, JD; Arthur, JR; Ward, BJ; Gyorkos, TW; Curtis, MA; Kokoskin, E			Common-source outbreak of acute infection due to the North American liver fluke Metorchis conjunctus	LANCET			English	Article								Background We investigated an outbreak of acute clinical illness among 19 people who ate raw fish (sashimi) prepared from the white sucker, Catostomus commersoni, caught in a river north of Montreal, Canada. Methods We collected epidemiological, clinical, laboratory, and serological data on 19 individuals who ate the sashimi and six who did not. Because of the suggestive clinical picture, we set out to recover helminth parasites from uneaten fish. Findings The illness consisted of persistent upper abdominal pain, low grade fever, high blood eosinophil concentrations, and raised liver enzymes. After 10 days, opisthorchiid-like eggs were found in stools. Symptoms persisted for 3 days to 4 weeks without treatment, but responded rapidly to praziquantel therapy. Necropsy of golden hamsters infected with metacercariae from uneaten fish revealed adult flukes identified as Metorchis conjunctus. Interpretation We describe an acute illness caused by the North American liver fluke M conjunctus. This is a new human disease and is the first report of a common-source outbreak of an acute illness caused by liver flukes of the family Opisthorchiidae.	FISHERIES & OCEANS CANADA, MAURICE LAMONTAGNE INST, MONTREAL, PQ, CANADA; MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, MONTREAL, PQ, CANADA; MCGILL UNIV, INST PARASITOL, MONTREAL, PQ, CANADA	Fisheries & Oceans Canada; McGill University; McGill University	MacLean, JD (corresponding author), MCGILL UNIV, MONTREAL GEN HOSP, CTR TROP DIS, 1650 CEDAR AVE, MONTREAL, PQ H3G 1A4, CANADA.							ALLEN J. A., 1934, CANADIAN JOUR RES, V10, P404; BABERO BERT B., 1952, PROC HELMINTHOL SOC WASHINGTON, V19, P15; BRASSARD P, 1985, CAN J PUBLIC HEALTH, V76, P322; BRONSHTEIN AM, 1985, MED PARAZITOL MOSK, V5, P31; Burch J. B, 1982, FRESHWATER SNAILS MO; CAMERON T W M, 1945, Can J Comp Med Vet Sci, V9, P302; Cameron Thomas W. M., 1944, CANADIAN JOUR RES SECT D ZOOL SCI, V22, P6; CAMERON THOMAS W. M., 1940, CANADIAN JOUR RES SECT D ZOOL SCI, V18, P325; CARTWRIGHT GE, 1949, AM J MED, V6, P259, DOI 10.1016/0002-9343(49)90021-2; CLARKE A.H., 1981, FRESHWATER MOLLUSCS; Cobbold T. S., 1860, P LINNEAN SOC LONDON, V17, P1; DITRICH O, 1992, FOLIA PARASIT, V39, P123; EVANS WS, 1963, THESIS U MANITOBA WI; FREEMAN AE, 1937, T AM MICROSC SOC, V57, P113; HARKEMA R, 1964, J PARASITOL, V50, P60, DOI 10.2307/3276029; HASWELLELKINS MR, 1992, J GASTROEN HEPATOL, V7, P538, DOI 10.1111/j.1440-1746.1992.tb01035.x; KOENIGSTEIN RP, 1949, T ROY SOC TROP MED H, V42, P503, DOI 10.1016/0035-9203(49)90057-7; LEE D.S., 1980, ATLAS N AM FRESHWATE; MEL'NIKOV V I, 1979, Meditsinskaya Parazitologiya i Parazitarnye Bolezni, V48, P12; Mongeau N, 1961, Can Vet J, V2, P33; Rim H.-J., 1986, Korean Journal of Parasitology, V24, P1; Scott W. B., 1973, FISHERIES RES BOARD; SKRJABIN K.I., 1950, TREMATODES ANIMALS M, V4; SMITH JW, 1975, INT J PARASITOL, V5, P133, DOI 10.1016/0020-7519(75)90019-3; WATSON TG, 1979, CAN J PUBLIC HEALTH, V70, P179; WATSON TG, 1979, THESIS MCGILL U MONT; WOBESER G, 1983, J WILDLIFE DIS, V19, P353; XU Z, 1979, CHIN MED J, V93, P423; YOUNG KH, 1979, J CLIN MICROBIOL, V10, P852, DOI 10.1128/JCM.10.6.852-853.1979; 1995, WHO TECH REP SER, P849	30	32	38	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 20	1996	347	8995					154	158		10.1016/S0140-6736(96)90342-6	http://dx.doi.org/10.1016/S0140-6736(96)90342-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544550				2022-12-24	WOS:A1996TQ24400011
J	Ertem, G; Ferris, JP				Ertem, G; Ferris, JP			Synthesis of RNA oligomers on heterogeneous templates	NATURE			English	Article							5'-PHOSPHORIMIDAZOLIDE; RIBONUCLEOTIDES; MONTMORILLONITE; RIBOZYME; REPLICATION; ADENOSINE; MINERALS; CATALYST; MODEL; LIFE	THE concept of an RNA world(1,2) in the chemical origin of life is appealing, as nucleic acids are capable of both information storage and acting as templates that catalyse the synthesis of complementary molecules(3). Template-directed synthesis has been demonstrated for homogeneous oligonucleotides that, like natural nucleic acids, have 3',5' linkages between the nucleotide monomers(4-7). But it seems likely that prebiotic routes to RNA-like molecules would have produced heterogeneous molecules,vith various kinds of phosphodiester linkages and both linear and cyclic nucleotide chains. Here we show that such heterogeneity need be no obstacle to the templating of complementary molecules. Specifically, we show that heterogeneous oligocytidylates, formed by the montmorillonite clay-catalysed condensation of actuated monomers, can serve as templates for the synthesis of oligoguanylates. Furthermore, we show that oligocytidylates that are exclusively 2',5'-linked can also direct synthesis of oligoguanylates. Such heterogeneous templating reactions could have increased the diversity of the pool of protonucleic acids from which life ultimately emerged.			Ertem, G (corresponding author), RENSSELAER POLYTECH INST,DEPT CHEM,TROY,NY 12180, USA.							ATKINS RF, 1993, RNA WORLD; DOUDNA JA, 1993, BIOCHEMISTRY-US, V32, P2111, DOI 10.1021/bi00059a032; DOUDNA JA, 1991, SCIENCE, V251, P1605, DOI 10.1126/science.1707185; DOUGHERTY JP, 1992, J AM CHEM SOC, V114, P6254, DOI 10.1021/ja00041a058; FERRIS JP, 1993, J AM CHEM SOC, V115, P12270, DOI 10.1021/ja00079a006; FERRIS JP, 1992, ORIGINS LIFE EVOL B, V22, P369, DOI 10.1007/BF01809373; FERRIS JP, 1992, SCIENCE, V257, P1387, DOI 10.1126/science.1529338; FERRIS JP, 1993, ORIGINS LIFE EVOL B, V23, P229, DOI 10.1007/BF01581901; FERRIS JP, 1993, ORIGINS LIFE EVOL B, V23, P307, DOI 10.1007/BF01582081; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GREEN R, 1992, SCIENCE, V258, P1910, DOI 10.1126/science.1470913; GRZESKOWIAK K, 1986, J MOL EVOL, V23, P287, DOI 10.1007/BF02100635; HOHN T, 1967, BIOCHIM BIOPHYS ACTA, V138, P466, DOI 10.1016/0005-2787(67)90543-6; INOUE T, 1981, J AM CHEM SOC, V103, P7666, DOI 10.1021/ja00415a051; INOUE T, 1983, SCIENCE, V219, P859, DOI 10.1126/science.6186026; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; JUNG KE, 1994, J AM CHEM SOC, V116, P6059, DOI 10.1021/ja00093a001; KAWAMURA K, 1994, J AM CHEM SOC, V116, P7564, DOI 10.1021/ja00096a013; KIERZEK R, 1992, NUCLEIC ACIDS RES, V20, P1685, DOI 10.1093/nar/20.7.1685; LI T, 1994, NATURE, V369, P218, DOI 10.1038/369218a0; LOHRMANN R, 1980, SCIENCE, V208, P1464, DOI 10.1126/science.6247762; LOHRMANN R, 1982, J MOL EVOL, V18, P185, DOI 10.1007/BF01733045; ORGEL LE, 1992, NATURE, V358, P203, DOI 10.1038/358203a0; PRABAHAR KJ, 1994, J AM CHEM SOC, V116, P10914, DOI 10.1021/ja00103a006; SAWAI H, 1976, J AM CHEM SOC, V98, P7037, DOI 10.1021/ja00438a050; SAWAI H, 1992, J CHEM SOC PERK T 1, P505, DOI 10.1039/p19920000505; SIEVERS D, 1994, NATURE, V369, P221, DOI 10.1038/369221a0; STRIBLING R, 1991, J CHROMATOGR, V538, P474, DOI 10.1016/S0021-9673(01)88872-5	28	127	143	0	48	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					238	240		10.1038/379238a0	http://dx.doi.org/10.1038/379238a0			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538788				2022-12-24	WOS:A1996TQ16900040
J	Italiano, JE; Roberts, TM; Stewart, M; Fontana, CA				Italiano, JE; Roberts, TM; Stewart, M; Fontana, CA			Reconstitution in vitro of the motile apparatus from the amoeboid sperm of Ascaris shows that filament assembly and bundling move membranes	CELL			English	Article							HEAVY-CHAIN GENE; AMEBOID SPERM; PROTEIN MSP; DICTYOSTELIUM-DISCOIDEUM; CELL LOCOMOTION; ACTIN; NEMATODE; SUUM; CYTOSKELETON; PONTICULIN	We have developed an in vitro motility system from Ascaris sperm, unique amoeboid cells that use filament arrays composed of major sperm protein (MSP) instead of an actin-based apparatus for locomotion. Addition of ATP to sperm extracts induces formation of fibers similar to 2 mu m in diameter. These fibers display the key features of the MSP cytoskeleton in vivo. Each fiber consists of a meshwork of MSP filaments and has at one end a vesicle derived from the plasma membrane at the leading edge of the cell. Fiber growth is due to filament assembly at the vesicle; thus, fiber elongation results in vesicle translocation, This in vitro system demonstrates directly that localized polymerization and bundling of filaments can move membranes acid provides a powerful assay for evaluating the molecular mechanism of amoeboid cell motility.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	Italiano, JE (corresponding author), FLORIDA STATE UNIV,DEPT BIOL SCI,B-157,TALLAHASSEE,FL 32306, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029994, R01GM029994] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29994] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHIA CP, 1993, J CELL BIOL, V120, P909, DOI 10.1083/jcb.120.4.909; CONDEELIS J, 1992, CELL MOTIL CYTOSKEL, V22, P1, DOI 10.1002/cm.970220102; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; COOPER JA, 1991, ANN REV PHYSL, V53, P584; COSSART P, 1994, MOL MICROBIOL, V13, P395, DOI 10.1111/j.1365-2958.1994.tb00434.x; COX D, 1992, J CELL BIOL, V116, P943, DOI 10.1083/jcb.116.4.943; CRAMER LP, 1994, CURR OPIN CELL BIOL, V6, P82, DOI 10.1016/0955-0674(94)90120-1; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; FORSCHER P, 1992, NATURE, V357, P515, DOI 10.1038/357515a0; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HEATH JP, 1991, CELL MOTIL CYTOSKEL, V18, P245, DOI 10.1002/cm.970180402; HITT AL, 1994, J CELL BIOL, V126, P1433, DOI 10.1083/jcb.126.6.1433; Inoue S, 1986, VIDEO MICROSCOPY; KING KL, 1994, J CELL SCI, V107, P2941; KING KL, 1994, CELL MOTIL CYTOSKEL, V27, P193, DOI 10.1002/cm.970270302; KING KL, 1992, J CELL SCI, V101, P847; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; Lee Juliet, 1993, Trends in Cell Biology, V3, P366, DOI 10.1016/0962-8924(93)90084-E; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Oliver Tim, 1994, Seminars in Cell Biology, V5, P139, DOI 10.1006/scel.1994.1018; PESKIN CS, 1993, BIOPHYS J, V65, P316, DOI 10.1016/S0006-3495(93)81035-X; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; RIS H, 1985, J CELL BIOL, V100, P1474, DOI 10.1083/jcb.100.5.1474; ROBERTS TM, 1995, CURR OPIN CELL BIOL, V7, P13, DOI 10.1016/0955-0674(95)80039-5; ROBERTS TM, 1991, CELL MOTIL CYTOSKEL, V20, P228, DOI 10.1002/cm.970200306; ROYAL D, 1995, CELL MOTIL CYTOSKEL, V31, P241, DOI 10.1002/cm.970310307; SEPSENWOL S, 1986, J PARASITOL, V72, P962, DOI 10.2307/3281855; SEPSENWOL S, 1989, J CELL BIOL, V108, P55, DOI 10.1083/jcb.108.1.55; SHARIFF A, 1990, J CELL BIOL, V110, P681, DOI 10.1083/jcb.110.3.681; SOUTHWICK FS, 1994, BIOESSAYS, V16, P885, DOI 10.1002/bies.950161206; STEWART M, 1993, J MOL BIOL, V232, P298, DOI 10.1006/jmbi.1993.1383; STEWART M, 1994, J MOL BIOL, V242, P60; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; Theriot Julie A., 1992, Trends in Cell Biology, V2, P219, DOI 10.1016/0962-8924(92)90298-2; Tilney Lewis G., 1993, Trends in Microbiology, V1, P25, DOI 10.1016/0966-842X(93)90021-I; TILNEY LG, 1982, J CELL BIOL, V93, P820, DOI 10.1083/jcb.93.3.820; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; WARD S, 1981, J CELL BIOL, V91, P26, DOI 10.1083/jcb.91.1.26; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; ZIGMOND SH, 1993, CELL MOTIL CYTOSKEL, V25, P309, DOI 10.1002/cm.970250402	43	96	98	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					105	114		10.1016/S0092-8674(00)80997-6	http://dx.doi.org/10.1016/S0092-8674(00)80997-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548814	Bronze			2022-12-24	WOS:A1996TQ17000013
J	ONeill, EM; Kaffman, A; Jolly, ER; OShea, EK				ONeill, EM; Kaffman, A; Jolly, ER; OShea, EK			Regulation of PHO4 nuclear localization by the PHO80-PHO85 cyclin-CDK complex	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; YEAST; PHOSPHORYLATION; SEQUENCES; PROMOTER	PHO4, a transcription factor required for induction of the PHO5 gene in response to phosphate starvation, is phosphorylated by the PHO80-PHO85 cyclin-CDK (cyclin-dependent kinase) complex when yeast are grown in phosphate-rich medium. PHO4 was shown to be concentrated in the nucleus when yeast were starved for phosphate and was predominantly cytoplasmic when yeast were grown in phosphate-rich medium. The sites of phosphorylation on PHO4 were identified, and phosphorylation was shown to be required for full repression of PHO5 transcription when yeast were grown in high phosphate. Thus, phosphorylation of PHO4 by PHO80-PHO85 turns off PHO5 transcription by regulating the nuclear localization of PHO4.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco			Jolly, Emmitt R/I-6646-2012	Jolly, Emmitt R/0000-0002-7141-2307				BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; FISHER F, 1991, ONCOGENE, V6, P1099; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; JAYARAMAN PS, 1994, EMBO J, V13, P2192, DOI 10.1002/j.1460-2075.1994.tb06496.x; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; OCONNELL KF, 1992, GENETICS, V132, P63; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; ONEILL EM, UNPUB; OSHEA EK, UNPUB; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; YOSHIDA K, 1989, MOL GEN GENET, V217, P40, DOI 10.1007/BF00330940	20	274	279	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	1996	271	5246					209	212		10.1126/science.271.5246.209	http://dx.doi.org/10.1126/science.271.5246.209			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539622				2022-12-24	WOS:A1996TP36400044
J	Hiss, RG				Hiss, RG			Barriers to care in non-insulin-dependent diabetes mellitus - The Michigan experience	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat				Objective: To determine the barriers to optimal care at the community level for patients with non-insulin-dependent diabetes mellitus (NIDDM). Design: Comprehensive evaluation of the clinical, psychosocial, and educational status of community-based patients with NIDDM, with subsequent review by local diabetes advisory councils of this status and the care those patients have received. The frequency with which patients visited their physician for diabetes management, received patient education, received diet counseling, and were examined by an ophthalmologist-four services universally recognized to be components of optimal diabetes care-was determined for all patients. Setting: Eight Michigan communities, four large and four small. Patients: From 1988 to 1994, 1056 patients with NIDDM (defined by stimulated C-peptide criteria) were studied. Results: The frequency with which all patients with NIDDM visited their community primary care physician in 1994 was 3.7 times per year (4.6 times for patients taking insulin and 3.2 times for those not taking insulin). Thirty-three percent of all patients with NIDDM (48% of those taking insulin and 24% of those not taking insulin) had received all three other essential services, whereas 15% (6% taking insulin and 20% not taking insulin) had never received any of these services. Factors contributing to this level of care and barriers preventing more intensive management of community-based patients with NIDDM were identified by the diabetes advisory councils as they analyzed data from their own communities. The councils determined that the main barriers to optimal care of community-based patients with NIDDM are that 1) NIDDM is not considered or managed as a serious problem by most physicians and their patients; 2) the genetic basis for and refractory nature of obesity are not generally appreciated; and 3) as a complex, multisystemic chronic illness, diabetes fits poorly in a health care delivery system designed to deal with acute and episodic illnesses. Conclusion: Most community-based patients with NIDDM are not aggressively managed because of attitudinal, educational, and systemic factors that act as barriers to optimal health care delivery.			Hiss, RG (corresponding author), UNIV MICHIGAN, SCH MED, CTR DIABET RES & TRAINING, G1103 TOWSLEY CTR, BOX 0201, ANN ARBOR, MI 48109 USA.				NIADDK NIH HHS [P60-AM-20572] Funding Source: Medline	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1994, DIABETES CARE, V17, P519; [Anonymous], 1994, Diabetes Care, V17, P616; DCCT Res Grp, 1986, DIABETES, V35, P530; HISS RG, 1994, DIABETES CARE, V17, P1124, DOI 10.2337/diacare.17.10.1124; HISS RG, 1992, DIABETES COMMUNITIES, V2; HORTON ES, 1990, DIABETES MELLITUS TH, P457; LEWIS C E, 1988, American Journal of Preventive Medicine, V4, P9; Logsdon D N, 1984, J Ambul Care Manage, V7, P46; LURIE N, 1987, AM J PUBLIC HEALTH, V77, P801, DOI 10.2105/AJPH.77.7.801; MARX J, 1994, SCIENCE, V266, P1477, DOI 10.1126/science.7985012; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; 1989, GUIDE CLIN PREVENTIV, pR19; 1995, DIABETES CARE S1, V18, P1	13	76	76	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				146	148		10.7326/0003-4819-124-1_Part_2-199601011-00012	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554207				2022-12-24	WOS:A1996TL94400012
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PUBLIC WORKSHOP ON PRESCRIPTION DRUG INFORMATION FOR PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, FED REG         0824, V60, P44182; 1995, JAMA-J AM MED ASSOC, V274, P1109	2	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1903	1903						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568972				2022-12-24	WOS:A1995TL16900010
J	Hengst, L; Reed, SI				Hengst, L; Reed, SI			Translational control of p27(Kip1) accumulation during the cell cycle	SCIENCE			English	Article							KINASES; TUMOR	Cell cycle phase transitions in eukaryotic cells are driven by regulation of the activity of protein kinases known as cyclin-dependent kinases (Cdks). A broad spectrum Cdk-inhibitory activity associated with a 28-kilodalton protein (p28(lck1)) was induced in cells treated with the drug lovastatin or upon density-mediated growth arrest and was periodic in the cell cycle, with peak activity in G(1). The p28(lck1) protein was shown to be identical to p27(Kip1), and the periodic or induced inhibitory activity resulted from a periodic accumulation of the protein. Variations in the amount of p27 protein occurred, whereas the abundance of the p27 messenger RNA remained unchanged. In every instance investigated, the posttranscriptional alteration of p27 protein levels was achieved in part by a mechanism of translational control, although in density-arrested fibroblasts and thymidine-arrested HeLa cells the half-life of the protein was also changed.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				Hengst, Ludger/0000-0002-0605-0223	NIGMS NIH HHS [GM46006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM046006] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUNCE CM, 1994, LEUKEMIA, V8, P595; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1994, MOL CELL BIOL, V14, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HENGST L, UNPUB; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; MATRSUOKA S, 1995, GENE DEV, V9, P650; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	28	814	840	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1861	1864		10.1126/science.271.5257.1861	http://dx.doi.org/10.1126/science.271.5257.1861			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596954				2022-12-24	WOS:A1996UC77800045
J	Cane, EJ; Portmann, BC; Naoumov, NV; Smith, HM; Underhill, JA; Donaldson, PT; Maertens, G; Williams, R				Cane, EJ; Portmann, BC; Naoumov, NV; Smith, HM; Underhill, JA; Donaldson, PT; Maertens, G; Williams, R			Long-term outcome of hepatitis C infection after liver transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; NON-A; VIRUS	Background. End-stage cirrhosis related to hepatitis C virus (HCV) is a common reason for liver transplantation, although viremia is known to persist in most cases. We investigated the impact of persistent HCV infection after liver transplantation on patient and graft survival and the effects of the HCV genotype and the degree of HLA matching between donor and recipient on the severity of recurrent hepatitis. Methods. A group of 149 patients with HCV infection who received liver transplants between January 1982 and April 1994 were followed for a median of 36 months; 623 patients without HCV infection who underwent liver transplantation for end-stage chronic liver disease were used as a control group, A total of 528 liver-biopsy specimens from the HCV-infected recipients were reviewed, including 82 obtained one year after transplantation as scheduled and 39 obtained at five years as scheduled. In addition, biopsy specimens were obtained from 91 of the HCV-negative patients five years after transplantation. Results. Cumulative survival rates for the 149 patients with HCV infection were 79 percent after one year, 74 percent after three years, and 70 percent after five years, as compared with rates of 75 percent, 71 percent, and 69 percent, respectively, in the HCV-negative transplant recipients (P = 0.12). Of the 130 patients with hepatitis C infection who survived more than 6 months after transplantation, 15 (12 percent) had no evidence of chronic hepatitis on their most recent liver biopsy (median followup, 20 months), 70 (54 percent) had mild chronic hepatitis (median, 35 months), 35 (27 percent) had moderate chronic hepatitis (median, 35 months), and 10 (8 percent) had cirrhosis (median, 51 months). Graft loss occurred after a median of 303 days in 27 of the 149 patients, including 5 with HCV-related cirrhosis and 3 with HCV-related cholestatic hepatitis. Infection with HCV genotype Ib was associated with more severe graft injury, whereas the primary immunosuppressive regimen used and the extent of HLA mismatching between donors and recipients had no significant effect on this variable. Conclusions. After liver transplantation for HCV-related cirrhosis, persistent HCV infection can cause severe graft damage, and such damage is more frequent in patients infected with HCV genotype 1b than with other genotypes. After five years, the rates of graft and overall survival are similar between patients with and those without HCV infection. (C) 1996, Massachusetts Medical Society.	UNIV LONDON KINGS COLL, SCH MED & DENT, INST LIVER STUDIES, LONDON SE5 9PJ, ENGLAND; IMMUNOGENET, GHENT, BELGIUM	University of London; King's College London			Yang, Chen/G-1379-2010					ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; [Anonymous], 1994, Lancet, V344, P423; Armitage P., 2001, STAT METHODS MED RES; ASCHER NL, 1994, HEPATOLOGY, V20, pS24; BALLARDINI G, 1995, J CLIN INVEST, V95, P2067, DOI 10.1172/JCI117893; BOTARELLI P, 1993, GASTROENTEROLOGY, V104, P580, DOI 10.1016/0016-5085(93)90430-K; BUSUTTIL RW, 1994, NEW ENGL J MED, V331, P1110; CASAVILLA A, 1994, HEPATOLOGY, V20, pA133; CHAZOUILLERES O, 1994, GASTROENTEROLOGY, V106, P994, DOI 10.1016/0016-5085(94)90759-5; Cox D. R., 1984, ANAL SURVIVAL DATA; DAVIES SE, 1991, HEPATOLOGY, V13, P150, DOI 10.1002/hep.1840130122; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; DONALDSON P, 1993, HEPATOLOGY, V17, P1008, DOI 10.1002/hep.1840170611; DUSHEIKO G, 1994, HEPATOLOGY, V19, P13, DOI 10.1016/0270-9139(94)90046-9; FERAY C, 1995, GASTROENTEROLOGY, V108, P1088, DOI 10.1016/0016-5085(95)90207-4; FERAY C, 1994, HEPATOLOGY, V20, P1137, DOI 10.1016/0270-9139(94)90748-X; FERRARI C, 1994, HEPATOLOGY, V19, P286; Gane EJ, 1996, GASTROENTEROLOGY, V110, P167, DOI 10.1053/gast.1996.v110.pm8536853; GRETCH D, 1993, HEPATOLOGY, V18, pA108, DOI 10.1016/0270-9139(93)91960-Z; IZOPET J, 1994, HEPATOLOGY, V20, pA241; KONIG V, 1992, HEPATOLOGY, V16, P1137, DOI 10.1016/0270-9139(92)90005-T; KOZIEL MJ, 1993, J VIROL, V67, P7522, DOI 10.1128/JVI.67.12.7522-7532.1993; LIM HL, 1994, GASTROENTEROLOGY, V106, P248, DOI 10.1016/S0016-5085(94)95829-7; MAGRIN S, 1994, HEPATOLOGY, V19, P273; MCHUTCHISON G, 1993, HEPATOLOGY, V18, pA87; MONDELLI M, 1986, CLIN EXP IMMUNOL, V63, P147; NAGAYAMA R, 1993, J CLIN INVEST, V92, P1529, DOI 10.1172/JCI116731; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; POZZATO G, 1994, J MED VIROL, V43, P291, DOI 10.1002/jmv.1890430318; QU D, 1994, J HEPATOL, V21, P70, DOI 10.1016/S0168-8278(94)80139-8; Rosen H. R., 1995, Hepatology, V22, p132A; SCHLUGER LK, 1994, GASTROENTEROLOGY, V106, pA978; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SHAH GJ, 1992, GASTROENTEROLOGY, V103, P323, DOI 10.1016/0016-5085(92)91130-V; SHEINER PA, 1995, HEPATOLOGY, V21, P30, DOI 10.1016/0270-9139(95)90404-2; TANAKA T, 1994, HEPATOLOGY, V19, P1347, DOI 10.1016/0270-9139(94)90226-7; TERASAKI PI, 1974, DHEW NIH75545 PUBL, P67; TILSTON P, 1994, LANCET, V344, P201, DOI 10.1016/S0140-6736(94)92809-6; VANDOORN LJ, 1994, J HEPATOL, V21, P122, DOI 10.1016/S0168-8278(94)80148-7; WEINSTEIN JS, 1994, HEPATOLOGY, V20, pA133; WILLEMS M, 1994, J MED VIROL, V44, P266, DOI 10.1002/jmv.1890440310; WRIGHT TL, 1992, GASTROENTEROLOGY, V103, P317, DOI 10.1016/0016-5085(92)91129-R; YUKI N, 1995, J HEPATOL, V22, P457, DOI 10.1016/0168-8278(95)80109-X; ZHOU S, 1994, HEPATOLOGY, V20, pA134	45	775	781	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1996	334	13					815	820		10.1056/NEJM199603283341302	http://dx.doi.org/10.1056/NEJM199603283341302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB950	8596547	Bronze			2022-12-24	WOS:A1996UB95000002
J	OHare, JP; Hopper, A; Madhaven, C; Charny, M; Purewal, TS; Harney, B; Griffiths, J				OHare, JP; Hopper, A; Madhaven, C; Charny, M; Purewal, TS; Harney, B; Griffiths, J			Adding retinal photography to screening for diabetic retinopathy: A prospective study in primary care	BRITISH MEDICAL JOURNAL			English	Article							NONMYDRIATIC FUNDUS PHOTOGRAPHY; OPHTHALMOSCOPY	Objective-To evaluate whether adding retinal photography improved community screening for diabetic retinopathy. Setting-Mobile screening unit at rural and urban general practices in south west England. Subjects-1010 diabetic patients from primary care. Design-Prospective study; patients were examined by ophthalmoscopy by general practitioners or opticians without fundal photographs and again with photographs, and assessments were compared to those of an ophthalmologist. Main outcome measures-Whether fundal photography improved the sensitivity of detection of retinopathy and referrable diabetic retinopathy, and whether this sensitivity could be improved by including a review of the films by the specialist. Results-Diabetic retinopathy was detected by the ophthalmologist in 205 patients (20.5%) and referrable retinopathy in 49 (4.9%). The sensitivity of the general practitioners and opticians for referrable retinopathy with ophthalmoscopy was 65% and improved to 84% with retinal photographs. General practitioners' sensitivity in detecting background retinopathy improved with photographs from 22% to 65%; opticians' sensitivity in detecting background retinopathy improved from 43% to 71%. The sensitivity of detecting referrable retinopathy by general practitioners improved from 56% to 80% with photographs; for opticians it improved from 75% to 88%. Conclusion-Combining modalities of screening by providing photography with specialist review of all films in addition to direct ophthalmoscopy through dilated pupils improves assessment and referral for diabetic retinopathy by general practitioners and opticians. With further training and experience, primary care screeners should be able to achieve a sensitivity that will achieve an effective, acceptable, and economical community based screening programme for this condition.	ROYAL UNITED HOSP,DEPT OPHTHALMOL,BATH BA1 3NG,AVON,ENGLAND; WILTSHIRE & BATH HLTH COMMISS,DEVIZES SN10 5EQ,WILTS,ENGLAND		OHare, JP (corresponding author), ROYAL UNITED HOSP,DEPT MED,COMBE PK,BATH BA1 3NG,AVON,ENGLAND.							[Anonymous], 1981, OPHTHALMOLOGY, V88, P583; BUXTON MJ, 1991, DIABETIC MED, V8, P371, DOI 10.1111/j.1464-5491.1991.tb01612.x; CLARK JB, 1994, BRIT J OPHTHALMOL, V78, P741, DOI 10.1136/bjo.78.10.741; FINLAY R, 1991, HLTH TRENDS, V23, P104; Government Statistical Service, 1988, CAUS BLINDN PART SIG; GREY RHB, 1989, BRIT J OPHTHALMOL, V73, P88, DOI 10.1136/bjo.73.2.88; KLEIN R, 1985, OPHTHALMOLOGY, V92, P485; LEE VS, 1993, OPHTHALMOLOGY, V100, P1504; LEESE GP, 1992, DIABETIC MED, V9, P459, DOI 10.1111/j.1464-5491.1992.tb01817.x; MOLLENTZE WF, 1990, S AFR MED J, V78, P248; OWENS DR, 1991, DIABETIC MED, V8, pS4, DOI 10.1111/j.1464-5491.1991.tb02148.x; ROHAN T, 1989, BRIT MED J, V289, P1192; RYDER REJ, 1995, BRIT MED J, V331, P207; RYDER REJ, 1994, DIABETIC MED S2, V11, pS44; TAYLOR R, 1990, BRIT MED J, V301, P1243, DOI 10.1136/bmj.301.6763.1243; WAREHAM N, 1991, DIABETIC MED, V8, P607, DOI 10.1111/j.1464-5491.1991.tb01665.x; WHO/IDF Europe, 1990, DIABETIC MED, V7, P360; 1983, DIABETES, V32, P1010; 1993, NEW ENGL J MED, V329, P977	19	45	45	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					679	682						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597737				2022-12-24	WOS:A1996UB11000029
J	Erwin, J; Britten, N; Jones, R				Erwin, J; Britten, N; Jones, R			General practitioners' views on over the counter sales by community pharmacists	BRITISH MEDICAL JOURNAL			English	Article									UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,DEPT GEN PRACTICE,LONDON SE11 6SP,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London								BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; Department of Health, 1994, HLTH PERS SOC SERV S; FORD S, 1995, BRIT MED J, V310, P1620, DOI 10.1136/bmj.310.6995.1620; SPENCER JA, 1992, BRIT MED J, V304, P1670, DOI 10.1136/bmj.304.6843.1670; WILSON RPH, 1995, BRIT MED J, V311, P1347, DOI 10.1136/bmj.311.7016.1347	5	27	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					617	618						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595339				2022-12-24	WOS:A1996TZ84000029
J	Hicks, RCJ; Golledge, J; MirHasseine, R; Powell, JT				Hicks, RCJ; Golledge, J; MirHasseine, R; Powell, JT			Vasoactive effects of fibrinogen on saphenous vein	NATURE			English	Article							ENDOTHELIUM; SMOKING	Normal plasma fibrinogen concentrations are critical to haemostasis. Higher fibrinogen concentrations are associated with increasing risk of atherosclerotic disease(1) and with graft stenosis and occlusion after saphenous vein bypass surgery(2,3). Vein graft stenosis is characterized by the localized proliferation of intimal smooth muscle cells, causing narrowing of the graft with increased risk of thrombotic occlusion. In rabbit arteries, fibrinopeptide B is reported to have both vasoconstrictor and mitogenic properties(4,5). We report here that fibrinopeptides had no vasoactive effects on saphenous vein rings; however, fibrinogen (0-2 mu M) affected an endothelium-dependent relaxation, followed by recontraction at higher concentrations. The fibrinogen-mediated relaxation was inhibited by K+-channel blockers and antibodies to ICAM-1. Coupled signalling pathways for the synthesis of vasoactive mediators and mitogens could underlie the association between fibrinogen and the development of vein graft pathology.			Hicks, RCJ (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,CARDIOVASC & PULM RES DIV,LONDON W6 8RF,ENGLAND.		golledge, jonathan/I-2371-2013; Powell, Janet/AAW-8669-2021	Powell, Janet/0000-0002-3905-1468				DEJANA E, 1985, J CLIN INVEST, V75, P11, DOI 10.1172/JCI111661; HICKS RC, 1995, J VASC SURG, V9, P415; HIGMAN DJ, 1993, BRIT J SURG, V80, P1242, DOI 10.1002/bjs.1800801007; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; LEVENSON J, 1995, ARTERIOSCL THROM VAS, V15, P1263, DOI 10.1161/01.ATV.15.9.1263; MOORE PK, 1988, J PHARM PHARMACOL, V40, P558, DOI 10.1111/j.2042-7158.1988.tb05302.x; NAGAO T, 1993, AM J RESP CELL MOL, V8, P1; NAGEL T, 1994, J CLIN INVEST, V94, P885, DOI 10.1172/JCI117410; SINGH TM, 1990, AM J SURG, V160, P156, DOI 10.1016/S0002-9610(05)80297-1; WALDMAN SA, 1988, J CARDIOVASC PHARM, V12, pS115; WISEMAN S, 1989, BRIT MED J, V299, P643, DOI 10.1136/bmj.299.6700.643	11	43	46	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					818	820		10.1038/379818a0	http://dx.doi.org/10.1038/379818a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587603				2022-12-24	WOS:A1996TX50100056
J	Martin, WD; Hicks, GG; Mendiratta, SK; Leva, HI; Ruley, HE; VanKaer, L				Martin, WD; Hicks, GG; Mendiratta, SK; Leva, HI; Ruley, HE; VanKaer, L			H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection	CELL			English	Article							HLA-DR MOLECULES; INVARIANT CHAIN PEPTIDES; PROCESSING MUTANT; POSITIVE SELECTION; MHC; GENES; COMPLEX; SELF	H2-M is a nonconventional major histocompatibility complex (MHC) class II molecule that has been implicated in the loading of peptides onto conventional class II molecules. We generated mice with a targeted mutation in the H2-Ma gene, which encodes a subunit for H2-M. Although the mutant mice express normal class II cell surface levels, these are structurally distinct from the compact SDS-resistant complexes expressed by wild-type cells and are predominantly bound by class II-associated invariant chain peptides (CLIPs). Cells from these animals are unable to present intact protein antigens to class II-restricted T cells and show reduced capacity to present exogenous peptides. Numbers of mature CD4(+) T lymphocytes in mutant mice are reduced 3- to 4-fold and exhibit altered reactivities. Overall, this phenotype establishes an important role for H2-M in regulating MHC class II function in vivo and supports the notion that self-peptides contribute to the specificity of T cell positive selection.	VANDERBILT UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232	Vanderbilt University	Martin, WD (corresponding author), VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,221 KIRKLAND HALL,NASHVILLE,TN 37232, USA.		Van Kaer, Luc/H-1033-2015	Van Kaer, Luc/0000-0001-5275-2309; Hicks, Geoffrey/0000-0003-4688-2312				ALDRICH CJ, 1994, P NATL ACAD SCI USA, V91, P6525, DOI 10.1073/pnas.91.14.6525; ASHTONRICKARDT PG, 1994, IMMUNOL TODAY, V15, P362, DOI 10.1016/0167-5699(94)90174-0; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ASHTONRICKARDT PG, 1994, CELL, V76, P1464; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; BROOKS AG, 1994, J IMMUNOL, V153, P5382; CEMAN S, 1992, J IMMUNOL, V149, P754; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; EASTMAN S, 1996, IN PRESS EUR J IMMUN; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; GLAS R, 1994, J EXP MED, V179, P661, DOI 10.1084/jem.179.2.661; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; KROPSHOFER H, 1995, SCIENCE, V270, P1357, DOI 10.1126/science.270.5240.1357; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; MURPHY DB, 1992, J IMMUNOL, V148, P3483; NEWCOMB JR, 1993, J IMMUNOL, V150, P499; NOSSAL GJV, 1994, CELL, V76, P219; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; Sanderson F, 1996, IMMUNITY, V4, P87, DOI 10.1016/S1074-7613(00)80301-5; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; SCHMID SL, 1994, NATURE, V369, P103, DOI 10.1038/369103a0; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STEBBINS CC, 1995, J EXP MED, V181, P223, DOI 10.1084/jem.181.1.223; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411	42	269	272	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					543	550		10.1016/S0092-8674(00)81030-2	http://dx.doi.org/10.1016/S0092-8674(00)81030-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598041	Bronze			2022-12-24	WOS:A1996TX17600007
J	Rubin, N; Nakayama, K; Shapley, R				Rubin, N; Nakayama, K; Shapley, R			Enhanced perception of illusory contours in the lower versus upper visual hemifields	SCIENCE			English	Article							RANDOM-DOT STEREOGRAMS; STRIATE CORTEX; COMPLETION; MECHANISMS; ANISOTROPY; DYNAMICS; ISOTROPY; FIELD; FORM	The visual world consciously perceived is very different from the spatial array of photoreceptor activation present on our retinae; it is composed of segregated surfaces, organized into distinct objects. An important component of this organizational process, the segmentation of an image into figures and background, is shown to be performed much better in the lower visual field. This finding is demonstrated by the performance in two tasks that involve the perception of illusory contours. This asymmetry indicates a neural specialization that may be related to the anatomical discontinuity along the representation of the horizontal meridian in extrastriate visual cortex.	NYU,CTR NEURAL SCI,NEW YORK,NY 10003	New York University	Rubin, N (corresponding author), HARVARD UNIV,VIS SCI LAB,33 KIRKLAND ST,CAMBRIDGE,MA 02138, USA.		Rubin, Nava/J-5189-2012		NATIONAL EYE INSTITUTE [R01EY001472] Funding Source: NIH RePORTER; NEI NIH HHS [EY-01472] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON JC, 1993, CEREB CORTEX, V3, P412, DOI 10.1093/cercor/3.5.412; ANGERLEIDER LG, 1982, ANAL VISUAL BEHAVIOR; BLOMFIELD S, 1973, NATURE-NEW BIOL, V245, P256, DOI 10.1038/newbio245256a0; BREITMEYER B, 1975, SCIENCE, V187, P269, DOI 10.1126/science.1111104; Chernjavsky A, 1990, NEURAL COMPUT, V2, P334, DOI 10.1162/neco.1990.2.3.334; EDELMAN GM, 1987, NEURAL DARWINISM, pCH6; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FINKEL LH, 1992, NEURAL COMPUT, V4, P901, DOI 10.1162/neco.1992.4.6.901; Fletcher R, 1980, PRACTICAL METHODS OP; Gibson J. J., 1950, PERCEPTION VISUAL WO; GILBERT CD, 1993, CEREB CORTEX, V3, P373, DOI 10.1093/cercor/3.5.373; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; GROSSBERG S, 1985, PSYCHOL REV, V92, P173, DOI 10.1037/0033-295X.92.2.173; GULYAS B, 1993, FUNCTIONAL ORG HUMAN, P346; HEITGER F, 1993, P INT C COMP VISION, V4, P32; HIRSCH J, 1995, P NATL ACAD SCI USA, V92, P6469, DOI 10.1073/pnas.92.14.6469; HOLMES G, 1945, PROC R SOC SER B-BIO, V132, P348, DOI 10.1098/rspb.1945.0002; HORTON JC, 1991, ARCH OPHTHALMOL-CHIC, V109, P816, DOI 10.1001/archopht.1991.01080060080030; HORTON JC, 1991, BRAIN, V114, P1703, DOI 10.1093/brain/114.4.1703; JULESZ B, 1976, PERCEPTION, V5, P129, DOI 10.1068/p050129; JULESZ B, 1971, F CYCLOPEAN VISION; Kanizsa G., 1979, ORG VISION; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P405; LUND JS, 1993, CEREB CORTEX, V3, P148, DOI 10.1093/cercor/3.2.148; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; NAKAYAMA K, 1992, SCIENCE, V257, P1357, DOI 10.1126/science.1529336; Nitzberg M., 1993, FILTERING SEGMENTATI; PETERHANS E, 1989, J NEUROSCI, V9, P1749; PETERHANS E, 1991, TRENDS NEUROSCI, V14, P112, DOI 10.1016/0166-2236(91)90072-3; Petry S., 1987, PERCEPTION ILLUSORY; PREVIC FH, 1990, BEHAV BRAIN SCI, V13, P519, DOI 10.1017/S0140525X00080018; RINGACH D, 1993, PERCEPTION S, V22, P51; RUBIN N, UNPUB; Tyler C. W., 1991, BINOCULAR VISION; ULLMAN S, 1976, BIOL CYBERN, V25, P1; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; VONDERHEYDT R, 1989, J NEUROSCI, V9, P1731; WASSERSTEIN J, 1984, BRAIN COGNITION, V3, P51, DOI 10.1016/0278-2626(84)90006-X; WASSERSTEIN J, 1987, BRAIN COGNITION, V6, P1, DOI 10.1016/0278-2626(87)90042-X; WILLIAMS LR, 1995, P INT C COMP VIS, V5, P408	40	156	161	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					651	653		10.1126/science.271.5249.651	http://dx.doi.org/10.1126/science.271.5249.651			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571128				2022-12-24	WOS:A1996TT87000047
J	Abbott, A; Cohen, B; Howlett, R				Abbott, A; Cohen, B; Howlett, R			Complexity limits the powers of prediction	NATURE			English	Editorial Material																			0	4	4	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					390	390						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559236				2022-12-24	WOS:A1996TT30400016
J	Mayhew, M; daSilva, ACR; Martin, J; ErdjumentBromage, H; Tempst, P; Hartl, FU				Mayhew, M; daSilva, ACR; Martin, J; ErdjumentBromage, H; Tempst, P; Hartl, FU			Protein folding in the central cavity of the GroEL-GroES chaperonin complex	NATURE			English	Article							ESCHERICHIA-COLI; DIHYDROFOLATE-REDUCTASE; ATP HYDROLYSIS; BINDING; SUBSTRATE; CYCLE	The chaperonin GroEL is able to mediate protein folding in its central cavity. GroEL-bound dihydrofolate reductase assumes its native conformation when the GroES cofactor caps one end of the GroEL cylinder, thereby discharging the unfolded polypeptide into an enclosed cage. Folded dihydrofolate reductase emerges upon ATF-dependent GroES release. Other proteins, such as rhodanese, may leave GroEL after having attained a conformation that is committed to fold. Incompletely folded polypeptide rebinds to GroEL, resulting in structural rearrangement for another folding trial in the chaperonin cavity.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019	Erdjument-Bromage, Hediye/0000-0003-0224-3594				BOCHKAREVA ES, 1994, J BIOL CHEM, V269, P23869; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CORRALES FJ, 1995, P NATL ACAD SCI USA, V92, P5326, DOI 10.1073/pnas.92.12.5326; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; DOBSON CM, 1994, TRENDS BIOCHEM SCI, V19, P31, DOI 10.1016/0968-0004(94)90171-6; ELLIS RJ, 1994, OPIN STRUCT BIOL, V4, P117; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; FENTON WA, 1994, NATURE, V371, P615; FRIEDEN C, 1990, P NATL ACAD SCI USA, V87, P4413, DOI 10.1073/pnas.87.12.4413; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HARTL FU, 1994, NATURE, V371, P557, DOI 10.1038/371557a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; Hendrick JP, 1995, FASEB J, V9, P1559, DOI 10.1096/fasebj.9.15.8529835; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HODAN R, 1995, NAT STRUCT BIOL, V2, P587; HOROWITZ PM, 1990, J BIOL CHEM, V265, P2576; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1994, REV BIOPHSY BIOMOL S, V23, P645; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PRATT JM, 1984, TRANSCRIPTION TRANSL, P179; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; RASSOW J, 1995, MOL CELL BIOL, V15, P2654; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TOUCHETTE NA, 1986, BIOCHEMISTRY-US, V25, P5445, DOI 10.1021/bi00367a015; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V	47	324	330	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					420	426		10.1038/379420a0	http://dx.doi.org/10.1038/379420a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559246				2022-12-24	WOS:A1996TT30400050
J	Connolly, DL; Shanahan, CM; Weissberg, PL				Connolly, DL; Shanahan, CM; Weissberg, PL			Water channels in health and disease	LANCET			English	Editorial Material											Connolly, DL (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE,ENGLAND.			Shanahan, Catherine/0000-0002-8352-8171				AGRE P, 1993, AM J PHYSIOL, V265, pF463; AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; MARPLES D, 1995, J CLIN INVEST, V95, P838; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; SHIELS A, IN PRESS NATURE GENE; YANG BX, 1995, J BIOL CHEM, V270, P22907, DOI 10.1074/jbc.270.39.22907	13	13	15	2	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					210	212		10.1016/S0140-6736(96)90399-2	http://dx.doi.org/10.1016/S0140-6736(96)90399-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551876				2022-12-24	WOS:A1996TT06900005
J	GoodrichBlair, H; Shub, DA				GoodrichBlair, H; Shub, DA			Beyond homing: Competition between intron endonucleases confers a selective advantage on flanking genetic markers	CELL			English	Article							BACILLUS-SUBTILIS BACTERIOPHAGE-SPO1; DNA-POLYMERASE GENE; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; SITE; MECHANISM; SEQUENCE; PROTEIN; SUBUNIT; RECOMBINATION	The closely related B. subtilis bacteriophages SPO1 and SP82 have similar introns inserted into a conserved domain of their DNA polymerase genes. These introns encode endonucleases with unique properties. Other intron-encoded ''homing'' endonucleases cleave both strands of intronless DNA; subsequent repair results in unidirectional gene conversion to the intron-containing allele. In contrast, the enzymes described here cleave one strand on both intron-containing and intronless targets at different distances from their common intron insertion site. Most surprisingly, each enzyme prefers DNA of the heterologous phage. The SP82-encoded endonuclease is responsible for exclusion of the SPO1 intron and flanking genetic markers from the progeny of mixed infections, a novel selective advantage imparted by an intron to the genome in which it resides.	SUNY ALBANY, CTR GENET MOLEC, DEPT BIOL SCI, ALBANY, NY 12222 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany				Goodrich-Blair, Heidi/0000-0003-1934-2636	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037746] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37746] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYK M, 1995, J MOL BIOL, V247, P197, DOI 10.1006/jmbi.1994.0133; CULL M, 1990, METHOD ENZYMOL, V182, P147; CURRAN JF, 1985, VIROLOGY, V142, P78, DOI 10.1016/0042-6822(85)90424-6; DALGAARD JZ, 1993, P NATL ACAD SCI USA, V90, P5414, DOI 10.1073/pnas.90.12.5414; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; DUJON B, 1989, GENE, V82, P115, DOI 10.1016/0378-1119(89)90035-8; EDDY SR, 1991, GENE DEV, V5, P1032, DOI 10.1101/gad.5.6.1032; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; GLASSBERG J, 1977, J VIROL, V21, P147, DOI 10.1128/JVI.21.1.147-152.1977; GOODRICHBLAIR H, 1994, NUCLEIC ACIDS RES, V22, P3715, DOI 10.1093/nar/22.18.3715; GOODRICHBLAIR H, 1990, CELL, V63, P417, DOI 10.1016/0092-8674(90)90174-D; GORBALENYA AE, 1994, PROTEIN SCI, V3, P1117, DOI 10.1002/pro.5560030716; HARDY KG, 1985, DNA CLONING PRACTICA, V2, P1; HIRATA R, 1990, J BIOL CHEM, V265, P6726; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MARSHALL P, 1992, NUCLEIC ACIDS RES, V20, P6401, DOI 10.1093/nar/20.23.6401; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MUELLER JE, 1993, NUCLEASES, P111; MULBRY WW, 1989, J BACTERIOL, V171, P5322, DOI 10.1128/jb.171.10.5322-5324.1989; NAKAGAWA K, 1992, EMBO J, V11, P2707, DOI 10.1002/j.1460-2075.1992.tb05336.x; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; PERRIN A, 1993, EMBO J, V12, P2939, DOI 10.1002/j.1460-2075.1993.tb05956.x; RUSSELL DW, 1986, MOL CELL BIOL, V6, P4281, DOI 10.1128/MCB.6.12.4281; RUSSELL RL, 1974, GENETICS, V78, P989; SAYRE MH, 1988, J VIROL, V62, P3455, DOI 10.1128/JVI.62.9.3455-3462.1988; SCARLATO V, 1992, GENE, V118, P109, DOI 10.1016/0378-1119(92)90256-O; SHARMA M, 1994, J BACTERIOL, V176, P6439, DOI 10.1128/JB.176.21.6439-6448.1994; SHARMA M, 1992, P NATL ACAD SCI USA, V89, P6658, DOI 10.1073/pnas.89.14.6658; SHUB DA, 1994, TRENDS BIOCHEM SCI, V19, P402, DOI 10.1016/0968-0004(94)90086-8; SHUB DA, 1987, COLD SPRING HARB SYM, V52, P193, DOI 10.1101/SQB.1987.052.01.024; Shub DA, 1991, CURR OPIN GENET DEV, V1, P478, DOI 10.1016/S0959-437X(05)80195-9; Stewart Charles R., 1993, P813; STEWART CR, 1981, J VIROL, V38, P1081, DOI 10.1128/JVI.38.3.1081-1083.1981; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TURMEL M, 1995, NUCLEIC ACIDS RES, V23, P2519, DOI 10.1093/nar/23.13.2519	40	74	75	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					211	221		10.1016/S0092-8674(00)80976-9	http://dx.doi.org/10.1016/S0092-8674(00)80976-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565067	Bronze			2022-12-24	WOS:A1996TR59500008
J	Hargreaves, RM; Slack, MPE; Howard, AJ; Anderson, E; Ramsay, ME				Hargreaves, RM; Slack, MPE; Howard, AJ; Anderson, E; Ramsay, ME			Changing patterns of invasive Haemophilus influenzae disease in England and Wales after introduction of the Hib vaccination programme	BRITISH MEDICAL JOURNAL			English	Article									GWYNEDD PUBL HLTH LAB,BANGOR,GWYNEDD,WALES; PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND	Public Health England	Hargreaves, RM (corresponding author), JOHN RADCLIFFE HOSP,HAEMOPHILUS REFERENCE UNIT,OXFORD PUBL HLTH LAB,OXFORD OX3 9DU,ENGLAND.		Ramsay, Mary Elizabeth/S-8281-2016	Ramsay, Mary Elizabeth/0000-0002-7156-7640				ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; ANDERSON EC, 1995, EPIDEMIOL INFECT, V115, P89, DOI 10.1017/S0950268800058155; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; SLACK MPE, 1993, PHLS MICROBIOL DIG, V10, P122; 1991, PAEDIATRICS, V88, P169	5	77	79	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					160	161						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR325	8563536				2022-12-24	WOS:A1996TR32500024
J	Berger, JM; Gamblin, SJ; Harrison, SC; Wang, JC				Berger, JM; Gamblin, SJ; Harrison, SC; Wang, JC			Structure and mechanism of DNA topoisomerase II	NATURE			English	Article							GYRASE-B-PROTEIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; GENE; PURIFICATION; COMPLEXES; HOMOLOGY; SEQUENCE; FRAGMENT	The crystal structure of a large fragment of yeast type II DNA topoisomerase reveals a heart-shaped dimeric protein with a large central hole. It provides a molecular model of the enzyme as an ATP-modulated clamp with two sets of jaws at opposite ends, connected by multiple joints. An enzyme with bound DNA can admit a second DNA duplex through one set of jaws, transport it through the cleaved first duplex, and expel it through the other set of jaws.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Harvard University; Harvard University; Howard Hughes Medical Institute				Gamblin, Steve/0000-0001-5331-639X				ADACHI T, 1984, NUCLEIC ACIDS RES, V12, P6389, DOI 10.1093/nar/12.16.6389; ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BERNARD P, 1992, J MOL BIOL, V226, P735, DOI 10.1016/0022-2836(92)90629-X; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; BRUNGER AT, 1991, ANNU REV PHYS CHEM, V42, P197, DOI 10.1146/annurev.pc.42.100191.001213; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; Caron Paul R., 1994, V29B, P271; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; COWTAN KA, 1994, CCP4 DENSITY MODIFIC; Gellert M, 1981, Cold Spring Harb Symp Quant Biol, V45 Pt 1, P391; GELLERT M, 1979, P NATL ACAD SCI USA, V76, P6289, DOI 10.1073/pnas.76.12.6289; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; Hsieh TS, 1990, DNA TOPOLOGY ITS BIO, P243; Huang W M, 1994, Adv Pharmacol, V29A, P201; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KRAULIS P, 1991, J APPL CRYSTALLOGR, V24, P924; LEE MP, 1989, J BIOL CHEM, V264, P21779; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; MURZIN AG, 1994, CURR OPIN STRUC BIOL, V4, P441, DOI 10.1016/S0959-440X(94)90114-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SANDER M, 1983, J BIOL CHEM, V258, P8421; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; THOMAS W, 1991, GENETICS, V128, P703; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; Yanagida M, 1990, DNA TOPOLOGY ITS BIO, P299; YOSHIDA H, 1990, ANTIMICROB AGENTS CH, V34, P1271, DOI 10.1128/AAC.34.6.1271	43	708	731	2	75	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					225	232		10.1038/379225a0	http://dx.doi.org/10.1038/379225a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538787				2022-12-24	WOS:A1996TQ16900037
J	Gilbert, L; Nicholl, J; Alex, S; Smethurst, I; Mander, A; Andrews, A; Patrick, J				Gilbert, L; Nicholl, J; Alex, S; Smethurst, I; Mander, A; Andrews, A; Patrick, J			Ethnic differences in the outcome of serum screening for Down's syndrome	BRITISH MEDICAL JOURNAL			English	Article									OLDHAM NHS TRUST,DEPT OBSTET & GYNAECOL,OLDHAM OL1 2PN,ENGLAND; UNIV SHEFFIELD,MED CARE RES UNIT,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND; OLDHAM NHS TRUST,DEPT CLIN PATHOL,OLDHAM OL1 2PN,ENGLAND; ST MARYS HOSP,REG CYTOGENET DEPT,MANCHESTER M13 0JH,LANCS,ENGLAND	University of Sheffield; University of Manchester			Gilbert, Lucy/M-6879-2019; Nicholl, Jon/B-8257-2008	Gilbert, Lucy/0000-0001-8605-5472; 				BOGART MH, 1991, AM J OBSTET GYNECOL, V165, P663, DOI 10.1016/0002-9378(91)90305-B; CUCKLE HS, 1990, PRENATAL DIAGNOSIS P, P67; GARDNER MJ, 1989, STATISTICS CONFIDENC; REYNOLDS TN, 1989, NN CLIN BIOCH, V26, P26; RODGERS MS, 1986, BRIT J OBSTET GYNAEC, V93, P587	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					94	95						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555938				2022-12-24	WOS:A1996TQ16800025
J	Joseph, KS; Blais, L; Ernst, P; Suissa, S				Joseph, KS; Blais, L; Ernst, P; Suissa, S			Increased morbidity and mortality related to asthma among asthmatic patients who use major tranquillisers	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEATH; SCHIZOPHRENIA; CHILDHOOD; RISK	Objective - To assess the potentially increased risk of death or near death from asthma in asthmatic patients with psychosis. Design - Case-control study. Setting - The computerised health databases of the Canadian province of Saskatchewan. Subjects - 131 cases of death or near death from asthma identified within a cohort of asthmatic patients; 3930 matched non-cases. Exposure and outcome measures - The exposure of interest was the use of major tranquillisers in the period before an outcome event. Outcomes included death or near death from asthma. Results - Crude analyses showed that asthmatic patients who had used major tranquillisers in the previous 12 months were at a 3.2 (95% confidence interval 1.4 to 7.5) times greater risk of death or near death from asthma than asthmatic patients who did not use major tranquillisers. Past users of major tranquillisers who had recently discontinued use were at a particularly high risk (relative risk 6.6; 2.5 to 17.6). Adjustment for use of antiasthma drugs and other confounders abolished this excess risk. Conclusions - Asthmatic patients who use major tranquillisers seem to be at an increased risk of death or near death from asthma. Physicians treating asthmatic patients with a history of use of major tranquillisers should exercise greater caution with regard to management of such patients.	MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, MCGILL PHARMACOEPIDEMIOL RES UNIT, MONTREAL, PQ H3A 1A2, CANADA	McGill University				Joseph, K.S./0000-0003-2317-5607				BALDESSARINI RJ, 1990, GOODMAN GILMANS PHAR, P391; Banks T, 1993, Aust Fam Physician, V22, P1467; BENNET DR, 1994, DRUG EVALAUTION ANN, P272; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P94; BUDA M, 1988, ARCH GEN PSYCHIAT, V45, P283; CRANE J, 1992, INT J EPIDEMIOL, V21, P737, DOI 10.1093/ije/21.4.737; FRITZ GK, 1987, AM J ORTHOPSYCHIAT, V57, P253, DOI 10.1111/j.1939-0025.1987.tb03535.x; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P257; MASCIA A V, 1974, Journal of Asthma Research, V12, P73, DOI 10.3109/02770907409098935; MASTERSON E, 1984, BRIT J PSYCHIAT, V145, P429, DOI 10.1192/bjp.145.4.429; MCFADDEN ER, 1994, PRINCIPLES INTERNAL, P1172; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MIETTINEN OS, 1976, AM J EPIDEMIOL, V104, P609, DOI 10.1093/oxfordjournals.aje.a112339; MIETTINEN OS, 1989, J CLIN EPIDEMIOL, V42, P491, DOI 10.1016/0895-4356(89)90143-1; MILLER BD, 1987, J ALLERGY CLIN IMMUN, V80, P481, DOI 10.1016/0091-6749(87)90080-7; MORTENSEN PB, 1989, J EPIDEMIOL COMMUN H, V43, P43, DOI 10.1136/jech.43.1.43; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; SAUGSTAD LF, 1979, ACTA PSYCHIAT SCAND, V59, P431; SHERMAN S, 1992, EMERGENCY MED COMPRE; SONIN L, 1984, ARCH INTERN MED, V144, P554, DOI 10.1001/archinte.144.3.554; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STRAND LM, 1989, PHARMACOEPIDEM DR S, P189; STRUNK R C, 1985, Journal of the American Medical Association, V254, P1193, DOI 10.1001/jama.254.9.1193; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; TYRER PJ, 1980, DRUGS, V20, P300, DOI 10.2165/00003495-198020040-00004; WEINBERG CR, 1993, AM J EPIDEMIOL, V137, P1; WEST R, 1987, AM J PREV MED S2, V4, P25; 1992, CLIN EXP ALLERGY S1, V22, P1; 1990, EGRET EPIDEMIOLOGICA, P289	29	54	56	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 13	1996	312	7023					79	82						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TQ168	8555932				2022-12-24	WOS:A1996TQ16800019
J	Despres, JP; Lamarche, B; Mauriege, P; Cantin, B; Dagenais, GR; Moorjani, S; Lupien, PJ				Despres, JP; Lamarche, B; Mauriege, P; Cantin, B; Dagenais, GR; Moorjani, S; Lupien, PJ			Hyperinsulinemia as an independent risk factor for ischemic heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADIPOSE-TISSUE DISTRIBUTION; HIGH-DENSITY LIPOPROTEIN; INSULIN RESISTANCE; GLUCOSE-TOLERANCE; PLASMA-INSULIN; FOLLOW-UP; ABDOMINAL FAT; OBESE WOMEN; BODY-FAT; CORONARY	Background. Prospective studies suggest that hyperinsulinemia may be an important risk factor for ischemic heart disease. However, it has not been determined whether plasma insulin levels are independently related to ischemic heart disease after adjustment for other risk factors, including plasma lipoprotein levels. Methods. In 1985 we collected blood samples from 2103 men from suburbs of Quebec City, Canada, who were 45 to 75 years of age and who did not have ischemic heart disease. A first ischemic event (angina pectoris, acute myocardial infarction, or death from coronary heart disease) occurred in 114 men (case patients) between 1985 and 1990. Each case patient was matched for age, body-mass index, smoking habits, and alcohol consumption with a control selected from among the 1989 men who remained free of ischemic heart disease during follow-up. After excluding men with diabetes, we compared fasting plasma insulin and lipoprotein concentrations at base line in 91 case patients and 105 controls. Results. Pasting insulin concentrations at base line were 18 percent higher in the case patients than in the controls (P<0.001). Logistic-regression analysis showed that the insulin concentration remained associated with ischemic heart disease (odds ratio for ischemic heart disease with each increase of 1 SD in the insulin concentration, 1.7; 95 percent confidence interval, 1.3 to 2.4) after adjustment for systolic blood pressure, use of medications, and family history of ischemic heart disease. Further adjustment by multivariate analysis for plasma triglyceride, apolipoprotein B, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol concentrations did not significantly diminish the association between the insulin concentration and the risk of ischemic heart disease (odds ratio, 1.6; 95 percent confidence interval, 1.1 to 2.3). Conclusions. High fasting insulin concentrations appear to be an independent predictor of ischemic heart disease in men. (C) 1996, Massachusetts Medical Society.	UNIV MONTREAL,DEPT MED,MONTREAL,PQ H3C 3J7,CANADA	Universite de Montreal	Despres, JP (corresponding author), CHU LAVAL,RES CTR,LIPID RES CTR,2705 LAURIER BLVD,ST FOY,PQ G1V 4G2,CANADA.		Lamarche, Benoit/ABA-4785-2021	Lamarche, Benoit/0000-0002-4443-5378				ALBERS JJ, 1978, CLIN CHEM, V24, P853; BIERMAN EL, 1992, ARTERIOSCLER THROMB, V12, P647, DOI 10.1161/01.ATV.12.6.647; CASASSUS P, 1992, ARTERIOSCLER THROMB, V12, P1387, DOI 10.1161/01.ATV.12.12.1387; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; DAGENAIS GR, 1990, CAN J CARDIOL, V6, P274; DESPRES JP, 1989, ARTERIOSCLEROSIS, V9, P203, DOI 10.1161/01.ATV.9.2.203; DESPRES JP, 1989, DIABETES, V38, P304, DOI 10.2337/diabetes.38.3.304; DESPRES JP, 1994, BAILLIERE CLIN ENDOC, V8, P629, DOI 10.1016/S0950-351X(05)80289-7; DESPRES JP, 1990, ARTERIOSCLEROSIS, V10, P497, DOI 10.1161/01.ATV.10.4.497; ESCHWEGE E, 1985, HORM METAB RES, V15, P41; FONTBONNE A, 1994, DIABETOLOGIA, V37, P953, DOI 10.1007/s001250050203; FONTBONNE A, 1989, DIABETOLOGIA, V32, P300, DOI 10.1007/BF00265546; FONTBONNE A, 1991, DIABETOLOGIA, V34, P356, DOI 10.1007/BF00405009; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; HAFFNER SM, 1993, DIABETES, V42, P1297, DOI 10.2337/diabetes.42.9.1297; JUHANVAGUE I, 1991, DIABETOLOGIA, V34, P457, DOI 10.1007/BF00403280; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; LAMARCHE B, 1995, AM J CARDIOL, V75, P1189, DOI 10.1016/S0002-9149(99)80760-7; LAURELL CB, 1972, SCAND J CLIN LAB INV, V29, P21, DOI 10.3109/00365517209102748; LAWS A, 1992, J INTERN MED, V231, P25, DOI 10.1111/j.1365-2796.1992.tb00494.x; MARMOT MG, 1984, INT J EPIDEMIOL, V13, P160, DOI 10.1093/ije/13.2.160; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MOORJANI S, 1987, METABOLISM, V36, P244, DOI 10.1016/0026-0495(87)90183-1; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; ORCHARD TJ, 1983, AM J EPIDEMIOL, V118, P326, DOI 10.1093/oxfordjournals.aje.a113639; POULIOT MC, 1992, DIABETES, V41, P826, DOI 10.2337/diabetes.41.7.826; Pyorala K, 1979, Diabetes Care, V2, P131, DOI 10.2337/diacare.2.2.131; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; WINGARD DL, 1995, DIABETES CARE, V18, P1299, DOI 10.2337/diacare.18.9.1299; YARNELL JWG, 1994, BRIT HEART J, V171, P293; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	33	1401	1453	0	28	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1996	334	15					952	957		10.1056/NEJM199604113341504	http://dx.doi.org/10.1056/NEJM199604113341504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD596	8596596				2022-12-24	WOS:A1996UD59600004
J	Bhatia, S; Robison, LL; Oberlin, O; Greenberg, M; Bunin, G; FossatiBellani, F; Meadows, AT				Bhatia, S; Robison, LL; Oberlin, O; Greenberg, M; Bunin, G; FossatiBellani, F; Meadows, AT			Breast cancer and other second neoplasms after childhood Hodgkin's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							2ND MALIGNANT NEOPLASMS; FOLLOW-UP; ALKYLATING-AGENTS; ACUTE-LEUKEMIA; INCREASED RISK; THERAPY; CHEMOTHERAPY; SPLENECTOMY; RADIOTHERAPY; IRRADIATION	Background. Patients who survive Hodgkin's disease are at increased risk for second neoplasms, As survival times increase, solid tumors are emerging as a serious long-term complication. Methods. The Late Effects Study Group followed a cohort of 1380 children with Hodgkin's disease to deter mine the incidence of second neoplasms and the risk factors associated with them. Results. In this cohort, there were 88 second neoplasms as compared with 4.4 expected in the general population (standardized incidence ratio, 18.1; 95 percent confidence interval, 14.3 to 22.3), The estimated actuarial incidence of any second neoplasm 15 years after the diagnosis of Hodgkin's disease was 7.0 percent (95 percent confidence interval, 5.2 to 8.8 percent); the incidence of solid tumors was 3.9 percent (95 percent confidence interval, 2.3 to 5.5 percent), Breast cancer was the most common solid tumor (standardized incidence ratio, 75.3; 95 percent confidence interval, 44.9 to 118.4), with an estimated actuarial incidence in women that approached 35 percent (95 percent confidence interval, 17.4 to 52.6 percent) by 40 years of age, Older age (10 to 16 vs, <10 years) at the time of radiation treatment (relative risk, 1.9) and a higher dose (2000 to 4000 vs, <2000 cGy) of radiation (relative risk, 5.9) were associated with significantly increased risk of breast cancer, The estimated actuarial incidence of leukemia reached a plateau of 2.8 percent (95 percent confidence interval, 0.8 to 4.8 percent) 14 years after diagnosis. Treatment with alkylating agents, older age at the diagnosis of Hodgkin's disease, recurrence of Hodgkin's disease, and a late stage of disease at diagnosis were risk factors for leukemia. Conclusions. The risk of solid tumors, especially breast cancer, is high among women who were treated with radiation for childhood Hodgkin's disease. Systematic screening for breast cancer could be important in the health care of such women. (C) 1996, Massachusetts Medical Society.	UNIV MINNESOTA, DEPT PEDIAT, DIV PEDIAT EPIDEMIOL & CLIN RES, MINNEAPOLIS, MN 55455 USA; INST GUSTAVE ROUSSY, VILLEJUIF, FRANCE; HOSP SICK CHILDREN, TORONTO, ON M5G 1X8, CANADA; CHILDRENS HOSP PHILADELPHIA, PHILADELPHIA, PA 19104 USA; NATL TUMOR INST, MILAN, ITALY	University of Minnesota System; University of Minnesota Twin Cities; UNICANCER; Gustave Roussy; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia			Robison, Leslie/N-8122-2018					ABRAHAMSEN JF, 1993, J CLIN ONCOL, V11, P255, DOI 10.1200/JCO.1993.11.2.255; ANDRIEU JM, 1990, J CLIN ONCOL, V8, P1148, DOI 10.1200/JCO.1990.8.7.1148; ARSENEAU JC, 1972, NEW ENGL J MED, V287, P1119, DOI 10.1056/NEJM197211302872204; BARAL E, 1977, CANCER, V40, P2905, DOI 10.1002/1097-0142(197712)40:6<2905::AID-CNCR2820400621>3.0.CO;2-Y; BEATY O, 1995, J CLIN ONCOL, V13, P603, DOI 10.1200/JCO.1995.13.3.603; BLAYNEY DW, 1987, NEW ENGL J MED, V316, P710, DOI 10.1056/NEJM198703193161203; BOICE JD, 1979, RADIOLOGY, V131, P589, DOI 10.1148/131.3.589; BOIVIN JF, 1995, JNCI-J NATL CANCER I, V87, P732, DOI 10.1093/jnci/87.10.732; BOIVIN JF, 1984, JNCI-J NATL CANCER I, V72, P233; CANELLOS GP, 1975, LANCET, V1, P947; CIMINO G, 1991, J CLIN ONCOL, V9, P432, DOI 10.1200/JCO.1991.9.3.432; Coleman C. N., 1982, CANCER SURV, V1, P733; COLTMAN CA, 1982, CANCER TREAT REP, V66, P1023; CURTIS RE, 1988, NEW ENGL J MED, V319, P244; DEVITA VT, 1970, ANN INTERN MED, V73, P881, DOI 10.7326/0003-4819-73-6-881; GLICKSMAN AS, 1982, CANCER TREAT REP, V66, P1035; GREENE MH, 1985, 852714 NIH PUBL, P191; HANCOCK SL, 1993, J NATL CANCER I, V85, P25, DOI 10.1093/jnci/85.1.25; HORNING SJ, 1981, NEW ENGL J MED, V304, P1377, DOI 10.1056/NEJM198106043042301; KALDOR JM, 1987, INT J CANCER, V39, P571, DOI 10.1002/ijc.2910390506; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOLETSKY AJ, 1986, J CLIN ONCOL, V4, P311, DOI 10.1200/JCO.1986.4.3.311; MACKENZI.I, 1965, BRIT J CANCER, V19, P1, DOI 10.1038/bjc.1965.1; MEADOWS AT, 1989, MED PEDIATR ONCOL, V17, P477; MILLER AB, 1989, NEW ENGL J MED, V321, P1285, DOI 10.1056/NEJM198911093211902; MILLER BA, 1993, 932789 NIH PUBL; PARKIN DM, 1992, IARC SCI PUBLICATION, V120; PEDERSENBJERGAARD J, 1987, LANCET, V2, P83, DOI 10.1016/S0140-6736(87)92744-9; RODRIGUEZ MA, 1993, ANN ONCOL, V4, P125, DOI 10.1093/oxfordjournals.annonc.a058414; ROSENBERG SA, 1985, INT J RADIAT ONCOL, V11, P5, DOI 10.1016/0360-3016(85)90357-8; SHERINS RJ, 1973, ANN INTERN MED, V79, P216, DOI 10.7326/0003-4819-79-2-216; SHORE RE, 1986, J NATL CANCER I, V77, P689, DOI 10.1093/jnci/77.3.689; STORM HH, 1985, 852714 NIH PUBL, P389; TOKUNAGA M, 1987, RADIAT RES, V112, P243, DOI 10.2307/3577254; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; TUCKER MA, 1987, J NATL CANCER I, V78, P459, DOI 10.1093/jnci/78.3.459; TURA S, 1993, J CLIN ONCOL, V11, P925, DOI 10.1200/JCO.1993.11.5.925; VALAGUSSA P, 1986, J CLIN ONCOL, V4, P830, DOI 10.1200/JCO.1986.4.6.830; VANDENBROUCKE JP, 1982, AM J EPIDEMIOL, V115, P303, DOI 10.1093/oxfordjournals.aje.a113306; VANDERVELDEN JW, 1988, INT J CANCER, V42, P252, DOI 10.1002/ijc.2910420218; VANLEEUWEN FE, 1987, LANCET, V2, P210; VANLEEUWEN FE, 1989, J CLIN ONCOL, V7, P1046, DOI 10.1200/JCO.1989.7.8.1046; VANLEEUWEN FE, 1994, J CLIN ONCOL, V12, P312, DOI 10.1200/JCO.1994.12.2.312	44	674	685	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1996	334	12					745	751		10.1056/NEJM199603213341201	http://dx.doi.org/10.1056/NEJM199603213341201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ979	8592547				2022-12-24	WOS:A1996TZ97900001
J	Buchdahl, R; Parker, A; Stebbings, T; Babiker, A				Buchdahl, R; Parker, A; Stebbings, T; Babiker, A			Association between air pollution and acute childhood wheezy episodes: Prospective observational study	BRITISH MEDICAL JOURNAL			English	Article							LUNG-FUNCTION; ASTHMA; OZONE; CHILDREN; REGRESSION; EXPOSURES; BACTERIA; VIRUSES; VISITS	Objective-To examine the association between the air pollutants ozone, sulphur dioxide, and nitrogen dioxide and the incidence of acute childhood wheezy episodes. Design-Prospective observational study over one year. Setting-District general hospital. Subjects-1025 children attending the accident and emergency department with acute wheezy episodes; 4285 children with other conditions as the control group. Main outcome measures-Daily incidence of acute wheezy episodes. Results-After seasonal adjustment, day to day variations in daily average concentrations of ozone and sulphur dioxide were found to have significant associations with the incidence of acute wheezy episodes. The strongest association was with ozone, for which a non-linear U shaped relation was seen. In terms of the incidence rate ratio (1 at a mean 24 hour ozone concentration of 40 Alpha mu g/m(3) (SD=19.1)), children were more likely to attend when the concentration was two standard deviations below the mean (incidence rate ratio=3.01; 95% confidence interval 2.17 to 4.18) or two standard deviations above the mean (1.34; 1.09 to 1.66). Sulphur dioxide had a weaker log-linear relation with incidence (1.12; 1.05 to 1.19 for each standard deviation (14.1) increase in sulphur dioxide concentration). Further adjustment for temperature and wind speed did not significantly alter these associations. Conclusions-Independent of season, temperature, and wind speed, fluctuations in concentrations of atmospheric ozone and sulphur dioxide are strongly associated with patterns of attendance at accident and emergency departments for acute childhood wheezy episodes. A critical ozone concentration seems to exist in the atmosphere above or below which children are more likely to develop symptoms.	LONDON BOROUGH HILLINGDON, ENVIRONM PROTECT UNIT, UXBRIDGE UB8 1UN, MIDDX, ENGLAND; UCL, SCH MED, MRC, HIV CLIN TRIALS CTR, LONDON WC1E 6AU, ENGLAND	Medical Research Council Clinical Trials Unit; University of London; University College London; UCL Medical School	Buchdahl, R (corresponding author), HILLINGDON HOSP, UXBRIDGE UB8 3NN, MIDDX, ENGLAND.							ANDERSON HR, 1994, BRIT MED J, V308, P1600, DOI 10.1136/bmj.308.6944.1600; BATES DV, 1990, ENVIRON RES, V51, P51, DOI 10.1016/S0013-9351(05)80182-3; BRIDGMAN HA, 1990, GLOBAL AIR POLLUTION; BURLESON GR, 1975, APPL MICROBIOL, V29, P340, DOI 10.1128/AEM.29.3.340-344.1975; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; CODY RP, 1992, ENVIRON RES, V58, P184, DOI 10.1016/S0013-9351(05)80214-2; COX CS, 1989, SCI PROG, V73, P469; *DEP HLTH ADV GROU, 1991, 1 DEP HLTH ADV GROUP; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; GIRSH LS, 1967, J ALLERGY, V39, P347, DOI 10.1016/0021-8707(67)90047-0; GODLEE F, 1991, BRIT MED J, V303, P1539, DOI 10.1136/bmj.303.6816.1539; HIGGINS ITT, 1990, AM REV RESPIR DIS, V141, P1136, DOI 10.1164/ajrccm/141.5_Pt_1.1136; HYNDMAN SJ, 1994, BRIT MED J, V308, P1596, DOI 10.1136/bmj.308.6944.1596; KHOT A, 1984, BRIT MED J, V289, P235, DOI 10.1136/bmj.289.6439.235; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; PARTRIDGE RH, 1995, QU109 NAT PHYS LAB; PHELAN PD, 1994, BRIT MED J, V308, P1584, DOI 10.1136/bmj.308.6944.1584; READ C, 1991, AIR POLLUTION CHILD; RICHARDS W, 1981, ANN ALLERGY, V47, P348; ROSSI OVJ, 1993, THORAX, V48, P244, DOI 10.1136/thx.48.3.244; SCHWARTZ J, 1989, ENVIRON RES, V50, P309, DOI 10.1016/S0013-9351(89)80012-X; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; SOUKUP J, 1993, ENVIRON RES, V60, P178, DOI 10.1006/enrs.1993.1025; SPEKTOR DM, 1991, ENVIRON RES, V55, P107, DOI 10.1016/S0013-9351(05)80167-7; *STAT CORP, 1993, STAT REF MAN 3 1; TSENG RYM, 1990, ANN ALLERGY, V65, P379; VONZIEMSSEN H, 1875, CYCLOPAEDIA PRACTICE, V2; WALTERS S, 1994, THORAX, V49, P133, DOI 10.1136/thx.49.2.133	32	49	49	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					661	665						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597731				2022-12-24	WOS:A1996UB11000021
J	Northridge, D				Northridge, D			Frusemide or nitrates for acute heart failure?	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; FUROSEMIDE; RESPONSES; THERAPY; VOLUME				Northridge, D (corresponding author), WESTERN GEN HOSP,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BAYLISS J, 1987, BRIT HEART J, V57, P17; BIAGI RW, 1967, LANCET, V1, P849; BRAUNWALD E, 1994, AM HEART J, V72, pS68; CHATTERJEE K, 1973, CIRCULATION, V48, P1183, DOI 10.1161/01.CIR.48.6.1183; DIKSHIT K, 1973, NEW ENGL J MED, V288, P1087, DOI 10.1056/NEJM197305242882102; FRANCIOSA JA, 1982, CLIN PHARMACOL THER, V32, P62, DOI 10.1038/clpt.1982.127; FRANCIS GS, 1985, ANN INTERN MED, V103, P1, DOI 10.7326/0003-4819-103-1-1; Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico, 1994, LANCET, V343, P1115; Hampton J. R., 1994, British Heart Journal, V72, pS68; IKRAM H, 1980, CLIN SCI, V59, P443, DOI 10.1042/cs0590443; JOHNSTON GD, 1983, CIRC RES, V53, P630, DOI 10.1161/01.RES.53.5.630; KIELY J, 1973, CIRCULATION, V48, P581, DOI 10.1161/01.CIR.48.3.581; Kruck F, 1991, Drugs, V41 Suppl 3, P60; LAL S, 1969, BRIT HEART J, V31, P711; LARSEN FF, 1988, EUR HEART J, V9, P125, DOI 10.1093/oxfordjournals.eurheartj.a062465; MOND H, 1974, BRIT HEART J, V36, P44; NELSON GIC, 1983, LANCET, V1, P730; NELSON GIC, 1983, EUR HEART J, V4, P706, DOI 10.1093/oxfordjournals.eurheartj.a061382; NISHIMURA M, 1981, CRIT CARE MED, V9, P829; VALETTE H, 1983, EUR J CLIN PHARMACOL, V24, P163, DOI 10.1007/BF00613811; VERMA SP, 1987, BRIT J CLIN PHARMACO, V24, P21, DOI 10.1111/j.1365-2125.1987.tb03131.x	21	25	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					667	668		10.1016/S0140-6736(96)91209-X	http://dx.doi.org/10.1016/S0140-6736(96)91209-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596385				2022-12-24	WOS:A1996TZ28500017
J	Stensvold, I; Tverdal, A; Jacobsen, BK				Stensvold, I; Tverdal, A; Jacobsen, BK			Cohort study of coffee intake and death from coronary heart disease over 12 years	BRITISH MEDICAL JOURNAL			English	Article							BOILED COFFEE		UNIV TROMSO,INST COMMUNITY MED,TROMSO,NORWAY	UiT The Arctic University of Tromso	Stensvold, I (corresponding author), NATL HLTH SCREENING SERV,POB 8155,N-0033 OSLO,NORWAY.			Tverdal, Aage/0000-0002-2909-5678				AHOLA I, 1991, J INTERN MED, V230, P293, DOI 10.1111/j.1365-2796.1991.tb00447.x; GREENLAND S, 1993, EPIDEMIOLOGY, V4, P366, DOI 10.1097/00001648-199307000-00013; KAWACHI I, 1994, BRIT HEART J, V72, P269; TVERDAL A, 1990, BRIT MED J, V300, P566, DOI 10.1136/bmj.300.6724.566; ZOCK PL, 1990, LANCET, V335, P1235, DOI 10.1016/0140-6736(90)91302-Q	5	28	28	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					544	545		10.1136/bmj.312.7030.544	http://dx.doi.org/10.1136/bmj.312.7030.544			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595285	Green Published			2022-12-24	WOS:A1996TY88500025
J	Bradley, D; Carpenter, R; Copsey, L; Vincent, C; Rothstein, S; Coen, E				Bradley, D; Carpenter, R; Copsey, L; Vincent, C; Rothstein, S; Coen, E			Control of inflorescence architecture in Antirrhinum	NATURE			English	Article							FLOWER DEVELOPMENT; SACCHAROMYCES-CEREVISIAE; GENE; MAJUS; TRANSPOSON; MUTATIONS; MERISTEM; CLONING; LOCUS	Flowering plants exhibit two types of inflorescence architecture: determinate and indeterminate. The centroradialis mutation causes the normally indeterminate inflorescence of Antirrhinum to terminate in a flower. We show that centroradialis is expressed in the inflorescence apex a few days after floral induction, and interacts with the floral-meristemidentity gene floricaula to regulate flower position and morphology. The protein CEN is similar to animal proteins that associate with lipids and GTP-binding proteins. We propose a model for how different inflorescence structures may arise through the action and evolution of centroradialis.			Bradley, D (corresponding author), JOHN INNES CTR,DEPT GENET,COLNEY LANE,NORWICH NR4 7UH,NORFOLK,ENGLAND.		Rothstein, Steven J/A-4947-2013	Rothstein, Steven J/0000-0003-0737-1878				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; BRADLEY D, IN PRESS DEVELOPMENT; BUCQUOY S, 1994, EUR J BIOCHEM, V225, P1203, DOI 10.1111/j.1432-1033.1994.1203b.x; Carpenter R, 1995, PLANT CELL, V7, P2001, DOI 10.1105/tpc.7.12.2001; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; COEN EA, 1991, REV PL PHYSL PL MOL, V42, P241; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; COEN ES, 1994, DEVELOPMENT, P107; COEN ES, 1989, MOBILE DNA, P413; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRANDY DK, 1990, MOL ENDOCRINOL, V4, P1370, DOI 10.1210/mend-4-9-1370; Hammer K., 1990, Kulturpflanze, V38, P91; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; Keeble F, 1910, NEW PHYTOL, V9, P68, DOI DOI 10.1111/J.1469-8137.1910.TB05554.X; KUCKUCK H, 1930, INDUKT ABSTANIM VERE, V51, P51; LOBOS E, 1990, MOL BIOCHEM PARASIT, V39, P135, DOI 10.1016/0166-6851(90)90016-F; LUO D, 1991, PLANT J, V1, P59, DOI 10.1111/j.1365-313X.1991.00059.x; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; PIKIELNY CW, 1994, NEURON, V12, P35, DOI 10.1016/0896-6273(94)90150-3; ROBINSON LC, 1991, MOL GEN GENET, V230, P241, DOI 10.1007/BF00290674; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; SIMON R, 1994, CELL, V78, P99, DOI 10.1016/0092-8674(94)90576-2; Stebbins G.L., 1974, FLOWERING PLANTS EVO, DOI 10.4159/harvard.9780674864856; STUBBE H, 1966, GENETIK ZYTOLOGIE AN; TRIPP ML, 1989, MOL MICROBIOL, V3, P1319, DOI 10.1111/j.1365-2958.1989.tb00113.x; Weberling F, 1989, MORPHOLOGY FLOWERS I; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; WILLIAMS MH, 1988, PROTOPLASMA, V147, P77, DOI 10.1007/BF01403879	34	322	357	4	54	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					791	797		10.1038/379791a0	http://dx.doi.org/10.1038/379791a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587601				2022-12-24	WOS:A1996TX50100048
J	Nightingale, SL				Nightingale, SL			New Reporting requirements for device user facilities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5611 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					585	585		10.1001/jama.275.8.585	http://dx.doi.org/10.1001/jama.275.8.585			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594230				2022-12-24	WOS:A1996TW62700030
J	Desai, CJ; Gindhart, JG; Goldstein, LSB; Zinn, K				Desai, CJ; Gindhart, JG; Goldstein, LSB; Zinn, K			Receptor tyrosine phosphatases are required for motor axon guidance in the Drosophila embryo	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; P ELEMENTS; KINASE; TRANSPOSITION; CLONING; NEURONS; SUBSET; GENES; CNS	The receptor tyrosine phosphatases DPTP69D and DPTP99A are expressed on motor axons in Drosophila embryos. In mutant embryos lacking DPTP69D protein, motor neuron growth cones stop growing before reaching their muscle targets, or follow incorrect pathways that bypass these muscles. Mutant embryos lacking DPTP99A are indistinguishable from wild type. Motor axon defects in dptp69D dptp99A double mutant embryos, however, are much more severe than in embryos lacking only DPTP69D. Our results demonstrate that DPTP69D and DPTP99A are required for motor axon guidance and that they have partially redundant functions during development of the neuromuscular system.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,DIV CELLULAR & MOLEC MED,DEPT PHARMACOL,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego	Desai, CJ (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.				NIGMS NIH HHS [GM35252] Funding Source: Medline; NINDS NIH HHS [NS28182] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028182] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BATE M, 1995, NEURON, V15, P513, DOI 10.1016/0896-6273(95)90141-8; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; DALBY B, 1995, GENETICS, V139, P757; DESAI CJ, 1994, J NEUROSCI, V14, P7272; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FITZPATRICK KA, 1995, MECH DEVELOP, V53, P171, DOI 10.1016/0925-4773(95)00432-Z; GAUGER AK, 1993, J BIOL CHEM, V268, P13657; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; HALPERN ME, 1991, J NEUROSCI, V11, P3227; HAMILTON BA, 1995, ROUX ARCH DEV BIOL, V204, P187, DOI 10.1007/BF00241271; HAMILTON BA, 1994, DROSOPHILA MELANOGAS, P81; HARIHARAN IK, 1991, P NATL ACAD SCI USA, V88, P11266, DOI 10.1073/pnas.88.24.11266; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; KRUEGER NX, 1996, CELL, V84; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LITTLETON JT, 1993, CELL, V74, P1124; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PATEL NH, 1994, DROSOPHILA MELANOGAS, P446; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; SINK H, 1991, DEVELOPMENT, V112, P307; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STOKER AW, 1995, DEVELOPMENT, V121, P1833; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TOWER J, 1993, GENETICS, V133, P347; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; Zinn Kai, 1993, Seminars in Cell Biology, V4, P397, DOI 10.1006/scel.1993.1047	36	252	255	1	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					599	609		10.1016/S0092-8674(00)81035-1	http://dx.doi.org/10.1016/S0092-8674(00)81035-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598046	Bronze			2022-12-24	WOS:A1996TX17600012
J	NobenTrauth, N; Kropf, P; Muller, I				NobenTrauth, N; Kropf, P; Muller, I			Susceptibility to Leishmania major infection in interleukin-4-deficient mice	SCIENCE			English	Article							MURINE LEISHMANIASIS; INTERFERON-GAMMA; MONOCLONAL-ANTIBODY; BALB/C MOUSE; IFN-GAMMA; T-CELLS; IL-4; TH2; GROWTH; INTERLEUKIN-10	Interleukin-4 (IL-4), a pleiotropic cytokine, is a major regulator of the immune system and is considered crucial for the development of T helper cell type 2 (T(H)2) responses. The susceptibility of BALB/c mice to infection with Leishmania major has been associated with a polarized T(H)2 response and an inability to down-modulate IL-4 production. The role of IL-4 in vivo was examined directly by disrupting the IL-4 gene in BALB/c embryonic stem cells. Despite the absence of IL-4, the genetically pure BALB/c mutant mice remained susceptible to L. major infection, Showed no signs of lesion healing or parasite clearance, and did not switch to a T(H)1 phenotype.	JACKSON LAB, BAR HARBOR, ME 04609 USA	Jackson Laboratory	NobenTrauth, N (corresponding author), UNIV NOTRE DAME, DEPT BIOL SCI, NOTRE DAME, IN 46556 USA.				NIAID NIH HHS [1R29 AI37636-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI037636] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CARTER KC, 1989, EUR J IMMUNOL, V19, P779, DOI 10.1002/eji.1830190432; CHATELAIN R, 1992, J IMMUNOL, V148, P1182; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; DING A, 1990, J IMMUNOL, V145, P940; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GERLING IC, 1994, MAMM GENOME, V5, P318, DOI 10.1007/BF00389549; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; HJULSTROM S, 1995, EUR J IMMUNOL, V25, P1469, DOI 10.1002/eji.1830250552; HOWARD JG, 1986, INT REV EXP PATHOL, V28, P79; HSIEH CS, 1995, J EXP MED, V181, P713, DOI 10.1084/jem.181.2.713; KANAGAWA O, 1993, SCIENCE, V262, P240, DOI 10.1126/science.8211142; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEAL LMCC, 1993, EUR J IMMUNOL, V23, P566, DOI 10.1002/eji.1830230241; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LEZAMADAVILA CM, 1992, PARASITE IMMUNOL, V14, P37, DOI 10.1111/j.1365-3024.1992.tb00004.x; LIEW FY, 1989, IMMUNOL TODAY, V10, P40, DOI 10.1016/0167-5699(89)90302-2; LIEW FY, 1993, ADV PARASIT, V32, P162; LOCKSLEY RM, 1991, IMMUNOPARASITOL TOD, pA58, DOI 10.1016/S0167-5699(05)80017-9; MOCK B, 1993, EUR J IMMUNOGENET, V20, P335, DOI 10.1111/j.1744-313X.1993.tb00153.x; MORAWETZ RA, 1994, SCIENCE, V265, P264, DOI 10.1126/science.8023146; MOSMANN T, 1991, IMMUNOL TODAY, V12, P257, DOI 10.1016/0167-5699(91)90121-9; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MULLER I, 1991, INT IMMUNOL, V3, P587, DOI 10.1093/intimm/3.6.587; NABORS GS, 1994, INFECT IMMUN, V62, P5498, DOI 10.1128/IAI.62.12.5498-5504.1994; NACY CA, 1991, RES IMMUNOL, V142, P573, DOI 10.1016/0923-2494(91)90105-R; NOBENTRAUTH N, IN PRESS TRANSGENIC; NOBENTRAUTH N, UNPUB; OSWALD IP, 1992, J IMMUNOL, V148, P3578; POWRIE F, 1993, EUR J IMMUNOL, V23, P2223, DOI 10.1002/eji.1830230926; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; SADICK MD, 1991, INFECT IMMUN, V59, P4710, DOI 10.1128/IAI.59.12.4710-4714.1991; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SCOTT P, 1989, EXP PARASITOL, V68, P369, DOI 10.1016/0014-4894(89)90120-3; SHANKAR AH, 1995, J EXP MED, V181, P845, DOI 10.1084/jem.181.3.845; SLADE SJ, 1989, IMMUNOBIOLOGY, V179, P353, DOI 10.1016/S0171-2985(89)80041-5; SWAIN SL, 1990, J IMMUNOL, V145, P3796; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x; VONDERWEID T, 1994, EUR J IMMUNOL, V24, P2285, DOI 10.1002/eji.1830241004; WANG ZE, 1994, J EXP MED, V179, P1367, DOI 10.1084/jem.179.4.1367; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0	44	258	260	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 16	1996	271	5251					987	990		10.1126/science.271.5251.987	http://dx.doi.org/10.1126/science.271.5251.987			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584936				2022-12-24	WOS:A1996TV70400049
J	Grotzfeld, RM; Branda, N; Rebek, J				Grotzfeld, RM; Branda, N; Rebek, J			Reversible encapsulation of disc-shaped guests by a synthetic, self-assembled host	SCIENCE			English	Article							COMPLEX	Here, the synthesis of a bowl-shaped molecule is described and evidence of its reversible dimerization by means of hydrogen bonds is presented. The dimer features a flattened spherical cavity of peculiar symmetry and acts as a host for the encapsulation of guest molecules of complementary shape. Encapsulation of aromatic guests in chloroform solution and of cyclohexane in p-xylene solution was demonstrated by nuclear magnetic resonance experiments. The passage of guests into and out of the cavity is slow and occurs on a time scale of hours. The system was used to explore the effects of size, shape, and solvation on molecular recognition coupled with assembly.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)								BARTLE KD, 1965, TETRAHEDRON, V21, P3289, DOI 10.1016/S0040-4020(01)96950-9; BAXTER P, 1993, ANGEW CHEM INT EDIT, V32, P69, DOI 10.1002/anie.199300691; BONARLAW RP, 1993, TETRAHEDRON LETT, V34, P1677, DOI 10.1016/0040-4039(93)85039-Y; BRANDA N, 1994, SCIENCE, V263, P1267, DOI 10.1126/science.8122107; BRANDA N, 1995, J AM CHEM SOC, V117, P85, DOI 10.1021/ja00106a010; CHAPMAN KT, 1989, J AM CHEM SOC, V111, P3075, DOI 10.1021/ja00190a058; CHAPMAN RG, 1995, J AM CHEM SOC, V117, P9081, DOI 10.1021/ja00140a031; GHADIRI MR, 1993, NATURE, V366, P324, DOI 10.1038/366324a0; GHADIRI MR, 1995, ANGEW CHEM INT EDIT, V34, P93, DOI 10.1002/anie.199500931; MATHIAS JP, 1994, J AM CHEM SOC, V116, P4316, DOI 10.1021/ja00089a021; MATHIAS JP, 1994, J AM CHEM SOC, V116, P1725, DOI 10.1021/ja00084a013; MEISSNER RS, 1995, SCIENCE, V270, P1485, DOI 10.1126/science.270.5241.1485; QUAN MLC, 1991, J AM CHEM SOC, V113, P2754, DOI 10.1021/ja00007a060; SETO CT, 1991, J AM CHEM SOC, V113, P712, DOI 10.1021/ja00002a071; SIMARD M, 1991, J AM CHEM SOC, V113, P4696, DOI 10.1021/ja00012a057; VALDES C, 1995, ANGEW CHEM INT EDIT, V34, P1885, DOI 10.1002/anie.199518851; VOGEL AI, 1989, VOGELS TXB PRACTICAL, P939; WYLER R, 1993, ANGEW CHEM INT EDIT, V32, P1699, DOI 10.1002/anie.199316991; YANG J, 1993, J AM CHEM SOC, V115, P5314, DOI 10.1021/ja00065a061	19	102	102	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					487	489		10.1126/science.271.5248.487	http://dx.doi.org/10.1126/science.271.5248.487			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560261				2022-12-24	WOS:A1996TR32200035
J	Fisher, GJ; Datta, SC; Talwar, HS; Wang, ZQ; Varani, J; Kang, S; Voorhees, JJ				Fisher, GJ; Datta, SC; Talwar, HS; Wang, ZQ; Varani, J; Kang, S; Voorhees, JJ			Molecular basis of sun-induced premature skin ageing and retinoid antagonism	NATURE			English	Article							IV COLLAGENASE GENE; C-JUN; GLUCOCORTICOID RECEPTOR; ACID; EXPRESSION; GELATINASE; PROMOTER; BINDING; FORMS	DAMAGE to skin collagen and elastin (extracellular matrix) is the hallmark of long-term exposure to solar ultraviolet irradiation(1-3), and is believed to be responsible for the wrinkled appearance of sun-exposed skin(4,5). We report here that matrix-degrading metalloproteinase messenger RNAs, proteins and activities are induced in human skin in vivo within hours of exposure to ultraviolet-B irradiation (UVB). Induction of metalloproteinase proteins and activities occurred at UVB doses well below those that cause skin reddening. Within minutes, low-dose UVB upregulated the transcription factors AP-1 and NF-kappa B, which are known to be stimulators of metalloproteinase genes(6,7). All-trans retinoic acid, which transrepresses AP-1 (ref. 8), applied before irradiation with UVB, substantially reduced AP-1 and metalloproteinase induction, We propose that elevated metalloproteinases, resulting from activation of AP-1 and NF-kappa B by low dose solar irradiation, degrade collagen and elastin in skin, Such damage, if imperfectly repaired would result in solar scars, which through accumulation from a lifetime of repeated low-dose sunlight exposure could cause premature skin ageing (photoageing).	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	Fisher, GJ (corresponding author), UNIV MICHIGAN,SCH MED,DEPT DERMATOL,KRESGE 1,R6558,ANN ARBOR,MI 48109, USA.		DATTA, SUBHAS CHANDRA/GRY-6638-2022					ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Angel P, 1992, Matrix Suppl, V1, P156; BAILLY C, 1990, J INVEST DERMATOL, V94, P47, DOI 10.1111/1523-1747.ep12873342; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; EISEN AZ, 1969, J INVEST DERMATOL, V52, P442, DOI 10.1038/jid.1969.76; FISHER GJ, 1994, J BIOL CHEM, V269, P20629; FISHER GJ, 1991, J INVEST DERMATOL, V96, P699, DOI 10.1111/1523-1747.ep12470632; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HILL PA, 1995, BIOCHEM J, V308, P167, DOI 10.1042/bj3080167; HU CL, 1978, ANAL BIOCHEM, V88, P638, DOI 10.1016/0003-2697(78)90467-0; KLIGMAN LH, 1986, PHOTODERMATOLOGY, V3, P215; Lavker RM, 1979, J INVEST DERMATOL, V73, P559; MAUCH C, 1994, ARCH DERMATOL RES, V287, P107, DOI 10.1007/BF00370728; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OIKARINEN A, 1993, J INVEST DERMATOL, V101, P205, DOI 10.1111/1523-1747.ep12363823; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; QUINONES S, 1994, BIOCHEM J, V302, P471, DOI 10.1042/bj3020471; RAFAL ES, 1992, NEW ENGL J MED, V326, P368, DOI 10.1056/NEJM199202063260603; SAARIALHOKERE UK, 1994, J CLIN INVEST, V94, P79, DOI 10.1172/JCI117351; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SATO H, 1993, ONCOGENE, V8, P395; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SMITH JG, 1962, J INVEST DERMATOL, V39, P347, DOI 10.1038/jid.1962.122; TALWAR HS, 1995, J INVEST DERMATOL, V105, P285, DOI 10.1111/1523-1747.ep12318471; WEINSTEIN GD, 1960, J INVEST DERMATOL, V35, P227, DOI 10.1038/jid.1960.109; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WLASCHEK M, 1994, PHOTOCHEM PHOTOBIOL, V59, P550, DOI 10.1111/j.1751-1097.1994.tb02982.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	30	1048	1105	8	114	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					335	339		10.1038/379335a0	http://dx.doi.org/10.1038/379335a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552187	Green Submitted			2022-12-24	WOS:A1996TR32300056
J	Liston, P; Roy, N; Tamai, K; Lefebvre, C; Baird, S; ChertonHorvat, G; Farahani, R; McLean, M; Ikeda, JE; MacKenzie, A; Korneluk, RG				Liston, P; Roy, N; Tamai, K; Lefebvre, C; Baird, S; ChertonHorvat, G; Farahani, R; McLean, M; Ikeda, JE; MacKenzie, A; Korneluk, RG			Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes	NATURE			English	Article								DYSREGULATION Of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers(1), or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Recently, we isolated a candidate gene, encoding neuronal apoptosis inhibitor protein (NAIP)(2), for SMA. This gene is homologous to two baculovirus inhibitor of apoptosis proteins(3,4) (Cp-IAP and Op-IAP) and is partly deleted in individuals with type I SMA, A second SMA candidate gene encoding survival motor neuron (SMN), which is contiguous with the NAIP locus on 5q13.1, was also reported(5), Here we demonstrate a NAIP-mediated inhibition of apoptosis induced by a variety of signals, and have identified three additional human complementary DNAs and a Drosophila melanogaster sequence that are also homologous to the baculovirus IAPs, The four open reading frames (ORFs) possess three baculoviral inhibition of apoptosis protein repeat (BIR) domains and a carboxy-terminal RING zinc-finger. The human iap genes have a distinct but overlapping pattern of expression in fetal and adult tissues. These proteins significantly increase the number of known apoptotic suppressors.	CHILDRENS HOSP EASTERN ONTARIO,MOLEC GENET RES LAB,OTTAWA,ON K1H 8L1,CANADA; UNIV OTTAWA,APOPTOGEN INC,OTTAWA,ON K1H 8L1,CANADA; UNIV OTTAWA,DEPT BIOCHEM,OTTAWA,ON K1H 8M5,CANADA; UNIV OTTAWA,DEPT MICROBIOL & IMMUNOL,OTTAWA,ON K1H 8M5,CANADA; MED & BIOL LABS CO,NAKA KU,NAGOYA,AICHI 460,JAPAN; TOKAI UNIV,INST MED SCI,KANAGAWA 25911,JAPAN	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; University of Ottawa; Tokai University			Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FUJITA A, 1995, J VIROL, V69, P6180, DOI 10.1128/JVI.69.10.6180-6190.1995; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; ROTMAN B, 1961, P NATL ACAD SCI USA, V47, P1981, DOI 10.1073/pnas.47.12.1981; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THOR H, 1982, J BIOL CHEM, V257, P2419; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6	15	855	925	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					349	353		10.1038/379349a0	http://dx.doi.org/10.1038/379349a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552191				2022-12-24	WOS:A1996TR32300060
J	Bunsey, M; Eichenbaum, H				Bunsey, M; Eichenbaum, H			Conservation of hippocampal memory function in rats and humans	NATURE			English	Article							RHESUS-MONKEYS; ASSOCIATION; SYMMETRY; AMNESIA; LESIONS; PIGEONS	THE hippocampus is critical to declarative memory in humans(1). This kind of memory involves associations among items or events that can be accessed flexibly to guide memory expression in various and even new situations(2-4). In animals, there has been controversy about whether the hippocampus is specialized for spatial memory(5,6) or whether it mediates a general memory function(3,4), as it does in humans. To address this issue we trained normal rats and rats with hippocampal damage on non-spatial stimulus-stimulus associations, then probed the nature of their memory representations. We report here that normal rats demonstrated two forms of flexible memory expression, transitivity, the ability to judge inferentially across stimulus pairs that share a common element, and symmetry, the ability to associate paired elements presented in the reverse of training order. Rats with neurotoxic damage limited to the hippocampus demonstrated neither form of flexible expression, indicating that non-spatial declarative processing depends specifically on the hippocampus in animals as it does in humans.,			Bunsey, M (corresponding author), SUNY STONY BROOK,CTR BEHAV NEUROSCI,STONY BROOK,NY 11794, USA.							BUNSEY M, IN PRESS HIPPOCAMPUS; CHO YH, 1995, BEHAV BRAIN RES, V67, P91, DOI 10.1016/0166-4328(94)00109-S; Cohen N. J., 1984, NEUROPSYCHOLOGY MEMO, P83; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; Cohen NJ, 1993, MEMORY AMNESIA HIPPO; DAMATO MR, 1985, J EXP ANAL BEHAV, V44, P35, DOI 10.1901/jeab.1985.44-35; DAVIDSON TL, 1993, BEHAV NEUROSCI, V107, P227, DOI 10.1037/0735-7044.107.2.227; Dickinson A., 1980, CONT ANIMAL LEARNING; DOUGLAS RJ, 1966, NEUROPSYCHOLOGIA, V4, P197, DOI 10.1016/0028-3932(66)90028-5; EICHENBAUM H, 1994, BEHAV BRAIN SCI, V17, P449, DOI 10.1017/S0140525X00035391; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; EICHENBAUM H, 1989, BEHAV NEUROSCI, V103, P1207, DOI 10.1037/0735-7044.103.6.1207; EICHENBAUM H, 1990, J NEUROSCI, V10, P331; GAFFAN D, 1994, EXP BRAIN RES, V99, P411; HUNT ME, 1994, PSYCHOBIOLOGY, V22, P186; James W, 1918, PRINCIPLES PSYCHOL; JARRARD LE, 1989, J NEUROSCI METH, V29, P251, DOI 10.1016/0165-0270(89)90149-0; KIMBLE DP, 1968, PSYCHOL BULL, V70, P285, DOI 10.1037/h0026470; MCGONIGLE BO, 1977, NATURE, V267, P694, DOI 10.1038/267694a0; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Moscovitch Morris, 1994, P269; MURRAY EA, 1993, J NEUROSCI, V13, P4549; Musen G., 1993, NEUROPSYCHOLOGY, V7, P119, DOI DOI 10.1037/0894-4105.7.2.119; NADEL L, 1995, HIPPOCAMPUS, V5, P232, DOI 10.1002/hipo.450050309; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; SIDMAN M, 1982, J EXP ANAL BEHAV, V37, P23, DOI 10.1901/jeab.1982.37-23; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; TERRACE HS, 1993, PSYCHOL SCI, V4, P162, DOI 10.1111/j.1467-9280.1993.tb00481.x; TOLMAN EC, 1948, PSYCHOL REV, V55, P189, DOI 10.1037/h0061626; WEISKRANTZ L, 1975, HIPPOCAMPUS, V2, P411; ZOLAMORGAN S, 1994, HIPPOCAMPUS, V4, P483, DOI 10.1002/hipo.450040410; ZOLAMORGAN S, 1995, HIPPOCAMPUS, V5, P235, DOI 10.1002/hipo.450050310; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	33	470	479	1	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					255	257		10.1038/379255a0	http://dx.doi.org/10.1038/379255a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TQ169	8538790				2022-12-24	WOS:A1996TQ16900046
J	Mukhin, LM; Koscheev, AP; Dikov, YP; Huth, J; Wanke, H				Mukhin, LM; Koscheev, AP; Dikov, YP; Huth, J; Wanke, H			Experimental simulations of the photodecomposition of carbonates and sulphates on Mars	NATURE			English	Article							MARTIAN ATMOSPHERE	THERE is indirect spectroscopic evidence for the presence of sulphates and carbonates on the martian surface(1-5), and such minerals are also found in SNC meteorites(6), which are thought to be of martian origin. But although carbonates are expected to be abundant in the martian regolith(7-9), attempts to detect them directly have been unsuccessful(10,11). Here we report laboratory studies of the decomposition of calcium carbonate and magnesium sulphate under ultraviolet irradiation, which mimic the conditions under which photodecomposition of surface minerals by solar ultraviolet light might occur on Mars. We find that, even for a low abundance(6) of carbonate minerals in the martian regolith, the rate of CO2 release due to photodecomposition is higher than the rate of CO2 loss from the atmosphere by solar-wind-induced sputtering processes(12-15), making this profess a potential net source of atmospheric CO2 over time. SO2 is also released from the sulphate, albeit more slowly. The rate of carbonate degradation is high enough to explain the apparent absence of these compounds at the martian surface.	INST SPACE RES,MOSCOW,RUSSIA; KARPOV INST PHYS CHEM,ACT PARTICLE ABSORPT LAB,MOSCOW 103064,RUSSIA; RUSSIAN ACAD SCI,INST ORE DEPOSIT PETROG MINERAL & GEOCHEM,MOSCOW 109017,RUSSIA; MAX PLANCK INST CHEM,ABT KOSMOCHEM,D-55122 MAINZ,GERMANY	Russian Academy of Sciences; Space Research Institute of the Russian Academy of Sciences; Karpov Institute of Physical Chemistry; Russian Academy of Sciences; Max Planck Society	Mukhin, LM (corresponding author), EMBASSY RUSSIAN FEDERAT,2650 WISCONSIN AVE NW,WASHINGTON,DC 20007, USA.							BANIN A., 2000, MARS, P594; BELL JF, 1994, ICARUS, V111, P106, DOI 10.1006/icar.1994.1136; BIERMANN K, 1977, J GEOPHYS RES, V82, P4641; BLANEY DL, 1989, J GEOPHYS RES-SOLID, V94, P10159, DOI 10.1029/JB094iB08p10159; BLANEY DL, 1995, J GEOPHYS RES-PLANET, V100, P14433, DOI 10.1029/95JE00224; CALVIN WM, 1994, J GEOPHYS RES-PLANET, V99, P14659, DOI 10.1029/94JE01090; CLARK BC, 1981, ICARUS, V45, P370, DOI 10.1016/0019-1035(81)90041-5; Fanale F.P., 1992, MARS, P1135; GOODING JL, 1991, METEORITICS, V26, P135, DOI 10.1111/j.1945-5100.1991.tb01029.x; GREELEY R, 1982, J GEOPHYS RES, V87, P9, DOI 10.1029/JB087iB12p10009; Greeley R., 1992, MARS, P730; HABERLE RM, 1994, ICARUS, V109, P102, DOI 10.1006/icar.1994.1079; JAKOSKY BM, 1994, ICARUS, V111, P271, DOI 10.1006/icar.1994.1145; KRASNOPOLSKY VA, 1995, J GEOPHYS RES-PLANET, V100, P3263, DOI 10.1029/94JE03283; LUHMANN JG, 1992, GEOPHYS RES LETT, V19, P2151, DOI 10.1029/92GL02485; MCELROY MB, 1972, SCIENCE, V177, P986, DOI 10.1126/science.177.4053.986; MOUNT GH, 1983, J GEOPHYS RES-OCEANS, V88, P5403, DOI 10.1029/JC088iC09p05403; PEPIN RO, 1994, ICARUS, V111, P289, DOI 10.1006/icar.1994.1146; POLLACK JB, 1987, ICARUS, V71, P203, DOI 10.1016/0019-1035(87)90147-3; POLLACK JB, 1979, J GEOPHYS RES, V84, P2929, DOI 10.1029/JB084iB06p02929; POLLACK JB, 1990, J GEOPHYS RES-SOLID, V95, P14595, DOI 10.1029/JB095iB09p14595; WEBER MJ, 1986, HDB LASER SCI TECHNO, V4, P224; [No title captured]	23	38	38	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					141	143		10.1038/379141a0	http://dx.doi.org/10.1038/379141a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538763				2022-12-24	WOS:A1996TP36000050
J	OBrien, JP				OBrien, JP			Controversies in management - Should backache be treated with spinal fusion? Spinal fusion is the only treatment for discogenic pain	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LUMBAR SPINE; POSTERIOR											FARFAN HF, 1981, CLIN ORTHOP RELAT R, P198; Hibbs, 1911, NY MED J, V93, P1013, DOI 10.1097/BLO.0b013e3180686b30; HODGSON AR, 1956, BRIT J SURG, V44, P266, DOI 10.1002/bjs.18004418508; KUSLICH SD, 1991, ORTHOP CLIN N AM, V22, P181; MCCALL IW, 1979, SPINE, V4, P441, DOI 10.1097/00007632-197909000-00009; PARK WM, 1979, BRIT J RADIOL, V52, P382, DOI 10.1259/0007-1285-52-617-382; WEATHERLEY CR, 1986, J BONE JOINT SURG BR, V68, P142, DOI 10.1302/0301-620X.68B1.2934399; WILTSE LL, 1977, CLIN ORTHOP RELAT R, V129, P22; YOSHIZAWA H, 1980, J PATHOL, V132, P95, DOI 10.1002/path.1711320202; 1972, BLAKISTONS GOULD MED, P137	10	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 6	1996	312	7022					38	39		10.1136/bmj.312.7022.38	http://dx.doi.org/10.1136/bmj.312.7022.38			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555861	Green Published			2022-12-24	WOS:A1996TP20900027
J	Rothe, M; Pan, MG; Henzel, WJ; Ayres, TM; Goeddel, DV				Rothe, M; Pan, MG; Henzel, WJ; Ayres, TM; Goeddel, DV			The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral-inhibitor of apoptosis proteins	CELL			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR; ZINC-FINGER; IDENTIFICATION; SEQUENCE; CLONING; MOTIF	The 75 kDa tumor necrosis factor receptor (TNFR2) transduces extracellular signals via receptor-associated cytoplasmic proteins. Two of these signal transducers, TRAF1 and TRAF2, were isolated and characterized previously. We report here the biochemical purification and subsequent molecular cloning of two novel TNFR2-associated proteins, designated c-IAP1 and c-IAP2, that are closely related mammalian members of the inhibitor of apoptosis protein (IAP) family originally identified in baculoviruses. The viral and cellular IAPs contain N-terminal baculovirus IAP repeat (BIR) motifs and a C-terminal RING finger. The c-IAPs do not directly contact TNFR2, but rather associate with TRAF1 and TRAF2 through their N-terminal BIR motif-comprising domain. The recruitment of c-IAP1 or c-IAP2 to the TNFR2 signaling complex requires a TRAF2-TRAF1 heterocomplex.	GENENTECH INC, DEPT PROT CHEM, San Francisco, CA 94080 USA	Roche Holding; Genentech	Rothe, M (corresponding author), TULARIK INC, DEPT BIOL MOLEC, 270 E GRAND AVE, San Francisco, CA 94080 USA.			Henzel, William/0000-0003-2940-3797				Ausubel F.M., 1987, CURRENT PROTOCOLS MO; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BRAUNAGEL SC, 1992, VIROLOGY, V191, P1003, DOI 10.1016/0042-6822(92)90281-S; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEM RJ, 1994, APOPTOSIS, V2, P89; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU HM, 1994, J BIOL CHEM, V269, P30069; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PENNICA D, 1992, J BIOL CHEM, V267, P21172; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROTH E, 1995, M SCIENCE, V269, P1424; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Sambrook J., 1989, MOL CLONING LAB MANU; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6	43	1028	1091	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1243	1252		10.1016/0092-8674(95)90149-3	http://dx.doi.org/10.1016/0092-8674(95)90149-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548810	Bronze			2022-12-24	WOS:A1995TM76200019
J	FERMULLER, C; ALOIMONOS, Y				FERMULLER, C; ALOIMONOS, Y			DIRECT PERCEPTION OF 3-DIMENSIONAL MOTION FROM PATTERNS OF VISUAL-MOTION	SCIENCE			English	Article							OPTIC FLOW; FIELD	Measurements of retinal motion along a set of predetermined orientations on the retina of a moving system give rise to global patterns. Because the form and location of these patterns depend purely on three-dimensional (3D) motion, the effects of 3D motion and scene structure on image motion can be globally separated. The patterns are founded on easily derivable image measurements that depend only on the sign of image motion and do not require information about optical flow. The computational theory presented here explains how the self-motion of a system can be estimated by locating these patterns.	UNIV MARYLAND,CTR AUTOMAT RES,DEPT COMP SCI,COMP VIS LAB,COLLEGE PK,MD 20742; UNIV MARYLAND,INST ADV COMP STUDIES,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park			Aloimonos, Yiannis/AAI-2969-2020	Aloimonos, Yiannis/0000-0002-8152-4281				Aloimonos J., 1984, Proceedings of the Workshop on Computer Vision: Representation and Control, P72; ALOIMONOS Y, 1991, SCIENCE, V253, P1181; ALOIMONOS Y, 1993, INTEGRATION VISUAL M; ANCONA N, 1995, INT J COMPUT VISION, V14, P131, DOI 10.1007/BF01418979; BRODSKY T, 1995, CARTR780 U MAR CTR A; DUFFY CJ, 1991, J NEUROPHYSIOL, V65, P1329, DOI 10.1152/jn.1991.65.6.1329; FAUGERAS OD, 1990, INT J COMPUT VISION, V4, P225, DOI 10.1007/BF00054997; FERMULLER C, 1995, INT J COMPUT VISION, V15, P7, DOI 10.1007/BF01450848; FERMULLER C, 1993, INT J COMPUT VISION, V11, P165, DOI 10.1007/BF01469227; FERMULLER C, 1993, ACTIVE PERCEPTION, P103; FERMULLER C, IN PRESS VISUAL NAVI; FERMULLER C, 1994, CARTR732 U MAR CTR A; FERMULLER C, 1995, INT J COMPUT VISION, V114, P147; Gibson J. J, 1979, ECOLOGICAL APPROACH; Horn B. K. P., 1987, Proceedings of the First International Conference on Computer Vision (Cat. No.87CH2465-3), P2; KOENDERINK JJ, 1986, VISION RES, V26, P161, DOI 10.1016/0042-6989(86)90078-7; LONGUETHIGGINS HC, 1981, NATURE, V293, P133, DOI 10.1038/293133a0; LONGUETHIGGINS HC, 1984, P ROY SOC LOND B BIO, V208, P385; NELSON RC, 1989, IEEE T PATTERN ANAL, V11, P1102, DOI 10.1109/34.42840; POGGIO T, 1973, KYBERNETIK, V13, P223, DOI 10.1007/BF00274887; REICHARDT W, 1987, J COMP PHYSIOL A, V161, P533, DOI 10.1007/BF00603660; Reichardt W., 1961, S PRINC SENS COMM, P303; TANAKA K, 1989, J NEUROPHYSIOL, V62, P626, DOI 10.1152/jn.1989.62.3.626; TSAI RY, 1984, IEEE T PATTERN ANAL, V6, P13, DOI 10.1109/TPAMI.1984.4767471; Ullman S., 1979, PROC R SOC SER B-BIO, DOI 10.7551/mitpress/3877.003.0009; VANSANTEN JPH, 1984, J OPT SOC AM A, V1, P451, DOI 10.1364/JOSAA.1.000451; VERRI A, 1989, IEEE T PATTERN ANAL, V11, P490, DOI 10.1109/34.24781	27	52	54	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1973	1976		10.1126/science.270.5244.1973	http://dx.doi.org/10.1126/science.270.5244.1973			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533087				2022-12-24	WOS:A1995TL42000036
J	Chang, RW; Pellissier, JM; Hazen, GB				Chang, RW; Pellissier, JM; Hazen, GB			A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STOCHASTIC TREES; REPLACEMENT; ARTHRITIS; REVISION	Objective.-To quantify the trade-off between the expected increased short- and long-term costs and the expected increase in quality-adjusted life expectancy (QALE) associated with total hip arthroplasty (THA) for persons with functionally significant hip osteoarthritis. Design.-A cost-effectiveness study was performed from the societal perspective by constructing stochastic tree, decision analytic models designed to estimate lifetime functional outcomes and costs of THA and nonoperative managements. Main Outcome Measures.-A modified four-state American College of Rheumatology functional status classification was used to measure effectiveness. These functional classes were assigned utility values to allow the relative effectiveness of THA to be expressed in quality-adjusted life years (QALYs), Lifetime costs included costs associated with primary and potential revision surgeries and long-term care costs associated with the functionally dependent class. Data Used in the Cost-effectiveness Model.-Probability and incidence rate data were summarized from the literature. The THA hospital cost data were obtained from local teaching hospitals' cost accounting systems, Estimates of recurring medical costs for functionally significant hip osteoarthritis and for custodial care were derived from the literature. Results.-The THA cost-effectiveness ratio increases with age and is higher for men than for women, In the base-case scenario for 60-year-old white women who have functionally significant but not dependent hip osteoarthritis, the model predicts that THA is cost saving because of the high costs of custodial care associated with dependency due to worsening hip osteoarthritis and that the procedure increases QALE by about 6.9 years. In the base-case scenario for men aged 85 years and older, the average lifetime cost associated with THA is $9100 more than nonoperative management, with an average increase in QALE of about 2 years. Thus, the THA cost-effectiveness ratio for men aged 85 years and older is $4600 per QALY gained, less than that of procedures intended to extend life such as coronary artery bypass surgery or renal dialysis, Worst-case analysis suggests that THA remains minimally cost-effective for this oldest age category ($80 000/QALY) even if probabilities, rates, utilities, costs, and the discount rate are simultaneously varied to extreme values that bias the analysis against surgery. Conclusions.-For persons with hip osteoarthritis associated with significant functional limitation, THA can be cost saving or, at worst, cost-effective in improving QALE when both short- and long-term outcomes are considered, Further research is needed to determine whether this procedure is actually being used in this cost-effective manner, especially in older age categories.	NORTHWESTERN UNIV, INST HLTH SERV RES & POLICY STUDIES, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, DEPT PREVENT MED, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, DEPT MED, ARTHRITIS DIV, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, DEPT PHYS MED & REHABIL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, DEPT IND ENGN, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, INST HLTH SERV RES & POLICY STUDIES, EVANSTON, IL USA; NORTHWESTERN UNIV, DEPT PREVENT MED, EVANSTON, IL USA; NORTHWESTERN UNIV, DEPT MED, ARTHRITIS DIV, EVANSTON, IL USA; NORTHWESTERN UNIV, DEPT PHYS MED & REHABIL, EVANSTON, IL USA; NORTHWESTERN UNIV, DEPT IND ENGN, EVANSTON, IL USA; LOYOLA UNIV, DEPT MANAGEMENT SCI, CHICAGO, IL 60611 USA	Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Loyola University Chicago	Chang, RW (corresponding author), NORTHWESTERN UNIV, MULTIPURPOSE ARTHRITIS & MUSCULOSKELETAL DIS CTR, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA.		Hazen, Gordon/B-7463-2009		NIAMS NIH HHS [AR30692] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR030692] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		*AM AC ORTH SURG, 1993, ORTH KNOWL UPD, V4; *AM ASS HOM SERV A, 1994, BACKGR FACTS AG SERV; AMSTUTZ HC, 1982, CLIN ORTHOP RELAT R, V170, P21; ANDERSON M A, 1981, Orthopaedic Transactions, V5, P75; [Anonymous], 1995, JAMA, V273, P1950; BARBER TC, 1993, J BONE JOINT SURG AM, V75A, P321, DOI 10.2106/00004623-199303000-00002; BECKENBAUGH RD, 1978, J BONE JOINT SURG AM, V60, P306, DOI 10.2106/00004623-197860030-00005; BOOTH RE, 1988, TOTAL HIP ARTHROPLAS; BROUGHTON NS, 1982, ACTA ORTHOP SCAND, V53, P923, DOI 10.3109/17453678208992850; Cameron H U, 1981, Acta Orthop Belg, V47, P49; COLLIS DK, 1988, ORTHOP CLIN N AM, V19, P541; COVENTRY MB, 1974, J BONE JOINT SURG AM, VA 56, P273, DOI 10.2106/00004623-197456020-00005; COX DR, 1955, P CAMBRIDGE PHILOS S, V51, P313; DANIELSSON L, 1964, ACTA ORTHOP SCAND S, V66, P9; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ESSES S, 1983, CAN J SURG, V26, P345; ESTOCK DM, 1994, CLIN ORTHOP RELAT R, P190; ETCHASON J, 1995, NEW ENGL J MED, V332, P719, DOI 10.1056/NEJM199503163321106; FOWLER JL, 1988, ORTHOP CLIN N AM, V19, P477; FRIEDMAN B, 1993, MED CARE, V31, P581, DOI 10.1097/00005650-199307000-00002; GARNER TI, 1987, MED CARE, V25, P25, DOI 10.1097/00005650-198701000-00004; GUSTILO RB, 1984, P 12 ANN M HIP SOC S, P342; GUSTILO RB, 1988, CLIN ORTHOPAEDICS, V0235, P00111; HARRIS WH, 1990, NEW ENGL J MED, V323, P725, DOI 10.1056/NEJM199009133231106; HARRIS WH, 1969, J BONE JOINT SURG AM, VA 51, P737, DOI 10.2106/00004623-196951040-00012; HAZEN GB, 1993, MED DECIS MAKING, V13, P227, DOI 10.1177/0272989X9301300309; HAZEN GB, 1992, MED DECIS MAKING, V12, P163, DOI 10.1177/0272989X9201200302; HERBERTS P, 1989, CLIN ORTHOP RELAT R, V249, P48; HOOGLAND T, 1981, CLIN ORTHOP RELAT R, V161, P180; HUNTER GA, 1979, J BONE JOINT SURG BR, V61, P419, DOI 10.1302/0301-620X.61B4.500750; JAMES ETR, 1982, CLIN ORTHOP RELAT R, V170, P88; JINNAH RH, 1986, CLIN ORTHOP RELAT R, V211, P164; JONES JM, 1979, J BONE JOINT SURG AM, V61, P1029, DOI 10.2106/00004623-197961070-00010; KAPLAN RM, 1976, HEALTH SERV RES, V11, P478; KATZ JN, 1994, MED CARE, V32, P183, DOI 10.1097/00005650-199402000-00009; KAVANAGH BF, 1989, J BONE JOINT SURG AM, V71A, P1496, DOI 10.2106/00004623-198971100-00007; KAVANAGH BF, 1985, J BONE JOINT SURG AM, V67A, P517, DOI 10.2106/00004623-198567040-00003; KAVANAGH BF, 1987, J BONE JOINT SURG AM, V69A, P1144, DOI 10.2106/00004623-198769080-00006; KAVANAGH BF, 1985, CLIN ORTHOP RELAT R, V193, P133; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; LAUPACIS A, 1994, J ARTHROPLASTY, V9, P481, DOI 10.1016/0883-5403(94)90093-0; LAUPACIS A, 1993, J BONE JOINT SURG AM, V75A, P1619, DOI 10.2106/00004623-199311000-00006; LIANG MH, 1986, ARTHRITIS RHEUM, V29, P937, DOI 10.1002/art.1780290801; MARTI RK, 1990, J BONE JOINT SURG AM, V72A, P346, DOI 10.2106/00004623-199072030-00005; MCCOY TH, 1988, ORTHOP CLIN N AM, V19, P467; MULROY RD, 1990, J BONE JOINT SURG BR, V72, P757, DOI 10.1302/0301-620X.72B5.2211749; MUSHLIN AI, 1992, CANCER, V69, P1957, DOI 10.1002/1097-0142(19920401)69:7+<1957::AID-CNCR2820691716>3.0.CO;2-T; *NAT CTR HLTH STAT, 1993, VIT STAT US, V2, P12; PELLICCI PM, 1985, J BONE JOINT SURG AM, V67A, P513, DOI 10.2106/00004623-198567040-00002; PELLICCI PM, 1982, CLIN ORTHOP RELAT R, V170, P34; PELLISSIER JM, 1994, SOCIO ECON PLAN SCI, V28, P251, DOI 10.1016/0038-0121(94)90030-2; PELLISSIER JM, 1994, MED DECIS MAKING, V14, P439; REIGSTAD A, 1984, ARCH ORTHOP TRAUM SU, V103, P152, DOI 10.1007/BF00435545; Retpen J B, 1989, J Arthroplasty, V4, P311, DOI 10.1016/S0883-5403(89)80032-4; SANZEN L, 1988, CLIN ORTHOP RELAT R, P165; SCHULMAN KA, 1991, ANN INTERN MED, V114, P798, DOI 10.7326/0003-4819-114-9-798; SCHULTE KR, 1993, J BONE JOINT SURG AM, V75A, P961, DOI 10.2106/00004623-199307000-00002; SCHURMAN DJ, 1989, CLIN ORTHOP RELAT R, V240, P172; SCHUTZER SF, 1988, J BONE JOINT SURG AM, V70A, P724, DOI 10.2106/00004623-198870050-00013; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; WHITE RH, 1990, J GEN INTERN MED, V5, P304, DOI 10.1007/BF02600396; WHITTLE J, 1993, CLIN ORTHOP RELAT R, V295, P119; [No title captured]; [No title captured]; [No title captured]; [No title captured]; 1994, EC INDICATORS, P23; [No title captured]	70	406	410	3	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					858	865		10.1001/jama.275.11.858	http://dx.doi.org/10.1001/jama.275.11.858			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ971	8596224				2022-12-24	WOS:A1996TZ97100029
J	Inouye, SK; Charpentier, PA				Inouye, SK; Charpentier, PA			Precipitating factors for delirium in hospitalized elderly persons - Predictive model and interrelationship with baseline vulnerability	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE CONFUSIONAL STATES; MINI-MENTAL STATE; MEDICAL PATIENTS; RISK-FACTORS; SEVERITY; ILLNESS	Objectives.-To prospectively develop and validate a predictive model for delirium based on precipitating factors during hospitalization, and to examine the interrelationship of precipitating factors and baseline vulnerability. Design.-Two prospective cohort studies, in tandem. Setting.-General medical wards, university teaching hospital. Patients.-For the development cohort, 196 patients aged 70 years and older with no delirium at baseline, and for the validation cohort, 312 comparable patients. Main Outcome Measure.-New-onset delirium by hospital day 9, defined by the Confusion Assessment Method diagnostic criteria. Results.-Delirium developed in 35 patients (18%) in the development cohort. Five independent precipitating factors for delirium were identified: use of physical restraints (adjusted relative risk [RR], 4.4; 95% confidence interval [CI], 2.5 to 7.9), malnutrition (RR, 4.0; 95% CI, 2.2 to 7.4), more than three medications added (RR, 2.9; 95% CI, 1.6 to 5.4), use of bladder catheter (RR, 2.4; 95% CI, 1.2 to 4.7), and any iatrogenic event (RR, 1.9; 95% CI, 1.1 to 3.2). Each precipitating factor preceded the onset of delirium by more than 24 hours. A risk stratification system was developed by adding 1 point for each factor present. Rates of delirium for low-risk (0 points), intermediate-risk (1 to 2 points), and high-risk groups (greater than or equal to 3 points) were 3%, 20%, and 59%, respectively (P<.001). The corresponding rates in the validation cohort, in which 47 patients (15%) developed delirium, were 4%, 20%, and 35%, respectively (P<.001). When precipitating and baseline factors were analyzed in cross-stratified format, delirium rates increased progressively from low-risk to high-risk groups in all directions (double-gradient phenomenon). The contributions of baseline and precipitating factors were documented to be independent and statistically significant. Conclusions.-A simple predictive model based on the presence of five precipitating factors can be used to identify elderly medical patients at high risk for delirium. Precipitating and baseline vulnerability factors are highly interrelated and contribute to delirium in independent, substantive, and cumulative ways.	YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06510	Yale University; Yale University			Inouye, Sharon/R-7216-2019		NIA NIH HHS [P60AG10469] Funding Source: Medline; PHS HHS [K08AB00524] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P60AG010469] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BECK S, RAND PUBLICATION; BECKER PM, 1987, JAMA-J AM MED ASSOC, V257, P2313, DOI 10.1001/jama.257.17.2313; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; CHARLSON ME, 1986, J CHRON DIS, V39, P439, DOI 10.1016/0021-9681(86)90111-6; FEINSTEIN AR, 1987, CLINIMETRICS, P57; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOREMAN MD, 1989, RES NURS HEALTH, V12, P21, DOI 10.1002/nur.4770120105; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P525, DOI 10.1111/j.1532-5415.1988.tb04023.x; Hodkinson H M, 1973, J R Coll Physicians Lond, V7, P305; HOSMER DW, 1989, APPL LOGISTIC REGRES, P131; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; INOUYE SK, 1994, AM J MED, V97, P278, DOI 10.1016/0002-9343(94)90011-6; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; INOUYE SK, 1993, J GEN INTERN MED, V8, P645, DOI 10.1007/BF02598279; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; MCCULLAGH P, 1983, GEN LINEAR MODELS MO, P79; POMPEI P, 1994, J AM GERIATR SOC, V42, P809, DOI 10.1111/j.1532-5415.1994.tb06551.x; ROCKWOOD K, 1989, J AM GERIATR SOC, V37, P150, DOI 10.1111/j.1532-5415.1989.tb05874.x; ROGERS MP, 1989, INT J PSYCHIAT MED, V19, P109; ROSIN AJ, 1966, J CHRON DIS, V19, P307, DOI 10.1016/0021-9681(66)90134-2; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; TINETTI ME, 1995, JAMA-J AM MED ASSOC, V273, P1348, DOI 10.1001/jama.273.17.1348; UHLMANN RF, 1987, J GERONTOL, V42, P33, DOI 10.1093/geronj/42.1.33; VENTRY IM, 1982, EAR HEARING, V3, P128, DOI 10.1097/00003446-198205000-00006; WACHOLDER S, 1986, AM J EPIDEMIOL, V123, P174, DOI 10.1093/oxfordjournals.aje.a114212; WILLIAMS MA, 1985, RES NURS HEALTH, V8, P31, DOI 10.1002/nur.4770080107; WILLIAMSRUSSO P, 1992, J AM GERIATR SOC, V40, P759, DOI 10.1111/j.1532-5415.1992.tb01846.x	31	862	885	2	53	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					852	857		10.1001/jama.275.11.852	http://dx.doi.org/10.1001/jama.275.11.852			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TZ971	8596223				2022-12-24	WOS:A1996TZ97100028
J	Luo, LQ; Hensch, TK; Ackerman, L; Barbel, S; Jan, LY; Jan, YN				Luo, LQ; Hensch, TK; Ackerman, L; Barbel, S; Jan, LY; Jan, YN			Differential effects of the Rac GTPase on Purkinje cell axons and dendritic trunks and spines	NATURE			English	Article							CALCIUM-BINDING PROTEIN; ELECTRON-MICROSCOPY; CEREBELLAR CORTEX; EXPRESSION; MOUSE; CLONING; BRAIN; GENE; MICE	Neurons contain distinct compartments including dendrites, dendritic spines, axons and synaptic terminals(1). The molecular mechanisms that generate and distinguish these compartments, although largely unknown, may involve the small GTPases Rac and Cdc42 (ref. 2), which appear to regulate actin polymerization(3). Having shown that perturbations of Rad activity block the growth of axons but not dendrites of Drosophila neurons(2), we investigated whether this also applies to mammals by examining transgenic mice expressing constitutively active human Rad in Purkinje cells. We found that these mice were ataxic and had a reduction of Purkinje-cell axon terminals in the deep cerebellar nuclei, whereas the dendritic trees grew to normal height and branched extensively. Unexpectedly, the dendritic spines of Purkinje cells in developing and mature cerebella were much reduced in size but increased in number. These 'mini' spines often form supernumerary synapses. These differential effects of perturbing Rac1 activity indicate that there may be distinct mechanisms for the elaboration of axons, dendrites and dendritic spines.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM & BIOPHYS,GRAD PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	Luo, LQ (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.		Hensch, Takao/L-4182-2019	Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498				AJIMA A, 1991, NEUROSCI RES, V12, P281, DOI 10.1016/0168-0102(91)90117-H; ALTMAN J, 1972, J COMP NEUROL, V145, P399, DOI 10.1002/cne.901450402; BAPTISTA CA, 1994, NEURON, V12, P243, DOI 10.1016/0896-6273(94)90268-2; BERRY M, 1976, BRAIN RES, V112, P1, DOI 10.1016/0006-8993(76)90331-0; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; DUSART I, 1994, J COMP NEUROL, V347, P211, DOI 10.1002/cne.903470206; FAIREN A, 1992, MICROSC RES TECHNIQ, V23, P289, DOI 10.1002/jemt.1070230405; GUENET JL, 1983, J HERED, V74, P105, DOI 10.1093/oxfordjournals.jhered.a109729; HALL AA, 1994, REV CELL BIOL, V10, P31; HARRIS KM, 1988, J NEUROSCI, V8, P4455; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; Hogan B., 1986, MANIPULATING MOUSE E; Ito M, 1984, CEREBELLUM NEURAL CO; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JANDE SS, 1981, NATURE, V294, P765, DOI 10.1038/294765a0; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MOLL J, 1991, ONCOGENE, V6, P863; OBERDICK J, 1993, NEURON, V10, P1007, DOI 10.1016/0896-6273(93)90050-2; Palay S. L., 1974, CEREBELLAR CORTEX CY; RAKIC P, 1973, J COMP NEUROL, V152, P133, DOI 10.1002/cne.901520203; Ramon y Cajal S., 1897, HISTOLOGY NERVOUS SY, V1; ROFFLERTARLOV S, 1979, BRAIN RES, V168, P75, DOI 10.1016/0006-8993(79)90129-X; SMEYNE RJ, 1995, MOL CELL NEUROSCI, V6, P230, DOI 10.1006/mcne.1995.1019; SOTELO C, 1990, J NEUROCYTOL, V19, P737, DOI 10.1007/BF01188042; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WISDEN W, 1994, IN SITU HYBRIDIZATIO, P9; WOOD TL, 1988, DNA-J MOLEC CELL BIO, V7, P585, DOI 10.1089/dna.1988.7.585	30	380	386	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					837	840		10.1038/379837a0	http://dx.doi.org/10.1038/379837a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587609				2022-12-24	WOS:A1996TX50100062
J	Moxham, CM; Malbon, CC				Moxham, CM; Malbon, CC			Insulin action impaired by deficiency of the G-protein subunit G(i alpha 2)	NATURE			English	Article							PHOSPHATASE-ACTIVITIES; PHOSPHORYLATION STATE; GLUCOSE-TRANSPORT; ANTISENSE RNA; DIABETIC RATS; PHOSPHOTYROSINE	Integration of information between tyrosine kinase(1) and G-protein-mediated pathways(2) is necessary, but remains poorly understood. Here we use cells from transgenic mice harbouring inducible expression of RNA antisense to the gene encoding G(i alpha 2) (refs 3, 4) to show that G(i alpha 2) is critical for insulin action. G(i alpha 2) deficiency in adipose tissue and liver produces hyperinsulinaemia, impaired glucose tolerance and resistance to insulin in vivo. Insulin resistance affects glucose-transporter activity and recruitment, counterregulation of lipolysis, and activation of glycogen synthase, all of which are cardinal responses to insulin(5). G(i alpha 2) deficiency increases protein-tyrosine phosphatase activity and attenuates insulin-stimulated tyrosine phosphorylation of IRS (insulin-receptor substrate 1) in vivo. G(i alpha 2) deficiency creates a model for the insulin resistance characteristic of noninsulin-dependent diabetes mellitus (NIDDM)(6), implicating G(i alpha 2) as a positive regulator of insulin action.			Moxham, CM (corresponding author), SUNY STONY BROOK,UNIV MED CTR,DEPT MOLEC PHARMACOL,DIABET & METAB DIS RES PROGRAM,STONY BROOK,NY 11794, USA.		malbon, craig/ABF-3604-2020					AHMAD F, 1995, AM J PHYSIOL-ENDOC M, V268, pE932, DOI 10.1152/ajpendo.1995.268.5.E932; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BEGUM N, 1991, DIABETES, V40, P1620, DOI 10.2337/diabetes.40.12.1620; BOYLAN JM, 1992, J CLIN INVEST, V90, P174, DOI 10.1172/JCI115833; BUSHFIELD M, 1990, BIOCHEM J, V271, P365, DOI 10.1042/bj2710365; COHEN P, 1985, MOL BASIS INSULIN AC, P213; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; FOLEY JE, 1978, AM J PHYSIOL, V234, pE112, DOI 10.1152/ajpendo.1978.234.2.E112; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GAWLER D, 1987, NATURE, V327, P224; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; KAMIELI E, 1981, J BIOL CHEM, V256, P4772; KING MJ, 1988, BIOCHEM J, V256, P893, DOI 10.1042/bj2560893; LAVAN BE, 1994, BIOCHEM SOC T, V22, P676, DOI 10.1042/bst0220676; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAURO LJ, 1993, ADV PROT PHOSPHATASE, V7, P393; MCGUIRE MC, 1991, DIABETES, V40, P939, DOI 10.2337/diabetes.40.7.939; MEYER MG, 1994, MOL CELL BIOL, V14, P3577; MEYEROVITCH J, 1989, J CLIN INVEST, V84, P976, DOI 10.1172/JCI114261; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; MOXHAM CM, 1993, DEV GENET, V14, P266, DOI 10.1002/dvg.1020140404; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIELAND O, 1974, METHOD ENZYMAT AN, V3, P1404	30	181	186	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					840	844		10.1038/379840a0	http://dx.doi.org/10.1038/379840a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587610				2022-12-24	WOS:A1996TX50100063
J	Ignatowicz, L; Kappler, J; Marrack, P				Ignatowicz, L; Kappler, J; Marrack, P			The repertoire of T cells shaped by a single MHC/peptide ligand	CELL			English	Article							RECEPTOR TRANSGENIC MICE; INVARIANT CHAIN; MONOCLONAL-ANTIBODY; POSITIVE SELECTION; ANTIGEN RECEPTOR; THYMUS; TOLERANCE; RECOGNITION; PEPTIDES; LACKING	Although the thymus produces many immature thymocytes, few of these cells mature. Positive selection has been thought to limit thymocyte development. In thymuses expressing a single MHC/peptide combination, however, surprisingly large numbers of thymocytes are selected to mature. Many of these react with the selecting MHC, bound to other self-peptides. Therefore, the number of thymocytes that mature is limited by the fact that positively selected cells die because they react too well with MHC bound to self-peptides that are not identical to those involved in positive selection. T cells that mature in thymuses expressing a single MHC/peptide ligand react frequently with foreign MHC, suggesting that the repertoire of alpha beta receptors may be more biased toward reaction with MHC than was previously thought.	NATL JEWISH CTR IMMUNOL & RESP MED,HOWARD HUGHES MED INST,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT IMMUNOL,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80206	Howard Hughes Medical Institute; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Ignatowicz, L (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,1400 JACKSON ST,DENVER,CO 80206, USA.		Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687	PHS HHS [AL18785, AL22295, AL17134] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BLACKMAN M, 1986, CELL, V47, P349, DOI 10.1016/0092-8674(86)90591-X; BODMER H, 1994, SCIENCE, V263, P1284, DOI 10.1126/science.7510069; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; CARDELL S, 1995, J EXP MED, V182, P993, DOI 10.1084/jem.182.4.993; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DIANZANI U, 1992, J IMMUNOL, V148, P678; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; ELLIOTT EA, 1994, J EXP MED, V179, P681, DOI 10.1084/jem.179.2.681; FISCHERLINDAHL K, 1977, J EXP MED, V145, P508; GLAS R, 1994, J EXP MED, V179, P661, DOI 10.1084/jem.179.2.661; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; HUMBLET C, 1994, INT IMMUNOL, V6, P1949, DOI 10.1093/intimm/6.12.1949; HUNIG T, 1980, J EXP MED, V151, P1288, DOI 10.1084/jem.151.5.1288; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; IGNATOWICZ L, 1995, J IMMUNOL, V154, P3852; JERNE N K, 1971, European Journal of Immunology, V1, P1, DOI 10.1002/eji.1830010102; Kabat EA, 1991, SEQUENCES PROTEINS I; KAPPLER JW, 1976, NATURE, V262, P797, DOI 10.1038/262797a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KELLY KA, 1993, EUR J IMMUNOL, V23, P1922, DOI 10.1002/eji.1830230829; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KOZONO H, 1994, NATURE, V369, P151, DOI 10.1038/369151a0; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUSOFF U, 1993, J IMMUNOL METHODS, V166, P287; LAMB CA, 1992, J IMMUNOL, V148, P3478; LERNER EA, 1980, J EXP MED, V152, P1085, DOI 10.1084/jem.152.4.1085; LO D, 1986, IMMUNOL RES, V5, P221, DOI 10.1007/BF02919203; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MATHIS DJ, 1983, P NATL ACAD SCI-BIOL, V80, P273, DOI 10.1073/pnas.80.1.273; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; NAUJOKAS MF, 1995, IMMUNITY, V3, P359, DOI 10.1016/1074-7613(95)90120-5; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; SCHERER MT, 1995, J EXP MED, V182, P1493, DOI 10.1084/jem.182.5.1493; SCHUMACHER TNM, 1994, IMMUNITY, V1, P721, DOI 10.1016/S1074-7613(94)80013-8; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHACHAR I, 1995, IMMUNITY, V3, P373, DOI 10.1016/1074-7613(95)90121-3; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WHITE J, 1983, J IMMUNOL, V130, P1033; WHITE J, 1989, J IMMUNOL, V143, P1822; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882; ZINKERNAGEL RM, 1975, J EXP MED, V141, P1427, DOI 10.1084/jem.141.6.1427	55	381	392	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					521	529		10.1016/S0092-8674(00)81028-4	http://dx.doi.org/10.1016/S0092-8674(00)81028-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598039	Bronze			2022-12-24	WOS:A1996TX17600005
J	Amir, S; Stewart, J				Amir, S; Stewart, J			Resetting of the circadian clock by a conditioned stimulus	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; PHASE RESPONSE CURVES; SUPRACHIASMATIC NUCLEUS; GENE-EXPRESSION; SYRIAN-HAMSTER; C-FOS; RAT; RHYTHMS; IMMUNOREACTIVITY; PROJECTIONS	ENVIRONMENTAL, light is the dominant temporal cue for the entrainment of circadian rhythms. In mammals, light entrains circadian rhythms by daily resetting a pacemaker located in the hypothalamic suprachiasmatic nucleus (SCN)(1,2). Although it is widely held that phase resetting by light involves cellular elements within the SCN that are uniquely responsive to photic cues(1,3), we now report that non-photic cues that reliably precede the onset of light can, through associative learning, come to activate these elements. In rats, a neutral non-photic stimulus paired with light in pavlovian conditioning trials was capable of eliciting cellular and behavioural effects characteristic of phase-dependent resetting of the pacemaker by light, the expression of the transcription factor Fos in SCN cells, and phase shifts in free-running activity and temperature rhythms(4-7). Thus an associative learning process, pavlovian conditioning, provides a means whereby environmental cues that predict light onset can come to mimic the effect of light on the SCN pacemaker and thereby bring about entrainment of circadian rhythms.			Amir, S (corresponding author), CONCORDIA UNIV,DEPT PSYCHOL,CTR STUDIES BEHAV NEUROBIOL,1455 MAISONNEUVE BLVD,MONTREAL,PQ H3G 1M8,CANADA.		Amir, Shimon/AAE-4635-2022					AMIR S, 1995, NEUROSCIENCE, V69, P1005, DOI 10.1016/0306-4522(95)00393-W; CARD JP, 1982, J COMP NEUROL, V206, P390, DOI 10.1002/cne.902060407; CARD JP, 1989, J COMP NEUROL, V284, P135, DOI 10.1002/cne.902840110; CUTRERA RA, 1993, BRAIN RES, V602, P14, DOI 10.1016/0006-8993(93)90235-F; DAAN S, 1976, J COMP PHYSIOL, V106, P253, DOI 10.1007/BF01417857; DAVIDOWA H, 1992, BEHAV BRAIN RES, V50, P127, DOI 10.1016/S0166-4328(05)80294-3; EDELSTEIN K, 1995, BRAIN RES, V690, P254, DOI 10.1016/0006-8993(95)00736-A; Harrington M E, 1986, J Biol Rhythms, V1, P309, DOI 10.1177/074873048600100405; HARRINGTON ME, 1987, BRAIN RES, V410, P275, DOI 10.1016/0006-8993(87)90325-8; HICKEY TL, 1976, EXP BRAIN RES, V24, P523; JANIK D, 1992, NEUROREPORT, V3, P575, DOI 10.1097/00001756-199207000-00007; JOHNSON RF, 1988, BRAIN RES, V462, P301, DOI 10.1016/0006-8993(88)90558-6; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; MEAD S, 1992, J NEUROSCI, V12, P2516; MOGA MM, 1995, J COMP NEUROL, V359, P221, DOI 10.1002/cne.903590204; MOORE RY, 1972, J COMP NEUROL, V146, P1, DOI 10.1002/cne.901460102; MOORE RY, 1994, J COMP NEUROL, V344, P403, DOI 10.1002/cne.903440306; MORIN LP, 1994, BRAIN RES REV, V67, P102; MROSOVSKY N, 1988, J COMP PHYSIOL A, V162, P35, DOI 10.1007/BF01342701; PICARD GE, 1985, NEUROSCI LETT, V55, P211; PITTENDRIGH CS, 1981, HDB BEHAVIORAL NEURO, V4, P95; RUSAK B, 1989, BRAIN RES, V493, P283, DOI 10.1016/0006-8993(89)91163-3; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; SCHWARTZ WJ, 1994, NEUROSCIENCE, V58, P573, DOI 10.1016/0306-4522(94)90082-5; SHINOHARA K, 1993, NEUROSCIENCE, V56, P813, DOI 10.1016/0306-4522(93)90129-4; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; VANREETH O, 1989, NATURE, V339, P49, DOI 10.1038/339049a0; WICKLAND CR, 1991, AM J PHYSIOL, V261, pR1109, DOI 10.1152/ajpregu.1991.261.5.R1109; ZHANG Y, 1993, NEUROSCI LETT, V164, P203, DOI 10.1016/0304-3940(93)90892-O	29	72	72	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					542	545		10.1038/379542a0	http://dx.doi.org/10.1038/379542a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596633				2022-12-24	WOS:A1996TU69300051
J	Gilsdorf, JR				Gilsdorf, JR			Do you have a minute?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					343	343						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8568996				2022-12-24	WOS:A1996TT30300002
J	Baird, AG; Jewell, D; Walker, JJ				Baird, AG; Jewell, D; Walker, JJ			Management of labour in an isolated rural maternity hospital	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONER OBSTETRICS; PERINATAL-MORTALITY; DELIVERY; UNITS	Objectives-To evaluate the use of a maternity unit run by general practitioners and midwives, describing the outcome of labor in an unselected group of women and quantifying the contribution made by general practitioners. Design-Retrospective population based review of obstetric patients who had access to an isolated rural maternity unit. Setting-Rural area 120 km from a consultant maternity unit. Subjects-997 consecutive women delivered between January 1987 and May 1991. Main outcome measures-Mode of delivery and complications by place of booking and place of delivery; need for medical intervention and transfer. Results-530 women (53%) were booked for delivery in the rural unit; this group had a caesarean section rate of 3.8% and an unplanned transfer rate of 12.8% to the consultant unit in labour. Of the 462 who delivered in the low risk unit, 25 (5%) required a forceps delivery; postnatal complications requiring emergency medical support occurred in a further 33 (7%). Conclusions-Risk characterisation is possible, but medical support from general practitioners and obstetricians is required in almost a third of women at low risk for complications of delivery. Results of this study support the team approach to obstetric management but not the move towards isolated units without organised medical support.	UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL BS8 2PR,AVON,ENGLAND; UNIV LEEDS,ST JAMES HOSP,DEPT OBSTET & GYNAECOL,LEEDS LS9 7TS,W YORKSHIRE,ENGLAND	University of Bristol; Saint James's University Hospital; University of Leeds	Baird, AG (corresponding author), WHITE HOUSE,SANDHEAD,STRANRAER DG9 9JA,WIGTOWN,SCOTLAND.		Baird, Gordon/AAN-8026-2020; Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X; Baird, Gordon/0000-0002-8803-6520; Walker, James/0000-0002-8922-083X				BROWN DJ, 1994, BRIT MED J, V309, P777, DOI 10.1136/bmj.309.6957.777; Bull M J, 1980, J R Coll Gen Pract, V30, P208; CAVENAGH AJM, 1984, BRIT MED J, V288, P1438, DOI 10.1136/bmj.288.6428.1438; HEMMINKI E, 1985, SCAND J SOC MED, V13, P113, DOI 10.1177/140349488501300308; LOWE SW, 1987, J ROY COLL GEN PRACT, V37, P484; MACVICAR J, 1993, BRIT J OBSTET GYNAEC, V100, P316, DOI 10.1111/j.1471-0528.1993.tb12972.x; MARSH GN, 1989, BRIT MED J, V298, P1077, DOI 10.1136/bmj.298.6680.1077; REYNOLDS JL, 1988, J ROY COLL GEN PRACT, V38, P307; ROSENBLATT RA, 1985, LANCET, V1, P429; STREET P, 1991, BRIT MED J, V302, P698, DOI 10.1136/bmj.302.6778.698; TAYLOR GW, 1980, LANCET, V2, P1287; TUCKER J, 1994, J PUBLIC HEALTH MED, V16, P60, DOI 10.1093/oxfordjournals.pubmed.a042937; VANALTEN D, 1989, BRIT J OBSTET GYNAEC, V96, P656; YOUNG G, 1990, BRIT MED J, V301, P665, DOI 10.1136/bmj.301.6753.665-b; YOUNG G, 1987, BRIT MED J, V294, P744, DOI 10.1136/bmj.294.6574.744; YOUNG G, 1990, BRIT MED J, V301, P983; 1993, CHANGING CHILDBIRT 1; 1994, 1988 90 DEP HLTH REP; 1993, PROVISION MATERNITY	19	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					223	226						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TT486	8563590				2022-12-24	WOS:A1996TT48600030
J	Hsu, HL; Shu, HB; Pan, MG; Goeddel, DV				Hsu, HL; Shu, HB; Pan, MG; Goeddel, DV			TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways	CELL			English	Article							TUMOR-NECROSIS-FACTOR; MOLECULAR-CLONING; KAPPA-B; EXPRESSION; ACTIVATION; PROTEINS; DOMAIN; ALPHA	Tumor necrosis factor (TNF) can induce apoptosis and activate NF-kappa B through signaling cascades emanating from TNF receptor 1 (TNFR1). TRADD is a TNFR1-associated signal transducer that is involved in activating both pathways. Here we show that TRADD directly interacts with TRAF2 and FADD, signal transducers that activate NF-kappa B and induce apoptosis, respectively. A TRAF2 mutant lacking its N-terminal RING finger domain is a dominant-negative inhibitor of TNF-mediated NF-kappa B activation, but does not affect TNF-induced apoptosis. Conversely, a FADD mutant lacking its N-terminal 79 amino acids is a dominant-negative inhibitor of TNF-induced apoptosis, but does not inhibit NF-kappa B activation. Thus, these two TNFR1-TRADD signaling cascades appear to bifurcate at TRADD.			Hsu, HL (corresponding author), TULARIK INC,270 E GRAND AVE,S SAN FRANCISCO,CA 94080, USA.							ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU MH, 1994, J BIOL CHEM, V269, P30069; ITOH N, 1993, J BIOL CHEM, V268, P10932; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1994, J BIOL CHEM, V269, P22492; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WONG GHW, 1994, J IMMUNOL, V152, P1751	45	1691	1778	0	64	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					299	308		10.1016/S0092-8674(00)80984-8	http://dx.doi.org/10.1016/S0092-8674(00)80984-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565075	Bronze			2022-12-24	WOS:A1996TR59500016
J	Sanchez, Y; Desany, BA; Jones, WJ; Liu, QH; Wang, B; Elledge, SJ				Sanchez, Y; Desany, BA; Jones, WJ; Liu, QH; Wang, B; Elledge, SJ			Regulation of RAD53 by the ATM-like kinases MEC1 and TEL1 in yeast cell cycle checkpoint pathways	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; GENE; IDENTIFICATION; THREONINE; TYROSINE; PROTEINS; FAMILIES; ENCODES	Mutants of the Saccharomyces cerevisiae ataxia telangiectasia mutated (ATM) homolog MEC1/SAD3/ESR1 were identified that could live only if the RAD53/SAD1 checkpoint kinase was overproduced. MEC1 and a structurally related gene, TEL1, have overlapping functions in response to DNA damage and replication blocks that in mutants can be provided by overproduction of RAD53. Both MEC1 and TEL1 were found to control phosphorylation of Rad53p in response to DNA damage. These results indicate that RAD53 is a signal transducer in the DNA damage and replication checkpoint pathways and functions downstream of two members of the ATM lipid kinase family. Because several members of this pathway are conserved among eukaryotes, it is likely that a RAD53-related kinase will function downstream of the human ATM gene product and play an important role in the mammalian response to DNA damage.	BAYLOR COLL MED, HOWARD HUGHES MED INST, DEPT MOLEC & HUMAN GENET, DEPT BIOCHEM, HOUSTON, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute					NIDDK NIH HHS [DK07696] Funding Source: Medline; NIGMS NIH HHS [GM44664] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM044664, R01GM044664] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JB, 1994, YEAST, V10, P1267, DOI 10.1002/yea.320101003; Allen JB, 1994, GENE DEV, V8, P2416; BENTLEY N, COMMUNICATION; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DESANY B, UNPUB; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P662; GIETZ RD, 1994, MOL GENETICS YEAST P, pCH8; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARLOW E, 1988, ANTIBODIES LABORATOR; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; MOORE CW, 1978, MUTAT RES, V51, P165, DOI 10.1016/S0027-5107(78)80016-5; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; NASIM A, 1977, CAN J GENET CYTOL, V19, P323, DOI 10.1139/g77-035; NASR F, 1994, CR ACAD SCI III-VIE, V317, P607; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; STACK JH, 1994, J BIOL CHEM, V269, P31552; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; ZHENG P, 1993, MOL CELL BIOL, V13, P5829, DOI 10.1128/MCB.13.9.5829; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G; ZIELER HA, 1995, MOL CELL BIOL, V15, P3227	36	538	549	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	1996	271	5247					357	360		10.1126/science.271.5247.357	http://dx.doi.org/10.1126/science.271.5247.357			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553072				2022-12-24	WOS:A1996TQ52800043
J	Celermajer, DS; Adams, MR; Clarkson, P; Robinson, J; McCredie, R; Donald, A; Deanfield, JE				Celermajer, DS; Adams, MR; Clarkson, P; Robinson, J; McCredie, R; Donald, A; Deanfield, JE			Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-DISEASE; RISK; ATHEROSCLEROSIS; CHILDREN; CHOLESTEROL; LIPOPROTEIN; RABBITS; SMOKERS; INVIVO	Background. Passive smoking has been linked to an increased risk of dying from atherosclerotic heart disease. Since endothelial dysfunction is an early feature of atherogenesis and occurs in young adults who actively smoke cigarettes, we hypothesized that passive smoking might also be associated with endothelial damage in healthy young-adult nonsmokers. Methods. We studied 78 healthy subjects (39 male and 39 female) 15 to 30 years of age (mean +/-SD, 22+/-4): 26 control subjects who had never smoked or had regular exposure to environmental tobacco smoke, 26 who had never smoked but had been exposed to environmental tobacco smoke for at least one hour dally for three or more years, and 26 active smokers. Using ultrasonography, we measured the brachial-artery diameter under base-line conditions, during reactive hyperemia (with flow increase causing endothelium-dependent dilatation), and after sublingual administration of nitroglycerin (an endothelium-independent dilater). Results. Flow-mediated dilatation was observed in all control subjects (8.2+/-3.1 percent; range, 2.1 to 16.7) but was significantly impaired in the passive smokers (3.1+/-2.7 percent; range, 0 to 9; P<0.001 for the comparison with the controls) and in the active smokers (4.4+/-3.1 percent; range, 0 to 10; P<0.001 for the comparison with the controls; P=0.48 for the comparison with the passive smokers). In the passive smokers, there was an inverse relation between the intensity of exposure to tobacco smoke and flow-mediated dilatation (r=-0.67, P<0.001). In contrast, dilatation induced by nitroglycerin was similar in all groups. Conclusions. Passive smoking is associated with dose-related impairment of endothelium-dependent dilatation in healthy young adults, suggesting early arterial damage.	HEART RES INST, SYDNEY, NSW, AUSTRALIA; HOSP SICK CHILDREN, CARDIOTHORAC UNIT, LONDON WC1N 3JH, ENGLAND	University of Sydney; Heart Research Institute; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Celermajer, DS (corresponding author), ROYAL PRINCE ALFRED HOSP, DEPT CARDIOL, MISSENDEN RD, CAMPERDOWN, NSW 2050, AUSTRALIA.		Deanfield, John E/C-5178-2008	Robinson, Jacqui/0000-0001-6671-5437; Deanfield, John/0000-0001-8806-6052				ANDERSON TJ, 1995, J AM COLL CARDIOL, V26, P1235, DOI 10.1016/0735-1097(95)00327-4; BROWN RE, 1993, CIRCULATION, V88, P260; BURGHUBER OC, 1986, CHEST, V90, P34, DOI 10.1378/chest.90.1.34; CELERMAJER DS, 1993, CIRCULATION, V88, P2149, DOI 10.1161/01.CIR.88.5.2149; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; CHAUVEAU M, 1985, CARDIOVASC RES, V19, P700, DOI 10.1093/cvr/19.11.700; COLLEY JRT, 1974, LANCET, V2, P1031; COOKE JP, 1994, ARTERIOSCLER THROMB, V14, P653, DOI 10.1161/01.ATV.14.5.653; DAVIS JW, 1989, ARCH INTERN MED, V149, P386, DOI 10.1001/archinte.149.2.386; DAVIS JW, 1990, J VASC MED BIOL, V2, P289; DUTHIE GG, 1991, AM J CLIN NUTR, V53, pS1061, DOI 10.1093/ajcn/53.4.1061S; FELDMAN J, 1991, PEDIATRICS, V88, P259; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; FISH RD, 1988, J CLIN INVEST, V81, P21, DOI 10.1172/JCI113297; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; HOGG RV, 1978, INTRO MATH STATISTIC; HOWARD G, 1994, ARCH INTERN MED, V154, P1277; JENDRYCZKO A, 1993, NEOPLASMA, V40, P199; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; LIEBERMAN EH, 1994, CIRCULATION, V90, P138; MOORE S, 1973, LAB INVEST, V29, P478; MOSKOWITZ WB, 1990, CIRCULATION, V81, P586, DOI 10.1161/01.CIR.81.2.586; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; PENN A, 1993, CIRCULATION, V88, P1820, DOI 10.1161/01.CIR.88.4.1820; PENN A, 1994, CIRCULATION, V90, P1363, DOI 10.1161/01.CIR.90.3.1363; POHL U, 1986, HYPERTENSION, V8, P37, DOI 10.1161/01.HYP.8.1.37; RAIJ L, 1994, CIRCULATION, V90, P575; REPACE JL, 1985, ENVIRON INT, V11, P3, DOI 10.1016/0160-4120(85)90098-4; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SINZINGER H, 1989, WIEN KLIN WOCHENSCHR, V101, P694; SORENSEN KE, 1995, BRIT HEART J, V74, P247; STEENLAND K, 1992, JAMA-J AM MED ASSOC, V267, P94, DOI 10.1001/jama.267.1.94; SUN YP, 1994, CIRCULATION, V90, P459; TAYLOR AE, 1992, CIRCULATION, V86, P699, DOI 10.1161/01.CIR.86.2.699; TEIRSTEIN PS, 1993, J AM COLL CARDIOL, V21, P590, DOI 10.1016/0735-1097(93)90089-J; WELLS AJ, 1988, ENVIRON INT, V14, P249; WENDELHAG I, 1991, CLIN PHYSIOL, V11, P565, DOI 10.1111/j.1475-097X.1991.tb00676.x; ZHU BQ, 1993, J AM COLL CARDIOL, V21, P225, DOI 10.1016/0735-1097(93)90741-I; 1983, DHHS PHS8450204 PUBL	40	753	784	1	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 18	1996	334	3					150	154		10.1056/NEJM199601183340303	http://dx.doi.org/10.1056/NEJM199601183340303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ017	8531969				2022-12-24	WOS:A1996TQ01700003
J	Graeber, TG; Osmanian, C; Jacks, T; Housman, DE; Koch, CJ; Lowe, SW; Giaccia, AJ				Graeber, TG; Osmanian, C; Jacks, T; Housman, DE; Koch, CJ; Lowe, SW; Giaccia, AJ			Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours	NATURE			English	Article							CANCER; BCL-2; P53	APOPTOSIS is a genetically encoded programme of cell death that can be activated under physiological conditions(1,2) and may be an important safeguard against tumour development(3-6). Regions of low oxygen (hypoxia) and necrosis are common features of solid tumours(7,8). Here we report that hypoxia induces apoptosis in oncogenically transformed cells and that further genetic alterations, such as less of the p53 tumour-suppressor gene or overexpression of the apoptosis-inhibitor protein Bcl-2, substantially reduce hypoxia-induced cell death. Hypoxia also selects for cells with defects in apoptosis, because small numbers of transformed cells lacking p53 overtake similar cells expressing wild-type p53 when treated with hypoxia. Furthermore, highly apoptotic regions strongly correlate with hypoxic regions in transplanted tumours expressing wild-type p53, whereas little apoptosis occurs in hypoxic regions of p53-deficient tumours. We propose that hypoxia provides a physiological selective pressure in tumours for the expansion of variants that have lost their apoptotic potential, and in particular for cells acquiring p53 mutations.	STANFORD UNIV,SCH MED,DEPT RADIAT ONCOL,STANFORD,CA 94305; MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; UNIV PENN,PHILADELPHIA,PA 19104; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Stanford University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); University of Pennsylvania; Cold Spring Harbor Laboratory				Graeber, Thomas/0000-0001-8574-9181				BAKER SJ, 1990, CANCER RES, V50, P7717; BARDEESY N, 1995, CANCER RES, V55, P215; BECLI A, 1995, CANCER RES, V55, P1811; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HICKMAN JA, 1994, PHILOS T ROY SOC B, V345, P319, DOI 10.1098/rstb.1994.0112; HOCKEL M, 1993, GYNECOL ONCOL, V51, P141, DOI 10.1006/gyno.1993.1262; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; LANE DP, 1994, PHILOS T ROY SOC B, V345, P277, DOI 10.1098/rstb.1994.0106; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LORD EM, 1993, CANCER RES, V53, P5721; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LOWE SW, IN PRESS CURR OPIN O; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; SIRICROPE FA, 1995, CANCER RES, V55, P237; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaupel P., 1995, TUMOR OXYGENATION, P219; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	30	2052	2111	1	116	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					88	91		10.1038/379088a0	http://dx.doi.org/10.1038/379088a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538748				2022-12-24	WOS:A1996TN21600062
J	Harris, MI				Harris, MI			Medical care for patients with diabetes - Epidemiologic aspects	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			UNITED-STATES; BLOOD-GLUCOSE; COMPLICATIONS TRIAL; MELLITUS; ADULTS; INTERVENTIONS; RELIABILITY; INFORMATION; PHYSICIANS; BEHAVIORS	Objective: To describe the epidemiologic characteristics of physician care and self-care for adults with diabetes in the U.S. population. Design and Subjects: Data are drawn from the 1989 National Health Interview Survey, in which a personal household interview was administered to a representative sample of U.S. adults aged 18 years or older. The response rate was 96% (n = 84 572). All subjects identified as having diabetes previously diagnosed by a physician were asked a series of questions about their diabetes. Response rate for this representative sample of U.S. diabetic patients was 95% (n = 2405). Measurements: Self-reported information was obtained about various aspects of diabetes care, including care by physicians and self-care practices of the diabetic persons. Sociodemographic and clinical factors that may influence diabetes care were also determined. Results: More than 90% of diabetic adults had one physician for the usual care of their diabetes, but 32% made fewer than four visits to this physician each year. Most physician visits by diabetic patients were not made to diabetes specialists, and the visit rate to other health care professionals such as ophthalmologists, podiatrists, and nutritionists was low. About half of insulin-treated diabetic subjects used multiple daily insulin injections; and 40% of patients with insulin-dependent diabetes mellitus, 26% of those with non-insulin-dependent diabetes mellitus (NIDDM) who were taking insulin, and 5% of those with NIDDM who were not taking insulin monitored their blood glucose level daily. Diabetes patient education classes had been attended by 35% of diabetic adults. Conclusions: These and other data indicate that medical care for diabetic patients and their self-care practices may not be optimal for prevention of diabetes complications. The Diabetes Control and Complications Trial showed that achieving and maintaining near-normal glycemia, with a concomitant 50% to 70% reduction in diabetes complications, may require close monitoring and ongoing support from a health care team, ample financial resources, and advanced patient knowledge and motivation. Providing this level of diabetes management to all diabetic persons may require major changes in the health care system and in patient self-care practices.			Harris, MI (corresponding author), NIDDKD, NATCHER BLDG, ROOM 5AN24, 45 CTR DR, MSC 6600, BETHESDA, MD 20892 USA.							ADAMS PF, 1990, VITAL HLTH STAT, V176, P1; AMER DIABET ASSOC, 1993, DIABETES, V42, P1555; BRANSOME ED, 1992, DIABETES CARE, V15, P1; BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714; BROWN SA, 1990, PATIENT EDUC COUNS, V16, P189, DOI 10.1016/0738-3991(90)90070-2; BROWNLEE M, 1992, DIABETES CARE, V15, P1835, DOI 10.2337/diacare.15.12.1835; BUSH TL, 1989, AM J PUBLIC HEALTH, V79, P1554, DOI 10.2105/AJPH.79.11.1554; Cochran WG, 1977, SAMPLING TECHNIQUES, P319; COONROD BA, 1994, DIABETES CARE, V17, P852, DOI 10.2337/diacare.17.8.852; COWIE CC, 1995, NIH951468 US DEP HLT, P541; DUDL RJ, 1982, DIABETES CARE, V5, P649, DOI 10.2337/diacare.5.6.649; EASTMAN RC, 1993, J CLIN ENDOCR METAB, V77, P1105, DOI 10.1210/jc.77.5.1105; EASTMAN RC, 1993, DIABETES CARE, V16, P1095, DOI 10.2337/diacare.16.8.1095; GONDERFREDERICK LA, 1988, DIABETES CARE, V11, P579, DOI 10.2337/diacare.11.7.579; GREENE DA, 1992, DIABETES CARE, V15, P1902, DOI 10.2337/diacare.15.12.1902; GUTHRIE RA, 1991, AM FAM PHYSICIAN, V43, P570; HARRIS MI, 1994, DIABETES CARE, V17, P585, DOI 10.2337/diacare.17.6.585; HARRIS MI, 1994, DIABETES CARE, V17, P761, DOI 10.2337/diacare.17.7.761; HARRIS MI, 1993, DIABETES CARE, V16, P1116, DOI 10.2337/diacare.16.8.1116; HARRIS MI, 1994, DIABETES CARE, V17, P1337, DOI 10.2337/diacare.17.11.1337; HARRIS MI, 1990, DIABETES CARE, V13, P419, DOI 10.2337/diacare.13.4.419; HELIOVAARA M, 1993, J CLIN EPIDEMIOL, V46, P181, DOI 10.1016/0895-4356(93)90056-7; Janes GR, 1995, NIH PUBLICATION, P541; KEHOE R, 1994, AM J EPIDEMIOL, V139, P813, DOI 10.1093/oxfordjournals.aje.a117078; KLEIN R, 1995, DIABETES CARE, V18, P258, DOI 10.2337/diacare.18.2.258; LASKER RD, 1993, NEW ENGL J MED, V329, P1035, DOI 10.1056/NEJM199309303291410; MIDTHJELL K, 1992, J EPIDEMIOL COMMUN H, V46, P537, DOI 10.1136/jech.46.5.537; PADGETT D, 1988, J CLIN EPIDEMIOL, V41, P1007, DOI 10.1016/0895-4356(88)90040-6; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; PEYROT M, 1988, DIABETES S1, V37, pA53; RAND LI, 1985, NEW ENGL J MED, V313, P1433, DOI 10.1056/NEJM198512053132302; RUBIN RJ, 1994, J CLIN ENDOCR METAB, V78, pA809, DOI 10.1210/jcem.78.4.8157701; SHAH BV, 1984, SESUDAAN STANDARD ER; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIEBERT C, 1993, DIABETES CARE, V16, P759, DOI 10.2337/diacare.16.5.759; SONGER TJ, 1992, DIABETES CARE, V15, P15, DOI 10.2337/diacare.15.1.S15; TUTTLEMAN M, 1993, DIABETES CARE, V16, P765, DOI 10.2337/diacare.16.5.765; 1993, DIABETES CARE, V16, P113; 1995, DIABETES CARE S1, V18, P1	39	82	84	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				117	122		10.7326/0003-4819-124-1_Part_2-199601011-00007	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554202				2022-12-24	WOS:A1996TL94400007
J	Hay, BA; Wassarman, DA; Rubin, GM				Hay, BA; Wassarman, DA; Rubin, GM			Drosophila homologs of baculovirus inhibitor of apoptosis proteins function to block cell death	CELL			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; ZINC-FINGER; GENE; EYE; EXPRESSION; ROUGH; DIVERSITY; P35-GENE; MOTIF	Apoptotic cell death is a mechanism by which organisms eliminate superfluous or harmful cells. Expression of the cell death regulatory protein REAPER (RPR) in the developing Drosophila eye results in a small eye owing to excess cell death. We show that mutations in thread (th) are dominant enhancers of RPR-induced cell death and that th encodes a protein homologous to baculovirus inhibitors of apoptosis (IAPs), which we call Drosophila IAP1 (DIAP1). Overexpression of DIAP1 or a related protein, DIAP2, in the eye suppresses normally occurring cell death as well as death due to overexpression of rpr or head in volution defective. IAP death-preventing activity localizes to the N-terminal baculovirus IAP repeats, a motif found in both viral and cellular proteins associated with death prevention.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	Hay, BA (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA.			Rubin, Gerald/0000-0001-8762-8703				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASHBURNER M, 1989, DROSOPHILA LABORATOR; AYRES MD, 1994, VIROLOGY, V202, P586, DOI 10.1006/viro.1994.1380; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BLISSARD GW, 1990, ANNU REV ENTOMOL, V35, P127, DOI 10.1146/annurev.en.35.010190.001015; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CLEM RJ, 1993, J VIROL, V67, P3730, DOI 10.1128/JVI.67.7.3730-3738.1993; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; CLEM RJ, 1994, APOPTOSIS, V2, P89; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; ELLIS MC, 1993, DEVELOPMENT, V119, P855; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GOMBART AF, 1989, J GEN VIROL, V70, P1815, DOI 10.1099/0022-1317-70-7-1815; GOODING LR, 1994, INFECT AGENT DIS, V3, P106; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HAY BA, 1994, DEVELOPMENT, V120, P2121; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; KAMITA SG, 1993, J VIROL, V67, P455, DOI 10.1128/JVI.67.1.455-463.1993; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Martin Seamus J., 1993, Trends in Cell Biology, V3, P141, DOI 10.1016/0962-8924(93)90128-N; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MELAMED J, 1975, J ULTRA MOL STRUCT R, V51, P79, DOI 10.1016/S0022-5320(75)80010-4; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROBERTSON HM, 1988, GENETICS, V118, P461; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; SPREIJ T E, 1971, Netherlands Journal of Zoology, V21, P221; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WOLFF T, 1991, DEVELOPMENT, V113, P825; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0	53	617	636	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1253	1262		10.1016/0092-8674(95)90150-7	http://dx.doi.org/10.1016/0092-8674(95)90150-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548811	Bronze			2022-12-24	WOS:A1995TM76200020
J	Fazel, M				Fazel, M			Now show me your tongue: A taste of medicine in China	LANCET			English	Editorial Material											Fazel, M (corresponding author), LINCOLN COLL,OXFORD OX1 3DR,ENGLAND.			Fazel, Mina/0000-0001-9342-2365				WILSON A, 1991, BRIT J GEN PRACT, V41, P119	1	9	9	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1687	1688		10.1016/S0140-6736(95)92847-2	http://dx.doi.org/10.1016/S0140-6736(95)92847-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551831				2022-12-24	WOS:A1995TL42300017
J	Groves, KE				Groves, KE			How I'd like to be treated if I was terminally ill	BRITISH MEDICAL JOURNAL			English	Article											Groves, KE (corresponding author), QUEENSCOURT HOSPICE,SOUTHPORT PR8 6RE,MERSEYSIDE,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1690	1691		10.1136/bmj.311.7021.1690	http://dx.doi.org/10.1136/bmj.311.7021.1690			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541760	Green Published			2022-12-24	WOS:A1995TL94200020
